BENZOPYRIDINONES AND BENZOPYRIMIDINONES AS PI3K INHIBITORS

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Application No. 63/532,175, filed August 11, 2023, and U.S. Provisional Application No. 63/600,371, filed November 17, 2023, the disclosures of which are incorporated in their entireties for all purposes.

BACKGROUND OF THE INVENTION

[0002] Phosphatidylinositol lipids (PIs) and their various phosphorylated subspecies are second messengers involved in a wide array of cellular vesicle trafficking and signal transduction processes. Phosphoinositide 3' kinases (PI3Ks) are a family of enzymes responsible for phosphorylation of the 3' hydroxyl position of the inositol ring of PIs. PI3Ks are subdivided into 3 classes according to their structure and substrates. Class II PI3Ks (PI3K-C2α, PI3K-C2β, PI3K-C2γ) and Class III PI3Ks (vps34) are monomeric enzymes primarily associated with endocytosis and autophagy (Posor *et al.*, Biochim Biophys Acta **2015**, 1851, 794; Backer, Biochem J. **2016**, 473, 2251). The Class I PI3Ks are heterodimeric, consisting of a catalytic kinase subunit (p110α, β, γ, δ) and one of several regulatory subunits that determine binding partners and subcellular localization. Class I PI3Ks are activated upon interaction with receptor tyrosine kinases (RTKs), Ras-related GTPases, G-protein coupled receptors, and/or related adaptor proteins, and in their active form convert phosphatidylinositol 4,5-diphosphate (PIP2) to phosphatidyl 3,4,5-triphosphate (PIP3) (Fruman *et al.*, Cell **2017**, 170, 605).

[0003] High local concentrations of PIP3 promote the recruitment and activation of downstream signaling partners, including AKT and mTOR. Activation of the AKT/mTOR pathways are implicated in several growth-related roles and pathologies including glucose regulation, cell survival, angiogenesis, and proliferation (Porta *et al.*, Front Oncol. **2014**, 4, 1), indicating a role for Class I PI3Ks as a critical upstream regulator of these functions.

[0004] Class I PI3Ks are further subdivided into 4 isoforms (α, β, γ, and δ) based on the identity of their catalytic (p110α, p110β, p110γ, or p110δ) and regulatory (p85α or its various splice variants, p85β, p55γ, or p101) subunits, giving rise to distinct roles in cellular physiology (Vanhaesebroeck *et al.*, J Mol Med (Berl). **2016**, 94, 5). PI3Kγ and PI3Kδ are mostly expressed in leukocytes and play an important role in pro-inflammatory pathways (Hawkins *et. al.,* Biochimica et Biophysica Acta **2015**, 1851, 882; Okkenhaug *et al.*, Science **2002**, 297, 1031; Ali *et al.*, Nature **2004**, 431, 1007). PI3Kα and β are more ubiquitously expressed and share similar but not identical roles. For example, PI3Kα has a nonredundant role in angiogenesis (Soler *et al.*, J Exp

Med. **2013**, 210, 1937), while PI3Kβ is known to serve a specific function in platelet aggregation (Liu *et. al.,* Nat Rev Drug Discov. **2009**, 8, 627; Jackson *et al*., Nat Med. **2005**, 11, 507).

[0005] Elevation or constitutive activation of the PI3K pathway is one of the most frequent events in human cancers. The PI3K pathway is overactivated through a variety of mechanisms, including activating mutation of PI3K isoforms, up-regulation of PI3K isoforms, loss or inactivation of the tumor suppressor PTEN, or hyperactivation of tyrosine kinase growth factor receptors or other upstream signaling partners (Yang *et al*., *Mol Cancer* **2019**, 18, 1). Mutations in the gene coding for PI3Kα or mutations which lead to upregulation of PI3Kα have been found to occur in many human cancers such as lung, stomach, endometrial, ovarian, bladder, breast, colon, brain, prostate, and skin cancers (Goncalves *et al*., N Eng J Med. **2018**, 379,2052). In particular, PIK3CA, the gene encoding the p110α subunit of PI3Kα, is frequently mutated or amplified in a variety of tumor types. Missense mutations occur in all domains of p110α, but cluster in two 'hot spots', the most common being E542K and E545K in the helical domain, and H1047R in the kinase domain. Helical domain mutations reduce inhibition of p110α by p85 or facilitate direct interaction of p110α with insulin receptor substrate 1 (IRS1)37, whereas kinase domain mutations increase interaction of p110α with lipid membranes, concomitantly upregulating signaling events. (Thorpe *et al*., Nat Rev Cancer **2015**, 15, 7).


[0006] The development of inhibitors for the PI3K pathway has been challenging due to the inability to achieve dosing sufficient for tumor suppression without adverse events. To date PI3K inhibitors in the clinic (alpelisib, buparlisib, copanlisib, duvelisib, idelalisib, pictilisib, taselisib, and others) have caused dose-dependent adverse events such as hyperglycemia, rash, fatigue, diarrhea, etc. (Jiang *et al*., Mol Biol Rep. **2020**, 47, 4587) which are known on-target toxicities. Hyperglycemia is a result of the body not producing enough insulin or aberrant utilization. The pancreas regulates insulin release in response to changes in blood glucose levels, resulting in either glucose uptake by muscle and fat cells when insulin levels are high or gluconeogenesis by the liver when insulin levels are low. Tissue cellular response to insulin requires PI3K signaling through the ubiquitously expressed p110α sub-unit. As a result, pan-PI3K inhibition of the target disrupts glucose metabolism in tissues, leading to insulin resistance (Hopkins *et al*., Nature **2018**, 560, 499). To mitigate adverse events, selective PI3K isoform inhibitors were developed. The severity of the adverse event is dependent on the select isoform, for example PI3Kα inhibitors are associated with hyperglycemia and rash due to the p110α sub-unit role in insulin response (Rugo *et al*., The Breast **2022**, 61, 156). Similarly, use of a selective PI3Kδ inhibitor (idelalisib), where the p110δ sub-unit is highly expressed in immune cells, causes severe diarrhea and colitis. Inhibition with a dual inhibitor (taselisib), a potent PI3Kδ inhibitor possessing modest PI3Kα

inhibition led to gastrointestinal (GI) side effects, but a highly selective and potent PI3Kδ inhibitor (umbralisib) reported no GI related adverse events (Gadkar *et al*., CPT Pharmacometrics Syst Pharmacol. **2021**, 11, 616). Such amelioration of adverse events with highly isoform selective and potent inhibitors demonstrates that a strategy to mitigate toxicity by developing mutant selective isoform inhibitors is promising for decreasing the severity of toxicity. Furthermore, selective inhibition of the mutant PI3Kα isoform over wild type may suppress cancer signaling while having minimal effect on PI3K signaling in healthy cells bearing just wild type PI3Kα, leading to a reduction in the toxicities associated with nonselective PI3K inhibition (Castel *et al*., Nat Cancer **2021** 2, 587).

[0007] There is currently an interest in developing PI3K inhibitors for cancer therapy (WO 2023/081209, WO 2023/078401, WO 2023/060262, WO 2023/056407, WO 2021/202964). However, there is a continued need for novel potent and selective PI3K inhibitors, either as single agents or as combination therapies, in the treatment of cancer.

SUMMARY OF THE INVENTION

[0008] An aspect of the invention is a compound of Formula (1)




(1)

or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound thereof, or a pharmaceutically acceptable salt thereof,

wherein:

R_1 is selected from



;

each A is independently C_1-C_4 alkyl, fluoroalkyl, C_3-C_7 cycloalkyl, $N(R_a)_2$, $(CH_2)_{0-5}$-NR_a-C(O)-C_3-C_7 cycloalkyl, $(CH_2)_{1-5}$-O-$(CH_2)_{0-5}$-C_1-C_4 alkyl, $(CH_2)_{1-5}$-O-C_1-C_3 cycloalkyl, $(CH_2)_{1-5}$-O-$(CH_2)_{0-5}$-CF_3, $(CH_2)_{1-5}$-O-$(CH_2)_{1-5}$-C_1-C_3 fluoroalkyl, $(CH_2)_{0-5}$-aryl, $(CH_2)_{0-5}$-heteroaryl, $(CH_2)_{0-5}$-heterocyclyl, $(CH_2)_{0-5}$-NR_a-$(CH_2)_{0-5}$-heteroaryl or $(CH_2)_{0-5}$-NR_a-$(CH_2)_{1-5}$-N-heterocyclyl, where the alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl are substituted or unsubstituted, or alternatively, A and A together with the attached -P(=O)- moiety may form a substituted or unsubstituted heterocyclyl ring;

each B is independently H, C_1-C_4 alkyl, C_3-C_7 cycloalkyl, $(CH_2)_{1-5}$-OH, $(CH_2)_{0-5}$-$N(R_a)_2$, $(CH_2)_{1-5}$-NR_a-C(O)-C_3-C_7 cycloalkyl, $(CH_2)_{0-5}$-aryl, $(CH_2)_{0-5}$-heteroaryl, $(CH_2)_{0-5}$-heterocyclyl, $(CH_2)_{0-5}$-C(O)-$(CH_2)_{1-5}$-O-C_1-C_4 alkyl, $(CH_2)_{1-5}$-NR_a-$(CH_2)_{0-5}$-heteroaryl or $(CH_2)_{1-5}$-NR_a-$(CH_2)_{2-5}$-N-heterocyclyl, O-C_{1-5}-alkyl, O-C_{0-5}-cycloalkyl, O-C_{0-5}-heterocyclyl, where the alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl are substituted or unsubstituted, or alternatively, B and B together with the attached -[O or NH]-P(=O)-O- moiety may form a substituted or unsubstituted heterocyclyl ring, or alternatively, A and B together with the attached -P(=O)-O- moiety may form a substituted or unsubstituted heterocyclyl ring;

each R_a is independently H, C_1-C_4 alkyl, C_3-C_7 cycloalkyl, C(O)C_1-C_3 alkyl, $(CH_2)_{1-5}$-fluoroalkyl, $(CH_2)_{1-5}$-OH, $(CH_2)_{1-5}$-NH_2, $(CH_2)_{1-5}$-NH(C_1-C_4 alkyl), $(CH_2)_{1-5}$-N(C_1-C_4 alkyl)$_2$ or C(O)-$(CH_2)_{1-5}$-O-C_1-C_3 alkyl, where the alkyl and cycloalkyl are substituted or unsubstituted, or alternatively, for -S(=O)(A)(=NR_a) or for -S(=O)(A)(NR_a), R_a and A together with the attached atoms, may form a substituted or unsubstituted heterocyclyl ring;

R_2 is H, C_1-C_4 alkyl, C_3-C_7 cycloalkyl, CF_3, CFH_2 or CF_2H, and where R_2 is not H, the carbon atom attached to R_2 is a chiral center and exists as a (R)- and (S)-racemic mixture or as either the (R)- or (S)- enantiomer;

R_3 is H or C_1-C_4 alkyl;

R_4 is H, C_1-C_4 alkyl, C_3-C_7 cycloalkyl, halogen, CN, CF_3, OCF_3, CFH_2 or CF_2H;

R_6 is H, C_1-C_4 alkyl, C_3-C_7 cycloalkyl, heteroaromatic, CF_3, CFH_2 or CF_2H;

R_7 is H, C_1-C_4 alkyl, C_3-C_7 cycloalkyl, halogen, CN, CF_3, OCF_3, CFH_2 or CF_2H;

each R_8 is independently H, C_1-C_4 alkyl, C_3-C_7 cycloalkyl, halogen, CN, CF_3, OCF_3, CFH_2 or CF_2H;

each of X_1, X_2, X_3 and X_4 is independently N, CH or substituted C;

R_5 is

halogen;

-O-L_1-L_2-L_3-L_4-L_5-L_6-L_7-R_9;

-S-L_1-L_2-L_3-L_4-L_5-L_6-L_7-R_9;

-S(O)-L_1-L_2-L_3-L_5-L_6-L_7-R_9;

-$S(O)_2$-L_1-L_2-L_3-L_5-L_6-L_7-R_9;

-(NR_{10})-L_1-L_2-L_3-L_4-L_5-L_6-L_7-R_9; or

-L_8-L_9-L_{10}-L_{11}-L_{12}-R_{14},

wherein:

each of L_1, L_2, L_3, L_6 and L_7 is independently (CHR_{11}), (CHR_{11}-O), (CHR_{11}-S), (C_3-C_7 cycloalkyl), $(CH_2)_{1-4}$ or a bond;

L_4 is C=O, C=S or a bond;

L_5 is NR_{10}, S, O or a bond;

R_9 is H, C(=O)R_{12}, C(=O)$NR_{12}R_{13}$, $NR_{12}R_{13}$, C(=O)OR_{12}, C_1-C_6 alkyl, C_1-C_6 fluoroalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, where each of the C_1-C_6 alkyl, C_1-C_6 fluoroalkyl, cycloalkyl,

heterocyclyl, aryl or heteroaryl is unsubstituted or substituted; or alternatively when NR_{10} is present, R_9 and R_{10} together with the attached nitrogen atom may form a substituted or unsubstituted ring. In an exemplary embodiment, the ring is 4- to 7- membered substituted or unsubstituted non-aromatic heterocyclic ring containing (in addition to the nitrogen atom) 0, 1 or 2 heteroatoms which may be N, O, S or Si, with the proviso that if the ring size is 4 or 5, the number of additional heteroatoms will be 0 or 1 and if the ring size is from 6 to 7, the number of additional heteroatoms will be 0, 1 or 2, where if the ring is substituted, the substituents include, but are not limited to, one or more of CH_3, F, Cl, CF_3, CF_2H, CH_2F, OCH_3, cyclopropyl, CH_2CF_3, an oxetane ring, or COR_a where R_a is C_1-C_4 alkyl, O-C_1-C_4 alkyl, or NR_bR_c where R_b and R_c are independently H or C_1-C_4 alkyl;

each of R_{10} and R_{11} is independently H or C_1-C_4 alkyl (such as CH_3, CH_2CH_3 or $CH(CH_3)_2$), where the C_1-C_4 alkyl is unsubstituted or substituted;

each of R_{12} and R_{13} is independently H, C_1-C_6 alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, where each of the C_1-C_6 alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is unsubstituted or substituted; or alternatively, R_{12} and R_{13} together with the attached nitrogen atom may form a substituted or unsubstituted ring. In an exemplary embodiment, the ring is 4- to 7- membered substituted or unsubstituted non-aromatic heterocyclic ring containing (in addition to the nitrogen atom) 0, 1 or 2 heteroatoms which may be N, O, S or Si, with the proviso that if the ring size is 4 or 5, the number of additional heteroatoms will be 0 or 1 and if the ring size is from 6 to 7, the number of additional heteroatoms will be 0, 1 or 2, where if the ring is substituted, the substituents include, but are not limited to, one or more of CH_3, F, Cl, CF_3, CF_2H, CH_2F, OCH_3, cyclopropyl, CH_2CF_3, an oxetane ring, or COR_a where R_a is C_1-C_4 alkyl, O-C_1-C_4 alkyl, or NR_bR_c where R_b and R_c are independently H or C_1-C_4 alkyl;

L_8 is (CHR_{15}), (CHR_{15}-O), (CHR_{15}-S), (CHR_{15}-NR_{16}), C=O, C=S or a bond;

L_9 is C_3-C_7 cycloalkyl that is optionally part of a bridged, fused or spiro ring system, $C(R_{15})$=$C(R_{15})$, C≡C or a bond;

L_{10} is independently (CHR_{15}), O, S, (NCR_{15}), N(C=O) or a bond;

L_{11} is (CHR_{15}), C=O, C=S or a bond;

L_{12} is H, (C_3-C_7 cycloalkyl), heterocyclyl, aryl, heteroaryl or a bond, where each of the C_3-C_7 cycloalkyl, heterocyclyl, aryl or heteroaryl is unsubstituted or substituted, and the C_3-C_7 cycloalkyl and/or heterocyclyl is optionally part of a bridged, fused or spiro ring system;

R_{14} is H, $CR_{15}R_{16}R_{17}$, OR_{17}, SR_{17}, $NR_{16}R_{17}$, C_1-C_6 alkyl, C_1-C_6 fluoroalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, where each of the C_1-C_6 alkyl, C_1-C_6 fluoroalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is unsubstituted or substituted,

each of R_{15} and R_{16} is independently H or C_1-C_3 alkyl; and

each R_{17} is independently H, C_1-C_6 alkyl, C_1-C_6 fluoroalkyl, C_1-C_6 aminoalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, where each of the C_1-C_6 alkyl, C_1-C_6 fluoroalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is unsubstituted or substituted; or alternatively, R_{16} and R_{17} together with the attached nitrogen atom may form a substituted or unsubstituted ring. In an exemplary embodiment, the ring is 4- to 7- membered substituted or unsubstituted non-aromatic heterocyclic ring containing (in addition to the nitrogen atom) 0, 1 or 2 heteroatoms which may be N, O or S, with the proviso that if the ring size is 4 or 5, the number of additional heteroatoms will be 0 or 1 and if the ring size is from 6 to 7, the number of additional heteroatoms will be 0, 1 or 2, where if the ring is substituted, the substituents include, but are not limited to, one or more of Me, F, Cl, CF_3, CF_2H, CH_2F, OCH_3, cyclopropyl, CH_2CF_3, an oxetane ring, or COR_a where R_a is C_1-C_4 alkyl, O-C_1-C_4 alkyl, or NR_bR_c where R_b and R_c are independently H or C_1-C_4 alkyl;

with the proviso that when R_5 is -L_8-L_9-L_{10}-L_{11}-L_{12}-R_{14}, at least one of L_8, L_9, L_{10}, L_{11}, L_{12} and R_{14} is a carbon-containing moiety and R_5 is directly attached to the (benzopyridinone or benzopyrimidinone) core structure by a carbon atom;

or R_5 is

a non-aromatic N-linked heterocyclic ring 

, where the heterocyclic ring is substituted or unsubstituted, optionally contains one or more additional ring atoms selected from N, O, Si and S, and is optionally part of a bridged, fused or spiro ring system. In particular embodiments, the N-linked heterocyclyl ring is a substituted or unsubstituted azetidine, pyrrolidine, imidazoline, imidazolidine, piperazine, morpholine, thiomorpholine, piperidine, indoline, tetrahydroquinoline, decahydroquinoline, 2-oxa-7-azaspiro[3.5]nonane, 1, 4-dioxa-7-azaspiro[4.4]nonane or 2-azaadamantane.

[0009] In an exemplary embodiment, R_5 is -(NR_{10})-L_1-L_2-L_3-L_4-L_5-L_6-L_7-R_9, where L_1 to L_7, R_9 and R_{10} are as defined.

[00010] In an exemplary embodiment, R_5 is -O-L_1-L_2-L_3-L_4-L_5-L_6-L_7-R_9, where L_1 to L_7 and R_9 are as defined.

[0011] In an exemplary embodiment, R_5 is -S-L_1-L_2-L_3-L_4-L_5-L_6-L_7-R_9; -S(O)-L_1-L_2-L_3-L_5-L_6-L_7-R_9; or -$S(O)_2$-L_1-L_2-L_3-L_5-L_6-L_7-R_9, where L_1 to L_7 and R_9 are as defined.

[0012] In an exemplary embodiment, R_9 is a 6-membered aryl ring; or is a 5- to 6- membered heteroaryl ring containing from 1-3 nitrogen atoms; or is a non-aromatic 3- to 7- membered carbocycle; or is a non-aromatic 4- to 7- membered heterocycle containing from 1 to 3 heteroatoms selected from N, O, S and Si with the proviso that if the ring size is 4 or 5 then the number of heteroatoms will be 1 or 2 and if the ring size is 6 or 7 the number heteroatoms will be 1, 2 or 3; or is a C_1-C_6 alkyl group, where the aryl ring, the heteroaryl ring, the carbocycle, the heterocycle and the C_1-C_6 alkyl group are unsubstituted or substituted with one or more of CH_3, F, Cl, CF_3, CF_2H, CH_2F, OCH_3, -CH_2CF_3, cyclopropyl, -CN, $N(CH_3)_2$, an oxetane ring, a phenyl or phenoxy group optionally substituted with from 1 to 3 halogens (F, Cl or Br) or CH_3 groups, or COR_a where R_a is C_1-C_4alkyl, O-C_1-C_4 alkyl or NR_bR_c, where R_b and R_c are independently H or C_1-C_4 alkyl.

[0013] In an exemplary embodiment of R_5, each of L_8, L_{10} and L_{11} is a bond and L_9 is not a bond.

[0014] In an exemplary embodiment of R_5, each of L_8, L_{10} and L_{11} is a bond and L_9 is cycloalkyl that is optionally part of a bridged, fused or spiro ring system.

[0015] In an exemplary embodiment of R_5, each of L_8, L_{10} and L_{11} is a bond and L_9 is cycloalkyl that is part of a bridged ring system.

[0016] In an exemplary embodiment of R_5, each of L_8, L_{10} and L_{11} is a bond and L_9 is cycloalkyl that is part of a fused ring system.

[0017] In an exemplary embodiment of R_5, each of L_8, L_{10} and L_{11} is a bond and L_9 is cycloalkyl that is part of a spiro ring system.

[0018] In an exemplary embodiment of R_5, each of L_8, L_{10} and L_{11} is a bond and L_9 is $C(R_{15})=C(R_{15})$.

[0019] In an exemplary embodiment of R_5, each of L_8, L_{10} and L_{11} is a bond and L_9 is C≡C.

[0020] In an exemplary embodiment of R_5, each of L_8, L_9, L_{10} and L_{11} is a bond and L_{12} is cycloalkyl, heterocyclyl, aryl or heteroaryl, where each of the cycloalkyl, heterocyclyl, aryl or heteroaryl is unsubstituted or substituted.

[0021] In an exemplary embodiment of R_5, each of L_8, L_9, L_{10} and L_{11} is a bond and L_{12} is cycloalkyl, heterocyclyl, aryl or heteroaryl, where each of the cycloalkyl, heterocyclyl, aryl or heteroaryl is unsubstituted or substituted, and R_{14} is H.

[0022] In an exemplary embodiment of R_5, each of L_8, L_9, L_{10} and L_{11} is a bond and L_{12} is cycloalkyl, heterocyclyl, aryl or heteroaryl, where each of the cycloalkyl, heterocyclyl, aryl or heteroaryl is unsubstituted or substituted, and R_{14} is cycloalkyl, heterocyclyl, aryl or heteroaryl, where each of the C_1-C_6 alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is unsubstituted or substituted.


[0023] In an exemplary embodiment of R_5, each of L_8, L_9, L_{10} and L_{11} is a bond and L_{12} is cycloalkyl, heterocyclyl, aryl or heteroaryl, where each of the cycloalkyl, heterocyclyl, aryl or heteroaryl is unsubstituted or substituted, and R_{14} is $-CR_{14}R_{15}R_{16}$.

[0024] In an exemplary embodiment of R_5, each of L_8, L_9, L_{10} and L_{11} is a bond and L_{12} is cycloalkyl, heterocyclyl, aryl or heteroaryl, where each of the cycloalkyl, heterocyclyl, aryl or heteroaryl is unsubstituted or substituted, and R_{14} is $-OR_{16}$ or $-OR_{17}$.


[0025] In an exemplary embodiment of R_5, each of L_8, L_9, L_{10} and L_{11} is a bond and L_{12} is cycloalkyl, heterocyclyl, aryl or heteroaryl, where each of the cycloalkyl, heterocyclyl, aryl or heteroaryl is unsubstituted or substituted, and R_{14} is $-SR_{17}$.

[0026] In an exemplary embodiment of R_5, each of L_8, L_9, L_{10} and L_{11} is a bond and L_{12} is cycloalkyl, heterocyclyl, aryl or heteroaryl, where each of the cycloalkyl, heterocyclyl, aryl or heteroaryl is unsubstituted or substituted, and R_{14} is $-NR_{16}R_{17}$.

[0027] In an exemplary embodiment, R_5 is



where R_d is H or CH_3 and R_e is CH_3, C_3-C_6 cycloalkyl, a six-membered aromatic or heteroaromatic ring containing from 0, 1 or 2 nitrogen atoms which may be optionally substituted with CH_3, F, Cl, CF_3, CF_2H, CH_2F, OCH_3, cyclopropyl, CN or $N(CH_3)_2$, or R_d and R_e together with the attached nitrogen atom may form a 4- to 7- membered non-aromatic heterocycle containing from 1 to 2 heteroatoms which may be either N or O, with the proviso that if the ring size is 4 or 5 the number of heteroatoms will be 1 and if the ring size is from 6 to 7, the number of heteroatoms will be 1 or 2, where the ring is unsubstituted or is substituted with one or more that includes, but is not limited to, CH_3, F, Cl, CF_3, CF_2H, CH_2F, OCH_3, cyclopropyl, CH_2CF_3, an oxetane ring, or COR_a where R_a is C_1-C_4 alkyl, O-C_1-C_4 alkyl, or NR_bR_c where R_b and R_c are independently H or C_1-C_4 alkyl.

[0028] In an exemplary embodiment, R_5 is a N-linked non-aromatic heterocyclyl ring  , where the heterocyclyl ring is substituted or unsubstituted, optionally contains one or more

additional atoms selected from N, O, Si and S, and is optionally part of a bridged, fused or spiro ring system. In particular embodiments, the N-linked heterocyclyl ring is azetidine, pyrrolidine, imidazoline, imidazolidine, piperazine, morpholine, thiomorpholine, piperidine, indoline, tetrahydroquinoline, decahydroquinoline, 2-oxa-7-azaspiro[3.5]nonane, 1,3,8-triazaspiro[4.5]-decan-4-one, 1, 4-dioxa-7-azaspiro[4.4]nonane.

[0029] In an exemplary embodiment, the N-linked non-aromatic heterocyclyl ring is substituted or unsubstituted, optionally contains one or more additional atoms selected from N, O, Si and S, and is not part of a bridged, fused or spiro ring system.

[0030] In an exemplary embodiment, the N-linked non-aromatic heterocyclyl ring is substituted or unsubstituted, optionally contains one or more additional atoms selected from N, O, Si and S, and is part of a bridged, fused or spiro ring system.

[0031] In an exemplary embodiment, the N-linked non-aromatic heterocyclyl ring is substituted or unsubstituted, does not contain additional atoms selected from N, O, Si and S, and is not part of a bridged, fused or spiro ring system.

[0032] In an exemplary embodiment, the N-linked non-aromatic heterocyclyl ring is substituted or unsubstituted, does not contain additional atoms selected from N, O, Si and S, and is part of a bridged, fused or spiro ring system.

[0033] In an exemplary embodiment, the N-linked non-aromatic heterocyclyl ring is substituted or unsubstituted, contains at least one sulfur ring atom, and is not part of a bridged, fused or spiro ring system.

[0034] In an exemplary embodiment, the N-linked non-aromatic heterocyclyl ring is substituted or unsubstituted, contains at least one sulfur ring atom, and is part of a bridged, fused or spiro ring system.


[0035] In an exemplary embodiment, the N-linked non-aromatic heterocyclyl ring is substituted or unsubstituted, contains at least one oxygen ring atom, and is not part of a bridged, fused or spiro ring system.

[0036] In an exemplary embodiment, the N-linked non-aromatic heterocyclyl ring is substituted or unsubstituted, contains at least one oxygen ring atom, and is part of a bridged, fused or spiro ring system.

[0037] In an exemplary embodiment, the N-linked non-aromatic heterocyclyl ring is substituted or unsubstituted, contains at least one additional nitrogen ring atom, and is not part of a bridged, fused or spiro ring system.


[0038] In an exemplary embodiment, the N-linked non-aromatic heterocyclyl ring is substituted or unsubstituted, contains at least one additional nitrogen ring atom, and is part of a bridged, fused or spiro ring system.

[0039] In an exemplary embodiment of the compound of Formula (1), R_1 is selected from




where A and B are as defined.

[0040] In an exemplary embodiment of the compound of Formula (1), R_1 is selected from



where A, B and R_a are as defined.

[0041] In an exemplary embodiment of the compound of Formula (1), R_1 is selected from



where B is as defined.

[0042] In an exemplary embodiment of the compound of Formula (1), R_2 is CH_3.

[0043] In an exemplary embodiment of the compound of Formula (1), R_2 is CH_2F.

[0044] In an exemplary embodiment of the compound of Formula (1), R_3 is H.

[0045] In an exemplary embodiment of the compound of Formula (1), R_4 is H or F.

[0046] In an exemplary embodiment, X_1 is N, and X_2 and X_3 are independently CH or CF.

[0047] In an exemplary embodiment, X_2 is N, and X_1 and X_3 are independently CH or CF.

[0048] In an exemplary embodiment, X_3 is N, and X_1 and X_3 are independently CH or CF.

[0049] In an exemplary embodiment, X_1 and X_3 are N, and X_2 is CH or CF.

[0050] In an exemplary embodiment, X_1 and X_2 are N, and X_3 is CH or CF.

[0051] In an exemplary embodiment, X_2 and X_3 are N, and X_1 is CH or CF.

[0052] In an exemplary embodiment, X_1, X_2 and X_3 are N.

[0053] In an exemplary embodiment, X_1, X_2 and X_3 are independently CH or CF.

[0054] In an exemplary embodiment, X_4 is N.

[0055] In an exemplary embodiment, X_4 is CH or CF.

[0056] In an exemplary embodiment, X_1 is N, X_2 and X_3 are independently CH or CF, and X_4 is N.

[0057] In an exemplary embodiment, X_2 is N, X_1 and X_3 are independently CH or CF, and X_4 is N.

[0058] In an exemplary embodiment, X_3 is N, X_1 and X_3 are independently CH or CF, and X_4 is N.

[0059] In an exemplary embodiment, X_1 and X_3 are N, X_2 is CH or CF, and X_4 is N.

[0060] In an exemplary embodiment, X_1 and X_2 are N, X_3 is CH or CF, and X_4 is N.

[0061] In an exemplary embodiment, X_2 and X_3 are N, X_1 is CH or CF, and X_4 is N.

[0062] In an exemplary embodiment, X_1, X_2 and X_3 are N, and X_4 is N.

[0063] In an exemplary embodiment, X_1, X_2 and X_3 are independently CH or CF, and X_4 is N.

[0064] In an exemplary embodiment, X_1 is N, X_2 and X_3 are independently CH or CF, and X_4 is CH or CF.

[0065] In an exemplary embodiment, X_2 is N, X_1 and X_3 are independently CH or CF, and X_4 is CH or CF.

[0066] In an exemplary embodiment, X_3 is N, X_1 and X_3 are independently CH or CF, and X_4 is CH or CF.

[0067] In an exemplary embodiment, X_1 and X_3 are N, X_2 is CH or CF, and X_4 is CH or CF.

[0068] In an exemplary embodiment, X_1 and X_2 are N, X_3 is CH or CF, and X_4 is CH or CF.

[0069] In an exemplary embodiment, X_2 and X_3 are N, X_1 is CH or CF, and X_4 is CH or CF.

[0070] In an exemplary embodiment, X_1, X_2 and X_3 are N, and X_4 is CH or CF.

[0071] In an exemplary embodiment, X_1, X_2 and X_3 are independently CH or CF, and X_4 is CH or CF.

[0072] In an exemplary embodiment of the compound of Formula (1), R_5 is -O-L_1-L_2-L_3-L_4-L_5-L_6-L_7-R_9.

[0073] In an exemplary embodiment of the compound of Formula (1), R_5 is -S-L_1-L_2-L_3-L_4-L_5-L_6-L_7-R_9.

[0074] In an exemplary embodiment of the compound of Formula (1), R_5 is -S(O)-L_1-L_2-L_3-L_5-L_6-L_7-R_9.

[0075] In an exemplary embodiment of the compound of Formula (1), R_5 is -$S(O)_2$-L_1-L_2-L_3-L_5-L_6-L_7-R_9.

[0076] In an exemplary embodiment of the compound of Formula (1), R_5 is -(NR_{10})-L_1-L_2-L_3-L_4-L_5-L_6-L_7-R_9.


[0077] In an exemplary embodiment of the compound of Formula (1), R_5 is -L_8-L_9-L_{10}-L_{11}-L_{12}-R_{14}.

[0078] In an exemplary embodiment of the compound of Formula (1), R_6 is CH_3.

[0079] In an exemplary embodiment of the compound of Formula (1), R_7 is CH_3.


[0080] In an exemplary embodiment of the compound of Formula (1), each R_8 is independently H or F.

[0081] In an exemplary embodiment of the compound of Formula (1), R_2 is CH_3 or CH_2F, R_3 is H, and R_1 is selected from




where A and B are as defined.

[0082] In an exemplary embodiment of the compound of Formula (1), R_2 is CH_3 or CH_2F, R_3 is H, and R_1 is selected from




where A, B and R_a are as defined.

[0083] In an exemplary embodiment of the compound of Formula (1), R_2 is CH_3 or CH_2F, R_3 is H, and R_1 is selected from




where B is as defined.

[0084] In an exemplary embodiment of the compound of Formula (1), R_2 is CH_3 or CH_2F, R_3 is H, R_1 is selected from




where A and B are as defined, and R_5 is a N-linked heterocyclyl ring selected from azetidine, pyrrolidine, imidazoline, imidazolidine, piperazine, morpholine, thiomorpholine and piperidine, where each of these rings is unsubstituted or substituted.

[0085] In an exemplary embodiment of the compound of Formula (1), R_2 is CH_3 or CH_2F, R_3 is H, R_1 is selected from




where A, B and R_a are as defined, and R_5 is a N-linked heterocyclyl ring selected from azetidine, pyrrolidine, imidazoline, imidazolidine, piperazine, morpholine, thiomorpholine and piperidine, where each of these rings is unsubstituted or substituted.

[0086] In an exemplary embodiment of the compound of Formula (1), R_2 is CH_3 or CH_2F, R_3 is H, R_1 is selected from




where B is as defined, and R_5 is a N-linked heterocyclyl ring selected from azetidine, pyrrolidine, imidazoline, imidazolidine, piperazine, morpholine, thiomorpholine and piperidine, where each of these rings is unsubstituted or substituted.

[0087] In an exemplary embodiment of the compound of Formula (1), R_2 is CH_3 or CH_2F, R_3 is H, X_4 is N, and R_1 is selected from




where A and B are as defined.

[0088] In an exemplary embodiment of the compound of Formula (1), R_2 is CH_3 or CH_2F, R_3 is H, X_4 is N, and R_1 is selected from




where A, B and R_a are as defined.

[0089] In an exemplary embodiment of the compound of Formula (1), R_2 is CH_3 or CH_2F, R_3 is H, X_4 is N, and R_1 is selected from




where B is as defined.

[0090] In an exemplary embodiment of the compound of Formula (1), R_2 is CH_3 or CH_2F, R_3 is H, X_4 is N, R_1 is selected from




where A and B are as defined, and R_5 is a N-linked heterocyclyl ring selected from azetidine, pyrrolidine, imidazoline, imidazolidine, piperazine, morpholine, thiomorpholine and piperidine, where each of these rings is unsubstituted or substituted.

[0091] In an exemplary embodiment of the compound of Formula (1), R_2 is CH_3 or CH_2F, R_3 is H, X_4 is N, R_1 is selected from




where A, B and R_a are as defined, and R_5 is a N-linked heterocyclyl ring selected from azetidine, pyrrolidine, imidazoline, imidazolidine, piperazine, morpholine, thiomorpholine and piperidine, where each of these rings is unsubstituted or substituted.

[0092] In an exemplary embodiment of the compound of Formula (1), R_2 is CH_3 or CH_2F, R_3 is H, X_4 is N, R_1 is selected from




where B is as defined, and R_5 is a N-linked heterocyclyl ring selected from azetidine, pyrrolidine, imidazoline, imidazolidine, piperazine, morpholine, thiomorpholine and piperidine, where each of these rings is unsubstituted or substituted.

[0093] In an exemplary embodiment of the compound of Formula (1), R_2 is CH_3 or CH_2F, R_3 is H, X_4 is CH or CF, and R_1 is selected from




where A and B are as defined.

[0094] In an exemplary embodiment of the compound of Formula (1), R_2 is CH_3 or CH_2F, R_3 is H, X_4 is CH or CF, and R_1 is selected from




where A, B and R_a are as defined.

[0095] In an exemplary embodiment of the compound of Formula (1), R_2 is CH_3 or CH_2F, R_3 is H, X_4 is CH or CF, and R_1 is selected from




where B is as defined.

[0096] In an exemplary embodiment of the compound of Formula (1), R_2 is CH_3 or CH_2F, R_3 is H, X_4 is CH or CF, R_1 is selected from




where A and B are as defined, and R_5 is a N-linked heterocyclyl ring selected from azetidine, pyrrolidine, imidazoline, imidazolidine, piperazine, morpholine, thiomorpholine and piperidine, where each of these rings is unsubstituted or substituted.

[0097] In an exemplary embodiment of the compound of Formula (1), R_2 is CH_3 or CH_2F, R_3 is H, X_4 is CH or CF, R_1 is selected from




where A, B and R_a are as defined, and R_5 is a N-linked heterocyclyl ring selected from azetidine, pyrrolidine, imidazoline, imidazolidine, piperazine, morpholine, thiomorpholine and piperidine, where each of these rings is unsubstituted or substituted.

[0098] In an exemplary embodiment of the compound of Formula (1), R_2 is CH_3 or CH_2F, R_3 is H, X_4 is CH or CF, R_1 is selected from



where B is as defined, and R_5 is a N-linked heterocyclyl ring selected from azetidine, pyrrolidine, imidazoline, imidazolidine, piperazine, morpholine, thiomorpholine and piperidine, where each of these rings is unsubstituted or substituted.

[0099] In an exemplary embodiment, the compound of Formula (1) is a compound of Formula (2)



(2)


or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof,

wherein:

X_1, X_2, X_3, R_1 and R_5 are defined as in the compound of Formula (1), and

the carbon marked with * is a chiral center and exists as a (R)- and (S)-racemic mixture or as either the (R)- or (S)- enantiomer.

[00100] In an exemplary embodiment, the compound of Formula (1) is a compound of Formula (3)



(3)


or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof,

wherein:

X_1, X_2, X_3, R_1 and R_5 are defined as in the compound of Formula (1), and


the carbon marked with * is a chiral center and exists as a (R)- and (S)-racemic mixture or as either the (R)- or (S)- enantiomer.

[0101] In an exemplary embodiment of the compound of Formula (2) or Formula (3), R_1 is selected from




where A and B are defined as in the compound of Formula (1).

[0102] In an exemplary embodiment of the compound of Formula (2) or Formula (3), R_1 is selected from



where A, B and R_a are defined as in the compound of Formula (1).

[0103] In an exemplary embodiment of the compound of Formula (2) or Formula (3), R_1 is selected from



where B is defined as in the compound of Formula (1).

[0104] In an exemplary embodiment of the compound of Formula (2) or Formula (3), R_5 is -O-L_1-L_2-L_3-L_4-L_5-L_6-L_7-R_9 where -O-L_1-L_2-L_3-L_4-L_5-L_6-L_7-R_9 is defined as in the compound of Formula (1).


[0105] In an exemplary embodiment of the compound of Formula (2) or Formula (3), R_5 is -S-L_1-L_2-L_3-L_4-L_5-L_6-L_7-R_9 where -S-L_1-L_2-L_3-L_4-L_5-L_6-L_7-R_9 is defined as in the compound of Formula (1).

[0106] In an exemplary embodiment of the compound of Formula (2) or Formula (3), R_5 is -(NR_{10})-L_1-L_2-L_3-L_4-L_5-L_6-L_7-R_9 where -(NR_{10})-L_1-L_2-L_3-L_4-L_5-L_6-L_7-R_9 is defined as in the compound of Formula (1).

[0107] In an exemplary embodiment of the compound of Formula (2) or Formula (3), R_5 is -L_8-L_9-L_{10}-L_{11}-L_{12}-R_{14} where -L_8-L_9-L_{10}-L_{11}-L_{12}-R_{14} is defined as in the compound of Formula (1).


[0108] In an exemplary embodiment of the compound of Formula (2) or Formula (3), R_5 is -L_8-L_9-L_{10}-L_{11}-L_{12}-R_{14} where L_8, L_9, L_{10} and L_{11} are a bond; L_{12} is (C_3-C_7 cycloalkyl), heterocyclyl or heteroaryl, where each of the (C_3-C_7 cycloalkyl), heterocyclyl or heteroaryl is substituted or unsubstituted; and R_{14} is heterocyclyl or heteroaryl, where each of the heterocyclyl or heteroaryl is unsubstituted or substituted.

[0109] In an exemplary embodiment of the compound of Formula (2) or Formula (3), R_1 is selected from



where B is defined as in the compound of Formula (1); R_5 is -L_8-L_9-L_{10}-L_{11}-L_{12}-R_{14} where L_8, L_9, L_{10} and L_{11} are a bond; L_{12} is (C_3-C_7 cycloalkyl), heterocyclyl or heteroaryl, where each of the (C_3-C_7 cycloalkyl), heterocyclyl or heteroaryl is substituted or unsubstituted; and R_{14} is heterocyclyl or heteroaryl, where each of the heterocyclyl or heteroaryl is unsubstituted or substituted.


[0110] In an exemplary embodiment of the compound of Formula (2) or Formula (3), R_1 is selected from



where B is defined as in the compound of Formula (1); R_5 is -L_8-L_9-L_{10}-L_{11}-L_{12}-R_{14} where L_8, L_9, L_{10} and L_{11} are a bond; L_{12} is (C_3-C_7 cycloalkyl), heterocyclyl or heteroaryl, where each of the (C_3-C_7 cycloalkyl), heterocyclyl or heteroaryl is substituted or unsubstituted; R_{14} is heterocyclyl or heteroaryl, where each of the heterocyclyl or heteroaryl is unsubstituted or substituted; and one of X_1 or X_2 is N.


[0111] In an exemplary embodiment of the compound of Formula (2) or Formula (3), R_5 is -L_8-L_9-L_{10}-L_{11}-L_{12}-R_{14} where L_8, L_9, L_{10} and L_{11} are a bond; L_{12} is heterocyclyl or heteroaryl, where each of the heterocyclyl or heteroaryl is substituted or unsubstituted; and R_{14} is heterocyclyl or heteroaryl, where each of the heterocyclyl or heteroaryl is unsubstituted or substituted.

[0112] In an exemplary embodiment of the compound of Formula (2) or Formula (3), R_1 is selected from





where B is defined as in the compound of Formula (1); R_5 is -L_8-L_9-L_{10}-L_{11}-L_{12}-R_{14} where L_8, L_9, L_{10} and L_{11} are a bond; L_{12} is heterocyclyl or heteroaryl, where each of the heterocyclyl or heteroaryl is substituted or unsubstituted; and R_{14} is heterocyclyl or heteroaryl, where each of the heterocyclyl or heteroaryl is unsubstituted or substituted.

[0113] In an exemplary embodiment of the compound of Formula (2) or Formula (3), R_1 is selected from



where B is defined as in the compound of Formula (1); R_5 is -L_8-L_9-L_{10}-L_{11}-L_{12}-R_{14} where L_8, L_9, L_{10} and L_{11} are a bond; L_{12} is heterocyclyl or heteroaryl, where each of the heterocyclyl or heteroaryl is substituted or unsubstituted; R_{14} is heterocyclyl or heteroaryl, where each of the heterocyclyl or heteroaryl is unsubstituted or substituted; and one of X_1 or X_2 is N.

[0114] In an exemplary embodiment of the compound of Formula (2) or Formula (3), R_5 is a N-linked non-aromatic heterocyclyl ring  , where  is defined as in the compound of Formula (1).

[0115] In an exemplary embodiment of the compound of Formula (2) or Formula (3), X_1 is N, and X_2 and X_3 are independently CH or CF.

[0116] In an exemplary embodiment of the compound of Formula (2) or Formula (3), X_2 is N, and X_1 and X_3 are independently CH or CF.

[0117] In an exemplary embodiment of the compound of Formula (2) or Formula (3), X_3 is N, and X_1 and X_3 are independently CH or CF.

[0118] In an exemplary embodiment of the compound of Formula (2) or Formula (3), X_1 and X_3 are N, and X_2 is CH or CF.

[0119] In an exemplary embodiment of the compound of Formula (2) or Formula (3), X_1 and X_2 are N, and X_3 is CH or CF.

[0120] In an exemplary embodiment of the compound of Formula (2) or Formula (3), X_2 and X_3 are N, and X_1 is CH or CF.

[0121] In an exemplary embodiment of the compound of Formula (2) or Formula (3), X_1, X_2 and X_3 are N.

[0122] In an exemplary embodiment of the compound of Formula (2) or Formula (3), X_1, X_2 and X_3 are independently CH or CF.

[0123] An aspect of the invention is a pharmaceutical composition comprising any compound of the invention as described herein (such as any one of Formula (1), (2) or (3)) or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0124] In an exemplary embodiment, the pharmaceutical composition comprising any compound of the invention as described herein (such as any one of Formula (1), (2) or (3)) or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound thereof, or a pharmaceutically acceptable salt thereof further comprises one or more anti-cancer agents.

[0125] Another aspect of the invention is a method of treating a disease in which PI3K activity is implicated in a subject in need of such treatment, the method comprising administering to the subject a therapeutically effective amount of any compound of the invention as described herein (such as any one of Formula (1), (2), or (3)) or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound thereof, or a pharmaceutically acceptable salt thereof.

[0126] In an exemplary embodiment, the disease to be treated is cancer. In a particular embodiment, the disease is a cancer bearing a PI3Kα H1047 mutation (such as H1047R).

DETAILED DESCRIPTION OF THE INVENTION

[0127] The term "at risk for" as used herein, refers to a medical condition or set of medical conditions exhibited by a patient which may predispose the patient to a particular disease or affliction. For example, these conditions may result from influences that include, but are not limited to, behavioral, emotional, chemical, biochemical, or environmental influences.

[0128] The term "effective amount" as used herein, refers to a particular amount of a pharmaceutical composition comprising a therapeutic agent that achieves a clinically beneficial result (*i.e.*, for example, a reduction of symptoms). Toxicity and therapeutic efficacy of such compositions can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, for determining the LD_{50} (the dose lethal to 50% of the population) and the ED_{50} (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, which can be expressed as the ratio LD_{50}/ ED_{50}. Compounds that exhibit large therapeutic indices are preferred. The data obtained from these cell culture assays and additional animal studies can be used in formulating a range of dosages for human use. The dosages of such compounds lie preferably within a range of circulating concentrations that include the ED_{50} with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

[0129] The term "symptom" as used herein, refers to any subjective or objective evidence of disease or physical disturbance observed by the patient. For example, subjective evidence is usually based upon patient self-reporting and may include, but is not limited to, pain, headache, visual disturbances, nausea and/or vomiting. Alternatively, objective evidence is usually a result of medical testing including, but not limited to, body temperature, complete blood count, lipid panels, thyroid panels, blood pressure, heart rate, electrocardiogram, tissue body imaging scans and other medical testing results.

[0130] The term "disease" as used herein, refers to any impairment of the normal state of the living animal or one of its parts that interrupts or modifies the performance of the vital functions. Typically manifested by distinguishing signs and symptoms, a disease is usually a response to i) environmental factors (such as malnutrition, industrial hazards, or climate); ii) specific infective agents (such as worms, bacteria, or viruses); iii) inherent defects of the organism (such as genetic anomalies); and/or iv) combinations of these factors.

[0131] The terms "reduce", "inhibit", "diminish", "suppress", "decrease", "prevent" and grammatical equivalents thereof (including "lower", "smaller", *etc.*) when used in reference to the expression of any symptom in an untreated subject relative to a treated subject, indicate that the quantity and/or magnitude of the symptoms in the treated subject is lower than in the untreated subject by any amount that is recognized as clinically relevant by any medically trained personnel. In one embodiment, the quantity and/or magnitude of the symptoms in the treated subject is at least 10% lower than, at least 25% lower than, at least 50% lower than, at

least 75% lower than, and/or at least 90% lower than the quantity and/or magnitude of the symptoms in the untreated subject.

[0132] The term "inhibitory compound" as used herein, refers to any compound capable of interacting with (*i.e.*, for example, attaching, binding, *etc.*) to a binding partner under conditions such that the binding partner becomes unresponsive to its natural ligands. Inhibitory compounds may include, but are not limited to, small organic molecules, antibodies, and proteins/peptides.

[0133] The term "attached" as used herein, refers to any interaction between a medium (or carrier) and a drug. Attachment may be reversible or irreversible. Such attachment includes, but is not limited to, covalent bonding, ionic bonding, Van der Waals forces or friction, and the like. A drug is attached to a medium (or carrier) if it is impregnated, incorporated, coated, in suspension with, in solution with, mixed with, *etc*.

[0134] The term "drug" or "compound" as used herein, refers to any pharmacologically active substance capable of being administered which achieves a desired effect. Drugs or compounds can be synthetic or naturally occurring, non-peptide, proteins or peptides, oligonucleotides or nucleotides, polysaccharides, or sugars.

[0135] The term "administered" or "administering" as used herein, refers to any method of providing a composition to a patient such that the composition has its intended effect on the patient. An exemplary method of administering is by a direct mechanism such as, local tissue administration (*i.e.*, for example, extravascular administration, such as subcutaneous, intramuscular, or intraperitoneal), intravenous, oral ingestion, transdermal patch, topical, inhalation, suppository, etc.

[0136] The term "patient" as used herein, is a human or animal and needs not be hospitalized. For example, out-patients and persons in nursing homes are "patients." A patient may be a human or non-human animal of any age and therefore includes both adults and juveniles (*i.e.*, children). It is not intended that the term "patient" connote a need for medical treatment. Therefore, a patient may voluntarily be subject to experimentation, whether clinical or in support of basic science studies.

[0137] The term “subject” as used herein, refers to, but is not limited to, humans (e.g., a male or female of any age group, e.g., a pediatric subject (e.g., infant, child, adolescent) or adult subject (e.g., young adult, middle-aged adult or senior adult)) and/or other primates (e.g., monkeys); non-human mammals, such as cows, pigs, horses, sheep, mice, goats, cats, dogs; and/or birds, such as chickens, ducks and/or geese.

[0138] The term "affinity" as used herein, refers to any attractive force between substances or particles that causes them to enter into and remain in chemical combination. For example, an inhibitor compound that has a high affinity for a receptor will provide greater efficacy in preventing the receptor from interacting with its natural ligands, than an inhibitor with a low affinity.

[0139] The term "derived from" as used herein, refers to the source of a compound or sequence. In one respect, a compound or sequence may be derived from an organism or particular species. In another respect, a compound or sequence may be derived from a larger complex or sequence.

[0140] The term "test compound" as used herein, refers to any compound or molecule considered a candidate as an inhibitory compound.

[0141] The term "combination therapy" as used herein refers to refers to a dosing regimen of two or more different therapeutically active agents during a period of time, wherein the therapeutically active agents are administered together or separately. In one embodiment the combination therapy is a non-fixed combination.

[0142] The term "non-fixed combination" as used herein refers to two or more different therapeutic agents that are formulated as separate compositions or dosages such that they may be administered separately to a subject in need thereof either simultaneously or sequentially with variable intervening time limits.

[0143] The term "synergy" or "synergistic" as used herein refers to the phenomenon where the combination of two therapeutic agents of a combination therapy is greater in terms of measured results than the sum of the effect of each agent when administered alone.

[0144] The term "*in vivo*" as used herein refers to an event that takes place in a subject's body.

[0145] The term "*in vitro*" as used herein refers to an event that takes places outside of a subject's body.

[0146] The term "protein" as used herein, refers to any of numerous naturally occurring extremely complex substances (such as an enzyme or antibody) that contain amino acid residues joined by peptide bonds, and which include carbon, hydrogen, nitrogen, oxygen, and typically sulfur. In general, a protein comprises amino acids having an order of magnitude within the hundreds.

[0147] The term "peptide" as used herein, refers to any of various amides that are derived from two or more amino acids by combination of the amino group of one acid with the carboxyl group of another and are usually obtained by partial hydrolysis of proteins. In general, a peptide comprises amino acids having an order of magnitude with the tens.

[0148] The term "pharmaceutically acceptable" or "pharmacologically acceptable" as used herein, refers to molecular entities and compositions that do not produce adverse, allergic, or other untoward reactions when administered to an animal or a human.

[0149] The term, "pharmaceutically acceptable carrier" as used herein, includes any and all solvents, or a dispersion medium including, but not limited to, water, ethanol, a polyol (such as, for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, vegetable oils, coatings, isotonic and absorption delaying agents, liposome, commercially available cleansers, and the like. Supplementary bioactive ingredients also can be incorporated into such carriers.

[0150] The term "pharmaceutically acceptable salt" as used herein, refers to a salt that does not adversely impact the biological activity and properties of the compound and is suitable for use in contact with the tissues of subjects without undue toxicity, irritation and/or allergic response and the like. Pharmaceutically acceptable salts include those derived from suitable inorganic acids, organic acids and bases, and include hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, nitric acid, acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, malonic acid, ascorbic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, benzoic acid, naphthalene sulfonic acid, lactic acid, succinic acid, oxalic acid, stearic acid, and the like. In some instances, pharmaceutically acceptable salts are obtained by reacting a compound having acidic group described herein with a base to form a salt such as an ammonium salt, an alkali metal salt (*e.g.*, a sodium or a potassium salt), an alkaline earth metal salt (*e.g.*, a calcium or a magnesium salt), a salt formed from an organic base, and an amino acid salt. Pharmaceutically acceptable salts derived from appropriate bases include alkali metals, alkaline earth metals, and ammonium and quaternary ammonium compounds. Specific metals include, but are not limited to, sodium, lithium, potassium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like. Organic bases from which salts may be prepared include, for example, primary, secondary, and tertiary amines.

[0151] The term "prodrug" as used herein, refers to a compound that is transformed *in vivo* to yield a disclosed compound or a pharmaceutically acceptable form of the compound. A prodrug may be inactive when administered to a subject, but is converted *in vivo* to an active compound. In various instances, a prodrug has improved physicochemical properties (such as bioavailability) and/or delivery properties over the parent compound. Prodrugs are typically designed to enhance pharmaceutically and/or pharmacokinetically based properties associated with the parent compound. The prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in subject. Prodrugs include compounds wherein a hydroxy,

amino, or mercapto group is bonded to any group that, when the prodrug is administered to a subject, cleaves to form a free hydroxy, free amino, or free mercapto group, respectively. Prodrugs are well known to be prepared from carboxylic acids in the form of, for example, carboxylate esters or thioesters.

[0152] The term, "purified" or "isolated" as used herein, may refer to a composition (such as, for example, a peptide composition) that has been subjected to treatment (*e.g.*, fractionation) to remove various other components, and which composition substantially retains its expressed biological activity.

[0153] The term "sample" as used herein, includes, for example, environmental and biological samples. Environmental samples include material from the environment such as soil and water. Biological samples include animal (*e.g.*, human), fluids (*e.g.*, blood, plasma, and serum), solids (*e.g.*, stool), tissue, liquid foods (*e.g.*, milk), and solid foods (*e.g.*, vegetables). For example, a pulmonary sample may be collected by bronchoalveolar lavage (BAL) which comprises fluid and cells derived from lung tissues. A biological sample may comprise a cell, tissue extract, body fluid, chromosomes or extrachromosomal elements isolated from a cell, genomic DNA (in solution or bound to a solid support such as for Southern blot analysis), RNA (in solution or bound to a solid support such as for Northern blot analysis), cDNA (in solution or bound to a solid support) and the like.

[0154] The term "biologically active" as used herein, refers to any molecule having structural, regulatory or biochemical functions. For example, biological activity may be determined, for example, by restoration of wild-type growth in cells lacking protein activity. Cells lacking protein activity may be produced by many methods (i.e., for example, point mutation and frame-shift mutation). Complementation is achieved by transfecting cells which lack protein activity with an expression vector which expresses the protein, a derivative thereof, or a portion thereof.

[0155] The term "label" or "detectable label" as used herein, refers to any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means. Such labels include biotin for staining with labeled streptavidin conjugate, magnetic beads (*e.g.*, Dynabeads®), fluorescent dyes (*e.g.*, fluorescein, Texas Red®, rhodamine, green fluorescent protein, and the like), radiolabels (*e.g.*, ^{3}H, ^{125}I, ^{35}S, ^{14}C, or ^{32}P), enzymes (*e.g.*, horse radish peroxidase, alkaline phosphatase and others commonly used in an ELISA), and calorimetric labels such as colloidal gold or colored glass or plastic (*e.g.*, polystyrene, polypropylene, latex, etc.) beads. Patents teaching the use of such labels include, but are not limited to, U.S. Patent Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149;

and 4,366,241 (all herein incorporated by reference in their entireties). The labels contemplated in the present invention may be detected by conventional methods. For example, radiolabels may be detected using photographic film or scintillation counters, fluorescent markers may be detected using a photodetector to detect emitted light. Enzymatic labels are typically detected by providing the enzyme with a substrate and detecting, the reaction product produced by the action of the enzyme on the substrate, and calorimetric labels are detected by simply visualizing the colored label.

[0156] The term "conjugate" as used herein, refers to any compound that has been formed by the joining of two or more moieties.

[0157] A "moiety" or "group" as used herein, is any type of molecular arrangement designated by formula, chemical name, or structure. Within the context of certain embodiments, a conjugate comprises one or more moieties or chemical groups. This means that the formula of the moiety is substituted at some position in order to be joined and be a part of the molecular arrangement of the conjugate. Although moieties may be directly covalently joined, it is not intended that the joining of two or more moieties must be directly to each other. A linking group, a crosslinking group, or a joining group refers to any molecular arrangement that will connect moieties by covalent bonds such as, but not limited to, one or more amide group(s). Additionally, although the conjugate may be unsubstituted, the conjugate may have a variety of additional substituents connected to the linking groups and/or connected to the moieties.

[0158] A "polymer" or "polymer group" as used herein, refers to a chemical species or group composed of repeatedly linked moieties. Within certain embodiments, it is preferred that the number of repeating moieties is 3 or more or greater than 10. The linked moieties may be identical in structure or may vary in their moiety structures. A "monomeric polymer" or "homopolymer" is a polymer that contains the same repeating, asymmetric subunit. A "copolymer" is a polymer derived from two or more types of monomeric species (*i.e.*, two or more different chemical asymmetric subunits). "Block copolymers" are polymers comprised of two or more species of polymer subunits linked by covalent bonds.

[0159] The term "substituted" as used herein, refers to at least one hydrogen atom of a molecular arrangement that is replaced with a substituent. The number of substituents present depends on the number of hydrogen atoms available for replacement and includes replacement of more than one hydrogen atom bound to a single atom (such as in the case of a carbon atom or a silicon atom which may be available for mono-, di- or tri-substitution or in the case of a nitrogen atom which may be available for mono-, di- or tri-substitution or in the case of an oxygen atom

or a sulfur atom which may be available for mono-substitution). In the case of an oxo substituent ("=O"), two hydrogen atoms are replaced (which provides, for example, -(CH_2)-C(=O)-CH_3 as a substituent when the two hydrogen atoms of the middle carbon atom of -CH_2-CH_2-CH_3 are replaced). When substituted, one or more of the groups below are "substituents." Substituents include, but are not limited to, halogen (*e.g.*, F, Cl, Br, I), hydroxy (OH), hydroxyalkyl (*e.g.*, CH_2-OH, $CH(CH_3)OH$, $C(CH_3)_2OH$), oxo, cyano (CN), cyanoalkyl (*e.g.*, CH_2-CN, $CH(CH_3)CN$, $C(CH_3)_2CN$), nitro (NO_2), amino, alkylamino, dialkylamino, branched or unbranched alkyl (*e.g.*, methyl, ethyl, propyl, isopropyl, sec-butyl, *etc.*), cycloalkyl (*e.g.*, cyclopropyl), fluoroalkyl (*e.g.*, CF_3, CF_2H, CH_2F, CH_2CF_3, CH_2CF_2H, $CHFCHF_2$, CF_2CH_2F, CF_2CF_3, CF_2CH_3, $CF(CH_3)_2$, $CH_2CH_2CF_3$, $CF_2CH_2CF_3$, $CF_2CF_2CF_3$, *etc.*) or more generally, haloalkyl (*e.g.*, CH_2Cl, $CH(CH_3)Br$, *etc.*), O-alkyl (alkoxy) (*e.g.*, OCH_3, OCH_2CH_3, $OCH(CH_3)_2$, *etc.*), O-cycloalkyl (*e.g.*, O-cyclopropyl), O-haloalkyl (*e.g.*, OCF_2H, $OCFH_2$, OCF_3, OCH_2CF_3, OCH_2CF_2H, $OCHFCHF_2$, OCF_2CH_2F, OCF_2CF_3, OCF_2CH_3, $OCF(CH_3)_2$, $OCH_2CH_2CF_3$, $OCF_2CH_2CF_3$, $OCF_2CF_2CF_3$ or OCH_2Cl), O-aryl (e.g., O-phenyl), O-heteroaryl, O-heterocyclyl, $(CH_2)_{1-3}$-cycloalkyl, $(CH_2)_{1-3}$-haloalkyl, $(CH_2)_{1-3}$-heterocyclyl, $(CH_2)_{1-3}$-aryl, $(CH_2)_{1-3}$-heteroaryl, thioalkyl (*e.g.*, S-CH_3), hydroxyalkyl (*e.g.*, CH_2OH), alkyl ether (*e.g.*, CH_2OCH_3), alkynyl (e.g., -C≡CR_f), alkenyl (e.g., -CR_f=CR_fR_g), aryl (*e.g.*, phenyl), arylalkyl (*e.g.*, CH_2Ph), heteroaryl (*e.g.*, pyridyl or any 5- or 6- membered heteroaryl ring), heteroarylalkyl (*e.g.*, CH_2-pyridine), heterocyclyl, heterocycloalkyl and as well as, -NR_fR_g, -$NR_fC(=O)R_g$, -$NR_fC(=O)NR_fNR_g$, -NR_f-C(=O)$OR_fSO_2R_g$, -C(=O)R_f, -C(=O)OR_f, -C(=O)$(CH_2)_{1-3}R_f$, -C(=O)O$(CH_2)_{1-3}R_f$, -C(=O)$(CH(CH_3))(CH_2)_{0-3}R_f$, -C(=O)O$(CH(CH_3))(CH_2)_{0-3}R_f$, -C(=O)$(C(CH_3)_2)(CH_2)_{0-3}R_f$, -C(=O)O$(C(CH_3)_2)(CH_2)_{0-3}R_f$, -$OR_f$, -C(=O)$NR_fR_g$, -OC(=O)$NR_fR_g$, -$SR_f$, -$SOR_f$, -$S(=O)_2R_f$, -$OS(=O)_2R_f$, -S(=O)$OR_f$, and P(O)$R_fR_g$, where each R_f and R_g may be the same or different and are independently, hydrogen, alkyl (*e.g.*, CH_3), substituted alkyl, cycloalkyl, substituted cycloalkyl, haloalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocyclyl, substituted heterocyclyl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl or substituted heteroaryl. In addition, the above substituents may be further substituted with one or more of the above substituents, such that the substituent may constitute, for example, a substituted alkyl, a substituted aryl, a substituted heteroaryl, a substituted arylalkyl, a substituted heterocyclyl, or a substituted heterocycloalkyl.

[0160] The term "unsubstituted" as used herein, refers to any compound that does not contain extra substituents attached to the compound. An unsubstituted compound refers to the chemical makeup of the compound without extra substituents (*e.g.*, no non-hydrogen substituents). For example, unsubstituted proline is a proline amino acid even though the amino group of proline may be considered as disubstituted with alkyl groups.

[0161] The term “bond” as used herein in describing a substituent with atoms on both sides, refers to the absence of that substituent. For example, in the 4-atom sequence A-B-C-D, when B and C are both listed as being bonds, the result is the 2-atom sequence A-D. If only B is listed as being a bond, the result is the 3-atom sequence A-C-D.

[0162] The term "alkyl" as used herein, refers to any straight chain or branched, non-cyclic or cyclic, unsaturated or saturated aliphatic hydrocarbon containing from 1 to 10 carbon atoms, while the term "lower alkyl" has the same meaning as alkyl but contains from 1 to 3 carbon atoms. The term "higher alkyl" has the same meaning as alkyl but contains from 4 to 10 carbon atoms. Representative saturated straight chain alkyls include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, and the like, while saturated branched alkyls include, but are not limited to, isopropyl, sec-butyl, isobutyl, tert-butyl, isopentyl, and the like. As used herein, a methyl substituent may be depicted as “CH_3” or “Me” or as a terminal bond with no indication of specific atoms.

[0163] The term "cycloalkyl" as used herein, refers to saturated and unsaturated cyclic alkyls. Representative saturated cyclic alkyls include, but are not limited to, C_3-C_{14} (such as C_3-C_7) cycloalkyls, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclododecyl, and the like; while unsaturated cyclic alkyls include, but are not limited to, cyclobutenyl, cyclopentenyl and cyclohexenyl, cyclohexadiene, and the like. Cyclic alkyls are also referred to herein as "homocycles" or "homocyclic rings".

[0164] The term "bicyclic compounds" as used herein, encompasses "bridged" compounds, "fused" compounds and "spiro" compounds as described.

[0165] The term "spiro" or "spirocyclic" as used herein, refers to chemical structures having at least two rings sharing one common atom. The rings may be cycloalkyl, heterocyclyl or a combination thereof, and may include one or more aryl or heteroaryl rings. Exemplary embodiments include 1,4-dioxaspiro[4.5]decane, oxa-azaspiro[3.4]octane, diazaspiro[3.4]octane, diazaspiro[2.5]octane, spirocyclic azetidines and spirocyclic pyrrolidines and spirocyclic piperidines, where the other ring is cycloalkyl (*e.g.*, cyclobutane, cyclopentane or cyclohexane) or heterocyclyl (*e.g.*, piperidine, tetrahydropyran, tetrahydrofuran, azetidine or pyrrolidine).

[0166] The term "bridged" as used herein, refers to a compound containing two nonadjacent atoms common to two rings. Exemplary embodiments include, but are not limited to, norbornane, bicyclo[1.1.1]pentane, bicyclo[2.2.1]heptane, azabicyclo[3.1.0]hexane, 3,9-diazabicyclo[3.3.1]nonane, diazabicyclo[3.1.1]heptane, diazabicyclo[3.2.1]octane, 1,4-

azabicyclo[2.2.1]heptane, 1,4 azabicyclo[2.2.2]octane, 1,4-diazabicyclo[2.2.1]heptane, 1,4-diazabicyclo[2.2.2]octane, and other bridged piperazines and bridged piperidines.

[0167] The term “fused” as used herein, refers to polycyclic ring systems in which any two adjacent rings have two, and only two, adjacent atoms in common (ortho-fused) and polycyclic ring systems in which a ring contains two, and only two, adjacent atoms in common with each of two or more rings of a contiguous series of ortho-fused rings (ortho- and peri-fused). An exemplary embodiment is pentalene and dibenzoxepine (ortho-fused) and pyrene (ortho- and peri-fused). Ortho-fused systems have “n” common sides and “2n” common atoms while peri-fused systems have “n” common sides and less than “2n” atoms in common. Other exemplary fused systems include fused cyclopropyl rings, fused aziridines and fused azetidines, such as when these rings are fused to a pyrrolidine ring. Other examples include fused pyrrolidine rings (*e.g,* octahydropyrrolo[3,4-c]pyrrole and octahydrocyclopenta[c]pyrrole), fused pyridine rings, such as a pyridine ring fused with a cycloalkyl (*e.g.*, cyclopentane) or with a heterocyclyl (*e.g.*, tetrahydrofuran or tetrahydropyran), or other fused heteroaromatic rings (*e.g.,* dihydro-5H-pyrazolo[5,1-b][1,3]oxazine and 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine).

[0168] The term "aromatic" or "aryl" as used herein, refers to any aromatic carbocyclic (*i.e.*, all of the ring atoms are carbon) substituent such as, but not limited to, phenyl (from benzene), tolyl (from toluene), xylyl (from xylene) or multi-ring systems (e.g., naphthyl (from naphthalene) and anthracenyl (from anthracene).

[0169] The term "arylalkyl" or “aralkyl” as used herein, refers to any alkyl having at least one alkyl hydrogen atom replaced with an aryl moiety such as, but not limited to, benzyl, -$(CH_2)_2$phenyl, -$(CH_2)_3$phenyl, -CH$(phenyl)_2$, and the like.

[0170] The term "halogen" as used herein, refers to any fluoro, chloro, bromo, or iodo moiety.

[0171] The term "haloalkyl" as used herein, refers to any alkyl where at least one hydrogen atom (and including all hydrogen atoms) has been replaced with a halogen atom, such as, for example, trifluoromethyl, dichloromethyl, difluoromethyl, monofluoromethyl, monobromomethyl, 1,1,1-trifluoroethyl and the like.

[0172] The term "aminoalkyl" as used herein, refers to any alkyl where at least one hydrogen atom has been replaced with a nitrogen atom, such as, for example, -$(CH_2)_{1\text{-}5}$-NH_2, -$(CH_2)_{1\text{-}5}$-$NHCH_3$, -$(CH_2)_{1\text{-}5}$-$N(CH_3)_2$, -$(CH_2)_{1\text{-}5}$-NH-$(CH_2)_{1\text{-}5}$-$N(CH_3)_2$, and the like.

[0173] The term "heteroaromatic" or "heteroaryl" as used herein, refers to any aromatic heterocyclic ring of 5 to 10 or more members and having at least one heteroatom selected from

nitrogen, oxygen or sulfur, and containing at least 1 carbon atom, including, but not limited to, both mono- and bicyclic- ring systems, and where the nitrogen atom may be in an oxidized state. The heteroaryl ring may be attached as a substituent via a ring heteroatom or a carbon atom. Representative heteroaromatics include, but are not limited to, furan, benzofuran, thiophene, benzothiophene, pyrrole, indole, isoindole, indazole, 7-azaindole, 4-azaindole, 5-azaindole, 6-azaindole, 7-azaindazole, pyridine, pyridone (*e.g.*, 2-pyridone, 3-pyridone or 4-pyridone), pyrimidinone, oxopyrazine, pyridine oxide, quinoline, isoquinoline, oxazole, isoxazole, benzoxazole, pyrazole, imidazole, imidazopyrimidine, benzimidazole, thiazole, benzothiazole, isothiazole, 1,2,4-triazole, 1,2,3-triazole, tetrazole, oxadiazole (*e.g.*, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole), thiadiazole (*e.g.*, 1,2,3-thiadiazole, 1,2,4-thiadiazole, 1,2,5-thiadiazole, 1,3,4-thiadiazole), pyridazine, pyrimidine, pyrazine, 1,2,4-triazine, 1,3,5-triazine, triazolopyrazine, cinnoline, phthalazine, quinazoline, 1,8-naphthylpyridine, pyrido[3,2-d]pyrimidine, pyrido[4,3-d]pyrimidine, pyrido[3,4-b]pyrazine, pyrido[2,3-b]pyrazine, pteridine, triazolopyridines (*e.g.*, [1,2,4]triazolo[4,3-a]pyridine) and the like.

[0174] The term "heteroarylalkyl" as used herein, means any alkyl having at least one alkyl hydrogen atom replaced with a heteroaryl moiety, such as -CH_2pyridinyl, -CH_2pyrimidinyl, and the like.

[0175] The term "heterocycle" or “heterocyclyl” or "heterocyclic ring" as used herein, refers to a nonaromatic ring which is either saturated or unsaturated and which contains 1 or more heteroatoms independently selected from nitrogen, oxygen, sulfur, phosphorus and silicon, wherein each of the nitrogen, phosphorus and sulfur heteroatoms may be in an oxidized state, and each of the nitrogen and silicon heteroatoms is substituted or unsubstituted and the nitrogen heteroatoms may be optionally quaternized, and includes bicyclic rings in which any of the above heterocycles are fused to an aryl or heteroaryl ring. The heterocyclic ring may be attached as a substituent via a ring heteroatom or a carbon atom. In various embodiments, heterocycles may contain 3 to 14 or more ring atoms (such as 3- to 7-membered monocyclic rings or 7- to 10-membered bicyclic rings) and include, but are not limited to, 2H-azirine, azetidine, 2,3-dihydroazete, 1,3-diazetidine, 2H-oxete, thietane, 2H-thiete, azetidin-2-one, morpholine, thiomorpholine, pyrrolidinone, pyrrolidinine, 2-pyrroline, 3-pyrroline, pyrazolidine, 2-pyrazoline, pyridazinone, pyrazinone, oxazolidin-2-one, 2-imidazoline, imidazolidine, piperidine, oxopiperidine, tetrahydropyrimidinone, piperazine, oxopiperazine, diazepane, ethylene oxide (oxirane), ethylene imine (aziridine), 1,1-dioxoisothiazolidine, ethylene sulfide (thiirane), oxetane, propylene oxide, 1,3-dioxolane, 1,2-oxathiolane, 1,3-oxathiolane, sulfolane, 2,4-thiazolidinedione, succinimide, 4-methyl-1,4-azaphosphinane 4-oxide, oxadiazolone, dioxane

(e.g. 1,4-dioxane and 1,3-dioxane), hydantoin, valerolactam, tetrahydrofuran, tetrahydropyran, 2H-pyran, 4H-pyran, thiane, 2H-thiopyran, 1,3-dithiane, 1,4-dithiane, 1,3,5-trithiane, pyrrolizidine, 1,4,5,6-tetrahydrocyclopenta[b]pyrrole, tetrahydropyridine, tetrahydropyrimidine, dihydropyridazine, 6-oxo-1,6-dihydropyridazine, 6-oxo-1,4-dihydropyridazine, 6-oxo-1,6-dihydropyrazine, 6-oxo-1,4-dihydropyrazine, tetrahydrothiophene, tetrahydrothiopyran, tetrahydrotriazolopyrazine, tetrahydropyrazolopyridine, dihydrotriazolopyrazine, dihydropyrazolopyrazine, dihydroimidazopyrazine, indoline, isoindoline, decahydroisoquinoline, decahydroquinoline, 1,2,3,4-tetrahydroquinoline, 1,2-dihydroquinoline, 2H-benzo[e][1,3]oxazine, 2H-benzo[b][1,4]oxazine, quinolin-2(1H)-one, isoquinolin-1(2H)-one, quinuclidine, triethylenediamine, 1-azaadamantane, 2-azaadamantane, 2,3-dihydroazepine, 2,5-dihydroazepine, oxepane, azonane, spiro[cyclobutane-1,3'-indole], 1-oxaspiro[4,5]decane, 1,6-dioxaspiro[3,4]octane, 2-oxa-7-azaspiro[3,5]nonane, 1,4-dioxa-7-azaspiro[4,4]nonane, 1,3-diazaspiro[4,4]non-2-en-4-one, 2,9-diazaspiro[5,5]undecan-1-one, oxa-diazabicyclo[3.3.1]nonane, 8-azaspiro[4,5]decane-7,9-dione, 1,4-dithia-7-azaspiro[4,4]nonane, and the like.

[0176] The term "heterocycloalkyl" as used herein, refers to any alkyl having at least one alkyl hydrogen atom replaced with a heterocycle, such as -CH_2morpholinyl, and the like.

[0177] The term "alkylamino" as used herein, means at least one alkyl moiety attached through a nitrogen bridge (*i.e.*, -N-(alkyl)$_n$, where n = 1 or 2, such as alkylamino or dialkylamino) including, but not limited to, methylamino, ethylamino, dimethylamino, diethylamino, and the like.

[0178] The term "alkyloxy" or "alkoxy", as used herein, means any alkyl moiety attached through an oxygen bridge (*i.e.*, -O-alkyl) such as, but not limited to, methoxy, ethoxy, and the like.

[0179] The term "thioalkyl" as used herein, means any alkyl moiety attached through a sulfur bridge (*i.e.*, -S-alkyl) such as, but not limited to, methylthio, ethylthio, and the like.

[0180] The term "alkenyl" as used herein, refers to an unbranched or branched hydrocarbon chain having one or more carbon-carbon double bonds therein and may also be referred to as an "unsaturated alkyl". The double bond of an alkenyl group can be unconjugated or conjugated to another unsaturated group. Suitable alkenyl groups include, but are not limited to vinyl, allyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, hexadienyl, 2-ethylhexenyl, 2-propyl-2-butenyl, 4-(2-methyl-3-butene)-pentenyl. An alkenyl group can be unsubstituted or substituted with one or two suitable substituents.

[0181] The term "alkynyl" as used herein, refers to unbranched or branched hydrocarbon chain having one or more carbon-carbon triple bonds therein and may also be referred to as an

"unsaturated alkyl". The triple bond of an alkynyl group can be unconjugated or conjugated to another unsaturated group. Suitable alkynyl groups include, but are not limited to ethynyl, propynyl, butynyl, pentynyl, hexynyl, methylpropynyl, 4-methyl-1-butynyl, 4-propyl-2-pentynyl-, and 4-butyl-2-hexynyl. An alkynyl group can be unsubstituted or substituted with one or two suitable substituents.

[0182] As used herein, “reactive groups” refer to nucleophiles, electrophiles, or radically active groups, *i.e.*, groups that react in the presence of radicals. A nucleophile is a moiety that forms a chemical bond to its reaction partner (the electrophile) by donating both bonding electrons. Electrophiles accept these electrons. Nucleophiles may take part in nucleophilic substitution, whereby a nucleophile becomes attracted to a full or partial positive charge on an element and displaces the group it is bonded to. Alternatively, nucleophiles may take part in substitution of carbonyl group. Carboxylic acids are often made electrophilic by creating succinyl esters and reacting these esters with aminoalkyls to form amides. Other common nucleophilic groups are thiolalkyls, hydroxylalkyls, primary and secondary amines, and carbon nucleophiles such as enols and alkyl metal complexes. Other preferred methods of ligating proteins, oligosaccharides and cells using reactive groups are disclosed (Lemieux *et al.*, Trends in Biotechnology **1998**, 16, 506, incorporated herein by reference in its entirety). In yet another preferred method, one provides reactive groups for the Staudinger ligation, *i.e.*, "click chemistry" with an azide comprising moiety and alkynyl reactive groups to form triazoles. Michael additions of a carbon nucleophile enolate with an electrophilic carbonyl, or the Schiff base formation of a nucleophilic primary or secondary amine with an aldehyde or ketone may also be utilized. Other methods of bioconjugation are provided (Hang *et al.* Accounts of Chemical Research **2001**, 34, 727, and Kiick *et al.* Proc Natl Acad Sci US.A. **2002**, 99, 19, both of which are incorporated by reference in its entirety).

[0183] The term "biocompatible" as used herein, refers to any material that does not illicit a substantial detrimental response in the host. There is always concern when a foreign object is introduced into a living body that the object will induce an immune reaction, such as an inflammatory response that will have negative effects on the host. In the context of this invention, biocompatibility is evaluated according to the application for which it was designed: for example, a bandage is regarded as biocompatible with the skin, whereas an implanted medical device is regarded as biocompatible with the internal tissues of the body. Preferably, biocompatible materials include, but are not limited to, biodegradable and biostable materials. A substantial detrimental response has not occurred if an implant comprising the material is in close association to its implant site within the host animal and the response is better than a

tissue response recognized and established as suitable from materials provided in an ASTM. ASTM subcommittee F04.16 on Biocompatibility Test Methods has developed biocompatibility standards for medical and surgical materials and devices which includes E1262-88, F612-20, F719-20e1, F720-17, F748-16, F749-20, F750-20, F756-17; F763-04, F813-20, F895-11, F981-04, F1027-86, F1408-20a, F1439-03, F1877-16, F1903-18, F1904-14, F1983-14, F1984-99, F2147-01, F2148-18, F2382-18, F2808-17, F1288-19 and F2909-19, each of which is incorporated herein by reference. For example, materials that are to be used in contact with the blood stream must be composed of materials that meet hemocompatibility standards. One of these tests is for damage to red blood cells, which can result in hemolysis that is, rupturing of the cells, as described in F756-17 Standard Practice for Assessment of Hemolytic Properties of Materials.

[0184] As used herein, a "bioactive substance" refers to any of a variety of chemical moieties and that binds with a biomolecule such as, but not limited to, peptides, proteins, enzymes, receptors, substrates, lipids, antibodies, antigens, and nucleic acids. In certain preferred embodiments, the bioactive substance is a biomolecule but it is not intended that the bioactive substance be limited to biomolecules. In other preferred embodiments, the bioactive substances provide hydrophobic, hydrophilic, or electrostatic interactions, such as polycarboxylic acids that are anionic at physiological pH. In other preferred embodiment, the alkaline growth factors (with isoelectric point above 7) are retained via favorable electrostatic interactions by the polycarboxylates, and subsequently released in a controlled and sustained manner.

[0185] “Cancer” is a term used for a physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include, but are not limited to, carcinoma, lymphoma, leukemia, blastoma, and sarcoma. More particular examples of such cancers include squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer (NSCLC), glioma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, acute myeloid leukemia (AML), multiple myeloma, gastrointestinal cancer, renal cell carcinoma, renal cancer (*e.g.*, advanced renal cell carcinoma), ovarian cancer, liver cancer, lymphoblastic leukemia, lymphocytic leukemia, colorectal cancer, endometrial cancer, kidney cancer, prostate cancer, thyroid cancer, melanoma, chondrosarcoma, neuroblastoma, pancreatic cancer, glioblastoma multiforme, cervical cancer, brain cancer, stomach cancer, urothelial carcinoma (including local advanced or metastatic urothelial carcinoma), bladder cancer, hepatoma, breast cancer and head and neck cancer.

[0186] The term “stereoisomer” refers to compounds that have the same atomic connectivity but different atomic arrangement in space. Stereoisomers include cis-trans isomers, E and Z isomers, enantiomers, diastereomers and atropisomers. In the context of the present invention, the term

"enantiomerically pure" is understood to mean that the compound in question with respect to the absolute configuration of the chiral center is present in an enantiomeric excess of more than 95%, preferably more than 97%.

[0187] The present disclosure contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers isomers, (D)-isomers, (L)-isomers, atropisomers, tautomers and racemic and other mixtures thereof, such as enantiomers or diastereomeric enriched mixtures, all of which are within the scope of the present disclosure. Insofar as compounds of the invention as defined herein may exist in optically active or racemic forms by virtue of one or more asymmetric carbon atoms, the invention includes in its definition any such optically active or racemic form. The synthesis of optically active compounds may be carried out by standard techniques of organic chemistry well known in the art such as, for example, by synthesis from optically active starting materials or by resolution of a racemic compound. Similarly, the enantiomeric or diastereomeric purity of a compound may be evaluated using standard laboratory techniques.

[0188] The pharmaceutical compositions of the invention can take any suitable form for the desired route of administration. Where the composition is to be administered orally, any suitable orally deliverable dosage form can be used, including without limitation water, glycols, oils, alcohols, and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions, and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents, and the like in the case of powders, pills, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms. Injectable compositions or intravenous infusions are also provided in the form of solutions, suspensions, and emulsions. For parenteral compositions, the carrier usually comprises sterile water and possibly other ingredients to aid solubility. Injectable solutions may be prepared in which the carrier comprises a saline solution, a glucose solution, or a mixture of a saline and a glucose solution. Suitable oils include, for example, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, synthetic glycerol esters of long chain fatty acids, and mixtures of these and other oils. In compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives as needed, where the additives may facilitate administration of the composition to the skin and/or may facilitate preparation of the compositions to be delivered. These compositions may be administered in various ways, e.g., as a transdermal patch or as an ointment. Acid or base addition salts of the compounds of the

invention are typically more suitable in the preparation of aqueous compositions due to their increased water solubility over the corresponding neutral form of the compounds.

[0189] The pharmaceutical compositions of the invention may comprise one or more of a filler, diluent, adjuvant, vehicle, or other excipient to facilitate storage and/or administration of the active ingredients contained therein.

[0190] In an exemplary embodiment, a pharmaceutical composition according to the present invention may contain one or more additional therapeutic agents, for example, to increase efficacy or to decrease undesired side effects. In a particular embodiment, the pharmaceutical composition further contains one or more additional therapeutic agents useful to treat or inhibit a disease mediated directly or indirectly by PI3K. Examples of such agents include, without limitation, agents to treat or inhibit cancer, Huntington's disease, cystic fibrosis, liver fibrosis, renal fibrosis, pulmonary fibrosis, skin fibrosis, rheumatoid arthritis, diabetes, or heart failure.

[0191] In a specific embodiment, the additional therapeutic agent to be included is an anti-cancer agent. Examples of an anti-cancer agent include, but are not limited to, DNA-damaging cytotoxic drugs, alkylating agents such as cyclophosphamide, dacarbazine, and cisplatin; anti-metabolites such as methotrexate, mercaptopurine, thioguanine, fluorouracil, and cytarabine; plant alkaloids such as vinblastine and paclitaxel; antitumor antibiotics such as doxorubicin, bleomycin and mitomycin; hormones/antihormones such as prednisone, tamoxifen, and flutamide; other types of anticancer agents such as asparaginase, rituximab, trastuzumab, imatinib, retinoic acid, and derivatives, colony stimulating factors, amifostine, camptothecin, topotecan, thalidomide analogs such as lenalidomide, and proteasome inhibitors such as Velcade.

[0192] In another embodiment, the present invention provides a method of inhibiting or treating diseases arising from abnormal cell proliferation and/or differentiation in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of one or more compounds according to the present invention. In one embodiment, the method of inhibiting or treating disease comprises administering to a subject in need thereof, a composition comprising an effective amount of one or more compounds of the invention and a pharmaceutically acceptable carrier. The composition to be administered may further contain a therapeutic agent such as an anti-cancer agent.

[0193] The compounds of the invention are defined herein by their chemical structures and/or chemical names and are generally listed according to the IUPAC or CAS nomenclature system. Abbreviations that are well known to one of ordinary skill in the art may be used. When a compound is referred to by both a chemical structure and a chemical name, and the chemical

structure and chemical name conflict, the chemical structure is intended to be determinative of the compound's identity.

[0194] The present invention includes compounds labeled with various radioactive or nonradioactive isotopes. Examples of atomic isotopes may include, but are not limited to, deuterium (^{2}H), tritium (^{3}H), iodine-125 (^{125}I), carbon-14 (^{14}C), nitrogen-15 (^{15}N), sulfur-35 (^{35}S) and chlorine-36 (^{36}Cl). In an exemplary embodiment, one or more hydrogen atoms in a compound of the invention can be replaced by deuterium. In various embodiments, a compound of the invention includes at least one deuterium atom, or two or more deuterium atoms, or three or more deuterium atoms, *etc*. As described herein, compounds of the invention may also be radiolabeled with a radioactive isotope such as tritium (^{3}H), iodine-125 (^{125}I), and carbon-14 (^{14}C). A radiolabeled compound is useful as a therapeutic or prophylactic agent, provides a reagent for research such as for an assay, and/or provides a diagnostic agent for techniques such as *in vivo* imaging. Synthetic methods for incorporating isotopes into organic compounds are well known in the art.

[0195] In an embodiment of the invention, a compound of the invention as defined herein (such as a compound of any one of Formula (1), (2), (3) or (4)) or a pharmaceutically-acceptable salt thereof, exists as a single enantiomer being in an enantiomeric excess (% ee) of ≥ 95%, such as ≥ 98%, such as ≥ 99%.

[0196] In an embodiment of the invention, a pharmaceutical composition comprises a compound of the invention as defined herein (such as a compound of Formula I) or a pharmaceutically-acceptable salt thereof, where the compound exists as a single enantiomer being in an enantiomeric excess (% ee) of ≥ 95%, such as ≥ 98%, such as ≥ 99%.

[0197] In an exemplary embodiment of the invention, the disease or disorder to be treated by the compounds of the invention is selected from congenital lipomatous overgrowth, vascular malformations, epidermal naevi, scoliosis/skeletal and spinal syndrome (CLOVES), mosaic tissue overgrowth syndromes, venous malformations and brain malformations associated with severe epilepsy or PIK3CA-related overgrowth syndrome (PROS) (Keppler-Noreuil *et al.,* Am J Med Genet A. **2015**, 167A, 287; Kurek *et al.* Am. J. Hum. Genet. **2012**, 90, 1108).

[0198] In an exemplary embodiment of the invention, the cancer to be treated is a cancer bearing a PI3K H1047 mutation (such as H1047R) (Thorpe *et al*., Nat Rev Cancer **2015**, 15, 7).

[0199] The compounds of the invention (such as defined by Formula (1) through Formula (3)) are typically PI3Kα H1047R mutant-selective inhibitors that exhibit greater selectivity for the H1047R mutation over the wild-type. As such, the compounds may decrease the amount of

phosphorylated AKT (pAKT) and decrease proliferation selectively in PI3Kα H1047R mutant cell lines, preferably across several tumor types.


[0200] A PI3K H1047R mutant selective inhibitor of the invention (such as defined by Formula (1) through Formula (3)) dosed in combination with a selective estrogen receptor degrader (SERD) such as, but not limited to, fulvestrant, elacestrant, camizestrant or vepdegestrant may exhibit a combination benefit leading to tumor regression in ER+ / PI3K H1047R mutant tumors such as, but not limited to, the breast cancer xenograft model T47D, at doses where little or no regression would be observed with either single agent.

[0201] A PI3K H1047R mutant selective inhibitor of the invention (such as defined by Formula (1) through Formula (3)) dosed in combination with a HER2 inhibitor such as, but not limited to, tucatinib or trastuzumab may exhibit a combination benefit leading to tumor regression in ER- / HER2+ / PI3K H1047R mutant tumors such as, but not limited to, the breast cancer xenograft model HCC1954, at doses where little or no regression would be observed with either single agent.

[0202] Compounds of Formula (1) of the present invention may be generally prepared according to the synthetic routes identified in Schemes 1-16.

[0203] Substituted (hetero)aryl inputs necessary for the synthesis of compounds of Formula (1) are either commercially available or readily prepared via the use of known synthetic chemistry methods. For example, commercially available aminophenylphosphine oxide **1** may be used as a nucleophilic reactant in the subsequently described synthetic Schemes, or it can be transformed into the corresponding iodide **2** for use in transition metal-mediated couplings via a Sandmeyer reaction under standard reaction conditions, Scheme 1.

Scheme 1




1 **2**

[0204] The preparation of (hetero)aryl phosphate esters (e.g., dimethyl (2-bromophenyl)phosphonate **5**) may be accomplished by copper-oxide-mediate couplings of (hetero)aryl boronic acids (e.g., **3**) with dimethylphophonate to provide suitable coupling partners in transition metal-mediated couplings, Scheme 2. Such phosphate esters may be


transformed by reaction with Grignard reagents into alkyl phosphinates (e.g., **6**) that are also suitable for use as coupling partners.

Scheme 2




[0205] Halogen-substituted (hetero)aryl sulfones and sulfonamides are either readily available from commercial sources (e.g., **7** where R_a = CH_3 or NH_2, respectively) or can be prepared via known synthetic chemistry methods, Scheme 3. For example, benzene thiols such as **8** may be alkylated with alkyl halide (e.g., iodoethane) under basic conditions to provide thioethers such as **9**. Subsequently, the thioether functionality may be oxidized by any of a number of reagents (for example, such as meta-chloroperoxybenzoic acid) to afford aryl sulfones like **10**. Alternatively, aryl sulfones **10** can be prepared from the corresponding aryl sulfinic acids **8** via S_N2 alkylations with alkyl bromides or alkyl iodides in the presence of an appropriate base (e.g., potassium carbonate). Heteroarylsulfones (for example, pyridyl sulfone **13**) may be prepared by reacting sodium methylsulfinate with 2-fluoro- or 2-chloropyridines (such as **11**). The preparation of alkyl aryl sulfones (such as **19** or **20**) containing oxygen- or nitrogen-linked chains may be achieved from an appropriate halogen methyl-substituted sulfone (e.g., but not limited to, 1-bromo-2-((chloromethyl)sulfonyl)benzene **16**). The synthesis of **16** may be achieved by alkylating aryl sulfinate **14** with bromochloromethane. Oxygen- or nitrogen- linked species inputs, **19** or **20**, respectively) can be synthesized from **16** via alkylations of alcohols **17** or amines **18** in the presence of an appropriate base (e.g., but not limited to, sodium hydride or potassium carbonate).

Scheme 3



[0206] Sulfoximine-containing inputs may be prepared from thioethers, Scheme 4. Thioether-containing nitrobenzenes (for example, but not limited to, **21**) may be reacted with ammonium carbamate in the presence of phenyliodonium reagents to yield sulfoximine-containing intermediates like **22**. The sulfoximine may optionally be further functionalized via an alkylation step to yield species such as **23**. Reduction of the nitro group of **23** (e.g., by iron in the presence of ammonium chloride) can yield anilino sulfoximines **24**.


Scheme 4



[0207] The bicyclic cores of the present invention may be synthesized by any of a number of ring expansion or cyclization methodologies. In Scheme 1, the synthesis of isoquinolone core intermediates may begin with an appropriately substituted 2,3-dihydro-1*H*-inden-1-one **25**. In the case of **25**, where R_7 is methyl and each R_8 is hydrogen, this is commercially available. In other cases, the starting material may be prepared via established methods known to those skilled in the art. Nitrosation of **25** to convert to the oxime derivative **26** may be accomplished using established methods (for examples see Touster, O.; Org. Reactions, VII, **1953**, 327). A Beckmann-type rearrangement mediated by phosphorus pentachloride can convert **26** into **27** (Cushman, M.; Dekow, F.W. Tetrahedron **1978**, 34(10), 1435-9). Alkylation of **27** with an

appropriate electrophile and base will give **28**. In the case of where R_6 is methyl this may be accomplished with methyl iodide and an appropriate base (such as sodium hydride). Other electrophiles and alkylating agents, which would be known to those skilled in the art, may also be employed. In order to convert the bromide **28** to the methyl ketone **29**, a Stille coupling reaction may be employed using an appropriate tin reagent such as (□-ethoxyvinyl)-tributyl tin followed by acid hydrolysis (Sugiyama, *et al.*, Bull. Chem. Soc. Jpn. **1987**, 60(2), 767-768). Alternatively, conversion of **28** to **29** may be accomplished by other established methods, for example using a Heck coupling reaction with an appropriate enol-ether followed by acid hydrolysis (Mingcui, L. *et al.*, Org. Biomol. Chem., **2010**, 8, 2012–2015). Reduction of the ketone **29** to the alcohol **30** may then be accomplished by use of an appropriate hydride reducing agent (such as sodium borohydride). It should be understood that apart from the methodology described in Scheme 1, there are other reported methods that can be utilized to prepare isoquinolones such as **27** or **28** and their derivatives. For examples: Li, B. *et al.*, Tetrahedron Letters **2010**, 51(29), 3748-3751; Wang, R.; *et al.*, Organic & Biomolecular Chemistry **2011**, 9(16), 5802-5808).


Scheme 5



[0208] In Scheme 6, the alcohol **30** can be converted to amino derivatives **33** via a number of different methodologies. The alcohol may first be converted to intermediates **31** possessing a leaving group such as a bromide or a mesylate utilizing commonly known methods. Nucleophilic displacement on **31** gives compounds **33**. An alternative is to use a Mitsunobu type of reaction with (hetero)aryl amines **32** directly with the alcohol **30** to give compounds **33** directly. In some cases, the transient use of an activating group (such as a 2,4-dinitrobenzenesulfonyl group) on the (hetero)aryl amine functionality can facilitate the Mitsunobu reaction. The use of 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) and triphenylphosphine may also be employed in the direct reaction of the alcohol **30** with a (hetero)aryl amine (Shalit, T.; *et al.*, Tetrahedron Letters

2010, 51, 5988–5991; Iranpoor, N.; *et al.*, Tetrahedron **2009**, 65, 3893–3899; Panday, S. K., Mini-Reviews in Organic Chemistry **2019**, 16(2), 127-140; Fukuyama, Tohru; *et al.*, Tetrahedron Letters **1997**, 38(33), 5831-5834).


Scheme 6



[0209] A synthesis leading to a single enantiomer intermediate **38** is depicted in Scheme 7. This reaction sequence utilizes the formation of a chiral sulfinyl imine to control the stereochemistry. Such methods have been extensively reported. Ketone **28** may be converted to chiral sulfinyl-imine **34** via known procedures, which may then in turn be reduced to the sulfinyl-amine **35** in a stereo-controlled fashion using a suitable reducing agent (Datta and Ellman, J. Org. Chem. **2010**, 75, 6283–6285; Ellman *et al.*, Acc. Chem. Res. **2002**, 35, 984-995; Ellman *et al.*, J. Org. Chem. **2007**, 72, 626-629; Colyer *et al.*, Journal of Organic Chemistry **2006**, 71(18), 6859-6862). With use of the R isomer of the sulfinyl group, generally, resulting a predominantly the R, R – isomer of the product when (for example) the reducing agent used is a mixture of sodium borohydride and cerium chloride-heptahydrate. The use of this particular reducing system has been shown to be effective at reducing imines and may often give enhanced stereo-control in similar reductions (Hua *et al*, **Synthesis** 1991, (11), 970-4; Zhu *et al*, Journal of Chemical Research **2015**, 39(7), 390-393). In the instance within Scheme 7 that the R_2 moiety is methyl, the benzylic stereocenter of **35** is indeed formally labeled as the R isomer as is denoted within the Scheme. Alternate substitution patterns within R_2 may formally change the assignment of the stereocenter of such analogs to S, however, even though the relative configuration of such molecules **35** yet remains the same to the instance when R_2 is methyl. The major isomer may be separated from the other minor isomer via standard chromatographic means. As has been demonstrated in the preceding literature references a judicious choice of the antipode of the sulfinyl-imine and the reducing agent may give access to either antipode of the sulfinyl-amine. The sulfinyl-amine can be cleaved


to the single enantiomer of the chiral amine **36** using standard conditions (such as hydrogen chloride in dioxane). A standard coupling reaction of amine **36** with the (hetero)aryl halide **37** (such as an Ullman coupling or Buchwald-Hartwig coupling for **37**, Hal = I or Br) may then give the resulting (hetero)aryl amine derivative **38** (Yang *et al*, Organic Process Research & Development **2022**, 26(6), 1690-1750; Surry and Buchwald, Chemical Science **2011**, 2(1), 27-50). Alternatively, S_NAr reactions with amines **36** with (hetero)aryl halides **37** may also give rise to intermediates **38** should the inputs **37** be reactive enough (e.g., Hal = F or Cl and R_1 be an electron-withdrawing functionality).

Scheme 7




[0210] Certain final compounds **40** may be prepared as outlined in Scheme 8. Intermediate **33** may be reacted under suitable Buchwald-Hartwig coupling conditions with an amine **39**, wherein R' and R" may be either alkyl or aryl or one of R' and R" may be hydrogen. R' and R" may also be joined to form a ring. In some cases, the R' and/or R" groups may be further elaborated prior to subsequent steps. The racemic compound **40** may then be separated into its individual enantiomers (**41** and **42**) utilizing chiral chromatography (HPLC or SFC).

Scheme 8



[0211] The single enantiomer **32** may be prepared directly as shown in Scheme 9 from the enantiomerically pure intermediate **30** using chemistry analogous to that shown in Scheme 8.


Scheme 9



38 **39** **42**

[0212] In some cases, the order of reactions may be adjusted as shown in Scheme 10. In this case a Buchwald-Hartwig coupling with the intermediate **35** and an appropriately substituted amine **39** may give **43**. Removal of the sulfinyl group to give **44** may then be followed by a Buchwald-Hartwig coupling with (hetero)arylhalides (e.g., X = I or Br) to give compounds such as **46**. Alternatively, intermediate **44** may undergo an S_NAr reaction with suitably reactive (hetero)arylhalides **45** (e.g., X = F or Cl with R_1 being an electron-withdrawing group) to give compounds **46**.

Scheme 10




35 **39** **43** **44**

44 **45** **46**

[0213] Compounds where there is an oxygen or sulfur linked substitution from the 3-position of the isoquinolone ring may be prepared as shown in Scheme 11. The intermediate **38** may undergo a Buchwald-Hartwig coupling with an appropriate sulfhydryl compound to give **48**. Alternatively intermediate **38** may undergo an S_NAr reaction with an appropriate alcohol (this reaction may be mediated by a base, for example, sodium hydride) to give compounds such as **50**.


Scheme 11



38 47 48 38 49 50

[0214] In the cases where the substitution from the 3-position of the isoquinolone ring is either an alkyl or an alkenyl group, these compounds may be prepared as shown in Scheme 12. The intermediate **33** may undergo a Suzuki coupling reaction (Stanforth, S.P. Tetrahedron **1998**, 54(3/4), 263-303) with a suitable alkenyl-boronate (or boronic acid) **51** to give **52**. The racemate **52** may then be subjected to chiral chromatographic separation to give the enantiomers **53** and **54**. Alternatively the double bond of **52** may be reduced under standard hydrogenation conditions (e.g., hydrogen with a palladium catalyst). Following chiral chromatographic separation this may give the enantiomers **55** and **56**. In the case where R and R' do not form a symmetrical arrangement, further isomers may result which may also be separated chromatographically.


Scheme 12



33 51 52 53 54 55 56

[0215] In the case where the substitution from the 3-position of the isoquinolone group is an aryl or heteroaryl group, these types of compounds may be prepared in an analogous method to that shown in Scheme 12. As depicted in Scheme 13, a Suzuki coupling reaction between **33** and an appropriate aryl (or heteroaryl) bononate (or boronic acid) may give, following chiral separation, the enantiomers **57** and **58**.


Scheme 13



57 58

[0216] An alternative mode of synthesis of aryl- or heteroaryl-substituted isoquinolones is depicted in Scheme 14. A Suzuki coupling reaction between intermediate **35** and an appropriate aryl or heteroaryl boronate (or boronic acid) followed by removal of the sulfinyl group may give **59**. An Ullman or Buchwald-Hartwig coupling between **59** and (hetero)arylhalides **45** may give compounds such as **60**. Alternatively, **59** may undergo an S_NAr reaction with suitably (hetero)arylhalides **45** (e.g., where X = F or Cl and R_1 is an electron-withdrawing group) to also give compounds **60**.


Scheme 14



[0217] The synthesis of benzopyrimidinone core-containing compounds can be envisioned through known synthetic chemistry techniques, Scheme 15. Beginning from aminobenzoic acids **61** that are generally known or available commercially (such as from BLD Pharmatech Ltd.), intermediate quinazoline-2,4-diones **62** can be generated under cyclization conditions. In an exemplary embodiment when R_6 = H, cyclization may occur by treatment with urea at elevated temperatures. In exemplary embodiments when R_6 = alkyl, cyclization may occur via a 2-step process consisting first of amide coupling with the corresponding alkylamine and HATU, followed by treatment with triphosgene. Chlorination of **62** can furnish intermediates of general structure **63**. In an exemplary embodiment, chlorination can be effected by refluxing **62** in $POCl_3$ followed by neutralization with aqueous base (NaOH when R_6 = H, or alternatively $NaHCO_3$ when R_6 = alkyl). Intermediates of general structure **64** may then be generated by S_NAr substitution. In exemplary embodiments, treatment of **63** with an amine, an amine hydrochloride salt, an alcohol, or a thiol (depending on whether R_5 is desired to be an *N*-linked, *O*-linked, or *S*-linked moiety, respectively), in some embodiments with the addition of an appropriate base (e.g., but not limited to, DIEA, K_2CO_3, or NaH), in an appropriate solvent (e.g., but not limited to, ACN, NMP, or DMF) at room temperature or, in some embodiments, at elevated temperature (up to 140 °C), can yield intermediates of general structure **64**. Intermediates of general structure **65** may then be generated by carbonylation of **64**. In some exemplary embodiments, the bromine substituent of **64** is replaced with an acetyl group by treatment with tributyl(1-ethoxyvinyl)tin and a catalytic palladium species (e.g., but not limited to, $Pd(PPh_3)_4$ or $PdCl_2(PPh_3)_2$) at elevated temperature, followed by hydrolysis with aqueous HCl, to yield ketones **65**. Intermediates **65** when R_3 = H can also be generated by formylation of **64** through a variety of known methods (e.g., but not limited to, palladium-catalyzed carbonylation in the presence of H_2 (Klaus, *et al.,*

Angew. Chem. Int. Ed. **2006**, 45, 154), or cyanation followed by DIBAL reduction). Intermediates **65** can serve as a platform for further expansion into diverse R_2 substitutions (e.g., trifluoromethyl, difluoromethyl, fluoromethyl, alkyls, etc.) through a variety of known techniques (including but not limited to Prakash, *et al.*, J. Am. Chem. Soc. **1989**, 111, 393; Zhao, *et al.*, Org. Lett. **2011**, 13, 5342; Reichel, *et al.*, Angew. Chem. Int. Ed. **2020,** 59, 12268; etc.). Alcohol intermediates of general structure **66** can be prepared by reduction of **65**. In an exemplary embodiment, the reduction was performed by treatment of **65** with $NaBH_4$ in MeOH. Conversion of **66** to (hetero)arylamines of general structures **67** and **68** can be accomplished via reactions conditions analogous to those described in Schemes 6-14.


Scheme 15



[0218] An alternate mode of synthesis leading to single enantiomer benzopyrimidinone intermediates **71** is depicted in Scheme 16. This reaction sequence utilizes the formation of a chiral sulfinyl imine to set the stereocenter of the subsequent synthetic products. Ketones **65** may be converted to a chiral sulfinyl-imines **69** via known procedures, which may then in turn be reduced to sulfinyl-amines **70** in a stereo-controlled fashion using suitable reducing agents (Datta and Ellman, J. Org. Chem. **2010**, 75, 6283–6285; Ellman *et al.,* Acc. Chem. Res. **2002**, 35, 984-995; Ellman *et al.,* J. Org. Chem. **2007**, 72, 626-629; Colyer *et al.,* J. Org. Chem. **2006**, 71(18), 6859-6862). The use of the R isomer of the sulfinyl group **69**, generally, results predominantly in the R,R–isomer of **70** when (for example) the reducing agent used is a mixture of sodium borohydride and cerium chloride-heptahydrate. The use of this particular reducing system has been shown to be effective at reducing imines and may often give enhanced stereo-control in similar reductions (Hua *et al.,* Synthesis **1991**, (11), 970-4; Zhu *et al.,* J. Chem. Res. **2015**, 39(7), 390-393). In the instance within Scheme 16 that the R_2 moiety is methyl, the benzylic stereocenter of **35** is indeed formally labeled as the R isomer as is denoted within the Scheme. Alternate substitution patterns within R_2 may formally change the assignment of the stereocenter of such analogs to S, however, even though the relative configuration of such


molecules **35** yet remains the same to the instance when R_2 is methyl. The major isomer may be separated from the other minor isomer via standard chromatographic means. As has been demonstrated in the preceding literature references, a judicious choice of the antipode of the sulfinyl-imine and the reducing agent may give access to either antipode of the sulfinyl-amine. Sulfinyl-amines **70** can be cleaved to the single enantiomer of chiral amines **71** using standard conditions (such as hydrogen chloride in dioxane). Standard coupling reactions of amines **45** with aryl iodides or aryl bromides **45** (such as an Ullman coupling or Buchwald-Hartwig coupling) may then give the resulting final compounds **72** (Yang *et al.,* Org. Process Res. & Dev. **2022**, 26(6), 1690-1750; Surry and Buchwald, Chem. Sci. **2011**, 2(1), 27-50).

Scheme 16



[0219] The chemistries depicted in Schemes 1 to 16 demonstrate various modes of synthesis of the compounds described. It should be understood that other variations on these modes may be employed and that the precise protecting groups, the order of the listed reactions or the particular transition metals used in the catalyzed coupling reaction may be replaced with suitable alternatives that would be known to those skilled in the art.

[0220] The following compounds of Formula (1) represent various embodiments of the present invention:



Experimental

[0221] All commercially available solvents and reagents were used as received. All ^{1}H NMR spectra were recorded using a Bruker Avance III HD 300 MHz or Bruker Avance III HD 400 MHz. MS samples were analyzed on a Shimadzu LCMS-2020 mass spectrometer with electrospray ionization operating in positive and negative ion mode. Samples were introduced into the mass spectrometer using chromatography. All final products had a purity of ≥ 90 %, unless specified otherwise in the experimental details. HPLC purity was measured on a Shimadzu Acquity HPLC system.

[0222] The following represents acronyms used in the experimental section for well-known chemical solvents, reagents, parameters and techniques:

^{1}H NMR: proton nuclear magnetic resonance spectroscopy

ACN: acetonitrile

AcOH: acetic acid

B_2pin_2: 4,4,5,5-tetramethyl-2-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane

BINAP: 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl

$(Boc_2)O$: di-tert-butyl dicarbonate

c-Bu: cyclobutyl

c-Pr: cyclopropyl

CDI: carbonyl diimidazole

$CeCl_3$: cerium (III) chloride

CH_2Cl_2: dichloromethane

CH_3I: iodomethane

$CHCl_3$: chloroform

CO_2: carbon dioxide

Cs_2CO_3: cesium carbonate

CsF: cesium fluoride

CuCl: cuprous chloride

DAST: diethylaminosulfur trifluoride

DBAD: di-*tert*-butyl azodicarboxylate

DBU: 1,8-Diazabicyclo[5.4.0]undec-7-ene

DCM: dichloromethane

DIBAL: diisobutylaluminum hydride

DIEA: *N,N*-diisopropylethylamine

DMF: *N,N*-dimethylformamide

DMSO: dimethyl sulfoxide

DTAD: di-tert-butyl azodicarboxylate

EA: ethyl acetate

ee: enantiomeric excess

Et_2O: diethyl ether

Et_3N: triethylamine

Et_3SiH: triethylsilane

EtOAc: ethyl acetate

EtOH: ethanol

FA: formic acid

h: hours

H_2O: water

HATU: 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate

HCl: hydrochloric acid

Hex: hexanes

HPLC: high-performance liquid chromatography

IPA: isopropanol

K_2CO_3: potassium carbonate

K_3PO_4: potassium triphosphate

KOAc: potassium acetate

LiOH: lithium hydroxide

*m*CPBA: *meta*-chloroperoxybenzoic acid

Me: methyl

MeCN: acetonitrile

MeOH: methanol

mg: milligram

$MgSO_4$: magnesium sulfate

min: minutes

mL: milliliter

MsCl: methanesulfonyl chloride

Ms_2O: methanesulfonic anhydride

$NaBH_4$: sodium borohydride

N_2: nitrogen

NaCl: sodium chloride

Na_2CO_3: sodium carbonate

NaH: sodium hydride

NaI: sodium iodide

NaOH: sodium hydroxide

$NaHCO_3$: sodium bicarbonate

NaH_2PO_4: monosodium phosphate

Na_2SO_3: sodium sulfite

Na_2SO_4: sodium sulfate

NH_3: ammonia

NH_4Cl: ammonium chloride

NH_4HCO_3: ammonium bicarbonate

NH_4OH: ammonium hydroxide

$(NH_4)_2CO_3$: ammonium carbonate

NMP: *N*-methylpyrrolidone

Oxetane: 4-membered ring containing 3 carbon ring atoms and 1 oxygen ring atom.

PBr_3: phosphorous tribromide

PCl_5: phosphorous pentachloride

Pd/C: palladium on carbon

Pd-PEPPSI-IHeptCl 3-chloropyridine: dichloro[1,3-bis(2,6-di-4-heptylphenyl)imidazol-2-ylidene](3-chloropyridyl)palladium(II)

$Pd(amphos)Cl_2$: bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II)

$Pd(dppf)Cl_2$: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride

$Pd(PPh_3)_4$: tetrakis(triphenylphosphine)palladium(0)

$Pd_2(dba)_3$: tris(dibenzylideneacetone)dipalladium(0)

$PdCl_2(PPh_3)_2$: bis(triphenylphosphine)palladium(II) dichloride

PE: petroleum ether

$POCl_3$: phosphorus oxychloride

PPh_3: triphenylphosphine

Prep: preparative

PyBOP: benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate

RuPhos: 2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl

RuPhos-Pd-G3: methanesulfonato(2-dicyclohexylphosphino-2',6'-di-isopropoxy-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II)

SEM-Cl: 2-(trimethylsilyl)ethoxymethyl chloride

SiO_2: silica

T_4P: 2,4,6-tributyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide

TBAF: tetrabutylammonium fluoride

TBSCl: tert-butyldimethylsilyl chloride

TEA: triethylamine

TFA: trifluoroacetic acid

THF: tetrahydrofuran

$Ti(OEt)_4$: Titanium (IV) ethoxide

$Ti(Oi\text{-}Pr)_4$: Titanium(IV) isopropoxide

TLC: thin-layer chromatography

Xantphos: 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene

Xphos-Pd-G4: (SP-4-3)-[Dicyclohexyl[2′,4′,6′-tris(1-methylethyl)[1,1′-biphenyl]-2-yl]phosphine](methanesulfonato-κO)[2′-(methylamino-κN)[1,1′-biphenyl]-2-yl-κC]palladium

LCMS Method A
Column: Zorbax Eclipse Plus C18 (50 × 2.1 mm, 1.8 µm)
Column Temperature: 40 °C
Detection: UV @ 210-400 nm
Sample Diluent: Acetonitrile
Mobile Phase A: Water (with 0.1% FA)
Mobile Phase B: Acetonitrile (with 0.1% FA)

Flowrate: 0.8 mL/min

Gradient Program

Time(min)	%B
0.0	5
0.25	5
2.5	95
3.5	95
3.6	5
4.0	5

LCMS Method B

Column: Phenomenex Kinetex EVO C18 (3.0× 50 mm, 2.6 µm)

Column Temperature: 40 °C

Detection: UV @ 210-400 nm

Sample Diluent: Acetonitrile

Mobile Phase A: Water (10 mM Ammonium bicarbonate)

Mobile Phase B: Acetonitrile

Flowrate: 0.8 mL/min

Gradient Program

Time(min)	%B
0.01	5
0.20	5
2.50	98
3.55	98
3.60	5
4.00	5

LCMS Method C

Column: HALO C18 3.0 x 30 mm, 2.7 µm

Column Temperature: 50 °C

Detection: PDA (220 nm & 254 nm)

Sample Diluent: Acetonitrile

Mobile Phase A: 0.0375% TFA in water (v/v)

Mobile Phase B: 0.01875% TFA in Acetonitrile (v/v)

Flowrate: 2 mL/min

Gradient Program

Time(min)	%B
0.0	5
0.40	95

0.75	95
0.76	5
1.05	5

LCMS Method D

Column: HALO C18 3.0 x 30 mm, 5 µm

Column Temperature: 50 °C

Detection: PDA (220 nm & 254 nm)

Sample Diluent: Acetonitrile

Mobile Phase A: 0.0375% TFA in water (v/v)

Mobile Phase B: 0.01875% TFA in Acetonitrile (v/v)

Flowrate: 1.5 mL/min

Gradient Program

Time(min)	%B
0.0	5
0.50	95
0.80	95
0.81	5
1.05	5

LCMS Method E

Column: Kinetex EVO C18 30 mm x 2.1 mm, 5 µm

Column Temperature: 50 °C

Detection: PDA (220 nm & 254 nm)

Sample Diluent: Acetonitrile

Mobile Phase A: 0.0375% TFA in water (v/v)

Mobile Phase B: 0.01875% TFA in Acetonitrile (v/v)

Flowrate: 1.5 mL/min

Gradient Program

Time(min)	%B
0.0	5
0.80	95
1.20	95
1.21	5
1.55	5

LCMS Method F

Column: Kinetex EVO C18 2.1 x 30 mm, 5 µm

Column Temperature: 40 °C

Detection: PDA (220 nm & 254 nm)

Sample Diluent: Acetonitrile

Mobile Phase A: 0.025% $NH_3 \cdot H_2O$ in water (v/v)
Mobile Phase B: Acetonitrile
Flowrate: 1.5 mL/min
Gradient Program

Time(min)	%B
0.00	5
0.80	95
1.2	95
1.21	5
1.55	5

LCMS Method G
Column: Kinetex® EVO C18 2.1 mm x 30 mm, 5µm
Column Temperature: 50 °C
Detection: PDA (220 nm & 254 nm)
Sample Diluent: Acetonitrile
Mobile Phase A: 0.0375% TFA in water (v/v)
Mobile Phase B: 0.01875% TFA in Acetonitrile (v/v)
Flowrate: 2.0 mL/min
Gradient Program

Time(min)	%B

0.0	5
0.60	95
0.78	95
0.79	5
0.80	5

LCMS Method H

Column: XBridge C18 2.1 mm x 50 mm, 5 µm

Column Temperature: 40 °C

Detection: PDA (220 nm & 254 nm)

Sample Diluent: Acetonitrile

Mobile Phase A: 0.025% $NH_3 \bullet H_2O$ in water (v/v)

Mobile Phase B: Acetonitrile

Flowrate: 2.0 mL/min

Gradient Program

Time(min)	%B
0.00	5
0.80	95
0.94	95
0.95	5
1.00	5

LCMS Method I

Column: Kinetex® EVO C18 4.6 mm x 50 mm, 5 µm

Column Temperature: 50 °C

Detection: PDA (220 nm & 254 nm)

Sample Diluent: Acetonitrile

Mobile Phase A: 0.0375% TFA in water (v/v)

Mobile Phase B: 0.01875% TFA in Acetonitrile (v/v)

Flowrate: 1.0 mL/min; 2.0 mL/min

Gradient Program

Time(min)	B(%)	Flow(mL/min)
0.00	10	1.0
5.00	80	1.0
5.70	80	1.0
5.71	10	2.0
6.00	10	2.0

LCMS Method J

Column: Kinetex® EVO C18 4.6 mm x 50 mm, 5 µm

Column Temperature: 50 °C

Detection: PDA (220 nm & 254 nm)

Sample Diluent: Acetonitrile
Mobile Phase A: 0.0375% TFA in water (v/v)
Mobile Phase B: 0.01875% TFA in Acetonitrile (v/v)
Flowrate: 2.0 mL/min
Gradient Program

Time(min)	B(%)
0.0	5
2.40	95
2.70	95
2.71	5
3.00	5

LCMS Method K
Column: HALO C18 3.0 x 30 mm, 5 µm
Column Temperature: 50 °C
Detection: PDA (220 nm & 254 nm)
Sample Diluent: Acetonitrile
Mobile Phase A: 0.0375% TFA in water (v/v)
Mobile Phase B: 0.01875% TFA in Acetonitrile (v/v)
Flowrate: 2.0 mL/min

Gradient Program

Time(min)	%B
0.0	5
0.40	95
0.75	95
0.76	5
1.05	5

LCMS Method L

Column: HALO C18 3.0 x 30 mm, 2.7 µm

Column Temperature: 50 °C

Detection: PDA (220 nm & 254 nm)

Sample Diluent: Acetonitrile

Mobile Phase A: 0.0375% TFA in water (v/v)

Mobile Phase B: 0.01875% TFA in Acetonitrile (v/v)

Flowrate: 1.5 mL/min

Gradient Program

Time(min)	%B
0.0	5
0.50	95
0.80	95

0.81	5
1.05	5

LCMS Method AA

Column: HALO 90A C18 (30 × 3.0 mm, 2.0 µm)

Column Temperature: 40 °C

Detection: UV @ 190-400 nm

Sample Diluent: Acetonitrile

Mobile Phase A: Water (with 0.1% FA)

Mobile Phase B: Acetonitrile (with 0.1% FA)

Flowrate: 1.2 mL/min

Gradient Program

Shipping

Time(min)	%B
0.01	40
2.00	100
2.75	100
2.80	5
3.00	Stop

Normal

Time(min)	%B
0.01	5
1.20	100
1.80	100
1.82	5
2.00	Stop

LCMS Method AB
Column: Shim-pack Scepter C18-120 (3.0× 33 mm, 3.0 µm)
Column Temperature: 40 °C
Detection: UV @ 190-400 nm
Sample Diluent: Acetonitrile
Mobile Phase A: Water (5 mM Ammonium bicarbonate)
Mobile Phase B: Acetonitrile
Flowrate: 1.5 mL/min
Gradient Program


Time(min)	%B
0.01	10
1.20	95
1.80	95
1.82	10
2.00	stop

LCMS Method AC
Column: HALO 90A C18 (3.0× 3.0 mm, 2.0 µm)
Column Temperature: 40 °C


Detection: UV @ 190-400 nm
Sample Diluent: Acetonitrile
Mobile Phase A: Water (with 0.05% TFA)
Mobile Phase B: Acetonitrile (with 0.05% TFA)
Flowrate: 1.5 mL/min
Gradient Program

Time(min)	%B
0.01	5
1.20	100
1.80	100
1.82	5
2.00	stop

[0223] **Intermediate 1:** (R)-N-((R)-1-(3-Chloro-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)-2-methylpropane-2-sulfinamide




Step 1: Preparation of 4-bromo-2-(hydroxyimino)-6-methyl-2,3-dihydro-1H-inden-1-one




[0224] To a stirred solution of 4-bromo-6-methyl-2,3-dihydroinden-1-one (2 g, 8.89 mmol) in HCl (10 mL, 12 M) and Et_2O (10 mL) was added 3-methylbutyl nitrite (1.25 g, 10.66 mmol) slowly dropwise at 0 °C. The resulting solution was stirred for 4 h at room temperature. The mixture was cooled to 0 °C. and the precipitated solids were collected by filtration and washed with H_2O (3 x 50 mL). The resulting mixture was concentrated under vacuum. The crude product was used in the next step directly without further purification. This resulted in 4-bromo-2-(hydroxyimino)-6-methyl-2,3-dihydro-1H-inden-1-one (1.5 g, 66% yield) as an off-white solid. MS: (ES^+) m/z = 254.1 $[M+H]^+$.

Step 2: Preparation of 5-bromo-3-chloro-7-methyl-2H-isoquinolin-1-one



[0225] To a stirred solution of 4-bromo-2-(hydroxyimino)-6-methyl-2,3-dihydro-1H-inden-1-one (1.5 g, 5.90 mmol) in $CHCl_3$ (30 mL) was slowly added PCl_5 (2.46 g, 11.8 mmol) in portions at 0 °C. The resulting mixture was stirred for 3 h at room temperature and then concentrated under reduced pressure. To the crude product was added 4 M HCl in 1,4-dioxane (30 mL). The resulting solution was stirred overnight at room temperature and then concentrated under reduced pressure. The residue was purified by trituration with 5:1 PE/EtOAc to afford 5-bromo-3-chloro-7-methyl-2H-isoquinolin-1-one (1 g, 61% yield) as a yellow solid. MS: (ES^-) m/z = 269.9 $[M-1]^-$.


Step 3: 5-bromo-3-chloro-2,7-dimethylisoquinolin-1-one



[0226] To a stirred solution of 5-bromo-3-chloro-7-methyl-2H-isoquinolin-1-one (1.3 g, 4.77 mmol) in DMF (10 mL) was slowly added NaH (0.17 g, 7.16 mmol) in portions at 0 °C. The resulting solution was stirred for 20 min at 0 °C. Iodomethane (0.81 g, 5.72 mmol) was slowly added dropwise at 0 °C and the resulting solution was stirred overnight at room temperature. The


reaction was quenched with water (40 mL) and the resulting mixture was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (3 x 40 mL), dried over anhydrous Na_2SO_4, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE/EA = 4:1) to afford 5-bromo-3-chloro-2,7-dimethylisoquinolin-1-one (900 mg, 65% yield) as a reddish brown solid. MS: (ES^+) m/z = 286.0 $[M+H]^+$.

Step 4: Preparation of 5-acetyl-3-chloro-2,7-dimethylisoquinolin-1-one



[0227] A mixture of 5-bromo-3-chloro-2,7-dimethylisoquinolin-1-one (2.6 g, 9.07 mmol), tributyl(1-ethoxyethenyl)stannane (3.60 g, 9.98 mmol) and $Pd(PPh_3)_4$ (1.05 g, 0.91 mmol) in anhydrous 1,4-dioxane (25 mL) was stirred overnight at 100 °C under a nitrogen atmosphere. The reaction mixture was cooled to room temperature, treated with aqueous 1 N HCl (10 mL), and stirred for 15 min. The resulting mixture was diluted with water (60 mL) and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with water (3 x 60 mL) and brine (50 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to afford 5-acetyl-3-chloro-2,7-dimethylisoquinolin-1-one (1.9 g, 83% yield) as a yellow solid. MS: ES^+ (m/z) = 250.1 $[M+H]^+$.


Step 5: Preparation of (R,E)-N-(1-(3-chloro-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethylidene)-2-methylpropane-2-sulfinamide



[0228] To a stirred solution of 5-acetyl-3-chloro-2,7-dimethylisoquinolin-1-one (9.8 g, 39.2 mmol) and (R)-2-methylpropane-2-sulfinamide (23.78 g, 196.2 mmol) in THF (200 mL) was added $Ti(Oi\text{-}Pr)_4$ (55.78 g, 196.2 mmol). The resulting mixture was stirred overnight at 80 °C under a nitrogen atmosphere. The reaction was quenched with saturated aqueous sodium chloride (200 mL). The resulting mixture was filtered and the filter cake was


washed with ethyl acetate (3 x 300 mL). The filtrate was extracted with ethyl acetate (3 x 300 mL). The combined organic layers were washed with H_2O (3 x 200 mL), dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE/EA = 3:2) to afford (R,E)-N-(1-(3-chloro-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethylidene)-2-methylpropane-2-sulfinamide (9 g, 64% yield) as a yellow solid. MS: (ES^+) m/z = 353.1 $[M+H]^+$.

Step 6: Preparation of (R)-N-((R)-1-(3-chloro-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)-2-methylpropane-2-sulfinamide




[0229] To a stirred solution of (R,E)-N-(1-(3-chloro-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethylidene)-2-methylpropane-2-sulfinamide (10.5 g, 29.76 mmol) and $CeCl_3 \bullet 7H_2O$ (16.6 g, 44.6 mmol) in MeOH (120 mL) was added $NaBH_4$ (2.81 g, 74.4 mmol) at -78 °C. The resulting solution was stirred for 2 h at room temperature. The reaction mixture was quenched with saturated aqueous ammonium chloride (150 mL) and extracted with ethyl acetate (3 x 200 mL). The combined organic layers were washed with brine (2 x 200 mL), dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE:EA = 1:2) and then purified further by HP-Flash (25%-55% ACN in H_2O (0.1% FA) in 45 min) to afford (R)-N-((R)-1-(3-chloro-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)-2-methylpropane-2-sulfinamide (6.5 g, 61% yield) as an off-white solid. MS: (ES^+) m/z = 355.0 $[M+H]^+$.

[0230] **Intermediate 2:** (R)-5-(1-Aminoethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one




Step 1: Preparation of (R)-N-((R)-1-(2,7-dimethyl-1-oxo-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)-1,2-dihydroisoquinolin-5-yl)ethyl)-2-methylpropane-2-sulfinamide




[0231] To a stirred solution of (R)-N-((R)-1-(3-chloro-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)-2-methylpropane-2-sulfinamide (Intermediate 1) (3 g, 8.5 mmol) and 1-(2,2,2-trifluoroethyl)piperazine (3.55 g, 21.1 mmol) in dioxane (60 mL) was added $Pd_2(dba)_3$ (0.77 g, 0.85 mmol), Cs_2CO_3 (5.51 g, 16.9 mmol) and RuPhos (0.79 g, 1.69 mmol) at room temperature under nitrogen atmosphere. The resulting mixture was stirred for 4 h at 100 °C under a nitrogen atmosphere. The resulting mixture was filtered, and the filter cake was washed with EtOAc (50 mL x 2). The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluted with PE:EA = 2:1) to afford (R)-N-((R)-1-(2,7-dimethyl-1-oxo-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)-1,2-dihydroisoquinolin-5-yl)ethyl)-2-methylpropane-2-sulfinamide (3.6 g, 87% yield) as a yellow oil. MS: (ES^+) m/z = 487.3 $[M+H]^+$.

Step 2: Preparation of (R)-5-(1-aminoethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one




[0232] To a stirred solution of (R)-N-((R)-1-(2,7-dimethyl-1-oxo-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)-1,2-dihydroisoquinolin-5-yl)ethyl)-2-methylpropane-2-sulfinamide (3.6 g, 7.4 mmol) in MeOH (37 mL) was added 4 M HCl in EtOAc (3.7 mL, 14.8 mmol) dropwise at room temperature. The resulting mixture was stirred for 1 h at room temperature. The resulting mixture was concentrated under reduced pressure. The residue was diluted with EtOAc (50 mL) and was washed with saturated aqueous $NaHCO_3$ (3 x 15 mL). The organcs were then dried over anhydrous $MgSO_4$. After filtration, the filtrate was concentrated under reduced pressure to afford (R)-5-(1-aminoethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one (2.8 g, 98% yield) as a yellow solid. MS: (ES^+) *m/z* = 383.2 $[M+H]^+$.

[0233] **Intermediate 3:** 2-Amino-3-(1-((tert-butyldimethylsilyl)oxy)ethyl)-5-fluoro-N-methylbenzamide




Step 1: Preparation of 2-amino-3-bromo-5-fluoro-N-methylbenzamide




[0234] To a solution of 2-amino-3-bromo-5-fluorobenzoic acid (5 g, 21.4 mmol) in THF (50 mL) was added CDI (4.16 g, 25.6 mmol) at 25 °C. The mixture was then stirred at 70 °C for 1 hr, and then methylamine hydrochloride (5.77 g, 85.5 mmol) and TEA (2.16 g, 21.4 mmol, 3 mL) was added. The resulting mixture was stirred at 70 °C for 1 hr. The reaction was quenched with water (50 mL) and extracted with EA (50 mL x 3). The combined organics were washed with water (50 mL x 3), dried over Na_2SO_4, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (SiO_2, PE:EA = 1:0 to 1:1) to afford 2-amino-3-bromo-5-fluoro-N-methylbenzamide (4.7 g, 89% yield) as an off-white solid. LCMS (ESI^+) m/z = 247.1 (M+H), t_R = 0.491 min (Method C).

Step 2: Preparation of 3-acetyl-2-amino-5-fluoro-N-methylbenzamide




[0235] To a solution of 2-amino-3-bromo-5-fluoro-N-methylbenzamide (3.7 g, 15.0 mmol) and tributyl(1-ethoxyvinyl)stannane (7.45 g, 20.6 mmol) in dioxane (40 mL) under a nitrogen atmosphere was added $Pd(PPh_3)_4$ (1.73 g, 1.50 mmol). The mixture was then stirred at 100 °C for 15 hr. Then, the solution was cooled to 0 °C and aqueous 1 M HCl (5 mL) was added. The mixture was then stirred at 0 °C for 30 min. Then, a saturated aqueous KF solution (50 mL) was added. The reaction mixture was then diluted with H_2O (50 mL) and EA (50 mL) and stirred at 20 °C for 1 h. The mixture was filtered and extracted with EA (40 mL x 3). The combined organics were washed with brine (50 mL), dried over Na_2SO_4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, PE:EA =1:0 to 0:1) to afford 3-acetyl-2-amino-5-fluoro-N-methylbenzamide (2.5 g, 79% yield) as a yellow solid. LCMS (ESI^+) m/z = 211.2 (M+H), t_R = 0.514 min (Method C).

Step 3: Preparation of 2-amino-5-fluoro-3-(1-hydroxyethyl)-N-methylbenzamide




[0236] To a solution of 3-acetyl-2-amino-5-fluoro-N-methylbenzamide (2.5 g, 11.9 mmol) in MeOH (30 mL) was added $NaBH_4$ (1.45 g, 38.3 mmol) at 0 °C. The mixture was stirred at 25 °C for 1 hr and then quenched by addition of saturated aqueous NH_4Cl (10 mL) at 0 °C. The resulting mixture was diluted with water (30 mL) and extracted with EA (20 mL x 3). The combined organics were washed with brine (50 mL), dried over Na_2SO_4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, PE:EA = 0:1 to 4:1) to afford 2-amino-5-fluoro-3-(1-hydroxyethyl)-N-methylbenzamide (3.6 g, 99% yield) as a yellow oil. LCMS (ESI^+) m/z = 195.0 (M+H - H_2O), t_R = 0.362 min (Method C).

Step 4: Preparation of 2-amino-3-(1-((tert-butyldimethylsilyl)oxy)ethyl)-5-fluoro-N-methylbenzamide




[0237] To a solution of 2-amino-5-fluoro-3-(1-hydroxyethyl)-N-methylbenzamide (3.6 g, 17.0 mmol) and imidazole (3.46 g, 50.9 mmol) in DCM (30 mL) was added a solution of TBSCl (5.11 g, 33.9 mmol) in DMF (6 mL) at 0 °C. The mixture was stirred at 25 °C for 12 hr. The reaction mixture was then concentrated under reduced pressure. The mixture was then diluted with water (40 mL) and extracted with EA (30 mL x 3). The combined organics were washed with brine (30 mL), dried over Na_2SO_4, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (SiO_2, PE:EA = 1:0 to 10:1) to afford 2-amino-3-(1-((tert-butyldimethylsilyl)oxy)ethyl)-5-fluoro-N-methylbenzamide (4 g, 72% yield) as a white solid. LCMS (ESI^+) m/z = 327.1 (M+H), t_R = 0.623 min (Method C).

[0238] **Intermediate 4:** (R)-5-(1-Aminoethyl)-3-chloro-2,7-dimethylisoquinolin-1(2H)-one




[0239] To a solution of (R)-N-((R)-1-(3-chloro-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)-2-methylpropane-2-sulfinamide (Intermediate 1) (12 g, 33.8 mmol) was added 4 M HCl in dioxane (169 mL, 676 mmol). The mixture was stirred at 25 °C for 1 hr and then concentrated. The residue was recrystallized from PE:EA = 1:1 (100 mL). The suspension was then filtered, and the filter cake was dried under reduced pressure to afford (R)-5-(1-aminoethyl)-3-chloro-2,7-dimethylisoquinolin-1(2H)-one (9.9 g, HCl salt) as white solid. LCMS (ESI$^+$) m/z = 251.2 (M+H), t_R = 0.413 min (Method C).

[0240] **Intermediate 5:** (R)-5-(1-Aminoethyl)-3-chloro-7-fluoro-2-methylisoquinolin-1(2H)-one




[0241] This intermediate was prepared using methods similar to those described for Intermediate 1 and Intermediate 4, using 4-bromo-6-fluoro-2,3-dihydro-1H-inden-1-one in place of 4-bromo-6-methyl-2,3-dihydro-1H-inden-1-one.

[0242] **Intermediate 6:** (R)-8-(1-Aminoethyl)-3,6-dimethyl-2-(methylthio)quinazolin-4(3H)-one




Step 1: Preparation of 8-bromo-3,6-dimethyl-2-thioxo-2,3-dihydroquinazolin-4(1H)-one



[0243] Methyl isothiocyanate (19.0 g, 261 mmol) was added to a mixture of 2-amino-3-bromo-5-methylbenzoic acid (30.0 g, 130 mmol) and TEA (45 mL, 326 mmol) in EtOH (500 mL) at room


temperature under an argon atmosphere. The resulting mixture was stirred for 4 h at 100 °C. The mixture was then concentrated under reduced pressure. The residue was dissolved in Et_2O (500 mL), and the precipitated solids were collected by filtration and washed with Et_2O (2 x 300 mL) to afford 8-bromo-3,6-dimethyl-2-thioxo-2,3-dihydroquinazolin-4(1H)-one (31.8 g, 85% yield) as a brown solid. ^{1}H NMR (400 MHz, DMSO-d_6): δ 10.74 (s, 1H), 7.79-7.69 (m, 1H), 7.73-7.70 (m, 1H), 3.66 (s, 3H), 2.33 (s, 3H).

Step 2: Preparation of 8-bromo-3,6-dimethyl-2-(methylthio)quinazolin-4(3H)-one



[0244] Dimethyl sulfate (5.9 g, 47.3 mmol) was added portionwise to a stirred mixture of 8-bromo-3,6-dimethyl-2-thioxo-2,3-dihydroquinazolin-4(1H)-one (9.0 g, 31.5 mmol) and NaOH (2.52 g, 63.1) in DMF (90 mL) at room temperature under an argon atmosphere. The resulting mixture was stirred for 2 h at room temperature. The mixture was then cooled to 0 °C and quenched with ice water (50 mL). The resulting solid was washed with water (5 x 10 mL) and then dried under reduced pressure to afford 8-bromo-3,6-dimethyl-2-(methylthio)quinazolin-4(3H)-one (8.0 g, 85% yield) as a white solid. ^{1}H NMR (300 MHz, Chloroform-*d*): δ 7.99-7.91 (m, 1H), 7.83-7.76 (m, 1H), 3.60 (s, 3H), 2.73 (s, 3H), 2.46-2.40 (m, 3H).


Step 3: Preparation of 8-acetyl-3,6-dimethyl-2-(methylthio)quinazolin-4(3H)-one



[0245] To a stirred mixture of 8-bromo-3,6-dimethyl-2-(methylthio)quinazolin-4(3H)-one (7.1 g, 23.7 mmol) and tributyl(1-ethoxyethenyl)stannane (10.3 g, 28.5 mmol) in 1,4-dioxane (100 mL) was added tetrakis(triphenylphosphine)palladium(0) (2.7 g, 2.4 mmol) portionwise at room temperature under an argon atmosphere. The resulting mixture was stirred overnight at 100 °C. The mixture was then cooled to 0 °C. Aqueous 1 N HCl (14.4 mL) was added in portions over 5 min at 0 °C. The resulting mixture was then stirred for 1 h at room temperature and then diluted with ice water (50 mL). The mixture was then extracted with EtOAc (3 x 50 mL), and the organics were concentrated under reduced pressure. The residue was purified by silica gel column


chromatography, (PE:EA = 1:0 increased to 5:1 over 30 min) to afford 8-acetyl-3,6-dimethyl-2-(methylthio)quinazolin-4(3H)-one (4.0 g, 64% yield) as a white solid. ^{1}H NMR (300 MHz, Chloroform-*d*): δ 8.22-8.15 (m, 1H), 7.86-7.79 (m, 1H), 3.64 (s, 3H), 2.87 (s, 3H), 2.66 (s, 3H), 2.51-2.44 (m, 3H).

Step 4: Preparation of (R,E)-N-(1-(3,6-dimethyl-2-(methylthio)-4-oxo-3,4-dihydroquinazolin-8-yl)ethylidene)-2-methylpropane-2-sulfinamide



[0246] 8-Acetyl-3,6-dimethyl-2-(methylthio)quinazolin-4(3H)-one (10 g, 38.1 mmol), (R)-2-methylpropane-2-sulfinamide (9.23 g, 76.2 mmol), and $Ti(OEt)_4$ (21.7 g, 95.3 mmol) were combined in THF (200 mL) at room temperature under an argon atmosphere. The resulting mixture was stirred overnight at 80 °C. The reaction was quenched with ice and salt (400 mL) at 0 °C. The resulting mixture was filtered, the filter cake was washed with EtOAc (2 x 200 mL). The resulting filtrate was extracted with EtOAc (2 x 400 mL). The combined organics were washed with brine, dried over anhydrous Na_2SO_4, filtered, and concentrated under reduced pressure. The crude product was used in the next step directly without further purification. LCMS (ESI^+) m/z = 366.0 $(M+H)^+$.


Step 5: Preparation of (R)-N-((R)-1-(3,6-dimethyl-2-(methylthio)-4-oxo-3,4-dihydroquinazolin-8-yl)ethyl)-2-methylpropane-2-sulfinamide



[0247] To a stirred mixture of (R,E)-N-(1-(3,6-dimethyl-2-(methylthio)-4-oxo-3,4-dihydroquinazolin-8-yl)ethylidene)-2-methylpropane-2-sulfinamide (50 g, 137 mmol) and $CeCl_3 \cdot 7H_2O$ (76.5 g, 205 mmol) in MeOH (400 mL) was added $NaBH_4$ (12.9 g, 342 mmol) in portions at -78 °C under an argon atmosphere. The resulting mixture was stirred for 2 h from -78 °C to room temperature.


The reaction was quenched with saturated aqueous NH_4Cl (800 mL) at 0 °C. The resulting mixture was then extracted with CH_2Cl_2 (3 x 800 mL). The combined organics were washed with brine, dried over anhydrous Na_2SO_4, filtered, and concentrated under reduced pressure. The residue was purified by reversed-phase flash chromatography (column, C18 silica gel; mobile phase, MeCN in Water (10 mmol/L NH_4HCO_3), 40% to 95% gradient in 30 min; detector, UV 254 nm) to afford (R)-N-((R)-1-(3,6-dimethyl-2-(methylthio)-4-oxo-3,4-dihydroquinazolin-8-yl)ethyl)-2-methylpropane-2-sulfinamide (42.6 g, 85% yield) as a white solid. ^{1}H NMR (400 MHz, Chloroform-*d*) δ 7.91 – 7.85 (m, 1H), 7.42 (d, J = 2.1 Hz, 1H), 5.13-5.04 (m, 1H), 4.27 (d, J = 5.7 Hz, 1H), 3.53 (d, J = 1.7 Hz, 3H), 2.63 (d, J = 1.4 Hz, 3H), 2.38 (s, 3H), 1.59 – 1.54 (m, 3H), 1.15 (s, 9H).

Step 6: Preparation of (R)-8-(1-aminoethyl)-3,6-dimethyl-2-(methylthio)quinazolin-4(3H)-one




[0248] To a stirred mixture of (R)-N-((R)-1-(3,6-dimethyl-2-(methylthio)-4-oxo-3,4-dihydroquinazolin-8-yl)ethyl)-2-methylpropane-2-sulfinamide (4 g, 10.9 mmol) in EtOAc was added aqueous 8 N HCl (50 mL) in portions at room temperature under a nitrogen atmosphere. The resulting mixture was stirred for 2 h at room temperature. The reaction was quenched with ice and salt (60 mL) at 0 °C. The resulting mixture was extracted with EtOAc (3 x 60 mL). The aqueous layer was adjusted to pH 10 with the addition of concentrated NH_4OH. The resulting mixture was extracted with DCM (2 x 50 mL). The combined organics were washed with brine, dried over anhydrous Na_2SO_4, filtered, and concentrated under reduced pressure to afford (R)-8-(1-aminoethyl)-3,6-dimethyl-2-(methylthio)quinazolin-4(3H)-one (2.8 g, 97% yield) as a white solid. ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.76-7.70 (m, 2H), 4.83-4.73 (m, 1H), 3.50 (s, 3H), 2.63 (s, 3H), 2.41 (s, 3H), 1.33 (d, J = 6.6 Hz, 3H).

[0249] **Intermediate 7:** tert-Butyl (R)-(1-(3-chloro-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)carbamate




[0250] A solution of (R)-5-(1-aminoethyl)-3-chloro-2,7-dimethylisoquinolin-1(2H)-one (Intermediate 4, 3 g, 12.0 mmol), DIEA (1.55 g, 12.0 mmol) and $(Boc)_2O$ (3.92 g, 18.0 mmol) in THF (30 mL) was stirred at 25 °C for 0.5 h. The reaction mixture was then concentrated under reduced pressure to give the crude product. The crude product was triturated with PE (50 mL) at 25 °C for 30 min to give tert-butyl (R)-(1-(3-chloro-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)carbamate (3.4 g, 81% yield) as a light-yellow solid. LCMS (ESI^+) m/z = 351.2 (M+H).

[0251] **Intermediate 8:** 7-(5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine




Step 1: Preparation of 7-(5-bromopyrimidin-2-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine




[0252] To a solution of 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine (926 mg, 7.46 mmol) and 5-bromo-2-fluoro-pyrimidine (1.1 g, 6.22 mmol) in DMSO (10 mL) was added DIEA (3.25 mL, 18.7 mmol). The resulting mixture was stirred at 80 °C for 2 h. The reaction mixture was then diluted with H_2O (100 mL) and then extracted with 1:3 IPA:DCM (50 mL x 3). The combined organics were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was triturated with 10:1 PE:EA (20 mL), the resulting solids were collected via filtration, and the filter cake was washed with PE (20 mL) to afford 7-(5-bromopyrimidin-2-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine (1.5 g, 85% yield) as off-white solids. LCMS (ESI^+) m/z = 281.1 (M+H).

Step 2: Preparation of 7-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine




[0253] A mixture of 7-(5-bromopyrimidin-2-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine (600 mg, 2.13 mmol), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (813 mg, 3.20 mmol), KOAc (314 mg, 3.20 mmol) and $Pd(dppf)Cl_2 \bullet CH_2Cl_2$ (174 mg, 0.21 mmol) in dioxane (10 mL) was deoxygenated and purged with N_2 three times. The mixture was then stirred at 90 °C for 2 h. The reaction mixture was filtered, and the filtrate was used directly. LCMS (ESI^+) m/z = 329.2 (M+H).

[0254] **Intermediate 9:** (2-(1,3-Dimethyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)boronic acid




Step 1: Preparation of 4-bromo-1,3-dimethylpyridin-2(1H)-one




[0255] To a solution of 4-bromo-3-methylpyridin-2(1H)-one (900 mg, 4.79 mmol) in DMF (15 mL) was added K_2CO_3 (1.98 g, 14.4 mmol) and iodomethane (1.02 g, 7.18 mmol). The mixture was stirred at 25 °C for 8 h. The mixture was diluted with water (50 mL) and then extracted three times with DCM (25 mL each). The combined organics were washed with brine (4 x 40 mL), dried over anhydrous Na_2SO_4, filtered, and concentrated under reduced pressure to give 4-bromo-1,3-dimethylpyridin-2(1H)-one (1 g, 93% yield) as a white solid. LCMS (ESI^+) m/z = 202.0 (M+H).

Step 2: Preparation of 1,3-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one




[0256] To a mixture of 4-bromo-1,3-dimethylpyridin-2(1H)-one (950 mg, 4.70 mmol) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (2.39 g, 9.40 mmol) in dioxane (20 mL) was added KOAc (1.38 g, 14.1 mmol) and Pd(dppf)Cl_2 (344 mg, 0.47 mmol). The resulting mixture was degassed and purged with N_2 three times. The mixture was then heated to 100 °C and stirred for 1 h. The reaction was then concentrated under reduced pressure to give 1,3-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one (3 g crude yield) as a black-brown solid, which was used in the next step without further purification. LCMS (ESI^+) m/z = 250.2 (M+H).

Step 3: Preparation of 4-(5-bromopyrimidin-2-yl)-1,3-dimethylpyridin-2(1H)-one




[0257] To a mixture of 1,3-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one (1.17 g, 4.70 mmol) and 5-bromo-2-iodo-pyrimidine (1.61 g, 5.64 mmol) in dioxane (10 mL) and H_2O (1 mL) was added K_2CO_3 (1.95 g, 14.1 mmol) and Pd(dppf)Cl_2 (344 mg, 0.47 mmol). The resulting mixture was degassed and purged with N_2 three times. The mixture was heated to 100 °C and stirred for 2 h, then was filtered and the filtrate was dried over anhydrous Na_2SO_4, filtered, and concentrated under reduced pressure to give a crude product. The crude product was purified by silica gel column chromatography (eluted with PE:EA from 1:1 to 1:2) to afford 4-(5-bromopyrimidin-2-yl)-1,3-dimethylpyridin-2(1H)-one (900 mg, 61% yield) as a brown solid. LCMS (ESI^+) m/z = 280.0 (M+H).

Step 4: Preparation of (2-(1,3-dimethyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)boronic acid




[0258] To a mixture of 4-(5-bromopyrimidin-2-yl)-1,3-dimethylpyridin-2(1H)-one (300 mg, 1.07 mmol) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (544 mg, 2.14 mmol) in dioxane (10 mL) was added KOAc (315 mg, 3.21 mmol) and Pd(dppf)Cl_2 (78 mg, 0.11 mmol). The resulting mixture was degassed and purged with N_2 three times. The mixture was then heated to 100 °C and stirred for 1 hr. The reaction was concentrated under reduced pressure to give (2-(1,3-dimethyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)boronic acid (520 mg, crude yield) as a black-brown solid, which was used directly without further purification. LCMS (ESI^+) m/z = 246.1 (M+H).

[0259] **Intermediate 10:** 1-Methyl-6-(trimethylstannyl)pyrazin-2(1H)-one




Step 1: Preparation of 6-bromo-1-methylpyrazin-2-one




[0260] To a solution of 6-bromo-1H-pyrazin-2-one (6 g, 34.3 mmol) in DMF (60 mL) was added K_2CO_3 (14.2 g, 103 mmol) at room temperature under a nitrogen atmosphere. Iodomethane (9.73 g, 68.6 mmol) was added dropwise at 0 °C with stirring. The resulting mixture was then stirred at room temperature for 1 h. The reaction was then diluted with ice water (100 mL) at 0 °C and the resulting mixture was extracted with EtOAc (3 x 100 mL). The combined organics were then washed with brine, dried over anhydrous Na_2SO_4, filtered, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluted with PE:EA = 1:1) to afford 6-bromo-1-methylpyrazin-2-one (3 g, 46% yield) as a white solid. ^1H NMR (400 MHz, DMSO-d_6): δ 7.96 (d, J = 2.2 Hz, 1H), 7.62 (d, J = 2.2 Hz, 1H), 3.63 – 3.51 (m, 3H).

Step 2: Preparation of 1-methyl-6-(trimethylstannyl)pyrazin-2(1H)-one




[0261] To a solution of 6-bromo-1-methylpyrazin-2-one (2.0 g, 13.8 mmol) in dioxane (20 mL) was added $Pd(PPh_3)_4$ (3.19 g, 2.7 mmol) at room temperature under an argon atmosphere, followed by the dropwise addition of hexamethyldistannane (13.6 g, 41.5 mmol) with stirring. The resulting mixture was stirred at 100 °C overnight. The reaction was then quenched by the addition of ice water (50 mL) at 0 °C and the resulting mixture was extracted with EtOAc (3 x 50 mL). The combined organics were washed with brine, dried over anhydrous Na_2SO_4, filtered, and concentrated under reduced pressure. The residue was purified by reversed-phase flash chromatography to afford 1-methyl-6-(trimethylstannyl) pyrazin-2-one (700 mg, 18% yield) as a light-yellow oil. LCMS (ESI^+) m/z = 274.7 (M+H).

[0262] **Intermediate 11:** 1-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazin-2-one




[0263] To a stirred mixture of 6-bromo-1-methylpyrazin-2-one (Intermediate 10, Step 1, 200 mg, 1.06 mmol) and bis(pinacolato)diboron (403 mg, 1.59 mmol) in THF (5 mL) was added n-BuLi (0.63 mL, 1.59 mmol) in portions at -78 °C under an argon atmosphere. The resulting mixture was stirred at -78 °C for 5 h. The reaction was quenched by the addition of EtOH (20 mL) at 0 °C and the resulting mixture was concentrated under reduced pressure to afford 1-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazin-2-one (200 mg, 80% crude yield) as a white solid. The crude product was used directly without further purification. LCMS (ESI^+) m/z = 237.0 (M+H).

[0264] **Intermediate 12:** (2-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)boronic acid




Step 1: Preparation of 5-chloro-2-methylpyridazin-3(2H)-one



[0265] To a solution of 5-chloropyridazin-3(2H)-one (6 g, 46.0 mmol) and Cs_2CO_3 (15 g, 46 mmol) in DMF (150 mL) was added iodomethane (13.1 g, 91.9 mmol). The reaction mixture was stirred at 30 °C for 8 h. The reaction mixture was then diluted with H_2O (150 mL) and extracted with EtOAc (3 x 120 mL). The combined organics were dried over Na_2SO_4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by silica gel chromatography (eluted with PE:EA = 1:1) to give 5-chloro-2-methylpyridazin-3(2H)-one (5.2 g, 74% yield) as a white solid. ^{1}H NMR (400 MHz, $CDCl_3$): δ 7.71 (d, J = 2.0 Hz, 1H), 6.96 (d, J = 2.0 Hz, 1H), 3.76 (s, 3H).


Step 2: Preparation of (1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)boronic acid



[0266] To a solution of 5-chloro-2-methylpyridazin-3(2H)-one (2.0 g, 13.8 mmol) and XPhos (1.32 g, 2.77 mmol) in dioxane (50 mL) was added KOAc (2.72 g, 27. 7 mmol) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (7.03 g, 27. 7 mmol) and $Pd_2(dba)_3$ (1.27 g, 1.38 mmol). The reaction mixture was stirred at 90 °C for 4 h under a N_2 atmosphere. The reaction mixture was then concentrated to give a residue which was diluted with H_2O (50 mL) and EtOAc (3 x 40 mL). The aqueous phase was then lyophilized to give (1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)boronic acid (2.3 g, crude product) as a white solid,


which was used as is in the next step without further purification. LCMS (ESI^+) m/z = 155.0 (M+H).

Step 3: Preparation of 5-(5-bromopyrimidin-2-yl)-2-methylpyridazin-3(2H)-one




[0267] To a solution of (1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)boronic acid (1.5 g, 9.74 mmol) and 5-bromo-2-iodo-pyrimidine (2.78 g, 9.74 mmol) in dioxane (30 mL) and H_2O (3 mL) was added K_2CO_3 (2.69 g, 19.5 mmol) and Pd(dppf)Cl_2 (713 mg, 0.97 mmol). The reaction mixture was stirred at 90 °C for 1 h under a N_2 atmosphere. The reaction mixture was then diluted with H_2O (10 mL) and extracted with EtOAc (3 x 20 mL). The combined organic phases were dried over Na_2SO_4,filtered, and concentrated to give a residue. The residue was triturated with PE:EA = 5:1 (50 mL) to give 5-(5-bromopyrimidin-2-yl)-2-methylpyridazin-3(2H)-one (1.2 g, 40% yield) as a yellow solid. LCMS (ESI^+) m/z = 266.9 (M+H).

Step 4: Preparation of (2-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)boronic acid




[0268] To a solution of 5-(5-bromopyrimidin-2-yl)-2-methylpyridazin-3(2H)-one (0.50 g, 1.87 mmol) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (713 mg, 2.81 mmol) in dioxane (20 mL) was added KOAc (551 mg, 5.62 mmol) and Pd(dppf)Cl_2 (137 mg, 0.19 mmol). The reaction mixture was stirred at 90 °C for 2 h under a N_2 atmosphere. The reaction mixture was then filtered, and the filter cake was rinsed with EtOAc (3 x 30 mL). The filtrate was then concentrated to give (2-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)boronic acid (400 mg, crude product) as a gray solid which was used in the next step without further purification. LCMS (ESI^+) m/z = 232.9. (M+H).

[0269] **Intermediate 13:** 1,3-dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazin-2(1H)-one




Step 1: Preparation of 3-(benzyloxy)-5-chloro-2-methylpyrazine



[0270] A solution of 3,5-dichloro-2-methylpyrazine (5 g, 30.7 mmol) in THF (60 mL) was treated with NaH (1.1 g, 46.0 mmol) in portions at 0 °C under a nitrogen atmosphere. After 30 min, benzyl alcohol (4.98 g, 46.0) was added at 0 °C. The resulting mixture was then stirred at room temperature for 2 h. The reaction was quenched by the addition of water (100 mL) at 0°C. The resulting mixture was extracted with diethyl ether (3 x 200 mL). The combined organics were washed with brine, dried over anhydrous Na_2SO_4, filtered, and concentrated under reduced pressure to afford 3-(benzyloxy)-5-chloro-2-methylpyrazine (5.1 g, crude yield) as a yellow oil. LCMS (ESI^+) m/z = 235.1 (M+H).


Step 2: Preparation of 6-chloro-3-methylpyrazin-2-ol



[0271] To a stirred solution of 3-(benzyloxy)-5-chloro-2-methylpyrazine (8 g, 49.0 mmol) in toluene (50 mL) was added BBr_3 (1.0 M in dichloromethane, 147 mL, 147 mmol) dropwise at -78 °C under a nitrogen atmosphere. The resulting mixture was stirred at -78 °C for 1 h. The reaction was


quenched with MeOH at 0 °C and the resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluted with CH_2Cl_2:MeOH = 5:1) to afford 6-chloro-3-methylpyrazin-2-ol as a white solid (3.7 g, 75% yield). LCMS (ESI^+) m/z = 145.2 (M+H).

Step 3: Preparation of 6-chloro-1,3-dimethylpyrazin-2(1H)-one



[0272] To a stirred solution of 6-chloro-3-methylpyrazin-2-ol (2 g, 13.8 mmol) and K_2CO_3 (5.74 g, 41.5 mmol) in DMF (20 mL) was added iodomethane (3.93 g, 27.7 mmol) in portions at 0 °C under a nitrogen atmosphere. The resulting mixture was then stirred at room temperature for 1 h. The reaction was then quenched by the addition of water (100 mL) at 0 °C. The resulting mixture was extracted with EtOAc (3 x 100 mL). The combined organics were washed with brine, dried over anhydrous Na_2SO_4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluted with PE:EA = 1:1) to afford 6-chloro-1,3-dimethylpyrazin-2(1H)-one (1 g, crude yield) as an oil. LCMS (ESI^+) m/z = 159.2 (M+H).

Step 4: Preparation of 1,3-dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazin-2(1H)-one




[0273] To a stirred solution of 6-chloro-1,3-dimethylpyrazin-2-one (200 mg, 1.26 mmol) and 4,4,5,5-tetramethyl-2-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (1.6 g, 6.31 mmol) in 1,4-dioxane (2 mL) were added $Pd(dppf)Cl_2 \bullet CH_2Cl_2$ (103 mg, 0.13 mmol) and KOAc (371 mg, 3.78 mmol) at room temperature. The resulting mixture was stirred at 90°C for 1 h under a nitrogen atmosphere. The resulting mixture was filtered, the filter cake was washed with 1,4-dioxane (2


mL). The filtrate was concentrated and used directly without further purification. LCMS: (ESI^+) m/z = 251.4 (M+H).

EXAMPLES

[0274] **Example 1:** (R)-5-(1-((2-(Ethylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one




Step 1: Preparation of (2-bromophenyl)(ethyl)sulfane



[0275] To a solution of 2-bromobenzenethiol (2.7 g, 14.3 mmol) in acetone (10 mL) was added K_2CO_3 (1.97 g, 28.6 mmol) followed by iodoethane (4.45 g, 28.6 mmol). The solution was then stirred at 50 °C for 12 h. The solution was partitioned between ethyl acetate (20 mL) and water (50 mL). The aqueous layer was extracted with ethyl acetate (20 mL x 2). The combined organic layers were washed with brine (20 mL), dried over sodium sulfate, filtered, and concentrated to afford (2-bromophenyl)(ethyl)sulfane (3 g, 96% yield) as a yellow oil. ^1H NMR (400 MHz, $CDCl_3$): δ 7.50 - 7.41 (m, 1H), 7.25 - 7.10 (m, 2H), 6.99 - 6.89 (m, 1H), 2.89 (q, J = 7.2 Hz, 2H), 1.30 (t, J = 7.2 Hz, 3H).


Step 2: Preparation of 1-bromo-2-(ethylsulfonyl)benzene



[0276] To a solution of (2-bromophenyl)(ethyl)sulfane (2 g, 9.2 mmol) in DCM (20 mL) was added m-CPBA (4.8 g, 23.7 mmol, 85% purity) at 0 °C and the mixture was stirred at 25 °C for 1 hr. To


the mixture was added a solution of Na_2SO_3 (30 mL) and extracted with DCM (20 mL x 3). The organic layers were combined, washed with brine (10 mL), dried over Na_2SO_4, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (SiO_2, PE:EA = 1:0 to 10:1) to afford 1-bromo-2-(ethylsulfonyl)benzene (2.2 g, 89% yield) as a colorless oil. LCMS (ESI^+) m/z = 249.0 (M+H), t_R = 0.500 min (Method C).

Step 3: Preparation of (R)-5-(1-((2-(ethylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one




[0277] To a solution of (R)-5-(1-aminoethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one (Intermediate 2) (50 mg, 131 µmol) and 1-bromo-2-(ethylsulfonyl)benzene (100 mg, 401 µmol) in toluene (3 mL) was added Cs_2CO_3 (128 mg, 392 µmol) and RuPhos-Pd-G3 (22 mg, 26.2 µmol) and the mixture was stirred at 105 °C for 12 hr under a N_2 atmosphere. The reaction mixture was allowed to cool to room temperature and water (5 mL) was added. The mixture was then extracted with ethyl acetate (5 mL x 3) and the combined organic layers were washed with brine (5 mL), dried over anhydrous Na_2SO_4, filtered, and concentrated under reduced pressure. The residue was purified by prep-TLC (PE: EA = 1:2) to afford a brown oil. Then the oil was purified further by prep-HPLC (column: Phenomenex luna C18 150*25mm*10 µm; mobile phase: [water(FA)-ACN]; gradient: 65%-75% B over 10 min) and the eluent was lyophilized to afford (R)-5-(1-((2-(ethylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one (12.5 mg, 8% yield) as a yellow solid. LCMS (ESI^+) m/z = 551.2 (M+H), t_R = 0.592 min (Method C); ^1H NMR (400 MHz, DMSO-d6): δ 7.87 (s, 1H), 7.61 - 7.52 (m, 1H), 7.42 (s, 1H), 7.35 - 7.28 (m, 1H), 6.75 - 6.73 (m, 1H), 6.64 (br d, *J* = 6.0 Hz, 1H), 6.48 (d, *J* = 8.0 Hz, 1H), 6.36 (s, 1H), 5.21 - 5.18 (m, 1H), 3.48 (s, 3H), 3.29 - 3.23 (m, 4H), 3.02 - 2.71 (m, 8H), 2.31 (s, 3H), 1.52 (d, *J* = 6.4 Hz, 3H), 1.12 (t, *J* = 7.2 Hz, 3H).

[0278] **Example 2:** (R)-2,7-Dimethyl-5-(1-((2-(((2,2,2-trifluoroethoxy)methyl)sulfonyl)phenyl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one




Step 1: Preparation of (2-bromophenyl)(chloromethyl)sulfane



[0279] To a solution of 1-bromo-2-methylsulfanyl-benzene (500 mg, 2.46 mmol) in DCM (6 mL) was added NCS (362 mg, 2.71 mmol) portionwise. The mixture was stirred at 25 °C for 1 hour. The reaction mixture was filtered through a short pad of silica, eluting with DCM (20 mL). The solvent was removed under reduced pressure to afford (2-bromophenyl)(chloromethyl)sulfane (550 mg, crude) as a colorless oil. ^{1}H NMR (400 MHz, $CDCl_3$): δ 7.65 - 7.57 (m, 2H), 7.41 - 7.33 (m, 1H), 7.21 - 7.14 (m, 1H), 5.02 (s, 2H).


Step 2: Preparation of (2-bromophenyl)((2,2,2-trifluoroethoxy)methyl)sulfane



[0280] To a solution of 2,2,2-trifluoroethanol (569 mg, 5.68 mmol) in DMF (2 mL) was added NaH (129 mg, 3.22 mmol, 60% purity). The mixture was stirred at 0 °C for 1.5 h under a nitrogen atmosphere, followed by NaI (284 mg, 1.89 mmol) and (2-bromophenyl)(chloromethyl)sulfane (450 mg, 1.89 mmol), then the mixture was allowed to warm to 25 °C and stirred for 12 h under a nitrogen atmosphere. The reaction mixture was quenched with saturated aqueous NH_4Cl (20 mL) at 0 °C under a nitrogen atmosphere. The mixture was extracted with EtOAc (20 mL x 3), and the combined organic layers were washed with brine (20 mL x 2), dried over anhydrous Na_2SO_4, filtered, and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (ISCO®; 10 g SepaFlash® Silica Flash Column, eluent of 100% PE, 60 mL/min) to afford (2-bromophenyl)((2,2,2-trifluoroethoxy)methyl)sulfane (550 mg, crude) as a colorless oil.


^{1}H NMR (400 MHz, $CDCl_3$): δ 7.61 - 7.46 (m, 2H), 7.34 - 7.29 (m, 1H), 7.15 - 7.10 (m, 1H), 5.16 (s, 2H), 4.08 - 4.00 (m, 2H).

Step 3: Preparation of 1-bromo-2-(((2,2,2-trifluoroethoxy)methyl)sulfonyl)benzene



[0281] To a solution of (2-bromophenyl)((2,2,2-trifluoroethoxy)methyl)sulfane (550 mg, 1.83 mmol) in DCM (8 mL) was added m-CPBA (1.11 g, 5.48 mmol, 85% purity) at 0 °C. The mixture was stirred at 25 °C for 1 h. The mixture was then quenched with saturated Na_2SO_3 (60 mL) and the mixture was extracted with DCM (30 mL x 3). The combined organic phases were washed with brine (50 mL), dried over anhydrous Na_2SO_4, filtered, and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (ISCO®; 10 g SepaFlash® Silica Flash Column, Eluent of 0-20% EA/PE, gradient @ 60 mL/min) to afford 1-bromo-2-(((2,2,2-trifluoroethoxy)methyl)sulfonyl)benzene (480 mg, 79% yield) as a colorless oil. LCMS (ESI^+) *m/z* = 354.9/356.9 (M+Na), t_R = 0.781 min (Method E).

Step 4: Preparation of (R)-2,7-dimethyl-5-(1-((2-(((2,2,2-trifluoroethoxy)methyl)sulfonyl)phenyl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one




[0282] A mixture of (R)-5-(1-aminoethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one (Intermediate 2) (50 mg, 131 µmol), 1-bromo-2-(((2,2,2-trifluoroethoxy)methyl)sulfonyl)benzene (152 mg, 458 µmol), Cs_2CO_3 (170 mg, 523 µmol), RuPhos-Pd-G3 (109 mg, 131 µmol) in toluene (1 mL) was degassed and purged with N_2 three times, and then the mixture was stirred at 110 °C for 12 hrs under a nitrogen atmosphere. The mixture was then filtered and the filtrate was concentrated to give a residue. The residue was purified by prep-TLC (SiO_2, PE:EA = 2:1) to afford a crude product, which was then purified further by prep-HPLC (column: Phenomenex luna C18 150*25mm*10µm; mobile phase: [water(FA)-ACN]; gradient: 60%-90% B over 10 min) and prep-HPLC (column: Waters xbridge 150*25mm*10µm; mobile phase: [water(NH_4HCO_3)-ACN]; gradient: 60%-80% B over 8 min) to


afford a yellow solid, which was further purified by SFC (column: DAICEL CHIRALCEL OJ-H(250mm*30mm, 5μm); mobile phase: [CO_2-EtOH (0.1% NH_3•H_2O)]; B%: 20%, isocratic elution mode) to afford (R)-2,7-dimethyl-5-(1-((2-(((2,2,2-trifluoroethoxy)methyl)sulfonyl)phenyl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one (18.3 mg, 22% yield) as a white solid. LCMS (ESI^+) *m/z* = 635.3 (M+H), t_R = 0.606 min (Method C); ^1H NMR (400 MHz, DMSO-d_6): δ 7.89 (s, 1H), 7.60 - 7.58 (m, 1H), 7.46 (d, J = 1.2 Hz, 1H), 7.41 - 7.33 (m, 1H), 6.78 - 6.69 (m, 1H), 6.63 (d, J = 6.0 Hz, 1H), 6.48 (d, J = 8.4 Hz, 1H), 6.36 (s, 1H), 5.25 -5.16 (m, 1H), 5.14 - 5.03 (m, 2H), 4.47 - 4.35 (m, 2H), 3.49 (s, 3H), 3.29 - 3.24 (m, 2H), 3.12 - 2.68 (m, 8H), 2.32 (s, 3H), 1.53 (d, J = 6.4 Hz, 3H).

[0283] **Example 3:** 6-Fluoro-2-(3-(4-fluorophenyl)bicyclo[1.1.1]pentan-1-yl)-3-methyl-8-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)quinazolin-4(3H)-one (Enantiomer 1)

[0284] **Example 4:** 6-Fluoro-2-(3-(4-fluorophenyl)bicyclo[1.1.1]pentan-1-yl)-3-methyl-8-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)quinazolin-4(3H)-one (Enantiomer 2)




Step 1: Preparation of N-(2-(1-((tert-butyldimethylsilyl)oxy)ethyl)-4-fluoro-6-(methylcarbamoyl)phenyl)-3-(4-fluorophenyl)bicyclo[1.1.1]pentane-1-carboxamide




[0285] To a solution of 2-amino-3-(1-((tert-butyldimethylsilyl)oxy)ethyl)-5-fluoro-N-methylbenzamide (Intermediate 3) (500 mg, 1.53 mmol) and 3-(4-fluorophenyl)bicyclo[1.1.1]pentane-1-carboxylic acid (347 mg, 1.68 mmol) in EtOAc (10 mL) was added T_4P (3.31 g, 4.59 mmol, 50% purity) and pyridine (606 mg, 7.66 mmol). The mixture was then stirred at 25 °C for 3 hr. The reaction mixture was partitioned between H_2O (50 mL) and EtOAc (50 mL). The organic phase was separated, dried over Na_2SO_4, filtered, and concentrated under reduced pressure to give N-(2-(1-((tert-butyldimethylsilyl)oxy)ethyl)-4-fluoro-6-(methylcarbamoyl)phenyl)-3-(4-fluorophenyl)bicyclo[1.1.1]pentane-1-carboxamide (800 mg, crude) as an off-white solid. LCMS (ESI^+) *m/z* = 515.3 (M+H), t_R = 0.735 min (Method C).

Step 2: Preparation of 8-(1-((tert-butyldimethylsilyl)oxy)ethyl)-6-fluoro-2-(3-(4-fluorophenyl)bicyclo[1.1.1]pentan-1-yl)-3-methylquinazolin-4(3H)-one




[0286] To a solution of N-(2-(1-((tert-butyldimethylsilyl)oxy)ethyl)-4-fluoro-6-(methylcarbamoyl)phenyl)-3-(4-fluorophenyl)bicyclo[1.1.1]pentane-1-carboxamide (750 mg, 1.46 mmol) in DMF (10 mL) was added K_2CO_3 (604 mg, 4.37 mmol). The mixture was stirred at 90 °C for 12 hr. The reaction mixture was partitioned between H_2O (50 mL) and EtOAc (50 mL). The organic phase was separated, washed with brine (10 mL x 2), dried over Na_2SO_4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, PE:EA = 100:0 to 93:7) to afford 8-(1-((tert-butyldimethylsilyl)oxy)ethyl)-6-fluoro-2-(3-(4-fluorophenyl)bicyclo[1.1.1]pentan-1-yl)-3-methylquinazolin-4(3H)-one (670 mg, 92% yield) as a white solid. LCMS (ESI^+) m/z = 497.3 (M+H), t_R = 0.920 min (Method D).

Step 3: Preparation of 6-fluoro-2-(3-(4-fluorophenyl)bicyclo[1.1.1]pentan-1-yl)-8-(1-hydroxyethyl)-3-methylquinazolin-4(3H)-one




[0287] To a solution of 8-(1-((tert-butyldimethylsilyl)oxy)ethyl)-6-fluoro-2-(3-(4-fluorophenyl)bicyclo[1.1.1]pentan-1-yl)-3-methylquinazolin-4(3H)-one (620 mg, 1.25 mmol) in THF (5 mL) was added TBAF (1 M, 2.5 mL). The mixture was stirred at 25 °C for 0.5 hr. The reaction mixture was then partitioned between H_2O (20 mL) and EtOAc (20 mL). The organic phase was separated, dried over Na_2SO_4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, PE:EA = 100:0 to 4:1) to afford 6-fluoro-2-(3-(4-fluorophenyl)bicyclo[1.1.1]pentan-1-yl)-8-(1-hydroxyethyl)-3-methylquinazolin-4(3H)-one (410 mg, 85% yield) as a white solid. LCMS (ESI^+) *m/z* = 383.3 (M+H), t_R =1.044 min (Method E).

Step 4: Preparation of 8-(1-bromoethyl)-6-fluoro-2-(3-(4-fluorophenyl)bicyclo[1.1.1]pentan-1-yl)-3-methylquinazolin-4(3H)-one




[0288] To a solution of 6-fluoro-2-(3-(4-fluorophenyl)bicyclo[1.1.1]pentan-1-yl)-8-(1-hydroxyethyl)-3-methylquinazolin-4(3H)-one (320 mg, 837 µmol) in DCM (5 mL) was added PBr_3 (453 mg, 1.67 mmol) at 0 °C. The mixture was stirred at 0 °C for 0.5 hr. The reaction was then quenched with H_2O (10 mL) at 0 °C and the mixture was adjusted to pH 7 with a saturated aqueous $NaHCO_3$ solution. The resulting mixture was extracted with DCM (5 mL x 3). The combined organic layers were washed with brine (10 mL x 2), dried over anhydrous Na_2SO_4, and then concentrated under reduced pressure to afford 8-(1-bromoethyl)-6-fluoro-2-(3-(4-fluorophenyl)bicyclo[1.1.1]pentan-1-yl)-3-methylquinazolin-4(3H)-one (300 mg, crude) as a white solid. LCMS (ESI^+) *m/z* = 445.1 (M+H), t_R = 0.709 min (Method C).

Step 5: Preparation of 6-fluoro-2-(3-(4-fluorophenyl)bicyclo[1.1.1]pentan-1-yl)-3-methyl-8-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)quinazolin-4(3H)-one




[0289] To a solution of 2-methylsulfonylaniline (230 mg, 1.34 mmol) in DMF (5 mL) was added NaH (90 mg, 2.25 mmol, 60% purity) at 0 °C. The mixture was stirred at 0 °C for 30 min. 8-(1-Bromoethyl)-6-fluoro-2-(3-(4-fluorophenyl)bicyclo[1.1.1]pentan-1-yl)-3-methylquinazolin-4(3H)-one (350 mg, 786 µmol) was added to the mixture and stirred at 25 °C for another 0.5 hr. The reaction mixture was quenched by addition of saturated NH_4Cl solution (50 mL) at 0 °C, and then extracted with EtOAc (20 mL x 2). The combined organic phases were washed with brine (20 mL), dried over Na_2SO_4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (FA condition; column: Phenomenex luna C18 150*25mm*10µm; mobile phase: [water(FA)-ACN]; gradient: 58%-88% B over 10 min) to afford 6-fluoro-2-(3-(4-fluorophenyl)bicyclo[1.1.1]pentan-1-yl)-3-methyl-8-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)quinazolin-4(3H)-one (110 mg, 26% yield) as a white solid. LCMS (ESI^+) *m/z* = 536.3 (M+H), t_R = 0.736 min (Method C).

Step 6: Preparation of 6-fluoro-2-(3-(4-fluorophenyl)bicyclo[1.1.1]pentan-1-yl)-3-methyl-8-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)quinazolin-4(3H)-one (Enantiomer 1) and (S)-6-fluoro-2-(3-(4-fluorophenyl)bicyclo[1.1.1]pentan-1-yl)-3-methyl-8-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)quinazolin-4(3H)-one (Enantiomer 2)



Enantiomer 1



Enantiomer 2

[0290] The enantiomers of 6-fluoro-2-(3-(4-fluorophenyl)bicyclo[1.1.1]pentan-1-yl)-3-methyl-8-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)quinazolin-4(3H)-one (110 mg, 205 µmol) were separated by SFC (Neutral condition: column: DAICEL CHIRALPAK IC (250mm*30mm,10 µm); mobile phase: [CO_2-i-PrOH/ACN]; B%: 40%, isocratic elution mode) and isolated as white solids.


[0291] 6-fluoro-2-(3-(4-fluorophenyl)bicyclo[1.1.1]pentan-1-yl)-3-methyl-8-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)quinazolin-4(3H)-one (Enantiomer 1) (48.8 mg). LCMS (ESI^+) *m/z* = 536.3 (M+H), t_R = 0.666 min (Method C); ^1H NMR (400 MHz, $CDCl_3$): δ 7.80 - 7.77 (m, 2H), 7.45 - 7.42 (m, 1H), 7.26 - 7.21 (m, 2H), 7.06 - 7.02 (m, 2H), 6.85 - 6.62 (m, 2H), 6.51 (d, J = 8.4 Hz, 1H), 5.63 - 5.43 (m, 1H), 3.78 (s, 3H), 3.14 (s, 3H), 2.63 (s, 6H), 1.68 (d, J = 6.8 Hz, 3H).

[0292] 6-fluoro-2-(3-(4-fluorophenyl)bicyclo[1.1.1]pentan-1-yl)-3-methyl-8-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)quinazolin-4(3H)-one (Enantiomer 2) (52.6 mg). LCMS (ESI^+) *m/z* = 536.3 (M+H), t_R = 0.671 min (Method C); ^1H NMR (400 MHz, $CDCl_3$): δ 7.82 - 7.78 (m, 2H),


7.43 - 7.42 (m, 1H), 7.27 - 7.21 (m, 2H), 7.08 - 7.03 (m, 2H), 6.85 - 6.69 (m, 2H), 6.52 (d, J = 8.4 Hz, 1H), 5.58 - 5.52 (m, 1H), 3.81 (s, 3H), 3.15 (s, 3H), 2.65 (s, 6H), 1.70 (d, J = 6.8 Hz, 3H).

[0293] **Example 5:** (R)-7-Fluoro-2-methyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one

[0294] **Example 6:** (R)-4,7-Difluoro-2-methyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one




Step 1: Preparation of (R)-3-chloro-7-fluoro-2-methyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one




[0295] To a solution of (R)-5-(1-aminoethyl)-3-chloro-7-fluoro-2-methylisoquinolin-1(2H)-one (Intermediate 5) (300 mg, 1.18 mmol) and 1-bromo-2-methylsulfonyl-benzene (554 mg, 2.36 mmol) in toluene (3 mL) was added Cs_2CO_3 (1.15 g, 3.53 mmol), $Pd_2(dba)_3$ (108 mg, 118 µmol) and RuPhos (55 mg, 118 µmol). The mixture was stirred at 110 °C for 12 hr. The reaction mixture was concentrated under reduced pressure to remove solvent. The residue was purified by column chromatography (SiO_2, PE:EA = 100:1 to 5:1) to afford (R)-3-chloro-7-fluoro-2-methyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one (160 mg, 29% yield) as a yellow solid. LCMS (ESI^+) m/z = 409.0 (M+H), t_R =1.009 min (Method E).

Step 2: Preparation of (R)-7-fluoro-2-methyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one



[0296] To a solution of (R)-3-chloro-7-fluoro-2-methyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one (150 mg, 367 µmol) and 1-(2,2,2-trifluoroethyl)piperazine (124 mg, 734 µmol) in dioxane (2 mL) was added Cs_2CO_3 (359 mg, 1.10 mmol) and RuPhos-Pd-G3 (31 mg, 37 µmol). The mixture was stirred at 130 °C for 12 hr. The reaction mixture was concentrated under reduced pressure and the resulting residue was purified by prep-HPLC (Phenomenex luna C18 150*25mm*10µm; mobile phase: [water(FA)-ACN]; gradient: 48%-78% B over 10 min) to afford (R)-7-fluoro-2-methyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one (40 mg, 19% yield) as a white solid. LCMS (ESI^+) m/z = 541.2 (M+H), t_R = 0.570 min (Method C); ^1H NMR (400 MHz, $CDCl_3$): δ 8.06 - 7.94 (m, 1H), 7.92 - 7.77 (m, 1H), 7.45 - 7.35 (m, 1H), 7.27 - 7.20 (m, 1H), 6.89 - 6.70 (m, 2H), 6.37 - 6.18 (m, 2H), 5.05 - 4.86 (m, 1H), 3.64 (s, 3H), 3.16 (s, 3H), 3.16 - 2.69 (m, 10H), 1.65 (br d, *J* = 6.8 Hz, 3H).


Step 3: Preparation of (R)-4,7-difluoro-2-methyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one




[0297] To a solution of (R)-7-fluoro-2-methyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one (25 mg, 46 µmol) in ACN (2 mL) was added SelectFluor™ (49 mg, 139 µmol), Et_3SiH (8.1 mg, 69 µmol) and $Pd(PPh_3)_4$ (53 mg, 46 µmol). The mixture was stirred at 50 °C for 2 hr. The reaction mixture was then concentrated under reduced pressure and the resulting residue was purified by prep-HPLC (Phenomenex luna C18 150*25mm*10µm; mobile phase: [water(FA)-ACN]; gradient: 47%-77% B over 10 min) to afford (R)-4,7-difluoro-2-methyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one (17 mg, 62% yield) as a yellow solid. LCMS

(ESI$^+$) m/z = 559.2 (M+H), t_R = 0.920 min (Method E); ^{1}H NMR (400 MHz, $CDCl_3$): δ 8.06 - 7.98 (m, 1H), 7.81 - 7.79 (m, 1H), 7.54 - 7.52 (m, 1H), 7.26 - 7.22 (m, 1H), 6.84 - 6.72 (m, 2H), 6.34 (d, *J* = 8.4 Hz, 1H), 5.40 - 5.28 (m, 1H), 3.64 (s, 3H), 3.54 - 3.51 (m, 2H), 3.17 (s, 3H), 3.13 - 2.97 (m, 6H), 2.83 - 2.71 (m, 2H), 1.63 (br d, *J* = 6.4 Hz, 3H).

[0298] **Example 7:** (R)-2,7-Dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-3-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)isoquinolin-1(2H)-one




Step 1: Preparation of (R)-3-chloro-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one




[0299] A mixture of 1-bromo-2-methylsulfonyl-benzene (619 mg, 2.63 mmol), (R)-5-(1-aminoethyl)-3-chloro-2,7-dimethylisoquinolin-1(2H)-one (Intermediate 4) (330 mg, 1.32 mmol), $Pd_2(dba)_3$ (121 mg, 131 µmol), RuPhos (123 mg, 263 µmol) and Cs_2CO_3 (1.29 g, 3.95 mmol) in toluene (6 mL) was degassed and purged with N_2 three times, and then the mixture was stirred at 110 °C for 12 hr under a nitrogen atmosphere. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, PE:EA = 100:1 to 3:1) to afford (R)-3-chloro-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one (180 mg, 29% yield) as a yellow solid. LCMS (ESI$^+$) m/z = 405.2 (M+H), t_R = 0.597 min (Method C).

Step 2: Preparation of (R)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-3-(1-(2,2,2-trifluoroethyl)-1,2,3,6-tetrahydropyridin-4-yl)isoquinolin-1(2H)-one



[0300] A mixture of (R)-3-chloro-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one (170 mg, 420 µmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(2,2,2-trifluoroethyl)-3,6-dihydro-2H-pyridine (183 mg, 630 µmol), $Pd(dppf)Cl_2•CH_2Cl_2$ (69 mg, 84 µmol), and Na_2CO_3 (134 mg, 1.26 mmol) in dioxane (4 mL) and H_2O (0.5 mL) was degassed and purged with N_2 three times, and then the mixture was stirred at 90 °C for 12 hr under a nitrogen atmosphere. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, PE:EA = 100:1 to 2:1) to afford (R)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-3-(1-(2,2,2-trifluoroethyl)-1,2,3,6-tetrahydropyridin-4-yl)isoquinolin-1(2H)-one (150 mg, 60% yield) as a yellow solid. LCMS (ESI^+) m/z = 534.2 (M+H), t_R = 0.902 min (Method E).

Step 3: Preparation of (R)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-3-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)isoquinolin-1(2H)-one




[0301] To a mixture of 10% Pd/C (60 mg, 56 µmol) in MeOH (5 mL) was added (R)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-3-(1-(2,2,2-trifluoroethyl)-1,2,3,6-tetrahydropyridin-4-yl)isoquinolin-1(2H)-one (140 mg, 262 µmol) under a nitrogen atmosphere. The suspension was degassed and purged with H_2 three times. The mixture was stirred under H_2 (15 psi) at 25 °C for 12 hr. Then, 20% $Pd(OH)_2/C$ (37 mg, 52.5 µmol) was added to the mixture and stirred at 50 °C


for another 1 hr. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (FA condition; column: Phenomenex Luna C18 150*25mm*10µm; mobile phase: [water(FA)-ACN]; gradient: 48%-78% B over 10 min) to afford (R)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-3-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)isoquinolin-1(2H)-one (51 mg, 36% yield) as an off-white solid. LCMS (ESI^+) *m/z* = 536.3 (M+H), t_R = 0.555 min (Method C); ^1H NMR (400 MHz, $CDCl_3$): δ 8.16 (s, 1H), 7.79 (d, *J* = 8.0 Hz, 1H), 7.46 (s, 1H), 7.26 - 4.22 (m, 1H), 6.80 - 6.69 (m, 2H), 6.59 (s, 1H), 6.35 (d, *J* = 8.4 Hz, 1H), 5.08 - 4.95 (m, 1H), 3.69 (s, 3H), 3.24 - 3.13 (m, 5H), 3.12 -3.04 (m, 2H), 2.76 - 2.70 (m, 1H), 2.58 (t, *J* = 11.6 Hz, 2H), 2.41 (s, 3H), 2.01 (d, *J* = 12.4 Hz, 2H), 1.92 - 1.78 (m, 2H), 1.65 (br d, *J* = 6.4 Hz, 3H).

[0302] **Example 8:** 5-((1R)-1-((2-(N,S-Dimethylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one (Diastereomer 1)

[0303] **Example 9:** 5-((1R)-1-((2-(N,S-Dimethylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one (Diastereomer 2)




Step 1: Preparation of (2-fluorophenyl)(imino)(methyl)- λ6-sulfanone



[0304] To a solution of 1-fluoro-2-methylsulfanyl-benzene (2 g, 14.1 mmol) in MeOH (50 mL) was added $(NH_4)_2CO_3$ (2.03 g, 21.1 mmol) and (bis(acetoxy)iodo)benzene (11.3 g, 35.2 mmol). The mixture was stirred at 25 °C for 12 hr. The reaction mixture was then concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, PE:EA = 100:1 to 1:1) to afford (2-fluorophenyl)(imino)(methyl)-λ6-sulfanone (2.4 g, 98% yield) as


an off-white solid. ^{1}H NMR (400 MHz, $CDCl_3$): δ 7.98 - 7.95 (m, 1H), 7.68 - 7.56 (m, 1H), 7.33 (t, *J* = 7.6 Hz, 1H), 7.27 - 7.20 (m, 1H), 3.29 (s, 3H).

Step 2: Preparation of (2-fluorophenyl)(methyl)(methylimino)- λ6-sulfanone



[0305] To a solution of (2-fluorophenyl)(imino)(methyl)-λ6-sulfanone (1 g, 5.77 mmol) in DMF (10 mL) was added NaH (700 mg, 17.50 mmol, 60% purity) at 0 °C. The mixture was stirred at 0 °C for 0.5 hr. Then CH_3I (4.56 g, 32.1 mmol) was added to the mixture and the mixture was stirred at 25 °C for 0.5 hr. The reaction mixture was quenched by the addition of a saturated aqueous NH_4Cl solution (50 mL) at 0 °C. The resulting mixture was then extracted with EtOAc (30 mL x 2). The combined organic layers were washed with brine (30 mL x 2), dried over Na_2SO_4, filtered, and concentrated under reduced pressure to afford a residue. The residue was purified by column chromatography (SiO_2, PE:EA = 100:1 to 5:1) to afford (2-fluorophenyl)(methyl)(methylimino)- λ6-sulfanone (950 mg, 87% yield) as a yellow solid. LCMS (ESI^+) m/z = 188.1 (M+H), t_R = 0.387 min (Method L).


Step 3: Preparation of 5-((1R)-1-((2-(N,S-dimethylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one




[0306] To a solution of (2-fluorophenyl)(methyl)(methylimino)- λ6-sulfanone (147 mg, 784 µmol) and (R)-5-(1-aminoethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one (Intermediate 2) (100 mg, 261 µmol) in IPA (0.1 mL) was added DIEA (371 mg, 2.87 mmol, 0.5 mL) and 4Å molecular sieves (100 mg) at 25 °C. The mixture was then stirred at 110 °C for 5 hr. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (FA condition; column: Phenomenex luna C18 150*25mm*10µm; mobile phase: [water(FA)-ACN]; gradient: 44%-74% B over 10 min) to afford 5-((1R)-1-((2-(N,S-dimethylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-

trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one (50 mg, 34% yield) as a yellow solid. LCMS (ESI^+) *m/z* = 550.3 (M+H), t_R = 0.549 min (Method E); ^1H NMR (400 MHz, $CDCl_3$): δ 8.13 (br s, 1H), 7.84 - 7.74 (m, 1H), 7.49 - 7.36 (m, 2H), 7.26 - 7.21 (m, 1H), 6.81 - 6.71 (m, 1H), 6.38 - 6.30 (m, 1H), 6.24 (d, J = 13.6 Hz, 1H), 5.04 - 4.85 (m, 1H), 3.65 (s, 3H), 3.18 (d, J = 5.6 Hz, 3H), 3.15 - 2.85 (m, 10H), 2.78 (d, J = 4.0 Hz, 3H), 2.39 (d, J = 6.0 Hz, 3H), 1.62 - 1.60 (m, 3H).

Step 4: Preparation of 5-((1R)-1-((2-(N,S-dimethylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one (Diastereomer 1) and 5-((1R)-1-((2-(N,S-dimethylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one (Diastereomer 2)



Diastereomer 1



Diastereomer 2


[0307] 5-((1R)-1-((2-(N,S-dimethylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one (50 mg, 91 µmol) was purified by SFC (neutral condition; column: DAICEL CHIRALCEL OD-H(250mm*30mm,5µm); mobile phase: [CO_2-EtOH]; B%: 35%, isocratic elution mode) to afford 5-((1R)-1-((2-(N,S-dimethylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one (Diastereomer 1) and 5-((1R)-1-((2-(N,S-dimethylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one (Diastereomer 2) as yellow solids.

[0308] 5-((1R)-1-((2-(N,S-Dimethylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one (Diastereomer 1) (19 mg). LCMS (ESI^+) *m/z* = 550.3 (M+H), t_R = 0.519 min (Method C); ^1H NMR (400 MHz, $CDCl_3$): δ 8.11 (s, 1H), 7.77 - 7.75 (m, 1H), 7.42 (d, J = 1.6 Hz, 1H), 7.38 (br d, J = 6.4 Hz, 1H), 7.26 - 7.18 (m, 1H), 6.80 - 6.68 (m, 1H), 6.33 (d, J = 8.0 Hz, 1H), 6.21 (s, 1H), 5.03 - 4.87 (m, 1H), 3.63 (s, 3H), 3.15 (s, 3H), 3.13 - 2.79 (m, 10H), 2.77 (s, 3H), 2.37 (s, 3H), 1.62 (d, J = 6.8 Hz, 3H).


[0309] 5-((1R)-1-((2-(N,S-Dimethylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one (Diastereomer 2) (18 mg). LCMS (ESI^+) *m/z* = 550.3 (M+H), t_R = 0.513 min (Method C); ^1H NMR (400 MHz, $CDCl_3$): δ 8.12 (s, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.45 (s, 1H), 7.36 (br d, J = 4.0 Hz, 1H), 7.23 (t, J = 7.2 Hz, 1H), 6.75 (t, J = 7.6 Hz, 1H), 6.33

(d, J = 8.4 Hz, 1H), 6.24 (s, 1H), 5.01 - 4.84 (m, 1H), 3.63 (s, 3H), 3.16 (s, 3H), 3.14 - 2.78 (m, 10H), 2.76 (s, 3H), 2.39 (s, 3H), 1.62 (br d, J = 6.8 Hz, 3H).

[0310] **Example 10:** 2,7-Dimethyl-5-((1R)-1-((6-methyl-2-(S-methylsulfonimidoyl)pyridin-3-yl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one




Step 1: Preparation of 3-fluoro-6-methyl-2-(methylthio)pyridine




[0311] To a solution of 2,3-difluoro-6-methyl-pyridine (900 mg, 6.97 mmol) in DMF (10 mL) was added sodium methanethiolate (489 mg, 6.97 mmol) at 0 °C. The mixture was stirred at 25 °C for 0.5 hour. The reaction was quenched with water (10 mL) and extracted with EA (20 mL x 3). The organic phases were combined and washed with brine (30 mL), dried over Na_2SO_4, filtered, and concentrated under reduced pressure. The resulting residue was purified by silica gel chromatography (PE:EA = 1:0, 10:1) to afford 3-fluoro-6-methyl-2-(methylthio)pyridine (700 mg, 60% yield) as white oil. LCMS (ESI^+) *m/z* = 158.1 (M+H), t_R = 0.849 min (Method E).

Step 2: Preparation of (3-fluoro-6-methylpyridin-2-yl)(imino)(methyl)- λ6-sulfanone




[0312] To a mixture of 3-fluoro-6-methyl-2-(methylthio)pyridine (650 mg, 4.13 mmol) and (acetoxy(phenyl)-iodanyl)acetate (3.33 g, 10.3 mmol) in MeOH (5 mL) was added $(NH_4)_2CO_3$ (596 mg, 6.2 mmol). The mixture was stirred at 25°C for 12 hours and then concentrated under reduced pressure to give a residue. The residue was purified by silica gel chromatography (PE:EA = 1:0, 0:1) to afford (3-fluoro-6-methylpyridin-2-yl)(imino)(methyl)- λ6-sulfanone (630 mg, 72% yield) as yellow oil. LCMS (ESI^+) *m/z* = 188.9 (M+H), t_R = 0.248 min (Method E).

Step 3: Preparation of 2,7-dimethyl-5-((1R)-1-((6-methyl-2-(S-methylsulfonimidoyl)pyridin-3-yl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one




[0313] To a solution of (3-fluoro-6-methylpyridin-2-yl)(imino)(methyl)- λ6-sulfanone (148 mg, 784 µmol), (R)-5-(1-aminoethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one (Intermediate 2) (100 mg, 261 µmol) in IPA (0.5 mL) was added DIEA (371 mg, 2.87 mmol, 0.5 mL) and 4Å molecular sieves (80 mg). The mixture was stirred at 130 °C for 4 hr. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (Phenomenex luna C18 150*25mm*10µm; mobile phase: [water(FA)-ACN]; gradient: 43%-73% B over 10 min) to afford 2,7-dimethyl-5-((1R)-1-((6-methyl-2-(S-methylsulfonimidoyl)pyridin-3-yl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one (54 mg, 36% yield) as a yellow solid. LCMS (ESI^+) *m/z* = 551.1 (M+H), t_R = 0.922 min (Method E); ^1H NMR (400 MHz, $CDCl_3$): δ 8.07 (s, 1H), 7.63 - 7.51 (m, 1H), 7.42 (d, J = 2.4 Hz, 1H), 6.87 (d, J = 8.8 Hz, 1H), 6.50 - 6.40 (m, 1H), 6.19 (d, J = 5.2 Hz, 1H), 4.81 - 4.78 (m, 1H), 3.59 (s, 3H), 3.33 (d, J = 6.0 Hz, 3H), 3.09 - 2.70 (m, 10H), 2.37 - 2.33 (m, 6H), 1.58 (d, J = 6.8 Hz, 3H).

[0314] **Example 11:** (R)-2,7-Dimethyl-5-(1-((2-(((1-methyl-1H-pyrazol-4-yl)methyl)sulfonyl)phenyl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one




Step 1: Preparation of 4-(((2-fluorophenyl)thio)methyl)-1-methyl-1H-pyrazole



[0315] To a solution of 4-(chloromethyl)-1-methyl-pyrazole hydrochloride (300 mg, 1.80 mmol) in DMF (5 mL) was added K_2CO_3 (496 mg, 3.59 mmol) and 2-fluorobenzenethiol (230 mg, 1.80 mmol). The mixture was stirred at 60 °C for 12 hr. The reaction mixture was partitioned between H_2O (50 mL) and EtOAc (50 mL). The organic phase was separated, washed with brine (20 mL x 2), dried over Na_2SO_4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, PE:EA = 100:1 to 4:1) to afford 4-(((2-fluorophenyl)thio)methyl)-1-methyl-1H-pyrazole (340 mg, 85% yield) as an colorless oil. LCMS (ESI^+) *m/z* = 222.9 (M+H), t_R = 0.500 min (Method C).


Step 2: Preparation of 4-(((2-fluorophenyl)sulfonyl)methyl)-1-methyl-1H-pyrazole



[0316] To a solution of 4-(((2-fluorophenyl)thio)methyl)-1-methyl-1H-pyrazole (340 mg, 1.53 mmol) in DCM (5 mL) was added m-CPBA (620 mg, 3.05 mmol, 85% purity) at 0 °C. The mixture was stirred at 25 °C for 1 hr. The reaction mixture was quenched by adding aqueous Na_2SO_3 at 25 °C. The mixture was then diluted with H_2O (10 mL) and then extracted with DCM (20 mL x 2). The combined organic layers were washed with saturated $NaHCO_3$ solution (30 mL x 2), dried over Na_2SO_4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, PE:EA = 100:1 to 1:1) to afford 4-(((2-


fluorophenyl)sulfonyl)methyl)-1-methyl-1H-pyrazole (360 mg, 92% yield) as a colorless oil. LCMS (ESI^+) *m/z* = 255.1 (M+H), t_R = 0.516 min (Method C).

Step 3: Preparation of (R)-2,7-dimethyl-5-(1-((2-(((1-methyl-1H-pyrazol-4-yl)methyl)sulfonyl)phenyl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one




[0317] A mixture of 4-(((2-fluorophenyl)sulfonyl)methyl)-1-methyl-1H-pyrazole (133 mg, 523 µmol), (R)-5-(1-aminoethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one (Intermediate 2) (100 mg, 261 µmol), DIEA (371 mg, 2.87 mmol, 0.5 mL), and 4Å molecular sieves (50 mg) in IPA (0.1 mL) was degassed and purged with N_2 three times. The mixture was stirred at 130 °C for 6 hr under a nitrogen atmosphere. The reaction mixture was dissolved in ACN (2 mL) and filtered to give a filtrate. The filtrate was purified by prep-HPLC (FA condition; column: Phenomenex Luna C18 150*25mm*10µm; mobile phase: [water(FA)-ACN]; gradient: 45%-75% B over 10 min) to afford (R)-2,7-dimethyl-5-(1-((2-(((1-methyl-1H-pyrazol-4-yl)methyl)sulfonyl)phenyl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one (83 mg, 51% yield) as a white solid. LCMS (ESI^+) *m/z* = 617.3 (M+H), t_R = 0.593 min (Method C); ^1H NMR (400 MHz, $CDCl_3$): δ 8.11 (s, 1H), 7.48 - 7.47 (m, 1H), 7.41 (d, *J* = 1.6 Hz, 1H), 7.29 - 7.26 (m, 1H), 7.25 - 7.16 (m, 1H), 7.13 (s, 1H), 6.72 (br d, *J* = 5.2 Hz, 1H), 6.64 - 6.63 (m, 1H), 6.28 (d, *J* = 8.4 Hz, 1H), 6.21 (s, 1H), 4.95 - 4.81 (m, 1H), 4.41 - 4.25 (m, 2H), 3.86 (s, 3H), 3.63 (s, 3H), 3.22 - 2.72 (m, 10H), 2.38 (s, 3H), 1.59 (br d, *J* = 6.4 Hz, 3H).

[0318] **Example 12:** (R)-3-(4-(5-Fluoro-2-methylpyridin-3-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one




Step 1: Preparation of tert-butyl 4-(5-fluoro-2-methylpyridin-3-yl)piperazine-1-carboxylate



[0319] To the solution of 3-bromo-5-fluoro-2-methyl-pyridine (1.9 g, 10.0 mmol) and tert-butyl piperazine-1-carboxylate (2.79 g, 15.0 mmol) in toluene (30 mL) was added Cs_2CO_3 (9.77 g, 30.0 mmol), BINAP (623 mg, 1.0 mmol) and $Pd(OAc)_2$ (224 mg, 1.0 mmol) and the mixture was stirred at 80 °C for 12 hr under a nitrogen atmosphere. The solution was filtered through a celite pad, and the filtrate was concentrated. The residue was purified by column chromatography (SiO_2, PE:EA = 75:25 to 50:50) to afford tert-butyl 4-(5-fluoro-2-methylpyridin-3-yl)piperazine-1-carboxylate (2.5 g, 76% yield) as a yellow solid. LCMS (ESI^+) *m/z* = 296.3 (M+H), t_R = 0.514 min (Method C).


Step 2: Preparation of 1-(5-fluoro-2-methylpyridin-3-yl)piperazine



[0320] To a solution of tert-butyl 4-(5-fluoro-2-methylpyridin-3-yl)piperazine-1-carboxylate (2.5 g, 8.46 mmol) in DCM (9 mL) was added TFA (4.61 g, 40.4 mmol) at 0 °C and the solution stirred at 25 °C for 1 hr. The solution was concentrated to produce a crude product. The crude product was dissolved in MeOH (10 mL) and adjusted to pH 8 by the addition of aqueous ammonia. The

solution was purified by prep-HPLC purification (column: Kromasil Eternity XT 250*80mm*10μm; mobile phase: [water (NH_4OH)-ACN]; gradient: 1%-31% B over 20 min) and the eluent was lyophilized to afford 1-(5-fluoro-2-methylpyridin-3-yl)piperazine (0.8 g, 48% yield) as a yellow oil. ^1H NMR (400 MHz, $CDCl_3$) δ: 8.05 (d, *J* = 2.4 Hz, 1H), 7.01-6.95 (m, 1H), 3.14 - 2.96 (m, 4H), 2.95 - 2.73 (m, 4H), 2.46 (d, *J* = 0.4 Hz, 3H).


Step 3: Preparation of (R)-3-(4-(5-fluoro-2-methylpyridin-3-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one




[0321] A solution of (R)-3-chloro-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one (Example 7, Step 1) (0.2 g, 301 μmol), 1-(5-fluoro-2-methylpyridin-3-yl)piperazine (0.2 g, 1.02 mmol), Cs_2CO_3 (982 mg, 3.01 mmol) and BINAP-Pd-G3 (30 mg, 30 μmol) in dioxane (10 mL) was stirred at 100 °C for 12 hr under a nitrogen atmosphere. The solution was filtered through a celite pad, and the filtrate was concentrated. The residue was purified by prep-TLC (PE:EA = 1:4) to afford yellow oil. Then the yellow oil was purified further by prep-HPLC purification (column: Phenomenex Luna C18 150*25mm*10μm; mobile phase: [water(FA)-ACN]; gradient: 48%-78% B over 10 min) and the eluent was lyophilized to afford (R)-3-(4-(5-fluoro-2-methylpyridin-3-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one (64 mg, 37% yield) as a yellow solid. LCMS (ESI^+) m/z = 564.2 (M+H), t_R = 0.937 min (Method E); ^1H NMR (400 MHz, $CDCl_3$): δ 8.19 - 8.09 (m, 2H), 7.79 - 7.76 (m, 1H), 7.45 (d, J = 1.6 Hz, 1H), 7.27 - 7.20 (m, 1H), 7.13 - 7.11 (m, 1H), 6.80 - 6.66 (m, 2H), 6.39 (d, J = 8.4 Hz, 1H), 6.28 (s, 1H), 4.01 - 4.95 (m, 1H), 3.68 (s, 3H), 3.38 - 2.99 (m, 11H), 2.55 (s, 3H), 2.40 (s, 3H), 1.68 (d, J = 6.8 Hz, 3H).

[0322] **Example 13:** 3-(3,5'-Difluoro-2'-methyl-[2,3'-bipyridin]-5-yl)-5-((1R)-1-((2-(N,S-dimethylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one (Diastereomer 1)

[0323] **Example 14:** 3-(3,5'-Difluoro-2'-methyl-[2,3'-bipyridin]-5-yl)-5-((1R)-1-((2-(N,S-dimethylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one (Diastereomer 2)




Step 1: Preparation of 5-fluoro-2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine




[0324] A mixture of 3-bromo-5-fluoro-2-methyl-pyridine (500 mg, 2.63 mmol), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (735 mg, 2.89 mmol), $Pd(dppf)Cl_2 \bullet CH_2Cl_2$ (430 mg, 526 µmol) and KOAc (775 mg, 7.89 mmol) in dioxane (10 mL) was degassed and purged with N_2 three times, and then the mixture was stirred at 70 °C for 16 hr. The reaction mixture was filtered and concentrated under reduced pressure to afford 5-fluoro-2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (623 mg, crude) as brown oil, which was used in the next step without purification.

Step 2: Preparation of 5-bromo-3,5'-difluoro-2'-methyl-2,3'-bipyridine




[0325] A mixture of 5-fluoro-2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (623 mg, 2.63 mmol), 2,5-dibromo-3-fluoro-pyridine (670 mg, 2.63 mmol), K_2CO_3 (1.09 g, 7.88 mmol) and $Pd(PPh_3)_4$ (304 mg, 263 µmol) in dioxane (10 mL) and H_2O (1 mL) was degassed and purged with N_2 three times. The mixture was then stirred at 80 °C for 2 hr. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, PE:EA = 99:1 to 85:15) to afford 5-bromo-3,5'-difluoro-2'-methyl-2,3'-bipyridine (410 mg, 54% yield) as a yellow oil. LCMS (ESI^+) *m/z* = 285.0 (M+H), t_R = 0.633 min (Method C).

Step 3: Preparation of 3,5'-difluoro-2'-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3'-bipyridine




[0326] A mixture of 5-bromo-3,5'-difluoro-2'-methyl-2,3'-bipyridine (310 mg, 1.09 mmol), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (333 mg, 1.31 mmol), $Pd(dppf)Cl_2 \bullet CH_2Cl_2$ (93 mg, 114 µmol), and KOAc (320 mg, 3.26 mmol) in dioxane (2 mL) was degassed and purged with N_2 three times. The resulting mixture was then stirred at 80 °C for 12 hr. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, PE:EA = 100:1 to 5:1) to afford 3,5'-difluoro-2'-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3'-bipyridine (360 mg, 99% yield) as yellow oil. ^1H NMR (400 MHz, $CDCl_3$): δ 8.85 (s, 1H), 8.46 (d, *J* = 2.8 Hz, 1H), 7.89 (d, *J* = 9.6 Hz, 1H), 7.47 - 7.45 (m, 1H), 2.47 (s, 3H), 1.39 (s, 12H).

Step 4: Preparation of 3-chloro-5-((1R)-1-((2-(N,S-dimethylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one




[0327] To a solution of (2-fluorophenyl)(methyl)(methylimino)-λ6-sulfanone (224 mg, 1.20 mmol) and (R)-5-(1-aminoethyl)-3-chloro-2,7-dimethylisoquinolin-1(2H)-one (Intermediate 4) (200 mg, 798 µmol) in IPA (0.1 mL) was added DIEA (223 mg, 1.72 mmol) and 4Å molecular sieves (50 mg). The mixture was stirred at 130 °C for 12 hr. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-TLC (SiO_2, PE:EA = 1:1) to afford 3-chloro-5-((1R)-1-((2-(N,S-dimethylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one (80 mg, 17% yield) as a yellow solid. LCMS (ESI^+) *m/z* = 418.1 (M+H), t_R = 0.493 min (Method K).


Step 5: Preparation of 3-(3,5'-difluoro-2'-methyl-[2,3'-bipyridin]-5-yl)-5-((1R)-1-((2-(N,S-dimethylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one



[0328] A mixture of 3-chloro-5-((1R)-1-((2-(N,S-dimethylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one (230 mg, 550 µmol), 3,5'-difluoro-2'-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3'-bipyridine (150 mg, 452 µmol), 4-di-tert-butylphosphanyl-N,N-dimethyl-aniline palladium dichloride (39 mg, 55 µmol), and K_3PO_4 (350 mg, 1.65 mmol) in dioxane (4 mL) and H_2O (0.5 mL) was degassed and purged with N_2 three times. The mixture was stirred at 100 °C for 3 hr. The reaction mixture was then partitioned between H_2O (10 mL) and EtOAc (10 mL). The organic phase was separated and dried over Na_2SO_4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by prep-TLC (SiO_2, PE:EA = 1:2). Then the product was purified by prep-HPLC (FA condition; column: Phenomenex Luna C18 150*25mm*10µm; mobile phase: [water(FA)-ACN]; gradient: 44%-74% B over 10 min) to afford 3-(3,5'-difluoro-2'-methyl-[2,3'-bipyridin]-5-yl)-5-((1R)-1-((2-(N,S-dimethylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one (75 mg, 22% yield) as a white solid. LCMS (ESI^+) *m/z* = 588.3 (M+H), t_R = 0.534 min (Method C).

Step 6: Preparation of 3-(3,5'-difluoro-2'-methyl-[2,3'-bipyridin]-5-yl)-5-((1R)-1-((2-(N,S-dimethylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one (Diastereomer 1) and 3-(3,5'-difluoro-2'-methyl-[2,3'-bipyridin]-5-yl)-5-((1R)-1-((2-(N,S-dimethylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one (Diastereomer 2)






[0329] 3-(3,5'-Difluoro-2'-methyl-[2,3'-bipyridin]-5-yl)-5-((1R)-1-((2-(N,S-dimethylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one (75 mg, 128 µmol) was separated by SFC (column: DAICEL CHIRALCEL OD (250mm*30mm, 10µm); mobile phase: [CO_2-EtOH(0.1% NH_4OH)]; B%: 45%, isocratic elution mode) to afford 3-(3,5'-difluoro-2'-methyl-[2,3'-bipyridin]-5-yl)-5-((1R)-1-((2-(N,S-dimethylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one (Diastereomer 1) and 3-(3,5'-difluoro-2'-methyl-[2,3'-bipyridin]-5-yl)-5-((1R)-1-((2-(N,S-dimethylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one (Diastereomer 2) as white solids.


[0330] 3-(3,5'-Difluoro-2'-methyl-[2,3'-bipyridin]-5-yl)-5-((1R)-1-((2-(N,S-dimethylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one (Diastereomer 1) (30 mg). LCMS (ESI^+) *m/z* = 588.3 (M+H), t_R = 0.531 min (Method C); ^1H NMR (400 MHz, $CDCl_3$): δ 8.70 (s, 1H), 8.53 (d, *J* = 2.8 Hz, 1H), 8.24 (s, 1H), 7.78 - 7.76 (m, 1H), 7.69 - 7.67 (m, 1H), 7.57 - 7.52 (m, 2H), 7.49 (d, *J* = 6.4 Hz, 1H), 7.24 - 7.15 (m, 1H), 6.79 - 6.67 (m, 2H), 6.31 (d, *J* = 8.4 Hz, 1H), 5.05 – 4.98 (m, 1H), 3.56 (s, 3H), 3.14 (s, 3H), 2.81 (s, 3H), 2.57 (s, 3H), 2.45 (s, 3H), 1.65 (d, *J* = 6.8 Hz, 3H).

[0331] 3-(3,5'-difluoro-2'-methyl-[2,3'-bipyridin]-5-yl)-5-((1R)-1-((2-(N,S-dimethylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one (Diastereomer 2) (37 mg). LCMS (ESI^+) *m/z* = 588.3 (M+H), t_R = 0.540 min (Method C); ^1H NMR (400 MHz, $CDCl_3$): δ 8.70 (s, 1H), 8.52 (d, *J* = 2.8 Hz, 1H), 8.25 (s, 1H), 7.79 - 7.77 (m, 1H), 7.69 - 7.67 (m, 1H), 7.60 - 7.51 (m, 2H), 7.45 (d, *J* = 3.6 Hz, 1H), 7.25 - 7.20 (m, 1H), 6.81 - 6.73 (m, 2H), 6.32 (d, *J* = 8.4 Hz, 1H), 5.05 - 4.90 (m, 1H), 3.56 (s, 3H), 3.18 (s, 3H), 2.75 (s, 3H), 2.57 (s, 3H), 2.47 (s, 3H), 1.65 (d, *J* = 6.8 Hz, 3H).

[0332] **Example 15:** (R)-5-(1-((6-chloro-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one




Step 1: Preparation of 6-chloro-3-fluoro-2-(methylthio)pyridine




[0333] To a solution of 2,6-dichloro-3-fluoro-pyridine (1 g, 6.02 mmol) in DMF (10 mL) was added sodium methanethiolate (500 mg, 7.13 mmol) at 0 °C and then the mixture was stirred at 25 °C for 2 hr. The reaction mixture was partitioned between H_2O (50 mL) and EtOAc (50 mL). The organic phase was separated, washed with brine (50 mL), dried over Na_2SO_4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, PE:EA = 100:1 to 95:5) to afford 6-chloro-3-fluoro-2-(methylthio)pyridine (490 mg, 45% yield) as colorless oil. ^{1}H NMR (400 MHz, $CDCl_3$): δ 7.22 – 7.17 (m, 1H), 7.01 – 6.97 (m, 1H), 2.59 (s, 3H).

Step 2: 6-chloro-3-fluoro-2-(methylsulfonyl)pyridine




[0334] To a solution of 6-chloro-3-fluoro-2-(methylthio)pyridine (480 mg, 2.70 mmol) in EtOAc (10 mL) was added NaClO (12.1 g, 162 mmol) at 25 °C. The resulting mixture was stirred at 25 °C for 2 hr. The reaction mixture was then partitioned between H_2O (10 mL) and EtOAc (10 mL). The organic phase was separated, dried over Na_2SO_4, filtered, and concentrated under reduced pressure to afford 6-chloro-3-fluoro-2-(methylsulfonyl)pyridine (440 mg, crude) as a colorless oil, which was used for next step directly without purificaton. LCMS (ESI^+) *m/z* = 210.1 (M+H), t_R = 0.422 min (Method C).

Step 3: Preparation of (R)-5-(1-((6-chloro-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one




[0335] To a solution of (R)-5-(1-aminoethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one (Intermediate 2) (100 mg, 261 µmol) and 6-chloro-3-fluoro-2-(methylsulfonyl)pyridine (110 mg, 523 µmol) in ACN (0.5 mL) was added triethylamine (79 mg, 785 µmol). The resuliting mixture was stirred at 80 °C for 12 hr. The reaction mixture was then filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (FA condition; column: Phenomenex luna C18 150*25mm*10µm; mobile phase: [water(FA)-ACN]; gradient: 52%-82% B over 10 min) to afford (R)-5-(1-((6-chloro-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one (95 mg, 63% yield) as an off-white solid. LCMS (ESI^+) *m/z* = 572.3 (M+H), t_R = 0.616 min (Method C); ^1H NMR (400 MHz, $CDCl_3$): δ 8.12 (s, 1H), 7.42 (d, *J* = 2.0 Hz, 1H), 7.13 - 7.01 (m, 2H), 6.60 (d, *J* = 9.2 Hz, 1H), 6.19 (s, 1H), 4.92 - 4.74 (m, 1H), 3.62 (s, 3H), 3.36 (s, 3H), 3.21 - 2.65 (m, 10H), 2.40 (s, 3H), 1.64 (d, *J* = 6.8 Hz, 3H).

[0336] **Example 16:** (R)-5-(1-((6-ethynyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one




Step 1: Preparation of (R)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)-6-((trimethylsilyl)ethynyl)pyridin-3-yl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one



[0337] A mixture of (R)-5-(1-((6-chloro-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one (Example 15) (54 mg, 94 µmol), ethynyl(trimethyl)silane (93 mg, 944 µmol, 131 µL), Xphos-Pd-G4 (8 mg, 9.44 µmol), N-cyclohexyl-N-methyl-cyclohexanamine (55 mg, 283 µmol) in dioxane (1 mL) was degassed and purged with N_2 three times. The resulting mixture was stirred at 110 °C for 2 h. Then ethynyl(trimethyl)silane (93 mg, 944 µmol) was added and the mixture was stirred at 110 °C for another 12 hr under a nitrogen atmosphere. The reaction mixture was then filtered, and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by prep-TLC (SiO_2, PE:EA = 1:1) to afford (R)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)-6-((trimethylsilyl)ethynyl)pyridin-3-yl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one (60 mg, 89% yield) as yellow oil. LCMS (ESI^+) *m/z* = 634.2 (M+H), t_R = 0.729 min (Method E).


Step 2: Preparation of (R)-5-(1-((6-ethynyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one




[0338] To a solution of (R)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)-6-((trimethylsilyl)ethynyl)pyridin-3-yl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one (55 mg, 86.8 µmol) in DMF (0.5 mL) was added CsF (26 mg, 174 µmol). The mixture was stirred at 25 °C for 0.5 hr. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (FA condition; column: Phenomenex luna C18 150*25mm*10µm; mobile phase: [water(FA)-ACN]; gradient: 45%-75% B over 10 min) to afford (R)-5-(1-((6-ethynyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-

trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one (19 mg, 38% yield) as an off-white solid. LCMS (ESI^+) *m/z* = 562.3 (M+H), t_R = 0.602 min (Method C); ^1H NMR (400 MHz, $CDCl_3$): δ 8.12 (s, 1H), 7.42 (s, 1H), 7.26 - 7.16 (m, 2H), 6.55 (d, *J* = 8.8 Hz, 1H), 6.19 (s, 1H), 4.95 - 4.77 (m, 1H), 3.62 (s, 3H), 3.39 (s, 3H), 3.15 - 2.71 (m, 11H), 2.39 (s, 3H), 1.65 (d, *J* = 6.8 Hz, 3H).

[0339] **Example 17:** (R)-2-((1-(2,7-dimethyl-1-oxo-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzenesulfonamide




Step 1: Preparation of 2-bromo-N,N-bis((2-(trimethylsilyl)ethoxy)methyl)benzenesulfonamide




[0340] To a stirred solution of 2-bromobenzenesulfonamide (2.5 g, 10.6 mmol) in DMF (50 mL) was added NaH (1.27 g, 31.7mmol, 60 wt%) at 0 °C under a nitrogen atmosphere. After the mixture was stirred for 30 min at 0 °C, SEM-Cl (5.30 g, 31.7 mmol) was added dropwise at room temperature. The resulting mixture was stirred for 4 h at room temperature under a nitrogen atmosphere. The reaction was quenched with water (50 mL) at 0 °C and the aqueous phase was extracted with EtOAc (3 x 50 mL). The combined organics were washed with brine (3 x 20 mL) and dried over anhydrous Na_2SO_4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluted with PE:EA = 10:1) to afford 2-bromo-N,N-bis((2-(trimethylsilyl)ethoxy)methyl)benzenesulfonamide (4 g, 76% yield) as an oil. ^1H NMR (400 MHz, DMSO-d_6) δ 8.12 – 8.08 (m, 1H), 7.82 -7.78 (m, 1H), 7.60 – 7.55 (m, 2H), 4.81 (s, 4H), 3.37 – 3.28 (m, 4H), 0.73 – 0.63 (m, 4H), 0.01 (s, 18H).

Step 2: Preparation of (R)-2-((1-(2,7-dimethyl-1-oxo-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-N,N-bis((2-(trimethylsilyl)ethoxy)methyl)benzenesulfonamide



[0341] To a stirred solution of 2-bromo-N,N-bis((2-(trimethylsilyl)ethoxy)methyl)benzenesulfonamide (1.04 g, 2.09 mmol) and (R)-5-(1-aminoethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one (Intermediate 2) (400 mg, 1.05 mmol) in dioxane (10 mL) were added $Pd_2(dba)_3$ (96 mg, 0.11 mmol), Cs_2CO_3 (682 mg, 2.09 mmol) and Xantphos (121 mg, 0.21 mmol) at room temperature under a nitrogen atmosphere. The resulting mixture was stirred overnight at 100 °C. The resulting mixture was filtered and the filter cake was washed with EtOAc. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE:EA = 2:1) to afford (R)-2-((1-(2,7-dimethyl-1-oxo-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-N,N-bis((2-(trimethylsilyl)ethoxy)methyl)benzenesulfonamide (250 mg, 30% yield) as an oil. MS (ES^-) m/z = 796.2 $[M-H]^-$.


Step 3: Preparation of (R)-2-((1-(2,7-dimethyl-1-oxo-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzenesulfonamide



[0342] To a stirred solution of (R)-2-((1-(2,7-dimethyl-1-oxo-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-N,N-bis((2-(trimethylsilyl)ethoxy)methyl)benzenesulfonamide (150 mg, 0.19 mmol) in THF (10 mL) was added TBAF (1M in THF, 1.88 mL, 1.88 mmol) dropwise at room temperature under a nitrogen

atmosphere. The resulting mixture was stirred overnight at 50 °C. The reaction was then quenched with water (10 mL) at 0 °C and the mixture was extracted with EtOAc (3 x 20 mL). The combined organics were washed with brine (3 x 15 mL) and dried over anhydrous Na_2SO_4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by prep-HPLC with the following conditions (UV 254nm/220nm Xselect CSH Prep C18 Column, 30*150 mm, 5μm; Water (0.1% FA), ACN 60 mL/min, 43% B to 68 % B in 10 min) to afford (R)-2-((1-(2,7-dimethyl-1-oxo-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzenesulfonamide (66 mg, 65% yield) as a white solid. MS (ES^+) m/z = 538.2 $[M+H]^+$, t_R = 0.977 min; ^1H NMR (400 MHz, DMSO-d_6): δ 7.89 – 7.84 (m, 1H), 7.64 – 7.621 (m, 1H), 7.59 – 7.53 (m, 3H), 7.19 – 7.14 (m, 1H), 6.63 – 6.59 (m, 1H), 6.43 (s, 1H), 6.39 – 6.33 (m, 2H), 5.20 – 5.17 (m, 1H), 3.50 (s, 3H), 3.30 – 3.28 (m, 2H), 3.15 – 2.84 (m, 8H), 2.31 (s, 3H), 1.53 (d, J = 6.5 Hz, 3H).

[0343] **Example 18:** (R)-2-((1-(2,7-dimethyl-1-oxo-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-N-methylbenzenesulfonamide




Step 1: Preparation of 2-bromo-N-methyl-N-((2-(trimethylsilyl)ethoxy)methyl)benzenesulfonamide



[0344] A solution of 2-bromo-N-methylbenzenesulfonamide (700 mg, 2.80 mmol) in DMF (15 mL) was added NaH (244 mg, 5.60 mmol, 60 wt%) at 0 °C under a nitrogen atmosphere. After the mixture was stirred for 30 min at 0 °C, SEM-Cl was added (607 mg, 3.64 mmol) at 0 °C. The mixture was then stirred for 5 h at room temperature. The reaction was quenched with water (10 mL) at room temperature and the mixture was extracted with EtOAc (3 x 20 mL). The combined organics were washed with brine (3 x 20 mL) and dried over anhydrous Na_2SO_4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by prep-TLC (PE:EA = 5:1) to afford 2-bromo-N-methyl-N-((2-(trimethylsilyl)ethoxy)methyl)benzenesulfonamide (650 mg, 61% yield) as a colorless oil. ^1H NMR


(400 MHz, DMSO-d_6) δ 8.05 – 8.00 (m, 1H), 7.91 – 7.84 (m, 1H), 7.65 – 7.53 (m, 2H), 4.79 (s, 2H), 3.53 – 3.44 (m, 2H), 2.78 (s, 3H), 0.88 – 0.79 (m, 2H), 0.01 (s, 9H).

Step 2: Preparation of (R)-2-((1-(2,7-dimethyl-1-oxo-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-N-methyl-N-((2-(trimethylsilyl)ethoxy)methyl)benzenesulfonamide



[0345] A mixture of 2-bromo-N-methyl-N-((2-(trimethylsilyl)ethoxy)methyl)benzenesulfonamide (497 mg, 1.3 mmol), (R)-5-(1-aminoethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one (Intermediate 2) (200 mg, 0.52 mmol), $Pd_2(dba)_3$ (48 mg, 0.052 mmol), Xantphos (61 mg, 0.11 mmol), and Cs_2CO_3 (852 mg, 2.62 mmol) in dioxane (10 mL) was stirred overnight at 100 °C under a nitrogen atmosphere. The resulting mixture was filtered and the filter cake was washed with DCM (3 x 10 mL). The filtrate was concentrated under reduced pressure and the resulting residue was purified by prep-TLC (PE:EA = 1:1) to afford (R)-2-((1-(2,7-dimethyl-1-oxo-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-N-methyl-N-((2-(trimethylsilyl)ethoxy)methyl)benzenesulfonamide (150 mg, 42. % yield) as a light brown solid. MS (ES^+) m/z = 682.3 $[M+H]^+$.


Step 3: Preparation of (R)-2-((1-(2,7-dimethyl-1-oxo-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-N-methylbenzenesulfonamide




[0346] A mixture of afford (R)-2-((1-(2,7-dimethyl-1-oxo-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-N-methyl-N-((2-(trimethylsilyl)ethoxy)methyl)benzenesulfonamide (150 mg, 0.22 mmol) and TBAF (2.2 mL, 2.2

mmol) in THF (10 mL) was stirred for 20 h at 50 °C. The reaction was quenched with water (10 mL) at room temperature and the resulting mixture was extracted with EtOAc (3 x 20 mL). The combined organics were washed with brine (3 x 15 mL) and then dried over anhydrous Na_2SO_4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by prep-HPLC (Column: XBridge Prep OBD C18 Column, 50*250 mm, 10μm; Mobile Phase A: Water (10 nmol/L NH_4HCO_3), Mobile Phase B: ACN; Flow rate: 60 mL/min; Gradient: 45% B to 75% B in 20 min; Wave Length: 254 nm/220 nm) to afford (R)-2-((1-(2,7-dimethyl-1-oxo-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-N-methylbenzenesulfonamide (54 mg, 44%, yield) as a white solid. ^{1}H NMR (400 MHz, Methanol-d_4): δ 8.02 – 7.97 (m, 1H), 7.68 – 7.66 (m, 1H), 7.59 (d, J = 1.9 Hz, 1H), 7.24 – 7.15 (m, 1H), 6.70 – 6.66 (m, 1H), 6.51 (s, 1H), 6.43 (d, J = 8.4 Hz, 1H), 5.17 – 5.16 (m, 1H), 3.66 (s, 3H), 3.26 – 3.25 (m, 2H), 3.20 – 2.88 (m, 8H), 2.57 (s, 3H), 2.38 (s, 3H), 1.65 (d, J = 6.7, 3H). MS (ES$^-$) m/z = 550.4 [M-H]$^-$.

[0347] **Example 19:** (R)-3,6-dimethyl-8-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-2-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)quinazolin-4(3H)-one




Step 1: Preparation of (R)-3,6-dimethyl-8-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-2-(methylthio)quinazolin-4(3H)-one




[0348] To a stirred solution of (R)-8-(1-aminoethyl)-3,6-dimethyl-2-(methylthio)quinazolin-4(3H)-one (Intermediate 6) (300 mg, 1.1 mmol) and 1-iodo-2-methanesulfonylbenzene (321 mg, 1.1 mmol) in dioxane (10 mL) were added Cs_2CO_3 (1.1 g, 3.4 mmol) and [1,3-bis[2,6-bis(1-ethylpropyl)phenyl]-4,5-dichloro-imidazol-2-ylidene]-dichloro-(2-methylpyridin-1-ium-1-yl)palladium (16 mg, 0.019 mmol) in portions at room temperature under argon atmosphere. The resulting mixture was stirred overnight at 100 °C. The reaction was then quenched with water (60 mL) at room temperature and the resulting mixture was extracted with EtOAc (2 x 60 mL). The combined organics were washed with brine, dried over anhydrous Na_2SO_4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE:EA = 1:1) to afford (R)-3,6-dimethyl-8-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-2-(methylthio)quinazolin-4(3H)-one (100 mg, 21% yield) as a light yellow solid. ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.81-7.76 (m, 1H), 7.66-7.58 (m, 2H), 7.36-7.30 (m, 1H), 6.77-6.67 (m, 2H), 6.59 (d, J = 8.4 Hz, 1H), 5.53-5.41 (m, 1H), 3.53 (s, 3H), 3.20 (s, 3H), 2.68 (s, 3H), 2.36 (s, 3H), 1.63 (d, J = 6.6 Hz, 3H).

Step 2: Preparation of 3,6-dimethyl-2-(methylsulfinyl)-8-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)quinazolin-4(3H)-one



[0349] To a stirred solution of (R)-3,6-dimethyl-8-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-2-(methylthio)quinazolin-4(3H)-one (70 mg, 0.17 mmol) in THF (2 mL) was added oxone (169 mg, 1.0 mmol) in H_2O (2 mL) dropwise at 0 °C under an argon atmosphere. The resulting mixture was stirred for 1 h at room temperature and then was diluted with ice water (40 mL). The resulting mixture was extracted with EtOAc (2 x 40 mL) and the combined organics were washed with brine, dried over anhydrous Na_2SO_4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, (CH_2Cl_2:MeOH = 10:1) to afford 3,6-dimethyl-2-(methylsulfinyl)-8-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)quinazolin-4(3H)-one (40 mg, 55% yield) as a white solid. LCMS (ESI$^+$) *m/z* = 434.1 (M+H).


Step 3: Preparation of (R)-3,6-dimethyl-8-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-2-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)quinazolin-4(3H)-one




[0350] A mixture of 3,6-dimethyl-2-(methylsulfinyl)-8-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)quinazolin-4(3H)-one (40 mg, 0.092 mmol) and 1-(2,2,2-trifluoroethyl)piperazine (19 mg, 0.11 mmol) in NMP (2 mL) was stirred overnight at 130 °C. The mixture was then diluted with ice water (30 mL) and the resulting mixture was extracted with EtOAc (2 x 30 mL). The combined organics were washed with brine, dried over anhydrous Na_2SO_4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, (PE:EA = 1:1) to afford (R)-2-hydroxy-3,6-dimethyl-8-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)quinazolin-4(3H)-one (35 mg, 8%) as a white solid.

[0351] A solution of (R)-2-hydroxy-3,6-dimethyl-8-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)quinazolin-4(3H)-one (35 mg, 0.090 mmol) and PyBOP (141 mg, 0.270 mmol) in DMF (2 mL) under an argon atmosphere was stirred at room temperature for 10 min. Then, DBU (69 mg, 0.45 mmol) and 1-(2,2,2-trifluoroethyl)piperazine (23 mg, 0.14 mmol) were added in portions at room temperature. The resulting mixture was stirred for 3 h at room temperature and then was diluted with ice water (20 mL). The resulting mixture was extracted with EtOAc (2 x 20 mL). The combined organics were washed with brine, dried over anhydrous Na_2SO_4, filtered, and concentrated under reduced pressure. The residue was purified by reversed-phase flash chromatography (column, C18 silica gel; mobile phase, MeCN in Water, 5% to 95% gradient in 30 min; detector, UV 254 nm) to afford (R)-3,6-dimethyl-8-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-2-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)quinazolin-4(3H)-one (13 mg, 27% yield) as a white solid. LCMS (ESI^+) *m/z* = 538.2 [M+H]; ^1H NMR (400 MHz, DMSO-d_6): δ 7.76-7.20 (m, 1H), 7.64 – 7.54 (m, 2H), 7.37-7.29 (m, 1H), 6.77 (d, J = 7.0 Hz, 1H), 6.75 – 6.65 (m, 2H), 5.44-5.33 (m, 1H), 3.48 (s, 3H), 3.31 – 3.23 (m, 6H), 3.16 (s, 3H), 2.86-2.79 (m, 4H), 2.34 (s, 3H), 1.60 (d, J = 6.6 Hz, 3H).

[0352] **Example 85:** (R)-3-(2-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)pyrimidin-5-yl)-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one




Step 1: Preparation of (R)-3-chloro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one




[0353] To a solution of (R)-5-(1-aminoethyl)-3-chloro-2,7-dimethylisoquinolin-1(2H)-one (Intermediate 4, 200 mg, 0.80 mmol) and 1,4-difluoro-2-methylsulfonyl-benzene (200 mg, 1.04 mmol) in IPA (0.2 mL) was added 4Å molecular sieves (100 mg) and DIEA (0.40 mL, 2.30 mmol). The mixture was stirred at 130 °C for 12 hr. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, PE:EA = 10:1 to 4:1) to give (R)-3-chloro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one (170 mg, 50% yield) as a yellow solid. LCMS (ESI^+) m/z = 423.2 (M+H).

Step 2: Preparation of (R)-3-(2-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)pyrimidin-5-yl)-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one




[0354] A mixture of (R)-3-chloro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one (70 mg, 0.17 mmol), 7-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine (Intermediate 8, 81 mg, 0.25 mmol), mesylate[(di(1-adamantyl)-n-butylphosphine)-2-(2'-amino-1,1'-biphenyl)]palladium(II) (cataCXium® A Pd G3) (12 mg, 0.017 mmol), Na_2CO_3 (35 mg, 0.33 mmol) in dioxane (2 mL) and H_2O (0.2 mL) was degassed and purged with N_2 three times. The mixture was then stirred at 100 °C for 1 h. The reaction mixture was then diluted with H_2O (10 mL) and extracted with EA (10 mL x 3). The combined organics were washed with brine (30mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC to afford (R)-3-(2-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)pyrimidin-5-yl)-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one (30 mg, 30% yield) as a yellow solid. LCMS (ESI^+) m/z = 589.3 (M+H); ^1H NMR (400 MHz, $CDCl_3$): δ 8.53 (s, 2H), 8.23-8.19 (m, 2H), 7.53 - 7.52 (m, 1H), 7.47 (d, J = 1.6 Hz, 1H), 7.01 - 6.93 (m, 1H), 6.60 (s, 1H), 6.52 (d, J = 5.2 Hz, 1H), 6.26 - 6.24 (m, 1H), 5.32 (s, 2H), 4.92 - 4.89 (m, 1H), 4.42 - 4.41 (m, 2H), 4.27 - 4.20 (m, 2H), 3.52 (s, 3H), 3.16 (s, 3H), 2.44 (s, 3H), 1.62 (d, J = 6.8 Hz, 3H).

[0355] **Example 86:** (R)-3-(2-(1,3-dimethyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one




Step 1: Preparation of tert-butyl (R)-(1-(3-(2-(1,3-dimethyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)carbamate




[0356] A mixture of (2-(1,3-dimethyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)boronic acid (Intermediate 9, 280 mg, 0.86 mmol), tert-butyl (R)-(1-(3-chloro-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)carbamate (Intermediate 7, 300 mg, 0.86 mmol), mesylate[(di(1-adamantyl)-n-butylphosphine)-2-(2'-amino-1,1'- biphenyl)]palladium(II) (cataCXium® A Pd G3) (62 mg, 0.086 mmol), K_2CO_3 (355 mg, 2.57 mmol) in dioxane (5 mL) and H_2O (1 mL) was degassed and purged with N_2 three times. The mixture was then stirred at 100 °C for 1 h. The mixture was then filtered, and filtrate concentrated under reduced pressure affording a crude product. The crude product was purified by silica gel column chromatography (eluted with PE:EA from 1:0 to 1:1) to give tert-butyl (R)-(1-(3-(2-(1,3-dimethyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)carbamate (400 mg, 70% yield) as a black-brown solid. LCMS (ESI^+) m/z = 516.2 (M+H).

Step 2: Preparation of (R)-5-(1-aminoethyl)-3-(2-(1,3-dimethyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2,7-dimethylisoquinolin-1(2H)-one



[0357] A solution of tert-butyl (R)-(1-(3-(2-(1,3-dimethyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)carbamate (200 mg, 0.39 mmol) in a solution of HCl in dioxane (4 M, 2 mL) was prepared. The mixture was stirred at 25 °C for 0.3 h. The reaction was then concentrated under reduced pressure to give (R)-5-(1-aminoethyl)-3-(2-(1,3-dimethyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2,7-dimethylisoquinolin-1(2H)-one hydrochloride (152 mg, 76% yield) as a brown solid. LCMS (ESI^+) m/z = 416.2 (M+H).


Step 3: Preparation of (R)-3-(2-(1,3-dimethyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one




[0358] To a solution of (R)-5-(1-aminoethyl)-3-(2-(1,3-dimethyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2,7-dimethylisoquinolin-1(2H)-one (free base from the HCl salt reported in the previous step, generated via treating a 10:1 CH_2Cl_2/MeOH solution of the HCl salt with saturated aqueous $NaHCO_3$, 150 mg, 0.36 mmol), 3-bromo-6-methyl-2-(trifluoromethyl)pyridine (130 mg, 0.54 mmol), (SP-4-1)-[1,3-bis[2,6-bis(1-ethylpropyl)phenyl]-4,5-dichloro-1,3-dihydro-2H-imidazol-2-ylidene]dichloro(2-methylpyridine)palladium (30 mg, 0.036 mmol), Cs_2CO_3 (471 mg, 1.44 mmol) in dioxane (10 mL) was degassed and purged with N_2 three times. The mixture was then stirred at 90 °C for 1 h. The mixture was then filtered, and the filtrate was concentrated under reduced pressure to afford the crude product. The crude product was purified by silica gel

column chromatography (eluted with PE:EA from 1:1 to 1:4) and then purified further by prep-HPLC to afford (R)-3-(2-(1,3-dimethyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one (24 mg, 11% yield) as a yellow solid. LCMS (ESI^+) m/z = 575.3 (M+H), t_R =0 .517 min (Method X); ^{1}H NMR (400 MHz, DMSO-d_6): δ 9.25 (s, 2H), 8.01 (s, 1H), 7.70 - 7.68 (m, 1H), 7.59 (s, 1H), 7.16 (s, 1H), 7.13 - 7.11 (m, 1H), 6.86 - 6.84 (m, 1H), 6.61 - 6.59 (m, 1H), 5.60 - 5.68 (m, 1H), 5.30 - 5.27 (m, 1H), 3.51 (s, 3H), 3.45 (s, 3H), 2.38 (s, 3H), 2.28 (s, 3H), 2.27 (s, 3H), 1.55 (d, J = 6.8 Hz, 3H).

[0359] **Example 87:** (R)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-2,7-dimethyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one




Step 1: Preparation of 1-bromo-2-(difluoromethyl)-3,4-difluorobenzene




[0360] To a stirred solution of 6-bromo-2,3-difluorobenzaldehyde (15.0 g, 67.8 mmol) in DCM (30 mL) was added DAST (21.9 g, 136 mmol) dropwise at 0 °C under an argon atmosphere. The resulting mixture was stirred at room temperature for 2 h and then quenched by the addition of ice water (400 mL) at 0 °C. The resulting mixture was then extracted with CH_2Cl_2 (3 x 400 mL). The combined organics were dried over anhydrous Na_2SO_4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluted with PE:EA = 10:1) to afford 1-bromo-2-(difluoromethyl)-3,4-difluorobenzene (11.0 g, 67 %yield) as an off-white oil. ^{1}H NMR (400 MHz, DMSO-d_6) δ 7.73 – 7.63 (m, 2H), 7.45 – 7.14 (m, 1H).

Step 2: Preparation of (R)-3-chloro-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one




[0361] To a stirred solution of 1-bromo-2-(difluoromethyl)-3,4-difluorobenzene (1.0 g, 4.1 mmol) and (R)-5-(1-Aminoethyl)-3-chloro-2,7-dimethylisoquinolin-1(2H)-one (Intermediate 4, 1.6 g, 6.1 mmol) in dioxane (10 mL) was added Cs_2CO_3 (4.0 g, 12.3 mmol), XantPhos (0.48 g, 0.82 mmol) and $Pd_2(dba)_3$ (0.4 g, 0.4 mmol) at room temperature under an argon atmosphere. The resulting mixture was stirred at 100 °C overnight. The reaction was diluted with ice water (50 mL) at 0 °C and then extracted with EtOAc (3 x 50 mL). The combined organics were dried over anhydrous Na_2SO_4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluted with PE:EA = 1:1) to afford (R)-3-chloro-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one (960 mg, 56% yield) as a light-yellow oil. LCMS (ESI^+) m/z = 413 (M+H).

Step 3: Preparation of (R)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-2,7-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinolin-1(2H)-one




[0362] To a stirred solution (R)-3-chloro-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one (900 mg, 2.2 mmol) and 4,4,5,5-tetramethyl-2-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (11.0 g, 43.6 mmol) in dioxane (10 mL) were added KOAc (642 mg, 6.5 mmol) and $Pd(dppf)Cl_2$ (160 mg, 0.2 mmol) in portions at room temperature under an argon atmosphere. The resulting mixture was stirred at 90 °C for 2 h. The resulting mixture was then filtered, and the filter cake was washed with DCM (3 x 20 mL). The filtrate was then concentrated under reduced pressure. The crude product mixture was used in the next step directly without further purification. LCMS (ESI^+) *m/z* = 505 (M+H).

Step 4: Preparation of (R)-3-(2-bromopyrimidin-5-yl)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one




[0363] To a stirred solution (R)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-2,7-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinolin-1(2H)-one (900 mg, 1.8 mmol) and 2-bromo-5-iodopyrimidine (610 mg, 2.1 mmol) in dioxane (10 mL) and H_2O (2 mL) were added Na_2CO_3 (567 mg, 5.4 mmol) and $Pd(PPh_3)_4$ (206 mg, 0.2 mmol) in portions at room temperature under a nitrogen atmosphere. The resulting mixture was then stirred at 90 °C overnight. The mixture was diluted with ice water (30 mL) at 0 °C and the resulting mixture was extracted with EtOAc (3 x 30 mL). The combined organics were dried over anhydrous Na_2SO_4, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by reverse-phase flash chromatography to afford (R)-3-(2-bromopyrimidin-5-yl)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one (450 mg, 47% yield) as a light-yellow solid. LCMS (ESI^+) m/z = 535 (M+H).

Step 5: Preparation of (R)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-2,7-dimethyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one




[0364] To a stirred solution of (R)-3-(2-bromopyrimidin-5-yl)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one (100 mg, 0.2 mmol) and 1-methyl-6-(trimethylstannyl)pyrazin-2-one (Intermediate 10, 102 mg, 0.3 mmol) in DMF (0.5 mL) were added mesyl[(tri-t-butylphosphine)-2-(2-aminobiphenyl)]palladium(II) (9.6 mg, 0.02 mmol) and tri-tert-butylphosphonium tetrafluoroborate (5.4 mg, 0.019 mmol) in portions at room temperature under an argon atmosphere. The resulting mixture was then stirred at 80 °C overnight. The mixture was diluted with ice water (30 mL) at 0 °C and the resulting mixture was extracted with EtOAc (3 x 30 mL). The combined organics were dried over anhydrous Na_2SO_4, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by reverse-phase flash chromatography and then prep-HPLC to afford (R)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-2,7-dimethyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one (9.0 mg, 8.5% yield) as a light-yellow solid. LCMS (ESI^+) *m/z* = 565 (M+H); ^1H NMR (400 MHz, DMSO-d_6): δ 9.32 (s, 2H), 8.21 (s, 1H), 8.03 (s, 1H), 7.78 (s, 1H), 7.66 – 7.36 (m, 2H), 7.28 – 7.14 (m, 2H), 6.17 – 6.08 (m, 2H), 5.26 – 5.15 (m, 1H), 3.62 (s, 3H), 3.47 (s, 3H), 2.41 (s, 3H), 1.52 (d, J = 6.6 Hz, 3H).

[0365] **Example 88:** (R)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one




Step 1: Preparation of (R)-3-chloro-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one



To a stirred solution/mixture of (R)-5-(1-Aminoethyl)-3-chloro-2,7-dimethylisoquinolin-1(2H)-one (Intermediate 4, 1 g, 4.0 mmol) and 4-fluoro-1-iodo-2-(trifluoromethyl)benzene (1.73 g, 5.98 mmol) and Cs_2CO_3 (3.90 g, 12.0 mmol) and RuPhos (744 mg, 1.60 mmol) in 1,4-dioxane (10 mL) was added $Pd_2(dba)_3$ (730 mg, 0.80 mmol) in portions at room temperature under an argon atmosphere. The resulting mixture was then stirred at 100 °C for 2 h. The mixture was then diluted with ice water (50 mL) at 0 °C and the resulting mixture was extracted with EtOAc (3 x 50 mL). The combined organics were dried over anhydrous Na_2SO_4, filtered, and then the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluted with PE:EA = 5:1) to afford (R)-3-chloro-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one (600 mg, 36% yield) as a white solid. LCMS (ESI^+) m/z = 413 (M+H).


[0366] To a stirred solution/mixture of (R)-5-(1-Aminoethyl)-3-chloro-2,7-dimethylisoquinolin-1(2H)-one (Intermediate 4, 1 g, 4.0 mmol) and 4-fluoro-1-iodo-2-(trifluoromethyl)benzene (1.73 g, 5.98 mmol) and Cs_2CO_3 (3.90 g, 12.0 mmol) and RuPhos (744 mg, 1.60 mmol) in 1,4-dioxane (10 mL) was added $Pd_2(dba)_3$ (730 mg, 0.80 mmol) in portions at room temperature under an argon atmosphere. The resulting mixture was then stirred at 100 °C for 2 h. The mixture was then diluted with ice water (50 mL) at 0 °C and the resulting mixture was extracted with EtOAc (3 x 50 mL). The combined organics were dried over anhydrous Na_2SO_4, filtered, and then the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluted with PE:EA = 5:1) to afford (R)-3-chloro-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one (600 mg, 36% yield) as a white solid. LCMS (ESI^+) m/z = 413 (M+H).

Step 2: Preparation of (R)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinolin-1(2H)-one




[0367] To a stirred solution/mixture of (R)-3-chloro-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one (600 mg, 1.45 mmol) and 4,4,5,5-tetramethyl-2-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (738 mg, 2.91 mmol) and KOAc (428 mg, 4.36 mmol) in dioxane (10 mL) were added $Pd(dppf)Cl_2$ (213 mg, 0.29 mmol) dropwise at room temperature under an argon atmosphere. The resulting mixture was stirred at 110 °C overnight. The mixture was then filtered and concentrated under reduced pressure to afford a crude product that was used in the next step directly without characterization or further purification. LCMS (ESI^+) m/z = 505 (M+H).

Step 3: Preparation of (R)-3-(2-bromopyrimidin-5-yl)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one



[0368] To a stirred mixture of crude (R)-3-chloro-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one (600 mg, 1.19 mmol) and 2-bromo-5-iodopyrimidine (508 mg, 1.79 mmol) in dioxane (4 mL) and H_2O was added $Pd(PPh_3)_4$ (137 mg, 0.12 mmol) and Na_2CO_3 (378 mg, 3.57 mmol) under an argon atmosphere. The resulting mixture was stirred at 110 °C for 2 h and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluted with CH_2Cl_2:MeOH = 5:1) to afford (R)-3-(2-bromopyrimidin-5-yl)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one (450 mg, 71% yield) as a light-yellow solid. LCMS (ESI^+) m/z = 535.1 (M+H).


Step 4: Preparation of (R)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one




[0369] To a stirred mixture of (R)-3-(2-bromopyrimidin-5-yl)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one (50 mg, 0.093 mmol) and 1-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazin-2-one (Intermediate 11, 66 mg, 0.28 mmol) and $Pd(dppf)Cl_2$ (34 mg, 0.046 mmol) and Cs_2CO_3 (91 mg, 0.28 mmol) in DMF (2

mL) was added CuCl (18 mg, 0.19 mmol) in portions at room temperature under an argon atmosphere. The resulting mixture was stirred at 60 °C for 1 h, diluted with ice water (30 mL) at 0 °C, and then extracted with EtOAc (3 x 30 mL). The combined organics were dried over anhydrous Na_2SO_4, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by reverse-phase flash chromatography to afford (R)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one (9.4 mg, 18% yield) as a brown solid. LCMS (ESI^+) m/z = 565.2 (M+H); ^1H NMR (400 MHz, DMSO-d_6): δ 9.32 (s, 2H), 8.21 (s, 1H), 8.03 (d, J = 1.6 Hz, 1H), 7.78 (s, 1H), 7.60 (d, J = 1.8 Hz, 1H), 7.36 – 7.29 (m, 1H), 7.19 (s, 1H), 7.16 (s, 1H), 6.51 – 6.43 (m, 1H), 5.39 (d, J = 6.2 Hz, 1H), 5.31 – 5.23 (m, 1H), 3.62 (s, 3H), 3.47 (s, 3H), 2.39 (s, 3H), 1.55 (d, J = 6.6 Hz, 3H).

[0370] **Example 89:** (R)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one




Step 1: Preparation of tert-butyl (R)-(1-(2,7-dimethyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)carbamate



[0371] To a solution of (2-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)boronic acid (Intermediate 12, 516 mg, 2.22 mmol) and tert-butyl (R)-(1-(3-chloro-2,7-dimethyl-1-oxo-1,2-


dihydroisoquinolin-5-yl)ethyl)carbamate (Intermediate 7, 600 mg, 1.71 mmol) in dioxane (12 mL) and H_2O (1 mL) was added Na_2CO_3 (363 mg, 3.42 mmol) and mesylate[(di(1-adamantyl)-n-butylphosphine)-2-(2'-amino-1,1'- biphenyl)]palladium(II) (cataCXium® A Pd G3) (125 mg, 0.17 mmol). The reaction mixture was stirred at 90 °C for 2 h under a N_2 atmosphere. The reaction mixture was then concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (silica gel, eluted with PE:EA from 1:0 to 1:1) to give tert-butyl (R)-(1-(2,7-dimethyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)carbamate (250 mg, 29% yield) as a yellow solid. LCMS (ESI^+) m/z = 503.1 (M+H).

Step 2: Preparation of (R)-5-(1-aminoethyl)-2,7-dimethyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one hydrochloride




[0372] A mixture of tert-butyl (R)-(1-(2,7-dimethyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)carbamate (250 mg, 0.50 mmol) in a solution of HCl in dioxane (2 M, 6 mL, 12 mmol) was stirred at 25 °C for 12 h. The reaction mixture was concentrated under reduced pressure to give (R)-5-(1-aminoethyl)-2,7-dimethyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one hydrochloride (218 mg, 93% yield) was as a yellow solid. LCMS (ESI^+) m/z = 403.1 (M+H).

Step 3: Preparation of (R)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one




[0373] To a mixture of (R)-5-(1-aminoethyl)-2,7-dimethyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one hydrochloride (70 mg, 0.16 mmol) and 1-bromo-4-fluoro-2-(trifluoromethyl)benzene (78 mg, 0.32 mmo) in dioxane (2 mL) was added (SP-4-1)-[1,3-bis[2,6-bis(1-ethylpropyl)phenyl]-4,5-dichloro-1,3-dihydro-2H-imidazol-2-ylidene]dichloro(2-methylpyridine)palladium (13 mg, 0.016 mmol) and Cs_2CO_3 (130 mg, 0.40 mmol) in one portion at 25°C under a N_2 atmosphere. The mixture was then stirred at 100 °C for 16 h. The reaction mixture was diluted with water (2 mL) and extracted with ethyl acetate (2 x 2 mL). The combined organic phases were washed with brine (2 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The resulting residue was purified by prep-HPLC to afford (R)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one (19 mg, 21% yield) as a yellow solid. LCMS (ESI^+) m/z = 565.2 (M+H); ^1H NMR (400 MHz, $CDCl_3$): δ 9.01 (s, 2H), 8.80 (d, J = 2.0 Hz, 1H), 8.24 (s, 1H), 8.01 (d, J = 2.0 Hz, 1H), 7.57 (d, J = 1.6 Hz, 1H), 7.22 - 7.19 (m, 1H), 6.92 - 6.85 (m, 1H), 6.74 (s, 1H), 6.26 - 6.19 (m, 1H), 4.95 - 4.89 (m, 1H), 4.61-4.57 (m, 1H), 3.90 (s, 3H), 3.54 (s, 3H), 2.47 (s, 3H), 1.62 (d, J = 6.8 Hz, 3H).

[0374] **Example 90:** (R)-2,7-dimethyl-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one




Step 1: Preparation of 5-bromo-2'-methyl-2,5'-bipyrimidine




[0375] A mixture of (2-methylpyrimidin-5-yl)boronic acid (460 mg, 3.3 mmol), 5-bromo-2-iodo-pyrimidine (1 g, 3.5 mmol), $Pd(dppf)Cl_2 \bullet CH_2Cl_2$ (287 mg, 0.35 mmol) and Na_2CO_3 (744 mg, 7.0 mmol) in dioxane (20 mL) and H_2O (4 mL) was degassed and purged with N_2 three times. The mixture was then stirred at 90 °C for 3 h. The reaction mixture was poured into water (100 mL) and extracted with ethyl acetate 300 mL (3 x 100 mL). The combined organics were washed with brine (200 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford a crude product. The crude product was purified by silica gel column chromatography (eluted with PE:EA from 10:1 to 3:1) to afford 5-bromo-2'-methyl-2,5'-bipyrimidine (410 mg, 46% yield) as a white solid. LCMS (ESI^+) m/z = 251.2 (M+H).

Step 2: Preparation of 2'-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,5'-bipyrimidine



[0376] A mixture of 5-bromo-2'-methyl-2,5'-bipyrimidine (200 mg, 0.80 mmol), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (303 mg, 1.19 mmol), KOAc (235 mg, 2.39 mmol) and $Pd(dppf)Cl_2 \bullet CH_2Cl_2$ (65 mg, 0.080 mmol) in dioxane (5 mL) was degassed and purged with N_2 three times. The mixture was then stirred at 80 °C for 12 h. The mixture was then concentrated under reduced pressure to afford the crude product. The crude product was purified by silica gel column chromatography (eluted with PE:EA = 0/1) to give 2'-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,5'-bipyrimidine (340 mg, crude yield) as a black-brown solid which was used as is in the next step without further purification. LCMS (ESI^+) m/z = 217.3 (M+H, boric acid).


Step 3: Preparation of (R)-2,7-dimethyl-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one




[0377] A mixture of 2'-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,5'-bipyrimidine (58 mg, 0.24 mmol), (R)-3-chloro-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one (Example 7, Step 1, 50 mg, 0.12 mmol), Cs_2CO_3 (193 mg, 0.59 mmol) and bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II) (10 mg, 0.012 mmol) in dioxane (10 mL) in a sealable vessel was degassed and purged with nitrogen three times. The mixture was then stirred at 120 °C for 12 h. The reaction mixture was concentrated under reduced pressure to give

the crude product. The crude product was filtered through silica gel (eluted with MeOH) to give a residue which was purified further by prep-HPLC to give (R)-2,7-dimethyl-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one (46 mg, 36% yield) as a white solid. LCMS (ESI$^+$) m/z = 541.2 (M+H); ^{1}H NMR (400 MHz, DMSO-d_6): δ 9.59 (s, 2H), 9.28 (s, 2H), 8.04 (s, 1H), 7.64-7.62 (m, 1H), 7.60 (d, J = 1.2 Hz, 1H), 7.35 - 7.26 (m, 1H), 7.16 (s, 1H), 6.75-6.72 (m, 1H), 6.65 (d, J = 5.6 Hz, 1H), 6.48 (d, J = 8.4 Hz, 1H), 5.38 - 5.24 (m, 1H), 3.47 (s, 3H), 3.26 (s, 3H), 2.75 (s, 3H), 2.41 (s, 3H), 1.55 (d, J = 6.4 Hz, 3H).

[0378] **Example 91:** (R)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(1-(2-methylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)isoquinolin-1(2H)-one




Step 1: Preparation of 5-iodo-2-(2-methylpyrimidin-5-yl)pyridazin-3(2H)-one




[0379] A mixture of 4-iodo-1H-pyridazin-6-one (697 mg, 3.14 mmol), (2-methylpyrimidin-5-yl)boronic acid (1.3 g, 9.42 mmol), $Cu(OAc)_2$ (5.71 g, 31.4 mmol), and pyridine (2.49 g, 31.4 mmol) in dichloroethane (10 mL) was degassed and purged with O_2 three times. The mixture was then stirred at 60 °C for 12 hours under an O_2 atmosphere. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel chromatography (eluted with PE:EA = 1:0 to 72:28) to afford 5-iodo-2-(2-methylpyrimidin-5-yl)pyridazin-3(2H)-one (1.3 g, 87% yield) as yellow solid. LCMS (ESI$^+$) m/z = 314.9 (M+H).

Step 2: Preparation of (1-(2-methylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)boronic acid



[0380] A mixture of 5-iodo-2-(2-methylpyrimidin-5-yl)pyridazin-3(2H)-one (500 mg, 1.59 mmol), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (809 mg, 3.18 mmol), KOAc (469 mg, 4.78 mmol), and Pd(dppf)Cl_2 (116 mg, 0.16 mmol) in dioxane (3 mL) was degassed and purged with N_2 three times. The mixture was then stirred at 100 °C for 2 h. The reaction mixture was filtered and concentrated under reduced pressure to give (1-(2-methylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)boronic acid (500 mg, crude yield) as a brown oil, which was used into the next step without further purification. LCMS (ESI^+) m/z = 233.0 (M+H), t_R = 0.338 min (Method AJ).


Step 3: Preparation of tert-butyl (R)-(1-(2,7-dimethyl-3-(1-(2-methylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)carbamate



[0381] A mixture of (1-(2-methylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)boronic acid (500 mg, 1.59 mmol), tert-butyl (R)-(1-(3-chloro-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)carbamate (Intermediate 7, 447 mg, 1.27 mmol), mesylate[(di(1-adamantyl)-n-butylphosphine)-2-(2'-amino-1,1'- biphenyl)]palladium(II) (cataCXium® A Pd G3) (116 mg, 0.16 mmol) and K_2CO_3 (660 mg, 4.77 mmol) in dioxane (5 mL) and H_2O (0.5 mL) was degassed and purged with N_2 three times. The mixture was then stirred at 100 °C for 0.5 h. The reaction was dried with anhydrous Na_2SO_4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluted with PE:EA = 1:0, then DCM:MeOH = 95:5) to afford tert-butyl (R)-(1-(2,7-dimethyl-3-(1-(2-methylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-


4-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)carbamate (420 mg, 44% yield) as a yellow solid. LCMS (ESI^+) m/z = 503.3 (M+H).

Step 4: Preparation of (R)-5-(1-aminoethyl)-2,7-dimethyl-3-(1-(2-methylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)isoquinolin-1(2H)-one hydrochloride



[0382] To a solution of tert-butyl (R)-(1-(2,7-dimethyl-3-(1-(2-methylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)carbamate (400 mg, 0.80 mmol) in DCM (0.5 mL) was added a solution of HCl in dioxane (4 M, 4.0 mL, 16 mmol). The mixture was stirred at 25°C for 1 h and then concentrated under reduced pressure to give (R)-5-(1-aminoethyl)-2,7-dimethyl-3-(1-(2-methylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)isoquinolin-1(2H)-one hydrochloride (400 mg, crude yield) as a yellow solid that was used in the next step without further purification. LCMS (ESI^+) m/z = 403.2 (M+H).


Step 5: Preparation of (R)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(1-(2-methylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)isoquinolin-1(2H)-one




[0383] A mixture of (R)-5-(1-aminoethyl)-2,7-dimethyl-3-(1-(2-methylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)isoquinolin-1(2H)-one hydrochloride (200 mg, 0.46 mmol), 1-bromo-4-fluoro-2-(trifluoromethyl)benzene (166 mg, 0.68 mmol), [1,3-bis[2,6-bis(1-ethylpropyl)phenyl]-

4,5-dichloro-imidazol-2-ylidene]-dichloro-(2-methylpyridin-1-ium-1-yl)palladium (38 mg, 0.046 mmol) and Cs_2CO_3 (742 mg, 2.28 mmol) in dioxane (2 mL) was degassed and purged with N_2 three times. The mixture was then stirred at 100 °C for 4 h. The reaction mixture was then filtered and concentrated under reduced pressure to give the crude product. The crude product was purified by prep-TLC (silica gel, eluted with PE:EA = 1:2) and then by prep-HPLC to give (R)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(1-(2-methylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)isoquinolin-1(2H)-one (94 mg, 37% yield) as a yellow solid. LCMS (ESI^+) m/z = 565.3 (M+H); ^1H NMR (400 MHz, $CDCl_3$): δ 9.13 (s, 2H), 8.23 (s, 1H), 8.06 (d, J = 2.4 Hz, 1H), 7.58 (d, J = 1.2 Hz, 1H), 7.24 - 7.17 (m, 2H), 6.92 - 6.85 (m, 1H), 6.83 (s, 1H), 6.21 - 6.19 (m, 1H), 5.02 - 4.87 (m, 1H), 4.60 (br d, J = 3.2 Hz, 1H), 3.61 (s, 3H), 2.85 (s, 3H), 2.47 (s, 3H), 1.63 (d, J = 6.4 Hz, 3H).

[0384] **Example 92:** (R)-3-(5-(2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)pyrimidin-2-yl)-5-fluoro-2-methylpyridine 1-oxide




Step 1: Preparation of 5-fluoro-2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine



[0385] A solution of 3-bromo-5-fluoro-2-methylpyridine (200 mg, 1.05 mmol) in dioxane (3 mL) was treated with 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (401 mg, 1.58 mmol) at room temperature, followed by the addition of KOAc (155 mg, 1.58 mmol) and $Pd(dppf)Cl_2 \bullet CH_2Cl_2$ (86 mg, 0.11 mmol). The resulting mixture was stirred at


100 °C for 0.5 h under a nitrogen atmosphere. The resulting mixture was filtered and concentrated under reduced pressure. The crude product was used in the next step directly without further purification. LCMS (ES^+) m/z = 238.1 (M+H).

Step 2: Preparation of 5-bromo-2-(5-fluoro-2-methylpyridin-3-yl)pyrimidine




[0386] A solution of 5-fluoro-2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (200 mg, 0.84 mmol) in dioxane (3 mL) and H_2O (0.6 mL) was treated with 5-bromo-2-iodopyrimidine (240 mg, 0.84 mmol) at room temperature followed by the addition of $Pd(PPh_3)_4$ (97 mg, 0.084 mmol) and Na_2CO_3 (179 mg, 1.69 mmol). The resulting mixture was stirred at 100 °C for 3 h under a nitrogen atmosphere. The mixture was then filtered, and the filter cake was washed with EtOAc (2 x 10 mL). After further dilution with ethyl acetate, the filtrate was washed with brine (2 x 20 mL), dried over anhydrous Na_2SO_4, filtered, and concentrated under reduced pressure. The residue was purified by prep-TLC (eluted with EA) to afford 5-bromo-2-(5-fluoro-2-methylpyridin-3-yl)pyrimidine (100 mg, 46%) as an off-white solid. LCMS (ESI^+) m/z = 268.0 (M+H).

Step 3: Preparation of 3-(5-bromopyrimidin-2-yl)-5-fluoro-2-methylpyridine 1-oxide




[0387] A solution of 5-bromo-2-(5-fluoro-2-methylpyridin-3-yl)pyrimidine (110 mg, 0.41 mmol) in DCM (2 mL) was treated with m-CPBA (106 mg, 0.615 mmol) at 0 °C. The resulting mixture was stirred at room temperature overnight and then concentrated under reduced pressure. The residue was purified by prep-TLC (eluted with EA) to afford 3-(5-bromopyrimidin-2-yl)-5-fluoro-2-methylpyridine 1-oxide (50 mg, 43%) as an off-white solid. LCMS (ESI^+) m/z = 286.0 (M+H, bromine isotope).

Step 4: Preparation of 5-fluoro-2-methyl-3-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)pyridine 1-oxide



[0388] A solution of 3-(5-bromopyrimidin-2-yl)-5-fluoro-2-methylpyridin-1-ium-1-olate (200 mg, 0.704 mmol) in dioxane (3 mL) was treated with 4,4,5,5-tetramethyl-2-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (268 mg, 1.06 mmol) at room temperature, followed by the addition of $Pd(dppf)Cl_2$ (52 mg, 0.070 mmol) and KOAc (137 mg, 1.41 mmol). The resulting mixture was stirred at 100 °C for 1 h and then filtered. The filtrate was then concentrated under reduced pressure and the crude product was used in the next step directly without further purification. LCMS (ESI^+) m/z = 332.1 (M+H).


Step 5: Preparation of (R)-3-(5-(2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)pyrimidin-2-yl)-5-fluoro-2-methylpyridine 1-oxide




[0389] A solution of 5-fluoro-2-methyl-3-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)pyridine 1-oxide (300 mg, 0.91 mmol) in 1,4-dioxane (5 mL) was treated with (R)-3-chloro-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one (Example 7, Step 1, 367 mg, 0.91 mmol), Na_2CO_3 (192 mg, 1.81 mmol) and H_2O (1.0 mL) at room temperature, followed by the addition of $Pd(PPh_3)_4$ (105 mg, 0.091 mmol). The resulting mixture was stirred at 100 °C for 3 h under a nitrogen atmosphere. The reaction mixture was filtered and the filter cake was washed with 1,4-dioxane (3 x 10 mL). The filtrate was then concentrated under reduced pressure. The residue was dissolved in EtOAc (60 mL), washed with brine (2 x 20

mL), dried over anhydrous Na_2SO_4, filtered, and concentrated under reduced pressure. The crude product was purified by prep-HPLC to afford (R)-3-(5-(2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)pyrimidin-2-yl)-5-fluoro-2-methylpyridine 1-oxide (11 mg, 2% yield) as an off-white solid. LCMS (ESI^+) m/z = 574.4 (M+H); ^1H NMR (400 MHz, DMSO-d_6): δ 9.32 (s, 2H), 8.82–8.79 (m, 1H), 8.05 (s, 1H), 7.78–7.75 (m, 1H), 7.68–7.58 (m, 2H), 7.35–7.28 (m, 1H), 7.17 (s, 1H), 6.76–6.73 (m, 1H), 6.66 (d, J = 5.6 Hz, 1H), 6.48 (d, J = 8.5 Hz, 1H), 5.35–5.28 (m, 1H), 3.48 (s, 3H), 3.27 (s, 3H), 2.61 (s, 3H), 2.41 (s, 3H), 1.56 (d, J = 6.5 Hz, 3H).

[0390] **Example 93:** (R)-3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one




Step 1: Preparation of (R)-3-chloro-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one



[0391] To a stirred solution of (R)-5-(1-Aminoethyl)-3-chloro-2,7-dimethylisoquinolin-1(2H)-one (Intermediate 4, 1 g, 4.0 mmol) and 4-fluoro-1-iodo-2-(trifluoromethyl)benzene (1.73 g, 5.98 mmol) in 1,4-dioxane (10 mL) were added RuPhos (0.37 g, 0.80 mmol), $Pd_2(dba)_3$ (0.37 g, 0.40


mmol) and Cs_2CO_3 (3.90 g, 12.0 mmol) at room temperature. The resulting mixture was then stirred at 100 °C for 2 h under a nitrogen atmosphere. The reaction was quenched by the addition of water (20 mL) at 0 °C and the resulting mixture was extracted with EtOAc (3 x 30 mL). The combined organics were washed with brine, dried over anhydrous Na_2SO_4, filtered, and concentrated under reduced pressure. The residue was purified by trituration with MeCN (30 mL) to afford (R)-3-chloro-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one (460 mg, 55% yield) as a grey solid. LCMS (ESI^+) m/z = 413.1 (M+H).

Step 2: Preparation of (R)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinolin-1(2H)-one




[0392] To a stirred solution of (R)-3-chloro-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one (400 mg, 0.97 mmol) and 4,4,5,5-tetramethyl-2-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane in 1,4-dioxane (5 mL) were added $Pd(dppf)Cl_2$ (71 mg, 0.097 mmol) and KOAc (285 mg, 2.91 mmol). The resulting mixture was stirred at 100 °C for 2 h under a nitrogen atmosphere. The resulting mixture was then filtered, the filter cake was washed with DCM (2 x 20 mL), and the filtrate was concentrated under reduced pressure to afford (R)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinolin-1(2H)-one (400 mg, crude yield) as a brown oil, which was used as is directly in the next step without further purification. LCMS (ESI^+) m/z = 505.2 (M+H).

Step 3: Preparation of (R)-3-(2-bromopyrimidin-5-yl)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one



[0393] To a stirred solution of (R)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinolin-1(2H)-one (400 mg, 0.79 mmol) in dioxane (10 mL) and H_2O (2 mL) was added 2-bromo-5-iodopyrimidine (226 mg, 0.79 mmol), $Pd(PPh_3)_4$ (92 mg, 0.079 mmol) and Na_2CO_3 (252 mg, 2.38 mmol) at room temperature under a nitrogen atmosphere. The resulting mixture was stirred at 90 °C for 2 h. The resulting mixture was filtered, the filter cake was washed with DCM (3 x 20 mL). The filtrate was concentrated under reduced pressure. The residue was purified by prep-TLC (eluted with PE:EA = 1:1) to afford (R)-3-(2-bromopyrimidin-5-yl)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one (190 mg, 35% yield) as a light-yellow solid. LCMS: (ESI^+) m/z = 535.1 (M+H).

Step 4: Preparation of (R)-3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one










[0394] To a stirred solution of (R)-3-(2-bromopyrimidin-5-yl)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one (200 mg, 0.37 mmol) and 1,3-dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazin-2-one (Intermediate 14,





140 mg, 0.56 mmol) in H_2O (0.5 mL) and 1,4-dioxane (2 mL) were added Na_2CO_3 (119 mg, 1.12 mmol) and $Pd(PPh_3)_4$ (43 mg, 0.037 mmol) at room temperature. The resulting mixture was stirred at 90 °C for an additional 2 h under a nitrogen atmosphere. The reaction was then quenched by the addition of water (5 mL) at 0 °C. The resulting mixture was extracted with EtOAc (3 x 5 mL). The combined organics were washed with brine, dried over anhydrous Na_2SO_4, filtered, and concentrated under reduced pressure. The crude product was purified by prep-HPLC to afford (R)-3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one (4.3 mg, 2% yield) as a light-yellow solid. LCMS (ESI^+) m/z = 579.3 (M+H); ^1H NMR (400 MHz, Methanol-d_4): δ 9.20 (s, 2H), 8.15 (s, 1H), 7.82 (s, 1H), 7.68 (d, J = 1.9 Hz, 1H), 7.25–7.22 (m, 1H), 7.18 (s, 1H), 6.97 (d, J = 8.0 Hz, 1H), 6.44–6.42 (m, 1H), 5.27–5.16 (m, 1H), 5.01 (s, 1H), 3.79 (s, 3H), 3.58 (s, 3H), 2.52 (s, 3H), 2.46 (s, 3H), 1.64 (d, J = 6.6 Hz, 3H).





[0395] Examples 20 to 84, 94 to 955, 964, 967, 986, 989, 1022, 1025, 1044 to 1060, 1062, 1068, 1071, and 1072 appear in Tables 1 and 2 below and were prepared in manners similar to that described above for Examples 1 to 19 and 85 to 93. If not specified otherwise, each depicted chiral center exists as a (R)- and (S)-racemic mixture or separately as the (R)- or (S)- enantiomer. Each compound appearing in Table 1 is identified by both a chemical structure and a name, but the chemical structure should be afforded more weight regarding the representation of the compound.





Table 1. Examples 20 to 84 and 94 to 1170





Structure	Example	Structure Name
 $C_{29}H_{39}N_5O_5S$	20	N-((2-((1-(2-(4,4-dimethylpiperidin-1-yl)-3,6-dimethyl-4-oxo-3,4-dihydroquinazolin-8-yl)ethyl)amino)phenyl)sulfonyl)-3-methoxypropanamide, Enantiomer 1
 $C_{29}H_{39}N_5O_5S$	21	N-((2-((1-(2-(4,4-dimethylpiperidin-1-yl)-3,6-dimethyl-4-oxo-3,4-dihydroquinazolin-8-yl)ethyl)amino)phenyl)sulfonyl)-3-methoxypropanamide, Enantiomer 2
 $C_{26}H_{31}F_3N_4O_3S$	22	(R)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one





 $C_{25}H_{30}F_3N_5O_3S$	23	(R)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one
 $C_{23}H_{26}N_2O_3S$	24	(R)-3-cyclopropyl-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 $C_{24}H_{25}N_3O_3S_2$	25	(R)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-3-(2-methylthiazol-5-yl)isoquinolin-1(2H)-one
 $C_{26}H_{30}F_4N_4O_3S$	26	(R)-5-(1-((3-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one





 $C_{26}H_{32}F_3N_5O_3S$	27	(R)-2,7-dimethyl-5-(1-((6-methyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one
 $C_{24}H_{23}F_4N_3O_3S$	28	6-fluoro-3-methyl-8-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-2-(3-(trifluoromethyl)bicyclo[1.1.1]pentan-1-yl)quinazolin-4(3H)-one
 $C_{25}H_{29}F_4N_5O_3S$	29	(R)-2-((1-(2,7-dimethyl-1-oxo-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-6-fluorobenzenesulfonamide
 $C_{31}H_{28}F_2N_4O_3S$	30	(R)-3-(3,5'-difluoro-2'-methyl-[2,3'-bipyridin]-5-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 $C_{30}H_{26}F_2N_4O_3S$	31	(R)-3-(3,5'-difluoro-[2,3'-bipyridin]-5-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 $C_{31}H_{28}F_2N_4O_3S$	32	(R)-3-(3,5'-difluoro-6'-methyl-[2,3'-bipyridin]-5-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 $C_{28}H_{33}F_3N_4O_3S$	33	(R)-5-(1-((2-(cyclopropylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one
 $C_{26}H_{32}F_3N_5O_2S$	34	2,7-dimethyl-5-((1R)-1-((2-(S-methylsulfonimidoyl)phenyl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one





 $C_{27}H_{34}F_3N_5O_2S$	35	5-((1R)-1-((2-(N,S-dimethylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one
 $C_{27}H_{33}F_3N_4O_4S$	36	(R)-5-(1-((2-((methoxymethyl)sulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one
 $C_{31}H_{34}F_3N_5O_3S$	37	(R)-2,7-dimethyl-5-(1-((2-((pyridin-2-ylmethyl)sulfonyl)phenyl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one
 $C_{29}H_{33}F_3N_6O_3S$	38	(R)-5-(1-((2-(((1H-pyrazol-1-yl)methyl)sulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one





 $C_{28}H_{35}F_3N_4O_4S$	39	(R)-5-(1-((2-((ethoxymethyl)sulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one
 $C_{26}H_{32}F_3N_5O_2S$	40	2,7-dimethyl-5-((1R)-1-((2-(S-methylsulfonimidoyl)phenyl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 1
 $C_{26}H_{32}F_3N_5O_2S$	41	2,7-dimethyl-5-((1R)-1-((2-(S-methylsulfonimidoyl)phenyl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 2
 $C_{27}H_{26}F_3N_3O_4S$	42	(R)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-3-(6-(2,2,2-trifluoroethoxy)pyridin-3-yl)isoquinolin-1(2H)-one





 $C_{25}H_{31}N_3O_3S$	43	(R)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-3-(piperidin-1-yl)isoquinolin-1(2H)-one
 $C_{29}H_{32}N_4O_4S$	44	(R)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-3-(6-morpholinopyridin-3-yl)isoquinolin-1(2H)-one
 $C_{26}H_{30}F_4N_4O_3S$	45	(R)-5-(1-((2-((fluoromethyl)sulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one
 $C_{28}H_{27}FN_4O_3S$	46	(R)-3-(7-fluoro-2-methyl-2H-indazol-5-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 $C_{28}H_{29}N_3O_4S$	47	(R)-3-(6-cyclopropoxypyridin-3-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 $C_{29}H_{34}N_6O_3S$	48	(R)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 $C_{30}H_{35}N_5O_3S$	49	(R)-2,7-dimethyl-3-(4-(6-methylpyridin-3-yl)piperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 $C_{28}H_{34}F_3N_5O_3S$	50	N-((2-(((R)-1-(2,7-dimethyl-1-oxo-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)-1,2-dihydroisoquinolin-5-yl)ethyl)amino)phenyl)(methyl)(oxo)-λ6-sulfaneylidene)acetamide





 $C_{34}H_{33}F_2N_5O_2S$	51	3-(3,5'-difluoro-2'-methyl-[2,3'-bipyridin]-5-yl)-2,7-dimethyl-5-((1R)-1-((2-(N-methylcyclopropanesulfonimidoyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one, Diastereomer 1
 $C_{34}H_{33}F_2N_5O_2S$	52	3-(3,5'-difluoro-2'-methyl-[2,3'-bipyridin]-5-yl)-2,7-dimethyl-5-((1R)-1-((2-(N-methylcyclopropanesulfonimidoyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one, Diastereomer 2
 $C_{28}H_{34}F_3N_5O_3S$	53	N-((2-(((R)-1-(2,7-dimethyl-1-oxo-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)-1,2-dihydroisoquinolin-5-yl)ethyl)amino)phenyl)(methyl)(oxo)-λ6-sulfaneylidene)acetamide, Diastereomer 1
 $C_{28}H_{34}F_3N_5O_3S$	54	N-((2-(((R)-1-(2,7-dimethyl-1-oxo-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)-1,2-dihydroisoquinolin-5-yl)ethyl)amino)phenyl)(methyl)(oxo)-λ6-sulfaneylidene)acetamide, Diastereomer 2





 $C_{25}H_{31}F_3N_6O_3S$	55	(R)-3-((1-(2,7-dimethyl-1-oxo-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-6-methylpyridine-2-sulfonamide
 $C_{26}H_{31}F_3N_4O_3S$	56	2,7-dimethyl-5-((methyl(2-(methylsulfonyl)phenyl)amino)methyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one
 $C_{27}H_{33}F_3N_4O_3S$	57	5-((ethyl(2-(methylsulfonyl)phenyl)amino)methyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one
 $C_{31}H_{29}F_2N_5O_3S$	58	(R)-3-(3,5'-difluoro-2'-methyl-[2,3'-bipyridin]-5-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one





 $C_{28}H_{27}FN_4O_3S$	59	(R)-3-(7-fluoro-1-methyl-1H-indazol-5-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 $C_{31}H_{36}FN_5O_3S$	60	(R)-3-(5-fluoro-6-((4-methylpiperazin-1-yl)methyl)pyridin-3-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 $C_{29}H_{33}FN_4O_4S$	61	(R)-3-(6-(2-(dimethylamino)ethoxy)-5-fluoropyridin-3-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 $C_{26}H_{30}F_4N_4O_3S$	62	(R)-4-fluoro-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one





 $C_{27}H_{33}F_3N_4O_3S$	63	(R)-2,7-dimethyl-5-(1-(methyl(2-(methylsulfonyl)phenyl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one
 $C_{28}H_{35}F_3N_4O_3S$	64	(R)-5-(1-(ethyl(2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one
 $C_{32}H_{30}F_2N_4O_3S$	65	(R)-3-(2'-ethyl-3,5'-difluoro-[2,3'-bipyridin]-5-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 $C_{25}H_{29}F_4N_5O_3S$	66	(R)-2-((1-(4-fluoro-2,7-dimethyl-1-oxo-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzenesulfonamide





 $C_{27}H_{26}FN_5O_3S$	67	(R)-2-((1-(3-(7-fluoro-1-methyl-1H-indazol-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzenesulfonamide
 $C_{33}H_{30}F_2N_4O_3S$	68	(R)-5-(1-((2-(cyclopropylsulfonyl)phenyl)amino)ethyl)-3-(3,5'-difluoro-2'-methyl-[2,3'-bipyridin]-5-yl)-2,7-dimethylisoquinolin-1(2H)-one
 $C_{28}H_{33}F_5N_4O_4S$	69	(R)-5-(1-((2-(((2,2-difluoroethoxy)methyl)sulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one
 $C_{27}H_{26}FN_5O_3S$	70	(R)-2-((1-(3-(7-fluoro-2-methyl-2H-indazol-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzenesulfonamide





 $C_{30}H_{27}F_2N_5O_3S$	71	(R)-2-((1-(3-(3,5'-difluoro-2'-methyl-[2,3'-bipyridin]-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzenesulfonamide
 $C_{28}H_{36}N_4O_4S$	72	3-(3-ethoxy-3,8-diazabicyclo[3.2.1]octan-8-yl)-2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 $C_{25}H_{26}N_4O_3S$	73	(R)-2,7-dimethyl-3-(5-methylpyrazin-2-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 $C_{26}H_{27}N_3O_3S$	74	(R)-2,7-dimethyl-3-(5-methylpyridin-2-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 $C_{26}H_{27}N_3O_3S$	75	(R)-2,7-dimethyl-3-(6-methylpyridin-3-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 $C_{26}H_{27}N_3O_3S$	76	(R)-2,7-dimethyl-3-(2-methylpyridin-4-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 $C_{25}H_{26}N_4O_3S$	77	(R)-2,7-dimethyl-3-(2-methylpyrimidin-5-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 $C_{24}H_{26}N_4O_3S$	78	(R)-2,7-dimethyl-3-(1-methyl-1H-pyrazol-3-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 $C_{24}H_{26}N_4O_3S$	79	(R)-2,7-dimethyl-3-(1-methyl-1H-pyrazol-4-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 $C_{26}H_{29}F_5N_4O_3S$	80	(R)-5-(1-((2-((difluoromethyl)sulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one
 $C_{26}H_{34}N_4O_4S$	81	(R)-3-(4-ethoxypiperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 $C_{25}H_{29}F_2N_3O_3S$	82	(R)-3-(4,4-difluoropiperidin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 $C_{24}H_{27}F_2N_3O_3S$	83	(R)-3-(3,3-difluoropyrrolidin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 $C_{23}H_{26}FN_3O_3S$	84	(R)-3-(3-fluoroazetidin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C27H30F3N5O3S	94	(R)-5-(1-((6-ethynyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C27H35F3N6O2S	95	5-((1R)-1-((2-(N,S-dimethylsulfonimidoyl)-6-methylpyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 1





 C27H35F3N6O2S	96	5-((1R)-1-((2-(N,S-dimethylsulfonimidoyl)-6-methylpyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 2
 C28H36F3N5O3S	97	5-((1R)-1-((2-(N-(2-hydroxyethyl)-S-methylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 1
 C28H36F3N5O3S	98	5-((1R)-1-((2-(N-(2-hydroxyethyl)-S-methylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 2
 C31H43F3N6O2S	99	5-((1R)-1-((2-(N-(3-(dimethylamino)propyl)-S-methylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 1





 C31H43F3N6O2S	100	5-((1R)-1-((2-(N-(3-(dimethylamino)propyl)-S-methylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 2
 C25H26N4O3S	101	(R)-2,7-dimethyl-3-(2-methylpyrimidin-4-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C25H26N4O3S	102	(R)-2,7-dimethyl-3-(6-methylpyrimidin-4-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C25H26N4O3S	103	(R)-2,7-dimethyl-3-(5-methylpyrimidin-2-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C25H26N4O3S	104	(R)-2,7-dimethyl-3-(4-methylpyrimidin-2-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C25H26N4O3S	105	(R)-2,7-dimethyl-3-(6-methylpyridazin-3-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C25H26N4O3S	106	(R)-2,7-dimethyl-3-(6-methylpyridazin-4-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C26H24F3N3O3S	107	(R)-3-(6-(difluoromethyl)-5-fluoropyridin-3-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C23H25N5O3S	108	(R)-2,7-dimethyl-3-(1-methyl-1H-1,2,3-triazol-4-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C24H26N4O3S	109	(R)-2,7-dimethyl-3-(4-methyl-1H-imidazol-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C23H25F2N3O3S	110	(R)-3-(3,3-difluoroazetidin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C27H30N4O3S	111	(R)-3-(2-isopropylpyrimidin-5-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C26H32ClF3N6O2S	112	5-((1R)-1-((6-chloro-2-(N,S-dimethylsulfonimidoyl)pyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 1
 C26H32ClF3N6O2S	113	5-((1R)-1-((6-chloro-2-(N,S-dimethylsulfonimidoyl)pyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 2
 C26H31F4N5O2S	114	5-((1R)-1-((3-fluoro-2-(S-methylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 1
 C26H31F4N5O2S	115	5-((1R)-1-((3-fluoro-2-(S-methylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 2





 C28H34N6O3S	116	(R)-2,7-dimethyl-3-(4-(1-methyl-1H-pyrazol-4-yl)piperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C29H38F3N5O3S	117	5-((1R)-1-((3-fluoro-2-(S-methylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 2
 C29H38F3N5O3S	118	5-((1R)-1-((3-fluoro-2-(S-methylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 2
 C28H36F3N5O2S	119	5-((1R)-1-((3-fluoro-2-(S-methylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 2





 C28H36F3N5O2S	120	5-((1R)-1-((3-fluoro-2-(S-methylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 2
 C29H36F3N5O2S	121	5-((1R)-1-((3-fluoro-2-(S-methylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 2
 C29H36F3N5O2S	122	5-((1R)-1-((3-fluoro-2-(S-methylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 2
 C28H29F2N3O3S	123	(R)-3-(5-fluoro-6-(2-fluoropropan-2-yl)pyridin-3-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C27H26F3N3O3S	124	(R)-3-(6-(1,1-difluoroethyl)-5-fluoropyridin-3-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C26H26N4O3S	125	(R)-2,7-dimethyl-3-((1-methyl-1H-pyrazol-4-yl)ethynyl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C32H30FN5O3S	126	(R)-5-(1-((2-(cyclopropylsulfonyl)phenyl)amino)ethyl)-3-(5-fluoro-6-(2-methylpyrimidin-5-yl)pyridin-3-yl)-2,7-dimethylisoquinolin-1(2H)-one
 C26H33F3N6O2S	127	2,7-dimethyl-5-((1R)-1-((6-methyl-2-(S-methylsulfonimidoyl)pyridin-3-yl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 1





 C26H33F3N6O2S	128	2,7-dimethyl-5-((1R)-1-((6-methyl-2-(S-methylsulfonimidoyl)pyridin-3-yl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 2
 C26H33F3N6O2S	129	2,7-dimethyl-5-((1R)-1-((6-methyl-2-(S-methylsulfonimidoyl)pyridin-3-yl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one, mixture of diastereomers
 C30H41F3N6O2S	130	5-((1R)-1-((2-(N-(2-(dimethylamino)ethyl)-S-methylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 1
 C30H41F3N6O2S	131	5-((1R)-1-((2-(N-(2-(dimethylamino)ethyl)-S-methylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 2





 C28H32F4N4O3S	132	5-((1R)-1-((2-((2-fluorocyclopropyl)sulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one, trans-cyclopropyl Diastereomer 1
 C28H32F4N4O3S	133	5-((1R)-1-((2-((2-fluorocyclopropyl)sulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one, trans-cyclopropyl Diastereomer 2
 C23H25N5O3S	134	(R)-2,7-dimethyl-3-(4-methyl-1H-1,2,3-triazol-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C23H25N5O3S	135	(R)-2,7-dimethyl-3-(5-methyl-1H-1,2,3-triazol-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C31H36N6O3S	136	(R)-5-(1-((2-(cyclopropylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C30H36N6O3S	137	(R)-3-(4-(2,4-dimethylpyrimidin-5-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C31H36N6O3S	138	(R)-3-(4-(2-cyclopropylpyrimidin-5-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C29H32F2N6O3S	139	(R)-3-(4-(2-(difluoromethyl)pyrimidin-5-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C29H34N6O3S	140	(R)-2,7-dimethyl-3-(4-(5-methylpyrazin-2-yl)piperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C29H34N6O3S	141	(R)-2,7-dimethyl-3-(4-(6-methylpyridazin-3-yl)piperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C29H34N6O3S	142	(R)-2,7-dimethyl-3-(4-(5-methylpyrimidin-2-yl)piperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C29H34N6O2S	143	2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-5-((1R)-1-((2-(methylsulfinyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one, Diastereomer 1





 C29H34N6O2S	144	2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-5-((1R)-1-((2-(methylsulfinyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one, Diastereomer 2
 C28H34N6O3S	145	(R)-2,7-dimethyl-3-(4-(1-methyl-1H-pyrazol-3-yl)piperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C27H34N4O4S	146	(R)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-3-(4-(oxetan-3-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C30H37N6O3P	147	methyl (2-(((R)-1-(2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)phenyl)(methyl)phosphinate, Diastereomer 1





 C30H37N6O3P	148	methyl (2-(((R)-1-(2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)phenyl)(methyl)phosphinate, Diastereomer 2
 C23H25N5O3S	149	(R)-2,7-dimethyl-3-(4-methyl-2H-1,2,3-triazol-2-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C28H33N5O4S	150	(R)-2,7-dimethyl-3-(4-(3-methylisoxazol-5-yl)piperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C28H33N5O4S	151	(R)-2,7-dimethyl-3-(4-(5-methylisoxazol-3-yl)piperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C28H34F3N5O2S	152	2,7-dimethyl-5-((1R)-1-((2-(1-oxido-4,5-dihydro-3H-1l6-isothiazol-1-yl)phenyl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 1
 C28H34F3N5O2S	153	2,7-dimethyl-5-((1R)-1-((2-(1-oxido-4,5-dihydro-3H-1l6-isothiazol-1-yl)phenyl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 2
 C29H35N7O3S	154	(R)-2,7-dimethyl-5-(1-((6-methyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C30H40N4O5S	155	(R)-3-(4-(2,2-dimethyl-1,3-dioxan-5-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C30H28FN5O3S	156	(R)-3-(5-fluoro-6-(2-methylpyrimidin-5-yl)pyridin-3-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C28H33N5O4S	157	(R)-2,7-dimethyl-3-(4-(2-methyloxazol-5-yl)piperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C28H33N5O4S	158	(R)-2,7-dimethyl-3-(4-(5-methyloxazol-2-yl)piperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H37N7O2S	159	5-((1R)-1-((2-(N,S-dimethylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 1





 C30H37N7O2S	160	5-((1R)-1-((2-(N,S-dimethylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 2
 C28H36N4O5S	161	(R)-3-(4-((1,3-dioxolan-2-yl)methyl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H35N5O4S	162	(R)-2,7-dimethyl-3-(4-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)piperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H35N5O4S	163	(R)-2,7-dimethyl-3-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)piperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C29H35N7O2S	164	2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-5-((1R)-1-((2-(S-methylsulfonimidoyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one, mixture of diastereomers
 C28H36N4O5S	165	isopropyl (R)-4-(2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)piperazine-1-carboxylate
 C30H29F2N3O4S	166	(R)-3-(4-(3,3-difluoroazetidine-1-carbonyl)phenyl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C29H34FN7O3S	167	(R)-4-fluoro-2,7-dimethyl-5-(1-((6-methyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one





 C28H34F5N5O2S	168	5-((1R)-1-((2-(N-(2,2-difluoroethyl)-S-methylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 1
 C28H34F5N5O2S	169	5-((1R)-1-((2-(N-(2,2-difluoroethyl)-S-methylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 2
 C31H36N6O3S	170	2,7-dimethyl-3-(3-(2-methylpyrimidin-5-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H34N6O3S	171	2,7-dimethyl-3-(3-(2-methylpyrimidin-5-yl)-3,6-diazabicyclo[3.1.1]heptan-6-yl)-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C30H34N6O3S	172	2,7-dimethyl-3-((1R,4R)-5-(2-methylpyrimidin-5-yl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H34N6O3S	173	2,7-dimethyl-3-((1S,4S)-5-(2-methylpyrimidin-5-yl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H34N6O3S	174	(R)-2,7-dimethyl-3-(6-(2-methylpyrimidin-5-yl)-2,6-diazaspiro[3.3]heptan-2-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C29H33F2N7O3S	175	(R)-3-(4-(2-(difluoromethyl)pyrimidin-5-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one





 C31H28F2N4O4S	176	(R)-5-(2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)-3,5'-difluoro-2'-methyl-[2,3'-bipyridine] 1'-oxide
 C31H30FN5O3S	177	(R)-3-(6-(2,4-dimethylpyrimidin-5-yl)-5-fluoropyridin-3-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H33N7O3S	178	(R)-3-(4-(imidazo[1,2-b]pyridazin-6-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H35N5O4S	179	(R)-3-(4-(2-methoxypyridin-4-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C30H35N5O4S	180	(R)-3-(4-(6-methoxypyridin-3-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C27H31N5O3S	181	(R)-2,7-dimethyl-3-(2-methyl-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C26H30N6O3S	182	(R)-2,7-dimethyl-3-(3-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C26H29N5O3S	183	(R)-3-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C29H35N7O2S	184	2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-5-((1R)-1-((2-(S-methylsulfonimidoyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one, Diastereomer 1
 C29H35N7O2S	185	2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-5-((1R)-1-((2-(S-methylsulfonimidoyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one, Diastereomer 2
 C29H34ClN7O3S	186	(R)-4-chloro-2,7-dimethyl-5-(1-((6-methyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C31H36FN7O3S	187	(R)-5-(1-((2-(cyclopropylsulfonyl)-6-methylpyridin-3-yl)amino)ethyl)-4-fluoro-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one





 C31H37N7O3S	188	(R)-5-(1-((2-(cyclopropylsulfonyl)-6-methylpyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C29H32F2N6O3S	189	(R)-4-fluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C29H33FN6O3S	190	(R)-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C28H33F6N5O2S	191	2,7-dimethyl-5-((1R)-1-((2-(S-methyl-N-(2,2,2-trifluoroethyl)sulfonimidoyl)phenyl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 1





 C28H33F6N5O2S	192	2,7-dimethyl-5-((1R)-1-((2-(S-methyl-N-(2,2,2-trifluoroethyl)sulfonimidoyl)phenyl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 2
 C29H33FN6O3S	193	(R)-4-fluoro-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C28H32F2N6O3S	194	(R)-3-(4-(1-(difluoromethyl)-1H-pyrazol-4-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H32F2N4O3S	195	(R)-3-(5-fluoro-6-(4-fluoropiperidin-1-yl)pyridin-3-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C32H35FN4O4S	196	(R)-3-(5-fluoro-6-(2-oxa-7-azaspiro[3.5]nonan-7-yl)pyridin-3-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C31H37N7O3S	197	(R)-2-(4-(4-(2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)piperazin-1-yl)-1H-pyrazol-1-yl)-2-methylpropanenitrile
 C30H35N5O3S	198	(R)-2,7-dimethyl-3-(4-(2-methylpyridin-3-yl)piperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C29H33ClN6O3S	199	(R)-5-(1-((4-chloro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one





 C29H33N5O4S	200	(R)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-3-(4-(2-oxo-1,2-dihydropyridin-4-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C29H33N5O4S	201	(R)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-3-(4-(6-oxo-1,6-dihydropyridin-3-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C29H27F3N4O4S	202	(R)-3-(6-(3,3-difluoroazetidine-1-carbonyl)-5-fluoropyridin-3-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C31H34FN5O4S	203	(R)-3-(6-(4-acetylpiperazin-1-yl)-5-fluoropyridin-3-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C32H33FN6O3S	204	(R)-3-(5-fluoro-6-(2-methyl-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)pyridin-3-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C31H33N7O3S	205	(R)-2,7-dimethyl-3-(2-(2-methyl-6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl)pyrimidin-5-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C31H33N7O3S	206	(R)-2,7-dimethyl-3-(2-(2-methyl-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)pyrimidin-5-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C27H31N5O3S	207	(R)-2,7-dimethyl-3-(2-methyl-6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C26H29N5O3S	208	(R)-3-(5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C28H26F2N6O3S	209	(R)-3-(2-(1-(difluoromethyl)-1H-pyrazol-4-yl)pyrimidin-5-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C28H27N5O3S2	210	(R)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-3-(2-(2-methylthiazol-5-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one
 C29H32FN5O3S	211	(R)-3-(5-fluoro-6-(piperazin-1-yl)pyridin-3-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C28H34N4O5S	212	cyclopropyl (R)-4-(2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)piperazine-1-carboxylate
 C30H33N7O3S	213	(R)-4-((1-(2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-3-(methylsulfonyl)benzonitrile
 C29H32F2N6O3S	214	(S)-4-fluoro-5-(2-fluoro-1-((2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C29H33FN6O3S	215	(S)-5-(2-fluoro-1-((2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one





 C29H33ClN6O3S	216	(R)-4-chloro-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C33H32FN5O3S	217	(R)-5-(1-((2-(cyclopropylsulfonyl)phenyl)amino)ethyl)-3-(6-(2,4-dimethylpyrimidin-5-yl)-5-fluoropyridin-3-yl)-2,7-dimethylisoquinolin-1(2H)-one
 C28H32N6O4S	218	(R)-3-(4-(2-hydroxypyrimidin-5-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C31H37N7O3S	219	N-((2-(((R)-1-(2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)phenyl)(methyl)(oxo)-λ6-sulfaneylidene)acetamide, Diastereomer 1





 C31H37N7O3S	220	N-((2-(((R)-1-(2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)phenyl)(methyl)(oxo)-λ6-sulfaneylidene)acetamide, Diastereomer 2
 C30H31F3N4O3S	221	(R)-3-(6-(4,4-difluoropiperidin-1-yl)-5-fluoropyridin-3-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C32H39N4O4PS	222	(R)-3-(4-(3-(dimethylphosphoryl)phenyl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H38N8O2S	223	5-((1R)-1-((2-(N,S-dimethylsulfonimidoyl)-6-methylpyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one, Diasteromer 1





 C30H38N8O2S	224	5-((1R)-1-((2-(N,S-dimethylsulfonimidoyl)-6-methylpyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one, Diasteromer 2
 C29H34N6O3S	225	(R)-2,7-dimethyl-3-(4-(5-methylpyrimidin-4-yl)piperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C29H31F3N6O3S	226	(R)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-5-(1-((2-((trifluoromethyl)sulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C26H28N4O3S	227	(R)-3-(1-cyclopropyl-1H-pyrazol-4-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C25H25F3N4O3S	228	(R)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-3-(1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)isoquinolin-1(2H)-one
 C27H29N5O3S	229	(R)-2-(4-(2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)-1H-pyrazol-1-yl)-2-methylpropanenitrile
 C29H34N6O3S	230	(R)-2,7-dimethyl-3-(4-(3-methylpyrazin-2-yl)piperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C28H32FN7O3S	231	(R)-2-((1-(4-fluoro-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzenesulfonamide





 C30H35FN6O3S	232	(R)-3-(4-(5-fluoro-6-methylpyridin-3-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C28H31FN6O3S	233	(R)-3-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H33N7O3S	234	(R)-3-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H33N7O3S	235	(R)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-3-(4-(pyrazolo[1,5-a]pyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one





 C30H33N5O3S	236	(R)-2,7-dimethyl-3-(1-(2-methylpyrimidin-5-yl)-1,2,3,6-tetrahydropyridin-4-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H35N5O3S	237	(R)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperidin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C29H34N6O3S	238	(R)-2,7-dimethyl-3-(4-(4-methylpyridazin-3-yl)piperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H36N6O3S	239	(R)-3-(4-(4,6-dimethylpyridazin-3-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C28H27N5O3S2	240	(R)-2,7-dimethyl-3-(2-(2-methylpyrimidin-5-yl)thiazol-5-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C31H31FN6O3S	241	(R)-3-(6-(6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl)-5-fluoropyridin-3-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C32H33FN6O3S	242	(R)-3-(5-fluoro-6-(2-methyl-6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl)pyridin-3-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C31H32FN7O3S	243	(R)-3-(5-fluoro-6-(3-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)pyridin-3-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C30H29N5O3S	244	(R)-2,7-dimethyl-3-(6-(2-methylpyrimidin-5-yl)pyridin-3-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H29N5O3S	245	(R)-2,7-dimethyl-3-(2-(6-methylpyridin-3-yl)pyrimidin-5-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H34FN5O3S	246	(R)-3-(5-fluoro-6-(4-methylpiperazin-1-yl)pyridin-3-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C28H31N5O3S	247	(R)-2,7-dimethyl-3-(1-(2-methylpyrimidin-5-yl)azetidin-3-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C29H32F3N7O3S	248	(R)-3-(4-(2-(difluoromethyl)pyrimidin-5-yl)piperazin-1-yl)-4-fluoro-2,7-dimethyl-5-(1-((6-methyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C29H30F4N6O3S	249	(S)-3-(4-(2-(difluoromethyl)pyrimidin-5-yl)piperazin-1-yl)-4-fluoro-5-(2-fluoro-1-((2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one
 C29H31F3N6O3S	250	(S)-3-(4-(2-(difluoromethyl)pyrimidin-5-yl)piperazin-1-yl)-5-(2-fluoro-1-((2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one
 C29H38N4O5S	251	(R)-2,7-dimethyl-3-(4-(2-methyl-1,3-dioxan-5-yl)piperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one, Diastereomer 1





 C29H38N4O5S	252	(R)-2,7-dimethyl-3-(4-(2-methyl-1,3-dioxan-5-yl)piperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one, Diastereomer 2
 C31H36N6O2S	253	5-((1R)-1-((2-(cyclopropylsulfinyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 1
 C31H36N6O2S	254	5-((1R)-1-((2-(cyclopropylsulfinyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 2
 C31H38N6O4S	255	(R)-3-(4-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C32H37N7O3S	256	(R)-2-(5-(4-(2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)piperazin-1-yl)pyrimidin-2-yl)-2-methylpropanenitrile
 C32H40N5O4PS	257	(R)-3-(4-(5-(dimethylphosphoryl)-2-methylpyridin-3-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C29H36N6O3S	258	(R)-3-(4-(1,5-dimethyl-1H-pyrazol-4-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C29H36N6O3S	259	(R)-3-(4-(1,3-dimethyl-1H-pyrazol-4-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C31H38N6O3S	260	(R)-5-(1-((2-(isopropylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C32H38N6O3S	261	(R)-5-(1-((2-(cyclobutylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C29H29N3O4S	262	(R)-3-(6-(cyclopropanecarbonyl)pyridin-3-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C29H32F2N6O	263	(R)-5-(1-((2-(difluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one





 C29H34N6O4S	264	(R)-3-(4-(2-methoxypyrimidin-5-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H34F2N6O3S	265	(R)-4-fluoro-3-(4-(5-fluoro-6-methylpyridin-3-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C26H30N6O5S	266	(R)-3-(4-(2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)piperazin-1-yl)-1,2,4-oxadiazol-5(4H)-one
 C31H34N6O3S	267	(R)-5-(1-((4-ethynyl-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one





 C30H34FN5O3S	268	(R)-3-(4-(5-fluoro-3-methylpyridin-2-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H33N7O3S	269	(R)-3-(4-(imidazo[1,2-a]pyrimidin-6-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C29H33N5O4S	270	2,7-dimethyl-3-(3-((2-methylpyrimidin-5-yl)oxy)pyrrolidin-1-yl)-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one, Diastereomer 1
 C29H33N5O4S	271	2,7-dimethyl-3-(3-((2-methylpyrimidin-5-yl)oxy)pyrrolidin-1-yl)-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one, Diastereomer 2





 C28H31FN6O3S	272	(R)-7-fluoro-2-methyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C32H33FN6O3S	273	(R)-3-(5-fluoro-6-(2-methyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)pyridin-3-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C32H33FN6O3S	274	(R)-3-(5-fluoro-6-(1-methyl-1,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)pyridin-3-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H30FN7O3S	275	(R)-3-(6-(5,6-dihydro-[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl)-5-fluoropyridin-3-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C30H30FN7O3S	276	(R)-3-(6-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-5-fluoropyridin-3-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C31H33N7O3S	277	(R)-2,7-dimethyl-3-(2-(2-methyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)pyrimidin-5-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H36N6O3S	278	2,7-dimethyl-3-((R)-3-methyl-4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C31H36N6O4S	279	2,7-dimethyl-3-((1R,5S)-9-(2-methylpyrimidin-5-yl)-3-oxa-7,9-diazabicyclo[3.3.1]nonan-7-yl)-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C32H37N5O3S	280	(R)-2,7-dimethyl-3-(2-(6-methylpyridin-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C31H36N6O3S	281	(R)-2,7-dimethyl-3-(2-(5-methylpyrimidin-2-yl)-2,6-diazaspiro[3.4]octan-6-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C28H31N5O4S	282	(R)-2,7-dimethyl-3-(3-((5-methylpyrazin-2-yl)oxy)azetidin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C31H33F4N7O3S	283	(S)-5-(1-((2-(cyclopropylsulfonyl)-6-methylpyridin-3-yl)amino)-2-fluoroethyl)-3-(4-(2-(difluoromethyl)pyrimidin-5-yl)piperazin-1-yl)-4-fluoro-2,7-dimethylisoquinolin-1(2H)-one





 C31H34F3N7O3S	284	(S)-5-(1-((2-(cyclopropylsulfonyl)-6-methylpyridin-3-yl)amino)-2-fluoroethyl)-3-(4-(2-(difluoromethyl)pyrimidin-5-yl)piperazin-1-yl)-2,7-dimethylisoquinolin-1(2H)-one
 C28H33N7O3S	285	(R)-2,7-dimethyl-3-(4-(3-methyl-1,2,4-triazin-6-yl)piperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C26H28F2N2O3S	286	(R)-3-(3-(difluoromethyl)bicyclo[1.1.1]pentan-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C26H28F2N2O3S	287	(S)-3-(3-(difluoromethyl)bicyclo[1.1.1]pentan-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C30H32N4O3S	288	(R)-2,7-dimethyl-3-(3-(2-methylpyrimidin-5-yl)bicyclo[1.1.1]pentan-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H32N4O3S	289	(S)-2,7-dimethyl-3-(3-(2-methylpyrimidin-5-yl)bicyclo[1.1.1]pentan-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C29H35N7O2S	290	2,7-dimethyl-5-((1R)-1-((6-methyl-2-(methylsulfinyl)pyridin-3-yl)amino)ethyl)-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 1
 C29H35N7O2S	291	2,7-dimethyl-5-((1R)-1-((6-methyl-2-(methylsulfinyl)pyridin-3-yl)amino)ethyl)-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 2





 C29H33F2N7O	292	(R)-5-(1-((2-(difluoromethyl)-6-methylpyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C30H36N6O3S	293	(R)-3-(4-(3,5-dimethylpyrazin-2-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C31H36N6O3S	294	2,7-dimethyl-3-(8-(2-methylpyrimidin-5-yl)-3,8-diazabicyclo[3.2.1]octan-3-yl)-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C28H31ClN6O3S	295	(R)-7-chloro-2-methyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C28H32N6O3S	296	(R)-2-methyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C29H32F2N6O2	297	(R)-5-(1-((2-(difluoromethoxy)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C29H31F3N6O2	298	(R)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-5-(1-((2-(trifluoromethoxy)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H33N7O3S	299	(R)-5-(1-((6-ethynyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one





 C30H35N5O3S	300	(R)-2,7-dimethyl-3-(1-(2-methylpyrimidin-5-yl)piperidin-4-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C29H35N7O3S	301	(R)-3-(4-(3,5-dimethyl-1,2,4-triazin-6-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C31H37N7O3S	302	(R)-5-(1-((6-cyclopropyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C30H33N5O3S	303	2,7-dimethyl-3-((1R,5S,6S)-6-(2-methylpyrimidin-5-yl)-3-azabicyclo[3.1.0]hexan-3-yl)-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C27H31N5O3S	304	(R)-2,7-dimethyl-3-(2-methyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C27H31N5O3S	305	(R)-2,7-dimethyl-3-(1-methyl-1,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C29H33N5O3S	306	2,7-dimethyl-3-((1R,5S,6r)-3-(1-methyl-1H-pyrazol-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl)-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H36N6O3S	307	2,7-dimethyl-3-((S)-3-methyl-4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C31H36N6O3S	308	(R)-2,7-dimethyl-3-(2-(5-methylpyrazin-2-yl)-2,6-diazaspiro[3.4]octan-6-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H33FN4O4S	309	(R)-3-(5-fluoro-6-(3-methoxy-3-methylazetidin-1-yl)pyridin-3-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C29H31FN4O4S	310	(R)-3-(5-fluoro-6-(3-hydroxy-3-methylazetidin-1-yl)pyridin-3-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H30FN5O3S	311	(R)-1-(5-(2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)-3-fluoropyridin-2-yl)-3-methylazetidine-3-carbonitrile





 C31H33FN4O4S	312	(R)-3-(5-fluoro-6-(5-oxa-2-azaspiro[3.4]octan-2-yl)pyridin-3-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H32FN5O4S	313	(R)-3-(5-fluoro-6-(4-methyl-3-oxopiperazin-1-yl)pyridin-3-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C29H30FN5O4S	314	(R)-3-(5-fluoro-6-(3-oxopiperazin-1-yl)pyridin-3-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C31H41N5O4S	315	(R)-3-(4-(4-acetylpiperazin-1-yl)piperidin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C30H37FN8O2S	316	5-((1R)-1-((2-(N,S-dimethylsulfonimidoyl)-6-methylpyridin-3-yl)amino)ethyl)-4-fluoro-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 1
 C30H37FN8O2S	317	5-((1R)-1-((2-(N,S-dimethylsulfonimidoyl)-6-methylpyridin-3-yl)amino)ethyl)-4-fluoro-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 2
 C28H33FN8O3S	318	(R)-3-((1-(4-fluoro-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-6-methylpyridine-2-sulfonamide
 C28H34N8O3S	319	(R)-3-((1-(2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-6-methylpyridine-2-sulfonamide





 C29H36N8O2S	320	2,7-dimethyl-5-((1R)-1-((6-methyl-2-(S-methylsulfonimidoyl)pyridin-3-yl)amino)ethyl)-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 1
 C29H36N8O2S	321	2,7-dimethyl-5-((1R)-1-((6-methyl-2-(S-methylsulfonimidoyl)pyridin-3-yl)amino)ethyl)-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 2
 C29H34N6O3S	322	(R)-2,7-dimethyl-3-(4-(3-methylpyridazin-4-yl)piperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C29H34N4O3S	323	2-(2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)-5-methyloctahydrocyclopenta[c]pyrrole-5-carbonitrile, Diastereomer 1





 C29H34N4O3S	324	2-(2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)-5-methyloctahydrocyclopenta[c]pyrrole-5-carbonitrile, Diastereomer 2
 C27H28N6O3S	325	(R)-2,7-dimethyl-3-(1'-methyl-1'H-[1,4'-bipyrazol]-4-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H35F2N7O	326	(R)-5-(1-((2-(1,1-difluoroethyl)-6-methylpyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C30H36N6O4S	327	3-(4-((S)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)piperazin-1-yl)-2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C30H37N5O4S2	328	(R)-3-(4-(2-(2-hydroxypropan-2-yl)thiazol-5-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H35FN6O3S	329	(R)-3-(4-(5-fluoro-2-methylpyridin-3-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 $C_{30}H_{32}FN_7O_3S$	330	(R)-3-(4-(2,7-dimethyl-5-(1-((6-methyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)piperazin-1-yl)-5-fluoropicolinonitrile
 C31H37N7O3S	331	(R)-5-(1-((2-(azetidin-1-ylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one





 C30H37N7O3S	332	(R)-2-((1-(2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-N,N-dimethylbenzenesulfonamide
 C30H34FN5O3S	333	(R)-3-(4-fluoro-4-(2-methylpyrimidin-5-yl)piperidin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C28H34N4O4S	334	(R)-3-(4-(cyclopropanecarbonyl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H40N4O4S	335	3-(4-(5,5-dimethyltetrahydrofuran-3-yl)piperazin-1-yl)-2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one, Diastereomer 1





 C30H40N4O4S	336	3-(4-(5,5-dimethyltetrahydrofuran-3-yl)piperazin-1-yl)-2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one, Diastereomer 2
 C28H36N4O4S	337	2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)-3-(4-(tetrahydrofuran-3-yl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 1
 C28H36N4O4S	338	2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)-3-(4-(tetrahydrofuran-3-yl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 2
 C31H33N7O3S	339	(R)-2,7-dimethyl-3-(2-(1-methyl-1,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)pyrimidin-5-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C29H31F2N5O3S	340	3-((1R,5S,6r)-3-(1-(difluoromethyl)-1H-pyrazol-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl)-2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C32H36N6O3S	341	2-(4-((1R,5S,6r)-6-(2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)-3-azabicyclo[3.1.0]hexan-3-yl)-1H-pyrazol-1-yl)-2-methylpropanenitrile
 C31H38N6O3S	342	3-((3R,5S)-3,5-dimethyl-4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C29H32N6O4S	343	(R)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)-3-oxopiperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C31H36N6O3S	344	(R)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)-4,7-diazaspiro[2.5]octan-7-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C26H30N2O3S	345	3-(-[1,1'-bi(cyclopropan)]-2-yl)-2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one, trans Diastereomer 1
 C26H30N2O3S	346	3-(-[1,1'-bi(cyclopropan)]-2-yl)-2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one, trans Diastereomer 2
 C27H29F2N5O3S	347	(R)-3-(2-(difluoromethyl)-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C27H29F2N5O3S	348	(R)-3-(1-(difluoromethyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C32H32FN5O3S	349	(R)-3-(2-(4-fluorophenyl)-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C29H30F2N4O3S	350	(R)-3-(3-(1-(difluoromethyl)-1H-pyrazol-4-yl)bicyclo[1.1.1]pentan-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C29H30F2N4O3S	351	(S)-3-(3-(1-(difluoromethyl)-1H-pyrazol-4-yl)bicyclo[1.1.1]pentan-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C31H38N8O2S	352	5-((1R)-1-((2-(cyclopropanesulfonimidoyl)-6-methylpyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 1
 C31H38N8O2S	353	5-((1R)-1-((2-(cyclopropanesulfonimidoyl)-6-methylpyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 2
 C31H37N7O2S	354	5-((1R)-1-((2-(cyclopropylsulfinyl)-6-methylpyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 1
 C31H37N7O2S	355	5-((1R)-1-((2-(cyclopropylsulfinyl)-6-methylpyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 2





 C29H32ClFN6O3S	356	(R)-3-(4-(2-chloro-5-fluoropyridin-3-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C29H30F4N6O3S	357	(R)-3-(4-(2-(difluoromethyl)pyrimidin-5-yl)piperazin-1-yl)-4-fluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one
 C29H31F3N6O3S	358	(R)-3-(4-(2-(difluoromethyl)pyrimidin-5-yl)piperazin-1-yl)-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one
 C29H38N4O4S	359	2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)-3-(4-(tetrahydro-2H-pyran-3-yl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 1





 C29H38N4O4S	360	2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)-3-(4-(tetrahydro-2H-pyran-3-yl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 2
 C27H35N5O4S	361	(R)-4-(2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)-N,N-dimethylpiperazine-1-carboxamide
 C27H31F3N4O5S	362	2,2,2-trifluoroethyl (R)-4-(2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)piperazine-1-carboxylate
 C30H34N6O3S	363	2,7-dimethyl-3-(6-(2-methylpyrimidin-5-yl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C30H36N6O3S	364	(R)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)-1,4-diazepan-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C27H31ClN8O3S	365	(R)-6-chloro-3-((1-(2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)pyridine-2-sulfonamide
 C27H30ClFN8O3S	366	(R)-6-chloro-3-((1-(4-fluoro-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)pyridine-2-sulfonamide
 C28H33N7O3S	367	(R)-2,7-dimethyl-3-(4-(5-methyl-1,2,4-triazin-6-yl)piperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C29H36N4O5S	368	cyclopropylmethyl (R)-4-(2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)piperazine-1-carboxylate
 C31H38N6O3S	369	3-((3S,5S)-3,5-dimethyl-4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H33FN4O4S	370	3-(5-fluoro-6-(3-hydroxy-3-methylpyrrolidin-1-yl)pyridin-3-yl)-2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one, Diastereomer 1
 C30H33FN4O4S	371	3-(5-fluoro-6-(3-hydroxy-3-methylpyrrolidin-1-yl)pyridin-3-yl)-2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one, Diastereomer 2





 C31H32FN5O3S	372	1-(5-(2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)-3-fluoropyridin-2-yl)-3-methylpyrrolidine-3-carbonitrile, , Diastereomer 1
 C31H32FN5O3S	373	1-(5-(2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)-3-fluoropyridin-2-yl)-3-methylpyrrolidine-3-carbonitrile, , Diastereomer 2
 C29H33N5O3S	374	(R)-2,7-dimethyl-3-(3-((2-methylpyrimidin-5-yl)methyl)azetidin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C29H33N5O3S	375	(R)-2,7-dimethyl-3-(3-((5-methylpyrazin-2-yl)methyl)azetidin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C28H30N4O3S	376	2,7-dimethyl-3-(2-(2-methylpyrimidin-5-yl)cyclopropyl)-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one, trans Diastereomer 1
 C28H30N4O3S	377	2,7-dimethyl-3-(2-(2-methylpyrimidin-5-yl)cyclopropyl)-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one, trans Diastereomer 2
 C29H33N5O3S	378	(R)-3-(2-cyclopropyl-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C29H33N5O3S	379	(R)-3-(1-cyclopropyl-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C33H38N6O3S	380	(R)-2-(5-(1-(2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)piperidin-4-yl)pyrimidin-2-yl)-2-methylpropanenitrile
 C32H38FN5O4S	381	(R)-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-3-(4-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)piperidin-1-yl)-2,7-dimethylisoquinolin-1(2H)-one
 C29H33F2N7O3S	382	(R)-5-(1-((6-(difluoromethyl)-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C30H36N6O4S	383	3-(4-((R)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)piperazin-1-yl)-2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C29H31F3N6O3S	384	(S)-4-fluoro-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C29H32F2N6O3S	385	(S)-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C29H35FN8O2S	386	4-fluoro-2,7-dimethyl-5-((1R)-1-((6-methyl-2-(S-methylsulfonimidoyl)pyridin-3-yl)amino)ethyl)-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 1
 C29H35FN8O2S	387	4-fluoro-2,7-dimethyl-5-((1R)-1-((6-methyl-2-(S-methylsulfonimidoyl)pyridin-3-yl)amino)ethyl)-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 2





 C28H32FN7O3S	388	(R)-2-((1-(2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzenesulfonamide
 C29H32F3N7O3S	389	(S)-3-(4-(2-(difluoromethyl)pyrimidin-5-yl)piperazin-1-yl)-5-(2-fluoro-1-((6-methyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one
 C29H34FN7O3S	390	(S)-5-(2-fluoro-1-((6-methyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C29H33F2N7O3S	391	(S)-4-fluoro-5-(2-fluoro-1-((6-methyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one





 C30H36N6O3S	392	(R)-2,7-dimethyl-5-(1-((6-methyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)-3-(4-(2-methylpyrimidin-5-yl)piperidin-1-yl)isoquinolin-1(2H)-one
 C30H32F3N5O4S	393	(R)-5-fluoro-3-(4-(4-fluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-3-yl)piperazin-1-yl)-2-methylpyridine 1-oxide
 C30H33F2N5O4S	394	(R)-5-fluoro-3-(4-(5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-3-yl)piperazin-1-yl)-2-methylpyridine 1-oxide
 C30H33F2N5O4S	395	(R)-3-(4-(5-fluoro-1-methyl-6-oxo-1,6-dihydropyridin-2-yl)piperazin-1-yl)-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one





 C29H33FN6O4S	396	(R)-5-(4-(5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-3-yl)piperazin-1-yl)-2-methylpyrimidine 1-oxide
 C28H35N5O4S	397	(R)-N-cyclopropyl-4-(2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)piperazine-1-carboxamide
 C29H36N4O4S	398	(R)-3-(4-(2-cyclopropylacetyl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H38N4O4S	399	3-(4-(2-cyclopropylpropanoyl)piperazin-1-yl)-2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one, Diastereomer 1





 C30H38N4O4S	400	3-(4-(2-cyclopropylpropanoyl)piperazin-1-yl)-2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one, Diastereomer 2
 C30H35FN6O3S	401	(R)-3-(4-fluoro-4-(2-methylpyrimidin-5-yl)piperidin-1-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C30H34F2N6O3S	402	(R)-4-fluoro-3-(4-fluoro-4-(2-methylpyrimidin-5-yl)piperidin-1-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C30H35N5O4S	403	(R)-3-(4-hydroxy-4-(2-methylpyrimidin-5-yl)piperidin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C32H39N5O4S	404	(R)-3-(4-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)piperidin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C32H37F2N5O4S	405	(R)-4-fluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-3-(4-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)piperidin-1-yl)-2,7-dimethylisoquinolin-1(2H)-one
 C31H39N5O3S	406	1-(1-(2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)piperidin-4-yl)-3-methylpyrrolidine-3-carbonitrile, Diastereomer 1
 C31H39N5O3S	407	1-(1-(2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)piperidin-4-yl)-3-methylpyrrolidine-3-carbonitrile, Diastereomer 2





 C29H33N5O4S	408	3-(3-hydroxy-3-(2-methylpyrimidin-5-yl)pyrrolidin-1-yl)-2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one, Diastereomer 1
 C29H33N5O4S	409	3-(3-hydroxy-3-(2-methylpyrimidin-5-yl)pyrrolidin-1-yl)-2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one, Diastereomer 2
 C30H40N4O4S	410	3-(4-(3-hydroxy-3-methylpyrrolidin-1-yl)piperidin-1-yl)-2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one, Diastereomer 1
 C30H40N4O4S	411	3-(4-(3-hydroxy-3-methylpyrrolidin-1-yl)piperidin-1-yl)-2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one, Diastereomer 2





 C31H36N4O4S	412	(R)-4-(1-(2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)piperidin-4-yl)-2-methylpyridine 1-oxide
 C29H35FN4O4S	413	3-((R)-4-(cyclopropanecarbonyl)-3-methylpiperazin-1-yl)-5-((R)-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one
 C29H27FN6O3S	414	(R)-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)isoquinolin-1(2H)-one
 C29H29N7O3S	415	(R)-2,7-dimethyl-5-(1-((6-methyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)isoquinolin-1(2H)-one





 C30H37FN8O2S	416	5-((1S)-1-((2-(N,S-dimethylsulfonimidoyl)-6-methylpyridin-3-yl)amino)-2-fluoroethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 1
 C30H37FN8O2S	417	5-((1S)-1-((2-(N,S-dimethylsulfonimidoyl)-6-methylpyridin-3-yl)amino)-2-fluoroethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 2
 C29H30F4N6O3S	418	(S)-3-(4-(2-(difluoromethyl)pyrimidin-5-yl)piperazin-1-yl)-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one
 C28H32ClN7O3S	419	(R)-5-(1-((6-chloro-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one





 C28H31ClFN7O3S	420	(R)-5-(1-((6-chloro-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)-4-fluoro-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C28H31ClFN7O3S	421	(S)-5-(1-((6-chloro-2-(methylsulfonyl)pyridin-3-yl)amino)-2-fluoroethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C30H32F3N5O4S	422	(R)-4-fluoro-3-(4-(5-fluoro-1-methyl-6-oxo-1,6-dihydropyridin-2-yl)piperazin-1-yl)-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one
 C29H32F2N6O4S	423	(R)-5-(4-(4-fluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-3-yl)piperazin-1-yl)-2-methylpyrimidine 1-oxide





 C31H34F2N4O4S	424	(R)-5-fluoro-3-(1-(5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-3-yl)piperidin-4-yl)-2-methylpyridine 1-oxide
 C29H37N5O4S	425	(R)-N-cyclopropyl-4-(2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)-N-methylpiperazine-1-carboxamide
 C29H32F3N7O	426	(R)-5-(1-((2-(difluoromethyl)-6-methylpyridin-3-yl)amino)ethyl)-4-fluoro-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C30H31F2N7O	427	(R)-3-(difluoromethyl)-4-((1-(2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile





 C30H30F3N7O	428	(R)-3-(difluoromethyl)-4-((1-(4-fluoro-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C28H28F4N6O	429	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C31H36FN7O3S	430	(R)-5-(1-((2-((3-fluoroazetidin-1-yl)sulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C31H35F2N7O3S	431	(R)-5-(1-((2-((3,3-difluoroazetidin-1-yl)sulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one





 C29H31FN8O3S	432	(R)-5-cyano-2-((1-(4-fluoro-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzenesulfonamide
 C30H36N4O5S	433	cyclopropyl 8-(2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate
 C29H35FN6O3S	434	(R)-3-(4-(1,3-dimethyl-1H-pyrazol-4-yl)piperazin-1-yl)-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one
 C28H32F2N6O3S	435	(R)-3-(4-(1,3-dimethyl-1H-pyrazol-4-yl)piperazin-1-yl)-7-fluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methylisoquinolin-1(2H)-one





 C30H35N7O3S	436	(R)-4-((1-(3-(4-(1,3-dimethyl-1H-pyrazol-4-yl)piperazin-1-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-3-(methylsulfonyl)benzonitrile
 C29H35FN6O3S	437	(R)-3-(4-(1,5-dimethyl-1H-pyrazol-4-yl)piperazin-1-yl)-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one
 C30H35N7O3S	438	(R)-4-((1-(3-(4-(1,5-dimethyl-1H-pyrazol-4-yl)piperazin-1-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-3-(methylsulfonyl)benzonitrile
 C29H36FN7O3S	439	(R)-3-(4-(5-fluoro-1,3-dimethyl-1H-pyrazol-4-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one





 C29H37N7O3S	440	(R)-3-(4-(1,3-dimethyl-1H-pyrazol-4-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C29H37N7O3S	441	(R)-3-(4-(1,5-dimethyl-1H-pyrazol-4-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C30H37N7O3S	442	(R)-3-(4-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)piperidin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H37N7O3S	443	(R)-3-(4-(5,6-dihydro-[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl)piperidin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C30H31N7O3S	444	(R)-3-(2',4'-dimethyl-[2,5'-bipyrimidin]-5-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C29H32FN5O3S	445	3-(3-fluoro-3-(2-methylpyrimidin-5-yl)pyrrolidin-1-yl)-2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one, Diastereomer 1
 C29H32FN5O3S	446	3-(3-fluoro-3-(2-methylpyrimidin-5-yl)pyrrolidin-1-yl)-2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one, Diastereomer 2
 C31H33N5O3S	447	(R)-3-(6-(1,3-dimethyl-1H-pyrazol-4-yl)-5-methylpyridin-3-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C31H31N5O3S	448	(R)-2,7-dimethyl-3-(5-methyl-6-(2-methylpyrimidin-5-yl)pyridin-3-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C31H36FN5O4S	449	5-((R)-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-((R)-3-methyl-4-(1-methyl-6-oxo-1,6-dihydropyridin-2-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C32H38F2N6O4S	450	3-((R)-4-(5-((R)-1-((2-(N,N-dimethylsulfamoyl)-4-fluorophenyl)amino)ethyl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-3-yl)-2-methylpiperazin-1-yl)-5-fluoro-2-methylpyridine 1-oxide
 C31H35F2N5O4S	451	5-fluoro-3-((R)-4-(5-((R)-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-3-yl)-2-methylpiperazin-1-yl)-2-methylpyridine 1-oxide





 C29H35FN6O3S	452	5-((R)-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-((R)-3-methyl-4-(1-methyl-1H-pyrazol-4-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C29H36N4O5S	453	1-methylcyclopropyl (R)-4-(2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)piperazine-1-carboxylate
 C29H34F2N6O3S	454	(R)-3-(4-(1,5-dimethyl-1H-pyrazol-4-yl)piperazin-1-yl)-4-fluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one
 C30H34FN7O3S	455	(R)-4-((1-(3-(4-(1,5-dimethyl-1H-pyrazol-4-yl)piperazin-1-yl)-4-fluoro-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-3-(methylsulfonyl)benzonitrile





 C29H37N5O4S	456	(R)-2,7-dimethyl-5-(1-((6-methyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)-3-(4-(1-methylcyclopropane-1-carbonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C29H37N5O4S	457	3-((R)-4-(cyclopropanecarbonyl)-3-methylpiperazin-1-yl)-2,7-dimethyl-5-((R)-1-((6-methyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C29H37N5O4S	458	3-((S)-4-(cyclopropanecarbonyl)-3-methylpiperazin-1-yl)-2,7-dimethyl-5-((R)-1-((6-methyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C29H26F2N6O3S	459	(R)-6-fluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)isoquinolin-1(2H)-one





 C29H31F4N7O3S	460	(S)-3-(4-(2-(difluoromethyl)pyrimidin-5-yl)piperazin-1-yl)-4-fluoro-5-(2-fluoro-1-((6-methyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one
 C31H34F2N4O4S	461	(R)-3-fluoro-5-(1-(5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-3-yl)piperidin-4-yl)-2-methylpyridine 1-oxide
 C28H27F5N6O	462	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-4,7-difluoro-2-methyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C31H37N7O4S	463	(R)-5-(1-((2-((3-hydroxyazetidin-1-yl)sulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one




 C32H36F3N4O2P	464	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-3-(4-(3-(dimethylphosphoryl)phenyl)piperazin-1-yl)-2,7-dimethylisoquinolin-1(2H)-one
 C30H31F4N5O	465	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-3-(5-fluoro-6-(4-methylpiperazin-1-yl)pyridin-3-yl)-2,7-dimethylisoquinolin-1(2H)-one
 C31H31F4N5O2	466	(R)-3-(6-(4-acetylpiperazin-1-yl)-5-fluoropyridin-3-yl)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one
 C30H32FN7O3S	467	(R)-4-((1-(4-fluoro-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-3-(methylsulfonyl)benzonitrile





 C29H29F3N8O3S	468	(R)-5-cyano-2-((1-(3-(4-(2-(difluoromethyl)pyrimidin-5-yl)piperazin-1-yl)-4-fluoro-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzenesulfonamide
 C30H33N5O3S	469	(R)-2,7-dimethyl-5-(1-((6-methyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)-3-(3-(2-methylpyrimidin-5-yl)bicyclo[1.1.1]pentan-1-yl)isoquinolin-1(2H)-one
 C30H31FN4O3S	470	(R)-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(3-(2-methylpyrimidin-5-yl)bicyclo[1.1.1]pentan-1-yl)isoquinolin-1(2H)-one
 C30H31FN4O3S	471	(S)-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(3-(2-methylpyrimidin-5-yl)bicyclo[1.1.1]pentan-1-yl)isoquinolin-1(2H)-one





 C29H34F3N7O	472	(S)-5-(1-((2-(difluoromethyl)-6-methylpyridin-3-yl)amino)-2-fluoroethyl)-3-(4-(1,3-dimethyl-1H-pyrazol-4-yl)piperazin-1-yl)-2,7-dimethylisoquinolin-1(2H)-one
 C29H37N7O3S	473	2,7-dimethyl-5-((R)-1-((6-methyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)-3-((R)-3-methyl-4-(1-methyl-1H-pyrazol-4-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C29H31N7O3S	474	(R)-3-(2-(1,5-dimethyl-1H-pyrazol-4-yl)pyrimidin-5-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C29H31N7O3S	475	(R)-3-(2-(1,3-dimethyl-1H-pyrazol-4-yl)pyrimidin-5-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one





 C29H34N6O4S	476	(R)-3-(4-(1,3-dimethyl-1H-pyrazol-4-yl)-3-oxopiperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H33N5O3S	477	2,7-dimethyl-3-((1R,5S,6r)-3-(2-methylpyrimidin-5-yl)-3-azabicyclo[3.1.0]hexan-6-yl)-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C28H34FN7O3S	478	(R)-2-((1-(3-(4-(1,3-dimethyl-1H-pyrazol-4-yl)piperazin-1-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzenesulfonamide
 C29H32F2N6O3S	479	(R)-8-fluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one





 C29H26F2N6O3S	480	(R)-8-fluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)isoquinolin-1(2H)-one
 C30H29FN6O3S	481	(R)-3-(2',4-dimethyl-[2,5'-bipyrimidin]-5-yl)-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one
 C31H37N7O3S	482	(R)-N-cyclopropyl-2-((1-(2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzenesulfonamide
 C28H31F2N7O3S	483	(R)-5-fluoro-2-((1-(4-fluoro-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzenesulfonamide





 C29H34N8O3S	484	(R)-5-cyano-2-((1-(3-(4-(1,5-dimethyl-1H-pyrazol-4-yl)piperazin-1-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzenesulfonamide
 C28H34FN7O3S	485	(R)-2-((1-(3-(4-(1,5-dimethyl-1H-pyrazol-4-yl)piperazin-1-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzenesulfonamide
 C31H31N5O3S	486	(R)-4-((1-(2,7-dimethyl-3-(3-(2-methylpyrimidin-5-yl)bicyclo[1.1.1]pentan-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-3-(methylsulfonyl)benzonitrile




 C30H31F4N5O2	487	(R)-3-(4-(5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-3-yl)piperazin-1-yl)-5-fluoro-2-methylpyridine 1-oxide
 C31H25F5N4O2	488	(R)-5-(5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-3-yl)-3,5'-difluoro-2'-methyl-[2,3'-bipyridine] 1'-oxide
 C29H26F2N6O3S	489	(S)-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)isoquinolin-1(2H)-one
 C29H28FN7O3S	490	(S)-5-(2-fluoro-1-((6-methyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)isoquinolin-1(2H)-one





 C29H24F4N6O	491	(S)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)-2-fluoroethyl)-2,7-dimethyl-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)isoquinolin-1(2H)-one
 C28H34FN5O4S	492	(R)-3-(4-(azetidine-1-carbonyl)piperazin-1-yl)-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one
 C28H33F2N5O4S	493	(R)-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-3-(4-(3-fluoroazetidine-1-carbonyl)piperazin-1-yl)-2,7-dimethylisoquinolin-1(2H)-one
 C31H29F3N6O2	494	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-3-(2'-(2-hydroxypropan-2-yl)-[2,5'-bipyrimidin]-5-yl)-2,7-dimethylisoquinolin-1(2H)-one





 C31H30F4N4O2	495	3-((1R,5S,6r)-6-(5-((R)-1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-3-yl)-3-azabicyclo[3.1.0]hexan-3-yl)-5-fluoro-2-methylpyridine 1-oxide
 C25H29F3N4O3S	496	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-2,7-dimethyl-3-(4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C27H31F3N4O3S	497	(R)-3-(4-(cyclopropylsulfonyl)piperazin-1-yl)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one
 C30H32F3N5O2	498	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-3-(4-hydroxy-4-(2-methylpyrimidin-5-yl)piperidin-1-yl)-2,7-dimethylisoquinolin-1(2H)-one





 C31H29FN6O4S	499	(R)-3-(2'-cyclopropoxy-[2,5'-bipyrimidin]-5-yl)-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one
 C28H27FN6O3S	500	(R)-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(1-(2-methylpyrimidin-5-yl)-1H-pyrazol-4-yl)isoquinolin-1(2H)-one
 C29H29FN6O3S	501	(R)-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(3-methyl-1-(2-methylpyrimidin-5-yl)-1H-pyrazol-4-yl)isoquinolin-1(2H)-one
 C28H25F2N5O3S	502	(R)-7-fluoro-3-(5-fluoro-6-(4-methyl-1H-pyrazol-1-yl)pyridin-3-yl)-2-methyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C29H29FN6O3S	503	(R)-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(5-methyl-1-(2-methylpyrimidin-5-yl)-1H-pyrazol-4-yl)isoquinolin-1(2H)-one
 C27H25FN6O3S	504	(R)-7-fluoro-2-methyl-3-(2-(4-methyl-1H-pyrazol-1-yl)pyrimidin-5-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C31H30F2N6O2	505	(R)-5-(1-((2-(difluoromethyl)phenyl)amino)ethyl)-3-(2'-(2-hydroxypropan-2-yl)-[2,5'-bipyrimidin]-5-yl)-2,7-dimethylisoquinolin-1(2H)-one
 C30H37FN6O3S	506	3-((R)-4-(1,5-dimethyl-1H-pyrazol-4-yl)-3-methylpiperazin-1-yl)-5-((R)-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one





 C28H29F4N7O3S	507	(R)-2-((1-(3-(4-(2-(difluoromethyl)pyrimidin-5-yl)piperazin-1-yl)-4-fluoro-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzenesulfonamide
 C30H25F4N5O2	508	(R)-3-(5-(5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-3-yl)pyrimidin-2-yl)-5-fluoro-2-methylpyridine 1-oxide
 C30H26FN7O3S	509	(S)-4-((1-(2,7-dimethyl-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)-2-fluoroethyl)amino)-3-(methylsulfonyl)benzonitrile





 C30H24F3N7O	510	(S)-3-(difluoromethyl)-4-((1-(2,7-dimethyl-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)-2-fluoroethyl)amino)benzonitrile
 C31H37N5O4S	511	(R)-3-(4-methoxy-4-(2-methylpyrimidin-5-yl)piperidin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C28H25F2N7O3S	512	(S)-7-fluoro-5-(2-fluoro-1-((6-methyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)-2-methyl-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)isoquinolin-1(2H)-one
 C29H36N4O5S	513	cyclopropyl (R)-4-(2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)-3-methylpiperazine-1-carboxylate





 C29H36N4O5S	514	cyclopropyl (S)-4-(2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)-3-methylpiperazine-1-carboxylate
 C29H34F2N6O3S	515	(R)-3-(4-(1,3-dimethyl-1H-pyrazol-4-yl)piperazin-1-yl)-4-fluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one
 C30H35N5O3S	516	(R)-3-(3-(1,3-dimethyl-1H-pyrazol-4-yl)bicyclo[1.1.1]pentan-1-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(methylsulfonyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C30H28FN5O4S	517	(R)-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one





 C28H31F3N8O3S	518	(R)-3-((1-(3-(4-(2-(difluoromethyl)pyrimidin-5-yl)piperazin-1-yl)-4-fluoro-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-6-methylpyridine-2-sulfonamide
 C29H25F3N6O3S	519	(S)-4-fluoro-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)isoquinolin-1(2H)-one
 C30H25F4N7O3S	520	(S)-7-fluoro-5-(2-fluoro-1-((4-fluoro-2-((3-fluoroazetidin-1-yl)sulfonyl)phenyl)amino)ethyl)-2-methyl-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)isoquinolin-1(2H)-one
 C28H21F5N6O	521	(S)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)-2-fluoroethyl)-7-fluoro-2-methyl-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)isoquinolin-1(2H)-one





 C28H23F4N7O	522	(S)-5-(1-((2-(difluoromethyl)-6-methylpyridin-3-yl)amino)-2-fluoroethyl)-7-fluoro-2-methyl-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)isoquinolin-1(2H)-one
 C30H39FN4O5S	523	5-((R)-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-((R)-3-methyl-4-(2-methyl-1,3-dioxan-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C31H30F4N4O2	524	3-((1R,5S)-3-(5-((R)-1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl)-5-fluoro-2-methylpyridine 1-oxide
 C28H23F5N6O	525	(S)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)-2-fluoroethyl)-3-(2-(1,3-dimethyl-1H-pyrazol-4-yl)pyrimidin-5-yl)-7-fluoro-2-methylisoquinolin-1(2H)-one





 C30H24F4N4O3S	526	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-3-(2-(3-(methylsulfonyl)phenyl)pyrimidin-5-yl)isoquinolin-1(2H)-one
 C28H25F4N7O	527	(S)-5-(1-((2-(difluoromethyl)-6-methylpyridin-3-yl)amino)-2-fluoroethyl)-3-(2-(1,3-dimethyl-1H-pyrazol-4-yl)pyrimidin-5-yl)-7-fluoro-2-methylisoquinolin-1(2H)-one
 C30H34F2N6O2	528	(R)-5-(1-((2-(difluoromethyl)-6-methylpyridin-3-yl)amino)ethyl)-3-(4-hydroxy-4-(2-methylpyrimidin-5-yl)piperidin-1-yl)-2,7-dimethylisoquinolin-1(2H)-one
 C30H33F2N5O4S	529	(R)-4-fluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-3-(4-hydroxy-4-(2-methylpyrimidin-5-yl)piperidin-1-yl)-2,7-dimethylisoquinolin-1(2H)-one





 C28H24F2N6O3S	530	(R)-7-fluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methyl-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)isoquinolin-1(2H)-one
 C27H32FN7O3S	531	(R)-3-(4-(2,5-dimethyl-2H-1,2,3-triazol-4-yl)piperazin-1-yl)-7-fluoro-2-methyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C27H32FN7O3S	532	(R)-3-(4-(1,5-dimethyl-1H-1,2,4-triazol-3-yl)piperazin-1-yl)-7-fluoro-2-methyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H24F4N4O2S	533	5-((R)-1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-3-(2-(3-(methylsulfinyl)phenyl)pyrimidin-5-yl)isoquinolin-1(2H)-one, Diastereomer 1





 C30H24F4N4O2S	534	5-((R)-1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-3-(2-(3-(methylsulfinyl)phenyl)pyrimidin-5-yl)isoquinolin-1(2H)-one, Diastereomer 2
 C28H23F3N6O3S	535	(S)-7-fluoro-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methyl-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)isoquinolin-1(2H)-one
 C27H18F8N6O	536	(S)-3-(2-(1-(difluoromethyl)-3-fluoro-1H-pyrazol-4-yl)pyrimidin-5-yl)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)-2-fluoroethyl)-7-fluoro-2-methylisoquinolin-1(2H)-one
 C27H20F7N7O	537	(S)-3-(2-(1-(difluoromethyl)-3-fluoro-1H-pyrazol-4-yl)pyrimidin-5-yl)-5-(1-((2-(difluoromethyl)-6-methylpyridin-3-yl)amino)-2-fluoroethyl)-7-fluoro-2-methylisoquinolin-1(2H)-one





 C29H27F6N5O2	538	(S)-3-(4-(5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)-2-fluoroethyl)-7-fluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)piperazin-1-yl)-5-fluoro-2-methylpyridine 1-oxide
 C28H19F7N6O	539	(S)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)-2-fluoroethyl)-3-(2'-(difluoromethyl)-[2,5'-bipyrimidin]-5-yl)-7-fluoro-2-methylisoquinolin-1(2H)-one
 C29H31F5N4O2	540	5-((S)-1-((2-(difluoromethyl)-4-fluorophenyl)amino)-2-fluoroethyl)-7-fluoro-2-methyl-3-((R)-3-methyl-4-(1-methylcyclopropane-1-carbonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C29H31F5N4O2	541	5-((S)-1-((2-(difluoromethyl)-4-fluorophenyl)amino)-2-fluoroethyl)-7-fluoro-2-methyl-3-((S)-3-methyl-4-(1-methylcyclopropane-1-carbonyl)piperazin-1-yl)isoquinolin-1(2H)-one





 C29H33F3N4O4S	542	7-fluoro-5-((S)-2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methyl-3-((R)-3-methyl-4-(1-methylcyclopropane-1-carbonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C29H33F3N4O4S	543	7-fluoro-5-((S)-2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methyl-3-((S)-3-methyl-4-(1-methylcyclopropane-1-carbonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C31H28F4N5O2P	544	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-3-(2-(5-(dimethylphosphoryl)-6-methylpyridin-3-yl)pyrimidin-5-yl)-7-fluoro-2-methylisoquinolin-1(2H)-one
 C28H26F5N5O3S	545	3-((1R,5S,6R)-6-(1-(difluoromethyl)-1H-pyrazol-4-yl)-3-azabicyclo[3.1.0]hexan-3-yl)-7-fluoro-5-((S)-2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methylisoquinolin-1(2H)-one





 C27H23F3N6O3S	546	(S)-7-fluoro-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methyl-3-(2-(1-methyl-1H-pyrazol-4-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one
 C28H30F4N4O4S	547	3-((R)-4-(cyclopropanecarbonyl)-3-methylpiperazin-1-yl)-4,7-difluoro-5-((S)-2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methylisoquinolin-1(2H)-one
 C28H30F4N4O5S	548	1-methylcyclopropyl (S)-4-(4,7-difluoro-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)piperazine-1-carboxylate
 C29H25F3N6O3S	549	(S)-5-(2,2-difluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)isoquinolin-1(2H)-one





 C29H34N6O4S	550	(R)-2,7-dimethyl-3-(4-(1-methyl-1H-pyrazole-4-carbonyl)piperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C29H26F7N5O2	551	(S)-3-(4-(5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)-2-fluoroethyl)-4,7-difluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)piperazin-1-yl)-5-fluoro-2-methylpyridine 1-oxide
 C31H27F4N4O2P	552	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-3-(2-(3-(dimethylphosphoryl)phenyl)pyrimidin-5-yl)-7-fluoro-2-methylisoquinolin-1(2H)-one
 C28H30ClF3N6O3S	553	(R)-3-(4-(5-chloro-1-(difluoromethyl)-1H-pyrazol-4-yl)piperazin-1-yl)-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one





 C28H30ClF3N6O3S	554	(R)-3-(4-(3-chloro-1-(difluoromethyl)-1H-pyrazol-4-yl)piperazin-1-yl)-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one
 C29H34F2N6O3S	555	(R)-3-(4-(1-(difluoromethyl)-3-methyl-1H-pyrazol-4-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C29H22F5N5O2	556	(R)-3-(5-(5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)pyrimidin-2-yl)-5-fluoro-2-methylpyridine 1-oxide
 C27H20F6N6O3S	557	(S)-3-(2-(1-(difluoromethyl)-3-fluoro-1H-pyrazol-4-yl)pyrimidin-5-yl)-7-fluoro-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methylisoquinolin-1(2H)-one





 C28H21F2N7O	558	(R)-5-fluoro-2-((1-(7-fluoro-2-methyl-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C30H33N5O4S	559	(R)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)-3-(4-nicotinoylpiperazin-1-yl)isoquinolin-1(2H)-one
 C31H35N5O4S	560	(R)-2,7-dimethyl-3-(4-(6-methylnicotinoyl)piperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C31H35N5O4S	561	(R)-2,7-dimethyl-3-(4-(2-methylnicotinoyl)piperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C29H33F4N5O2	562	5-((S)-1-((2-(difluoromethyl)-6-methylpyridin-3-yl)amino)-2-fluoroethyl)-7-fluoro-2-methyl-3-((R)-3-methyl-4-(1-methylcyclopropane-1-carbonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C31H27F4N4O2P	563	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-3-(2-(4-(dimethylphosphoryl)phenyl)pyrimidin-5-yl)-7-fluoro-2-methylisoquinolin-1(2H)-one
 C28H31F3N4O4S	564	(S)-7-fluoro-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methyl-3-(4-(1-methylcyclopropane-1-carbonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C31H29F3N5O2P	565	(R)-5-(1-((2-(difluoromethyl)-6-methylpyridin-3-yl)amino)ethyl)-3-(2-(3-(dimethylphosphoryl)phenyl)pyrimidin-5-yl)-7-fluoro-2-methylisoquinolin-1(2H)-one





 C28H25F3N6O3S	566	(S)-3-(2-(1,3-dimethyl-1H-pyrazol-4-yl)pyrimidin-5-yl)-7-fluoro-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methylisoquinolin-1(2H)-one
 C27H21F5N6O3S	567	(S)-3-(2-(1-(difluoromethyl)-1H-pyrazol-4-yl)pyrimidin-5-yl)-7-fluoro-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methylisoquinolin-1(2H)-one
 C24H26F4N4O3S	568	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-3-(4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C28H24F3N7O	569	(R)-5-(1-((2-(difluoromethyl)-6-methylpyridin-3-yl)amino)ethyl)-7-fluoro-2-methyl-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)isoquinolin-1(2H)-one





 C29H32F4N4O2	570	5-((R)-1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-3-((R)-3-methyl-4-(1-methylcyclopropane-1-carbonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C29H34F3N5O2	571	5-((R)-1-((2-(difluoromethyl)-6-methylpyridin-3-yl)amino)ethyl)-7-fluoro-2-methyl-3-((R)-3-methyl-4-(1-methylcyclopropane-1-carbonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C28H25F5N4O3S	572	(S)-3-(3-(1-(difluoromethyl)-1H-pyrazol-4-yl)bicyclo[1.1.1]pentan-1-yl)-7-fluoro-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methylisoquinolin-1(2H)-one
 C28H24F3N7O2S	573	7-fluoro-5-((1S)-2-fluoro-1-((4-fluoro-2-(S-methylsulfonimidoyl)phenyl)amino)ethyl)-2-methyl-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)isoquinolin-1(2H)-one, Diastereomer 1





 C28H24F3N7O2S	574	7-fluoro-5-((1S)-2-fluoro-1-((4-fluoro-2-(S-methylsulfonimidoyl)phenyl)amino)ethyl)-2-methyl-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)isoquinolin-1(2H)-one, Diastereomer 2
 C29H25F5N4O3S	575	(S)-3-(3-(2-(difluoromethyl)pyrimidin-5-yl)bicyclo[1.1.1]pentan-1-yl)-7-fluoro-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methylisoquinolin-1(2H)-one
 C28H22F4N6O3S	576	(S)-4,7-difluoro-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methyl-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)isoquinolin-1(2H)-one
 C29H20F7N5O2	577	(S)-5-fluoro-3-(5-(7-fluoro-5-(2-fluoro-1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)pyrimidin-2-yl)-2-methylpyridine 1-oxide





 C24H25F5N4O3S	578	(S)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)-2-fluoroethyl)-7-fluoro-2-methyl-3-(4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C29H28F5N5O2	579	(R)-3-(4-(5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)piperazin-1-yl)-5-fluoro-2-methylpyridine 1-oxide
 C28H28F4N4O	580	(3aR,6aS)-2-(5-((R)-1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)-5-methyloctahydrocyclopenta[c]pyrrole-5-carbonitrile, Diastereomer 1
 C28H28F4N4O	581	(3aR,6aS)-2-(5-((R)-1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)-5-methyloctahydrocyclopenta[c]pyrrole-5-carbonitrile, Diastereomer 2





 C28H30F4N6O3S	582	(R)-3-(4-(1-(difluoromethyl)-3-methyl-1H-pyrazol-4-yl)piperazin-1-yl)-7-fluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methylisoquinolin-1(2H)-one
 C28H25F4N7O3S	583	(S)-2-((1-(3-(2-(1-(difluoromethyl)-3-methyl-1H-pyrazol-4-yl)pyrimidin-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)-2-fluoroethyl)amino)-6-fluorobenzenesulfonamide
 C28H25F4N7O3S	584	(S)-2-((1-(3-(2-(1-(difluoromethyl)-5-methyl-1H-pyrazol-4-yl)pyrimidin-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)-2-fluoroethyl)amino)-6-fluorobenzenesulfonamide
 C24H25F5N4O3S	585	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-4,7-difluoro-2-methyl-3-(4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one





 C24H22F4N4O3S	586	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-3-(3-methyl-1-(methylsulfonyl)-1H-pyrazol-4-yl)isoquinolin-1(2H)-one
 C28H26F2N6O3S	587	(R)-7-fluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methyl-3-(5-methyl-1-(2-methylpyrimidin-5-yl)-1H-pyrazol-4-yl)isoquinolin-1(2H)-one
 C30H22F6N4O2	588	(R)-5-(5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)-3,5'-difluoro-2'-methyl-[2,3'-bipyridine] 1'-oxide
 C29H34F3N5O2	589	5-((R)-1-((2-(difluoromethyl)-6-methylpyridin-3-yl)amino)ethyl)-7-fluoro-2-methyl-3-((S)-3-methyl-4-(1-methylcyclopropane-1-carbonyl)piperazin-1-yl)isoquinolin-1(2H)-one





 C28H30F4N4O4S	590	(S)-4,7-difluoro-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methyl-3-(4-(1-methylcyclopropane-1-carbonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C27H27F5N6O	591	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-3-(4-(5-fluoro-1-methyl-1H-pyrazol-4-yl)piperazin-1-yl)-2-methylisoquinolin-1(2H)-one
 C27H25F7N6O	592	(R)-3-(4-(1-(difluoromethyl)-1H-pyrazol-4-yl)piperazin-1-yl)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-4,7-difluoro-2-methylisoquinolin-1(2H)-one
 C28H32F4N4O3	593	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-3-(4-(2-methyl-1,3-dioxan-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 1





 C28H32F4N4O3	594	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-3-(4-(2-methyl-1,3-dioxan-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one, Diastereomer 2
 C30H26F6N4O2	595	3-((1R,5S)-3-(5-((R)-1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-4,7-difluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl)-5-fluoro-2-methylpyridine 1-oxide
 C25H21F4N3O3S	596	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-3-(6-(methylsulfonyl)pyridin-3-yl)isoquinolin-1(2H)-one
 C29H28F5N5O4S	597	(S)-3-(4-(4,7-difluoro-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)piperazin-1-yl)-5-fluoro-2-methylpyridine 1-oxide





 C27H20F7N7O	598	(S)-3-(2-(1-(difluoromethyl)-5-fluoro-1H-pyrazol-4-yl)pyrimidin-5-yl)-5-(1-((2-(difluoromethyl)-6-methylpyridin-3-yl)amino)-2-fluoroethyl)-7-fluoro-2-methylisoquinolin-1(2H)-one
 C29H23F4N5O4S	599	(S)-5-fluoro-3-(5-(7-fluoro-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)pyrimidin-2-yl)-2-methylpyridine 1-oxide
 C28H25F6N3O2	600	(S)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)-2-fluoroethyl)-7-fluoro-3-(3-(3-fluoroazetidine-1-carbonyl)bicyclo[1.1.1]pentan-1-yl)-2-methylisoquinolin-1(2H)-one
 C29H22F5N5O2	601	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-3-(2-(5-fluoro-1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2-methylisoquinolin-1(2H)-one





 C30H22F6N4O2	602	(R)-3-(3,5'-difluoro-1'-methyl-6'-oxo-1',6'-dihydro-[2,2'-bipyridin]-5-yl)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methylisoquinolin-1(2H)-one
 C29H21F6N5O2	603	(R)-5-fluoro-3-(5-(7-fluoro-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)pyrimidin-2-yl)-2-methylpyridine 1-oxide
 C25H28F4N4O3S	604	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-4-fluoro-2,7-dimethyl-3-(4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C24H24F6N4O3S	605	(R)-4,7-difluoro-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2-methyl-3-(4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one





 C29H27F6N5O2	606	(R)-3-(4-(5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-4,7-difluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)piperazin-1-yl)-5-fluoro-2-methylpyridine 1-oxide
 C27H25F4N5O	607	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-3-(3-(4-methyl-1H-1,2,3-triazol-1-yl)bicyclo[1.1.1]pentan-1-yl)isoquinolin-1(2H)-one
 C28H27F5N4O	608	(3aR,6aS)-2-(5-((R)-1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-4,7-difluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)-5-methyloctahydrocyclopenta[c]pyrrole-5-carbonitrile
 C28H27F5N4O	609	(3aR,6aS)-2-(5-((R)-1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-4,7-difluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)-5-methyloctahydrocyclopenta[c]pyrrole-5-carbonitrile





 C31H38N4O4S	610	3-((1R)-9-(cyclopropanecarbonyl)-3,9-diazabicyclo[3.3.1]nonan-3-yl)-2,7-dimethyl-5-((R)-1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C28H22F4N6O	611	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)isoquinolin-1(2H)-one
 C27H22F4N6O	612	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-3-(2-(1-methyl-1H-pyrazol-4-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one
 C24H25F5N4O3S	613	(R)-5-(1-((2-(difluoromethyl)-3-fluorophenyl)amino)ethyl)-4,7-difluoro-2-methyl-3-(4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one





 C24H24F6N4O3S	614	(R)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-4,7-difluoro-2-methyl-3-(4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C29H32F4N4O2	615	5-((R)-1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-3-((S)-3-methyl-4-(1-methylcyclopropane-1-carbonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C26H21F3N6O3S	616	(R)-7-fluoro-3-(2-(3-fluoro-1H-pyrazol-4-yl)pyrimidin-5-yl)-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methylisoquinolin-1(2H)-one
 C25H22F4N4O3S	617	(R)-3-(1-(cyclopropylsulfonyl)-1H-pyrazol-4-yl)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methylisoquinolin-1(2H)-one





 C25H22F4N4O3S	618	(S)-3-(1-(cyclopropylsulfonyl)-1H-pyrazol-4-yl)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methylisoquinolin-1(2H)-one
 C25H25F4N3O3S	619	5-((R)-1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-3-((1R,5S,6r)-3-(methylsulfonyl)-3-azabicyclo[3.1.0]hexan-6-yl)isoquinolin-1(2H)-one
 C29H31F5N4O2	620	5-((R)-1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-4,7-difluoro-2-methyl-3-((R)-3-methyl-4-(1-methylcyclopropane-1-carbonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C28H25F3N6O3S	621	(S)-7-fluoro-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methyl-3-(5-methyl-1-(2-methylpyrimidin-5-yl)-1H-pyrazol-4-yl)isoquinolin-1(2H)-one





 C28H31F3N6O3S	622	(S)-3-(4-(1,3-dimethyl-1H-pyrazol-4-yl)piperazin-1-yl)-7-fluoro-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methylisoquinolin-1(2H)-one
 C24H26F5N5O3S	623	(R)-4,7-difluoro-2-methyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-(4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C28H29F5N4O2	624	3-((R)-4-(cyclopropanecarbonyl)-3-methylpiperazin-1-yl)-5-((R)-1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-4,7-difluoro-2-methylisoquinolin-1(2H)-one
 C27H27F6N5O2	625	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-4,7-difluoro-3-(4-(3-fluoroazetidine-1-carbonyl)piperazin-1-yl)-2-methylisoquinolin-1(2H)-one





 C28H28F4N6O3S	626	(S)-4,7-difluoro-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methyl-3-(4-(2-methylpyrimidin-5-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C29H25F5N4O3S	627	(S)-3-(2,2-difluoro-3-(2-methylpyrimidin-5-yl)bicyclo[1.1.1]pentan-1-yl)-7-fluoro-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methylisoquinolin-1(2H)-one
 C28H27F3N4O3S	628	(S)-7-fluoro-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methyl-3-(3-(1-methyl-1H-pyrazol-4-yl)bicyclo[1.1.1]pentan-1-yl)isoquinolin-1(2H)-one
 C28H26F5N3O2	629	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-3-(3-(3-fluoroazetidine-1-carbonyl)bicyclo[1.1.1]pentan-1-yl)-2-methylisoquinolin-1(2H)-one





 C27H19F7N6O	630	(R)-3-(2-(1-(difluoromethyl)-3-fluoro-1H-pyrazol-4-yl)pyrimidin-5-yl)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methylisoquinolin-1(2H)-one
 C27H19F7N6O	631	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-3-(2-(1-(difluoromethyl)-5-fluoro-1H-pyrazol-4-yl)pyrimidin-5-yl)-7-fluoro-2-methylisoquinolin-1(2H)-one
 C28H26F5N5O	632	(R)-3-(3-(1-(difluoromethyl)-1H-pyrazol-4-yl)bicyclo[1.1.1]pentan-1-yl)-5-(1-((2-(difluoromethyl)-6-methylpyridin-3-yl)amino)ethyl)-7-fluoro-2-methylisoquinolin-1(2H)-one
 C27H23F4N3O3S	633	(R)-3-(6-(cyclopropylsulfonyl)pyridin-3-yl)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methylisoquinolin-1(2H)-one





 C29H28F4N6O2	634	(R)-3-(2-(4-acetylpiperazin-1-yl)pyrimidin-5-yl)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methylisoquinolin-1(2H)-one
 C27H29F3N6O3S	635	(S)-7-fluoro-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methyl-3-(4-(1-methyl-1H-pyrazol-4-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C27H27F5N6O3S	636	(S)-3-(4-(1-(difluoromethyl)-1H-pyrazol-4-yl)piperazin-1-yl)-7-fluoro-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methylisoquinolin-1(2H)-one
 C27H27F4N3O3S	637	3-((1R,5S,6r)-3-(cyclopropylsulfonyl)-3-azabicyclo[3.1.0]hexan-6-yl)-5-((R)-1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methylisoquinolin-1(2H)-one





 C28H27F5N4O2	638	5-((R)-1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-3-((1R,5S,6r)-3-(3-fluoroazetidine-1-carbonyl)-3-azabicyclo[3.1.0]hexan-6-yl)-2-methylisoquinolin-1(2H)-one
 C23H20F4N4O3S	639	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-3-(1-(methylsulfonyl)-1H-pyrazol-4-yl)isoquinolin-1(2H)-one
 C28H22F4N6O2	640	(R)-5-(5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)-2'-methyl-[2,5'-bipyrimidine] 1'-oxide
 C26H25F5N6O2	641	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-4,7-difluoro-2-methyl-3-(4-(5-methyl-1,3,4-oxadiazol-2-yl)piperazin-1-yl)isoquinolin-1(2H)-one





 C28H29F5N4O2	642	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-4,7-difluoro-2-methyl-3-(4-(1-methylcyclopropane-1-carbonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C27H27F5N4O2	643	(R)-3-(4-(cyclopropanecarbonyl)piperazin-1-yl)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-4,7-difluoro-2-methylisoquinolin-1(2H)-one
 C27H24F4N4O2	644	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-3-(3-(5-methyl-1,3,4-oxadiazol-2-yl)bicyclo[1.1.1]pentan-1-yl)isoquinolin-1(2H)-one
 C28H29F4N3O2	645	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-3-(3-morpholinobicyclo[1.1.1]pentan-1-yl)isoquinolin-1(2H)-one





 C29H30F4N6O2	646	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-3-(4-(1,5-dimethyl-6-oxo-1,6-dihydropyrazin-2-yl)piperazin-1-yl)-7-fluoro-2-methylisoquinolin-1(2H)-one
 C29H27F2N5O4S	647	(R)-7-fluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methyl-3-(3-methyl-1-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)-1H-pyrazol-4-yl)isoquinolin-1(2H)-one
 C27H28ClF4N7O	648	(S)-5-(1-((6-chloro-2-(difluoromethyl)pyridin-3-yl)amino)-2-fluoroethyl)-3-(4-(1,3-dimethyl-1H-pyrazol-4-yl)piperazin-1-yl)-7-fluoro-2-methylisoquinolin-1(2H)-one
 C28H30F4N4O2	649	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-3-(4-(1-methylcyclopropane-1-carbonyl)piperazin-1-yl)isoquinolin-1(2H)-one





 C29H23F4N5O3S	650	(S)-7-fluoro-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-3-(2-(5-fluoro-2-methylpyridin-3-yl)pyrimidin-5-yl)-2-methylisoquinolin-1(2H)-one
 C28H29F3N4O3S	651	(3aR,6aS)-2-(7-fluoro-5-((S)-2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)-5-methyloctahydrocyclopenta[c]pyrrole-5-carbonitrile, Diastereomer 1
 C28H29F3N4O3S	652	(3aR,6aS)-2-(7-fluoro-5-((S)-2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)-5-methyloctahydrocyclopenta[c]pyrrole-5-carbonitrile, Diastereomer 2
 C30H23F5N4O4S	653	(S)-3,5'-difluoro-5-(7-fluoro-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)-2'-methyl-[2,3'-bipyridine] 1'-oxide





 C30H23F5N4O3S	654	(S)-3-(3,5'-difluoro-2'-methyl-[2,3'-bipyridin]-5-yl)-7-fluoro-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methylisoquinolin-1(2H)-one
 C27H24F4N4OS	655	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-3-(3-(5-methyl-1,3,4-thiadiazol-2-yl)bicyclo[1.1.1]pentan-1-yl)isoquinolin-1(2H)-one
 C27H24F4N4OS	656	(S)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-3-(3-(5-methyl-1,3,4-thiadiazol-2-yl)bicyclo[1.1.1]pentan-1-yl)isoquinolin-1(2H)-one
 C28H24F3N5O4S	657	(R)-7-fluoro-3-(1-(5-fluoro-1-methyl-6-oxo-1,6-dihydropyridin-2-yl)-1H-pyrazol-4-yl)-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methylisoquinolin-1(2H)-one





 C29H22F5N5O2	658	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-3-(2-(5-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2-methylisoquinolin-1(2H)-one
 C29H22F5N5O2	659	(S)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-3-(2-(5-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2-methylisoquinolin-1(2H)-one
 C28H31F4N7O	660	(S)-5-(1-((2-(difluoromethyl)-6-methylpyridin-3-yl)amino)-2-fluoroethyl)-3-(4-(1,3-dimethyl-1H-pyrazol-4-yl)piperazin-1-yl)-7-fluoro-2-methylisoquinolin-1(2H)-one
 C30H34N6O4S	661	(R)-2,7-dimethyl-3-(4-(2-methylpyrimidine-5-carbonyl)piperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C28H29F3N4O4S	662	7-fluoro-5-((R)-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-3-((1R,5S,6r)-3-(3-fluoroazetidine-1-carbonyl)-3-azabicyclo[3.1.0]hexan-6-yl)-2-methylisoquinolin-1(2H)-one
 C24H22F4N4O3S	663	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-3-(5-methyl-1-(methylsulfonyl)-1H-pyrazol-4-yl)isoquinolin-1(2H)-one
 C25H30F3N5O3S	664	(R)-5-(1-((2-(difluoromethyl)-6-methylpyridin-3-yl)amino)ethyl)-4-fluoro-2,7-dimethyl-3-(4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C25H31F2N5O3S	665	(R)-5-(1-((2-(difluoromethyl)-6-methylpyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one





 C27H29F4N5O4S	666	(S)-7-fluoro-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-3-(4-(3-fluoroazetidine-1-carbonyl)piperazin-1-yl)-2-methylisoquinolin-1(2H)-one
 C27H28F4N6O	667	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-3-(4-(1-methyl-1H-pyrazol-4-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C26H27F4N3O3S	668	(R)-N-(3-(5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)bicyclo[1.1.1]pentan-1-yl)-N-methylmethanesulfonamide
 C28H24F3N5O4S	669	(R)-5-fluoro-3-(4-(7-fluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)-1H-pyrazol-1-yl)-2-methylpyridine 1-oxide





 C29H27F2N5O4S	670	(R)-7-fluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methyl-3-(5-methyl-1-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)-1H-pyrazol-4-yl)isoquinolin-1(2H)-one
 C28H28F3N3O4S	671	(R)-7-fluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-3-(3-(3-fluoroazetidine-1-carbonyl)bicyclo[1.1.1]pentan-1-yl)-2-methylisoquinolin-1(2H)-one
 C28H27F3N4O2	672	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-2,7-dimethyl-3-(3-(5-methyl-1,3,4-oxadiazol-2-yl)bicyclo[1.1.1]pentan-1-yl)isoquinolin-1(2H)-one
 C29H33F3N4O2	673	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-2,7-dimethyl-3-(4-(1-methylcyclopropane-1-carbonyl)piperazin-1-yl)isoquinolin-1(2H)-one





 C31H35N5O4S	674	(R)-2,7-dimethyl-3-(4-(3-methylpicolinoyl)piperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C31H35N5O4S	675	(R)-2,7-dimethyl-3-(4-(2-methylisonicotinoyl)piperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H36N6O4S	676	(R)-3-(4-(1,5-dimethyl-1H-pyrazole-4-carbonyl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C28H27F4N3O4S	677	(S)-7-fluoro-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-3-(3-(3-fluoroazetidine-1-carbonyl)bicyclo[1.1.1]pentan-1-yl)-2-methylisoquinolin-1(2H)-one





 C24H27F4N5O3S	678	(R)-5-(1-((2-(difluoromethyl)-6-methylpyridin-3-yl)amino)ethyl)-4,7-difluoro-2-methyl-3-(4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C24H28F3N5O3S	679	(R)-5-(1-((2-(difluoromethyl)-6-methylpyridin-3-yl)amino)ethyl)-7-fluoro-2-methyl-3-(4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C29H31F3N6O4S	680	(S)-3-(4-(1,5-dimethyl-6-oxo-1,6-dihydropyrazin-2-yl)piperazin-1-yl)-7-fluoro-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methylisoquinolin-1(2H)-one
 C28H26F2N6O3S	681	(S)-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(1-(2-methylpyrimidin-5-yl)-1H-pyrazol-4-yl)isoquinolin-1(2H)-one





 C28H30F5N7O	682	(S)-5-(1-((2-(difluoromethyl)-6-methylpyridin-3-yl)amino)-2-fluoroethyl)-7-fluoro-3-(4-(5-fluoro-1,3-dimethyl-1H-pyrazol-4-yl)piperazin-1-yl)-2-methylisoquinolin-1(2H)-one
 C29H28F2N4O3S	683	(R)-7-fluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methyl-3-(3-(2-methylpyrimidin-5-yl)bicyclo[1.1.1]pentan-1-yl)isoquinolin-1(2H)-one
 C27H27F5N4O2	684	(S)-3-(4-(cyclopropanecarbonyl)piperazin-1-yl)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)-2-fluoroethyl)-7-fluoro-2-methylisoquinolin-1(2H)-one
 C27H29F4N7O	685	(R)-7-fluoro-2-methyl-3-(4-(1-methyl-1H-pyrazol-4-yl)piperazin-1-yl)-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one





 C31H36N6O4S	686	(R)-3-(4-(2,4-dimethylpyrimidine-5-carbonyl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C32H37N5O4S	687	(R)-3-(4-(4,6-dimethylnicotinoyl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C32H37N5O4S	688	(R)-3-(4-(5,6-dimethylnicotinoyl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C31H35N5O4S	689	(R)-2,7-dimethyl-3-(4-(5-methylpicolinoyl)piperazin-1-yl)-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one





 C29H21F6N5O2	690	(R)-3-(5-(5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-7-fluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)pyrimidin-2-yl)-5-fluoro-2-methylpyridine 1-oxide
 C28H29F3N6O4S	691	(S)-7-fluoro-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methyl-3-(4-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C28H27F5N6O2	692	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-4,7-difluoro-2-methyl-3-(4-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C28H28F4N6O2	693	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-3-(4-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)piperazin-1-yl)isoquinolin-1(2H)-one





 C28H27F5N6O2	694	(S)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)-2-fluoroethyl)-7-fluoro-2-methyl-3-(4-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C28H32F2N4O5S	695	cyclopropyl (R)-4-(4-fluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-3-yl)piperazine-1-carboxylate
 C28H33FN4O5S	696	cyclopropyl (R)-4-(5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-3-yl)piperazine-1-carboxylate
 C28H31F3N6O3S	697	(R)-7-fluoro-3-(4-(5-fluoro-1,3-dimethyl-1H-pyrazol-4-yl)piperazin-1-yl)-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methylisoquinolin-1(2H)-one





 C28H24F4N6O2	698	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-3-(1-(1,5-dimethyl-6-oxo-1,6-dihydropyrazin-2-yl)-1H-pyrazol-4-yl)-7-fluoro-2-methylisoquinolin-1(2H)-one
 C28H22F5N5O	699	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-3-(1-(5-fluoro-2-methylpyridin-3-yl)-1H-pyrazol-4-yl)-2-methylisoquinolin-1(2H)-one
 C28H24F3N5O3S	700	(R)-7-fluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-3-(1-(5-fluoro-2-methylpyridin-3-yl)-1H-pyrazol-4-yl)-2-methylisoquinolin-1(2H)-one
 C27H27F5N4O3	701	cyclopropyl (R)-4-(5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-4,7-difluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)piperazine-1-carboxylate





 C27H28F4N4O3	702	cyclopropyl (R)-4-(5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)piperazine-1-carboxylate
 C29H32F4N4O2	703	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-4-fluoro-2,7-dimethyl-3-(4-(1-methylcyclopropane-1-carbonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C30H37F2N5O2	704	5-((R)-1-((2-(difluoromethyl)-6-methylpyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-((R)-3-methyl-4-(1-methylcyclopropane-1-carbonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C29H35F2N5O2	705	(R)-5-(1-((2-(difluoromethyl)-6-methylpyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(4-(1-methylcyclopropane-1-carbonyl)piperazin-1-yl)isoquinolin-1(2H)-one





 C29H29F4N5O4S	706	(S)-7-fluoro-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-3-(4-(5-fluoro-1-methyl-6-oxo-1,6-dihydropyridin-2-yl)piperazin-1-yl)-2-methylisoquinolin-1(2H)-one
 C24H20F4N4O3S	707	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-3-(2-(methylsulfonyl)pyrimidin-5-yl)isoquinolin-1(2H)-one
 C29H29F5N6O2	708	(S)-5-(1-((2-(difluoromethyl)-6-methylpyridin-3-yl)amino)-2-fluoroethyl)-7-fluoro-3-(4-(5-fluoro-1-methyl-6-oxo-1,6-dihydropyridin-2-yl)piperazin-1-yl)-2-methylisoquinolin-1(2H)-one
 C27H28F5N7O	709	(S)-5-(1-((2-(difluoromethyl)-6-methylpyridin-3-yl)amino)-2-fluoroethyl)-7-fluoro-3-(4-(3-fluoro-1-methyl-1H-pyrazol-4-yl)piperazin-1-yl)-2-methylisoquinolin-1(2H)-one





 C27H26F6N4O2	710	(S)-3-(4-(cyclopropanecarbonyl)piperazin-1-yl)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)-2-fluoroethyl)-4,7-difluoro-2-methylisoquinolin-1(2H)-one
 C29H27F2N7O	711	(R)-5-(1-((2-(difluoromethyl)-6-methylpyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)isoquinolin-1(2H)-one
 C29H21F6N5O2	712	(R)-7-fluoro-3-(2-(5-fluoro-1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2-methylisoquinolin-1(2H)-one
 C30H26F4N6O2	713	(R)-3-(2-(5-fluoro-1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one





 C29H26F3N7O	714	(R)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)isoquinolin-1(2H)-one
 C25H31FN4O5S2	715	(R)-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C24H28F2N4O5S2	716	(R)-7-fluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methyl-3-(4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C25H28FN5O3S	717	(R)-2-((1-(2,7-dimethyl-3-(4-(methylsulfonyl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile





 C27H24F6N6O3S	718	6-(((S)-1-(3-((1R,5S,6r)-3-(1-(difluoromethyl)-1H-pyrazol-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl)-7-fluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)-2-fluoroethyl)amino)-2,3-difluorobenzenesulfonamide
 C28H22F4N6O2	719	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one
 C31H34F4N5O2P	720	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-3-(4-(5-(dimethylphosphoryl)-6-methylpyridin-3-yl)piperazin-1-yl)-7-fluoro-2-methylisoquinolin-1(2H)-one
 C28H31F4N5O2	721	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-3-(4-(3-fluoroazetidine-1-carbonyl)piperazin-1-yl)-2,7-dimethylisoquinolin-1(2H)-one





 C28H33F3N6O2	722	(R)-5-(1-((2-(difluoromethyl)-6-methylpyridin-3-yl)amino)ethyl)-3-(4-(3-fluoroazetidine-1-carbonyl)piperazin-1-yl)-2,7-dimethylisoquinolin-1(2H)-one
 C23H25ClF3N5O3S	723	(R)-5-(1-((6-chloro-2-(difluoromethyl)pyridin-3-yl)amino)ethyl)-7-fluoro-2-methyl-3-(4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C27H31F4N5O3S	724	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-3-(4-((3-fluoroazetidin-1-yl)sulfonyl)piperazin-1-yl)-2,7-dimethylisoquinolin-1(2H)-one
 C27H30F2N6O3S	725	(R)-5-fluoro-2-((1-(3-(4-((3-fluoroazetidin-1-yl)sulfonyl)piperazin-1-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile





 C28H30F4N6O3S	726	(R)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-((1-methyl-1H-pyrazol-4-yl)sulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C27H28F4N6O2	727	(R)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(5-methyl-1,3,4-oxadiazol-2-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C27H31F3N4O2	728	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-2,7-dimethyl-3-(4-(oxetan-3-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C26H26F4N6O2	729	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-3-(4-(5-methyl-1,3,4-oxadiazol-2-yl)piperazin-1-yl)isoquinolin-1(2H)-one





 C28H31F3N4O2	730	(R)-3-(4-(cyclopropanecarbonyl)piperazin-1-yl)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one
 C30H36F3N5O2	731	5-((R)-1-((2-(difluoromethyl)-6-methylpyridin-3-yl)amino)ethyl)-4-fluoro-2,7-dimethyl-3-((R)-3-methyl-4-(1-methylcyclopropane-1-carbonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C29H34F3N5O2	732	(R)-5-(1-((2-(difluoromethyl)-6-methylpyridin-3-yl)amino)ethyl)-4-fluoro-2,7-dimethyl-3-(4-(1-methylcyclopropane-1-carbonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C25H29F4N5O3S	733	(R)-4-fluoro-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-(4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one





 C25H30F3N5O3S	734	(R)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-(4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C28H30F2N6O2	735	(R)-5-fluoro-2-((1-(3-(4-(3-fluoroazetidine-1-carbonyl)piperazin-1-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C28H29F3N6O2	736	(R)-5-fluoro-2-((1-(4-fluoro-3-(4-(3-fluoroazetidine-1-carbonyl)piperazin-1-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C27H25F7N6O	737	(S)-3-(4-(1-(difluoromethyl)-1H-pyrazol-4-yl)piperazin-1-yl)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)-2-fluoroethyl)-7-fluoro-2-methylisoquinolin-1(2H)-one





 C28H24ClF2N7O	738	(R)-5-(1-((6-chloro-2-(difluoromethyl)pyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)isoquinolin-1(2H)-one
 C25H30F2N4O5S2	739	(R)-4-fluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C24H27F3N4O5S2	740	(R)-4,7-difluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methyl-3-(4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C25H30F2N4O5S2	741	(S)-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one





 C29H23F2N7O	742	(S)-2-((1-(2,7-dimethyl-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)-2-fluoroethyl)amino)-5-fluorobenzonitrile
 C28H30FN7O	743	(R)-2-((1-(2,7-dimethyl-3-(4-(1-methyl-1H-pyrazol-4-yl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C28H29F2N7O	744	(S)-2-((1-(2,7-dimethyl-3-(4-(1-methyl-1H-pyrazol-4-yl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)-2-fluoroethyl)amino)-5-fluorobenzonitrile
 C25H27F2N5O3S	745	(S)-2-((1-(2,7-dimethyl-3-(4-(methylsulfonyl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)-2-fluoroethyl)amino)-5-fluorobenzonitrile





 C29H26F3N7O2	746	(R)-5-(1-((2-(1,1-difluoro-2-hydroxyethyl)-6-methylpyridin-3-yl)amino)ethyl)-7-fluoro-2-methyl-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)isoquinolin-1(2H)-one
 C30H26F2N6O3S	747	(R)-2-cyclopropyl-7-fluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)isoquinolin-1(2H)-one
 C31H33F5N5O2P	748	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-3-(4-(5-(dimethylphosphoryl)-6-methylpyridin-3-yl)piperazin-1-yl)-4,7-difluoro-2-methylisoquinolin-1(2H)-one
 C29H35FN4O5S	749	1-methylcyclopropyl (R)-4-(5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-3-yl)piperazine-1-carboxylate





 C27H30F3N5O4S	750	(R)-7-fluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-3-(4-(3-fluoroazetidine-1-carbonyl)piperazin-1-yl)-2-methylisoquinolin-1(2H)-one
 C28H32F3N5O4S	751	(S)-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-3-(4-(3-fluoroazetidine-1-carbonyl)piperazin-1-yl)-2,7-dimethylisoquinolin-1(2H)-one
 C27H21F5N6O	752	(R)-7-fluoro-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2-methyl-3-(1-(2-methylpyrimidin-5-yl)-1H-pyrazol-4-yl)isoquinolin-1(2H)-one
 C27H20F6N6O	753	(S)-7-fluoro-5-(2-fluoro-1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2-methyl-3-(1-(2-methylpyrimidin-5-yl)-1H-pyrazol-4-yl)isoquinolin-1(2H)-one





 C23H19F5N4O3S	754	(S)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)-2-fluoroethyl)-7-fluoro-2-methyl-3-(1-(methylsulfonyl)-1H-pyrazol-4-yl)isoquinolin-1(2H)-one
 C28H27FN6O3S	755	(R)-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(2-methylpyrimidin-5-yl)-1H-pyrazol-1-yl)isoquinolin-1(2H)-one
 C30H27F3N6O2	756	(R)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-(2-(1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one
 C28H29F2N7O3S	757	(R)-4-(4-(7-fluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)piperazin-1-yl)-1-methyl-1H-pyrazole-3-carbonitrile





 C28H29F5N6O	758	(S)-5-(2-fluoro-1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(1-methyl-1H-pyrazol-4-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C27H30F4N4O2	759	(R)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(3-morpholinoazetidin-1-yl)isoquinolin-1(2H)-one
 C28H24F4N6O	760	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-3-(5-methyl-1-(2-methylpyrimidin-5-yl)-1H-pyrazol-4-yl)isoquinolin-1(2H)-one
 C29H26F4N4O3S	761	(R)-3-(2,2-difluoro-3-(2-methylpyrimidin-5-yl)bicyclo[1.1.1]pentan-1-yl)-7-fluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methylisoquinolin-1(2H)-one





 C29H32F3N7O3S	762	(R)-7-fluoro-5-(1-((4-fluoro-2-((3-fluoroazetidin-1-yl)sulfonyl)phenyl)amino)ethyl)-2-methyl-3-(4-(1-methyl-1H-pyrazol-4-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C30H34F3N7O3S	763	(S)-5-(2-fluoro-1-((4-fluoro-2-((3-fluoroazetidin-1-yl)sulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(1-methyl-1H-pyrazol-4-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C31H29F2N7O3S	764	(R)-5-(1-((4-fluoro-2-((3-fluoroazetidin-1-yl)sulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)isoquinolin-1(2H)-one
 C33H36F2N6O4S	765	(R)-5-(1-((4-fluoro-2-((3-fluoroazetidin-1-yl)sulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(6-methylnicotinoyl)piperazin-1-yl)isoquinolin-1(2H)-one





 C28H29F3N6O2	766	(S)-5-fluoro-2-((2-fluoro-1-(3-(4-(3-fluoroazetidine-1-carbonyl)piperazin-1-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C25H27F2N5O3S	767	(R)-5-fluoro-2-((1-(4-fluoro-2,7-dimethyl-3-(4-(methylsulfonyl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C25H26F3N5O3S	768	(S)-5-fluoro-2-((2-fluoro-1-(4-fluoro-2,7-dimethyl-3-(4-(methylsulfonyl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C29H30F4N6O2	769	(R)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(1-methyl-6-oxo-1,6-dihydropyrazin-2-yl)piperazin-1-yl)isoquinolin-1(2H)-one





 C29H33F3N4O2	770	(R)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-(3-morpholinobicyclo[1.1.1]pentan-1-yl)isoquinolin-1(2H)-one
 C29H30F4N6O2	771	(R)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-2,7-dimethyl-3-(4-(1-methyl-6-oxo-1,6-dihydropyrazin-2-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C29H29F5N6O2	772	(S)-5-(2-fluoro-1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(1-methyl-6-oxo-1,6-dihydropyrazin-2-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C29H28F6N6O2	773	(S)-4-fluoro-5-(2-fluoro-1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(1-methyl-6-oxo-1,6-dihydropyrazin-2-yl)piperazin-1-yl)isoquinolin-1(2H)-one





 C28H23F4N7O	774	(R)-7-fluoro-2-methyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)isoquinolin-1(2H)-one
 C28H23F4N7O	775	(S)-7-fluoro-2-methyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)isoquinolin-1(2H)-one
 C29H26F3N5O4S	776	(R)-3-fluoro-5-(4-(7-fluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)-5-methyl-1H-pyrazol-1-yl)-2-methylpyridine 1-oxide
 C28H30F4N4O2	777	(R)-3-(4-(cyclopropanecarbonyl)piperazin-1-yl)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-4-fluoro-2,7-dimethylisoquinolin-1(2H)-one





 C27H28F4N6O3S	778	(R)-4,7-difluoro-3-(4-(3-fluoro-1-methyl-1H-pyrazol-4-yl)piperazin-1-yl)-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methylisoquinolin-1(2H)-one
 C29H29F5N6O2	779	(R)-4-fluoro-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(1-methyl-6-oxo-1,6-dihydropyrazin-2-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C29H31F4N3O2	780	(R)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(3-morpholinobicyclo[1.1.1]pentan-1-yl)isoquinolin-1(2H)-one
 C29H31F4N3O2	781	(R)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-2,7-dimethyl-3-(3-morpholinobicyclo[1.1.1]pentan-1-yl)isoquinolin-1(2H)-one





 C29H31F4N3O2	782	(S)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-2,7-dimethyl-3-(3-morpholinobicyclo[1.1.1]pentan-1-yl)isoquinolin-1(2H)-one
 C30H28F3N7O	783	(R)-3-(2',4'-dimethyl-[2,5'-bipyrimidin]-5-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C30H26F4N6O2	784	(R)-3-(5-(2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)pyrimidin-2-yl)-5-fluoro-2-methylpyridine 1-oxide
 C29H24F4N6O2	785	(R)-7-fluoro-2-methyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-(2-(1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one





 C29H22F5N5O2	786	(R)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-7-fluoro-2-methyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one
 C28H32F3N7O	787	(R)-2,7-dimethyl-3-(4-(1-methyl-1H-pyrazol-4-yl)piperazin-1-yl)-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C28H31F4N7O	788	(S)-5-(2-fluoro-1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(4-(1-methyl-1H-pyrazol-4-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C28H26F5N5O3S	789	3-((1R,5S,6r)-3-(1-(difluoromethyl)-1H-pyrazol-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl)-7-fluoro-5-((S)-2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methylisoquinolin-1(2H)-one





 C29H34F2N4O5S	790	1-methylcyclopropyl (S)-4-(5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-3-yl)piperazine-1-carboxylate
 C24H22F4N4O3S	791	(R)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(methylsulfonyl)-1H-pyrazol-1-yl)isoquinolin-1(2H)-one
 C29H22F5N5O2	792	(R)-7-fluoro-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2-methyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one
 C27H31F3N8O	793	(R)-2,7-dimethyl-3-(4-(1-methyl-1H-1,2,3-triazol-4-yl)piperazin-1-yl)-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one





 C28H27F4N5O	794	(R)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(3-(2-methylpyrimidin-5-yl)azetidin-1-yl)isoquinolin-1(2H)-one
 C27H27F4N5O	795	(R)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(1-(1-methyl-1H-pyrazol-4-yl)azetidin-3-yl)isoquinolin-1(2H)-one
 C29H28F4N4O2	796	(R)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(1-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)azetidin-3-yl)isoquinolin-1(2H)-one
 C31H24F4N6O	797	(R)-5-(5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-3-yl)-2-(2-methylpyrimidin-5-yl)nicotinonitrile





 C31H26F3N7O	798	(R)-5-(2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)-2-(2-methylpyrimidin-5-yl)nicotinonitrile
 C31H27FN6O3S	799	(R)-5-(5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-3-yl)-2-(2-methylpyrimidin-5-yl)nicotinonitrile
 C28H31F3N6O3S	800	(R)-3-(4-(1,3-dimethyl-1H-pyrazol-4-yl)piperazin-1-yl)-4,7-difluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methylisoquinolin-1(2H)-one
 C29H24F4N6O2	801	(R)-5-(1-((2-(difluoromethyl)-4-fluorophenyl)amino)ethyl)-3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)-7-fluoro-2-methylisoquinolin-1(2H)-one





 C25H29F3N4O5S2	802	(S)-4-fluoro-5-(2-fluoro-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C26H32F3N5O3S	803	2,7-dimethyl-5-((R)-1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-((R)-3-methyl-4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C31H29F3N6O	804	(R)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-(5-methyl-6-(2-methylpyrimidin-5-yl)pyridin-3-yl)isoquinolin-1(2H)-one
 C29H34F3N7O	805	2,7-dimethyl-5-((R)-1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-((R)-3-methyl-4-(1-methyl-1H-pyrazol-4-yl)piperazin-1-yl)isoquinolin-1(2H)-one





 C29H30F5N7O	806	(R)-3-(4-(2-(difluoromethyl)pyrimidin-5-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C28H32N8O	807	(R)-3-((1-(2,7-dimethyl-3-(4-(1-methyl-1H-pyrazol-4-yl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-6-methylpicolinonitrile
 C27H30FN5O2	808	(R)-2-((1-(2,7-dimethyl-3-(4-(oxetan-3-yl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C27H32F3N5O2	809	(R)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-(4-(oxetan-3-yl)piperazin-1-yl)isoquinolin-1(2H)-one





 C29H30F4N6O2	810	(R)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C29H29F5N6O2	811	(R)-4-fluoro-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C29H26F3N7O2	812	(R)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-(2-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one
 C29H24F4N6O2	813	(R)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one





 C29H24F4N6O2	814	(R)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-2,7-dimethyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one
 C30H27F3N6O2	815	(R)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-(1-(2-methylpyrimidin-5-yl)-2-oxo-1,2-dihydropyridin-4-yl)isoquinolin-1(2H)-one
 C30H28FN5O4S	816	(R)-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(1-(2-methylpyrimidin-5-yl)-2-oxo-1,2-dihydropyridin-4-yl)isoquinolin-1(2H)-one
 C28H27F4N5O2	817	(R)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(3-(1-methyl-6-oxo-1,6-dihydropyrazin-2-yl)azetidin-1-yl)isoquinolin-1(2H)-one





 C29H24F4N6O2	818	(R)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one
 C29H24F4N6O2	819	(R)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-2,7-dimethyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one
 C28H32F4N6O2	820	(R)-5-(1-((2-(difluoromethyl)-6-methylpyridin-3-yl)amino)ethyl)-4-fluoro-3-(4-(3-fluoroazetidine-1-carbonyl)piperazin-1-yl)-2,7-dimethylisoquinolin-1(2H)-one
 C28H32F3N7OS	821	2,7-dimethyl-5-((R)-1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-((R)-3-methyl-4-(5-methyl-1,3,4-thiadiazol-2-yl)piperazin-1-yl)isoquinolin-1(2H)-one





 C27H30F3N7OS	822	(R)-2,7-dimethyl-3-(4-(5-methyl-1,3,4-thiadiazol-2-yl)piperazin-1-yl)-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C29H28F3N7O	823	(R)-6-(4-(5-(1-((2-(difluoromethyl)-6-methylpyridin-3-yl)amino)ethyl)-7-fluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)piperazin-1-yl)picolinonitrile
 C29H25F4N7O2	824	(R)-6-(4-(7-fluoro-2-methyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)-2-oxopiperazin-1-yl)picolinonitrile
 C28H29F2N7O	825	(R)-2-((1-(3-(4-(1,3-dimethyl-1H-pyrazol-4-yl)piperazin-1-yl)-7-fluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile





 C27H32F4N6O3S	826	(R)-3-(4-((3-fluoroazetidin-1-yl)sulfonyl)piperazin-1-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C28H32F4N6O2	827	(R)-3-(4-(3-fluoroazetidine-1-carbonyl)piperazin-1-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C28H31F5N6O2	828	(R)-4-fluoro-3-(4-(3-fluoroazetidine-1-carbonyl)piperazin-1-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C31H35F4N6O2P	829	(R)-3-(4-(5-(dimethylphosphoryl)-6-methylpyridin-3-yl)piperazin-1-yl)-7-fluoro-2-methyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one





 C28H27F5N6O2	830	(R)-7-fluoro-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2-methyl-3-(4-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C28H26F6N6O2	831	(R)-4,7-difluoro-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2-methyl-3-(4-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C31H29F3N6O2	832	(R)-3-(5-(2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)pyrimidin-2-yl)-2,6-dimethylpyridine 1-oxide
 C28H27F4N5O2	833	(R)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(1-(1-methyl-6-oxo-1,6-dihydropyrazin-2-yl)azetidin-3-yl)isoquinolin-1(2H)-one





 C29H26F3N7O2	834	(R)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-(2-(1-methyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one
 C30H28F3N7O2	835	(R)-3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C26H31F4N5O3S	836	4-fluoro-2,7-dimethyl-5-((R)-1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-((R)-3-methyl-4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C28H32F3N5O2	837	(R)-3-(4-(cyclopropanecarbonyl)piperazin-1-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one





 C30H31F3N8O	838	(R)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-5-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C29H27F4N7O	839	(R)-6-(4-(7-fluoro-2-methyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)piperazin-1-yl)picolinonitrile
 C29H21F4N7O	840	(R)-6-(5-(7-fluoro-2-methyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)pyrimidin-2-yl)picolinonitrile
 C32H38F3N6O2P	841	(R)-3-(4-(5-(dimethylphosphoryl)-6-methylpyridin-3-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one





 C30H28F3N7O2	842	(R)-3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C29H32F3N6O2P	843	(R)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-(2-(4-methyl-4-oxido-1,4-azaphosphinan-1-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one
 C30H27F3N6O2	844	(R)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-(2-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one
 C31H29F3N6O2	845	(R)-3-(2-(1,3-dimethyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one





 C29H31F3N8O	846	(R)-4-(4-(2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)piperazin-1-yl)-1-methyl-1H-pyrazole-3-carbonitrile
 C29H28F3N9O	847	(R)-3-(2-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)pyrimidin-5-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C29H30F3N7O2	848	(R)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-(2-(4-methyl-3-oxopiperazin-1-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one
 C29H28FN7O2	849	(R)-2-((1-(2,7-dimethyl-3-(2-(4-methyl-3-oxopiperazin-1-yl)pyrimidin-5-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile





 C30H32F3N7O2	850	(R)-3-(2-(4-acetylpiperazin-1-yl)pyrimidin-5-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C28H31F4N5O2	851	(R)-5-(1-((2-(difluoromethyl)-6-methylpyridin-3-yl)amino)ethyl)-4-fluoro-3-(4-(1-fluorocyclopropane-1-carbonyl)piperazin-1-yl)-2,7-dimethylisoquinolin-1(2H)-one
 C28H31F4N5O2	852	(R)-3-(4-(cyclopropanecarbonyl)piperazin-1-yl)-4-fluoro-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C30H31F3N8O	853	(R)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-7-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one





 C27H29F2N5O2	854	(R)-5-fluoro-2-((1-(4-fluoro-2,7-dimethyl-3-(4-(oxetan-3-yl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C27H31F5N6O3S	855	(R)-4-fluoro-3-(4-((3-fluoroazetidin-1-yl)sulfonyl)piperazin-1-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C29H29FN8O3S	856	(R)-3-(2-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)pyrimidin-5-yl)-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one
 C29H26FN9O	857	(R)-2-((1-(3-(2-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)pyrimidin-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile





 C26H29F3N4O5S2	858	(R)-3-(4-(cyclopropylsulfonyl)piperazin-1-yl)-4,7-difluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methylisoquinolin-1(2H)-one
 C30H29FN6O4S	859	(R)-3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one
 C30H26FN7O2	860	(R)-2-((1-(3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C29H21F3N6O2	861	(R)-3-(5-(5-(1-((2-cyano-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)pyrimidin-2-yl)-5-fluoro-2-methylpyridine 1-oxide





 C26H26F3N5O3S	862	(R)-2-((1-(3-(4-(cyclopropylsulfonyl)piperazin-1-yl)-4,7-difluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C29H29F2N7O2	863	(R)-5-fluoro-2-((1-(4-fluoro-2,7-dimethyl-3-(4-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C24H27ClF2N4O5S2	864	(R)-5-(1-((4-chloro-2-(methylsulfonyl)phenyl)amino)ethyl)-4,7-difluoro-2-methyl-3-(4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C27H27F5N6O	865	(R)-7-fluoro-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2-methyl-3-(4-(3-methyl-1H-pyrazol-4-yl)piperazin-1-yl)isoquinolin-1(2H)-one





 C28H24F2N6O4S	866	(R)-7-fluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one
 C29H33F4N5O2	867	(R)-4-fluoro-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-(4-(1-methylcyclopropane-1-carbonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C28H30F5N5O2	868	(R)-4-fluoro-3-(4-(1-fluorocyclopropane-1-carbonyl)piperazin-1-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C27H30F4N8O	869	(R)-4-fluoro-2,7-dimethyl-3-(4-(1-methyl-1H-1,2,3-triazol-4-yl)piperazin-1-yl)-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one





 C27H29F4N7OS	870	(R)-4-fluoro-2,7-dimethyl-3-(4-(5-methyl-1,3,4-thiadiazol-2-yl)piperazin-1-yl)-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C30H26F4N6O2	871	(R)-3-(2-(3-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C29H30F4N8O	872	(R)-4-(4-(4-fluoro-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)piperazin-1-yl)-1-methyl-1H-pyrazole-3-carbonitrile
 C29H26F2N6O4S	873	(R)-3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)-7-fluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methylisoquinolin-1(2H)-one





 C29H25F4N7O2	874	(R)-3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)-7-fluoro-2-methyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C29H23F2N7O2	875	(R)-2-((1-(3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)-7-fluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C29H24F3N5O4S	876	(R)-5-fluoro-3-(5-(7-fluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)pyrimidin-2-yl)-2-methylpyridine 1-oxide
 C28H21F2N7O2	877	(R)-5-fluoro-2-((1-(7-fluoro-2-methyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile





 C27H29F2N5O3S	878	(R)-2-((1-(3-(4-(cyclopropylsulfonyl)piperazin-1-yl)-4-fluoro-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C25H30ClFN4O5S2	879	(R)-5-(1-((4-chloro-2-(methylsulfonyl)phenyl)amino)ethyl)-4-fluoro-2,7-dimethyl-3-(4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C25H30F2N4O5S2	880	(R)-5-(1-((3,6-difluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C29H31F4N7O2	881	(R)-4-fluoro-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-(4-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)piperazin-1-yl)isoquinolin-1(2H)-one





 C25H27ClFN5O3S	882	(R)-5-chloro-2-((1-(4-fluoro-2,7-dimethyl-3-(4-(methylsulfonyl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C31H36F2N6O3S	883	(R)-5-(1-((2-(difluoromethyl)-6-methylpyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(4-(6-methyl-5-(methylsulfonyl)pyridin-3-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C31H24F4N6O2	884	(R)-4-((1-(3-(2-(5-fluoro-1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-3-(trifluoromethyl)benzonitrile
 C31H26F3N7O2	885	(R)-4-((1-(3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-3-(trifluoromethyl)benzonitrile





 C30H30F4N8O	886	(R)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-5-yl)piperazin-1-yl)-4-fluoro-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C30H33N7O3S	887	(R)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-5-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)phenyl)amino)ethyl)isoquinolin-1(2H)-one
 C30H31F3N8O	888	(R)-3-(4-([1,2,4]triazolo[1,5-a]pyridin-5-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C30H31F3N8O	889	(R)-3-(4-(imidazo[1,2-a]pyrazin-5-yl)piperazin-1-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one





 C26H28F3N5O3S	890	(R)-3-((1-(2,7-dimethyl-3-(4-(methylsulfonyl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-2-(trifluoromethyl)benzonitrile
 C29H21F4N7O	891	(R)-3-((1-(7-fluoro-2-methyl-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-2-(trifluoromethyl)benzonitrile
 C29H23F5N6O2	892	(R)-3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)-7-fluoro-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2-methylisoquinolin-1(2H)-one
 C29H23F5N6O2	893	(R)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)-7-fluoro-2-methylisoquinolin-1(2H)-one





 C24H24ClF2N5O3S	894	(R)-5-chloro-2-((1-(4,7-difluoro-2-methyl-3-(4-(methylsulfonyl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C29H28F3N7O3S	895	(R)-4,7-difluoro-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-3-(4-(imidazo[1,2-a]pyrimidin-6-yl)piperazin-1-yl)-2-methylisoquinolin-1(2H)-one
 C28H29F2N5O3	896	(R)-5-fluoro-2-((1-(4-fluoro-2,7-dimethyl-1-oxo-3-(4-(2-oxooxazolidin-3-yl)piperidin-1-yl)-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C29H31F2N5O2	897	(R)-5-fluoro-2-((1-(4-fluoro-2,7-dimethyl-1-oxo-3-(4-(2-oxopyrrolidin-1-yl)piperidin-1-yl)-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile





 C29H24F4N6O2	898	(R)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(1-(2-methylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)isoquinolin-1(2H)-one
 C29H24FN7O2	899	(R)-2-((1-(2,7-dimethyl-3-(1-(2-methylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C27H22FN5O2	900	(R)-2-((1-(2,7-dimethyl-3-((1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)ethynyl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C27H22F4N4O2	901	(R)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-((1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)ethynyl)isoquinolin-1(2H)-one





 C31H35F3N6O3S	902	(R)-5-(1-((2-(difluoromethyl)-6-methylpyridin-3-yl)amino)ethyl)-4-fluoro-2,7-dimethyl-3-(4-(6-methyl-5-(methylsulfonyl)pyridin-3-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C30H30F4N8O	903	(R)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-7-yl)piperazin-1-yl)-4-fluoro-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C30H24F2N6O2	904	(R)-2-((1-(3-(2-(1,3-dimethyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-7-fluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C28H21F2N7O2	905	(R)-5-fluoro-2-((1-(7-fluoro-2-methyl-3-(1-(2-methylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile





 C28H21F5N6O2	906	(R)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-7-fluoro-2-methyl-3-(1-(2-methylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)isoquinolin-1(2H)-one
 C28H21F5N6O2	907	(R)-7-fluoro-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2-methyl-3-(1-(2-methylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)isoquinolin-1(2H)-one
 C31H26F3N7O	908	(R)-5-(5-(2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)pyrimidin-2-yl)-4-methylnicotinonitrile
 C26H32ClFN4O5S2	909	5-((R)-1-((4-chloro-2-(methylsulfonyl)phenyl)amino)ethyl)-4-fluoro-2,7-dimethyl-3-((S)-3-methyl-4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one





 C31H29F3N6O2	910	(R)-3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C26H31F3N4O4S	911	(R)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-((1-(methylsulfonyl)piperidin-4-yl)oxy)isoquinolin-1(2H)-one
 C26H29FN4O4S	912	(R)-2-((1-(2,7-dimethyl-3-((1-(methylsulfonyl)piperidin-4-yl)oxy)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C29H24FN7O2	913	(R)-2-((1-(2,7-dimethyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile





 C30H29FN6O4S	914	(R)-3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)-5-(1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one
 C30H26FN7O2	915	(R)-2-((1-(3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C30H26ClF3N6O2	916	(R)-7-chloro-3-(2-(1,3-dimethyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2-methyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C29H23F5N6O	917	(R)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-3-(2',4'-dimethyl-[2,5'-bipyrimidin]-5-yl)-7-fluoro-2-methylisoquinolin-1(2H)-one





 C26H28F3N5O3S	918	(R)-2-((1-(2,7-dimethyl-3-(4-(methylsulfonyl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-(trifluoromethyl)benzonitrile
 C26H29F2N5O3S	919	(R)-5-(difluoromethyl)-2-((1-(2,7-dimethyl-3-(4-(methylsulfonyl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C25H26F3N5O3S	920	(R)-2,3-difluoro-6-((1-(4-fluoro-2,7-dimethyl-3-(4-(methylsulfonyl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C28H33F4N5O3S	921	(R)-3-(4-(1,1-dioxidoisothiazolidin-2-yl)piperidin-1-yl)-4-fluoro-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one





 C28H31F5N4O3S	922	(R)-3-(4-(1,1-dioxidoisothiazolidin-2-yl)piperidin-1-yl)-4-fluoro-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one
 C28H31ClFN5O3S	923	(R)-5-chloro-2-((1-(3-(4-(1,1-dioxidoisothiazolidin-2-yl)piperidin-1-yl)-4-fluoro-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C29H26F3N7O2	924	(R)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-(1-(2-methylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)isoquinolin-1(2H)-one
 C26H28F7N5O	925	(R)-4-fluoro-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)isoquinolin-1(2H)-one





 C30H24ClFN6O2	926	(R)-3-(5-(5-(1-((4-chloro-2-cyanophenyl)amino)ethyl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-3-yl)pyrimidin-2-yl)-5-fluoro-2-methylpyridine 1-oxide
 C29H25F3N8O	927	(R)-1-(5-(2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)pyrimidin-2-yl)-5-methyl-1H-imidazole-4-carbonitrile
 C26H32ClFN4O5S2	928	5-((R)-1-((4-chloro-2-(methylsulfonyl)phenyl)amino)ethyl)-4-fluoro-2,7-dimethyl-3-((R)-3-methyl-4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C28H31F2N5O3S	929	(R)-2-((1-(3-(4-(1,1-dioxidoisothiazolidin-2-yl)piperidin-1-yl)-4-fluoro-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile





 C25H27F2N5O3S	930	(R)-2-((1-(2,7-dimethyl-3-(4-(methylsulfonyl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-4,5-difluorobenzonitrile
 C25H27F2N5O3S	931	(R)-6-((1-(2,7-dimethyl-3-(4-(methylsulfonyl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-2,3-difluorobenzonitrile
 C31H27ClN6O2	932	(R)-3-(5-(5-(1-((4-chloro-2-cyanophenyl)amino)ethyl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-3-yl)pyrimidin-2-yl)-2,6-dimethylpyridine 1-oxide
 C31H26F2N6O2	933	(R)-3-(5-(5-(1-((2-cyano-3,4-difluorophenyl)amino)ethyl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-3-yl)pyrimidin-2-yl)-2,6-dimethylpyridine 1-oxide





 C30H23F3N6O2	934	(R)-3-(5-(5-(1-((2-cyano-3,4-difluorophenyl)amino)ethyl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-3-yl)pyrimidin-2-yl)-5-fluoro-2-methylpyridine 1-oxide
 C31H27FN6O2	935	(R)-3-(5-(5-(1-((2-cyano-4-fluorophenyl)amino)ethyl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-3-yl)pyrimidin-2-yl)-2,6-dimethylpyridine 1-oxide
 C30H24F2N6O2	936	(R)-3-(5-(5-(1-((2-cyano-4-fluorophenyl)amino)ethyl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-3-yl)pyrimidin-2-yl)-5-fluoro-2-methylpyridine 1-oxide
 C26H26F5N5O	937	(R)-5-fluoro-2-((1-(4-fluoro-2,7-dimethyl-1-oxo-3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile





 C30H25FN6O2	938	(R)-2-((1-(2,7-dimethyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C26H32F2N4O5S2	939	4-fluoro-5-((R)-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-((S)-3-methyl-4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C26H32F2N4O5S2	940	4-fluoro-5-((R)-1-((4-fluoro-2-(methylsulfonyl)phenyl)amino)ethyl)-2,7-dimethyl-3-((R)-3-methyl-4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C31H26F3N7O2	941	(R)-2-((1-(3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-(trifluoromethyl)benzonitrile





 C30H26ClN7O2	942	(R)-5-chloro-2-((1-(3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C30H33F4N7O2	943	(R)-3-(4-(1,5-dimethyl-6-oxo-1,6-dihydropyrazin-2-yl)piperazin-1-yl)-4-fluoro-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C29H31F4N7O2	944	(R)-4-fluoro-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-(4-(1-methyl-6-oxo-1,6-dihydropyrazin-2-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C28H26FN7O3S	945	(R)-2-((1-(2,7-dimethyl-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzenesulfonamide





 C26H28F3N3O3S	946	(R)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl)isoquinolin-1(2H)-one
 C30H28F3N7O3S	947	(R)-3-(2',4'-dimethyl-[2,5'-bipyrimidin]-5-yl)-2,7-dimethyl-5-(1-((2-(methylsulfonyl)-6-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C31H27FN6O2	948	(R)-2-((1-(3-(2-(1,3-dimethyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C28H29F2N5O2	949	(R)-2-((1-(3-(4-(cyclopropanecarbonyl)piperazin-1-yl)-4-fluoro-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile





 C30H26FN7O	950	(R)-2-((1-(3-(2',4'-dimethyl-[2,5'-bipyrimidin]-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C29H28FN7O2S	951	5-((1R)-1-((4-fluoro-2-(S-methylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)isoquinolin-1(2H)-one, Diastereomer 1
 C29H28FN7O2S	952	5-((1R)-1-((4-fluoro-2-(S-methylsulfonimidoyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(2'-methyl-[2,5'-bipyrimidin]-5-yl)isoquinolin-1(2H)-one, Diastereomer 2
 C30H34F3N6O3P	953	(S)-3-(2-(4-ethoxy-4-oxido-1,4-azaphosphinan-1-yl)pyrimidin-5-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one





 C30H34F3N6O3P	954	(R)-3-(2-(4-ethoxy-4-oxido-1,4-azaphosphinan-1-yl)pyrimidin-5-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C28H28F3N7O	955	(R)-2-((1-(3-(4-(1,3-dimethyl-1H-pyrazol-4-yl)piperazin-1-yl)-4,7-difluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C29H21ClF2N6O2	956	(R)-2-((1-(3-(2-(3-chloro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-7-fluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C29H21Cl2FN6O2	957	(R)-2-((1-(7-chloro-3-(2-(3-chloro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile





 C30H24ClFN6O2	958	(R)-2-((1-(3-(2-(3-chloro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C29H21Cl2FN6O2	959	(R)-5-chloro-2-((1-(3-(2-(3-chloro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-7-fluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C29H21Cl3N6O2	960	(R)-5-chloro-2-((1-(7-chloro-3-(2-(3-chloro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C30H24Cl2N6O2	961	(R)-5-chloro-2-((1-(3-(2-(3-chloro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile





 C30H24F2N6O2	962	(R)-2-((1-(3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-7-fluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C30H24ClFN6O2	963	(R)-2-((1-(7-chloro-3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C31H27FN6O2	964	(R)-2-((1-(3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C30H24ClFN6O2	965	(R)-5-chloro-2-((1-(3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-7-fluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile





 C30H24Cl2N6O2	966	(R)-5-chloro-2-((1-(7-chloro-3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C31H27ClN6O2	967	(R)-5-chloro-2-((1-(3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C30H24F2N6O2	968	(R)-3-(5-(5-(1-((2-cyano-4-fluorophenyl)amino)ethyl)-7-fluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)pyrimidin-2-yl)-2,6-dimethylpyridine 1-oxide
 C30H24ClFN6O2	969	(R)-3-(5-(7-chloro-5-(1-((2-cyano-4-fluorophenyl)amino)ethyl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)pyrimidin-2-yl)-2,6-dimethylpyridine 1-oxide





 C30H24ClFN6O2	970	(R)-3-(5-(5-(1-((4-chloro-2-cyanophenyl)amino)ethyl)-7-fluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)pyrimidin-2-yl)-2,6-dimethylpyridine 1-oxide
 C30H24Cl2N6O2	971	(R)-3-(5-(7-chloro-5-(1-((4-chloro-2-cyanophenyl)amino)ethyl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)pyrimidin-2-yl)-2,6-dimethylpyridine 1-oxide
 C29H21F3N6O2	972	(R)-5-fluoro-2-((1-(7-fluoro-3-(2-(5-fluoro-1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C29H21ClF2N6O2	973	(R)-2-((1-(7-chloro-3-(2-(5-fluoro-1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile





 C30H24F2N6O2	974	(R)-5-fluoro-2-((1-(3-(2-(5-fluoro-1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C29H21ClF2N6O2	975	(R)-5-chloro-2-((1-(7-fluoro-3-(2-(5-fluoro-1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C29H21Cl2FN6O2	976	(R)-5-chloro-2-((1-(7-chloro-3-(2-(5-fluoro-1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C30H24ClFN6O2	977	(R)-5-chloro-2-((1-(3-(2-(5-fluoro-1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile





 C29H23F2N7O	978	(R)-2-((1-(3-(2',4'-dimethyl-[2,5'-bipyrimidin]-5-yl)-7-fluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C29H23ClFN7O	979	(R)-2-((1-(7-chloro-3-(2',4'-dimethyl-[2,5'-bipyrimidin]-5-yl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C30H26FN7O	980	(R)-2-((1-(3-(2',4'-dimethyl-[2,5'-bipyrimidin]-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C29H23ClFN7O	981	(R)-5-chloro-2-((1-(3-(2',4'-dimethyl-[2,5'-bipyrimidin]-5-yl)-7-fluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile





 C29H23Cl2N7O	982	(R)-5-chloro-2-((1-(7-chloro-3-(2',4'-dimethyl-[2,5'-bipyrimidin]-5-yl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C30H26ClN7O	983	(R)-5-chloro-2-((1-(3-(2',4'-dimethyl-[2,5'-bipyrimidin]-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C30H25F2N7O	984	(R)-5-fluoro-2-((1-(7-fluoro-2-methyl-1-oxo-3-(2',4,4'-trimethyl-[2,5'-bipyrimidin]-5-yl)-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C30H25ClFN7O	985	(R)-2-((1-(7-chloro-2-methyl-1-oxo-3-(2',4,4'-trimethyl-[2,5'-bipyrimidin]-5-yl)-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile





 C31H28FN7O	986	(R)-2-((1-(2,7-dimethyl-1-oxo-3-(2',4,4'-trimethyl-[2,5'-bipyrimidin]-5-yl)-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C30H25ClFN7O	987	(R)-5-chloro-2-((1-(7-fluoro-2-methyl-1-oxo-3-(2',4,4'-trimethyl-[2,5'-bipyrimidin]-5-yl)-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C30H25Cl2N7O	988	(R)-5-chloro-2-((1-(7-chloro-2-methyl-1-oxo-3-(2',4,4'-trimethyl-[2,5'-bipyrimidin]-5-yl)-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C31H28ClN7O	989	(R)-5-chloro-2-((1-(2,7-dimethyl-1-oxo-3-(2',4,4'-trimethyl-[2,5'-bipyrimidin]-5-yl)-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile





 C29H22ClFN6O2	990	(R)-5-chloro-2-((1-(7-fluoro-2-methyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C29H22Cl2N6O2	991	(R)-5-chloro-2-((1-(7-chloro-2-methyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C30H25ClN6O2	992	(R)-5-chloro-2-((1-(2,7-dimethyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C28H21ClFN7O2	993	(R)-5-chloro-2-((1-(7-fluoro-2-methyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile





 C28H21Cl2N7O2	994	(R)-5-chloro-2-((1-(7-chloro-2-methyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C29H24ClN7O2	995	(R)-5-chloro-2-((1-(2,7-dimethyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C29H23ClFN7O2	996	(R)-5-chloro-2-((1-(3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)-7-fluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C29H23Cl2N7O2	997	(R)-5-chloro-2-((1-(7-chloro-3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile





 C30H26ClN7O2	998	(R)-5-chloro-2-((1-(3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C30H24ClFN6O2	999	(R)-5-chloro-2-((1-(3-(2-(1,3-dimethyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-7-fluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C30H24Cl2N6O2	1000	(R)-5-chloro-2-((1-(7-chloro-3-(2-(1,3-dimethyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C31H27ClN6O2	1001	(R)-5-chloro-2-((1-(3-(2-(1,3-dimethyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile





 C29H21F3N6O2	1002	(R)-5-fluoro-2-((1-(7-fluoro-3-(2-(3-fluoro-1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C29H21ClF2N6O2	1003	(R)-2-((1-(7-chloro-3-(2-(3-fluoro-1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C30H24F2N6O2	1004	(R)-5-fluoro-2-((1-(3-(2-(3-fluoro-1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C29H21ClF2N6O2	1005	(R)-5-chloro-2-((1-(7-fluoro-3-(2-(3-fluoro-1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile





 C29H21Cl2FN6O2	1006	(R)-5-chloro-2-((1-(7-chloro-3-(2-(3-fluoro-1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C30H24ClFN6O2	1007	(R)-5-chloro-2-((1-(3-(2-(3-fluoro-1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C30H22F4N6O2	1008	(R)-2-((1-(3-(2-(3-(difluoromethyl)-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-7-fluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C30H22ClF3N6O2	1009	(R)-2-((1-(7-chloro-3-(2-(3-(difluoromethyl)-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile





 C31H25F3N6O2	1010	(R)-2-((1-(3-(2-(3-(difluoromethyl)-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C30H22ClF3N6O2	1011	(R)-5-chloro-2-((1-(3-(2-(3-(difluoromethyl)-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-7-fluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C30H22Cl2F2N6O2	1012	(R)-5-chloro-2-((1-(7-chloro-3-(2-(3-(difluoromethyl)-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C31H25ClF2N6O2	1013	(R)-5-chloro-2-((1-(3-(2-(3-(difluoromethyl)-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile





 C28H21F2N7O2	1014	(R)-5-fluoro-2-((1-(7-fluoro-2-methyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C28H21ClFN7O2	1015	(R)-2-((1-(7-chloro-2-methyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C29H24FN7O2	1016	(R)-2-((1-(2,7-dimethyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C28H21ClFN7O2	1017	(R)-5-chloro-2-((1-(7-fluoro-2-methyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile





 C28H21Cl2N7O2	1018	(R)-5-chloro-2-((1-(7-chloro-2-methyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C29H24ClN7O2	1019	(R)-5-chloro-2-((1-(2,7-dimethyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C29H21F3N6O2	1020	(R)-5-fluoro-2-((1-(7-fluoro-3-(2-(3-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C29H21ClF2N6O2	1021	(R)-2-((1-(7-chloro-3-(2-(3-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile





 C30H24F2N6O2	1022	(R)-5-fluoro-2-((1-(3-(2-(3-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C29H21ClF2N6O2	1023	(R)-5-chloro-2-((1-(7-fluoro-3-(2-(3-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C29H21Cl2FN6O2	1024	(R)-5-chloro-2-((1-(7-chloro-3-(2-(3-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C30H24ClFN6O2	1025	(R)-5-chloro-2-((1-(3-(2-(3-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile





 C28H21F2N7O2	1026	(R)-5-fluoro-2-((1-(7-fluoro-2-methyl-3-(1-(2-methylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C28H21ClFN7O2	1027	(R)-2-((1-(7-chloro-2-methyl-3-(1-(2-methylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C29H24FN7O2	1028	(R)-2-((1-(2,7-dimethyl-3-(1-(2-methylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C28H21ClFN7O2	1029	(R)-5-chloro-2-((1-(7-fluoro-2-methyl-3-(1-(2-methylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile





 C28H21Cl2N7O2	1030	(R)-5-chloro-2-((1-(7-chloro-2-methyl-3-(1-(2-methylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C29H24ClN7O2	1031	(R)-5-chloro-2-((1-(2,7-dimethyl-3-(1-(2-methylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C29H20F4N6O2	1032	(R)-2-((1-(3-(2-(1-(difluoromethyl)-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-7-fluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C29H20ClF3N6O2	1033	(R)-2-((1-(7-chloro-3-(2-(1-(difluoromethyl)-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile





 C30H23F3N6O2	1034	(R)-2-((1-(3-(2-(1-(difluoromethyl)-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C29H20ClF3N6O2	1035	(R)-5-chloro-2-((1-(3-(2-(1-(difluoromethyl)-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-7-fluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C29H20Cl2F2N6O2	1036	(R)-5-chloro-2-((1-(7-chloro-3-(2-(1-(difluoromethyl)-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C30H23ClF2N6O2	1037	(R)-5-chloro-2-((1-(3-(2-(1-(difluoromethyl)-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile





 C29H23ClF4N6O2	1038	(R)-3-(2-(3-chloro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-7-fluoro-2-methyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C29H23Cl2F3N6O2	1039	(R)-7-chloro-3-(2-(3-chloro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2-methyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C30H26ClF3N6O2	1040	(R)-3-(2-(3-chloro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C30H24F6N6O2	1041	(R)-3-(2-(3-(difluoromethyl)-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-7-fluoro-2-methyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one





 C30H24ClF5N6O2	1042	(R)-7-chloro-3-(2-(3-(difluoromethyl)-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2-methyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C31H27F5N6O2	1043	(R)-3-(2-(3-(difluoromethyl)-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C25H26F3N5O3S	1044	(R)-4,5-difluoro-2-((1-(4-fluoro-2,7-dimethyl-3-(4-(methylsulfonyl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C26H28F3N5O3S	1045	(R)-5-(difluoromethyl)-2-((1-(4-fluoro-2,7-dimethyl-3-(4-(methylsulfonyl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile





 C26H27F4N5O3S	1046	(R)-2-((1-(4-fluoro-2,7-dimethyl-3-(4-(methylsulfonyl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-(trifluoromethyl)benzonitrile
 C30H26F4N6O2	1047	(R)-3-(2-(1,3-dimethyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-7-fluoro-2-methyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C30H28F3N7O	1048	(R)-3-(2',4-dimethyl-[2,5'-bipyrimidin]-5-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C30H26FN7O	1049	(R)-2-((1-(3-(2',4-dimethyl-[2,5'-bipyrimidin]-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile





 C30H26ClN7O	1050	(R)-5-chloro-2-((1-(3-(2',4-dimethyl-[2,5'-bipyrimidin]-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C27H31F4N5O2	1051	(R)-4-fluoro-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-(4-(oxetan-3-yl)piperazin-1-yl)isoquinolin-1(2H)-one
 C26H31F4N5O2	1052	(R)-3-(4-ethoxypiperazin-1-yl)-4-fluoro-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C31H27ClN6O2	1053	(R)-5-chloro-2-((1-(3-(2-(1,3-dimethyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile





 C31H26F2N6O2	1054	(R)-6-((1-(3-(2-(1,3-dimethyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-2,3-difluorobenzonitrile
 C26H31F4N5O3S	1055	4-fluoro-2,7-dimethyl-5-((R)-1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-((S)-3-methyl-4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C25H27F5N4O3S	1056	(R)-4-fluoro-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-3-(4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C25H27F5N4O3S	1057	(R)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-4-fluoro-2,7-dimethyl-3-(4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one





 C26H29F5N4O3S	1058	5-((R)-1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-4-fluoro-2,7-dimethyl-3-((R)-3-methyl-4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C26H29F5N4O3S	1059	5-((R)-1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-4-fluoro-2,7-dimethyl-3-((S)-3-methyl-4-(methylsulfonyl)piperazin-1-yl)isoquinolin-1(2H)-one
 C26H29F2N5O2	1060	(R)-2-((1-(3-(4-ethoxypiperazin-1-yl)-4-fluoro-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C31H26F3N7O	1061	(R)-3-(5-(2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-1-oxo-1,2-dihydroisoquinolin-3-yl)pyrimidin-2-yl)-5-methylpicolinonitrile





 C31H27F5N6O2	1062	(R)-3-(2-(1-(difluoromethyl)-5-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C30H27F3N6O3	1063	(R)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-(1-(1-methyl-6-oxo-1,6-dihydropyridin-2-yl)-6-oxo-1,6-dihydropyridazin-4-yl)isoquinolin-1(2H)-one
 C30H26ClF3N6O3	1064	(R)-3-(1-(3-chloro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)-6-oxo-1,6-dihydropyridazin-4-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C29H24F4N6O2	1065	(R)-5-(5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethyl-1-oxo-1,2-dihydroisoquinolin-3-yl)-2'-methyl-[2,5'-bipyrimidine] 1-oxide





 C30H28F3N7O2	1066	(R)-3-(1',5'-dimethyl-6'-oxo-1',6'-dihydro-[2,4'-bipyrimidin]-5-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C24H27F3N4O4S	1067	(R)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-((1-(methylsulfonyl)azetidin-3-yl)oxy)isoquinolin-1(2H)-one
 C26H29ClFN5O3S	1068	5-chloro-2-(((R)-1-(4-fluoro-2,7-dimethyl-3-((R)-3-methyl-4-(methylsulfonyl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C29H30F4N6O2	1069	(R)-4-fluoro-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-(4-(6-oxopyridazin-1(6H)-yl)piperidin-1-yl)isoquinolin-1(2H)-one





 C30H31F4N5O2	1070	(R)-4-fluoro-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-(4-(2-oxopyridin-1(2H)-yl)piperidin-1-yl)isoquinolin-1(2H)-one
 C26H29ClFN5O3S	1071	5-chloro-2-(((R)-1-(4-fluoro-2,7-dimethyl-3-((S)-3-methyl-4-(methylsulfonyl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C27H29ClFN5O2	1072	(R)-5-chloro-2-((1-(4-fluoro-2,7-dimethyl-3-(4-(oxetan-3-yl)piperazin-1-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C29H22F2N6O2	1073	(R)-5-fluoro-2-((1-(7-fluoro-2-methyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile





 C29H22ClFN6O2	1074	(R)-2-((1-(7-chloro-2-methyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C28H21F2N7O2	1075	(R)-5-fluoro-2-((1-(7-fluoro-2-methyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)benzonitrile
 C28H21ClFN7O2	1076	(R)-2-((1-(7-chloro-2-methyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C29H23F2N7O2	1077	(R)-2-((1-(3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)-7-fluoro-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile





 C29H23ClFN7O2	1078	(R)-2-((1-(7-chloro-3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C30H24ClFN6O2	1079	(R)-2-((1-(7-chloro-3-(2-(1,3-dimethyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)ethyl)amino)-5-fluorobenzonitrile
 C30H28F3N7O2	1080	(R)-3-(1-(2,4-dimethylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C29H23F5N6O2	1081	(R)-3-(1-(2,4-dimethylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)-7-fluoro-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2-methylisoquinolin-1(2H)-one





 C29H23F5N6O2	1082	(R)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-3-(1-(2,4-dimethylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)-7-fluoro-2-methylisoquinolin-1(2H)-one
 C29H25ClF3N7O2	1083	(R)-7-chloro-3-(1-(2,4-dimethylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)-2-methyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C30H26F4N6O2	1084	(R)-3-(1-(2,4-dimethylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one
 C30H26F4N6O2	1085	(R)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-3-(1-(2,4-dimethylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)-2,7-dimethylisoquinolin-1(2H)-one





 C28H23ClF3N7O2	1086	(R)-7-chloro-2-methyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-(1-(2-methylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)isoquinolin-1(2H)-one
 C29H23ClF4N6O2	1087	(R)-7-chloro-3-(2-(5-fluoro-1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2-methyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C28H23ClF3N7O2	1088	(R)-7-chloro-2-methyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-(1-(2-methylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)isoquinolin-1(2H)-one
 C30H26ClF3N6O2	1089	(R)-7-chloro-3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2-methyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one





 C27H30ClF4N5O3S	1090	(R)-7-chloro-3-(4-(1,1-dioxidoisothiazolidin-2-yl)piperidin-1-yl)-4-fluoro-2-methyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C29H24ClF3N6O2	1091	(R)-7-chloro-2-methyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-(2-(1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one
 C28H23ClF3N7O2	1092	(R)-7-chloro-2-methyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-(2-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one
 C29H25ClF3N7O2	1093	(R)-7-chloro-3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)-2-methyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one





 C29H25ClF3N7O2	1094	(R)-7-chloro-3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)-2-methyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C28H23ClF3N7O2	1095	(R)-7-chloro-2-methyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)-3-(2-(1-methyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one
 C29H22ClF5N6O2	1096	(R)-7-chloro-3-(2-(1-(difluoromethyl)-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2-methyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C30H24ClF5N6O2	1097	(R)-7-chloro-3-(2-(1-(difluoromethyl)-5-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2-methyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one





 C29H23ClF4N6O2	1098	(R)-7-chloro-3-(2-(3-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2-methyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C29H23Cl2F3N6O2	1099	(R)-7-chloro-3-(2-(3-chloro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2-methyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C30H24ClF5N6O2	1100	(R)-7-chloro-3-(2-(3-(difluoromethyl)-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2-methyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C31H25F6N5O2	1101	(R)-3-(2-(1-(difluoromethyl)-5-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one





 C30H22F7N5O2	1102	(R)-3-(2-(1-(difluoromethyl)-5-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-7-fluoro-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2-methylisoquinolin-1(2H)-one
 C31H25F6N5O2	1103	(R)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-3-(2-(1-(difluoromethyl)-5-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2,7-dimethylisoquinolin-1(2H)-one
 C30H22F7N5O2	1104	(R)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-3-(2-(1-(difluoromethyl)-5-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-7-fluoro-2-methylisoquinolin-1(2H)-one
 C30H24ClF4N5O2	1105	(R)-3-(2-(3-chloro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one





 C29H21ClF5N5O2	1106	(R)-3-(2-(3-chloro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-7-fluoro-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2-methylisoquinolin-1(2H)-one
 C30H24ClF4N5O2	1107	(R)-3-(2-(3-chloro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one
 C29H21ClF5N5O2	1108	(R)-3-(2-(3-chloro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-7-fluoro-2-methylisoquinolin-1(2H)-one
 C31H25F6N5O2	1109	(R)-3-(2-(3-(difluoromethyl)-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one





 C30H22F7N5O2	1110	(R)-3-(2-(3-(difluoromethyl)-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-7-fluoro-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2-methylisoquinolin-1(2H)-one
 C31H25F6N5O2	1111	(R)-3-(2-(3-(difluoromethyl)-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one
 C30H22F7N5O2	1112	(R)-3-(2-(3-(difluoromethyl)-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-7-fluoro-2-methylisoquinolin-1(2H)-one
 C29H21Cl2FN6O2	1113	(R)-3-(5-(7-chloro-5-(1-((4-chloro-2-cyanophenyl)amino)ethyl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)pyrimidin-2-yl)-5-fluoro-2-methylpyridine 1-oxide





 C29H21ClF2N6O2	1114	(R)-3-(5-(7-chloro-5-(1-((2-cyano-4-fluorophenyl)amino)ethyl)-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)pyrimidin-2-yl)-5-fluoro-2-methylpyridine 1-oxide
 C30H24F5N5O2	1115	(R)-3-(2-(3-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one
 C29H21F6N5O2	1116	(R)-7-fluoro-3-(2-(3-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2-methylisoquinolin-1(2H)-one
 C30H24F5N5O2	1117	(R)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-3-(2-(3-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2,7-dimethylisoquinolin-1(2H)-one





 C29H21F6N5O2	1118	(R)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-7-fluoro-3-(2-(3-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2-methylisoquinolin-1(2H)-one
 C30H23F6N5O2	1119	(R)-3-(2-(1-(difluoromethyl)-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one
 C29H20F7N5O2	1120	(R)-3-(2-(1-(difluoromethyl)-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-7-fluoro-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2-methylisoquinolin-1(2H)-one
 C30H23F6N5O2	1121	(R)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-3-(2-(1-(difluoromethyl)-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2,7-dimethylisoquinolin-1(2H)-one





 C29H20F7N5O2	1122	(R)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-3-(2-(1-(difluoromethyl)-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-7-fluoro-2-methylisoquinolin-1(2H)-one
 C31H25F6N5O2	1123	(R)-3-(2-(1-(difluoromethyl)-5-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one
 C30H22F7N5O2	1124	(R)-3-(2-(1-(difluoromethyl)-5-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-7-fluoro-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2-methylisoquinolin-1(2H)-one
 C31H25F6N5O2	1125	(R)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-3-(2-(1-(difluoromethyl)-5-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2,7-dimethylisoquinolin-1(2H)-one





 C30H22F7N5O2	1126	(R)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-3-(2-(1-(difluoromethyl)-5-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-7-fluoro-2-methylisoquinolin-1(2H)-one
 C30H22F7N5O2	1127	(R)-3-(2-(1-(difluoromethyl)-5-fluoro-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one
 C29H19F8N5O2	1128	(R)-3-(2-(1-(difluoromethyl)-5-fluoro-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-7-fluoro-5-(1-((4-fluoro-2-(trifluoromethyl)phenyl)amino)ethyl)-2-methylisoquinolin-1(2H)-one
 C30H22F7N5O2	1129	(R)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-3-(2-(1-(difluoromethyl)-5-fluoro-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2,7-dimethylisoquinolin-1(2H)-one





 C29H19F8N5O2	1130	(R)-5-(1-((2-(difluoromethyl)-3,4-difluorophenyl)amino)ethyl)-3-(2-(1-(difluoromethyl)-5-fluoro-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-7-fluoro-2-methylisoquinolin-1(2H)-one
 C30H28F3N7O2	1131	(R)-3-(1-(2,4-dimethylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)-2,7-dimethyl-5-(1-((6-methyl-2-(trifluoromethyl)pyridin-3-yl)amino)ethyl)isoquinolin-1(2H)-one
 C30H28F2N6O3	1132	(R)-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one
 C29H25ClF2N6O3	1133	(R)-7-chloro-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-2-methyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one





 C29H25F3N6O3	1134	(R)-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-7-fluoro-2-methyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one
 C30H27F3N6O3	1135	(R)-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-3-(2-(5-fluoro-1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2,7-dimethylisoquinolin-1(2H)-one
 C29H24ClF3N6O3	1136	(R)-7-chloro-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-3-(2-(5-fluoro-1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2-methylisoquinolin-1(2H)-one
 C29H24F4N6O3	1137	(R)-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-7-fluoro-3-(2-(5-fluoro-1-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2-methylisoquinolin-1(2H)-one





 C31H30F2N6O3	1138	(R)-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2,7-dimethylisoquinolin-1(2H)-one
 C30H27ClF2N6O3	1139	(R)-7-chloro-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2-methylisoquinolin-1(2H)-one
 C30H27F3N6O3	1140	(R)-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-7-fluoro-2-methylisoquinolin-1(2H)-one
 C31H28F4N6O3	1141	(R)-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-3-(2-(1-(difluoromethyl)-5-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2,7-dimethylisoquinolin-1(2H)-one





 C30H25ClF4N6O3	1142	(R)-7-chloro-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-3-(2-(1-(difluoromethyl)-5-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2-methylisoquinolin-1(2H)-one
 C30H25F5N6O3	1143	(R)-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-3-(2-(1-(difluoromethyl)-5-methyl-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-7-fluoro-2-methylisoquinolin-1(2H)-one
 C30H26F4N6O3	1144	(R)-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-3-(2-(1-(difluoromethyl)-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2,7-dimethylisoquinolin-1(2H)-one
 C29H23ClF4N6O3	1145	(R)-7-chloro-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-3-(2-(1-(difluoromethyl)-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-2-methylisoquinolin-1(2H)-one





 C29H23F5N6O3	1146	(R)-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-3-(2-(1-(difluoromethyl)-6-oxo-1,6-dihydropyridin-2-yl)pyrimidin-5-yl)-7-fluoro-2-methylisoquinolin-1(2H)-one
 C29H27F2N7O3	1147	(R)-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one
 C28H24ClF2N7O3	1148	(R)-7-chloro-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-2-methyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one
 C28H24F3N7O3	1149	(R)-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-7-fluoro-2-methyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one

 C30H29F2N7O3	1150	(R)-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)-2,7-dimethylisoquinolin-1(2H)-one
 C29H26ClF2N7O3	1151	(R)-7-chloro-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)-2-methylisoquinolin-1(2H)-one
 C29H26F3N7O3	1152	(R)-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyrazin-2-yl)pyrimidin-5-yl)-7-fluoro-2-methylisoquinolin-1(2H)-one
 C29H27F2N7O3	1153	(R)-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one

 C28H24ClF2N7O3	1154	(R)-7-chloro-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-2-methyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one
 C28H24F3N7O3	1155	(R)-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-7-fluoro-2-methyl-3-(2-(1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)isoquinolin-1(2H)-one
 C30H29F2N7O3	1156	(R)-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)-2,7-dimethylisoquinolin-1(2H)-one
 C29H26ClF2N7O3	1157	(R)-7-chloro-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)-2-methylisoquinolin-1(2H)-one

 C29H26F3N7O3	1158	(R)-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-3-(2-(1,5-dimethyl-6-oxo-1,6-dihydropyridazin-4-yl)pyrimidin-5-yl)-7-fluoro-2-methylisoquinolin-1(2H)-one
 C31H30F2N6O3	1159	(R)-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-3-(2-(1,3-dimethyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2,7-dimethylisoquinolin-1(2H)-one
 C30H27ClF2N6O3	1160	(R)-7-chloro-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-3-(2-(1,3-dimethyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2-methylisoquinolin-1(2H)-one
 C30H27F3N6O3	1161	(R)-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-3-(2-(1,3-dimethyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-7-fluoro-2-methylisoquinolin-1(2H)-one

 C30H27F3N6O3	1162	(R)-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-3-(2-(3-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2,7-dimethylisoquinolin-1(2H)-one
 C29H24ClF3N6O3	1163	(R)-7-chloro-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-3-(2-(3-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2-methylisoquinolin-1(2H)-one
 C29H24F4N6O3	1164	(R)-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-7-fluoro-3-(2-(3-fluoro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-2-methylisoquinolin-1(2H)-one
 C30H27ClF2N6O3	1165	(R)-3-(2-(3-chloro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-2,7-dimethylisoquinolin-1(2H)-one

 C29H24Cl2F2N6O3	1166	(R)-7-chloro-3-(2-(3-chloro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-2-methylisoquinolin-1(2H)-one
 C29H24ClF3N6O3	1167	(R)-3-(2-(3-chloro-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)pyrimidin-5-yl)-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-7-fluoro-2-methylisoquinolin-1(2H)-one
 C29H27F2N7O3	1168	(R)-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-2,7-dimethyl-3-(1-(2-methylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)isoquinolin-1(2H)-one
 C28H24ClF2N7O3	1169	(R)-7-chloro-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-2-methyl-3-(1-(2-methylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)isoquinolin-1(2H)-one


 C28H24F3N7O3	1170	(R)-5-(1-((2-(difluoromethoxy)-6-methylpyridin-3-yl)amino)ethyl)-7-fluoro-2-methyl-3-(1-(2-methylpyrimidin-5-yl)-6-oxo-1,6-dihydropyridazin-4-yl)isoquinolin-1(2H)-one

Table 2. LCMS and NMR Spectra of Selected Examples from Table 1

Example	LCMS (m/z)	^{1}H NMR Data (MHz, Solvent, ppm)
20	(ES+) 570.4 [M+H]	^{1}H NMR (300 MHz, DMSO-d_6): δ 12.25 (s, 1H), 7.75 – 7.58 (m, 3H), 7.23 – 7.20 (m, 1H), 6.67 – 6.47 (m, 3H), 5.46 – 5.40 (m, 1H), 3.54 – 3.43 (m, 5H), 3.23 – 3.20 (m, 4H), 3.15 (s, 3H), 2.32 (s, 3H), 1.54 – 1.50 (m, 6H), 1.24 (s, 3H), 1.01 (s, 6H).
21	(ES+) 570.4 [M+H]	^{1}H NMR (300 MHz, DMSO-d_6): δ 12.26 (s, 1H), 7.81 – 7.54 (m, 3H), 7.23 – 7.20 (m, 1H), 6.56 – 6.50 (m, 3H), 5.54 – 5.50 (m, 1H), 3.59 – 3.29 (m, 5H), 3.28 – 3.19 (m, 4H), 3.15 (s, 3H), 2.32 (s, 3H), 1.54 – 1.49 (m, 6H), 1.23 (s, 3H), 1.01 (s, 6H).
22	(ES+) 537.3 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.01 (s, 1H), 7.77 – 7.69 (m, 1H), 7.56 (d, J = 1.9 Hz, 1H), 7.37 – 7.23 (m, 1H), 6.83 – 6.70 (m, 1H), 6.53 (d, J = 8.4 Hz, 1H), 6.48 (s, 1H), 5.27 – 5.19 (m, 1H), 3.65 (s, 3H), 3.27 – 3.17 (m, 2H), 3.16 (s, 3H), 3.15 – 2.70 (m, 8H), 2.40 (s, 3H), 1.67 (d, J = 6.6 Hz, 3H).
23	(ES+) 538.3 [M+H]	^{1}H NMR: (400 MHz, $CDCl_3$): δ 8.12 (s, 1H), 7.89 (d, J = 3.6 Hz, 1H), 7.46 (s, 1H), 7.14 - 7.00 (m, 2H), 6.62 (d, J = 8.4 Hz, 1H), 6.22 (s, 1H), 4.88 - 4.81 (m, 1H), 3.63 (s, 3H), 3.34 (s, 3H), 3.17 - 2.70 (m, 10H), 2.39 (s, 3H), 1.64 (d, J = 6.8 Hz, 3H).
24	(ES+) 411.1 [M+H]	^{1}H-NMR (400MHz, CD_3OD): δ 8.10 – 7.99 (m, 1H), 7.81 – 7.66 (m, 1H), 7.57 (d, J = 1.8 Hz, 1H), 7.34 – 7.19 (m, 1H), 6.85 – 6.71 (m, 2H), 6.48 (d, J = 8.4 Hz, 1H), 5.27 – 5.11 (m, 1H), 3.84 (s, 3H), 3.15 (s, 3H), 2.41 (s, 3H), 2.13 – 1.91 (m, 1H), 1.64 (d, J = 6.7 Hz, 3H), 1.20 – 1.00 (m, 2H), 0.97 – 0.69 (m, 2H).
25	(ES+) 468.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.04 – 7.98 (m, 1H), 7.94 (s, 1H), 7.66 – 7.63 (m, 1H), 7.54 (s, 1H), 7.35 – 7.30 (m, 1H), 7.08 (s, 1H), 6.79 – 6.70 (m, 1H), 6.61 (d, J = 5.6 Hz, 1H), 6.47 (d, J = 8.4 Hz, 1H), 5.29 – 5.20 (m, 1H), 3.46 (s, 3H), 3.24 (s, 3H), 2.74 (s, 3H), 2.39 (s, 3H), 1.53 (d, J = 6.5 Hz, 3H).

26	(ES+) 555.3 [M+H]	^{1}H NMR: (400 MHz, $CDCl_3$): δ 8.11 (s, 1H), 7.79 (d, J = 5.2 Hz, 1H), 7.44 (d, J = 1.6 Hz, 1H), 7.15 - 7.04 (m, 1H), 6.37 - 6.32 (m, 1H), 6.23 (s, 1H), 6.04 (d, J = 8.8 Hz, 1H), 4.92 - 4.77 (m, 1H), 3.62 (s, 3H), 3.33 (s, 3H), 3.21 - 2.71 (m, 10H), 2.40 (s, 3H), 1.61 (d, J = 6.8 Hz, 3H).
27	(ES+) 552.3 [M+H]	^{1}H NMR: (400 MHz, $CDCl_3$): δ 8.10 (s, 1H), 7.46 (d, J = 1.6 Hz, 1H), 6.97 - 6.88 (m, 2H), 6.55 (d, J = 8.8 Hz, 1H), 6.23 (s, 1H), 4.89 - 4.76 (m, 1H), 3.62 (s, 3H), 3.33 (s, 3H), 3.19 - 2.73 (m, 10H), 2.38 (s, 6H), 1.63 - 1.61 (m, 3H).
28	(ES+) 510.3 [M+H]	^{1}H NMR: (400 MHz, $CDCl_3$): δ 7.80 - 7.75 (m, 2H), 7.44 - 7.42 (m, 1H), 7.27 - 7.23 (m, 1H), 6.86 - 6.70 (m, 2H), 6.44 (d, J = 8.4 Hz, 1H), 5.49 - 5.42 (m, 1H), 3.73 (s, 3H), 3.13 (s, 3H), 2.65 - 2.54 (m, 6H), 1.66 (d, J = 6.8 Hz, 3H).
29	(ES+) 556.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.89 (d, J = 1.9 Hz, 1H), 7.78 – 7.77 (m, 2H), 7.46 – 7.35 (m, 2H), 7.16- 7.05 (m, 1H), 6.48 – 6.38 (m, 2H), 6.20 (d, J = 8.6 Hz, 1H), 5.14-5.02 (m, 1H), 3.50 (s, 3H), 3.32 – 3.25 (m, 2H), 3.24 – 2.53 (m, 8H), 2.35 (s, 3H), 1.50 (d, J = 6.5 Hz, 3H).
30	(ES+) 575.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.87 – 8.86 (m, 1H), 8.64 (d, J = 2.9 Hz, 1H), 8.33 – 8.31 (m, 1H), 8.08 – 8.03 (m, 1H), 7.87 – 7.85 (m, 1H), 7.68 – 7.63 (m, 1H), 7.60 – 7.59 (m, 1H), 7.32 – 7.30 (m, 1H), 7.11 (s, 1H), 6.79 – 6.71 (m, 1H), 6.66 (d, J = 5.6 Hz, 1H), 6.50 (d, J = 8.4 Hz, 1H), 5.32 – 5.30 (m, 1H), 3.46 (s, 3H), 3.26 (s, 3H), 2.46 (s, 3H), 2.41 (s, 3H), 1.57 (d, J = 6.5 Hz, 3H).
31	(ES+) 561.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.07 (s, 1H), 8.91 – 8.90 (m, 1H), 8.77 (d, J = 2.8 Hz, 1H), 8.36 – 8.33 (m, 1H), 8.27 – 8.25 (m, 1H), 8.05 (d, J = 1.9 Hz, 1H), 7.65 – 7.63 (m, 1H), 7.60 (d, J = 1.9 Hz, 1H), 7.32 – 7.30 (m, 1H), 7.11 (s, 1H), 6.79 – 6.71 (m, 1H), 6.66 (d, J = 5.6 Hz, 1H), 6.49 (d, J = 8.5 Hz, 1H), 5.32 – 5.30 (m, 1H), 3.46 (s, 3H), 3.27 (s, 3H), 2.41 (s, 3H), 1.56 (d, J = 6.5 Hz, 3H).
32	(ES+) 575.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.95 – 8.94 (m, 1H), 8.88 – 8.87 (m, 1H), 8.34 – 8.30 (m, 1H), 8.21 – 8.14 (m, 1H), 8.08 – 8.03 (m, 1H), 7.65 – 7.59 (m, 2H), 7.32 – 7.29 (m, 1H), 7.10 (s, 1H), 6.79 – 6.70 (m, 1H), 6.65 (d, J = 5.7 Hz, 1H), 6.49 (d, J = 8.4 Hz, 1H), 5.31 – 5.30 (m, 1H), 3.32 (s, 3H), 3.26 (s, 3H), 2.56 (d, J = 3.0 Hz, 3H), 2.41 (s, 3H), 1.55 (d, J = 6.5 Hz, 3H).
33	(ES+) 563.3 [M+H]	^{1}H NMR: (400 MHz, DMSO-d6): δ 7.89 (s, 1H), 7.57 - 7.55 (m, 1H), 7.47 (d, J = 1.6 Hz, 1H), 7.34 - 7.27 (m, 1H), 6.76 - 6.66 (m, 2H), 6.47 (d, J = 8.4 Hz, 1H), 6.39 (s, 1H), 5.25 - 5.15 (m, 1H), 3.50 (s, 3H), 3.31 - 3.24 (m, 2H), 3.19 - 2.68 (m, 9H), 2.33 (s, 3H), 1.54 (d, J = 6.8 Hz, 3H), 1.17 - 1.03 (m, 4H).

34	(ES+) 558.3 [M+Na]	^{1}H NMR: (400 MHz, $CDCl_3$): δ 8.11 (s, 1H), 7.92 - 7.81 (m, 1H), 7.53 - 7.38 (m, 2H), 7.23 - 7.19 (m, 1H), 6.75 - 6.70 (m, 1H), 6.32 - 6.30 (m, 1H), 6.22 (d, J = 9.2 Hz, 1H), 5.01 - 4.87 (m, 1H), 3.63 (s, 3H), 3.19 (d, J = 5.6 Hz, 3H), 3.14 - 2.82 (m, 10H), 2.38 (s, 3H), 1.64 - 1.62 (m, 3H).
35	(ES+) 550.1 [M+H]	^{1}H NMR: (400 MHz, $CDCl_3$): δ 8.13 (br s, 1H), 7.84 - 7.74 (m, 1H), 7.49 - 7.36 (m, 2H), 7.26 - 7.21 (m, 1H), 6.81 - 6.71 (m, 1H), 6.38 - 6.30 (m, 1H), 6.24 (d, J = 13.6 Hz, 1H), 5.04 - 4.85 (m, 1H), 3.65 (s, 3H), 3.18 (d, J = 5.6 Hz, 3H), 3.15 - 2.85 (m, 10H), 2.78 (d, J = 4.0 Hz, 3H), 2.39 (d, J = 6.0 Hz, 3H), 1.62 - 1.60 (m, 3H).
36	(ES+) 567.3 [M+H]	^{1}H NMR: (400 MHz, DMSO-d_6): δ 7.88 (s, 1H), 7.59 - 7.57 (m, 1H), 7.48 (d, J = 1.6 Hz, 1H), 7.38 - 7.29 (m, 1H), 6.76 - 6.67 (m, 2H), 6.45 (d, J = 8.6 Hz, 1H), 6.38 (s, 1H), 5.21 - 5.18 (m, 1H), 4.82 (s, 2H), 3.51 (s, 3H), 3.50 (s, 3H), 3.29 - 3.27 (m, 2H), 3.04 - 2.70 (m, 8H), 2.32 (s, 3H), 1.53 (d, J = 6.4 Hz, 3H).
37	(ES+) 636.5 [M+Na]	^{1}H NMR: (400 MHz, $CDCl_3$): δ 8.49 - 8.48 (m, 1H), 8.11 (s, 1H), 7.66 (d, J = 1.6 Hz, 1H), 7.49 (s, 1H), 7.42 - 7.32 (m, 2H), 7.26 - 7.22 (m, 1H), 7.21 - 7.13 (m, 1H), 6.57 - 6.55 (m, 1H), 6.53 - 6.52 (m, 1H), 6.28 (d, J = 8.4 Hz, 1H), 6.21 (s, 1H), 4.95 - 4.84 (m, 1H), 4.73 - 4.60 (m, 2H), 3.63 (s, 3H), 3.18 - 2.68 (m, 10H), 2.39 (s, 3H), 1.60 (d, J = 6.4 Hz, 3H).
38	(ES+) 603.1 [M+H]	^{1}H NMR: (400 MHz, $CDCl_3$): δ 8.11 (s, 1H), 7.53 (d, J = 2.4 Hz, 1H), 7.45 (d, J = 1.6 Hz, 2H), 7.35 - 7.34 (m, 1H), 7.24 - 7.16 (m, 1H), 6.60 (d, J = 6.4 Hz, 2H), 6.32 - 6.31 (m, 1H), 6.27 (d, J = 8.4 Hz, 1H), 6.19 (s, 1H), 5.51 (s, 2H), 4.93 - 4.82 (m, 1H), 3.63 (s, 3H), 3.21 - 2.64 (m, 10H), 2.39 (s, 3H), 1.59 (s, 3H).
39	(ES+) 581.1 [M+H]	^{1}H NMR: (400 MHz, CD_3CN): δ 7.99 (s, 1H), 7.68 - 7.67 (m, 1H), 7.53 (d, J = 1.2 Hz, 1H), 7.43 - 7.24 (m, 1H), 6.83 - 6.67 (m, 2H), 6.50 (d, J = 8.4 Hz, 1H), 6.30 (s, 1H), 5.17 - 5.12 (m, 1H), 4.70 (s, 2H), 3.87 - 3.70 (m, 2H), 3.56 (s, 3H), 3.22 - 3.14 (m, 2H), 3.14 - 2.59 (m, 8H), 2.37 (s, 3H), 1.61 (d, J = 6.4 Hz, 3H), 1.13 (t, J = 6.8 Hz, 3H).
40	(ES+) 558.3 [M+Na]	^{1}H NMR: (400 MHz, $CDCl_3$): δ 8.12 (s, 1H), 7.86 - 7.84 (m, 1H), 7.50 (d, J = 5.6 Hz, 1H), 7.42 (s, 1H), 7.23 (t, J = 8.4 Hz, 1H), 6.74 (t, J = 7.6 Hz, 1H), 6.35 (d, J = 8.4 Hz, 1H), 6.23 (s, 1H), 5.04 - 4.86 (m, 1H), 3.64 (s, 3H), 3.20 (s, 3H), 3.12 - 2.76 (m, 10H), 2.40 (s, 3H), 1.65 (d, J = 6.8 Hz, 3H).
41	(ES+) 558.3 [M+Na]	^{1}H NMR: (400 MHz, $CDCl_3$): δ 8.11 (s, 1H), 7.90 - 7.81 (m, 1H), 7.52 - 7.41 (m, 2H), 7.21 (t, J = 7.6 Hz, 1H), 6.73 (t, J = 7.6 Hz, 1H), 6.31 (d, J = 8.4 Hz, 1H), 6.23 (s, 1H), 5.01 - 4.84 (m, 1H), 3.63 (s, 3H), 3.20 (s, 3H), 3.14 - 2.80 (m, 10H), 2.38 (s, 3H), 1.63 (d, J = 6.8 Hz, 3H).
42	(ES+) 546.1 [M+H]	^{1}H NMR: (400 MHz, DMSO-d_6): δ 8.46 (s, 1H), 8.10 - 8.08 (m, 1H), 8.01 (s, 1H), 7.66 - 7.60 (m, 1H), 7.57 (s, 1H), 7.31 (t, J = 7.6 Hz, 1H), 7.16 (d, J = 8.4 Hz, 1H), 6.93 (s, 1H), 6.73 (t, J = 7.6 Hz, 1H), 6.62 (d, J = 5.6 Hz, 1H), 6.47 (d, J = 8.4 Hz, 1H), 5.28 - 5.26 (m, 1H), 5.12 - 5.08 (m, 2H), 3.35 (s, 3H), 3.24 (s, 3H), 2.39 (s, 3H), 1.53 (d, J = 6.8 Hz, 3H).

43	(ES+) 454.3 [M+H]	^{1}H NMR: (400 MHz, $CDCl_3$): δ 8.10 (s, 1H), 7.78 - 7.76 (m, 1H), 7.41 (d, J = 1.6 Hz, 1H), 7.26 - 7.21 (m, 1H), 6.77 - 6.71 (m, 1H), 6.68 (d, J = 5.2 Hz, 1H), 6.36 (d, J = 8.4 Hz, 1H), 6.15 (s, 1H), 4.98 - 4.91 (m, 1H), 3.63 (s, 3H), 3.38 - 3.14 (m, 2H), 3.13 (s, 3H), 2.79 - 2.48 (m, 2H), 2.37 (s, 3H), 2.05 - 1.67 (m, 6H), 1.65 (d, J = 6.8 Hz, 3H).
44	(ES+) 533.1 [M+H]	^{1}H NMR: (400 MHz, DMSO-d_6): δ 8.35 (d, J = 2.4 Hz, 1H), 7.99 (s, 1H), 7.82 - 7.79 (m, 1H), 7.63 - 7.62 (m, 1H), 7.54 (d, J = 1.2 Hz, 1H), 7.36 - 7.26 (m, 1H), 6.96 (d, J = 8.8 Hz, 1H), 6.84 (s, 1H), 6.73 (t, J = 7.6 Hz, 1H), 6.61 (d, J = 5.6 Hz, 1H), 6.47 (d, J = 8.4 Hz, 1H), 5.26 - 5.23 (m, 1H), 3.75 - 3.69 (m, 4H), 3.60 - 3.49 (m, 4H), 3.38 (s, 3H), 3.24 (s, 3H), 2.38 (s, 3H), 1.53 (d, J = 6.4 Hz, 3H).
45	(ES+) 555.05 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.89 (s, 1H), 7.63-7.59 (m, 1H), 7.46 (d, J = 1.9 Hz, 1H), 7.43 – 7.34 (m, 1H), 6.79 – 6.69 (m, 2H), 6.49 (d, J = 8.6 Hz, 1H), 6.38 (s, 1H), 5.76 (d, J = 1.2 Hz, 1H), 5.64 (d, J = 1.2 Hz, 1H), 5.24-5.20 (m, 1H), 3.50 (s, 3H), 3.31 – 3.23 (m, 2H), 3.12 – 2.61 (m, 8H), 2.32 (s, 3H), 1.53 (d, J = 6.5 Hz, 3H).
46	(ES+) 519.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.60 (d, J = 2.7 Hz, 1H), 8.03 (s, 1H), 7.77 (d, J = 1.3 Hz, 1H), 7.64 – 7.60 (m, 1H), 7.57 (d, J = 1.9 Hz, 1H), 7.36 – 7.27 (m, 2H), 6.92 (s, 1H), 6.78 – 6.70 (m, 1H), 6.62 (d, J = 5.6 Hz, 1H), 6.49 (d, J = 8.5 Hz, 1H), 5.28 – 5.25 (m, 1H), 4.26 (s, 3H), 3.37 (s, 3H), 3.24 (s, 3H), 2.39 (s, 3H), 1.55 (d, J = 6.5 Hz, 3H).
47	(ES+) 504.1 [M+H]	^{1}H NMR: (400 MHz, $CDCl_3$): δ 8.37 (d, J = 2.4 Hz, 1H), 8.21 (s, 1H), 7.78 - 7.76 (m, 1H), 7.69 - 7.67 (m, 1H), 7.50 (d, J = 1.2 Hz, 1H), 7.26 - 7.19 (m, 1H), 6.91 (d, J = 8.8 Hz, 1H), 6.79 - 6.70 (m, 2H), 6.65 (s, 1H), 6.32 (d, J = 8.4 Hz, 1H), 5.05 - 4.93 (m, 1H), 4.31 - 4.28 (m, 1H), 3.49 (s, 3H), 3.13 (s, 3H), 2.43 (s, 3H), 1.63 (d, J = 6.4 Hz, 3H), 0.92 - 0.80 (m, 4H).
48	(ES+) 547.3 [M+H]	^{1}H NMR: (400 MHz, DMSO-d_6): δ 8.47 (s, 2H), 7.91 (s, 1H), 7.63 - 7.60 (m, 1H), 7.49 (d, J = 1.2 Hz, 1H), 7.33 (t, J = 7.2 Hz, 1H), 6.74 (t, J = 7.6 Hz, 1H), 6.61 (d, J = 5.6 Hz, 1H), 6.51 (d, J = 8.4 Hz, 1H), 6.42 (s, 1H), 5.20 - 5.18 (m, 1H), 3.55 (s, 3H), 3.35 - 2.75 (m, 11H), 2.51 (s, 3H), 2.34 (s, 3H), 1.56 (d, J = 6.4 Hz, 3H).
49	(ES+) 546.3 [M+H]	^{1}H NMR: (400 MHz, DMSO-d_6): δ 8.23 (d, J = 2.8 Hz, 1H), 7.91 (s, 1H), 7.64 - 7.62 (m, 1H), 7.49 (d, J = 1.6 Hz, 1H), 7.37 - 7.30 (m, 2H), 7.12 (d, J = 8.4 Hz, 1H), 6.74 (t, J = 7.5 Hz, 1H), 6.61 (d, J = 5.6 Hz, 1H), 6.51 (d, J = 8.4 Hz, 1H), 6.42 (s, 1H), 5.24 - 5.20 (m, 1H), 3.55 (s, 3H), 3.34 - 2.88 (m, 11H), 2.37 (s, 3H), 2.34 (s, 3H), 1.56 (d, J = 6.4 Hz, 3H).
50	(ES+) 600.2 [M+Na]	^{1}H NMR: (400 MHz, $CDCl_3$): δ 8.13 (s, 1H), 7.84 - 7.81 (m, 1H), 7.44 (d, J = 12.4 Hz, 1H), 7.37 - 7.22 (m, 1H), 7.07 - 6.95 (m, 1H), 6.84 – 6.78 (m, 1H), 6.54 - 6.29 (m, 1H), 6.26 - 6.08 (m, 1H), 5.06 - 4.84 (m, 1H), 3.63 (d, J = 7.2 Hz, 3H), 3.52 - 3.39 (m, 3H), 3.18 - 2.64 (m, 10H), 2.40 (d, J = 8.4 Hz, 3H), 2.25 - 1.88 (m, 3H), 1.68 - 1.61 (m, 3H).

51	(ES+) 614.3 [M+H]	^{1}H NMR: (400 MHz, $CDCl_3$): δ 8.70 (s, 1H), 8.52 (d, J = 2.8 Hz, 1H), 8.25 (s, 1H), 7.71 - 7.65 (m, 2H), 7.60 (d, J = 1.6 Hz, 2H), 7.55 - 7.53 (m, 1H), 7.24 - 7.15 (m, 1H), 6.79 (s, 1H), 6.73 (t, J = 7.6 Hz, 1H), 6.31 (d, J = 8.4 Hz, 1H), 5.01 - 4.91 (m, 1H), 3.56 (s, 3H), 2.88 - 2.78 (m, 4H), 2.57 (s, 3H), 2.45 (s, 3H), 1.65 (d, J = 6.8 Hz, 3H), 1.54 - 1.49 (m, 1H), 1.17 - 1.07 (m, 2H), 0.89 - 0.84 (m, 1H).
52	(ES+) 614.3 [M+H]	^{1}H NMR: (400 MHz, $CDCl_3$): δ 8.70 (s, 1H), 8.52 (d, J = 2.8 Hz, 1H), 8.24 (s, 1H), 7.73 - 7.63 (m, 3H), 7.60 - 7.50 (m, 2H), 7.24 - 7.14 (m, 1H), 6.76 (s, 1H), 6.73 - 6.67 (m, 1H), 6.29 (d, J = 8.4 Hz, 1H), 5.01 - 4.98 (m, 1H), 3.56 (s, 3H), 2.85 (s, 3H), 2.81 - 2.73 (m, 1H), 2.57 (s, 3H), 2.46 (s, 3H), 1.65 (d, J = 6.8 Hz, 3H), 1.52 - 1.46 (m, 1H), 1.17 - 1.07 (m, 2H), 0.89 - 0.82 (m, 1H).
53	(ES+) 578.3 [M+H]	^{1}H NMR: (400 MHz, $CDCl_3$): δ 8.13 (s, 1H), 7.83 - 7.81 (m, 1H), 7.45 (d, J = 1.2 Hz, 1H), 7.27 - 7.22 (m, 1H), 7.04 (d, J = 3.6 Hz, 1H), 6.82 - 6.80 (m, 1H), 6.34 (d, J = 8.4 Hz, 1H), 6.22 (s, 1H), 4.94 – 4.90 (m, 1H), 3.64 (s, 3H), 3.50 (s, 3H), 3.18 - 2.73 (m, 10H), 2.40 (s, 3H), 2.21 (s, 3H), 1.63 (d, J = 6.8 Hz, 3H).
54	(ES+) 600.3 [M+Na]	^{1}H NMR: (400 MHz, $CDCl_3$): δ 8.13 (s, 1H), 7.83 - 7.81 (m, 1H), 7.42 (s, 1H), 7.35 - 7.30 (m, 1H), 6.98 (d, J = 6.0 Hz, 1H), 6.82 (t, J = 7.6 Hz, 1H), 6.50 (d, J = 8.4 Hz, 1H), 6.10 (s, 1H), 5.06 - 4.90 (m, 1H), 3.62 (s, 3H), 3.41 (s, 3H), 3.18 - 2.67 (m, 10H), 2.41 (s, 3H), 1.94 (s, 3H), 1.65 (d, J = 6.8 Hz, 3H).
55	(ES+) 553.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.88 (s, 1H), 7.56 – 7.47 (m, 3H), 7.10 (d, J = 8.5 Hz, 1H), 6.80 (d, J = 8.6 Hz, 1H), 6.62 (d, J = 6.3 Hz, 1H), 6.41 (s, 1H), 5.22 – 5.14 (m, 1H), 3.50 (s, 3H), 3.28 – 3.24 (m, 2H), 3.03 – 2.84 (m, 8H), 2.30 – 2.21 (m, 6H), 1.51 (d, J = 6.5 Hz, 3H).
56	(ES+) 537.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.20 – 8.11 (m, 2H), 7.54 – 7.45 (m, 2H), 7.39 – 7.31 (m, 1H), 7.18 – 7.11 (m, 1H), 5.99 (s, 1H), 4.53 (s, 2H), 3.57 (s, 3H), 3.31 (s, 3H), 3.24 – 3.13 (m, 2H), 3.12 – 2.83 (m, 8H), 2.80 (s, 3H), 2.49 (s, 3H).
57	(ES+) 551.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.97 – 7.92 (m, 1H), 7.89 (d, J = 1.6 Hz, 1H), 7.59 – 7.54 (m, 1H), 7.51 (d, J = 1.9 Hz, 1H), 7.41 – 7.32 (m, 2H), 6.03 (s, 1H), 4.50 – 4.49 (m, 2H), 3.42 (s, 3H), 3.28 – 3.26 (m, 2H), 3.16 – 3.12 (m, 5H), 3.01 – 2.80 (m, 8H), 2.38 (s, 3H), 1.07-1.03 (m, 3H).
58	(ES+) 590.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.88 – 8.87 (m, 1H), 8.64 (d, J = 2.9 Hz, 1H), 8.35 – 8.32 (m, 1H), 8.05 (s, 1H), 7.88 – 7.86 (m, 1H), 7.57 (d, J = 1.8 Hz, 1H), 7.20 (d, J = 8.7 Hz, 1H), 7.08 (s, 1H), 6.94 (d, J = 8.7 Hz, 1H), 6.87 (d, J = 6.4 Hz, 1H), 5.35 – 5.32 (m, 1H), 3.45 (s, 3H), 3.35 (s, 3H), 2.47 – 2.42 (m, 6H), 2.32 (s, 3H), 1.53 (d, J = 6.5 Hz, 3H).

59	(ES+) 519.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.24 (d, J = 2.3 Hz, 1H), 8.03 (s, 1H), 7.82 (d, J = 1.2 Hz, 1H), 7.64 – 7.60 (m, 1H), 7.59 – 7.51 (m, 2H), 7.32 – 7.30 (m, 1H), 6.90 (s, 1H), 6.74 (d, J = 7.6 Hz, 1H), 6.62 (d, J = 5.6 Hz, 1H), 6.48 (d, J = 8.4 Hz, 1H), 5.27 – 5.24 (m, 1H), 4.24 (s, 3H), 3.30 (s, 3H), 3.24 (s, 3H), 2.40 (s, 3H), 1.54 (d, J = 6.5 Hz, 3H).
60	(ES+) 578.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.62 (s, 1H), 8.14 (s, 1H), 7.92 (d, J = 9.6 Hz, 1H), 7.65 – 7.55 (m, 2H), 7.26 (s, 1H), 7.05 (s, 1H), 6.74 – 6.70 (m, 1H), 6.48 (d, J = 8.0 Hz, 1H), 5.22 (s, 1H), 3.87 (s, 2H), 3.49 (s, 3H), 3.19 – 3.13 (m, 3H), 2.69 (s, 3H), 2.53 (s, 3H), 2.45 – 2.20 (m, 8H), 1.64 (d, J = 6.6 Hz, 3H).
61	(ES+) 553.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.24 (d, J = 2.0 Hz, 1H), 8.08 – 8.06 (m, 1H), 8.04 – 7.99 (m, 1H), 7.63 – 7.62 (m, 1H), 7.57 (d, J = 1.8 Hz, 1H), 7.31 – 7.30 (m, 1H), 6.96 (s, 1H), 6.78 – 6.70 (m, 1H), 6.63 (d, J = 5.7 Hz, 1H), 6.47 (d, J = 8.4 Hz, 1H), 5.27 – 5.26 (m, 1H), 4.52 – 4.50 (m, 2H), 3.38 (s, 3H), 3.25 (s, 3H), 2.70 (m, 2H), 2.39 (s, 3H), 2.24 (s, 6H), 1.53 (d, J = 6.6 Hz, 3H).
62	(ES+) 555.1 [M+H]	^{1}H NMR: (400 MHz, $CDCl_3$): δ 8.17 (s, 1H), 7.79 - 7.77 (m, 1H), 7.57 (d, J = 1.6 Hz, 1H), 7.26 - 7.20 (m, 1H), 6.79 - 6.65 (m, 2H), 6.39 (d, J = 8.4 Hz, 1H), 5.46 - 5.18 (m, 1H), 3.64 (s, 3H), 3.58 - 3.48 (m, 2H), 3.15 (s, 3H), 3.14 - 2.98 (m, 6H), 2.75 (t, J = 10.8 Hz, 2H), 2.38 (s, 3H), 1.62 (d, J = 6.8 Hz, 3H).
63	(ES+) 551.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.01 – 7.92 (m, 1H), 7.89 – 7.88 (m, 2H), 7.60 – 7.55 (m, 1H), 7.45 – 7.40 (m, 2H), 6.06 (s, 1H), 5.10 – 5.05 (m, 1H), 3.48 (s, 3H), 3.44 (s, 3H), 3.35 – 3.26 (m, 2H), 3.12 – 2.59 (m, 8H), 2.53 – 2.45 (m, 6H), 1.31 – 1.27 (m, 3H).
64	(ES+) 565.5 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.02 – 8.01 (m, 1H), 7.94 – 7.92 (m, 1H), 7.79 (d, J = 1.9 Hz, 1H), 7.42 – 7.34 (m, 2H), 6.95 (d, J = 7.8 Hz, 1H), 5.68 (s, 1H), 5.30 – 5.28 (m, 1H), 3.54 (s, 3H), 3.28 (s, 3H), 3.25 – 3.23 (m, 1H), 3.22 – 3.20 (m, 3H), 3.00 – 2.60 (m, 8H), 2.47 (s, 3H), 1.47 (d, J = 6.7 Hz, 3H), 0.81 – 0.78 (m, 3H).
65	(ES+) 589.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.86 – 8.85 (m, 1H), 8.69 (d, J = 2.9 Hz, 1H), 8.32 – 8.30 (m, 1H), 8.08 – 8.03 (m, 1H), 7.85 – 7.83 (m, 1H), 7.68 – 7.58 (m, 2H), 7.32 – 7.30 (m, 1H), 7.11 (s, 1H), 6.75 – 6.73 (m, 1H), 6.66 (d, J = 5.6 Hz, 1H), 6.50 (d, J = 8.5 Hz, 1H), 5.33 – 5.31 (m, 1H), 3.46 (s, 3H), 3.32 (s, 3H), 2.73 – 2.72 (m, 2H), 2.42 (s, 3H), 1.57 (d, J = 6.5 Hz, 3H), 1.20 – 1.19 (m, 3H).
66	(ES+) 556.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.99 (s, 1H), 7.76 (d, J = 2.0 Hz, 1H), 7.66 – 7.64 (m, 1H), 7.58 (s, 2H), 7.20 – 7.18 (m, 1H), 6.66 – 6.62 (m, 1H), 6.44 – 6.38 (m, 1H), 6.33 (d, J = 8.4 Hz, 1H), 5.32 – 5.29 (m, 1H), 3.52 (s, 3H), 3.32 – 3.28 (m, 4H), 3.19 – 3.12 (m, 2H), 2.95 – 2.92 (m, 2H), 2.73 – 2.63 (m, 2H), 2.33 (s, 3H), 1.56 (d, J = 6.4 Hz, 3H).

67	(ES+) 520.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.24 – 8.23 (m, 1H), 8.01 – 8.00 (m, 1H), 7.85 (d, J = 1.2 Hz, 1H), 7.69 – 7.61 (m, 2H), 7.57 – 7.56 (m, 3H), 7.17 – 7.05 (m, 1H), 6.93 (s, 1H), 6.67 – 6.58 (m, 1H), 6.40 – 6.33 (m, 2H), 5.39 – 5.08 (m, 1H), 4.24 (s, 3H), 3.37 (s, 3H), 2.37 (s, 3H), 1.52 (d, J = 6.5 Hz, 3H).
68	(ES+) 601.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.88 – 8.87 (m, 1H), 8.64 (d, J = 2.9 Hz, 1H), 8.34 – 8.31 (m, 1H), 8.06 (s, 1H), 7.88 – 7.85 (m, 1H), 7.59 – 7.56 (m, 2H), 7.32 – 7.28 (m, 1H), 7.11 (s, 1H), 6.76 – 6.68 (m, 2H), 6.47 (d, J = 8.5 Hz, 1H), 5.33 – 5.31 (m, 1H), 3.46 (s, 3H), 3.04 – 3.01 (m, 1H), 2.49 – 2.46 (m, 3H), 2.41 (s, 3H), 1.56 (d, J = 6.5 Hz, 3H), 1.26 – 1.02 (m, 4H).
69	(ES+) 617.3 [M+H]	^{1}H NMR: (400 MHz, DMSO-d_6): δ 7.89 (s, 1H), 7.61 - 7.58 (m, 1H), 7.47 (d, J = 1.2 Hz, 1H), 7.40 - 7.32 (m, 1H), 6.73 (t, J = 7.6 Hz, 1H), 6.66 (d, J = 6.0 Hz, 1H), 6.47 (d, J = 8.4 Hz, 1H), 6.37 (s, 1H), 6.29 - 5.97 (m, 1H), 5.24 - 5.14 (m, 1H), 5.07 - 4.96 (m, 2H), 4.07 - 3.94 (m, 2H), 3.50 (s, 3H), 3.31 - 3.23 (m, 2H), 3.13 - 2.61 (m, 8H), 2.32 (s, 3H), 1.53 (d, J = 6.4 Hz, 3H).
70	(ES+) 520.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.44 – 8.43 (m, 1H), 8.13 – 8.08 (m, 1H), 7.75 – 7.68 (m, 3H), 7.20 – 7.08 (m, 2H), 7.02 (s, 1H), 6.65 – 6.51 (m, 1H), 6.37 (d, J = 8.2 Hz, 1H), 5.18 – 5.10 (m, 1H), 4.30 (s, 3H), 3.50 (s, 3H), 2.43 (s, 3H), 1.64 (d, J = 6.7 Hz, 3H).
71	(ES+) 576.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.88 (s, 1H), 8.64 (d, J = 2.9 Hz, 1H), 8.34 – 8.32 (m, 1H), 8.03 (s, 1H), 7.88 – 7.85 (m, 1H), 7.70 (d, J = 1.9 Hz, 1H), 7.65 – 7.63 (m, 1H), 7.57 – 7.56 (m, 2H), 7.22 – 7.13 (m, 1H), 7.13 (s, 1H), 6.65 – 6.61 (m, 1H), 6.43 – 6.36 (m, 2H), 5.32 – 5.29 (m, 1H), 3.46 (s, 3H), 2.47 (s, 3H), 2.39 (s, 3H), 1.55 (d, J = 6.5 Hz, 3H).
72	(ES+) 525.3 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.05 – 7.93 (m, 1H), 7.80 – 7.68 (m, 1H), 7.55 (d, J = 1.8 Hz, 1H), 7.44 – 7.26 (m, 1H), 6.88 – 6.74 (m, 1H), 6.70 – 6.55 (m, 1H), 6.25 (s, 1H), 5.21 – 5.00 (m, 1H), 3.97 – 3.90 (m, 1H), 3.86 – 3.80 (m, 1H), 3.79 – 3.72 (m, 2H), 3.71 (s, 3H), 3.32 – 3.20 (m, 2H), 3.11 (s, 3H), 2.95 – 2.81 (m, 2H), 2.40 (s, 3H), 2.13 – 1.83 (m, 4H), 1.67 (d, J = 6.8 Hz, 3H), 1.27 – 1.06 (m, 3H).
73	(ES+) 463.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.93 (d, J = 1.5 Hz, 1H), 8.72 (d, J = 1.4 Hz, 1H), 8.07 – 8.02 (m, 1H), 7.67 – 7.58 (m, 2H), 7.33 – 7.29 (m, 1H), 7.16 (s, 1H), 6.76 – 6.72 (m, 1H), 6.65 (d, J = 5.7 Hz, 1H), 6.48 (d, J = 8.4 Hz, 1H), 5.33 – 5.29 (m, 1H), 3.44 (s, 3H), 3.26 (s, 3H), 2.62 (s, 3H), 2.41 (s, 3H), 1.55 (d, J = 6.6 Hz, 3H).
74	(ES+) 462.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.61 – 8.56 (m, 1H), 8.06 – 8.01 (m, 1H), 7.86 – 7.79 (m, 1H), 7.69 (d, J = 7.9 Hz, 1H), 7.67 – 7.63 (m, 1H), 7.58 (d, J = 1.9 Hz, 1H), 7.33 – 7.29 (m, 1H), 6.98 (s, 1H), 6.79 – 6.70 (m, 1H), 6.63 (d, J = 5.6 Hz, 1H), 6.47 (d, J = 8.4 Hz, 1H), 5.29 – 5.24 (m, 1H), 3.40 (s, 3H), 3.24 (s, 3H), 2.41 (s, 6H), 1.55 (d, J = 6.6 Hz, 3H).

75	(ES+) 462.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.68 – 8.67 (m, 1H), 8.02 (s, 1H), 7.95 – 7.64 (m, 1H), 7.63 – 7.62 (m, 1H), 7.57 (d, J = 1.9 Hz, 1H), 7.42 (d, J = 8.0 Hz, 1H), 7.31 – 7.29 (m, 1H), 6.91 (s, 1H), 6.74 – 6.72 (m, 1H), 6.62 (d, J = 5.7 Hz, 1H), 6.48 (d, J = 8.3 Hz, 1H), 5.26 – 5.25 (m, 1H), 3.35 (s, 3H), 3.24 (s, 3H), 2.57 (s, 3H), 2.39 (s, 3H), 1.53 (d, J = 6.5 Hz, 3H).
76	(ES+) 462.1 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.58 – 8.55 (m, 1H), 8.17 – 8.12 (m, 1H), 7.73 – 7.70 (m, 1H), 7.66 (d, J = 1.9 Hz, 1H), 7.56 – 7.51 (m, 1H), 7.45 – 7.40 (m, 1H), 7.27 – 7.25 (m, 1H), 6.99 (s, 1H), 6.81 – 6.71 (m, 1H), 6.49 (d, J = 8.1 Hz, 1H), 5.21 – 5.20 (m, 1H), 3.48 (s, 3H), 3.16 (s, 3H), 2.66 (s, 3H), 2.46 (s, 3H), 1.65 (d, J = 6.7 Hz, 3H).
77	(ES+) 463.1 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.94 (s, 2H), 8.16 – 8.10 (m, 1H), 7.71 – 7.70 (m, 1H), 7.65 (d, J = 1.8 Hz, 1H), 7.25 – 7.20 (m, 1H), 7.07 (s, 1H), 6.74 – 6.70 (m, 1H), 6.48 – 6.45 (m, 1H), 5.24 – 5.22 (m, 1H), 3.49 (s, 3H), 3.17 (s, 3H), 2.81 (s, 3H), 2.44 (s, 3H), 1.64 (d, J = 6.7 Hz, 3H).
78	(ES+) 451.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.14 – 8.09 (m, 1H), 7.79 – 7.69 (m, 2H), 7.64 (d, J = 1.9 Hz, 1H), 7.31 – 7.21 (m, 1H), 7.12 (s, 1H), 6.80 – 6.70 (m, 1H), 6.65 – 6.60 (m, 1H), 6.50 – 6.55 (m, 1H), 5.25 – 5.16 (m, 1H), 4.02 (s, 3H), 3.64 (s, 3H), 3.17 (s, 3H), 2.44 (s, 3H), 1.68 (d, J = 6.8 Hz, 3H).
79	(ES+) 451.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.09 (s, 1H), 7.98 (s, 1H), 7.77 (s, 1H), 7.76 – 7.68 (m, 1H), 7.61 (d, J = 1.9 Hz, 1H), 7.30 – 7.21 (m, 1H), 6.99 (s, 1H), 6.80 – 6.70 (m, 1H), 6.48 (d, J = 8.4 Hz, 1H), 5.25 – 5.16 (m, 1H), 4.00 (s, 3H), 3.63 (s, 3H), 3.16 (s, 3H), 2.43 (s, 3H), 1.68 (d, J = 6.8 Hz, 3H).
80	(ES+) 573.3 [M+H]	^{1}H NMR (300 MHz, DMSO-d_6): δ 7.90 (s, 1H), 7.65 – 7.56 (m, 1H), 7.53 – 7.14 (m, 3H), 6.86 (d, J = 5.7 Hz, 1H), 6.79-6.74 (m, 1H), 6.52 (d, J = 8.6 Hz, 1H), 6.40 (s, 1H), 5.29-5.24 (m, 1H), 3.50 (s, 3H), 3.37–2.47 (m, 10H), 2.32 (s, 3H), 1.53 (d, J = 6.3 Hz, 3H).
81	(ES+) 499.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.88 (s, 1H), 7.65-7.63 (m, 1H), 7.47 (d, J = 2.0 Hz, 1H), 7.35-7.31 (m, 1H), 6.75-6.73 (m, 1H), 6.60 (d, J = 5.8 Hz, 1H), 6.49 (d, J = 8.4 Hz, 1H), 6.39 (s, 1H), 5.24-5.17 (m, 1H), 3.71 (q, J = 6.9 Hz, 2H), 3.50 (s, 3H), 3.38-3.12 (s, 7H), 3.01 – 2.62 (m, 4H), 2.33 (s, 3H), 1.54 (d, J = 6.5 Hz, 3H), 1.15-1.11 (m, 3H).
82	(ES+) 490.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.92 – 7.87 (m, 1H), 7.65-7.61 (m, 1H), 7.48 (d, J = 2.0 Hz, 1H), 7.35-7.31 (m, 1H), 6.78 – 6.70 (m, 1H), 6.60 (d, J = 5.8 Hz, 1H), 6.49 (d, J = 8.4 Hz, 1H), 6.44 (s, 1H), 5.27-5.19 (m, 1H), 3.53 (s, 3H), 3.23 (s, 3H), 3.20-2.97 (m, 4H), 2.33 (s, 3H), 2.30-2.16 (m, 4H), 1.54 (d, J = 6.6 Hz, 3H).
83	(ES+) 476.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.91–7.86 (m, 1H), 7.66-7.63 (m, 1H), 7.48 (d, J = 1.9 Hz, 1H), 7.35-7.31 (m, 1H), 6.76-6.72 (m, 1H), 6.61 (d, J = 5.8 Hz, 1H), 6.52 – 6.45 (m, 1H), 6.42 (s, 1H), 5.24-5.21 (m, 1H), 3.67 – 3.56 (m, 2H), 3.50 (s, 3H), 3.41-3.37 (m, 2H), 3.24 (s, 3H), 2.57 – 2.52 (m, 1H), 2.49-2.45 (m, 1H), 2.33 (s, 3H), 1.55 (d, J = 6.5 Hz, 3H).

84	(ES+) 444.3 [M+H]	^{1}H NMR (400 MHz, CD_3CN): δ 7.92 (s, 1H), 7.71-7.67 (m, 1H), 7.46 (s, 1H), 7.32 – 7.22 (m, 1H), 6.77-7.73 (m, 1H), 6.63 (d, J = 5.7 Hz, 1H), 6.47 (d, J = 8.4 Hz, 1H), 5.85 (d, J = 1.5 Hz, 1H), 5.46-5.29 (m, 1H), 5.26-5.01 (m, 1H), 4.31 – 4.16 (m, 2H), 4.06 – 3.91 (m, 2H), 3.45 (d, J = 1.6 Hz, 3H), 3.11 (d, J = 1.6 Hz, 3H), 2.32 (s, 3H), 1.61-1.59 (m, 3H).
94	(ES+) 562.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.12 (s, 1H), 7.42 (s, 1H), 7.26 - 7.16 (m, 2H), 6.55 (d, J = 8.8 Hz, 1H), 6.19 (s, 1H), 4.95 - 4.77 (m, 1H), 3.62 (s, 3H), 3.39 (s, 3H), 3.15 - 2.71 (m, 11H), 2.39 (s, 3H), 1.65 (d, J = 6.8 Hz, 3H).
95	(ES+) 565.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.10 (s, 1H), 7.71 (d, J = 5.6 Hz, 1H), 7.45 (d, J = 1.6 Hz, 1H), 6.88 (d, J = 8.8 Hz, 1H), 6.53 (d, J = 8.8 Hz, 1H), 6.24 (s, 1H), 4.85 - 4.81 (m, 1H), 3.62 (s, 3H), 3.34 (s, 3H), 3.20 - 2.88 (m, 8H), 2.87 (s, 3H), 2.86 - 2.58 (m, 2H), 2.38 (d, J = 2.4 Hz, 6H), 1.62 (d, J = 6.8Hz, 3H).
96	(ES+) 565.6 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.10 (s, 1H), 7.65 (d, J = 5.6 Hz, 1H), 7.47 (d, J = 1.6 Hz, 1H), 6.89 (d, J = 8.8 Hz, 1H), 6.52 (d, J = 8.8 Hz, 1H), 6.24 (s, 1H), 4.83 - 4.81 (m, 1H), 3.63 (s, 3H), 3.34 (s, 3H), 3.19 - 2.90 (m, 8H), 2.86 (s, 3H), 2.86 - 2.68 (m, 2H), 2.38 (d, J = 13.6 Hz, 6H), 1.61 (d, J = 6.8 Hz, 3H).
97	(ES+) 580.4 [M+H]	
98	(ES+) 580.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.89 (s, 1H), 7.65 – 7.63 (m, 1H), 7.49 – 7.47 (m, 2H), 7.28 – 7.26 (m, 1H), 6.76 – 6.68 (m, 1H), 6.46 – 6.39 (m, 2H), 5.19 – 5.08 (m, 1H), 4.59 (s, 1H), 3.55 - 3.40 (s, 5H), 3.39 – 3.23 (m, 2H), 3.15 (s, 3H), 3.02 – 2.51 (m, 10H), 2.31 (s, 3H), 1.52 (d, J = 6.4 Hz, 3H).
99	(ES+) 621.4 [M+H]	
100	(ES+) 621.4 [M+H]	
101	(ES+) 463.2 [M+H]	
102	(ES+) 463.2 [M+H]	
103	(ES+) 463.2 [M+H]	
104	(ES+) 463.1 [M+H]	
105	(ES+) 463.3 [M+H]	

106	(ES+) 463.1 [M+H]	
107	(ES+) 516.3 [M+H]	
108	(ES+) 452.2 [M+H]	
109	(ES+) 451.1 [M+H]	
110	(ES+) 462.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.85 (s, 1H), 7.65 – 7.64 (m, 1H), 7.46 – 7.43 (m, 1H), 7.34 – 7.32 (m, 1H), 6.78 – 6.70 (m, 1H), 6.62 (d, J = 5.7 Hz, 1H), 6.45 (d, J = 8.4 Hz, 1H), 6.07 (s, 1H), 5.27 – 5.19 (m, 1H), 4.58 – 4.39 (m, 4H), 3.43 – 3.40 (m, 3H), 3.39 – 3.24 (m, 3H), 2.31 (s, 3H), 1.53 (d, 3H).
111	(ES+) 491.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.03 (s, 2H), 8.02 (d, J = 1.6 Hz, 1H), 7.66 – 7.62 (m, 1H), 7.58 (d, J = 2.0 Hz, 1H), 7.34 – 7.26 (m, 1H), 7.07 (s, 1H), 6.78 – 6.69 (m, 1H), 6.64 (d, J = 5.8 Hz, 1H), 6.47 (d, J = 8.3 Hz, 1H), 5.32 – 5.29 (m, 1H), 3.39 (s, 3H), 3.29 – 3.18 (m, 4H), 2.39 (s, 3H), 1.53 (d, J = 6.6 Hz, 3H), 1.35 (d, J = 6.9 Hz, 6H).
112	(ES+) 585.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.12 (s, 1H), 7.93 (d, J = 4.8 Hz, 1H), 7.41 (d, J = 1.2 Hz, 1H), 7.03 - 6.97 (m, 1H), 6.57 (d, J = 8.8 Hz, 1H), 6.21 (s, 1H), 4.85 - 4.78 (m, 1H), 3.63 (s, 3H), 3.35 (s, 3H), 3.16 - 2.72 (m, 13H), 2.39 (s, 3H), 1.63 (d, J = 6.8 Hz, 3H).
113	(ES+) 585.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.12 (s, 1H), 7.87 (d, J = 4.4 Hz, 1H), 7.41 (d, J = 1.6 Hz, 1H), 7.01 (d, J = 8.8 Hz, 1H), 6.56 (d, J = 8.8 Hz, 1H), 6.19 (s, 1H), 4.93 - 4.72 (m, 1H), 3.63 (s, 3H), 3.35 (s, 3H), 3.17 - 2.74 (m, 13H), 2.36 (s, 3H), 1.63 (d, J = 6.8 Hz, 3H).
114	(ES+) 554.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.47 - 8.37 (m, 1H), 8.12 (s, 1H), 7.44 (d, J = 1.6 Hz, 1H), 7.07 - 7.04 (m, 1H), 6.35 - 6.30 (m, 1H), 6.25 (s, 1H), 6.05 (d, J = 8.8 Hz, 1H), 4.93 - 4.75 (m, 1H), 3.64 (s, 3H), 3.42 (s, 3H), 3.16 - 2.77 (m, 10H), 2.42 (s, 3H), 1.61 (d, J = 6.8 Hz, 3H).
115	(ES+) 554.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.39 (d, J = 5.2 Hz, 1H), 8.12 (s, 1H), 7.46 (d, J = 1.6 Hz, 1H), 7.07 - 7.05 (m, 1H), 6.42 - 6.28 (m, 1H), 6.25 (s, 1H), 6.03 (d, J = 8.8 Hz, 1H), 4.89 - 4.79 (m, 1H), 3.64 (s, 3H), 3.41 (s, 3H), 3.19 - 2.74 (m, 10H), 2.42 (s, 3H), 1.61 (d, J = 6.8 Hz, 3H).
116	(ES+) 535.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.90 (s, 1H), 7.65 – 7.62 (m, 1H), 7.49 (d, J = 1.9 Hz, 1H), 7.39 – 7.30 (m, 2H), 7.21 (d, J = 0.9 Hz, 1H), 6.79 – 6.71 (m, 1H), 6.60 (d, J = 5.7 Hz, 1H), 6.52 (d, J = 8.3 Hz, 1H), 6.39 (s, 1H), 5.26 – 5.18 (m, 1H), 3.75 (s, 3H), 3.53 (s, 3H), 3.23 (s, 3H), 3.06 (s, 8H), 2.34 (s, 3H), 1.56 (d, J = 6.6 Hz, 3H).

117	(ES+) 594.2 [M+H]	
118	(ES+) 594.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.02 (d, J = 1.7 Hz, 1H), 7.78 – 7.70 (m, 1H), 7.57 (d, J = 1.8 Hz, 1H), 7.38 – 7.28 (m, 1H), 6.82 – 6.73 (m, 1H), 6.58 – 6.52 (m, 1H), 6.41 (s, 1H), 5.21 – 5.12 (m, 1H), 3.65 (s, 3H), 3.61 – 3.51 (m, 2H), 3.25 – 2.75 (m, 15H), 2.41 (s, 3H), 1.74 – 1.55 (m, 5H).
119	(ES+) 564.4 [M+H]	^{1}H-NMR (400 MHz, DMSO -d4): δ 7.92 – 7.86 (m, 1H), 7.63 – 7.61 (m, 1H), 7.51 (d, J = 6.9 Hz, 1H), 7.42 (d, J = 1.9 Hz, 1H), 7.30 – 7.27 (m, 1H), 6.75 – 6.67 (m, 1H), 6.51 (d, J = 8.2 Hz, 1H), 6.34 (s, 1H), 5.21 – 5.20 (m, 1H), 3.50 (s, 3H), 3.28 – 3.25 (m, 2H), 3.13 (s, 3H), 3.01 – 2.77 (m, 10H), 2.32 (s, 3H), 1.53 (d, J = 6.5 Hz, 3H), 1.05 – 1.01 (m, 3H).
120	(ES+) 564.4 [M+H]	
121	(ES+) 576.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.90 (d, J = 1.9 Hz, 1H), 7.71 – 7.64 (m, 1H), 7.51 (d, J = 6.9 Hz, 1H), 7.47 (d, J = 1.9 Hz, 1H), 7.35 – 7.25 (m, 1H), 6.77 – 6.67 (m, 1H), 6.46 – 6.40 (m, 2H), 5.27 – 5.17 (m, 1H), 3.50 (s, 3H), 3.31 – 3.22 (m, 2H), 3.16 (s, 3H), 3.12 – 2.65 (m, 8H), 2.45 – 2.38 (m, 1H), 2.32 (s, 3H), 1.52 (d, J = 6.5 Hz, 3H), 0.57 – 0.25 (m, 4H).
122	(ES+) 576.3 [M+H]	
123	(ES+) 526.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.59 (s, 1H), 8.14 (s, 1H), 7.96 – 7.88 (m, 1H), 7.76 – 7.68 (m, 1H), 7.65 (d, J = 1.6 Hz, 1H), 7.30 – 7.20 (m, 1H), 7.05 (s, 1H), 6.80 – 6.70 (m, 1H), 6.47 (d, J = 8.0, 1H), 5.26 – 5.18 (m, 1H), 3.50 (s, 3H), 3.17 (s, 3H), 2.45 (s, 3H), 1.87 (s, 3H), 1.81 (s, 3H), 1.64 (d, J = 6.8 Hz, 3H).
124	(ES+) 530.1 [M+H]	
125	(ES+) 475.2 [M+H]	
126	(ES+) 584.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.27 (d, J = 1.2 Hz, 2H), 8.90-8.35 (m, 2H), 8.05 (s, 1H), 7.62 – 7.54 (m, 2H), 7.34 – 7.25 (m, 1H), 7.10 (s, 1H), 6.78 – 6.68 (m, 2H), 6.47 (d, J = 8.5 Hz, 1H), 5.45-5.08 m, 1H), 3.45 (s, 3H), 3.09 – 3.02 (m, 1H), 2.74 (s, 3H), 2.41 (s, 3H), 1.55 (d, J = 6.5 Hz, 3H), 1.23 – 1.02 (m, 4H).
127	(ES+) 551.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.10 (s, 1H), 7.45 (d, J = 1.6 Hz, 1H), 6.92 (d, J = 8.8 Hz, 1H), 6.56 (d, J = 8.8 Hz, 1H), 6.25 (s, 1H), 4.84 - 4.43 (m, 1H), 3.63 (s, 3H), 3.43 (s, 3H), 3.17 - 2.79 (m, 10H), 2.39 (d, J = 3.6 Hz, 6H), 1.63 (d, J = 6.8 Hz, 3H).

128	(ES+) 551.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.09 (s, 1H), 7.45 (s, 1H), 6.92 (d, J = 8.8 Hz, 1H), 6.54 (d, J = 8.8 Hz, 1H), 6.21 (s, 1H), 4.85- 4.80 (m, 1H), 3.61 (s, 3H), 3.40 (br s, 3H), 3.14 - 2.72 (m, 10H), 2.38 (d, J = 6.0 Hz, 6H), 1.61 (d, J = 6.8 Hz, 3H).
129	(ES+) 551.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.07 (s, 1H), 7.63 - 7.51 (m, 1H), 7.42 (d, J = 2.4 Hz, 1H), 6.87 (d, J = 8.8 Hz, 1H), 6.50 - 6.49 (m, 1H), 6.19 (d, J = 5.2 Hz, 1H), 4.80 - 4.78 (m, 1H), 3.59 (s, 3H), 3.33 (d, J = 6.0 Hz, 3H), 3.06 (q, J = 9.6 Hz, 10H), 2.37 - 2.33 (m, 6H), 1.58 (d, J = 6.8 Hz, 3H).
130	(ES+) 607.3 [M+H]	
131	(ES+) 607.3 [M+H]	
132	(ES+) 581.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.15 – 8.10 (m, 1H), 7.72 – 7.65 (m, 1H), 7.47 (d, J = 1.9 Hz, 1H), 7.27 – 7.23 (m, 1H), 6.78 – 6.70 (m, 2H), 6.36 (d, J = 8.3 Hz, 1H), 6.22 (s, 1H), 5.21 – 4.89 (m, 2H), 3.64 (s, 3H), 3.20 – 2.70 (m, 10H), 2.39 (s, 3H), 1.77 – 1.57 (m, 6H).
133	(ES+) 581.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.15 – 8.10 (m, 1H), 7.72 – 7.65 (m, 1H), 7.47 (d, J = 1.9 Hz, 1H), 7.27 – 7.23 (m, 1H), 6.78 – 6.70 (m, 2H), 6.36 (d, J = 8.3 Hz, 1H), 6.22 (s, 1H), 5.21 – 4.89 (m, 2H), 3.64 (s, 3H), 3.20 – 2.70 (m, 10H), 2.39 (s, 3H), 1.77 – 1.57 (m, 6H).
134	(ES+) 452.2 [M+H]	
135	(ES+) 452.2 [M+H]	
136	(ES+) 573.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.38 (s, 2H), 8.14 (d, J = 1.9 Hz, 1H), 7.69 – 7.68 (m, 1H), 7.49 (d, J = 1.9 Hz, 1H), 7.24 – 7.20 (m, 1H), 6.87 (d, J = 5.2 Hz, 1H), 6.77 – 6.68 (m, 1H), 6.37 (d, J = 8.4 Hz, 1H), 6.28 (s, 1H), 4.96 – 4.90 (m, 1H), 3.68 – 3.60 (m, 5H), 3.23 – 3.20 (m, 6H), 2.72 – 2.65 (m, 4H), 2.41 (s, 3H), 1.67 – 1.60 (m, 3H), 1.39 –1.30 (m, 2H), 1.12 – 1.00 (m, 2H).
137	(ES+) 561.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.38 (s, 1H), 7.92 (s, 1H), 7.65 (d, J = 8.0 1H), 7.50 (s, 1H), 7.38 – 7.30 (m, 1H), 6.79 – 6.71 (m, 1H), 6.62 (d, J = 5.2 Hz, 1H), 6.53 (d, J = 8.4 Hz, 1H), 6.47 (s, 1H), 5.30 – 5.19 (m, 1H), 3.57 (s, 3H), 3.25 (s, 3H), 3.24 – 2.91 (m, 8H), 2.53 (s, 3H), 2.46 (s, 3H), 2.35 (s, 3H), 1.58 (d, J = 6.4 Hz, 3H).
138	(ES+) 573.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.44 (s, 2H), 7.92 (s, 1H), 7.64 – 7.62 (m, 1H), 7.49 (d, J = 1.6 Hz, 1H), 7.35 – 7.32 (m, 1H), 6.79 – 6.70 (m, 1H), 6.61 (d, J = 6.0 Hz, 1H), 6.52 (d, J = 8.4 Hz, 1H), 6.43 (s, 1H), 5.25 – 5.21 (m, 1H), 3.98 – 3.56 (m, 5H), 3.32 – 3.24 (m, 6H), 3.23 (s, 3H), 2.34 (s, 3H), 2.15 – 2.09 (m, 1H), 1.57 (d, J = 6.4 Hz, 3H), 0.95 – 0.94 (m, 2H), 0.98 – 0.89 (m, 2H).

139	(ES+) 583.3 [M+H]	^{1}H-NMR (400 MHz, DMSO –d6): δ 8.68 (s, 2H), 7.94 – 7.89 (m, 1H), 7.64 – 7.61 (m, 1H), 7.49 (d, J = 1.9 Hz, 1H), 7.35 – 7.30 (m, 1H), 6.86 (s, 1H), 6.78 – 6.69 (m, 1H), 6.61 (d, J = 5.8 Hz, 1H), 6.50 (d, J = 8.3 Hz, 1H), 6.44 (s, 1H), 5.24 – 5.21 (m, 1H), 4.30 – 3.70 (m, 2H), 3.57 (s, 3H), 3.32 – 3.23 (m, 9H), 2.34 (s, 3H), 1.56 (d, J = 6.5 Hz, 3H).
140	(ES+) 547.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.14 (d, J = 1.6 Hz, 1H), 8.04 (s, 1H), 7.81 – 7.78 (m, 1H), 7.60 – 7.50 (m, 1H), 7.45 (d, J = 1.8 Hz, 1H), 7.29 – 7.21 (m, 1H), 6.77 – 6.74 (m, 1H), 6.71 (d, J = 5.3 Hz, 1H), 6.37 (d, J = 8.4 Hz, 1H), 6.23 (s, 1H), 5.29 – 5.20 (m, 1H), 4.70 – 3.80 (m, 2H), 3.70 (s, 3H), 3.13 – 2.73 (m, 9H), 2.47 (s, 3H), 2.40 (s, 3H), 1.66 (d, J = 6.7 Hz, 3H).
141	(ES+) 547.3 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.03 (s, 1H), 7.73 - 7.70 (m, 1H), 7.57 s, 1H), 7.40 – 7.24 (m, 3H), 6.79 – 6.66 (m, 1H), 6.55 – 6.49 (m, 2H), 5.25 – 5.15 (m, 1H), 4.55 - 4.26 (m, 2H), 3.72 (s, 3H), 3.53 - 3.42 (m 1H), 3.29 - 3.15 (m, 2H), 3.14 (s, 3H), 3.05 – 2.80 (m, 2H) , 2.53 (s, 3H), 2.40 (s, 3H), 1.66 (d, J = 6.4 Hz, 3H).
142	(ES+) 547.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.28 (s, 2H), 7.91 (d, J = 1.9 Hz, 1H), 7.65 – 7.60 (m, 1H), 7.48 (d, J = 1.9 Hz, 1H), 7.32 – 7.10 (m, 1H), 6.73 – 6.60 (m, 1H), 6.59 (d, J = 5.8 Hz, 1H), 6.50 (d, J = 8.5 Hz, 1H), 6.39 (s, 1H), 5.21 – 5.19 (m, 1H), 4.61 (s, 2H), 3.58 (s, 3H), 3.22 (s, 9H), 2.34 (s, 3H), 2.11 (s, 3H), 1.55 (d, J = 6.6 Hz, 3H).
143	(ES-) 529.2 [M-H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.47 (s, 2H), 8.03 – 7.98 (m, 1H), 7.55 (d, J = 1.9 Hz, 1H), 7.35 – 7.28 (m, 1H), 7.21 – 7.16 (m, 1H), 6.75 – 6.68 (m, 1H), 6.54 (s, 1H), 6.53 – 6.47 (m, 1H), 5.25 – 5.17 (m, 1H), 3.89 – 3.80 (m, 2H), 3.70 (s, 3H), 3.40 – 3.29 (m, 6H), 3.03 (s, 3H), 2.61 (s, 3H), 2.39 (s, 3H), 1.66 (d, J = 6.7 Hz, 3H).
144	(ES-) 529.2 [M-H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.47 (s, 2H), 8.03 – 7.98 (m, 1H), 7.69 (d, J = 1.9 Hz, 1H), 7.40 – 7.30 (m, 1H), 7.25 – 7.15 (m, 1H), 6.79 – 6.68 (m, 1H), 6.56 (s, 1H), 6.53 – 6.47 (m, 1H), 5.27 – 5.19 (m, 1H), 3.89 – 3.80 (m, 2H), 3.70 (s, 3H), 3.41 – 3.31 (m, 6H), 3.03 (s, 3H), 2.61 (s, 3H), 2.39 (s, 3H), 1.66 (d, J = 6.7 Hz, 3H).
145	(ES+) 535.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.90 (s, 1H), 7.65-7.62 (m, 1H), 7.49-7.46 (m, 2H), 7.39 – 7.30 (m, 1H), 6.76-6.73 (m, 1H), 6.59 (d, J = 5.8 Hz, 1H), 6.53 (d, J = 8.4 Hz, 1H), 6.37 (s, 1H), 5.74 (d, J = 2.3 Hz, 1H), 5.23-5.20 (m, 1H), 3.67 (s, 3H), 3.53 (s, 3H), 3.34 (s, 2H), 3.31 (s, 1H), 3.22 (s, 3H), 3.04 (s, 5H), 2.34 (s, 3H), 1.56 (d, J = 6.4 Hz, 3H).
146	(ES+) 511.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.36 (s, 1H), 7.89 (s, 1H), 7.65 –7.63 (m, 1H), 7.48 (d, J = 1.9 Hz, 1H), 7.38 – 7.30 (m, 1H), 6.76 – 6.74 (m, 1H), 6.60 (d, 1H), 6.51 (d, 1H), 6.37 (s, 1H), 5.21 – 5.18 (m, 1H), 4.59 – 4.57 (m, 2H), 4.47 – 4.45 (m, 2H), 3.62 – 3.55 (m, 7H), 3.36 – 3.23 (m, 3H), 3.04 - 3.01 (m, 4H), 2.33 (s, 3H), 1.56 (d, J = 6.5 Hz, 3H).

147	(ES+) 561.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.37 (s, 2H), 8.11 (s, 1H), 7.78 (d, J = 4.4 Hz, 1H), 7.54 (d, J = 1.2 Hz, 1H), 7.33 - 7.28 (m, 1H), 7.14 - 7.12 (m, 1H), 6.64 - 6.61 (m, 1H), 6.34 (s, 1H), 6.26 - 6.22 (m, 1H), 5.04 - 4.75 (m, 1H), 3.71 (d, J = 11.2 Hz, 3H), 3.67 (s, 3H), 3.67 - 2.82 (m, 8H), 2.68 (s, 3H), 2.40 (s, 3H), 1.73 (d, J = 14.8 Hz, 3H), 1.62 (d, J = 6.8 Hz, 3H).
148	(ES+) 561.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.37 (s, 2H), 8.10 (s, 1H), 7.86 (d, J = 5.6 Hz, 1H), 7.54 (d, J = 1.6 Hz, 1H), 7.30 - 7.27 (m, 1H), 7.13 - 7.10 (m, 1H), 6.63 - 6.60 (m, 1H), 6.33 (s, 1H), 6.23 - 6.21 (m, 1H), 5.14 - 4.63 (m, 1H), 3.71 (d, J = 11.6 Hz, 3H), 3.67 (s, 3H), 3.67 - 2.73 (m, 8H), 2.68 (s, 3H), 2.37 (s, 3H), 1.74 (d, J = 14.8 Hz, 3H), 1.62 (d, J = 6.8 Hz, 3H).
149	(ES+) 452.2 [M+H]	
150	(ES-) 534.2 [M-H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.03 (d, J = 1.7 Hz, 1H), 7.83 – 7.69 (m, 1H), 7.58 (d, J = 1.9 Hz, 1H), 7.33 – 7.14 (m, 1H), 6.81 – 6.68 (m, 2H), 6.57 – 6.50 (m, 2H), 5.21 (s, 1H), 5.20 – 5.07 (m, 1H), 3.80 – 3.71 (m, 2H), 3.70 (s, 3H), 3.15 (s, 3H), 3.08 - 2.90 (m, 2 H), 2.41 (s, 3H), 2.19 (s, 3H), 1.67 (d, J = 6.6 Hz, 3H).
151	(ES+) 536.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.91 (s, 1H), 7.65 – 7.62 (m, 1H), 7.49 (d, J = 1.2 Hz, 1H), 7.34 – 7.31 (m, 1H), 6.79 – 6.70 (m, 1H), 6.60 (d, J = 5.6 Hz, 1H), 6.51 (d, J = 8.4 Hz, 1H), 6.40 (s, 1H), 6.13 (s, 1H), 5.24 - 5.20 (m, 1H), 3.55 (s, 3H), 3.32 – 3.23 (m, 7H), 3.21 - 2.89 (m, 4H), 2.34 (s, 3H), 2.29 (s, 3H), 1.56 (d, J = 6.4 Hz, 3H).
152	(ES+) 562.5 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.13 (s, 1H), 7.85 (d, J = 7.8 Hz, 1H), 7.52 – 7.18 (m, 3H), 6.78 – 6.69 (m, 1H), 6.29 (d, J = 8.4 Hz, 1H), 6.24 (s, 1H), 4.95 – 4.86 (m, 1H), 4.13 – 4.03 (m, 1H), 3.84 – 3.80 (m, 1H), 3.64 (s, 3H), 3.46 – 3.39 (m, 2H), 3.10 – 2.75 (m, 10H), 2.55 – 2.50 (m, 1H), 2.40 (s, 3H), 2.35 – 2.30 (m, 1H), 1.60 (d, J = 6.6 Hz, 3H).
153	(ES+) 562.5 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.13 (s, 1H), 7.89 (d, J = 7.8 Hz, 1H), 7.52 – 7.18 (m, 3H), 6.78 – 6.69 (m, 1H), 6.36 (d, J = 8.4 Hz, 1H), 6.21 (s, 1H), 4.95 – 4.86 (m, 1H), 4.13 – 4.03 (m, 1H), 3.84 – 3.80 (m, 1H), 3.49 (s, 3H), 3.14 – 3.09 (m, 2H), 3.02 – 2.59 (m, 10H), 2.55 – 2.50 (m, 1H), 2.40 (s, 3H), 2.35 – 2.30 (m, 1H), 1.64 (d, J = 4.0 Hz, 3H).
154	(ES+) 562.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.40 (s, 2H), 8.14 (s, 1H), 7.50 (s, 1H), 6.95 (d, J = 8.7 Hz, 2H), 6.61 (d, J = 8.7 Hz, 1H), 6.33 (s, 1H), 4.85 (s, 1H), 3.82 – 3.50 (m, 5H), 3.45 – 3.25 (m, 5H), 3.20 – 3.95 (m, 4H), 2.71 (s, 3H), 2.51 – 2.38 (m, 6H), 1.67 (d, J = 6.7 Hz, 3H).
155	(ES+) 569.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.90 (s, 1H), 7.64 (d, J = 7.9 Hz, 1H), 7.48 (s, 1H), 7.36 – 7.32 (m, 1H), 6.76 – 6.73 (m, 1H), 6.60 (d, J = 5.7 Hz, 1H), 6.51 (d, J = 8.5 Hz, 1H), 6.35 (s, 1H), 5.21 – 5.18 (m, 1H), 3.95 – 3.91 (m, 2H), 3.78 – 3.75 (m, 2H), 3.51 (s, 3H), 3.24 (s, 3H), 3.18 - 2.95 (m, 8H), 2.58 – 2.55 (m, 1H), 2.34 (s, 3H), 1.55 (d, J = 6.4 Hz, 3H), 1.34 (s, 3H), 1.33 (s, 3H).

156	(ES+) 558.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.27 (d, J = 1.2 Hz, 2H), 8.90 – 8.35 (m, 2H), 8.05 (s, 1H), 7.64 – 7.60 (m, 1H), 7.60 (d, J = 1.9 Hz, 1H), 7.36 – 7.27 (m, 1H), 7.10 (s, 1H), 6.79 – 6.70 (m, 1H), 6.65 (d, J = 5.6 Hz, 1H), 6.49 (d, J = 8.5 Hz, 1H), 5.42 – 5.19 (m, 1H), 3.52 – 3.41 (m, 3H), 3.45 (s, 3H), 2.74 (s, 3H), 2.41 (s, 3H), 1.55 (d, J = 6.5 Hz, 3H).
157	(ES+) 536.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.91 (s, 1H), 7.73 – 7.60 (m, 1H), 7.49 (d, J = 2.0 Hz, 1H), 7.38-7.30 (m, 1H), 6.79 – 6.70 (m, 1H), 6.60 (d, J = 5.7 Hz, 1H), 6.51 (d, J = 8.4 Hz, 1H), 6.40 (s, 1H), 6.09 (s, 1H), 5.25-5.18 (m, 1H), 3.53 (s, 3H), 3.23 (s, 11H), 2.32 (d, J = 17.1 Hz, 6H), 1.56 (d, J = 6.5 Hz, 3H).
158	(ES+) 536.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.90 (s, 1H), 7.64-7.62 (m, 1H), 7.48 (d, J = 1.9 Hz, 1H), 7.35-7.31 (m, 1H), 6.76-6.72 (m, 1H), 6.60 (d, J = 5.8 Hz, 1H), 6.53 – 6.46 (m, 2H), 6.39 (s, 1H), 5.23-5.20 m, 1H), 3.83 (s, 2H), 3.54 (s, 3H), 3.23 (s, 3H), 3.22-2.88 (m, 6H), 2.34 (s, 3H), 2.19 (d, J = 1.4 Hz, 3H), 1.55 (d, J = 6.5 Hz, 3H).
159	(ES+) 560.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.47 (s, 2H), 7.91 (s, 1H), 7.62 – 7.59 (m, 1H), 7.46 – 7.39 (m, 2H), 7.32 – 7.28 (m, 1H), 6.73 – 6.69 (m, 1H), 6.50 – 6.46 (m, 1H), 6.40 (s, 1H), 5.23 – 5.19 (m, 1H), 3.93 – 3.65 (m, 2H), 3.55 (s, 3H), 3.45 – 3.36 (m, 2H), 3.31 – 3.19 (m, 2H), 3.14 (s, 3H), 3.12 – 2.91 (m, 2H), 2.57 (s, 3H), 2.52 (s, 3H), 2.33 (s, 3H), 1.55 – 1.53 (m, 3H).
160	(ES+) 560.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.47 (s, 2H), 7.91 (s, 1H), 7.63 – 7.60 (m, 1H), 7.54 – 7.50 (m, 1H), 7.43 – 7.40 (m, 1H), 7.33 – 7.28 (m, 1H), 6.75 – 6.71 (m, 1H), 6.47 – 6.43 (m, 2H), 5.18 – 5.14 (m, 1H), 3.79 – 3.60 (m, 2H), 3.56 (s, 3H), 3.41 – 3.34 (m, 2H), 3.29 – 3.20 (m, 2H), 3.16 (s, 3H), 3.14 – 3.08 (m, 2H), 2.57 (s, 3H), 2.51 (s, 3H), 2.35 (s, 3H), 1.53 – 1.51 (m, 3H).
161	(ES+) 541.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.89 (d, J = 1.9 Hz, 1H), 7.65 – 7.63 (m, 1H), 7.48 (d, J = 1.9 Hz, 1H), 7.35 – 7.33 (m, 1H), 6.79 – 6.70 (m, 1H), 6.59 (d, J = 5.8 Hz, 1H), 6.51 (d, J = 8.5 Hz, 1H), 6.34 (s, 1H), 5.20 – 5.18 (m, 1H), 4.97 – 4.94 (m, 1H), 3.94 – 3.87 (m, 2H), 3.87 – 3.75 (m, 2H), 3.49 (s, 3H), 3.32 (s, 3H), 3.23 – 2.73 (m, 6H), 2.67 – 2.59 (m, 4H), 2.33 (s, 3H), 1.55 (d, J = 6.5 Hz, 3H).
162	(ES+) 562.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.13 (s, 1H), 7.77 - 7.76 (m, 1H), 7.44 (d, J = 1.6 Hz, 1H), 7.26 - 7.21 (m, 1H), 7.16 (d, J = 7.6 Hz, 1H), 6.79 - 6.67 (m, 2H), 6.36 (d, J = 8.4 Hz, 1H), 6.21 (s, 1H), 6.02 - 5.95 (m, 1H), 5.92 - 5.88 (m, 1H), 5.02 - 4.87 (m, 1H), 3.90 - 3.57 (m, 5H), 3.49 (s, 3H), 3.33 - 3.06 (m, 7H), 3.04 - 2.80 (m, 2H), 2.40 (s, 3H), 1.65 (d, J = 6.8 Hz, 3H).
163	(ES+) 562.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.13 (s, 1H), 7.78 - 7.76 (m, 1H), 7.45 (d, J = 1.6 Hz, 1H), 7.32 - 7.30 (m, 1H), 7.27 - 7.22 (m, 1H), 6.83 (s, 1H), 6.79 - 6.68 (m, 2H), 6.62 (d, J = 9.6 Hz, 1H), 6.38 (d, J = 8.4 Hz, 1H), 6.25 (s, 1H), 5.01 - 4.90 (m, 1H), 3.65 (s, 3H), 3.56 (s, 3H), 3.35 - 2.86 (m, 11H), 2.40 (s, 3H), 1.67 (d, J = 6.8 Hz, 3H).

164	(ES+) 546.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.39 (s, 2H), 8.13 (s, 1H), 7.87 – 7.83 (m, 1H), 7.55 - 7.38 (m, 2H), 7.25 - 7.16 (m, 1H), 6.79 - 6.70 (m, 1H), 6.38 - 3.33 (m, 1H), 6.26 (d, J = 9.2 Hz, 1H), 5.05 – 4.85 (m, 1H), 3.78 - 3.57 (m, 5H), 3.39 - 3.25 (m, 2H), 3.23 - 2.99 (m, 7H), 2.70 (s, 3H), 2.40 (d, J = 2.0 Hz, 3H), 1.67 – 1.64 (m, 3H).
165	(ES+) 541.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.12 (s, 1H), 7.78 - 7.76 (m, 1H), 7.43 (d, J = 1.6 Hz, 1H), 7.26 - 7.21 (m, 1H), 6.78 - 6.72 (m, 1H), 6.70 (d, J = 5.6 Hz, 1H), 6.34 (d, J = 8.4 Hz, 1H), 6.18 (s, 1H), 5.03 - 4.87 (m, 2H), 4.47 - 3.91 (m, 2H), 3.65 (s, 3H), 3.24 - 2.93 (m, 7H), 2.91 - 2.66 (m, 2H), 2.39 (s, 3H), 1.64 (d, J = 6.8 Hz, 3H), 1.29 (d, J = 6.4 Hz, 6H).
166	(ES+) 566.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.22 (s, 1H), 7.83 - 7.74 (m, 3H), 7.59 - 7.48 (m, 3H), 7.26 - 7.17 (m, 1H), 6.79 - 6.70 (m, 2H), 6.64 (s, 1H), 6.33 (d, J = 8.4 Hz, 1H), 5.08 - 4.90 (m, 1H), 4.62 - 4.55 (m, 4H), 3.46 (s, 3H), 3.12 (s, 3H), 2.44 (s, 3H), 1.64 (d, J = 6.8 Hz, 3H).
167	(ES+) 580.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.39 (s, 2H), 8.20 (s, 1H), 7.68 (s, 1H), 6.96 (d, J = 8.6 Hz, 2H), 6.67 (d, J = 8.7 Hz, 1H), 5.28 (s, 1H), 3.62 – 3.68 (m, 7H), 3.36 (s, 3H), 3.29 – 3.25 (m, 2H), 3.16 – 3.13 (m, 2H), 2.70 (s, 3H), 2.42 – 2.40 (m, 6H), 1.62 – 1.60 (m, 3H).
168	(ES+) 600.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.88 (d, J = 1.8 Hz, 1H), 7.66 – 7.64 (m, 1H), 7.46 – 7.40 (m, 2H), 7.32 – 7.28 (m, 1H), 6.77 – 6.69 (m, 1H), 6.46 (d, J = 8.4 Hz, 1H), 6.38 (s, 1H), 6.06 – 6.04 (m, 1H), 5.23 – 5.20 (m, 1H), 3.50 – 3.44 (m, 5H), 3.49 – 3.38 (m, 2H), 3.42 – 2.83 (m, 11H), 2.31 (s, 3H), 1.52 (d, J = 6.5 Hz, 3H).
169	(ES+) 600.4 [M+H]	
170	(ES+) 573.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.36 (s, 2H), 7.89 (s, 1H), 7.69 – 7.59 (m, 1H), 7.48 (s, 1H), 7.39 – 7.33 (m, 1H), 6.80 – 6.73 (m, 1H), 6.60 – 6.53 (m, 2H), 6.19 (s, 1H), 5.27 – 5.20 (m, 1H), 4.12 – 4.06 (m, 2H), 3.70 – 3.63 (m, 2H), 3.62 (s, 3H), 3.15 (s, 3H), 3.13 – 3.09 (m, 2H), 2.52 (s, 3H), 2.34 (s, 3H), 2.10 – 1.82 (m, 4H), 1.57 (d, J = 6.4 Hz, 3H).
171	(ES+) 559.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.13 (s, 2H), 7.80 – 7.75 (m, 1H), 7.66 – 7.63 (m, 1H), 7.38 (d, J = 1.9 Hz, 1H), 7.19 – 7.10 (m, 1H), 6.74 – 6.71 (m, 1H), 6.61 (d, J = 5.6 Hz, 1H), 6.34 (d, J = 8.4 Hz, 1H), 6.14 (s, 1H), 5.19 – 5.15 (m, 1H), 4.64 – 4.55 (m, 2H), 3.88 – 3.85 (m, 2H), 3.53 – 3.44 (m, 5H), 3.48 (s, 3H), 2.95-2.92 (m, 1H), 2.45 (s, 3H), 2.26 (s, 3H), 1.80 – 1.77 (m, 1H), 1.48 (d, J = 6.4 Hz, 3H).
172	(ES+) 559.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.14 (s, 1H), 8.09 (s, 1H), 7.82 – 7.76 (m, 1H), 7.42 (d, J = 1.8 Hz, 1H), 7.26 – 7.23 (m, 1H), 6.81 – 6.73 (m, 1H), 6.66 (d, J = 5.4 Hz, 1H), 6.36 (d, J = 8.4 Hz, 1H), 6.04 (s, 1H), 4.82 – 4.75 (m, 1H), 4.52 (s, 1H), 4.25 (s, 1H), 3.63 – 3.55 (m, 4H), 3.48 – 3.43 (m, 1H), 3.42 – 3.33 (m, 2H), 3.10 (s, 3H), 2.72 (s, 3H), 2.39 (s, 3H), 2.23 – 2.16 (m, 2H), 1.55 (d, J = 6.6 Hz, 3H).

173	(ES+) 559.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.16 (s, 2H), 7.85 – 7.80 (m, 1H), 7.67 – 7.61 (m, 1H), 7.44 (s, 1H), 7.39 – 7.33 (m, 1H), 6.79 – 6.71 (m, 1H), 6.57 – 6.48 (m, 2H), 6.13 (s, 1H), 5.10 – 5.05 (m, 1H), 4.71 (s, 1H), 4.37 (s, 1H), 3.60 – 3.55 (m, 2H), 3.46 – 3.39 (m, 4H), 3.21 (s, 3H), 2.32 (s, 3H), 2.06 – 1.95 (m, 2H), 1.55 (d, J = 6.6 Hz, 3H).
174	(ES+) 559.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.09 (s, 1H), 7.97 (s, 2H), 7.79 (d, J = 7.9 Hz, 1H), 7.42 (s, 1H), 7.28 – 7.24 (m, 1H), 6.78 – 6.69 (m, 2H), 6.41 (d, J = 8.4 Hz, 1H), 5.78 (s, 1H), 5.00 – 4.90 (m, 1H), 4.30 – 4.03 (m, 8H), 3.51 (s, 3H), 3.13 (s, 3H), 2.68 (s, 3H), 2.39 (s, 3H), 1.68 (d, J = 6.6 Hz, 3H).
175	(ES+) 598.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.67 (s, 2H), 7.92 (s, 1H), 7.79 (d, J = 7.9 Hz, 1H), 7.61 (d, J = 1.9 Hz, 1H), 7.00 – 6.86 (m, 2H), 6.62 – 6.36 (m, 1H), 6.30 (s, 1H), 5.98 – 5.81 (m, 1H), 4.29 – 3.65 (m, 2H), 3.54 (s, 3H), 3.32 – 3.11 (m, 7H), 2.99 – 2.74 (m, 2H), 2.42 (s, 3H), 2.31 (s, 3H), 1.61 (d, J = 6.8 Hz, 3H).
176	(ES-) 589.2 [M-H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.87 (d, 1H), 8.80 – 8.78 (m, 1H), 8.36 – 8.34 (m, 1H), 8.05 (d, 1H), 7.65 – 7.55 (m, 3H), 7.33 – 7.31 (m, 1H), 7.10 (s, 1H), 6.76 – 6.74 (m, 1H), 6.65 (d, J = 5.6 Hz, 1H), 6.48 (d, J = 8.4 Hz, 1H), 5.30 – 2.28 (m, 1H), 3.45 (s, 3H), 3.34 – 3.26 (m, 3H), 2.50 (s, 3H), 2.40 (s, 3H), 1.55 (d, 3H).
177	(ES+) 572.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.90-8.84 (m, 1H), 8.74 (d, J = 1.2 Hz, 1H), 8.35-8.28 (m, 1H), 8.05 (s, 1H), 7.67-7.61 (m, 1H), 7.60 (d, J = 1.9 Hz, 1H), 7.36 – 7.27 (m, 1H), 7.11 (s, 1H), 6.78-6.70 (m, 1H), 6.65 (d, J = 5.6 Hz, 1H), 6.48 (d, J = 8.5 Hz, 1H), 5.35-5.27 (m, 1H), 3.45 (s, 3H), 3.26 (s, 3H), 2.68 (s, 3H), 2.47 (d, J = 1.4 Hz, 3H), 2.41 (s, 3H), 1.55 (d, J = 6.5 Hz, 3H).
178	(ES+) 572.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.94 – 7.89 (m, 3H), 7.63 – 7.61 (m, 1H), 7.52 – 7.48 (m, 2H), 7.34 – 7.30 (m, 1H), 7.27 – 7.24 (m, 1H), 6.74 – 6.72 (m, 1H), 6.60 – 6.59 (m, 1H), 6.51 – 6.49 (m, 1H), 6.42 (s, 1H), 5.26 – 5.18 (m, 1H), 4.11 (s, 2H), 3.58 (s, 3H), 3.38 – 3.34 (m, 2H), 3.22 (s, 3H), 3.19 – 2.86 (m, 4H), 2.34 (s, 3H), 1.56 – 1.54 (m, 3H).
179	(ES+) 562.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.13 (s, 1H), 7.96 (d, J = 6.0 Hz, 1H), 7.76-7.78 (m, 1H), 7.44 (d, J = 1.2 Hz, 1H), 7.27 - 7.17 (m, 1H), 6.82 - 6.66 (m, 2H), 6.46-6.48 (m, 1H), 6.37 (d, J = 8.4 Hz, 1H), 6.22 (s, 1H), 6.13 (s, 1H), 5.04 - 4.86 (m, 1H), 3.95 (s, 3H), 3.93 - 3.69 (m, 2H), 3.67 (s, 3H), 3.46 - 3.13 (m, 4H), 3.12 (s, 3H), 3.06 - 2.80 (m, 2H), 2.40 (s, 3H), 1.66 (d, J = 6.4 Hz, 3H).
180	(ES+) 562.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.13 (s, 1H), 7.88 (s, 1H), 7.78 - 7.77 (m, 1H), 7.44 (s, 1H), 7.41 - 7.35 (m, 1H), 7.26 - 7.22 (m, 1H), 6.79 - 6.68 (m, 3H), 6.38 (d, J = 8.4 Hz, 1H), 6.26 (s, 1H), 4.97 - 4.95 (m, 1H), 3.93 (s, 3H), 3.67 (s, 3H), 3.60 - 3.36 (m, 2H), 3.34 - 3.15 (m, 3H), 3.13 (s, 3H), 3.11 - 2.95 (m, 3H), 2.40 (s, 3H), 1.66 (d, J = 6.4 Hz, 3H).

181	(ES+) 506.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.90 (s, 1H), 7.65 -7.62 (m, 1H), 7.51 - 7.44 (m, 2H), 7.40 - 7.29 (m, 1H), 6.77 - 6.72 (m, 1H), 6.58 (d, J = 5.6 Hz, 1H), 6.51 (d, J = 8.8 Hz, 1H), 6.42 (s, 1H), 5.19 - 5.16 (m, 1H), 4.03 (s, 2H), 3.77 (s, 3H), 3.50 (s, 3H), 3.31 - 3.25 (m, 2H), 3.21 (s, 3H), 2.98 - 2.69 (m, 2H), 2.33 (s, 3H), 1.55 (d, J = 6.8 Hz, 3H).
182	(ES+) 507.0 [M+H]	
183	(ES+) 492.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.92 (s, 1H), 7.64 - 7.62 (m, 1H), 7.49 (d, J = 1.6 Hz, 1H), 7.38 - 7.29 (m, 1H), 7.16 (s, 1H), 6.92 (s, 1H), 6.77 - 6.72 (m, 1H), 6.62 (d, J = 6.0 Hz, 1H), 6.57 - 6.45 (m, 2H), 5.22 - 5.21 (m, 1H), 4.32 (s, 2H), 4.16 (br s, 2H), 3.55 (s, 3H), 3.30 - 3.16 (m, 5H), 2.34 (s, 3H), 1.54 (d, J = 6.4 Hz, 3H).
184	(ES+) 546.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.41 (s, 2H), 8.13 (s, 1H), 7.86 – 7.83 (m, 1H), 7.60 - 7.43 (m, 2H), 7.25 - 7.21 (m, 1H), 6.73 - 6.71 (m, 1H), 6.37 (d, J = 8.0 Hz, 1H), 6.25 (s, 1H), 5.04 - 4.87 (m, 1H), 3.80 - 3.58 (m, 5H), 3.35 - 2.97 (m, 9H), 2.73 (s, 3H), 2.41 (s, 3H), 1.66 (d, J = 6.8 Hz, 3H).
185	(ES+) 546.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.32 (s, 2H), 8.05 (s, 1H), 7.79 – 7.76 (m, 1H), 7.39 (d, J = 1.6 Hz, 2H), 7.18 - 7.10 (m, 1H), 6.68 -6.64 (m, 1H), 6.27 (d, J = 8.4 Hz, 1H), 6.19 (s, 1H), 4.86 - 4.84 (m, 1H), 3.60 - 5.50 (m, 5H), 3.30 - 2.90 (m, 9H), 2.63 (s, 3H), 2.32 (s, 3H), 1.58 (d, J = 6.8 Hz, 3H).
186	(ES+) 597.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.47 (s, 2H), 8.19 - 7.91 (m, 1H), 7.70 (d, J = 2.3 Hz, 1H), 7.22 (d, J = 8.7 Hz, 1H), 6.92 – 6.72 (m, 2H), 6.03 – 5.83 (m, 1H), 3.73 – 3.67 (m, 2H), 3.67 – 3.53 (m, 5H), 3.38 – 3.26 (m, 8H), 3.19 – 3.06 (m, 2H), 2.36 (s, 3H), 2.31 (s, 3H), 1.57 (d, J = 6.5 Hz, 3H).
187	(ES+) 606.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.42 (s, 2H), 8.20 (s, 1H), 7.65 (s, 1H), 7.00 (d, J = 5.6 Hz, 1H), 6.95 (d, J = 8.6 Hz, 1H), 6.65 (d, J = 8.7 Hz, 1H), 5.33 – 5.26 (m, 1H), 3.70 – 3.63 (m, 7H), 3.35 – 3.05 (m, 5H), 2.74 (s, 3H), 2.41 – 2.39 (m, 6H), 1.60 (d, J = 6.5 Hz, 3H), 1.48 – 1.40 (m, 2H), 1.17 – 1.07 (m, 2H).
188	(ES+) 588.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.42 (s, 2H), 8.16 – 8.11 (m, 1H), 7.46 (d, J = 1.8 Hz, 1H), 6.99 (d, J = 5.0 Hz, 1H), 6.93 (d, J = 8.6 Hz, 1H), 6.60 (d, J = 8.7 Hz, 1H), 6.33 (s, 1H), 4.88 – 4.80 (m, 1H), 3.74 – 3.64 (m, 5H), 3.35 – 3.03 (m, 7H), 2.75 (s, 3H), 2.41 – 2.39 (m, 6H), 1.65 (d, J = 8.0 Hz, 3H), 1.42 – 1.38 (m, 2H), 1.11 – 1.00 (m, 2H).
189	(ES+) 583.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.39 (s, 2H), 8.22 (s, 1H), 7.60 – 7.52 (m, 2H), 7.06 – 6.96 (m, 1H), 6.55 (d, J = 5.9 Hz, 1H), 6.42 – 6.32 (m, 1H), 5.38 – 5.29 (m, 1H), 3.81 – 3.60 (m, 7H), 3.45 – 3.01 (m, 7H), 2.70 (s, 3H), 2.41 (s, 3H), 1.64 (d, J = 6.4 Hz, 3H).

190	(ES+) 565.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.46 (s, 2H), 8.15 (s, 1H), 7.57 – 7.47 (m, 1H), 7.43 (d, J = 1.9 Hz, 1H), 7.03 – 6.94 (m, 1H), 6.54 (d, J = 5.2 Hz, 1H), 6.36 – 6.28 (m, 1H), 6.27 (s, 1H), 4.94 – 4.86 (m, 1H), 3.80 – 3.70 (m, 2H), 3.68 (s, 3H), 3.45 – 3.30 (m, 4H), 3.18 (s, 3H), 3.15 – 3.06 (m, 2H), 2.81 (s, 3H), 2.42 (s, 3H), 1.67 (d, J = 6.6 Hz, 3H).
191	(ES+) 640.1 [M+Na]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.87 (s, 1H), 7.66 – 7.64 (m, 1H), 7.42 – 7.36 (m, 2H), 7.32 – 7.30 (m, 1H), 6.76 – 6.72 (m, 1H), 6.48 (d, J = 8.4 Hz, 1H), 6.38 (s, 1H), 5.26 – 5.22 (m, 1H), 3.84 – 3.88 (m, 1H), 3.64 – 3.51 (m, 1H), 3.50 (s, 3H), 3.49 – 3.30 (m, 5H), 3.25 – 2.51 (m, 8H), 2.30 (s, 3H), 1.50 (d, J = 6.4 Hz, 3H).
192	(ES+) 640.1 [M+Na]	
193	(ES+) 565.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.47 (s, 2H), 8.03 (s, 1H), 7.66 (d, J = 7.1 Hz, 2H), 7.37 – 7.33 (m, 1H), 6.78-6.75 (m, 1H), 6.68 (s, 1H), 6.45 (s, 1H), 5.32 (s, 1H), 3.82 – 3.75 (m, 2H), 3.57 (s, 3H), 3.44 – 3.32 (m, 7H), 3.28 (s, 3H), 3.03-3.00 (m, 2H), 2.36 (s, 3H), 1.59 (d, J = 6.4 Hz, 3H).
194	(ES+) 571.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.91 (d, J = 1.7 Hz, 1H), 7.85 – 7.48 (m, 5H), 7.39 – 7.31 (m, 1H), 6.78 – 6.72 (m, 1H), 6.63 – 6.58 (m, 1H), 6.55 – 6.51 (m, 1H), 6.40 (s, 1H), 5.27 – 5.20 (m, 1H), 3.51 (s, 3H), 3.28 – 2.75 (m, 8H), 2.35 (s, 3H), 1.57 (d, J = 6.5 Hz, 3H).
195	(ES+) 567.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.22 (s, 1H), 8.15 (s, 1H), 7.80 – 7.48 (m, 1H), 7.51 (d, J = 1.9 Hz, 1H), 7.37 (d, J = 13.5 Hz, 1H), 7.28 – 7.19 (m, 1H), 6.80 – 6.71 (m, 2H), 6.66 (s, 1H), 6.33 (d, J = 8.4 Hz, 1H), 5.02 – 4.95 (m, 2H), 4.87 (d, J = 6.7 Hz, 1H), 3.83 – 3.67 (m, 4H), 3.52 (s, 3H), 3.15 (s, 3H), 2.44 (s, 3H), 2.17 – 1.96 (m, 4H), 1.64 (d, J = 6.7 Hz, 3H).
196	(ES+) 591.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.23 (s, 1H), 8.00 (s, 1H), 7.88 (d, J = 1.6 Hz, 1H), 7.65 - 7.62 (m, 1H), 7.56 (s, 1H), 7.36 – 7.27 (m, 1H), 6.92 (s, 1H), 6.78 – 6.70 (m, 1H), 6.63 (d, J = 5.6 Hz, 1H), 6.47 (d, J = 8.4 Hz, 1H), 5.30 - 5.23 (m, 1H), 4.38 (s, 4H), 3.50 – 3.43 (m, 4H), 3.40 (s, 3H), 3.25 (s, 3H), 2.39 (s, 3H), 1.95 – 1.90 (m, 4H), 1.53 (d, J = 6.4 Hz, 3H).
197	(ES+) 588.5 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.03 (s, 1H), 7.80 – 7.72 (m, 1H), 7.68 (d, J = 2.8 Hz, 1H), 7.57 (d, J = 1.2 Hz, 1H), 7.33 – 7.29 (m, 1H), 6.79 – 6.75 (m, 1H), 6.56 – 6.51 (m, 2H), 5.94 (d, J = 2.4 Hz, 1H), 5.28 – 5.13 (m, 1H), 4.00 – 3.59 (m, 5H), 3.30 – 2.81 (m, 9H), 2.41 (s, 3H), 1.97 (s, 6H), 1.68 (d, J = 6.6 Hz, 3H).
198	(ES+) 546.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.18 (d, J = 4.7 Hz, 1H), 7.92 (s, 1H), 7.65 (d, J = 7.9 Hz, 1H), 7.53 – 7.48 (m, 2H), 7.40 – 7.32 (m, 1H), 7.25 – 7.19 (m, 1H), 6.79 – 6.71 (m, 1H), 6.62 (d, J = 5.7 Hz, 1H), 6.54 (d, J = 8.4 Hz, 1H), 6.47 (s, 1H), 5.29 – 5.22 (m, 1H), 3.57 (s, 3H), 3.24 (s, 3H), 3.20 – 2.92 (m, 7H), 2.35 (s, 3H), 1.58 (d, J = 6.5 Hz, 3H).

199	(ES+) 581.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.47 (s, 2H), 7.91 (s, 1H), 7.60 (d, J = 2.6 Hz, 1H), 7.46 (s, 1H), 7.46-7.39 (m, 1H), 6.64 (d, J = 5.8 Hz, 1H), 6.51 (d, J = 9.2 Hz, 1H), 6.41 (s, 1H), 5.27 – 5.19 (m, 1H), 3.55 (s, 3H), 3.31 (s, 2H), 3.15 (s, 3H), 3.14 (s, 6H), 2.52 (s, 3H), 2.34 (s, 3H), 1.56 (d, J = 6.5 Hz, 3H).
200	(ES+) 548.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 12.54 - 11.65 (m, 1H), 8.13 (s, 1H), 7.77-7.76 (m, 1H), 7.44 (d, J = 1.2 Hz, 1H), 7.27 - 7.20 (m, 2H), 6.84 - 6.67 (m, 2H), 6.36 (d, J = 8.4 Hz, 1H), 6.21 (s, 1H), 6.04- 6.06 (m, 1H), 5.82 (s, 1H), 5.06 - 4.85 (m, 1H), 4.10 - 3.69 (m, 2H), 3.67 (s, 3H), 3.49 - 3.14 (m, 4H), 3.12 (s, 3H), 3.08 - 2.84 (m, 2H), 2.40 (s, 3H), 1.65 (d, J = 6.4 Hz, 3H).
201	(ES+) 548.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.18 - 8.11 (m, 1H), 7.82 - 7.75 (m, 1H), 7.48 - 7.40 (m, 2H), 7.26 - 7.21 (m, 1H), 6.89 (d, J = 2.8 Hz, 1H), 6.80 - 6.69 (m, 2H), 6.63 (d, J = 9.6 Hz, 1H), 6.38 (d, J = 8.0 Hz, 1H), 6.25 (s, 1H), 4.98 - 4.93 (m, 1H), 3.66 (s, 3H), 3.40 - 3.14 (m, 4H), 3.13 (s, 3H), 3.08 - 2.78 (m, 4H), 2.40 (s, 3H), 1.66 (d, J = 6.4 Hz, 3H).
202	(ES+) 585.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.74 (s, 1H), 8.29 (d, J = 11.2 Hz, 1H), 8.03 (s, 1H), 7.70 - 7.55 (m, 2H), 7.34 - 7.26 (m, 1H), 7.07 (s, 1H), 6.74 - 6.71 (m, 1H), 6.64 (d, J = 5.2 Hz, 1H), 6.46 (d, J = 8.4 Hz, 1H), 5.36 - 5.21 (m, 1H), 4.84 - 4.80 (m, 2H), 4.58 - 4.55 (m, 2H), 3.39 (s, 3H), 3.26 (s, 3H), 2.40 (s, 3H), 1.53 (d, J = 6.0 Hz, 3H).
203	(ES+) 592.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.12 (s, 1H), 8.06 (s, 1H), 7.71 - 7.69 (m, 1H), 7.42 (s, 1H), 7.56 - 7.50 (m, 1H), 7.41 - 7.31 (m, 1H), 6.67 - 6.65 (m, 2H), 6.64 (s, 1H), 6.64 - 6.62 (m, 1H), 4.91 - 4.85 (m, 1H), 3.73 - 3.70 (m, 2H), 3.58 - 3.53 (m, 6H), 3.42 (s, 3H), 3.05 (s, 3H), 2.35 (s, 3H), 2.09 (s, 3H), 1.55 (d, J = 6.4 Hz, 3H).
204	(ES+) 601.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.20 (s, 1H), 8.12 (d, J = 1.6 Hz, 1H), 7.79 – 7.76 (m, 1H), 7.49 (d, J = 1.6 Hz, 1H), 7.36 – 7.31 (m, 1H), 7.26 - 7.18 (m, 2H), 6.78 - 6.68 (m, 2H), 6.64 (s, 1H), 6.31 (d, J = 8.4 Hz, 1H), 5.00 - 4.93 (m, 1H), 4.71 (s, 2H), 3.97 – 3.94 (m, 2H), 3.88 (s, 3H), 3.51 (s, 3H), 3.13 (s, 3H), 3.02 - 2.93 (m, 2H), 2.43 (s, 3H), 1.62 (d, J = 6.8 Hz, 3H).
205	(ES+) 584.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.50 (s, 2H), 8.20 (s, 1H), 7.78 - 7.74 (m, 1H), 7.50 (s, 1H), 7.26 - 7.17 (m, 1H), 6.79 - 6.71 (m, 2H), 6.61 (s, 1H), 6.32 (d, J = 8.4 Hz, 1H), 5.95 (s, 1H), 5.06 (s, 2H), 5.01 - 4.90 (m, 1H), 4.46 - 4.35 (m, 2H), 4.32 - 4.20 (m, 2H), 3.52 (s, 3H), 3.13 (s, 3H), 2.43 (s, 3H), 2.29 (s, 3H), 1.63 (d, J = 6.8 Hz, 3H).
206	(ES+) 584.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.46 (s, 2H), 8.20 (s, 1H), 7.79 - 7.76 (m, 1H), 7.48 (d, J = 1.6 Hz, 1H), 7.25 - 7.14 (m, 2H), 6.84 - 6.68 (m, 2H), 6.61 (s, 1H), 6.31 (d, J = 8.4 Hz, 1H), 5.01 - 4.88 (m, 3H), 4.24 - 4.22 (m, 2H), 3.88 (s, 3H), 3.53 (s, 3H), 3.13 (s, 3H), 2.93 -2.88 (m, 2H), 2.42 (s, 3H), 1.62 (d, J = 6.8 Hz, 3H).

207	(ES+) 506.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.89 (s, 1H), 7.62 - 7.61 (m, 1H), 7.48 (d, J = 1.2 Hz, 1H), 7.32 - 7.29 (m, 1H), 6.74 - 6.72 (m, 1H), 6.57 (d, J = 5.6 Hz, 1H), 6.51 - 6.40 (m, 2H), 5.90 (s, 1H), 5.22 - 5.08 (m, 1H), 4.27 - 4.21 (m, 2H), 4.19 - 4.05 (m, 2H), 3.70 - 3.64 (m, 2H), 3.51 (s, 3H), 3.19 (s, 3H), 2.32 (s, 3H), 2.13 (s, 3H), 1.52 (d, J = 6.8 Hz, 3H).
208	(ES+) 492.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): 7.91 (s, 1H), 7.65 - 7.63 (m, 2H), 7.49 (s, 1H), 7.33 - 7.30 (m, 1H), 6.76 - 6.74 (m, 2H), 6.62- 6.60 (m, 1H), 6.49 - 6.47 (m, 2H), 5.20 - 5.17 (m, 1H), 4.27 - 4.19 (m, 4H), 3.53 (s, 3H), 3.48 - 3.25 (m, 2H), 3.23 (s, 3H), 2.34 (s, 3H), 1.54 (d, J = 5.2 Hz, 3H).
209	(ES+) 565.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.12 (s, 2H), 8.97 (s, 1H), 8.46 (s, 1H), 8.08 - 7.77 (m, 2H), 7.63 - 7.62 (m, 1H), 7.59 (d, J = 1.6 Hz, 1H), 7.37 - 7.27 (m, 1H), 7.13 (s, 1H), 6.74 - 6.71 (m, 1H), 6.65 (d, J = 5.6 Hz, 1H), 6.48 (d, J = 8.4 Hz, 1H), 5.30 - 5.28 (m, 1H), 3.45 (s, 3H), 3.26 (s, 3H), 2.40 (s, 3H), 1.54 (d, J = 6.8 Hz, 3H).
210	(ES+) 546.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.12 (s, 2H), 8.48 (s, 1H), 8.03 (s, 1H), 7.63 - 7.62 (m, 1H), 7.58 (s, 1H), 7.31 - 7.28 m, 1H), 7.14 (s, 1H), 6.74 - 6.73 (m, 1H), 6.65 (d, J = 6.4 Hz, 1H), 6.47 (d, J = 8.0 Hz, 1H), 5.31 - 5.27 (m, 1H), 3.45 (s, 3H), 3.26 (s, 3H), 2.75 (s, 3H), 2.40 (s, 3H), 1.54 (d, J = 6.4 Hz, 3H).
211	(ES+) 550.2 [M+H]	^{1}H NMR (400 MHz, CD_3CN): δ 8.31 (s, 1H), 8.16 - 8.15 (m, 1H), 8.07 (s, 1H), 7.68 - 7.67 (m, 1H), 7.59 - 7.50 (m, 2H), 7.28 - 7.21 (m, 1H), 6.78 (s, 1H), 6.75 - 6.70 (m, 1H), 6.65 (d, J = 5.2 Hz, 1H), 6.44 (d, J = 8.4 Hz, 1H), 5.15 - 5.09 (m, 1H), 3.66 - 3.62 (m, 4H), 3.40 (s, 3H), 3.11 (s, 3H), 3.10 - 3.05 (m, 4H), 2.39 (s, 3H), 1.58 (d, J = 6.4 Hz, 3H).
212	(ES+) 539.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.89 (s, 1H), 7.65 - 7.62 (m, 1H), 7.47 (s, 1H), 7.32 - 7.30 (m, 1H), 6.75 - 6.73 (m, 1H), 6.63 - 6.57 (m, 1H), 6.48 - 6.46 (m, 1H), 6.36 (s, 1H), 5.23 - 5.16 (m, 1H), 3.90 - 3.60 (m, 2H), 3.53 (s, 3H), 3.23 (s, 3H), 3.20 - 2.60 (m, 6H), 2.33 (s, 3H), 1.54 (d, J = 6.4 Hz, 3H), 0.69 - 0.64 (m, 4H).
213	(ES+) 572.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.46 (s, 2H), 8.06 (d, J = 2.0 Hz, 2H), 7.60 - 7.56 (m, 1H), 7.55 (s, 1H), 6.64 (d, J = 8.8 Hz, 1H), 6.51 (s, 1H), 5.34 - 5.28 (m, 1H), 3.85 - 3.71 (m, 2H), 3.70 (s, 3H), 3.35 - 3.12 (m, 9H), 2.61 (s, 3H), 2.41 (s, 3H), 1.71 (d, J = 6.8 Hz, 3H).
214	(ES+) 583.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.44 (s, 2H), 8.27 (s, 1H), 7.84 (d, J = 7.9 Hz, 1H), 7.66 (s, 1H), 7.30 – 7.28 (m, 1H), 7.09 (d, J = 6.7 Hz, 1H), 6.83 – 6.82 (m, 1H), 6.44 (d, J = 8.4 Hz, 1H), 5.62 (s, 1H), 4.93 – 4.49 (m, 2H), 3.69 – 3.64 (m, 7H), 3.36 – 3.20 (m, 2H), 3.18 (s, 5H), 2.76 (s, 3H), 2.43 (s, 3H).
215	(ES+) 565.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.42 (s, 2H), 8.22 (s, 1H), 7.83 – 7.81 (m, 1H), 7.51 (d, J = 1.8 Hz, 1H), 7.01 (d, J = 5.3 Hz, 1H), 6.83 – 6.80 (m, 1H), 6.42 (d, J = 8.3 Hz, 1H), 6.27 (s, 1H), 5.21 – 5.14 (m, 1H), 4.83 – 4.51 (m, 2H), 3.71 – 3.64 (m, 4H), 3.60 – 2.98 (m, 10H), 2.74 (s, 3H), 2.43 (s, 3H).

216	(ES+) 582.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.47 (s, 2H), 8.04 (d, J = 2.0 Hz, 1H), 7.74 (d, J = 2.0 Hz, 1H), 7.72 – 7.53 (m, 1H), 7.40 – 7.31 (m, 1H), 6.80 – 6.70 (m, 1H), 6.67 (d, J = 5.9 Hz, 1H), 6.48 (d, J = 8.5 Hz, 1H), 6.09 – 5.97 (m, 1H), 3.76 – 3.65 (m, 2H), 3.66 – 3.51 (m, 5H), 3.31 – 3.29 (m, 5H), 3.25 (s, 3H), 3.17 – 3.05 (m, 2H), 2.35 (s, 3H), 1.60 (d, J = 6.5 Hz, 3H).
217	(ES+) 598.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.88 (s, 1H), 8.75 (s, 1H), 8.33 (d, J = 10.5 Hz, 1H), 8.06 (s, 1H), 7.58 (d, J = 9.3 Hz, 2H), 7.31 – 7.25 (m, 1H), 7.11 (s, 1H), 6.79 – 6.68 (m, 2H), 6.47 (d, J = 8.6 Hz, 1H), 5.38 – 5.25 (m, 1H), 3.46 (s, 3H), 3.03 (s, 1H), 2.69 (s, 3H), 2.48 (s, 3H), 2.41 (s, 3H), 1.56 (d, J = 6.5 Hz, 3H), 1.22 – 1.05 (m, 4H).
218	(ES+) 549.4 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.18 (s, 2H), 8.04 (s, 1H), 7.73 (d, J = 8.0, 1H), 7.59 (s, 1H), 7.33 – 7.29 (m, 1H), 6.80 – 6.75 (m, 1H), 6.60 – 6.50 (m, 2H), 5.23 – 5.18 (m, 1H), 3.69 (s, 3H), 3.49 – 3.36 (m, 4H), 3.16 (s, 3H), 3.15 – 2.90 (m, 4H), 2.41 (s, 3H), 1.69 (d, J = 6.4 Hz, 3H).
219	(ES+) 588.4 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.45 (s, 2H), 8.05 (s, 1H), 7.80 (d, J = 8.0 Hz, 1H), 7.59 (s, 1H), 7.53 – 7.39 (m, 1H), 6.95 – 6.85 (m, 1H), 6.77 (d, J = 8.5 Hz, 1H), 6.38 (s, 1H), 5.35 – 5.20 (m, 1H), 4.03 – 3.57 (m, 5H), 3.40 (s, 3H), 3.31 – 2.88 (m, 6H), 2.62 (s, 3H), 2.44 (s, 3H), 1.78 (s, 3H), 1.71 (d, J = 6.8 Hz, 3H).
220	(ES+) 588.4 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.47 (s, 2H), 8.04 (s, 1H), 7.76 (d, J = 8.1 Hz, 1H), 7.66 (s, 1H), 7.37 – 7.28 (m, 1H), 6.86 – 6.77 (m, 1H), 6.60 – 6.48 (m, 2H), 5.28 – 5.17 (m, 1H), 3.61 – 4.00 (m, 5H), 3.48 (s, 3H), 3.31 – 2.94 (m, 6H), 2.62 (s, 3H), 2.42 (s, 3H), 2.15 (s, 3H), 1.69 (d, J = 6.8 Hz, 3H).
221	(ES+) 585.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.31 - 8.22 (m, 1H), 8.01 (s, 1H), 7.97 – 7.89 (m, 1H), 7.67 – 7.57 (m, 1H), 7.56 (d, J = 1.9 Hz, 1H), 7.37 – 7.26 (m, 1H), 6.93 (s, 1H), 6.77 – 6.68 (m, 1H), 6.63 (d, J = 5.7 Hz, 1H), 6.46 (d, J = 8.4 Hz, 1H), 5.31 – 5.22 (m, 1H), 3.73 – 3.62 (m, 4H), 3.40 (s, 3H), 3.25 (s, 3H), 2.38 (s, 3H), 2.18 – 2.04 (m, 4H), 1.53 (d, J = 6.5 Hz, 3H).
222	(ES+) 607.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.14 (s, 1H), 7.79 (m, 1H), 7.60 (d, J = 13.2 Hz, 1H), 7.51 – 7.42 (m, 2H), 7.21 – 7.12 (m, 2H), 6.80 – 6.72 (m, 1H), 6.72 (d, J = 5.4 Hz, 1H), 6.40 (d, J = 8.4 Hz, 1H), 6.38 (s, 1H), 6.26 (s, 1H), 5.02 – 4.95 (m, 1H), 3.79 – 3.72 (m, 2H), 3.69 (s, 3H), 3.30 – 3.13 (m, 9H), 2.41 (s, 3H), 1.79 (s, 3H), 1.68 (s, 3H), 1.69 – 1.66 (m, 3H).
223	(ES+) 575.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.48 (s, 2H), 8.06 – 8.01 (m, 1H), 7.58 (d, J = 1.8 Hz, 1H), 7.13 (d, J = 8.7 Hz, 1H), 6.89 (d, J = 8.7 Hz, 1H), 6.56 (s, 1H), 5.21 – 5.13 (m, 1H), 3.98 – 3.69 (m, 2H), 3.71 (s, 3H), 3.48 (s, 3H), 3.31 – 3.28 (m, 2H), 3.27 – 3.02 (m, 4H), 2.79 (s, 3H), 2.62 (s, 3H), 2.42 (s, 3H), 2.38 (s, 3H), 1.71-1.66 (m, 3H).

224	(ES+) 575.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.47 (s, 2H), 8.06 – 8.01 (m, 1H), 7.59 (d, J = 1.8 Hz, 1H), 7.08 (d, J = 8.7 Hz, 1H), 6.83 (d, J = 8.7 Hz, 1H), 6.56 (s, 1H), 5.21 – 5.08 (m, 1H), 3.98 – 3.69 (m, 2H), 3.71 (s, 3H), 3.31 (s, 2H), 3.27 – 3.25 (m, 3H), 3.22 – 3.01 (m, 4H), 2.75 (s, 3H), 2.62 (s, 3H), 2.39 (s, 3H), 2.37 (s, 3H), 1.64 (d, J = 6.6 Hz, 3H).
225	(ES+) 547.4 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.54 (s, 1H), 8.18 (s, 1H), 8.04 (s, 1H), 7.73 – 7.71 (m, 1H), 7.58 (s, 1H), 7.32 – 7.28 (m, 1H), 6.77 – 6.73 (m, 1H), 6.57 – 6.52 (m, 2H), 5.22 – 5.17 (m, 1H), 4.41 – 3.95 (m, 2H), 3.72 (s, 3H), 3.32 - 3.20 (m, 3H), 3.20 – 2.89 (m, 6H), 2.42 (s, 3H), 2.34 (s, 3H), 1.67 (d, J = 6.4 Hz, 3H).
226	(ES+) 601.4 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.49 (s, 2H), 8.06 (s, 1H), 7.77 – 7.70 (m, 1H), 7.54 (d, J = 1.8 Hz, 1H), 7.51 – 7.42 (m, 1H), 6.85 – 6.76 (m, 1H), 6.58 (d, J = 8.7 Hz, 1H), 6.53 (s, 1H), 5.31 – 5.22 (m, 1H), 4.10 – 3.50 (m, 5H), 3.50 – 3.00 (m, 6H), 2.63 (s, 3H), 2.41 (s, 3H), 1.67 (d, J = 6.6 Hz, 3H).
227	(ES+) 477.0 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6) δ 8.24 (s, 1H), 7.97 (s, 1H), 7.82 (s, 1H), 7.64 (d, J = 7.9 Hz, 1H), 7.53 (s, 1H), 7.32 –7.30 (m, 1H), 6.90 (s, 1H), 6.74 – 6.70 (m, 1H), 6.63 (d, J = 5.6 Hz, 1H), 6.46 (d, J = 8.4 Hz, 1H), 5.25 – 5.20 (m, 1H), 3.81 – 3.75 (m, 1H), 3.55 (s, 3H), 3.25 (s, 3H), 2.37 (s, 3H), 1.55 – 1.49 (m, 3H), 1.13 – 1.10 (m, 2H), 1.04 – 1.00 (m, 2H).
228	(ES+) 519.0 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.32 (s, 1H), 7.99 – 7.98 (m, 2H), 7.64 – 7.62 (m, 1H), 7.54 (d, J = 1.9 Hz, 1H), 7.33 – 7.29 (m, 1H), 6.94 (s, 1H), 6.78 – 6.69 (m, 1H), 6.63 (d, J = 5.6 Hz, 1H), 6.46 (d, J = 8.4 Hz, 1H), 5.32 – 5.21 (m, 3H), 3.52 (s, 3H), 3.24 (s, 3H), 2.37 (s, 3H), 1.55 (d, J = 6.5 Hz, 3H).
229	(ES+) 504.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.45 (s, 1H), 8.04 (s, 1H), 8.01 – 7.96 (m, 1H), 7.69 – 7.60 (m, 1H), 7.54 (d, J = 1.8 Hz, 1H), 7.36 – 7.27 (m, 1H), 6.97 (s, 1H), 6.78 – 6.70 (m, 1H), 6.64 (d, J = 5.6 Hz, 1H), 6.45 (d, J = 8.4 Hz, 1H), 5.30 – 5.22 (m, 1H), 3.54 (s, 3H), 3.25 (s, 3H), 2.37 (s, 3H), 2.05 (s, 6H), 1.55 (d, J = 6.5 Hz, 3H).
230	(ES+) 547.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): 8.17 - 8.11 (m, 2H), 7.92 (s, 1H), 7.66 - 7.62 (m, 1H), 7.50 (d, J = 1.2 Hz, 1H), 7.37 - 7.32 (m, 1H), 6.78 - 6.61 (m, 1H), 6.61 (d, J = 6.0 Hz, 1H), 6.53 (d, J = 8.4 Hz, 1H), 6.45 (s, 1H), 5.27 - 5.23 (m, 1H), 3.57 (s, 3H), 3.57 - 3.32 (m, 3H), 3.30 - 2.99 (m, 8H), 2.53 (s, 3H), 2.35 (s, 3H), 1.58 (d, J = 6.8 Hz, 3H).
231	(ES+) 566.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.47 (s, 2H), 8.00 (s, 1H), 7.77 (d, J = 1.9 Hz, 1H), 7.70-7.60 (m, 1H), 7.23 – 7.14 (m, 1H), 6.68-6.60 (m, 1H), 6.41 (s, 1H), 6.34 (d, J = 8.5 Hz, 1H), 5.35-5.28 (m, 1H), 3.78 (d, J = 11.6 Hz, 2H), 3.56 (s, 3H), 3.42-3.29 (m, 4H), 3.07-2.97 (m, 2H), 2.55-2.48 (m, 3H), 2.33 (s, 3H), 1.56 (d, J = 6.4 Hz, 3H).

232	(ES+) 579.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.15-8.09 (m, 1H), 7.90 (d, J = 1.7 Hz, 1H), 7.46 (d, J = 1.9 Hz, 1H), 7.36-7.28 (m, 1H), 7.20 (d, J = 8.7 Hz, 1H), 6.92 (d, J = 8.8 Hz, 1H), 6.84 (d, J = 6.4 Hz, 1H), 6.42 (s, 1H), 5.26-5.18 (m, 1H), 3.87-3.65 (m, 2H), 3.54-3.51 (m, 3H), 3.33 (s, 3H), 3.24-2.86 (m, 6H), 2.36 – 2.26 (m, 9H), 1.53 (d, 3H).
233	(ES+) 551.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.51 (d, J = 0.8 Hz, 2H), 7.91 (d, J = 1.8 Hz, 1H), 7.62 (d, J = 7.9 Hz, 1H), 7.48 (d, J = 1.9 Hz, 1H), 7.34 – 7.28 (m, 1H), 6.79 – 6.69 (m, 1H), 6.59 (d, J = 5.8 Hz, 1H), 6.49 (d, J = 8.4 Hz, 1H), 6.39 (s, 1H), 5.25 – 5.15 (m, 1H), 4.57 (s, 2H), 3.57 (s, 3H), 3.23 (s, 2H), 3.23 (s, 3H), 3.20 – 2.69 (m, 4H), 2.34 (s, 3H), 1.54 (d, J = 6.5 Hz, 3H).
234	(ES+) 572.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.68 (d, J = 7.7 Hz, 1H), 8.23 (s, 1H), 7.92 (d, J = 1.8 Hz, 1H), 7.64 – 7.62 (m, 1H), 7.49 (d, J = 1.9 Hz, 1H), 7.35 – 7.31 (m, 1H), 7.12 – 7.09 (m, 1H), 7.00 (d, J = 2.6 Hz, 1H), 6.78 – 6.69 (m, 1H), 6.61 (d, J = 5.8 Hz, 1H), 6.51 (d, J = 8.4 Hz, 1H), 6.43 (s, 1H), 5.26 – 5.20 (m, 1H), 3.80 (d, J = 39.8 Hz, 2H), 3.58 (s, 3H), 3.23 (s, 9H), 2.34 (s, 3H), 1.56 (d, J = 6.5 Hz, 3H).
235	(ES+) 572.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.70 (d, J = 7.9 Hz, 1H), 7.97 – 7.81 (m, 2H), 7.64 – 6.68 (m, 1H), 7.48 (d, J = 1.9 Hz, 1H), 7.35 – 7.27 (m, 1H), 6.81 (d, J = 7.9 Hz, 1H), 6.77 – 6.68 (m, 1H), 6.59 (d, J = 5.8 Hz, 1H), 6.48 (d, J = 8.4 Hz, 1H), 6.42 (s, 1H), 6.09 – 6.05 (m, 1H), 5.24 – 5.17 (m, 1H), 4.80 – 4.25 (m, 2H), 3.59 (s, 3H), 3.39 (s, 3H), 3.39 – 2.75 (m, 4H), 3.22 (s, 2H), 2.34 (s, 3H), 1.54 (d, J = 6.5 Hz, 3H).
236	(ES+) 544.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.46 (s, 2H), 7.97 (d, J = 1.9 Hz, 1H), 7.66 – 7.60 (m, 1H), 7.54 (d, J = 1.9 Hz, 1H), 7.35 – 7.28 (m, 1H), 6.80 (s, 1H), 6.77 – 6.71 (m, 1H), 6.61 (d, J = 5.6 Hz, 1H), 6.47 (d, J = 8.4 Hz, 1H), 6.18 – 6.11 (m, 1H), 5.24 – 5.18 (m, 1H), 3.93 (m, 2H), 3.59 – 3.53 (m , 2H), 3.44 (s, 3H), 3.25 (s, 3H), 2.54 (d, J = 6.6 Hz, 2H), 2.51 (s, 3H), 2.37 (s, 3H), 1.55 (d, J = 6.5 Hz, 3H).
237	(ES+) 546.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.69 (s, 2H), 7.90 (d, J = 1.8 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.49 (d, J = 2.0 Hz, 1H), 7.38 – 7.31 (m, 1H), 6.80 – 6.70 (m, 1H), 6.61 (d, J = 5.7 Hz, 1H), 6.51 (d, J = 8.4 Hz, 1H), 6.36 (s, 1H), 5.20 (d, J = 6.3 Hz, 1H), 3.55 (s, 3H), 3.35 (s, 1H), 3.24 (s, 3H), 2.84 – 2.74 (m, 4H), 2.60 (s, 3H), 2.34 (s, 3H), 1.97 – 1.92 (m, 4H), 1.57 (d, J = 6.5 Hz, 3H).
238	(ES+) 547.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.76 (d, J = 4.8 Hz, 1H), 7.91 (s, 1H), 7.66 – 7.22 (m, 1H), 7.49 (d, J = 1.9 Hz, 1H), 7.45 – 7.40 (m, 1H), 7.37 – 7.30 (m, 1H), 6.75 (d, J = 7.7 Hz, 1H), 6.61 (d, J = 5.7 Hz, 1H), 6.52 (d, J = 8.4 Hz, 1H), 6.44 (s, 1H), 5.27 – 5.20 (m, 1H), 3.72 – 3.59 (m, 1H), 3.57 (s, 3H), 3.49 – 3.33 (m, 3H), 3.22 (s, 3H), 3.20 – 2.99 (m, 4H), 2.36 – 2.32 (m, 6H), 1.57 (d, J = 6.5 Hz, 3H).

239	(ES+) 561.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.91 (s, 1H), 7.63 (s, 1H), 7.49 (d, J = 1.9 Hz, 1H), 7.37 – 7.29 (m, 2H), 6.77 – 6.70 (m, 1H), 6.61 (d, J = 5.8 Hz, 1H), 6.52 (d, J = 8.5 Hz, 1H), 6.44 (s, 1H), 5.26 – 5.21 (m, 1H), 3.57 (s, 3H), 3.54-3.31 (m, 4H), 3.22 (s, 3H), 3.20-3.03 (m, 4H), 2.48 (s, 3H), 2.34 (s, 3H), 2.29 (s, 3H), 1.57 (d, J = 6.5 Hz, 3H).
240	(ES+) 546.1 [M+H]	^{1}H NMR (400 MHz, CD_3CN): δ 9.20 (s, 2H), 8.12 - 8.06 (m, 2H), 7.70 - 7.68 (m, 1H), 7.61 (d, J = 1.2 Hz, 1H), 7.26 - 7.23 (m, 1H), 7.06 (s, 1H), 6.74 - 6.72 (m, 1H), 6.66 (d, J = 5.2 Hz, 1H), 6.47 (d, J = 8.4 Hz, 1H), 5.14 - 5.10 (m, 1H), 3.53 (s, 3H), 3.11 (s, 3H), 2.73 (s, 3H), 2.42 (s, 3H), 1.60 (d, J = 6.4 Hz, 3H).
241	(ES+) 587.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.29 (s, 1H), 8.05 - 7.95 (m, 2H), 7.64 - 7.62 (m, 1H), 7.55 (s, 1H), 7.44 (d, J = 1.6 Hz, 1H), 7.30 - 7.29 (m, 1H), 6.94 (s, 1H), 6.73 - 6.70 (m, 1H), 6.62 (d, J = 5.6 Hz, 1H), 6.45 (d, J = 8.4 Hz, 1H), 6.18 (d, J = 1.2 Hz, 1H), 5.26 - 5.22 (m, 1H), 4.83 (s, 2H), 4.26 - 4.24 (m, 2H), 4.12 - 4.04 (m, 2H), 3.40 (s, 3H), 3.24 (s, 3H), 2.38 (s, 3H), 1.52 (d, J = 6.4 Hz, 3H).
242	(ES+) 601.3 [M+H]	^{1}H NMR: (400 MHz, $CDCl_3$): δ 8.20 (s, 1H), 8.15 (s, 1H), 7.79 -7.76 (m, 1H), 7.50 (d, J = 1.2 Hz, 1H), 7.44 - 7.43 (m, 1H), 7.25 - 7.19 (m, 1H), 6.79 - 6.69 (m, 2H), 6.64 (s, 1H), 6.31 (d, J = 8.4 Hz, 1H), 5.92 (s, 1H), 4.99-4.93 (m, 1H), 4.85 (s, 2H), 4.36 - 4.29 (m, 2H), 4.17 - 4.08 (m, 2H), 3.50 (s, 3H), 3.13 (s, 3H), 2.43 (s, 3H), 2.29 (s, 3H), 1.62 (d, J = 6.4 Hz, 3H).
243	(ES+) 602.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.24 - 8.13 (m, 2H), 7.78 (br d, J = 8.0 Hz, 1H), 7.51 - 7.41 (m, 3H), 6.78 - 6.69 (m, 2H), 6.68 - 6.60 (m, 1H), 6.35 - 6.27 (m, 1H), 5.07-4.99 (m, 2H), 4.97 - 4.94 (m, 1H), 4.18-4.05 (m, 4H), 3.57 - 3.43 (m, 3H), 3.13 (s, 3H), 2.51 - 2.41 (m, 6H), 1.63 (d, J = 6.0 Hz, 3H).
244	(ES+) 540.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.43 (s, 2H), 8.98 (s, 1H), 8.38 - 8.15 (m, 2H), 8.04 (s, 1H), 7.63 (d, J = 7.2 Hz, 1H), 7.59 (s, 1H), 7.31 - 7.29 (m, 1H), 7.03 (s, 1H), 6.74 (m, 1H), 6.63 (d, J = 6.0 Hz, 1H), 6.49 (d, J = 8.4 Hz, 1H), 5.30 - 5.28 (m, 1H), 3.42 (s, 3H), 3.25 (s, 3H), 2.72 (s, 3H), 2.40 (s, 3H), 1.54 (d, J = 6.4 Hz, 3H).
245	(ES+) 540.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.63 (s, 1H), 8.97 (s, 2H), 8.75 - 8.65 (m, 1H), 8.24 (s, 1H), 7.79 (d, J = 7.2 Hz, 1H), 7.54 (s, 1H), 7.37 (d, J = 7.6 Hz, 1H), 7.23 - 7.21 (m, 1H), 6.78 - 6.71 (m, 3H), 6.33 (d, J = 8.4 Hz, 1H), 5.03 - 4.96 (m, 1H), 3.56 (s, 3H), 3.14 (s, 3H), 2.72 (s, 3H), 2.46 (s, 3H), 1.65 (d, J = 6.4 Hz, 3H).
246	(ES+) 564.3 [M+H]	^{1}H NMR (400 MHz, CD_3CN): δ 8.14 (s, 1H), 8.07 (s, 1H), 7.69 - 7.67 (m, 1H), 7.57 (d, J = 1.6 Hz, 1H), 7.50 - 7.48 (m, 1H), 7.30 - 7.20 (m, 1H), 6.77 (s, 1H), 6.75 - 6.70 (m, 1H), 6.65 (d, J = 5.6 Hz, 1H), 6.44 (d, J = 8.4 Hz, 1H), 5.14 - 5.11 (m, 1H), 3.61 - 3.53 (m, 4H), 3.40 (s, 3H), 3.11 (s, 3H), 2.56 - 2.49 (m, 4H), 2.39 (s, 3H), 2.29 (s, 3H), 1.58 (d, J = 6.4 Hz, 3H).

247	(ES+) 518.1 [M+H]	
248	(ES+) 616.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.68 (s, 2H), 8.00 (s, 1H), 7.80 (d, J = 7.9 Hz, 1H), 7.72 (d, J = 1.8 Hz, 1H), 7.13 (s, 1H), 7.00 – 6.86 (m, 1H), 6.70 – 6.65 (m, 1H), 6.10-6.05 (m, 1H), 4.05 – 3.60 (m, 2H), 3.58 (s, 3H), 3.39 – 3.33 (m, 2H), 3.28 – 3.22 (m, 2H), 3.21 – 3.19 (m, 3H), 3.18 – 3.14 (m, 2H), 2.40 (s, 3H), 2.20 (s, 3H), 1.57 (d, J = 6.8 Hz, 3H).
249	(ES+) 619.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.68 (s, 2H), 8.09 (s, 1H), 7.69 – 7.67 (m, 2H), 7.37 – 7.35 (m, 1H), 7.07 – 6.97 (m, 1H), 6.88 – 6.72 (m, 2H), 6.51 (d, J = 8.5 Hz, 1H), 5.60 – 5.52 (m, 1H), 5.01 – 4.98 (m, 2H), 4.05 – 3.97 (m, 2H), 3.62 (s, 3H), 3.41 – 3.33 (m, 4H), 3.25 (s, 3H), 3.20 – 3.15 (m, 2H), 2.37 (s, 3H).
250	(ES+) 601.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.70 (s, 2H), 7.98 (d, J = 1.7 Hz, 1H), 7.67 – 7.65 (m, 1H), 7.51 (d, J = 1.9 Hz, 1H), 7.41 – 7.32 (m, 1H), 7.02 – 6.70 (m, 3H), 6.53 (d, J = 8.4 Hz, 1H), 6.49 (s, 1H), 5.60 – 5.51 (m, 1H), 4.91 – 4.62 (m, 2H), 4.31 – 3.71 (m, 2H), 3.58 (s, 3H), 3.33 (s, 1H), 3.31 – 2.99 (m, 8H), 2.35 (s, 3H).
251	(ES+) 555.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.89 (s, 1H), 7.64 – 7.63 (m, 1H), 7.48 (s, 1H), 7.35 – 7.33 (m, 1H), 6.76 – 6.73 (m, 1H), 6.60 (d, J = 5.7 Hz, 1H), 6.50 (d, J = 8.5 Hz, 1H), 6.34 (s, 1H), 5.20 – 5.17 (m, 1H), 4.58 – 4.57 (m, 1H), 4.20 – 4.16 (m, 2H), 3.54 – 3.49 (m, 5H), 3.32 (s, 3H), 3.11 – 2.78 (m, 8H), 2.34 – 2.33 (m, 4H), 1.55 (d, J = 6.5 Hz, 3H), 1.19 (d, J = 4.8 Hz, 3H).
252	(ES+) 555.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.90 (s, 1H), 7.65 – 7.63 (m, 1H), 7.48 (s, 1H), 7.39 – 7.30 (m, 1H), 6.76 – 6.72 (m, 1H), 6.61 (d, J = 5.8 Hz, 1H), 6.51 (d, J = 8.5 Hz, 1H), 6.37 (s, 1H), 5.22 – 5.19 (m, 1H), 4.75 – 4.73 (m, 1H), 4.19 – 4.16 (m, 2H), 3.91 – 3.88 (m, 2H), 3.52 (s, 3H), 3.24 (s, 3H), 3.17 – 2.87 (m, 8H), 2.34 – 2.32 (m, 4H), 1.56 (d, J = 6.5 Hz, 3H), 1.19 (d, J = 5.0 Hz, 3H).
253	(ES+) 557.4 [M+H]	^{1}H NMR (400 MHz, CD_3OD) δ 8.47 (s, 2H), 8.04 (d, J = 1.7 Hz, 1H), 7.58 (d, J = 1.9 Hz, 1H), 7.29 – 7.25 (m, 1H), 7.22 – 7.13 (m, 1H), 6.72 – 6.70 (m, 1H), 6.55 (s, 1H), 6.49 (d, J = 8.4 Hz, 1H), 5.21 – 5.20 (m, 1H), 4.00 – 3.60 (m, 5H), 3.34 – 3.30 (m, 1H), 3.30 – 2.79 (m, 6H), 2.62 (s, 3H), 2.40 (s, 3H), 1.67 – 1.60 (m, 3H), 1.29 – 1.19 (m, 2H), 0.96 – 0.90 (m, 2H).
254	(ES+) 557.4 [M+H]	^{1}H NMR (400 MHz, CD_3OD) δ 8.47 (s, 2H), 8.04 (d, J = 1.7 Hz, 1H), 7.71 (d, J = 1.9 Hz, 1H), 7.32 – 7.30 (m, 1H), 7.21 – 7.20 (m, 1H), 6.72 – 6.70 (m, 1H), 6.57 (s, 1H), 6.50 (d, J = 8.2 Hz, 1H), 5.13 – 5.10 (m, 1H), 4.00 – 3.60 (m, 5H), 3.34 – 3.30 (m, 1H), 3.02 – 2.90 (m, 6H), 2.62 (s, 3H), 2.43 (s, 3H), 1.66 – 1.60 (m, 3H), 1.29 – 1.14 (m, 2H), 0.95 – 0.92 (m, 2H).

255	(ES+) 591.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.56 (s, 2H), 7.91 (s, 1H), 7.65-7.62 (m, 1H), 7.49 (d, J = 1.9 Hz, 1H), 7.38 – 7.29 (m, 1H), 6.76-6.73 (m, 1H), 6.61 (d, J = 5.7 Hz, 1H), 6.52 (d, J = 8.5 Hz, 1H), 6.44 (s, 1H), 5.26 – 5.23 (m, 1H), 4.88 (s, 1H), 4.10 – 3.81 (m, 2H), 3.56 (s, 3H), 3.32-3.24 (m, 6H), 3.15 (s, 3H), 2.34 (s, 3H), 1.57 (d, J = 6.5 Hz, 3H), 1.47 (s, 6H).
256	(ES+) 600.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.46 (s, 2H), 8.16 (d, J = 1.8 Hz, 1H), 7.82 – 7.76 (m, 1H), 7.47 (d, J = 1.9 Hz, 1H), 7.29 – 7.22 (m, 1H), 6.81 – 6.71 (m, 2H), 6.40 (d, J = 8.4 Hz, 1H), 6.27 (s, 1H), 5.02 – 4.91 (m, 1H), 3.85 – 3.60 (m, 5H), 3.50 – 2.80 (m, 9H), 2.42 (s, 3H), 1.82 (s, 6H), 1.68 (d, J = 6.7 Hz, 3H).
257	(ES+) 622.2 [M+H]	
258	(ES+) 549.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.13 (s, 1H), 7.82 – 7.77 (m, 1H), 7.45 (s, 1H), 7.40 (s, 1H), 7.28 – 7.24 (m, 1H), 6.78 – 6.71 (m, 2H), 6.38 (d, J = 8.4 Hz, 1H), 6.28 (s, 1H), 5.00 – 4.97 (m, 1H), 3.80 (s, 3H), 3.68 (s, 3H), 3.38 – 2.93 (m, 11H), 2.40 (s, 3H), 2.30 (s, 3H), 1.67 (d, J = 6.4 Hz, 3H).
259	(ES+) 549.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.14 (s, 1H), 7.83 – 7.75 (m, 1H), 7.46 (d, J = 1.9 Hz, 1H), 7.26 – 7.22 (m, 2H), 6.80 – 6.68 (m, 2H), 6.39 (d, J = 8.4 Hz, 1H), 6.28 (s, 1H), 5.03 – 4.95 (m, 1H), 3.84 (s, 3H), 3.68 (s, 3H), 3.23 – 3.13 (m, 11H), 2.41 (s, 3H), 2.32 (s, 3H), 1.68 (d, J = 6.6 Hz, 3H).
260	(ES+) 575.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.48 (s, 2H), 7.92 (d, J = 1.8 Hz, 1H), 7.55 (d, J = 8.0, 1.6 Hz, 1H), 7.44 (d, J = 1.9 Hz, 1H), 7.34 (d, J = 8.7, 7.1, 1.6 Hz, 1H), 6.81 (d, J = 5.9 Hz, 1H), 6.73 (d, J = 7.5 Hz, 1H), 6.53 – 6.47 (m, 1H), 6.43 (s, 1H), 5.22 (d, J = 6.4 Hz, 1H), 3.71 – 3.61 (m, 1H), 3.56 (s, 3H), 3.45 (d, J = 6.8 Hz, 1H), 3.32 – 3.27 (m, 2H), 3.25 – 2.95 (m, 5H), 2.46 (s, 3H), 2.34 (s, 3H), 1.54 (d, J = 6.5 Hz, 3H), 1.23 (d, J = 6.8, 2.6 Hz, 6H).
261	(ES+) 587.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.48 (s, 2H), 7.92 (d, J = 1.7 Hz, 1H), 7.57 (d, J = 8.0, 1.6 Hz, 1H), 7.46 (d, J = 1.9 Hz, 1H), 7.40 – 7.29 (m, 1H), 6.79 – 6.68 (m, 2H), 6.49 (d, J = 8.7 Hz, 1H), 6.42 (s, 1H), 5.21 (d, J = 6.4 Hz, 1H), 4.15 (d, J = 8.1 Hz, 1H), 3.95 – 3.69 (m, 1H), 3.56 (s, 3H), 3.27 (s, 2H), 3.25 – 2.86 (m, 4H), 2.35 (s, 3H), 2.25 (s, 1H), 2.16 (s, 3H), 2.14 (s, 2H), 2.10 (s, 2H), 2.01 – 1.85 (m, 2H), 1.55 (d, J = 6.5 Hz, 3H).
262	(ES+) 516.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.88 (d, J = 2.3 Hz, 1H), 8.25 (d, J = 1.7 Hz, 1H), 8.20 (d, J = 8.1 Hz, 1H), 7.97 – 7.84 (m, 1H), 7.79 – 7.63 (m, 1H), 7.54 (d, J = 1.7 Hz, 1H), 7.28 – 7.19 (m, 3H), 6.70 (s, 1H), 6.34 (d, J = 8.4 Hz, 1H), 5.04 – 4.93 (m, 1H), 3.61 – 3.51 (m, 1H), 3.50 (s, 3H), 3.14 (s, 3H), 2.46 (s, 3H), 1.65 (d, J = 6.7 Hz, 3H), 1.35 – 1.25 (m, 2H), 1.25 – 1.15 (m, 2H).

263	(ES-) 517.2 [M-H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.46 (s, 2H), 8.01 (s, 1H), 7.62 (s, 1H), 7.29 (d, J = 7.6 Hz, 1H), 7.13 – 7.09 (m, 1H), 7.04 – 7.67 (m, 1H), 6.68 – 6.63 (m, 1H), 6.57 (s, 1H), 6.41 (d, J = 7.6 Hz, 1H), 5.16 – 5.11 (m, 1H), 3.86-3.76 (m, 2H), 3.71 (s, 3H), 3.49 – 3.36 (m, 2H), 3.25 – 2.90 (m, 4H), 2.62 (s, 3H), 2.40 (s, 3H), 1.65 (d, J = 6.4 Hz, 3H).
264	(ES+) 563.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.42 (s, 2H), 7.91 (s, 1H), 7.65 – 7.64 (m, 1H), 7.49 (d, J = 1.6 Hz, 1H), 7.36 – 7.32 (m, 1H), 6.80 – 6.70 (m, 1H), 6.61 (d, J = 6.0 Hz, 1H), 6.52 (d, J = 8.4 Hz, 1H), 6.43 (s, 1H), 5.25 – 5.21 (m, 1H), 3.86 (s, 3H), 3.80 – 3.70 (m, 1H), 3.55 (s, 3H), 3.50 – 3.41 (m, 1H), 3.30 –3.28 (m, 2H), 3.24 (s, 3H), 3.21 – 2.80 (m, 4H), 2.34 (s, 3H), 1.57 (d, J = 6.4 Hz, 3H).
265	(ES+) 597.6 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.13 – 8.09 (m, 1H), 8.01 (s, 1H), 7.62 (s, 1H), 7.34 – 7.27 (m, 1H), 7.18 (d, J = 8.7 Hz, 1H), 6.94 – 6.80 (m, 2H), 5.35 – 5.22 (m, 1H), 3.77 (d, J = 11.7 Hz, 2H), 3.56 (s, 3H), 3.42 – 3.31 (m, 5H), 3.30-3.25 (m, 2H), 3.05 - 2.95 (d, J = 11.9 Hz, 2H), 2.38 – 2.28 (m, 9H), 1.58 – 1.51 (m, 3H).
266	(ES+) 539.5 [M+H]	
267	(ES+) 571.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.47 (s, 2H), 7.92 (s, 1H), 7.69 (d, J = 2.0 Hz, 1H), 7.49 – 7.40 (m, 2H), 6.84 (d, J = 5.9 Hz, 1H), 6.50 (d, J = 8.8 Hz, 1H), 6.41 (s, 1H), 5.31 – 5.24 (m, 1H), 4.03 (s, 1H), 3.90-3.49 (m, 5H), 3.30 (s, 3H), 3.28-2.85 (m, 6H), 2.52 (s, 3H), 2.34 (s, 3H), 1.57 (d, J = 6.5 Hz, 3H).
268	(ES+) 564.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.13 (d, J = 3.0 Hz, 1H), 7.91 (s, 1H), 7.66 – 7.62 (m, 1H), 7.59 – 7.55 (m, 1H), 7.49 (d, J = 1.9 Hz, 1H), 7.37 – 7.32 (m, 1H), 6.78 – 6.71 (m, 1H), 6.60 (d, J = 5.8 Hz, 1H), 6.52 (d, J = 8.3 Hz, 1H), 6.43 (s, 1H), 5.28 – 5.20 (m, 1H), 3.55 (s, 3H), 3.45-3.02 (m, 11H), 2.34 (s, 3H), 2.32 (s, 3H), 1.57 (d, J = 6.5 Hz, 3H).
269	(ES+) 572.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.68 (d, J = 3.0 Hz, 1H), 8.51 (d, J = 2.9 Hz, 1H), 7.91 (s, 1H), 7.78 (d, J = 1.3 Hz, 1H), 7.66 – 7.59 (m, 2H), 7.49 (d, J = 1.8 Hz, 1H), 7.34 (m, 1H), 6.74 (m, 1H), 6.61 (d, J = 5.8 Hz, 1H), 6.52 (d, J = 8.5 Hz, 1H), 6.44 (s, 1H), 5.27 – 5.20 (m, 1H), 3.56 (s, 3H), 3.31 – 3.26 (m, 2H), 3.26 – 3.21 (m, 4H), 3.21 – 2.68 (m, 5H), 2.34 (s, 3H), 1.57 (d, J = 6.5 Hz, 3H).
270	(ES+) 548.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.46 (s, 2H), 7.87 (s, 1H), 7.65 – 7.61 (m, 1H), 7.45 (d, J = 1.9 Hz, 1H), 7.36 – 7.30 (m, 1H), 6.76 – 6.71 (m, 1H), 6.58 (d, J = 5.8 Hz, 1H), 6.49 (d, J = 8.4 Hz, 1H), 6.31 (s, 1H), 5.26 –5.14 (m, 2H), 3.67-3.61 (m, 1H), 3.54-3.19 (m, 3H), 3.47-3.40 (m, 1H), 3.35-3.32 (m, 1H), 3.28 - 3.18 (m, 4H), 2.55 (s, 3H), 2.47-2.39 (m, 1H), 2.32 (s, 3H), 2.13 – 2.02 (m, 1H), 1.54 (d, J = 6.5 Hz, 3H).

271	(ES+) 548.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.46 (s, 2H), 7.87 (s, 1H), 7.65 – 7.61 (m, 1H), 7.45 (d, J = 1.9 Hz, 1H), 7.34–7.29 (m, 1H), 6.76 – 6.70 (m, 1H), 6.59 (d, J = 5.7 Hz, 1H), 6.48 (d, J = 8.4 Hz, 1H), 6.31 (s, 1H), 5.25 (d, J = 6.3 Hz, 1H), 5.21 – 5.13 (m, 1H), 3.65 – 3.61 (m, 1H), 3.56 - 3.41 (m, 4H), 3.36 - 3.32 (m, 1H), 3.22 (s, 4H), 2.55 (s, 3H), 2.47-2.39 (m, 1H), 2.32 (s, 3H), 2.13 – 2.04 (m, 1H), 1.55 (d, J = 6.5 Hz, 3H).
272	(ES+) 551.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.48 (s, 2H), 7.77-7.73 (m, 1H), 7.67-7.63 (m, 1H), 7.51-7.47 (m, 1H), 7.37-7.31 (m, 1H), 6.81 – 6.74 (m, 1H), 6.62 (d, J = 5.5 Hz, 1H), 6.49 (s, 1H), 6.44 (d, J = 8.4 Hz, 1H), 5.33 – 5.25 (m, 1H), 4.10 - 3.40 (m, 6H), 3.28 (s, 3H), 3.28 - 2.86 (m, 5H), 2.51 (s, 3H), 1.58 (d, J = 6.5 Hz, 3H).
273	(ES+) 601.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.25 (s, 1H), 8.00 (s, 1H), 7.90 - 7.88 (m, 1H), 7.69 - 7.61 (m, 1H), 7.55 (s, 1H), 7.45 (s, 1H), 7.30 - 7.27 (m, 1H), 6.93 (s, 1H), 6.73 - 6.70 (m, 1H), 6.62 (d, J = 5.6 Hz, 1H), 6.45 (d, J = 8.4 Hz, 1H), 5.28 - 5.25 (m, 1H), 4.62 (s, 2H), 3.81 - 3.75 (m, 5H), 3.40 (s, 3H), 3.24 (s, 3H), 2.72 - 2.71 (m, 2H), 2.38 (s, 3H), 1.52 (d, J = 6.4 Hz, 3H).
274	(ES+) 601.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.27 (s, 1H), 8.00 (s, 1H), 7.94 - 7.91 (m, 1H), 7.63 - 7.61 (m, 1H), 7.55 (d, J = 1.2 Hz, 1H), 7.34 - 7.26 (m, 1H), 7.24 (s, 1H), 6.93 (s, 1H), 6.73 - 6.71 (m, 1H), 6.62 (d, J = 5.6 Hz, 1H), 6.46 (d, J = 8.4 Hz, 1H), 5.26 - 5.24 (m, 1H), 4.69 (s, 2H), 3.74 - 3.70 (m, 5H), 3.40 (s, 3H), 3.25 (s, 3H), 2.68 - 2.66 (m, 2H), 2.38 (s, 3H), 1.52 (d, J = 6.4 Hz, 3H).
275	(ES+) 588.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.31 (s, 1H), 8.04 (d, J = 1.6 Hz, 2H), 7.98 (s, 1H), 7.63 - 7.61 (m, 1H), 7.56 (s, 1H), 7.30 - 7.29 (m, 1H), 6.94 (s, 1H), 6.73 - 6.71 (m, 1H), 6.62 (d, J = 5.6 Hz, 1H), 6.45 (d, J = 8.4 Hz, 1H), 5.26 - 5.24 (m, 1H), 4.87 (s, 2H), 4.32 - 4.29 (m, 2H) , 4.15 - 4.08 (m, 2H), 3.39 (s, 3H), 3.25 (s, 3H), 2.38 (s, 3H), 1.52 (d, J = 6.4 Hz, 3H).
276	(ES+) 588.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.24 - 8.14 (m, 3H), 7.77 - 7.76 (m, 1H), 7.50 (d, J = 1.2 Hz, 1H), 7.45 - 7.42 (m, 1H), 7.25 - 7.17 (m, 1H), 6.81 - 6.69 (m, 2H), 6.64 (s, 1H), 6.31 (d, J = 8.4 Hz, 1H), 5.06 (s, 2H), 5.01 - 4.89 (m, 1H), 4.39 - 4.23 (m, 2H), 4.11 - 4.09 (m, 2H), 3.49 (s, 3H), 3.13 (s, 3H), 2.43 (s, 3H), 1.62 (d, J = 6.8 Hz, 3H).
277	(ES+) 584.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.67 (s, 2H), 7.99 (s, 1H), 7.63 (d, J = 7.6 Hz, 1H), 7.54 (s, 1H), 7.46 (s, 1H), 7.34 - 7.25 (m, 1H), 6.94 (s, 1H), 6.76 - 6.69 (m, 1H), 6.62 (d, J = 5.2 Hz, 1H), 6.46 (d, J = 8.4 Hz, 1H), 5.33 - 5.21 (m, 1H), 4.87 (s, 2H), 4.11 - 4.06 (m, 2H), 3.77 (s, 3H), 3.42 (s, 3H), 3.25 (s, 3H), 2.64 - 2.60 (m, 2H), 2.38 (s, 3H), 1.52 (d, J = 6.4 Hz, 3H).

278	(ES+) 561.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.45-8.20 (m, 2H), 8.16 - 8.12 (m, 1H), 7.78 - 7.77 (m, 1H), 7.44 (s, 1H), 7.26 - 7.22 (m, 1H), 6.79 - 6.70 (m, 2H), 6.37 (d, J = 8.4 Hz, 1H), 6.25 (s, 1H), 5.00 - 4.91 (m, 1H), 4.27 - 4.09 (m, 1H), 3.71 (s, 3H), 3.49 - 3.28 (m, 3H), 3.26 - 3.17 (m, 2H), 3.13 (s, 3H), 3.02 - 2.83 (m, 1H), 2.70 (s, 3H), 2.40 (s, 3H), 1.67 (d, J = 6.8 Hz, 3H), 1.39 - 1.25 (m, 3H).
279	(ES+) 589.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.29 (s, 2H), 8.12 (s, 1H), 7.75 - 7.22 (m, 1H), 7.42 (d, J = 1.2 Hz, 1H), 7.25 - 7.19 (m, 1H), 6.77 - 6.65 (m, 2H), 6.35 (d, J = 8.4 Hz, 1H), 6.15 (s, 1H), 4.90 - 4.87 (m, 1H), 4.23-4.10 (m, 4H), 3.94 - 3.69 (m, 5H), 3.40 - 3.28 (m, 4H), 3.10 (s, 3H), 2.68 (s, 3H), 2.39 (s, 3H), 1.63 (d, J = 6.8 Hz, 3H).
280	(ES+) 572.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.10 (s, 1H), 7.85 - 7.74 (m, 2H), 7.41 (d, J = 1.6 Hz, 1H), 7.26 - 7.22 (m, 1H), 7.03 (d, J = 8.4 Hz, 1H), 6.80 - 6.65 (m, 3H), 6.39 (d, J = 8.4 Hz, 1H), 6.14 (s, 1H), 5.00 - 4.84 (m, 1H), 3.99 - 3.92 (m, 2H), 3.91 - 3.86 (m, 2H), 3.62 (s, 3H), 3.48 - 3.38 (m, 2H), 3.33 - 3.22 (m, 2H), 3.12 (s, 3H), 2.49 (s, 3H), 2.38 (s, 3H), 2.30 (m, 2H), 1.66 (d, J = 6.4 Hz, 3H).
281	(ES+) 573.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.22 (s, 2H), 8.10 (s, 1H), 7.77 - 7.76 (m, 1H), 7.41 (d, J = 1.6 Hz, 1H), 7.26 - 7.21 (m, 1H), 6.79 - 6.72 (m, 1H), 6.68 (d, J = 5.2 Hz, 1H), 6.38 (d, J = 8.4 Hz, 1H), 6.14 (s, 1H), 4.93 - 4.91 (m, 1H), 4.26 - 4.09 (m, 4H), 3.62 (s, 3H), 3.48 - 3.36 (m, 2H), 3.34 - 3.25 (m, 2H), 3.12 (s, 3H), 2.38 (s, 3H), 2.32 - 2.30 (m, 2H), 2.17 (s, 3H), 1.65 (d, J = 6.8 Hz, 3H).
282	(ES+) 534.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.22 (d, J = 1.2 Hz, 1H), 8.07 (s, 1H), 7.94 (s, 1H), 7.77 - 7.75 (m, 1H), 7.40 (d, J = 1.2Hz, 1H), 7.25 - 7.20 (m, 1H), 6.76 - 6.66 (m, 2H), 6.37 (d, J = 8.4 Hz, 1H), 5.79 (s, 1H), 5.46 - 5.45 (m, 1H), 4.92 - 4.90 (m, 1H), 4.45 - 4.32 (m, 2H), 4.00 - 3.86 (m, 2H), 3.58 (s, 3H), 3.12 (s, 3H), 2.51 (s, 3H), 2.36 (s, 3H), 1.65 (d, J = 6.4 Hz, 3H).
283	(ES+) 660.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.52 (s, 2H), 8.27 (s, 1H), 7.70 (d, J = 1.8 Hz, 1H), 7.42 (d, J = 5.8 Hz, 1H), 7.01 (d, J = 8.8 Hz, 1H), 6.79 – 6.51 (m, 2H), 5.56 – 5.49 (m, 1H), 4.91 – 4.48 (m, 2H), 3.84 – 3.70 (m, 2H), 3.65 (s, 3H), 3.50 – 3.05 (m, 6H), 2.45 – 2.40 (m, 6H), 1.51 – 1.30 (m, 3H), 1.21 – 1.00 (m, 2H).
284	(ES+) 642.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.51 (s, 2H), 8.21 (s, 1H), 7.53 (d, J = 1.9 Hz, 1H), 7.34 (d, J = 4.5 Hz, 1H), 6.97 (d, J = 8.6 Hz, 1H), 6.80 – 6.66 (m, 2H), 6.32 (s, 1H), 5.11 – 5.01 (m, 1H), 4.82 – 4.52 (m, 2H), 3.90 - 3.83 (m, 2H), 3.68 (s, 3H), 3.39 – 3.02 (m, 6H), 2.44 (s, 3H), 2.43 (s, 3H), 1.51 – 1.30 (m, 3H), 1.21 – 1.00 (m, 2H).
285	(ES+) 548.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.19 – 8.12 (m, 2H), 7.84 – 7.72 (m, 1H), 7.45 (d, J = 1.8 Hz, 1H), 7.30 – 7.20 (m, 1H), 6.80 – 6.71 (m, 1H), 6.71 (d, J = 5.4 Hz, 1H), 6.36 (d, J = 8.4 Hz, 1H), 6.23 (s, 1H), 5.01 – 4.85 (m, 3H), 3.72 (s, 3H), 3.56 - 3.15 (m, 4H), 3.11 (s, 3H), 2.95 - 2.80 (m, 2H), 2.56 (s, 3H), 2.38 (s, 3H), 1.65 (d, J = 6.4 Hz, 3H).

286	(ES+) 487.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.06 (s, 1H), 7.75-7.73 (m, 1H), 7.61 (s, 1H), 7.34-7.30 (m, 1H), 6.80-6.73 (m, 2H), 6.56-6.54 (m, 1H), 6.08-5.80 (m, 1H), 5.24– 5.20 (m, 1H), 3.75 (s, 3H), 3.14 (s, 3H), 2.43-2.38 (m, 9H), 1.68 (d, J = 6.8 Hz, 3H).
287	(ES+) 487.2 [M+H]	
288	(ES+) 529.7 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.68 (d, J = 1.3 Hz, 2H), 8.07 (d, J = 1.8 Hz, 1H), 7.75 – 7.70 (m, 1H), 7.63 (d, J = 1.8 Hz, 1H), 7.32 – 7.30 (m, 1H), 6.82 – 6.73 (m, 2H), 6.56 – 6.50 (m, 1H), 5.24 – 5.00 (m, 1H), 3.81 (d, J = 1.7 Hz, 3H), 3.15 (s, 3H), 2.73 – 2.62 (m, 9H), 2.44 (d, J = 1.7 Hz, 3H), 1.70 (d, J = 6.6 Hz, 3H).
289	(ES+) 529.7 [M+H]	
290	(ES+) 546.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6) δ 8.48 (s, 2H), 7.88 (d, J = 1.7 Hz, 1H), 7.50 (d, J = 7.8 Hz, 1H), 7.43 (d, J = 1.9 Hz, 1H), 7.00 (d, J = 8.5 Hz, 1H), 6.77 (d, J = 8.6 Hz, 1H), 6.44 (s, 1H), 5.16 – 5.10 (m, 1H), 4.00 – 3.60 (m, 5H), 3.25 – 3.00 (m, 6H), 2.96 (s, 3H), 2.52 (s, 3H), 2.33 (s, 3H), 2.25 (s, 3H), 1.51 – 1.49 (m, 3H).
291	(ES+) 546.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6) δ 8.47 (s, 2H), 7.88 (d, J = 1.7 Hz, 1H), 7.57 (d, J = 1.9 Hz, 1H), 7.37 (d, J = 5.2 Hz, 1H), 7.03 (d, J = 8.5 Hz, 1H), 6.78 (d, J = 8.6 Hz, 1H), 6.44 (s, 1H), 5.14 – 5.06 (m, 1H), 4.00 – 3.60 (m, 5H), 3.25 – 3.00 (m, 6H), 2.96 (s, 3H), 2.52 (s, 3H), 2.33 (s, 3H), 2.25 (s, 3H), 1.51 – 1.49 (m, 3H).
292	(ES+) 534.4 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.47 (s, 2H), 8.02 (s, 1H), 7.59 (d, J = 1.6 Hz, 1H), 7.02 – 6.97 (m, 1H), 6.83 – 6.70 (m, 2H), 6.57 (s, 1H), 5.17 – 5.12 (m, 1H), 3.98 – 3.75 (m, 2H), 3.71 (s, 3H), 3.50 – 3.35 (m, 2H), 3.27 – 2.86 (m, 4H), 2.62 (s, 3H), 2.40 (s, 3H), 2.35 (s, 3H), 1.65 (d, J = 6.4 Hz, 3H).
293	(ES+) 561.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.03 (s, 1H), 7.91 (s, 1H), 7.64 – 7.62 (m, 1H), 7.49 (d, J = 1.9 Hz, 1H), 7.34 – 7.32 (m, 1H), 6.78 – 6.70 (m, 1H), 6.61 (d, J = 5.8 Hz, 1H), 6.52 (d, J = 8.4 Hz, 1H), 6.44 (s, 1H), 5.28 – 5.20 (m, 1H), 3.55 (s, 3H), 3.32 (s, 2H), 3.31 – 2.91 (m, 9H), 2.48 (s, 3H), 2.38 (s, 3H), 2.34 (s, 3H), 1.57 (d, J = 6.5 Hz, 3H).
294	(ES+) 573.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6) δ 8.38 (s, 2H), 7.89 (s, 1H), 7.62 – 7.61 (m, 1H), 7.46 (d, J = 2.0 Hz, 1H), 7.34 – 7.25 (m, 1H), 6.73 (d, J = 7.5 Hz, 1H), 6.53 (d, J = 5.8 Hz, 1H), 6.46 (d, J = 8.5 Hz, 1H), 6.36 (s, 1H), 5.20 – 5.16 (m, 1H), 4.75 – 4.65 (m, 2H), 3.60 (s, 3H), 3.16 (s, 3H), 3.11 – 3.09 (m, 1H), 3.03 – 3.00 (m, 1H), 2.94 – 2.88 (m, 2H), 2.51 (s, 3H), 2.33 (s, 3H), 2.14 – 2.05 (m, 2H), 2.01 – 1.94 (m, 2H), 1.50 – 1.45 (d, 3H).

295	(ES+) 567.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.40 (s, 2H), 8.32 (d, J = 2.3 Hz, 1H), 7.85 – 7.78 (m, 1H), 7.60 (d, J = 2.3 Hz, 1H), 7.33 – 7.24 (m, 1H), 6.85 – 6.70 (m, 2H), 6.34 (d, J = 8.3 Hz, 1H), 6.24 (s, 1H), 4.97 – 4.89 (m, 1H), 3.90 – 3.53 (m, 5H), 3.48 – 2.88 (m, 9H), 2.73 (s, 3H), 1.69 (d, J = 6.7 Hz, 3H).
296	(ES+) 533.2 [M+H]	
297	(ES-) 533.4 [M-H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.48 (s, 2H), 7.88 (d, J = 2.0 Hz, 1H), 7.51 (d, J = 1.9 Hz, 1H), 7.35 – 6.93 (m, 2H), 6.86 (d, J = 7.8 Hz, 1H), 6.53 (d, J = 7.7 Hz, 1H), 6.46 (s, 1H), 6.34 (d, J = 8.2 Hz, 1H), 5.56 (d, J = 6.7 Hz, 1H), 5.15 - 5.01 (m, 1H), 4.20 - 3.61 (m, 2H), 3.56 (s, 3H), 3.29-2.72 (m, 6H), 2.52 (s, 3H), 2.32 (s, 3H), 1.53 (d, J = 6.6 Hz, 3H).
298	(ES-) 551.4 [M-H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.48 (s, 2H), 7.87 (d, J = 1.6 Hz, 1H), 7.50 (d, J = 2.0 Hz, 1H), 7.15 (d, J = 8.1 Hz, 1H), 7.00 - 6.94 (m, 1H), 6.58 – 6.51 (m, 1H), 6.47 (s, 1H), 6.38 (d, J = 8.4 Hz, 1H), 6.04 (d, J = 6.7 Hz, 1H), 5.17-5.07 (m, 1H), 3.98 – 3.64 (m, 2H), 3.56 (s, 3H), 3.29 – 2.87 (m, 6H), 2.52 (s, 3H), 2.32 (s, 3H), 1.54 (d, J = 6.6 Hz, 3H).
299	(ES+) 572.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.54 (d, J = 1.3 Hz, 2H), 7.92 (s, 1H), 7.53 – 7.44 (m, 2H), 7.19 (d, J = 6.2 Hz, 1H), 6.95 (d, J = 9.0 Hz, 1H), 6.41 (s, 1H), 5.31 – 5.25 (m, 1H), 4.22 (s, 1H), 3.55 (s, 3H), 3.39 (s, 3H), 3.34 - 2.80 (m, 8H), 2.55 (s, 3H), 2.35 (s, 3H), 1.56 (d, J = 6.5 Hz, 3H).
300	(ES+) 546.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.43 (s, 2H), 7.95 (s, 1H), 7.64 – 7.61 (m, 1H), 7.51 (d, J = 1.9 Hz, 1H), 7.36 – 7.27 (m, 1H), 6.77 – 6.68 (m, 2H), 6.58 (d, J = 5.9 Hz, 1H), 6.52 (d, J = 8.5 Hz, 1H), 5.32 – 5.25 (m, 1H), 3.93 – 3.85 (m, 2H), 3.63 (s, 3H), 3.20 (s, 3H), 3.06 – 3.01 (m, 1H), 2.92 – 2.86 (m, 2H), 2.49 (s, 3H), 2.36 (s, 3H), 2.07 – 1.98 (m, 2H), 1.88 – 1.74 (m, 2H), 1.55 (d, J = 6.5 Hz, 3H).
301	(ES+) 562.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.91 (s, 1H), 7.66-7.59 (m, 1H), 7.48 (d, J = 1.9 Hz, 1H), 7.36-7.27 (m, 1H), 6.77-6.69 (m, 1H), 6.60 (d, J = 5.8 Hz, 1H), 6.49 (d, J = 8.5 Hz, 1H), 6.40 (s, 1H), 5.27-5.16 (m, 1H), 4.90 - 3.88 (m, 2H), 3.59 (s, 3H), 3.28 - 2.58 (m, 9H), 2.45 (s, 3H), 2.38 (s, 3H), 2.34 (s, 3H), 1.54 (d, J = 6.5 Hz, 3H).
302	(ES+) 588.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.47 (s, 2H), 7.90 (d, J = 1.7 Hz, 1H), 7.46 (d, J = 1.9 Hz, 1H), 7.22 (d, J = 8.8 Hz, 1H), 6.91 (d, J = 8.9 Hz, 1H), 6.73 (d, J = 6.4 Hz, 1H), 6.43 (s, 1H), 5.25 - 5.19 (m, 1H), 3.80 - 3.57 (m, 2H), 3.55 (s, 3H), 3.31 (s, 3H), 3.30 - 2.81 (m, 6H), 2.52 (s, 3H), 2.34 (s, 3H), 1.98 - 1.92 (m, 1H), 1.52 (d, J = 6.5 Hz, 3H), 0.88 - 0.84 (m, 2H), 0.79 - 0.73 (m, 2H).

303	(ES+) 544.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.48 (s, 2H), 8.21 (s, 1H), 7.81 – 7.77 (m, 1H), 7.46 (d, J = 1.9 Hz, 1H), 7.24 – 7.21 (m, 1H), 6.79 – 6.73 (m, 1H), 6.72 – 6.69 (m, 1H), 6.41 – 6.37 (m, 1H), 6.28 (s, 1H), 4.97 – 4.91 (m, 1H), 3.67 – 3.60 (m, 5H), 3.42 – 3.37 (m, 2H), 3.17 – 3.12 (m, 3H), 2.48 (s, 3H), 2.40 – 2.36 (m, 3H), 2.34 – 2.30 (m, 1H), 2.05 – 2.00 (m, 2H), 1.67 (d, J = 6.4 Hz, 3H).
304	(ES+) 506.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.12 (s, 1H), 7.78 - 7.76 (m, 1H), 7.44 (s, 1H), 7.27 - 7.20 (m, 2H), 6.74 - 6.72 (m, 1H), 6.68 (s, 1H), 6.44 - 6.22 (m, 2H), 4.94 - 4.92 (m, 1H), 4.41 - 4.13 (m, 3H), 3.91 (s, 3H), 3.68 (s, 3H), 3.54 - 3.35 (m, 1H), 3.13 (s, 3H), 3.00 - 2.65 (m, 2H), 2.39 (s, 3H), 1.62 (d, J = 5.2 Hz, 3H).
305	(ES+) 506.3 [M+H]	
306	(ES+) 532.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.16 (s, 1H), 8.00-7.77 (m, 1H), 7.45 (s, 1H), 7.25 - 7.21 (m, 1H), 7.18 - 7.06 (m, 1H), 7.04 - 6.79 (m, 1H), 6.78 - 6.70 (m, 2H), 6.52 (s, 1H), 6.36 (d, J = 8.4 Hz, 1H), 5.00 - 4.96 (m, 1H), 3.85 (s, 3H), 3.78 (s, 3H), 3.73 - 3.54 (m, 2H), 3.28 - 3.01 (m, 5H), 2.47 - 2.20 (m, 4H), 2.13 - 1.99 (m, 2H), 1.66 (d, J = 6.4 Hz, 3H).
307	(ES+) 561.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.42 (s, 2H), 7.91 (s, 1H), 7.64 - 7.62 (m, 1H), 7.49 (d, J = 1.6 Hz, 1H), 7.38 - 7.30 (m, 1H), 6.74 - 6.72 (m, 1H), 6.60 (d, J = 5.6 Hz, 1H), 6.51 (d, J = 8.4 Hz, 1H), 6.42 (s, 1H), 5.29 - 5.17 (m, 1H), 4.51 - 4.00 (m, 1H), 3.60 (s, 3H), 3.55 - 3.48 (m, 1H), 3.30 - 3.25 (m, 2H), 3.24 (s, 3H), 3.20-3.10 (m, 2H), 2.94 - 2.83 (m, 1H), 2.51 (s, 3H), 2.34 (s, 3H), 1.56 (d, J = 6.4 Hz, 3H), 1.24-1.10 (m, 3H).
308	(ES+) 573.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.10 (s, 1H), 7.95 (d, J = 0.8 Hz, 1H), 7.80 - 7.74 (m, 2H), 7.42 (d, J = 1.6 Hz, 1H), 7.26 - 7.21 (m, 1H), 6.79 - 6.72 (m, 1H), 6.69 (m, 1H), 6.38 (d, J = 8.4 Hz, 1H), 6.15 (s, 1H), 5.00 - 4.84 (m, 1H), 4.14 - 4.03 (m, 4H), 3.62 (s, 3H), 3.48 - 3.38 (m, 2H), 3.29 (m, 2H), 3.12 (s, 3H), 2.43 (s, 3H), 2.38 (s, 3H), 2.32 - 2.28 (m, 2H), 1.66 (d, J = 6.8 Hz, 3H).
309	(ES+) 565.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.20 (s, 1H), 8.05 (s, 1H), 7.78 - 7.24 (m, 1H), 7.49 (s, 1H), 7.26 - 7.16 (m, 2H), 6.79 - 6.70 (m, 2H), 6.62 (s, 1H), 6.32 (d, J = 8.4 Hz, 1H), 4.96 - 4.94 (m, 1H), 4.25 (d, J = 9.0 Hz, 2H), 4.06 (d, J = 8.4 Hz, 2H), 3.50 (s, 3H), 3.32 (s, 3H), 3.13 (s, 3H), 2.42 (s, 3H), 1.64 - 1.60 (m, 6H).
310	(ES+) 551.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.19 (s, 1H), 8.05 (s, 1H), 7.78 - 7.76 (m, 1H), 7.49 (d, J = 1.2 Hz, 1H), 7.26 - 7.17 (m, 2H), 6.77 - 6.70 (m, 2H), 6.63 (s, 1H), 6.32 (d, J = 8.4 Hz, 1H), 4.96 - 4.94 (m, 1H), 4.24-4.16 (m, 4H), 3.49 (s, 3H), 3.13 (s, 3H), 2.42 (s, 3H), 2.23 - 2.10 (m, 1H), 1.68 (s, 3H), 1.62 (d, J = 6.8 Hz, 3H).

311	(ES+) 560.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.20 (s, 1H), 8.09 (s, 1H), 7.78 - 7.76 (m, 1H), 7.49 (d, J = 1.2 Hz, 1H), 7.32 - 7.30 (m, 1H), 7.25 - 7.18 (m, 1H), 6.79 - 6.70 (m, 2H), 6.62 (s, 1H), 6.32 (d, J = 8.4 Hz, 1H), 4.96 - 4.92 (m, 1H), 4.62 - 4.59 (m, 2H), 4.16 - 4.14 (m, 2H), 3.49 (s, 3H), 3.13 (s, 3H), 2.43 (s, 3H), 1.83 (s, 3H), 1.63 (d, J = 6.8 Hz, 3H).
312	(ES+) 577.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.19 (s, 1H), 8.05 (s, 1H), 7.78 - 7.76 (m, 1H), 7.48 (d, J = 1.6 Hz, 1H), 7.25 - 7.17 (m, 2H), 6.76 - 6.70 (m, 2H), 6.62 (s, 1H), 6.32 (d, J = 8.4 Hz, 1H), 5.03 - 4.91 (m, 1H), 4.37 - 4.31 (m, 2H), 4.26 - 4.20 (m, 2H), 3.96-3.90 (m, 2H), 3.50 (s, 3H), 3.13 (s, 3H), 2.42 (s, 3H), 2.25 - 2.20 (m, 2H), 2.03 - 1.97 (m, 2H), 1.62 (d, J = 6.4 Hz, 3H).
313	(ES+) 578.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.20 (s, 1H), 8.14 (s, 1H), 7.79 - 7.77 (m, 1H), 7.49 (s, 1H), 7.39 - 7.36 (m, 1H), 7.30 - 7.27 (m, 1H), 6.74 - 6.72 (m, 2H), 6.63 (s, 1H), 6.32 - 6.30 (m, 1H), 5.02 - 4.98 (m, 1H), 4.32 (s, 2H), 3.95 - 3.92 (m, 2H), 3.54 - 3.53 (m, 2H), 3.50 (s, 3H), 3.13 (s, 3H), 3.06 (s, 3H), 2.43 (s, 3H), 1.63 (d, J = 6.4 Hz, 3H).
314	(ES+) 564.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.20 (s, 1H), 8.15 (s, 1H), 7.78 - 7.76 (m, 1H), 7.50 - 7.49 (m, 1H), 7.38 - 7.37 (m, 1H), 7.27 - 7.25 (m, 1H), 6.74 - 6.73 (m, 2H), 6.64 (s, 1H), 6.32 - 6.30 (m, 1H), 6.12 - 6.10 (m, 1H), 4.99 - 4.95 (m, 1H), 4.35 (s, 2H), 3.95 - 3.93 (m, 2H), 3.59 - 3.58 (m, 2H), 3.50 (s, 3H), 3.13 (s, 3H), 2.43 (s, 3H), 1.63 (d, J = 6.4 Hz, 3H).
315	(ES+) 580.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.11 (s, 1H), 7.79 – 7.60 (m, 1H), 7.42 (s, 1H), 7.26 - 7.19 (m, 1H), 6.81 - 6.63 (m, 2H), 6.36 (d, J = 8.4 Hz, 1H), 6.17 (s, 1H), 5.04 - 4.83 (m, 1H), 3.78 - 3.42 (m, 7H), 3.40 - 3.23 (m, 2H), 3.12 (s, 3H), 2.80 - 2.34 (m, 10H), 2.11 (s, 3H), 2.08 - 1.90 (m, 2H), 1.87 - 1.71 (m, 2H), 1.64 (d, J = 6.8 Hz, 3H).
316	(ES+) 593.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.48 (s, 2H), 8.12 (s, 1H), 7.73 (s, 1H), 7.09 (d, J = 8.8 Hz, 1H), 6.82 (d, J = 8.8 Hz, 1H), 5.45 – 5.35 (m, 1H), 3.83 - 3.77 (m, 2H), 3.71 (s, 3H), 3.64 - 3.59 (m, 2H), 3.40 - 3.31 (m, 5H), 3.19 - 3.13 (m, 2H), 2.78 (s, 3H), 2.62 (s, 3H), 2.42 (s, 3H), 2.37 (s, 3H), 1.63 (d, J = 6.4 Hz, 3H), 1.57 - 1.51 (m, 1H).
317	(ES+) 593.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.48 (s, 2H), 8.12 (s, 1H), 7.77 (d, J = 1.8 Hz, 1H), 7.09 (d, J = 8.6 Hz, 1H), 6.81 (d, J = 8.7 Hz, 1H), 5.50 – 5.28 (m, 1H), 3.84 - 3.76 (m, 2H), 3.72 (s, 3H), 3.70 – 3.50 (m, 2H), 3.42 – 3.33 (m, 2H), 3.34 (s, 3H), 3.21 – 3.11 (m, 2H), 2.79 (s, 3H), 2.62 (s, 3H), 2.42 (s, 3H), 2.37 (s, 3H), 1.63 (d, J = 6.4 Hz, 3H).
318	(ES-) 579.3 [M-H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.47 (d, J = 2.9 Hz, 2H), 8.01 (s, 1H), 7.70 – 7.45 (m, 3H), 7.10 – 7.08 (m, 1H), 6.75 (d, J = 8.5 Hz, 1H), 6.67 (s, 1H), 5.35 - 5.20 (m, 1H), 3.78 – 3.75 (m, 2H), 3.57 (s, 3H), 3.56 – 3.40 (m, 4H), 3.33 – 3.04 (m, 3H), 3.06 - 2. 96 (m, 2H), 2.51 – 2.33 (m, 6H), 1.54 (d, J = 6.3 Hz, 3H).

319	(ES-) 561.3 [M-H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.48 (s, 2H), 7.90 (s, 1H), 7.57 (s, 1H), 7.48 (d, J = 1.9 Hz, 1H), 7.10 (d, J = 8.6 Hz, 1H), 6.80 (d, J = 8.6 Hz, 1H), 6.63 (d, J = 6.3 Hz, 1H), 6.45 (s, 1H), 5.24 – 5.16 (m, 1H), 3.94 – 3.67 (m, 2H), 3.56 (s, 3H), 3.32 – 2.52 (m, 9H), 2.34 (s, 3H), 2.31 (s, 3H), 1.52 (d, J = 6.5 Hz, 3H).
320	(ES+) 561.3 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.47 (s, 2H), 8.02 (s, 1H), 7.62 (d, J = 1.8 Hz, 1H), 7.07 (d, J = 8.7 Hz, 1H), 6.81 (d, J = 8.7 Hz, 1H), 6.58 (s, 1H), 5.14 – 5.12 (m, 1H), 3.90 – 3.80 (m, 2H), 3.70 (s, 3H), 3.33 – 3.32 (m, 6H), 3.31 (s, 3H), 2.61 (s, 3H), 2.40 – 2.36 (m, 6H), 1.65 (d, J = 6.7 Hz, 3H).
321	(ES+) 561.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.47 (s, 2H), 8.02 (s, 1H), 7.62 (d, J = 1.8 Hz, 1H), 7.08 (d, J = 8.6 Hz, 1H), 6.81 (d, J = 8.7 Hz, 1H), 6.56 (s, 1H), 5.14 – 5.12 (m, 1H), 3.90 – 3.80 (m, 2H), 3.71 (s, 3H), 3.33 – 3.32 (m, 6H), 3.31 (s, 3H), 2.61 (s, 3H), 2.40 – 2.36 (m, 6H), 1.65 (d, J = 6.6 Hz, 3H).
322	(ES+) 547.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.85 (d, J = 5.7 Hz, 1H), 7.92 (s, 1H), 7.64 – 7.60 (m, 1H), 7.50 (d, J = 1.9 Hz, 1H), 7.39 – 7.30 (m, 1H), 7.13 (d, J = 5.7 Hz, 1H), 6.73 – 6.69 (m, 1H), 6.62 (d, J = 5.8 Hz, 1H), 6.53 (d, J = 8.5 Hz, 1H), 6.47 (s, 1H), 5.30 – 5.20 (m, 1H), 3.56 (s, 3H), 3.51 (s, 3H), 3.30 - 3.20 (m, 4H), 3.20 - 3.05 (m, 4H), 2.63 (s, 3H), 2.35 (s, 3H), 1.58 (d, J = 6.5 Hz, 3H).
323	(ES+) 519.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.12 (s, 1H), 7.83 – 7.75 (m, 1H), 7.44 (d, J = 1.8 Hz, 1H), 7.27 – 7.21 (m, 1H), 6.81 – 6.73 (m, 1H), 6.71 (d, J = 5.3 Hz, 1H), 6.37 (d, J = 8.4 Hz, 1H), 6.22 (s, 1H), 4.98 – 4.89 (m, 1H), 3.64 (s, 3H), 3.24 – 3.02 (m, 6H), 3.00 – 2.87 (m, 2H), 2.59 – 2.47 (m, 2H), 2.40 (s, 3H), 1.66 (d, J = 6.7 Hz, 3H), 1.55 – 1.43 (m, 6H).
324	(ES+) 519.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.12 (s, 1H), 7.83 – 7.75 (m, 1H), 7.44 (d, J = 1.8 Hz, 1H), 7.27 – 7.21 (m, 1H), 6.81 – 6.73 (m, 1H), 6.71 (d, J = 5.3 Hz, 1H), 6.37 (d, J = 8.4 Hz, 1H), 6.22 (s, 1H), 4.98 – 4.89 (m, 1H), 3.64 (s, 3H), 3.24 – 3.02 (m, 6H), 3.00 – 2.87 (m, 2H), 2.59 – 2.47 (m, 2H), 2.40 (s, 3H), 1.66 (d, J = 6.7 Hz, 3H), 1.55 – 1.43 (m, 6H).
325	(ES+) 517.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.38 (d, J = 0.7 Hz, 1H), 8.11 (d, J = 5.6 Hz, 2H), 7.96 (s, 1H), 7.90 (d, J = 0.8 Hz, 1H), 7.75 – 7.72 (m, 1H), 7.64 (d, J = 1.8 Hz, 1H), 7.29 – 7.26 (m, 1H), 7.08 (s, 1H), 6.78 – 6.74 (m, 1H), 6.50 (d, J = 8.6 Hz, 1H), 5.23 – 5.15 (m, 1H), 3.98 (s, 3H), 3.69 (s, 3H), 3.17 (s, 3H), 2.45 (s, 3H), 1.67 (d, J = 6.7 Hz, 3H).
326	(ES+) 577.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.48 (s, 2H), 7.89 (s, 1H), 7.46 (s, 1H), 7.02 (d, J = 8.5 Hz, 1H), 6.74 (d, J = 8.5 Hz, 1H), 6.45 (s, 1H), 5.20 – 5.16 (m, 1H), 3.81 (s, 1H), 3.55 (s, 3H), 3.35 (s, 3H), 3.31 - 2.88 (m, 5H), 2.55-2.45 (m, 3H), 2.32 (s, 3H), 2.27 (s, 3H), 2.15 - 1.99 (m, 3H), 1.54 (d, J = 6.3 Hz, 3H).

327	(ES+) 548.4 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.01 (s, 1H), 7.72 – 7.68 (m, 1H), 7.56 (d, J = 1.8 Hz, 1H), 7.35 – 7.25 (m, 2H), 6.80 – 6.71 (m, 1H), 6.68 (d, J = 5.9 Hz, 1H), 6.53 (d, J = 8.4 Hz, 1H), 6.46 (s, 1H), 5.52 (d, J = 2.1 Hz, 1H), 5.17 – 5.05 (m, 1H), 4.48 – 4.43 (m, 2H), 4.34 – 4.27 (m, 2H), 3.66 (s, 3H), 3.24 – 3.06 (m, 11H), 2.40 (s, 3H), 1.66 (d, J = 6.6 Hz, 3H).
328	(ES+) 596.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.91 (d, J = 1.8 Hz, 1H), 7.68 – 7.61 (m, 1H), 7.50 (d, J = 1.9 Hz, 1H), 7.39 – 7.30 (m, 1H), 6.90 (s, 1H), 6.79 – 6.71 (m, 1H), 6.61 (d, J = 5.7 Hz, 1H), 6.52 (d, J = 8.5 Hz, 1H), 6.42 (s, 1H), 5.78 (s, 1H), 5.27 – 5.17 (m, 1H), 3.60 (s, 3H), 3.45 – 3.20 (m, 6H), 3.18 – 2.97 (m, 5H), 2.35 (s, 3H), 1.57 (d, J = 6.5 Hz, 3H), 1.46 (s, 6H).
329	(ES+) 579.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6) δ 8.17 (d, J = 2.5 Hz, 1H), 7.91 (s, 1H), 7.45 – 7.40 (m, 2H), 7.21 (d, J = 8.7 Hz, 1H), 6.94 (d, J = 8.7 Hz, 1H), 6.86 (d, J = 6.3 Hz, 1H), 6.48 (s, 1H), 5.29 - 5.21 (m, 1H), 3.56 (s, 3H), 3.34 (s, 3H), 3.15 – 3.10 (m, 8H), 2.48 (s, 3H), 2.35 (s, 3H), 2.32 (s, 3H), 1.54 (d, J = 6.5 Hz, 3H).
330	(ES+) 590.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6) δ 8.36 (d, J = 2.3 Hz, 1H), 7.91 (d, J = 1.9 Hz, 1H), 7.75 – 7.70 (m, 1H), 7.46 (d, J = 1.9 Hz, 1H), 7.21 (d, J = 8.7 Hz, 1H), 6.94 (d, J = 8.8 Hz, 1H), 6.84 (d, J = 6.4 Hz, 1H), 6.48 (s, 1H), 5.28 – 5.20 (m, 1H), 3.56 – 3.33 (m, 1H), 3.32 (s, 3H), 3.27 – 3.25 (m, 1H) 3.23 (s, 3H), 3.20 – 3.00 (m, 6H), 2.35 (s, 3H), 2.31 (s, 3H), 1.53 – 1.50 (d, J = 6.6 Hz, 3H).
331	(ES+) 588.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.41 (s, 2H), 8.14 (s, 1H), 7.71 (d, J = 7.6, 1H), 7.50 (s, 1H), 7.26 – 7.22 (m, 1H), 6.77 – 6.29 (m, 2H), 6.38 (d, J = 8.4 Hz, 1H), 6.29 (s, 1H), 4.97 – 4.94 (m, 1H), 3.93 – 3.89 (m, 4H), 3.73 - 3.62 (m, 5H), 3.47 – 2.90 (m, 6H), 2.72 (s, 3H), 2.41 (s, 3H), 2.22 – 2.15 (m, 2H), 1.66 (d, J = 6.8 Hz, 3H).
332	(ES+) 576.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.48 (s, 2H), 7.91 (s, 1H), 7.53 – 7.49 (m, 1H), 7.42 (d, J = 1.2 Hz, 1H), 7.33 – 7.25 (m, 1H), 6.74 – 6.65 (m, 2H), 6.53 – 6.42 (m, 1H), 6.44 (s, 1H), 5.27 – 5.15 (m, 1H), 4.15 – 3.57 (m, 2H), 3.56 (s, 3H), 3.30 – 2.85 (m, 6H), 2.80 - 2.60 (m, 6H), 2.49 (s, 3H), 2.33 (s, 3H), 1.54 (d, J = 6.4 Hz, 3H).
333	(ES+) 564.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.88 (s, 2H), 7.91 (s, 1H), 7.70 – 7.60 (m, 1H), 7.49 (d, J = 1.9 Hz, 1H), 7.40 – 7.31 (m, 1H), 6.81 – 6.66 (m, 1H), 6.61 (d, J = 5.8 Hz, 1H), 6.54 (d, J = 8.5 Hz, 1H), 6.45 (s, 1H), 5.35 – 5.18 (m, 1H), 3.59 (s, 3H), 3.30 – 3.20 (m, 5H), 3.16 – 2.98 (m, 2H), 2.63 (s, 3H), 2.55 – 2.38 (m, 5H), 2.22 – 2.08 (m, 2H), 1.57 (d, J = 6.5 Hz, 3H).
334	(ES+) 523.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.93 (s, 1H), 7.55 – 7.63 (m, 1H), 7.49 (d, J = 1.6 Hz, 1H), 7.36 – 7.31 (m, 1H), 6.79 – 6.70 (m, 1H), 6.61 (d, J = 5.6 Hz, 1H), 6.49 (d, J = 8.4 Hz, 1H), 6.42 (s, 1H), 5.25 – 5.16 (m, 1H), 4.78 – 3.85 (m, 2H), 3.56 (s, 3H), 3.32 (s, 3H), 3.24 (s, 3H), 3.18 – 2.75 (m, 3H), 2.34 (s, 3H), 2.09 - 2.00 (m, 1H), 1.55 (d, J = 6.8 Hz, 3H), 0.80 - 0.70 (m, 4H).

335	(ES+) 553.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.89 (d, J = 1.6 Hz, 1H), 7.65 – 7.62 (m, 1H), 7.47 (d, J = 1.9 Hz, 1H), 7.36 – 7.31 (m, 1H), 6.76 – 6.73 (m, 1H), 6.59 (d, J = 5.8 Hz, 1H), 6.50 (d, J = 8.5 Hz, 1H), 6.34 (s, 1H), 5.22 – 5.16 (m, 1H), 3.93 – 3.89 (m, 1H), 3.59 – 3.54 (m, 1H), 3.49 (s, 3H), 3.37 - 3.27 (m, 5H), 3.17 – 2.62 (m, 7H), 2.33 (s, 3H), 1.97 – 1.92 (m, 1H), 1.61 – 1.54 (m, 4H), 1.24 (s, 3H), 1.16 (s, 3H).
336	(ES+) 553.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.89 (s, 1H), 7.64 – 7.62 (m, 1H), 7.47 (d, J = 1.9 Hz, 1H), 7.35 – 7.31 (m, 1H), 6.79 – 6.70 (m, 1H), 6.59 (d, J = 5.8 Hz, 1H), 6.50 (d, J = 8.5 Hz, 1H), 6.34 (s, 1H), 5.22 – 5.16 (m, 1H), 3.93 – 3.89 (m, 1H), 3.57 – 3.55 (m, 1H), 3.49 (s, 3H), 3.23 (s, 3H), 3.20 – 2.54 (m, 8H), 2.38 - 2.25 (m, 4H), 1.97 – 1.92 (m, 1H), 1.61 – 1.52 (m, 4H), 1.24 (s, 3H), 1.16 (s, 3H).
337	(ES+) 525.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.89 (d, J = 1.8 Hz, 1H), 7.66-7.62 (m, 1H), 7.47 (d, J = 1.9 Hz, 1H), 7.36-7.31 (m, 1H), 6.76-6.72 (m, 1H), 6.59 (d, J = 5.8 Hz, 1H), 6.50 (d, J = 8.2 Hz, 1H), 6.34 (s, 1H), 5.20-5.17 (m, 1H), 3.83-3.80 (m, 2H), 3.69-3.65 (m, 1H), 3.55-3.51 (m, 1H), 3.50 (s, 3H), 3.36 - 3.28 (m, 2H), 3.23 (s, 3H), 3.02-2.95 (m, 6H), 2.33 (s, 3H), 2.02-1.98 (m, 1H), 1.79-1.76 (m, 1H), 1.55 (d, J = 6.5 Hz, 3H), 1.31 - 1.20 (m, 1H).
338	(ES+) 525.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.89 (d, J = 1.8 Hz, 1H), 7.66-7.62 (m, 1H), 7.47 (d, J = 1.9 Hz, 1H), 7.36-7.31 (m, 1H), 6.76-6.72 (m, 1H), 6.59 (d, J = 5.8 Hz, 1H), 6.50 (d, J = 8.2 Hz, 1H), 6.34 (s, 1H), 5.20-5.17 (m, 1H), 3.83-3.80 (m, 2H), 3.69-3.65 (m, 1H), 3.55-3.51 (m, 1H), 3.50 (s, 3H), 3.32 (s, 2H), 3.23 (s, 3H), 3.02-2.92 (m, 6H), 2.33 (s, 3H), 2.02-1.98 (m, 1H), 1.79-1.76 (m, 1H), 1.55 (d, J = 6.5 Hz, 3H), 1.33 - 1.19 (m, 1H).
339	(ES+) 584.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.69 (s, 2H), 8.00 (s, 1H), 7.63 - 7.62 (m, 1H), 7.55 (d, J = 1.6 Hz, 1H), 7.30 - 7.28 (m, 1H), 7.25 (s, 1H), 6.96 (s, 1H), 6.73 - 6.71 (m, 1H), 6.63 (d, J = 5.6 Hz, 1H), 6.46 (d, J = 8.4 Hz, 1H), 5.27 - 5.25 (m, 1H), 4.95 (s, 2H), 4.08 - 4.06 (m, 2H), 3.76 (s, 3H), 3.43 (s, 3H), 3.25 (s, 3H), 2.62 - 2.60 (m, 2H), 2.38 (s, 3H), 1.53 (d, J = 6.8 Hz, 3H).
340	(ES+) 568.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.17 (s, 1H), 7.82 – 7.77 (m, 1H), 7.47 (d, J = 1.2 Hz, 1H), 7.33 (s, 1H), 7.28 - 7.22 (m, 1H), 7.19 (s, 1H), 7.15 - 6.92 (m, 1H), 6.81 - 6.69 (m, 2H), 6.55 (s, 1H), 6.38 (d, J = 8.4 Hz, 1H), 5.04 – 4.97 (m, 1H), 3.79 (s, 3H), 3.67 (d, J = 8.8 Hz, 2H), 3.27 – 3.21 (m, 2H), 3.14 (s, 3H), 2.42 (s, 3H), 2.19 (d, J = 3.6 Hz, 1H), 2.16 - 2.01 (m, 2H), 1.67 (d, J = 6.8 Hz, 3H).
341	(ES+) 585.5 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.16 (s, 1H), 7.80 – 7.77 (m, 1H), 7.46 (s, 1H), 7.26 - 7.22 (m, 2H), 7.21 - 7.09 (m, 1H), 6.79 - 6.70 (m, 2H), 6.53 (s, 1H), 6.37 (d, J = 8.4 Hz, 1H), 5.12 - 4.91 (m, 1H), 3.77 (s, 3H), 3.66 (d, J = 8.4 Hz, 2H), 3.23 - 3.16 (m, 2H), 3.13 (s, 3H), 2.40 (s, 3H), 2.32 - 2.20 (m, 1H), 2.14 - 2.00 (m, 2H), 1.98 (s, 6H), 1.68 - 1.64 (m, 3H).

342	(ES+) 575.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.59 - 8.36 (m, 2H), 8.10 (s, 1H), 7.75 - 7.73 (m, 1H), 7.41 (d, J = 1.6 Hz, 1H), 7.23 - 7.18 (m, 1H), 6.74 - 6.65 (m, 2H), 6.36 (d, J = 8.4 Hz, 1H), 6.18 (s, 1H), 4.97 - 4.90 (m, 1H), 3.67 (s, 3H), 3.48 - 3.25 (m, 2H), 3.23 - 3.12 (m, 2H), 3.08 (s, 3H), 2.72 (s, 3H), 2.67 - 2.53 (m, 2H), 2.36 (s, 3H), 1.63 (d, J = 6.8 Hz, 3H), 0.86 - 0.75 (m, 6H).
343	(ES+) 583.2 [M+Na]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.75 (s, 2H), 8.15 (s, 1H), 7.78 - 7.76 (m, 1H), 7.48 (d, J = 1.6 Hz, 1H), 7.26 - 7.21 (m, 1H), 6.79 - 6.71 (m, 2H), 6.39 - 6.28 (m, 2H), 4.99 - 4.79 (m, 1H), 4.08 - 3.80 (m, 4H), 3.71 (s, 3H), 3.58 - 3.38 (m, 2H), 3.13 (s, 3H), 2.79 (s, 3H), 2.42 (s, 3H), 1.66 (d, J = 6.8 Hz, 3H).
344	(ES+) 573.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.46 (s, 2H), 8.11 (s, 1H), 7.83 - 7.68 (m, 1H), 7.42 (d, J = 1.2 Hz, 1H), 7.25 - 7.15 (m, 1H), 6.80 - 6.61 (m, 2H), 6.43 - 6.28 (m, 1H), 6.18 - 6.02 (m, 1H), 4.89 - 4.86 (m, 1H), 3.95 - 3.77 (m, 2H), 3.68 (s, 3H), 3.60 - 3.39 (m, 1H), 3.09 (s, 3H), 3.04 - 2.91 (m, 1H), 2.88 - 2.74 (m, 1H), 2.68 (s, 3H), 2.43-2.28 (m, 4H), 1.63 (d, J = 6.8 Hz, 3H), 1.14 - 0.93 (m, 4H).
345	(ES+) 451.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.14 (s, 1H), 7.78 - 7.77 (m, 1H), 7.43 (d, J = 1.6 Hz, 1H), 7.27 - 7.20 (m, 1H), 6.79 - 6.71 (m, 1H), 6.67 (d, J = 5.2 Hz, 1H), 6.45 (s, 1H), 6.35 (d, J = 8.4 Hz, 1H), 4.99 - 4.92 (m, 1H), 3.81 (s, 3H), 3.12 (s, 3H), 2.39 (s, 3H), 1.78 - 1.71 (m, 1H), 1.62 (d, J = 6.8 Hz, 3H), 1.11 - 1.00 (m, 1H), 1.00 - 0.90 (m, 2H), 0.84 - 0.80 (m, 1H), 0.66 - 0.56 (m, 1H), 0.52 - 0.43 (m, 1H), 0.30 - 0.13 (m, 2H).
346	(ES+) 451.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.15 (s, 1H), 7.79 - 7.76 (m, 1H), 7.43 (d, J = 0.8 Hz, 1H), 7.26 - 7.18 (m, 1H), 6.74 - 6.70 (m, 1H), 6.66 (d, J = 5.2 Hz, 1H), 6.46 (s, 1H), 6.34 (d, J = 8.4 Hz, 1H), 5.02 - 4.90 (m, 1H), 3.81 (s, 3H), 3.11 (s, 3H), 2.39 (s, 3H), 1.77 - 1.69 (m, 1H), 1.62 (d, J = 6.7 Hz, 3H), 1.15 - 1.05 (m, 1H), 1.02 - 0.88 (m, 2H), 0.83 - 0.80 (m, 1H), 0.59 - 0.55 (m, 1H), 0.48 - 0.44 (m, 1H), 0.32 - 0.13 (m, 2H).
347	(ES+) 542.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.14 (s, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.64 (s, 1H), 7.44 (s, 1H), 7.32 - 7.30 (m, 1H), 7.27 - 7.21 (m, 1H), 6.76 - 6.70 (m, 1H), 6.70 (s, 1H), 6.38 (d, J = 8.4 Hz, 1H), 6.29 (s, 1H), 4.91 - 4.88 (m, 1H), 4.32 - 3.97 (m, 2H), 3.66 (s, 3H), 3.62 - 3.42 (m, 1H), 3.33 - 3.14 (m, 1H), 3.12 (s, 3H), 3.11 - 2.78 (m, 2H), 2.40 (s, 3H), 1.64 (d, J = 6.4 Hz, 3H).
348	(ES+) 542.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.14 (s, 1H), 7.85 - 7.75 (m, 1H), 7.49 (s, 1H), 7.44 (d, J = 1.6 Hz, 1H), 7.37- 7.25 (m, 1H), 7.23 - 7.07 (m, 1H), 6.77-6.75 (m, 1H), 6.70 (d, J = 4.8 Hz, 1H), 6.37 (d, J = 8.4 Hz, 1H), 6.30 (s, 1H), 5.01 - 4.81 (m, 1H), 4.28 - 3.88 (m, 2H), 3.65 (s, 3H), 3.60 - 3.41 (m, 1H), 3.25 - 3.13 (m, 2H), 3.12 (s, 3H), 3.10 - 2.97 (m, 1H), 2.40 (s, 3H), 1.64 (d, J = 6.4 Hz, 3H).

349	(ES+) 586.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.27 (s, 1H), 7.91 (s, 1H), 7.86 - 7.79 (m, 2H), 7.64 - 7.60 (m, 1H), 7.49 (s, 1H), 7.39 - 7.30 (m, 3H), 6.75 - 6.70 (m, 1H), 6.60 (d, J = 6.0 Hz, 1H), 6.56 - 6.48 (m, 2H), 5.22 - 5.19 (m, 1H), 4.18 (s, 2H), 3.54 (s, 3H), 3.23 (s, 3H), 3.16 - 2.88 (m, 4H), 2.35 (s, 3H), 1.56 (d, J = 6.4 Hz, 3H).
350	(ES+) 553.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.10 – 8.03 (m, 1H), 7.99 (s, 1H), 7.81 - 7.78 (m, 1H), 7.69 (s, 1H), 7.64 – 7.28 (m, 3H), 6.85 – 6.72 (m, 2H), 6.59 – 6.50 (m, 1H), 5.28 - 5.18 (m, 1H), 3.80 (s, 3H), 3.15 (s, 3H), 2.63 – 2.50 (m, 6H), 2.43 (s, 3H), 1.69 (d, J = 6.7 Hz, 3H).
351	(ES+) 553.2 [M+H]	
352	(ES+) 587.5 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.51 - 8.39 (m, 3H), 7.89 (s, 1H), 7.48 (d, J = 1.9 Hz, 1H), 7.10 (d, J = 8.6 Hz, 1H), 6.81 (d, J = 8.7 Hz, 1H), 6.44 (s, 1H), 5.15 – 5.13 (m, 1H), 4.68 (s, 1H), 4.01 – 3.60 (m, 1H), 3.04 – 3.01 (m, 3H), 3.26 (s, 3H), 3.23 – 2.81 (m, 6H), 2.52 (s, 3H), 2.34 (s, 3H), 2.30 (s, 3H), 1.28 – 1.17 (m, 2H), 1.04 – 0.84 (m, 3H).
353	(ES+) 587.5 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.67 (d, J = 6.9 Hz, 1H), 8.48 (s, 2H), 7.89 (s, 1H), 7.43 (d, J = 2.0 Hz, 1H), 7.09 (d, J = 8.6 Hz, 1H), 6.82 (d, J = 8.6 Hz, 1H), 6.44 (s, 1H), 5.19 – 5.17 (m, 1H), 4.69 (s, 1H), 4.00 – 3.60 (m, 1H), 3.56 (s, 3H), 3.42 – 2.70 (m, 7H), 2.55 (s, 3H), 2.33 (s, 3H), 2.30 (s, 3H), 1.50 (d, J = 6.4 Hz, 3H), 1.31 – 1.18 (m, 2H), 1.10 – 0.96 (m, 1H), 0.95 – 0.82 (m, 1H), 0.81– 0.75 (m, 1H).
354	(ES+) 572.5 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.48 (s, 2H), 7.89 (s, 1H), 7.50 (d, J = 7.9 Hz, 1H), 7.43 (d, J = 1.9 Hz, 1H), 7.00 (d, J = 8.5 Hz, 1H), 6.76 (d, J = 8.6 Hz, 1H), 6.44 (s, 1H), 5.17 – 5.15 (m, 1H), 4.01 – 3.63 (m, 1H), 3.55 (s, 3H), 3.32 – 2.90 (m, 6H), 2.84 – 2.82 (m, 1H), 2.53 (s, 3H), 2.33 (s, 3H), 2.26 (s, 3H), 1.51 (d, J = 6.5 Hz, 3H), 1.23 (d, J = 8.4 Hz, 1H), 1.23 – 1.14 (m, 1H), 1.12 – 1.02 (m, 1H), 1.02 – 0.91 (m, 1H), 0.94 – 0.84 (m, 1H).
355	(ES+) 572.5 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.48 (s, 2H), 7.89 (s, 1H), 7.50 (d, J = 7.9 Hz, 1H), 7.43 (d, J = 1.9 Hz, 1H), 7.00 (d, J = 8.5 Hz, 1H), 6.76 (d, J = 8.6 Hz, 1H), 6.44 (s, 1H), 5.17 – 5.15 (m, 1H), 4.01 – 3.63 (m, 1H), 3.55 (s, 3H), 3.32 (s, 2H), 3.25 – 2.81 (m, 5H), 2.84 – 2.82 (m, 1H), 2.53 (s, 3H), 2.33 (s, 3H), 2.26 (s, 3H), 1.51 (d, J = 6.5 Hz, 3H), 1.23 – 1.14 (m, 1H), 1.12 – 1.02 (m, 1H), 1.02 – 0.91 (m, 1H), 0.94 – 0.84 (m, 1H).
356	(ES+) 599.1 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.02 – 8.00 (m, 2H), 7.59 (d, J = 1.9 Hz, 1H), 7.54 – 7.49 (m, 1H), 7.12 (d, J = 8.7 Hz, 1H), 6.98 – 6.86 (m, 1H), 6.60 (s, 1H), 5.18 – 5.09 (m, 1H), 3.71 (s, 3H), 3.53 – 3.49 (m, 4H), 3.31 (s, 3H), 3.30 – 3.00 (m, 4H), 2.42 (s, 3H), 2.37 (s, 3H), 1.67 (d, J = 6.6 Hz, 3H).

357	(ES+) 619.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.52 (s, 2H), 8.22 (s, 1H), 7.61 – 7.52 (m, 2H), 7.05 – 6.96 (m, 1H), 6.80 – 6.60 (m, 2H), 6.42 – 6.21 (m, 1H), 5.35 – 5.30 (m, 1H), 3.84 – 3.80 (m, 2H), 3.70 (s, 3H), 3.68 – 3.57 (m, 2H), 3.38 – 3.14 (m, 4H), 3.19 (s, 3H), 2.42 (s, 3H), , 1.71 – 1.15 (m, 3H).
358	(ES-) 599.1 [M-H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.51 (s, 2H), 8.19 – 8.14 (m, 1H), 7.58 – 7.50 (m, 1H), 7.44 (d, J = 1.9 Hz, 1H), 7.00 – 6.89 (m, 1H), 6.81 – 6.42 (m, 2H), 6.35 – 6.24 (m, 1H), 6.22 (s, 1H), 4.99 – 4.86 (m, 1H), 3.91 – 3.72 (m, 2H), 3.73 (s, 3H), 3.50 – 3.30 (m, 4H), 3.17 (s, 3H), 3.15 – 3.00 (m, 2H), 2.42 (s, 3H), 1.67 (d, J = 6.6 Hz, 3H).
359	(ES+) 539.4 [M+H]	^{1}H NMR(400 MHz, DMSO-d_6): δ 7.89 (s, 1H), 7.65 – 7.62 (m, 1H), 7.48 (d, J = 1.6 Hz, 1H), 7.34 – 7.31 (m, 1H), 6.79 – 6.71 (m, 1H), 6.60 (d, J = 6.0 Hz, 1H), 6.50 (d, J = 8.4 Hz, 1H), 6.35 (s, 1H), 5.22 – 5.18 (m, 1H), 3.95 – 3.91 (m, 1H), 3.85 - 3.81 (m, 1H), 3.50 (s, 3H), 3.32 (s, 3H), 3.31-3.26 (m, 2H), 3.24 – 2.67 (m, 7H), 2.41 – 2.37 (m, 1H), 2.34 (s, 3H), 1.96 (d, J = 11.8 Hz, 1H), 1.72 – 1.64 (m, 1H), 1.55 (d, J = 6.4 Hz, 3H), 1.50-1.45 (m, 2H), 1.22 - 1.25 (m, 1H).
360	(ES+) 539.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.89 (d, J = 1.9 Hz, 1H), 7.64 – 7.62 (m, 1H), 7.48 (d, J = 1.6 Hz, 1H), 7.34 – 7.31 (m, 1H), 6.79 – 6.71 (m, 1H), 6.60 (d, J = 5.8 Hz, 1H), 6.50 (d, J = 8.3 Hz, 1H), 6.35 (s, 1H), 5.21 – 5.18 (m, 1H), 3.97 – 3.88 (m, 1H), 3.75 (m, 1H), 3.50 (s, 3H), 3.32 (s, 5H), 3.24 – 2.67 (m, 7H), 2.41 – 2.37 (m, 1H), 2.34 (s, 3H), 1.96 (d, J = 11.3 Hz, 1H), 1.72 – 1.64 (m, 1H), 1.55 (d, J = 6.6 Hz, 3H), 1.46 (m, 2H), 1.22 - 1.25 (m, 1 H).
361	(ES+) 526.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.15 – 8.11 (m, 1H), 7.80 – 7.78 (m, 1H), 7.44 (d, J = 1.8 Hz, 1H), 7.26-7.23 (m, 1H), 6.79 – 6.69 (m, 2H), 6.36 (d, J = 8.4 Hz, 1H), 6.21 (s, 1H), 4.98 – 4.95 (m, 1H), 3.72 – 3.66 (m, 5H), 3.45 – 3.09 (m, 7H), 2.91 – 2.60 (m, 8H), 2.40 (s, 3H), 1.66 (m, 3H).
362	(ES+) 581.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.91 (s, 1H), 7.64 – 7.62 (m, 1H), 7.49 (d, J = 1.6 Hz, 1H), 7.35 – 7.31 (m, 1H), 6.74 – 6.72 (m, 1H), 6.61 (d, J = 5.6 Hz, 1H), 6.49 (d, J = 8.4 Hz, 1H), 6.42 (s, 1H), 5.24 – 5.20 (m, 1H), 4.81 – 4.72 (m, 2H), 4.21 – 3.85 (m, 2H), 3.541 (s, 3H), 3.34 (s, 3H), 3.03 – 2.86 (m, 3H), 2.34 (s, 3H), 1.55 (d, J = 6.4 Hz, 3H).
363	(ES+) 559.2 [M+H]	
364	(ES+) 561.3 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.30 (s, 2H), 8.00 (m, 1H), 7.73 – 7.70 (m, 1H), 7.54 (d, J = 1.2 Hz, 1H), 7.31 – 7.26 (m, 1H), 6.77 – 6.68 (m, 1H), 6.67 (s, 1H), 6.51 – 6.46 (m, 2H), 5.10 – 5.04 (m, 1H), 3.81 – 3.78 (m, 2H), 3.78 – 3.70 (m, 2H), 3.64 (s, 3H), 3.42 – 3.37 (m, 2H), 3.23 – 3.15 (m, 2H), 3.14 (s, 3H), 2.54 (s, 3H), 2.40 (s, 3H), 2.23 – 2.13 (m, 2H), 1.62 (d, J = 6.4 Hz, 3H).

365	(ES+) 583.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.48 (s, 2H), 7.91 (s, 1H), 7.85 (s, 2H), 7.46 (d, J = 1.9 Hz, 1H), 7.36 (d, J = 8.8 Hz, 1H), 6.93 (d, J = 8.9 Hz, 1H), 6.78 (d, J = 6.2 Hz, 1H), 6.43 (s, 1H), 5.26 (m, 1H), 3.55 (s, 5H), 3.16 (s, 6H), 2.52 (s, 3H), 2.33 (s, 3H), 1.54 (d, J = 6.5 Hz, 3H).
366	(ES+) 601.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.47 (s, 2H), 8.02 (s, 1H), 7.86 (s, 2H), 7.63 (s, 1H), 7.32 (d, J = 8.8 Hz, 1H), 6.99 – 6.71 (m, 2H), 5.36 – 5.15 (m, 1H), 3.78 (d, J = 11.7 Hz, 2H), 3.56 (s, 3H), 3.39 (s, 4H), 3.02 (m, 2H), 2.51 (d, J = 1.5 Hz, 3H), 2.35 (s, 3H), 1.56 (d, J = 6.4 Hz, 3H).
367	(ES+) 548.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.61 (s, 1H), 7.91 (s, 1H), 7.66 – 7.59 (m, 1H), 7.49 (s, 1H), 7.36-7.29 (m, 1H), 6.76-6.70 (m, 1H), 6.60 (d, J = 5.8 Hz, 1H), 6.49 (d, J = 8.5 Hz, 1H), 6.41 (s, 1H), 5.24 – 5.17 (m, 1H), 4.70 (s, 2H), 3.59 (s, 3H), 3.23 (s, 9H), 2.35 (d, J = 9.1 Hz, 6H), 1.54 (d, J = 6.2 Hz, 3H).
368	(ES+) 553.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.92 – 7.87 (m, 1H), 7.63 (dd, J = 8.0, 1.6 Hz, 1H), 7.48 (d, J = 1.9 Hz, 1H), 7.37 – 7.28 (m, 1H), 6.75-6.71 (m, 1H), 6.60 (d, J = 5.8 Hz, 1H), 6.49 (d, J = 8.3 Hz, 1H), 6.40 (s, 1H), 5.22-5.19 (m, 1H), 3.89 (d, J = 7.2 Hz, 4H), 3.53 (m, 4H), 3.31-3.23 (m, 4H), 2.50 - 2.49 (m, 4H), 2.33 (s, 3H), 1.54 (d, J = 6.5 Hz, 3H), 1.11 (m, 1H), 0.56 – 0.47 (m, 2H), 0.32 – 0.24 (m, 2H).
369	(ES+) 575.5 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.42 (s, 2H), 8.14 (s, 1H), 7.79 - 7.78 (m, 1H), 7.45 (d, J = 1.2 Hz, 1H), 7.31 - 7.30 (m, 1H), 6.80 - 6.70 (m, 2H), 6.40 (d, J = 8.4 Hz, 1H), 6.23 (s, 1H), 4.97 - 4.95 (m, 1H), 3.94 - 3.77 (m, 1H), 3.71 (s, 3H), 3.69 - 3.56 (m, 1H), 3.36 - 3.03 (m, 6H), 2.75 (s, 3H), 2.69 - 2.47 (m, 1H), 2.40 (s, 3H), 1.67 (d, J = 6.4 Hz, 3H), 1.28 - 0.98 (m, 6H).
370	(ES+) 565.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.19 (s, 1H), 8.06 (s, 1H), 7.78 - 7.76 (m, 1H), 7.48 (d, J = 1.6 Hz, 1H), 7.24 - 7.19 (m, 1H), 6.78 - 6.69 (m, 2H), 6.64 (s, 1H), 6.32 (d, J = 8.6 Hz, 1H), 4.97 - 4.95 (m, 1H), 4.03 - 3.87 (m, 2H), 3.82 (d, J = 10.0 Hz, 1H), 3.71 - 3.64 (m, 1H), 3.51 (s, 3H), 3.13 (s, 3H), 2.42 (s, 3H), 2.11 - 1.99 (m, 2H), 1.62 (d, J = 6.4 Hz, 3H), 1.55 (s, 3H).
371	(ES+) 565.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.19 (s, 1H), 8.06 (d, J = 1.6 Hz, 1H), 7.78 - 7.76 (m, 1H), 7.48 (d, J = 1.6 Hz, 1H), 7.24 - 7.19 (m, 1H), 6.80 - 6.69 (m, 2H), 6.63 (s, 1H), 6.32 (d, J = 8.4 Hz, 1H), 4.97 - 4.93 (m, 1H), 4.02 - 3.87 (m, 2H), 3.82 - 3.80 (m, 1H), 3.67 - 3.65 (m, 1H), 3.51 (s, 3H) 3.13 (s, 3H), 2.42 (s, 3H), 2.12 - 1.99 (m, 2H), 1.62 (d, J = 6.4 Hz, 3H), 1.55 (s, 3H).
372	(ES+) 574.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.20 (s, 1H), 8.08 - 8.07 (m, 1H), 7.78 - 7.76 (m, 1H), 7.49 (d, J = 1.6 Hz, 1H), 7.32 - 7.30 (m, 1H), 7.24 - 7.18 (m, 1H), 6.79 - 6.69 (m, 2H), 6.64 (s, 1H), 6.32 (d, J = 8.4 Hz, 1H), 5.02 - 4.92 (m, 1H), 4.29 - 4.21 (m, 1H), 4.07 - 3.90 (m, 2H), 3.67 - 3.60 (m, 1H), 3.51 (s, 3H), 3.13 (s, 3H), 2.58 - 2.48 (m, 1H), 2.43 (s, 3H), 2.08 - 2.06 (m, 1H), 1.64 - 1.61 (m, 6H).

373	(ES+) 574.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.20 (s, 1H), 8.08 -8.06 (m, 1H), 7.78 - 7.75 (m, 1H), 7.49 (d, J = 1.6 Hz, 1H), 7.32 - 7.30 (m, 1H), 7.25 - 7.20 (m, 1H), 6.77 - 6.70 (m, 2H), 6.64 (s, 1H), 6.32 (d, J = 8.4 Hz, 1H), 5.02 - 4.91 (m, 1H), 4.28 - 4.22 (m, 2H), 4.07 - 3.90 (m, 1H), 3.68 - 3.60 (m, 1H), 3.51 (s, 3H), 3.13 (s, 3H),, 2.43 (s, 3H), 2.12 - 2.02 (m, 2H), 1.62 (d, J = 6.4 Hz, 3H), 1.55 (s, 3H).
374	(ES+) 532.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.63 (s, 2H), 7.81 (s, 1H), 7.63 (d, J = 8.0 Hz, 1H), 7.40 (s, 1H), 7.33 - 7.30 (m, 1H), 6.72 - 6.70 (m, 1H), 6.58 (d, J = 5.6 Hz, 1H), 6.47 (d, J = 8.4 Hz, 1H), 5.80 (s, 1H), 5.22 - 5.04 (m, 1H), 4.01 (d, J = 2.8 Hz, 2H), 3.68 (d, J = 4.0 Hz, 2H), 3.39 (s, 3H), 3.22 (s, 3H), 2.93 (s, 3H), 2.58 (s, 3H), 2.29 (s, 3H), 1.54 (d, J = 6.4 Hz, 3H).
375	(ES+) 532.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.40 (d, J = 8.4 Hz, 2H), 8.05 (s, 1H), 7.77 - 7.76 (m, 1H), 7.38 (d, J = 1.6 Hz, 1H), 7.26 - 7.20 (m, 1H), 6.73 - 6.71 (m, 1H), 6.67 (d, J = 5.6 Hz, 1H), 6.37 (d, J = 8.4 Hz, 1H), 5.72 (s, 1H), 4.95 - 4.86 (m, 1H), 4.06 - 4.04 (m, 2H), 3.77 - 3.65 (m, 2H), 3.53 (s, 3H), 3.17 (s, 3H), 3.12 (s, 3H), 2.56 (s, 3H), 2.35 (s, 3H), 1.64 (d, J = 6.8 Hz, 3H).
376	(ES+) 503.3 [M+H]	
377	(ES+) 503.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.50 (s, 2H), 8.17 (s, 1H), 7.79 (d, J = 7.2 Hz, 1H), 7.48 (s, 1H), 7.24 (s, 1H), 6.81 - 6.69 (m, 2H), 6.59 (s, 1H), 6.40 (d, J = 8.4 Hz, 1H), 5.05 - 4.92 (m, 1H), 3.67 (s, 3H), 3.12 (s, 3H), 2.76 (s, 3H), 2.42 (s, 3H), 2.28 (br d, J = 7.6 Hz, 1H), 2.18 - 2.08 (m, 1H), 1.74 - 1.69 (m, 1H), 1.66 (br d, J = 6.8 Hz, 3H), 1.61 - 1.54 (m, 1H).
378	(ES+) 532.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.13 (s, 1H), 7.78 - 7.77 (m, 1H), 7.43 (d, J = 1.2 Hz, 1H), 7.27 - 7.22 (m, 2H), 6.75 - 6.73 (m, 1H), 6.69 (br d, J = 4.0 Hz, 1H), 6.37 (d, J = 8.4 Hz, 1H), 6.28 (s, 1H), 4.92 - 4.90 (m, 1H), 4.16 - 3.90 (m, 2H), 3.65 (s, 3H), 3.57 - 3.55 (m, 1H), 3.53 - 3.38 (m, 1H), 3.12 (s, 3H), 3.11 - 2.76 (m, 3H), 2.39 (s, 3H), 1.64 (br s, 3H), 1.14 - 1.08 (m, 2H), 1.07 - 1.01 (m, 2H).
379	(ES+) 532.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.13 (s, 1H), 7.78 - 7.77 (m, 1H), 7.43 (d, J = 1.2 Hz, 1H), 7.29 (br d, J = 3.2 Hz, 1H), 7.27 - 7.22 (m, 1H), 6.75 - 6.73 (m, 1H), 6.69 (d, J = 5.2 Hz, 1H), 6.37 (d, J = 8.4 Hz, 1H), 6.29 (s, 1H), 4.97 - 4.85 (m, 1H), 4.16 - 3.89 (m, 2H), 3.66 (s, 3H), 3.59 - 3.46 (m, 1H), 3.37 (br d, J = 3.2 Hz, 1H), 3.12 (s, 3H), 3.12 - 2.77 (m, 3H), 2.39 (s, 3H), 1.63 (br s, 3H), 1.18 (br s, 2H), 1.05 (br d, J = 6.4 Hz, 2H).
380	(ES+) 599.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.90 (s, 2H), 7.91 (s, 1H), 7.64 (m, 1H), 7.49 (d, J = 1.2 Hz, 1H), 7.41 - 7.27 (m, 1H), 6.75 - 6.73 (m, 1H), 6.61 (m, 1H), 6.52 (d, J = 8.8 Hz, 1H), 6.38 (s, 1H), 5.22 - 5.18 (m, 1H), 3.56 (s, 3H), 3.37 (br s, 2H), 3.24 (s, 3H), 2.84 (m, 3H), 2.34 (s, 3H), 1.97 (br s, 4H), 1.74 (s, 6H), 1.58 (br d, J = 6.4 Hz, 3H).

381	(ES+) 608.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.68 (br s, 2H), 8.14 (s, 1H), 7.54 - 7.52 (m, 1H), 7.41 (d, J = 1.6 Hz, 1H), 7.07 - 6.91 (m, 1H), 6.51 (br d, J = 4.4 Hz, 1H), 6.31 (m, 1H), 6.23 (s, 1H), 4.97 - 4.83 (m, 1H), 3.68 (s, 3H), 3.48 - 3.34 (m, 2H), 3.20 - 3.14 (m, 3H), 2.97 - 2.73 (m, 3H), 2.40 (s, 3H), 2.12 - 1.97 (m, 4H), 1.68 - 1.62 (m, 9H).
382	(ES+) 598.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.46 (s, 2H), 8.06 (s, 1H), 7.59 (d, J = 1.6 Hz, 1H), 7.53 (d, J = 8.8 Hz, 1H), 7.30 (m, 1H), 7.08 (d, J = 9.2 Hz, 1H), 6.56 - 6.43 (m, 2H), 5.25 – 5.20 (m, 1H), 3.86 – 3.40 (m, 6H), 3.41 - 3.36 (m, 4H), 3.231 – 3.15 (m, 4H), 2.61 (s, 3H), 2.43 (s, 3H), 1.70 (d, J = 6.4 Hz, 3H).
383	(ES+) 548.4 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.01 (s, 1H), 7.72 – 7.68 (m, 1H), 7.55 (d, J = 1.9 Hz, 1H), 7.34 – 7.25 (m, 2H), 6.80 – 6.71 (m, 1H), 6.53 (d, J = 8.5 Hz, 1H), 6.45 (s, 1H), 5.51 (d, J = 2.1 Hz, 1H), 5.17 – 5.05 (m, 1H), 4.48 – 4.43 (m, 2H), 4.34 – 4.27 (m, 2H), 3.65 (s, 3H), 3.31 – 3.06 (m, 12H), 2.39 (s, 3H), 1.65 (d, J = 6.7 Hz, 3H).
384	(ES+) 601.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.39 (s, 2H), 8.28 (d, J = 2.3 Hz, 1H), 7.65 – 7.55 (m, 2H), 7.08 – 7.00 (m, 1H), 6.87 (d, J = 6.5 Hz, 1H), 6.43 – 6.35 (m, 1H), 5.69 – 5.48 (m, 1H), 4.93 – 4.75 – 4.46 (m, 2H), 3.72 – 3.63 (m, 7H), 3.34 – 3.09 (m, 7H), 2.70 (s, 3H), 2.44 (s, 3H).
385	(ES+) 583.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.43 (s, 2H), 8.22 (s, 1H), 7.62 – 7.54 (m, 1H), 7.48 (d, J = 1.9 Hz, 1H), 7.06 – 6.97 (m, 1H), 6.81 (d, J = 4.9 Hz, 1H), 6.38 – 6.30 (m, 1H), 6.26 (s, 1H), 5.23 – 5.10 (s, 1H), 4.85 – 4.47 (m, 2H), 3.81 – 3.56 (m, 5H), 3.47 – 2.99 (m, 9H), 2.74 (s, 3H), 2.43 (s, 3H).
386	(ES+) 579.3 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.47 (s, 2H), 8.11 (s, 1H), 7.78 (d, J = 1.9 Hz, 1H), 7.08 (d, J = 8.6 Hz, 1H), 6.79 (d, J = 8.6 Hz, 1H), 5.38 – 5.36 (m, 1H), 3.85 – 3.75 (m, 2H), 3.78 – 3.16 (m, 10H), 3.16 – 3.13 (m, 2H), 2.61 (s, 3H), 2.41 (s, 3H), 2.37 (s, 3H), 1.63 (d, J = 6.4 Hz, 3H).
387	(ES+) 579.3 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.47 (s, 2H), 8.11 (s, 1H), 7.80 (d, J = 1.9 Hz, 1H), 7.08 (d, J = 8.6 Hz, 1H), 6.79 (d, J = 8.6 Hz, 1H), 5.38 – 5.36 (m, 1H), 3.85 – 3.75 (m, 2H), 3.71 – 3.17 (m, 10H), 3.16 – 3.13 (m, 2H), 2.61 (s, 3H), 2.41 (s, 3H), 2.37 (s, 3H), 1.63 (d, J = 6.4 Hz, 3H).
388	(ES+) 566.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.48 (s, 2H), 7.89 (s, 1H), 7.68 – 7.65 (m, 2H), 7.55 (d, J = 1.9 Hz, 1H), 7.42 – 7.39 (m, 1H), 7.14 – 7.09 (m, 1H), 6.47 (s, 1H), 6.37 – 6.34 (m, 1H), 6.23 (d, J = 5.5 Hz, 1H), 5.20 – 5.17 (m, 1H), 3.77 – 3.56 (m, 5H), 3.16 – 2.91 (m, 9H), 2.32 (s, 3H), 1.54 (d, J = 6.4 Hz, 3H).
389	(ES+) 616.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.62 (s, 2H), 8.12 – 8.07 (m, 1H), 7.63 (d, J = 1.9 Hz, 1H), 7.31 (d, J = 5.9 Hz, 1H), 7.21 – 7.10 (m, 1H), 6.98 – 6.91 (m, 1H), 6.81 – 6.51 (m, 2H), 5. 54 – 5.29 (m, 1H), 4.93 – 4.58 (m, 2H), 4.00 – 3.80 (m, 2H), 3.72 (s, 3H), 3.40 – 3.00 (m, 9H), 2.43 (s, 3H), 2.38 (s, 3H).

390	(ES+) 580.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.47 (s, 2H), 8.09 (d, J = 1.7 Hz, 1H), 7.63 (d, J = 1.9 Hz, 1H), 7.31 (d, J = 5.9 Hz, 1H), 7.15 (d, J = 8.7 Hz, 1H), 6.96 (d, J = 1.7 Hz, 1H), 6.57 (s, 1H), 5.48 – 5.37 (m, 1H), 4.98 – 4.62 (m, 2H), 4.02 – 3.84 (m, 2H), 3.79 (s, 3H), 3.50 – 3.35 (m, 1H), 3.33 – 3.29 (m, 4H), 3.25 – 3.10 (m, 4H), 2.62 (s, 3H), 2.41 – 2.39 (m, 6H).
391	(ES+) 598.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.47 (s, 2H), 8.09 (d, J = 1.7 Hz, 1H), 7.63 (d, J = 1.9 Hz, 1H), 7.15 (d, J = 8.7 Hz, 1H), 6.96 (d, J = 1.7 Hz, 1H), 5.47 – 5.37 (m, 1H), 4.98 – 4.62 (m, 2H), 3.83 – 3.75 (m, 2H), 3.73 (s, 3H), 3.65 – 3.75 (m, 2H), 3.43 – 3.34 (m, 2H), 3.31 (s, 3H), 3.25 – 3.15 (m, 2H), 2.62 (s, 3H), 2.41 – 2.39 (m, 6H).
392	(ES+) 561.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.77 (s, 2H), 8.14 (d, J = 1.7 Hz, 1H), 7.48 (d, J = 1.9 Hz, 1H), 6.95 (d, J = 8.8 Hz, 2H), 6.62 (d, J = 8.6 Hz, 1H), 6.34 (s, 1H), 4.88 – 4.80 (m, 1H), 3.67 (s, 3H), 3.42 – 3.30 (m, 2H), 3.35 (s, 3H), 2.92 – 2.87 (m, 6H), 2.41 (m, 6H), 2.24 – 1.85 (m, 4H), 1.68 (d, J = 6.7 Hz, 3H).
393	(ES+) 616.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6) δ 8.32 –8.30 (m, 1H), 8.03 (s, 1H), 7.65 (s, 1H), 7.45 –7.40 (m, 1H), 7.35 – 7.14 (m, 2H), 6.50 (d, J = 34.3 Hz, 2H), 5.45 – 5.25 (m, 1H), 3.57 (s, 3H), 3.50 – 3.42 (m, 2H), 3.35 (s, 3H), 3.32 – 3.25 (m, 2H), 3.17 – 3.06 (m, 2H), 3.05 – 3.00 (m, 2H), 2.36 (s, 3H), 2.35 (s, 3H), 1.59 (d, J = 6.4 Hz, 3H).
394	(ES+) 598.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6) δ 8.33 – 8.30 (m, 1H), 7.92 (s, 1H), 7.49 (d, J = 1.9 Hz, 1H), 7.44 – 7.40 (m, 1H), 7.30 – 7.29 (m, 1H), 7.22 –7.20 (m, 1H), 6.49 – 6.45 (m, 3H), 5.27 – 5.19 (m, 1H), 3.56 (s, 3H), 3.32 (s, 3H), 3.22 – 3.04 (m, 8H), 2.36 (s, 3H), 2.35 (s, 3H), 1.56 (d, J = 6.5 Hz, 3H).
395	(ES+) 598.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.24 (s, 1H), 7.57 – 7.50 (m, 1H), 7.48 (s, 1H), 7.44 (d, J = 1.9 Hz, 1H), 6.99 (d, J = 7.9 Hz, 1H), 6.54 (s, 1H), 6.32 – 6.30 (m, 1H), 6.29 (s, 1H), 5.82 – 5.73 (m, 1H), 4.85 – 4.95 (m, 1H), 3.74 – 3.65 (m, 6H), 3.32 – 3.07 (m, 11H), 2.42 (s, 3H), 1.68 – 1.63 (m, 3H).
396	(ES+) 581.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.62 (s, 1H), 8.24 (s, 1H), 8.16 (s, 1H), 7.57 – 7.50 (m, 1H), 7.44 (d, J = 1.9 Hz, 1H), 6.99 (d, J = 7.9 Hz, 1H), 6.54 (s, 1H), 6.36 – 6.28 (m, 1H), 6.26 (s, 1H), 4.88 (m, 1H), 3.80 – 3.50 (m, 5H), 3.50 – 3.25 (m, 4H), 3.32 (s, 3H), 3.10 – 2.90 (m, 2H), 2.77 (s, 3H), 2.42 (s, 3H), 1.68 (s, 3H).
397	(ES-) 536.2 [M-H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.89 (s, 1H), 7.67 – 7.60 (m, 1H), 7.50 – 7.45 (m, 1H), 7.34 – 7.29 (m, 1H), 6.78 – 6.68 (m, 2H), 6.60 (d, J = 5.7 Hz, 1H), 6.49 (d, J = 8.5 Hz, 1H), 6.37 (s, 1H), 5.23 – 5.18 (m, 1H), 3.94 (s, 1H), 3.52 (s, 3H), 3.32 (s, 2H) , 3.23 (s, 3H) , 3.05 – 2.67 (m, 6H), 2.33 (d, J = 3.8 Hz, 3H), 1.54 (d, J = 6.3 Hz, 3H), 0.60 – 0.55 (m, 2H), 0.41 – 0.38 (m, 2H).

398	(ES+) 559.2 [M+Na]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.91 (s, 1H), 7.65 – 7.62 (m, 1H), 7.49 (d, J = 1.6 Hz, 1H), 7.35 – 7.31 (m, 1H), 6.76 – 6.72 (m, 1H), 6.61 (d, J = 6.0 Hz, 1H), 6.49 (d, J = 8.4 Hz, 1H), 6.39 (s, 1H), 5.23 – 5.20 (m, 1H), 4.69 – 4.20 (m, 1H), 4.21 – 3.60 (m, 2H), 3.54 (s, 3H), 3.23 (s, 3H), 3.23 – 2.69 (m, 5H), 2.34 – 2.30 (m, 5H), 1.55 (d, J = 6.4 Hz, 3H), 0.99 – 0.94 (m, 1H), 0.50 – 0.45 (m, 2H), 0.16 – 0.12 (m, 2H).
399	(ES+) 551.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.88 (s, 1H), 7.66- 7.61 (m, , 1H), 7.48 (d, J = 1.6 Hz, 1H), 7.37 – 7.29 (m, 1H), 6.80 – 6.69 (m, 1H), 6.60 (d, J = 5.6 Hz, 1H), 6.48 (d, J = 8.4 Hz, 1H), 6.39 (s, 1H), 5.25 - 5.19 (m, 1H), 4.75 - 4.26 (m, 1H), 4.25 – 3.59 (m, 4H), 3.52 (s, 3H), 3.24 (s, 3H), 3.18 - 2.75 (m, 3H), 2.34 (s, 3H), 2.33 - 2.24 (m, 1H), 1.55 (d, J = 6.4 Hz, 3H), 1.10 - 1.06 (d, J = 6.8 Hz, 3H), 1.00 – 0.94 (m, 1H), 0.47 – 0.36 (m, 2H), 0.21 – 0.13 (m, 2H).
400	(ES+) 551.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.90 (s, 1H), 7.70 – 7.58 (m, 1H), 7.48 (d, J = 1.6 Hz, 1H), 7.37 – 7.29 (m, 1H), 6.80 – 6.69 (m, 1H), 6.60 (d, J = 5.6 Hz, 1H), 6.48 (d, J = 8.4 Hz, 1H), 6.39 (s, 1H), 5.25 - 5.19 (m, 1H), 4.90 – 3.65 (m, 2H), 3.55 (s, 3H), 3.45 – 3.25 (m, 6H), 3.24 (s, 3H), 2.34 (s, 3H), 2.32 – 2.20 (m, 1H), 1.55 (d, J = 6.4 Hz, 3H), 1.10 (d, J = 6.7 Hz, 3H), 1.05 – 0.89 (m, 1H), 0.50 – 0.34 (m, 2H), 0.25 – 0.10 (m, 2H).
401	(ES+) 579.5 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6) δ 8.89 (s, 2H), 7.91 (s, 1H), 7.46 (d, J = 1.9 Hz, 1H), 7.21 (d, J = 8.7 Hz, 1H), 6.95 (d, J = 8.7 Hz, 1H), 6.84 (d, J = 6.3 Hz, 1H), 6.45 (s, 1H), 5.25 – 5.20 (m, 1H), 3.58 (s, 3H), 3.34 (s, 3H), 3.29 – 3.21 (m, 2H), 3.11 – 3.10 (m, 2H), 2.66 (s, 3H), 2.46 – 2.40 (m, 1H), 2.33 (d, J = 11.8 Hz, 7H), 2.22 – 2.10 (m, 2H), 1.54 (d, J = 6.5 Hz, 3H).
402	(ES+) 597.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6) δ 8.88 (s, 2H), 8.02 (s, 1H), 7.63 (s, 1H), 7.19 (d, J = 8.6 Hz, 1H), 6.88 – 6.80 (m, 2H), 5.31 – 5.30 (m, 1H), 3.60 (s, 3H), 3.52 – 3.50 (m, 2H), 3.49 (s, 3H), 3.36 – 3.33 (m, 2H), 2.51 – 2.50 (m, 3H), 2.48 – 2.44 (m, 1H), 2.34 (d, J = 16.0 Hz, 7H), 2.16 – 2.06 (m, 2H), 1.56 (d, J = 6.4 Hz, 3H).
403	(ES+) 562.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.91 (s, 2H), 8.03 (d, J = 1.7 Hz, 1H), 7.77 – 7.72 (m, 1H), 7.58 (d, J = 1.9 Hz, 1H), 7.35 – 7.30 (m, 1H), 6.79 – 6.72 (m, 1H), 6.59 – 6.52 (m, 2H), 5.22 – 5.17 (m, 1H), 3.72 (s, 3H), 3.28 – 3.25 (m, 2H), 3.25 – 3.15 (m, 5H), 2.72 (s, 3H), 2.50 – 2.37 (m, 5H), 1.94 (d, J = 13.3 Hz, 2H), 1.69 (d, J = 6.6 Hz, 3H).
404	(ES+) 590.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.67 (s, 2H), 8.14 (s, 1H), 7.79 - 7.77 (m, 1H), 7.44 (d, J = 1.2 Hz, 1H), 7.26 - 7.25 (m, 1H), 6.78 - 6.71 (m, 2H), 6.38 (d, J = 8.4 Hz, 1H), 6.24 (s, 1H), 5.00 - 4.92 (m, 1H), 3.67 (s, 3H), 3.43 - 3.36 (m, 2H), 3.14 (s, 3H), 2.89 - 2.75 (m, 3H), 2.40 (s, 3H), 2.13 - 1.93 (m, 5H), 1.67 (br d, J = 6.8 Hz, 3H), 1.62 (s, 6H).

405	(ES+) 648.4 [M+Na]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.79 - 8.63 (m, 2H), 8.30 - 8.12 (m, 1H), 7.58 - 7.52 (m, 2H), 7.05 - 6.96 (m, 1H), 6.61 - 6.49 (m, 1H), 6.46 - 6.26 (m, 1H), 5.47 - 5.18 (m, 1H), 3.80 - 3.64 (m, 3H), 3.51 - 3.43 (m, 2H), 3.40 - 3.28 (m, 2H), 3.19 (s, 3H), 2.90 - 2.75 (m, 1H), 2.40 (s, 3H), 2.10 - 1.96 (m, 4H), 1.58 (br s, 9H).
406	(ES+) 562.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.13 (s, 1H), 7.77 - 7.75 (m, 1H), 7.43 (s, 1H), 7.26 - 7.21 (m, 1H), 6.83 - 6.63 (m, 2H), 6.38 (br d, J = 6.0 Hz, 1H), 6.22 (br s, 1H), 4.99 - 4.82 (m, 1H), 4.08 - 3.87 (m, 1H), 3.84 - 3.71 (m, 1H), 3.61 (s, 3H), 3.53 (br s, 1H), 3.47 - 3.16 (m, 4H), 3.12 (s, 3H), 2.90 - 2.64 (m, 2H), 2.64 - 2.45 (m, 2H), 2.40 (s, 3H), 2.36 - 2.10 (m, 4H), 1.75 (br s, 3H), 1.66 (br d, J = 5.2 Hz, 3H).
407	(ES+) 562.5 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.14 (br s, 1H), 7.79 (br d, J = 7.2 Hz, 1H), 7.45 (br s, 1H), 7.27 (br s, 1H), 6.82 - 6.69 (m, 2H), 6.40 (br s, 1H), 6.24 (br s, 1H), 5.05 - 4.81 (m, 1H), 4.08 - 3.90 (m, 1H), 3.81 - 3.75 (m, 1H), 3.63 (br s, 3H), 3.59 - 3.48 (m, 1H), 3.46 - 3.18 (m, 4H), 3.14 (br s, 3H), 2.89 - 2.65 (m, 2H), 2.64 - 2.48 (m, 2H), 2.42 (br s, 3H), 2.38 (br s, 4H), 1.82 - 1.73 (m, 3H), 1.68 (br s, 3H).
408	(ES+) 548.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.82 (s, 2H), 8.07 (s, 1H), 7.73 - 7.71 (m, 1H), 7.39 (d, J = 1.2 Hz, 1H), 7.23 - 7.19 (m, 1H), 6.74 - 6.60 (m, 2H), 6.39 (d, J = 8.4 Hz, 1H), 6.22 (s, 1H), 4.88 - 4.86 (m, 1H), 3.67 - 3.65 (m, 1H), 3.61 (s, 3H), 3.50 - 3.41 (m, 2H), 3.30 - 3.28 (m, 1H), 3.07 (s, 3H), 2.75 (s, 3H), 2.67 - 2.56 (m, 1H), 2.51 - 2.49 (m, 1H), 2.45 - 2.38 (m, 1H), 2.36 (s, 3H), 1.62 (d, J = 6.8 Hz, 3H).
409	(ES+) 548.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.85 (s, 2H), 8.10 (s, 1H), 7.73 - 7.72 (m, 1H), 7.43 (d, J = 1.6 Hz, 1H), 7.26 - 7.21 (m, 1H), 6.75 - 6.65 (m, 2H), 6.43 (d, J = 8.4 Hz, 1H), 6.31 (s, 1H), 5.06 - 4.78 (m, 1H), 3.81 - 3.73 (m, 1H), 3.64 (s, 3H), 3.55 (d, J = 10.4 Hz, 1H), 3.39 - 3.35 (m, 1H), 3.31 - 3.28 (m, 1H), 3.10 (s, 3H), 2.78 (s, 3H), 2.60 - 2.50 (m, 1H), 2.48 - 2.42 (m, 1H), 2.40 (s, 3H), 1.68 (d, J = 6.8 Hz, 3H).
410	(ES+) 553.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.11 (s, 1H), 7.78 - 7.76 (m, 1H), 7.41 (d, J = 1.6 Hz, 1H), 7.26 - 7.21 (m, 1H), 6.74 - 6.72 (m, 1H), 6.69 (br d, J = 4.8 Hz, 1H), 6.36 (br d, J = 8.4 Hz, 1H), 6.17 (s, 1H), 4.99 - 4.87 (m, 1H), 3.62 (s, 3H), 3.32 - 3.15 (m, 3H), 3.13 (s, 3H), 2.93 (br d, J = 8.8 Hz, 1H), 2.75 - 2.61 (m, 2H), 2.58 - 2.43 (m, 2H), 2.38 (s, 3H), 2.10 - 2.01 (m, 2H), 1.99 - 1.90 (m, 3H), 1.86 - 1.73 (m, 3H), 1.65 (d, J = 6.8 Hz, 3H), 1.41 (s, 3H).
411	(ES+) 553.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.11 (s, 1H), 7.77 (d, J = 8.0 Hz, 1H), 7.42 (s, 1H), 7.26 - 7.20 (m, 1H), 6.74 - 6.72 (m, 1H), 6.70 (m, 1H), 6.37 (d, J = 8.0 Hz, 1H), 6.18 (s, 1H), 4.98 - 4.88 (m, 1H), 3.61 (s, 3H), 3.37 - 3.25 (m, 3H), 3.12 (s, 3H), 2.96 - 2.82 (m, 2H), 2.73 - 2.63 (m, 3H), 2.57 - 2.47 (m, 2H), 2.38 (s, 3H), 2.11 - 1.97 (m, 4H), 1.94 - 1.84 (m, 2H), 1.65 (d, J = 6.8 Hz, 3H), 1.43 (s, 3H).

412	(ES+) 561.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.25 (d, J = 6.4 Hz, 1H), 8.13 (s, 1H), 7.78 - 7.76 (m, 1H), 7.44 (d, J = 1.2 Hz, 1H), 7.27 - 7.22 (m, 1H), 7.18 (d, J = 2.0 Hz, 1H), 7.08 - 7.06 (m, 1H), 6.80 - 6.67 (m, 2H), 6.38 (d, J = 8.4 Hz, 1H), 6.23 (s, 1H), 5.02 - 4.89 (m, 1H), 3.65 (s, 3H), 3.37 (br d, J = 11.6 Hz, 2H), 3.13 (s, 3H), 2.88 - 2.75 (m, 2H), 2.74 - 2.65 (m, 1H), 2.56 (s, 3H), 2.39 (s, 3H), 2.03 (br d, J = 11.2 Hz, 2H), 1.96 - 1.84 (m, 2H), 1.67 (d, J = 6.8 Hz, 3H).
413	(ES+) 555.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.94 (s, 1H), 7.49 (s, 1H), 7.43 - 4.41 (m, 1H), 7.24 - 7.22 (m, 1H), 6.57 - 6.56 (m, 1H), 6.46 (d, J = 5.6 Hz, 1H), 6.38 (s, 1H), 5.16 (J = 6.4 Hz, 1H), 4.68 (s, 1H), 4.26 (d, J = 13.6 Hz, 1H), 3.60 (s, 3H), 3.45 - 3.27 (m, 1H), 3.25 (s, 3H), 3.23 (s, 1H), 3.13 (d, J = 11.6 Hz, 1H), 2.91 (d, J = 8.8 Hz, 1H), 2.75 - 2.67 (m, 1H), 2.36 (s, 3H), 1.99 - 1.92 (m, 1H), 1.57 (d, J = 6.4 Hz, 3H), 1.40 (d, J = 6.4 Hz, 3H), 0.83 - 0.72 (m, 4H).
414	(ES+) 559.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.59 (s, 2H), 9.28 (s, 2H), 8.05 (s, 1H), 7.59 (d, J = 1.6 Hz, 1H), 7.43 (m, 1H), 7.26 - 7.25 (m, 1H), 7.16 (s, 1H), 6.56 - 6.41 (m, 2H), 5.29 (m, 1H), 3.47 (s, 3H), 3.32 (s, 3H), 2.75 (s, 3H), 2.41 (s, 3H), 1.54 (d, J = 6.4 Hz, 3H).
415	(ES+) 556.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.68 (s, 2H), 8.99 (s, 2H), 8.23 (s, 1H), 7.59 (s, 1H), 7.01 - 6.86 (m, 2H), 6.72 (s, 1H), 6.57 (d, J = 8.4 Hz, 1H), 5.02 - 4.77 (m, 1H), 3.54 (s, 3H), 3.34 (s, 3H), 2.88 (s, 3H), 2.55 - 2.33 (m, 6H), 1.64 (br d, J = 6.8 Hz, 3H).
416	(ES+) 593.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.41 (s, 2H), 8.22 (s, 1H), 7.84 (s, 1H), 7.53 – 7.48 (m, 1H), 7.06 – 6.95 (m, 1H), 6.68 (d, J = 8.6 Hz, 1H), 6.26 (s, 1H), 5.19 – 5.09 (m, 1H), 4.84 – 4.51 (m, 2H), 3.83 – 3.64 (m, 8H), 3.44 – 3.05 (m, 6H), 2.91 (s, 3H), 2.72 (s, 3H), 2.46 – 2.43 (m, 6H).
417	(ES+) 593.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.40 (s, 2H), 8.22 (s, 1H), 7.87 (s, 1H), 7.53 – 7.48 (m, 1H), 7.06 – 6.95 (m, 1H), 6.65 (d, J = 8.6 Hz, 1H), 6.25 (s, 1H), 5.19 – 5.09 (m, 1H) 4.82 – 4.51 (m, 2H), 3.73 – 3.55 (m, 8H), 3.40 – 3.04 (m, 6H), 2.88 (s, 3H), 2.71 (s, 3H), 2.46 – 2.43 (m, 6H).
418	(ES+) 619.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.62 (s, 2H), 8.10 (d, J = 1.8 Hz, 1H), 7.61 (d, J = 1.8 Hz, 1H), 7.52 (m, 1H), 7.08 (m, 1H), 6.90 (d, J = 5.9 Hz, 1H), 6.81 – 6.51 (m, 2H), 5.50 – 5.40 (m, 1H), 4.94 – 4.73 (m, 2H), 4.65 – 4.01 (s, 2H), 3.73 (s, 3H), 3.45 (s, 4H), 3.24 (s, 3H), 3.18 – 3.12 (m, 2H), 2.42 (s, 3H).
419	(ES-) 580.1 [M-H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.48 (s, 2H), 8.05 (d, J = 1.7 Hz, 1H), 7.58 (d, J = 1.8 Hz, 1H), 7.26 (d, J = 9.0 Hz, 1H), 7.14 (d, J = 5.6 Hz, 1H), 6.98 (d, J = 9.0 Hz, 1H), 6.56 (s, 1H), 5.29 – 5.08 (m, 1H), 3.99 – 3.80 (m, 2H), 3.72 (s, 3H), 3.35 (s, 3H), 3.30 – 3.27 (m, 2H), 3.25 – 3.00 (m, 4H), 2.62 (s, 3H), 2.43 (s, 3H), 1.68 (d, J = 6.6 Hz, 3H).

420	(ES+) 600.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.48 (s, 2H), 8.14 (s, 1H), 7.74 (d, J = 1.8 Hz, 1H), 7.31 – 7.19 (m, 1H), 7.16 (d, J = 5.7 Hz, 1H), 6.98 (d, J = 8.9 Hz, 1H), 5.55 – 5.25 (m, 1H), 3.86 – 3.72 (m, 2H), 3.72 (s, 3H), 3.71 – 3.51 (m, 2H), 3.36 (s, 5H), 3.28 – 3.07 (m, 2H), 2.62 (s, 3H), 2.44 (s, 3H), 1.67 (d, J = 6.2 Hz, 3H).
421	(ES+) 601.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.45 (s, 2H), 8.23 (s, 1H), 7.54 – 7.45 (m, 2H), 7.13 (d, J = 8.8 Hz, 1H), 6.75 (d, J = 8.9 Hz, 1H), 6.30 (s, 1H), 5.13 – 5.02 (m, 1H), 4.84 – 4.55 (m, 2H), 3.84 – 3.02 (m, 14H), 2.79 (d, J = 2.5 Hz, 3H), 2.45 (s, 3H).
422	(ES+) 616.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.24 (s, 1H), 7.57 – 7.50 (m, 1H), 7.44 (d, J = 1.9 Hz, 1H), 7.26-7.10 (m, 1H), 6.99 (m, 1H), 6.54 (s, 1H), 6.32 – 6.30 (m, 1H), 5.77 – 5.73 (m, 1H), 5.32 (s, 1H), 3.74 – 3.65 (m, 8H), 3.32 – 3.07 (m, 9H), 2.42 (s, 3H), 1.68 – 1.63 (m, 3H).
423	(ES+) 599.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.62 - 8.24 (m, 2H), 8.16 (s, 1H), 7.57 – 7.50 (m, 2H), 6.99 (m, 1H), 6.54 (s, 1H), 6.36 – 6.28 (m, 1H), 5.30 (s, 1H), 3.80 – 3.50 (m, 7H), 3.50 – 3.00 (m, 7H), 3.00 – 2.70 (m, 3H), 2.45 (s, 3H), 1.68 (s, 3H).
424	(ES-) 595.1 [M-H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.91 (s, 1H), 7.50 – 7.40 (m, 3H), 7.30 – 7.27 (m, 2H), 6.54 – 6.44 (m, 2H), 6.42 (s, 1H), 5.22 – 5.16 (m, 1H), 3.92 – 3.82 (m, 1H), 3.55 (s, 3H), 3.35 – 3.30 (m, 2H), 3.36 – 3.31 (m, 3H), 2.89 – 2.82 (m, 2H), 2.40 – 2.30 (m, 8H), 1.92 – 1.85 (m, 2H), 1.57 (d, J = 6.5 Hz, 3H).
425	(ES+) 552.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.90 (s, 1H), 7.65 – 7.61 (m, 1H), 7.48 (s, 1H), 7.34 – 7.30 (m, 1H), 6.76 – 6.72 (m, 1H), 6.59 (d, J = 5.7 Hz, 1H), 6.50 (d, J = 8.5 Hz, 1H), 6.37 (s, 1H), 5.25 – 5.18 (m, 1H), 3.70 (s, 1H), 3.52 (s, 3H), 3.32 (s, 3H), 3.10 (s, 4H), 2.88 (s, 3H), 2.66 – 2.60 (m, 1H), 2.34 (s, 3H), 2.08 (s, 3H), 1.55 (d, J = 6.4 Hz, 3H), 0.72 – 0.66 (m, 2H), 0.57 – 0.52 (m, 2H).
426	(ES+) 552.5 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.48 (s, 2H), 8.11 (s, 1H), 7.77 (s, 1H), 7.06 – 6.67 (m, 3H), 5.40 – 5.38 (m, 1H), 3.81 (d, J = 11.6 Hz, 2H), 3.72 (s, 3H), 3.68 – 3.55 (m, 2H), 3.43 – 3.35 (m, 2H), 3.25 – 3.10 (m, 2H), 2.62 (s, 3H), 2.40 (s, 3H), 2.35 (s, 3H), 1.64 (d, J = 6.4 Hz, 3H).
427	(ES+) 544.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.47 (s, 2H), 8.03 (s, 1H), 7.66 (s, 1H), 7.55 (s, 1H), 7.44 (d, J = 8.0 Hz, 1H), 7.16 – 6.89 (m, 1H), 6.53 – 6.46 (m, 2H), 6.11 (m, 1H), 5.32 – 5.24 (m, 1H), 3.96 – 3.78 (m, 2H), 3.71 (s, 3H), 3.50 – 3.41 (m, 2H), 3.25 – 2.99 (m, 4H), 2.61 (s, 3H), 2.40 (s, 3H), 1.68 (d, J = 6.4 Hz, 3H).
428	(ES+) 562.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.48 (s, 2H), 8.12 (s, 1H), 7.71 (s, 1 H), 7.67 (s, 1H), 7.43 (d, J = 8.8, 1H), 7.22 – 6.93 (m, 1H), 6.46 (d, J = 9.2 Hz, 1H), 5.49 – 5.45 (m, 1H), 3.82 – 3.78 (m, 2H), 3.72 (s, 3H), 3.67 – 3.57 (m, 2H), 3.39 – 3.36 (m, 2H), 3.21 – 3.13 (m, 2H), 2.61 (s, 3H), 2.40 (s, 3H), 1.67 (d, J = 6.4 Hz, 3H).

429	(ES+) 541.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.46 – 8.42 (m, 2H), 7.82 – 7.79 (m, 1H), 7.52 – 7.49 (m, 1H), 7.14 – 7.12 (m, 1H), 7.11 – 6.91 (m, 1H), 6.90 – 6.80 (m, 1H), 6.57 (s, 1H), 6.33 – 6.30 (m, 1H), 5.16 – 5.11 (m, 1H), 3.88 – 3.71 (m, 5H), 3.69 – 3.63 (m, 2H), 3.52 – 2.86 (m, 4H), 2.61 (s, 3H), 1.65 (d, J = 6.8 Hz, 3H).
430	(ES+) 606.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.46 (s, 2H), 8.03 (s, 1H), 7.68 – 7.64 (m, 1H), 7.58 (d, J = 1.6 Hz, 1H), 7.34 – 7.29 (m, 1H), 6.74 – 6.72 (m, 1H), 6.67 (d, J = 7.5 Hz, 1H), 6.57 (d, J = 8.4 Hz, 1H), 6.54 (s, 1H), 5.32 – 5.13 (m, 2H), 4.16 – 4.09 (m, 2H), 3.95 – 3.86 (m, 2H), 3.82 – 3.75 (m, 1H), 3.70 (s, 3H), 3.34 – 2.90 (m, 7H), 2.61 (s, 3H), 2.41 (s, 3H), 1.66 (d, J = 6.4 Hz, 3H).
431	(ES+) 624.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.47 (s, 2H), 8.04 (s, 1H), 7.71 – 7.69 (m, 1H), 7.58 (d, J = 1.2 Hz, 1H), 7.35 – 7.31 (m, 1H), 6.77 – 6.73 (m, 1H), 6.58 (d, J = 8.4 Hz, 1H), 6.54 (s, 1H), 5.27 – 5.20 (m, 1H), 4.30 – 4.23 (m, 4H), 3.86 - 3.73 (m, 1H), 3.71 (s, 3H), 3.34 – 2.90 (m, 7H), 2.62 (s, 3H), 2.41 (s, 3H), 1.67 (d, J = 6.8 Hz, 3H).
432	(ES+) 591.5 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.48 (s, 2H), 8.03 (s, 1H), 7.97 (d, J = 2.1 Hz, 1H), 7.89 (s, 2H), 7.69 (s, 1H), 7.61 (d, J = 8.7, 2.1 Hz, 1H), 6.93 (s, 1H), 6.48 (d, J = 8.8 Hz, 1H), 5.41 (d, J = 7.9 Hz, 1H), 3.79 (d, J = 11.6 Hz, 2H), 3.57 (s, 3H), 3.40 (s, 3H), 3.29 (s, 1H), 3.03 (d, J = 11.7 Hz, 2H), 2.61 - 2.51 (m, 3H), 2.34 (s, 3H), 1.61 (d, J = 6.5 Hz, 3H).
433	(ES+) 565.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.87 (d, J = 1.9 Hz, 1H), 7.65-7.62 (m, 1H), 7.46 (d, J = 1.9 Hz, 1H), 7.37-7.32 (m, 1H), 6.77-6.73 (m, 1H), 6.55-6.52 (m, 2H), 6.08 (s, 1H), 5.21 – 5.14 (m, 1H), 4.05-4.01 (m, 1H), 3.91 (d, J = 25.9 Hz, 2H), 3.79-3.74 (m, 1H), 3.57 (s, 4H), 3.19 (s, 5H), 2.33 (s, 3H), 2.00 (s, 1H), 1.89 (s, 1H), 1.60 (s, 2H), 1.54 (d, J = 6.5 Hz, 3H), 0.71 – 0.57 (m, 4H).
434	(ES+) 567.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.90 (d, J = 1.8 Hz, 1H), 7.49 – 7.41 (m, 2H), 7.38 (s, 1H), 7.29 (d, J = 8.6, 3.1 Hz, 1H), 6.67 – 6.34 (m, 3H), 5.35 – 5.13 (m, 1H), 3.68 (s, 3H), 3.53 (s, 3H), 3.31 (d, J = 5.0 Hz, 3H), 3.21 (d, J = 31.2 Hz, 8H), 2.34 (s, 3H), 2.09 (s, 3H), 1.55 (d, J = 6.5 Hz, 3H).
435	(ES+) 571.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.76 – 7.73 (m, 1H), 7.50 – 7.44 (m, 2H), 7.38 (s, 1H), 7.32 – 7.27 (m, 1H), 6.50 – 6.40 (m, 3H), 5.31 – 5.23 (m, 1H), 3.68 (s, 3H), 3.55 (s, 3H), 3.34 (s, 3H), 3.21 – 2.81 (m, 8H), 2.09 (s, 3H), 1.57 (d, J = 6.4 Hz, 3H).
436	(ES+) 574.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.01 (d, J = 2.0 Hz, 1H), 7.92 (s, 1H), 7.81 – 7.68 (m, 1H), 7.47 (d, J = 1.9 Hz, 1H), 7.38 (s, 1H), 7.24 (d, J = 6.0 Hz, 1H), 6.63 (d, J = 9.0 Hz, 1H), 6.39 (s, 1H), 5.43 – 5.27 (m, 1H), 3.68 (s, 3H), 3.53 (s, 3H), 3.35 (s, 3H), 3.09 (s, 8H), 2.35 (s, 3H), 2.09 (s, 3H), 1.59 (d, J = 6.5 Hz, 3H).

437	(ES+) 567.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.90 (d, J = 1.9 Hz, 1H), 7.50 – 7.40 (m, 2H), 7.34 – 7.25 (m, 2H), 6.52 – 6.49 (m, 1H), 6.46 (d, J = 5.7 Hz, 1H), 6.42 (s, 1H), 5.21 (m, 1H), 3.68 (s, 3H), 3.54 (s, 3H), 3.31 (s, 3H), 3.19 – 2.87 (m, 8H), 2.34 (s, 3H), 2.17 (s, 3H), 1.55 (d, J = 6.5 Hz, 3H).
438	(ES+) 574.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.01 (d, J = 2.0 Hz, 1H), 7.92 (s, 1H), 7.75 (d, J = 6.9 Hz, 1H), 7.47 (s, 1H), 7.29 – 7.22 (m, 2H), 6.64 (d, J = 9.1 Hz, 1H), 6.38 (s, 1H), 5.35 (s, 1H), 3.68 (s, 3H), 3.53 (s, 3H), 3.35 (s, 3H), 3.01 (d, J = 51.4 Hz, 8H), 2.35 (s, 3H), 2.17 (s, 3H), 1.59 (d, J = 6.5 Hz, 3H).
439	(ES+) 582.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.89 (s, 1H), 7.45 (s, 1H), 7.20 (d, J = 8.7 Hz, 1H), 6.92 (d, J = 8.8 Hz, 1H), 6.84 (d, J = 6.3 Hz, 1H), 6.43 (s, 1H), 5.27 – 5.21 (m, 1H), 3.57 (s, 3H), 3.53 (s, 3H), 3.32 (s, 3H), 3.14-2.92 (m, 8H), 2.32 (d, J = 10.1 Hz, 6H), 2.09 (s, 3H), 1.52 (d, J = 6.5 Hz, 3H).
440	(ES+) 564.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.89 (s, 1H), 7.45 (d, J = 1.9 Hz, 1H), 7.38 (s, 1H), 7.20 (d, J = 8.7 Hz, 1H), 6.93 (d, J = 8.8 Hz, 1H), 6.84 (d, J = 6.4 Hz, 1H), 6.43 (s, 1H), 5.27-5.19 (m, 1H), 3.68 (s, 3H), 3.52 (s, 3H), 3.33 (s, 3H), 3.20 – 2.80 (m, 8H), 2.32 (d, J = 10.4 Hz, 6H), 2.09 (s, 3H), 1.52 (d, J = 6.5 Hz, 3H).
441	(ES+) 564.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.92 – 7.87 (m, 1H), 7.45 (d, J = 2.0 Hz, 1H), 7.28 (s, 1H), 7.21 (d, J = 8.7 Hz, 1H), 6.93 (d, J = 8.8 Hz, 1H), 6.84 (d, J = 6.4 Hz, 1H), 6.43 (s, 1H), 5.25-5.21 (m, 1H), 3.68 (s, 3H), 3.53 (s, 3H), 3.34 (s, 3H), 3.10 (s, 4H), 2.96 (s, 4H), 2.32 (d, J = 10.0 Hz, 6H), 2.17 (s, 3H), 1.53 (d, J = 6.5 Hz, 3H).
442	(ES+) 576.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.13 (d, J = 4.8 Hz, 2H), 7.78 (br d, J = 7.2 Hz, 1H), 7.43 (s, 1H), 7.25 - 7.22 (m, 1H), 6.77 - 6.73 (m, 2H), 6.37 (br d, J = 8.4 Hz, 1H), 6.19 (s, 1H), 4.98 - 4.90 (m, 1H), 4.11 - 4.09 (m, 2H), 4.06 (s, 2H), 3.63 (s, 3H), 3.34 (br d, J = 8.4 Hz, 2H), 3.12 (s, 3H), 3.07 - 3.05 (m, 2H), 2.80 - 2.69 (m, 3H), 2.39 (s, 3H), 2.05 (br d, J = 11.2 Hz, 2H), 1.87 - 1.78 (m, 2H), 1.65 (d, J = 6.8 Hz, 3H).
443	(ES+) 576.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.12 (s, 1H), 7.89 (s, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.43 (s, 1H), 7.26 - 7.20 (m, 1H), 6.75 - 6.73 (m, 1H), 6.70 (d, J = 4.8 Hz, 1H), 6.37 (d, J = 8.4 Hz, 1H), 6.19 (s, 1H), 4.94 - 4.92 (m, 1H), 4.23 - 4.22 (m, 2H), 3.99 (s, 2H), 3.63 (s, 3H), 3.42 - 3.27 (m, 2H), 3.18 - 3.13 (m, 2H), 3.13 (s, 3H), 2.82 - 2.64 (m, 3H), 2.39 (s, 3H), 2.06 (d, J = 11.2 Hz, 2H), 1.90 - 1.76 (m, 2H), 1.65 (d, J = 6.8 Hz, 3H).
444	(ES+) 570.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.32 (s, 1H), 9.03 (s, 2H), 8.24 (s, 1H), 7.59 (s, 1H), 6.93 (br d, J = 8.4 Hz, 2H), 6.74 (s, 1H), 6.56 (d, J = 8.8 Hz, 1H), 4.90 - 4.86 (m, 1H), 3.56 (s, 3H), 3.34 (s, 3H), 2.93 (s, 3H), 2.82 (s, 3H), 2.47 (s, 3H), 2.38 (s, 3H), 1.65 (d, J = 6.8 Hz, 3H).

445	(ES+) 550.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.79 (s, 2H), 8.12 (s, 1H), 7.76 - 7.75 (m, 1H), 7.44 (d, J = 1.6 Hz, 1H), 7.25 - 7.21 (m, 1H), 6.76 - 6.68 (m, 2H), 6.42 (d, J = 8.4 Hz, 1H), 6.29 (s, 1H), 4.93 - 4.89 (m, 1H), 3.77 - 3.68 (m, 2H), 3.66 (s, 3H), 3.64 - 3.58 (m, 1H), 3.40 - 3.39 (m, 1H), 3.11 (s, 3H), 2.81 (s, 3H), 2.74 - 2.62 (m, 1H), 2.61 - 2.46 (m, 1H), 2.40 (s, 3H), 1.68 (d, J = 6.8 Hz, 3H).
446	(ES+) 550.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.80 (s, 2H), 8.13 (s, 1H), 7.78 - 7.77 (m, 1H), 7.45 (d, J = 1.6 Hz, 1H), 7.28 - 7.21 (m, 1H), 6.79 - 6.68 (m, 2H), 6.43 (d, J = 8.4 Hz, 1H), 6.29 (s, 1H), 5.04 - 4.84 (m, 1H), 3.75 - 3.65 (m, 5H), 3.64 - 3.44 (m, 2H), 3.13 (s, 3H), 2.83 (s, 3H), 2.73 - 2.50 (m, 2H), 2.41 (s, 3H), 1.68 (d, J = 6.7 Hz, 3H).
447	(ES+) 556.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.62 (d, J = 1.6 Hz, 1H), 8.23 (s, 1H), 7.78 (m, 1H), 7.66 (s, 1H), 7.56 (s, 1H), 7.51 (d, J = 1.2 Hz, 1H), 7.26 - 7.19 (m, 1H), 6.81 - 6.72 (m, 2H), 6.69 (s, 1H), 6.35 (d, J = 8.4 Hz, 1H), 5.08 - 4.94 (m, 1H), 3.94 (s, 3H), 3.53 (s, 3H), 3.13 (s, 3H), 2.45 (d, J = 2.8 Hz, 6H), 2.41 (s, 3H), 1.65 (d, J = 6.4 Hz, 3H).
448	(ES+) 554.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.96 (s, 2H), 8.72 (d, J = 2.0 Hz, 1H), 8.24 (s, 1H), 7.81 - 7.75 (m, 2H), 7.52 (d, J = 1.6 Hz, 1H), 7.25 - 7.21 (m, 1H), 6.78 - 6.73 (m, 2H), 6.69 (s, 1H), 6.34 (d, J = 8.4 Hz, 1H), 5.03 - 4.94 (m, 1H), 3.53 (s, 3H), 3.14 (s, 3H), 2.86 (s, 3H), 2.55 (s, 3H), 2.45 (s, 3H), 1.65 (d, J = 6.8 Hz, 3H).
449	(ES+) 594.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.94 (s, 1H), 7.50 (s, 1H), 7.45 - 7.37 (m, 2H), 7.26 - 7.24 (m, 1H), 6.50 - 6.44 (m, 3H), 6.33-6.21 (m, 1H), 5.20 - 5.18 (m, 1H), 3.58 (s, 3H), 3.49 (s, 3H), 3.41 (s, 3H), 3.29 - 2.50 (m, 7H), 2.37 (s, 3H), 1.60 (d, J = 6.8 Hz, 3H), 0.97 - 0.93 (m, 3H).
450	(ES+) 641.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.19 - 8.07 (m, 2H), 7.42 (d, J = 1.6 Hz, 1H), 7.39 - 7.33 (m, 1H), 7.13 - 6.82 (m, 2H), 6.74 - 6.63 (m, 1H), 6.30 - 6.20 (m, 2H), 4.93 - 4.80 (m, 1H), 3.68 (s, 3H), 3.39 - 3.14 (m, 3H), 3.11 - 2.88 (m, 3H), 2.87 (s, 6H), 2.69 (m, 1H)2.54 (br s, 3H), 2.39 (s, 3H), 1.67 - 1.64 (m, 3H), 1.27 - 0.91 (m, 3H).
451	(ES+) 612.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.22 - 8.06 (m, 2H), 7.56 - 7.51 (m, 1H), 7.42 (d, J = 1.2 Hz, 1H), 7.14 - 6.77 (m, 2H), 6.59 - 6.47 (m, 1H), 6.35 - 6.28 (m, 1H), 6.27 - 6.17 (m, 1H), 4.97 - 4.85 (m, 1H), 3.69 (s, 3H), 3.36 - 3.19 (m, 3H), 3.16 (s, 3H), 3.12 - 2.90 (m, 3H), 2.79 - 2.60 (m, 1H), 2.55 (br s, 3H), 2.40 (s, 3H), 1.69 - 1.65 (m, 3H), 0.98 (d, J = 2.8 Hz, 3H).
452	(ES+) 567.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.12 (s, 1H), 7.53 (m, 1H), 7.40 (s, 1H), 7.27 - 7.12 (m, 1H), 7.02 - 6.94 (m, 1H), 6.48 (br d, J = 4.8 Hz, 1H), 6.28 (m, 1H), 6.22 (s, 1H), 4.97 - 4.83 (m, 1H), 3.88 (br s, 3H), 3.68 (s, 3H), 3.33 - 2.88 (m, 9H), 2.84 - 2.50 (m, 1H), 2.38 (s, 3H), 1.64 (d, J = 6.8 Hz, 3H), 1.35 - 1.04 (m, 3H).

453	(ES+) 553.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.89 (s, 1H), 7.65–7.61 (m, 1H), 7.48 (d, J = 1.8 Hz, 1H), 7.36 – 7.29 (m, 1H), 6.77–6.71 (m, 1H), 6.60 (d, J = 5.8 Hz, 1H), 6.53 – 6.45 (m, 1H), 6.38 (s, 1H), 5.24 – 5.16 (m, 1H), 4.07 – 3.70 (m, 2H), 3.52 (s, 3H), 3.23 (s, 3H), 3.19 – 2.69 (m, 6H), 2.33 (s, 3H), 1.58 – 1.47 (m, 6H), 0.84 – 0.77 (m, 2H), 0.67 – 0.60 (m, 2H).
454	(ES+) 585.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.02 (s, 1H), 7.64 (s, 1H), 7.45 (dd, J = 8.4, 3.1 Hz, 1H), 7.32 – 7.22 (m, 2H), 6.53 (s, 1H), 6.44 (s, 1H), 5.29 (s, 1H), 3.68 (s, 3H), 3.55 (s, 3H), 3.43 (d, J = 13.5 Hz, 2H), 3.34 (s, 3H), 3.20 (s, 2H), 2.98 (d, J = 10.8 Hz, 2H), 2.87 (s, 2H), 2.35 (s, 3H), 2.17 (s, 3H), 1.58 (d, J = 6.4 Hz, 3H).
455	(ES+) 592.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.05 – 8.01 (m, 2H), 7.69 – 7.74 (m, 1H), 7.62 (s, 1H), 7.27 (s, 2H), 6.56 (s, 1H), 5.39 (s, 1H), 3.68 (s, 3H), 3.55 (s, 3H), 3.38 (s, 5H), 3.20 (s, 2H), 2.98 (d, J = 11.1 Hz, 2H), 2.88 (d, J = 11.4 Hz, 2H), 2.37 (s, 3H), 2.17 (s, 3H), 1.63 (d, J = 6.5 Hz, 3H).
456	(ES+) 552.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.11 (d, J = 1.8 Hz, 1H), 7.46 (d, J = 1.8 Hz, 1H), 6.92 (d, J = 8.6 Hz, 2H), 6.58 (d, J = 8.7 Hz, 1H), 6.23 (s, 1H), 4.81 (d, J = 6.8 Hz, 1H), 4.53 (s, 2H), 3.65 (s, 3H), 3.32 (s, 3H), 3.20 (s, 4H), 2.78 (s, 2H), 2.38 (d, J = 6.6 Hz, 6H), 1.63 (d, J = 6.7 Hz, 3H), 1.37 (s, 3H), 1.02 – 0.96 (m, 2H), 0.67 – 0.61 (m, 2H).
457	(ES+) 552.2 [M+H]	^{1}H NMR (400 MHz, CD_3CN): δ 7.99 – 7.95 (m, 1H), 7.49 (d, J = 1.9 Hz, 1H), 7.04 (d, J = 8.8 Hz, 1H), 6.89 (d, J = 6.0 Hz, 1H), 6.79 (d, J = 8.7 Hz, 1H), 6.29 (s, 1H), 5.07-5.01 (m, 1H), 4.69 (d, J = 74.2 Hz, 1H), 4.26 (d, J = 87.1 Hz, 1H), 3.61 (s, 3H), 3.23 (s, 6H), 2.91 (d, J = 35.0 Hz, 1H) , 2.67 (d, J = 32.0 Hz, 1H), 2.34 (d, J = 13.2 Hz, 6H), 1.86 (d, J = 14.7 Hz, 1H), 1.57 (d, J = 6.7 Hz, 3H), 1.42 (d, J = 60.7 Hz, 3H), 0.89 – 0.69 (m, 4H).
458	(ES+) 552.3 [M+H]	^{1}H NMR (300 MHz, $CDCl_3$): δ 8.13 (s, 1H), 7.49 (s, 1H), 6.95 (d, J = 8.6 Hz, 2H), 6.59 (d, J = 8.7 Hz, 1H), 6.24 (s, 1H), 4.83 (d, J = 6.8 Hz, 1H), 4.63 (s, 1H), 3.71 (s, 3H), 3.36 (s, 3H), 3.26 (d, J = 11.8 Hz, 1H), 3.15 (s, 2H), 2.49 (s, 1H), 2.41 (d, J = 2.2 Hz, 6H), 1.83 (s, 3H), 1.65 (d, J = 6.6 Hz, 3H), 1.53 (s, 3H), 1.05 (d, J = 4.6 Hz, 2H), 0.84 (d, J = 7.7 Hz, 2H).
459	(ES+) 577.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.61 (s, 2H), 9.28 (s, 2H), 8.20 (d, J = 7.6 Hz, 1H), 7.42 – 7.31 (m, 3H), 6.78 – 6.67 (m, 2H), 5.48 – 5.40 (m, 1H), 3.44 (s, 3H), 3.18 (s, 3H), 2.76 (s, 3H), 2.37 (s, 3H), 1.63 (d, J = 6.7 Hz, 3H).
460	(ES+) 634.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.63 (s, 2H), 8.18 (s, 1H), 7.78 (d, J = 1.9 Hz, 1H), 7.37 (d, J = 6.4 Hz, 1H), 7.16 (d, J = 8.7 Hz, 1H), 6.94 (d, J = 8.9 Hz, 1H), 6.81 – 6.53 (m, 1H), 5.72 – 5.67 (m, 1H), 4.97 – 4.63 (m, 2H), 4.08 – 3.94 (m, 2H), 3.73 (s, 3H), 3.61 – 3.50 (m, 2H), 3.41 – 3.33 (m, 2H), 3.34 (s, 3H), 3.29 – 3.18 (m, 2H), 2.43 (s, 3H), 2.38 (s, 3H).

461	(ES+) 597.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.30 (s, 1H), 7.91 (d, J = 1.9 Hz, 1H), 7.47 – 7.42 (m, 3H), 7.32 – 7.27 (m, 1H), 6.53 – 6.44 (m, 2H), 6.36 (s, 1H), 5.19 – 5.16 (m, 1H), 3.55 (s, 3H), 3.32 – 3.30 (m, 5H), 2.80 – 2.77 (m, 3H), 2.36 – 2.28 (m, 6H), 1.91 – 1.85 (m, 4H), 1.56 (d, J = 6.5 Hz, 3H).
462	(ES+) 559.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD) δ 8.48 (s, 2H), 7.91 – 7.90 (m, 1H), 7.70 – 7.65 (m, 1H), 7.19 – 7.10 (m, 1H), 7.03 – 7.00 (m, 1H), 6.89 – 6.85 (m, 1H), 6.31 – 6.29 (m, 1H), 5.37 – 5.30 (m, 1H), 3.81 – 3.78 (m, 2H), 3.72 (s, 3H), 3.61 – 3.58 (m, 2H), 3.42 – 3.34 (m, 2H), 3.16 – 3.10 (m, 2H), 2.61 (s, 3H), 1.63 – 1.60 (m, 3H).
463	(ES+) 604.3 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.46 (s, 2H), 8.03 (s, 1H), 7.68 – 7.64 (m, 1H), 7.60 (s, 1H), 7.34 – 7.26 (m, 1H), 6.75 – 6.70 (m, 1H), 6.57 - 6.53 (m, 2H), 5.21 – 5.15 (m, 1H), 4.48 - 4.42 (m, 1H), 4.09 - 3.99 (m, 2H), 3.95 – 3.86 (m, 1H), 3.70 (s, 3H), 3.69 – 3.60 (m, 2H), 3.29 – 2.90 (m, 7H), 2.61 (s, 3H), 2.41 (s, 3H), 1.66 (d, J = 6.4 Hz, 3H).
464	(ES-) 595.3 [M-H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.01 (s, 1H), 7.68 – 7.55 (m, 1H), 7.51 – 7.38 (m, 2H), 7.30 – 7.18 (m, 2H), 7.16 – 6.79 (m, 3H), 6.58 (s, 1H), 6.42 – 6.33 (m, 1H), 5.17 – 5.01 (m, 1H), 4.01 – 3.65 (m, 5H), 3.38 – 3.09 (m, 6H), 2.40 (s, 3H), 1.81 – 1.75 (m, 6H), 1.64 (d, J = 6.6 Hz, 3H).
465	(ES+) 554.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.21 (d, J = 1.7 Hz, 1H), 8.17 – 8.13 (m, 1H), 7.55 (d, J = 1.8 Hz, 1H), 7.38 (d, J = 13.3 Hz, 1H), 7.07 – 6.99 (m, 1H), 6.88 – 6.79 (m, 1H), 6.67 (d, J = 5.0 Hz, 2H), 6.25 – 6.17 (m, 1H), 4.96 – 4.86 (m, 1H), 4.59 (s, 1H), 4.30 – 3.70 (m, 4H), 3.51 (s, 3H), 2.88 (s, 2H), 2.65 (s, 2H), 2.45 (s, 3H), 1.70 – 1.60 (m, 6H).
466	(ES+) 582.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.24 – 8.16 (m, 2H), 7.57 (s, 1H), 7.45 (d, J = 13.1 Hz, 1H), 7.07-7.00 (m, 1H), 6.88 – 6.79 (m, 1H), 6.73 – 6.63 (m, 2H), 6.24 (s, 1H), 4.97 – 4.87 (m, 1H), 3.87 – 3.68 (m, 9H), 3.51 (s, 3H), 2.46 (s, 3H), 2.20 (s, 3H), 1.61 (d, J = 6.3 Hz, 3H).
467	(ES+) 590.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.47 (s, 2H), 8.07 – 8.00 (m, 2H), 7.71 – 7.70 (m, 1H), 7.63 (s, 1H), 7.29 (s, 1H), 6.57 (s, 1H), 5.39 (s, 1H), 3.78 (d, J = 11.6 Hz, 2H), 3.57 (s, 3H), 3.52 (s, 4H), 3.34 (s, 3H), 3.02 (m, 2H), 2.38 (s, 3H), 1.63 (d, J = 6.4 Hz, 3H).
468	(ES+) 627.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.63 (s, 2H), 8.14 (s, 1H), 8.08 (d, J = 2.0 Hz, 1H), 7.77 (d, J = 1.8 Hz, 1H), 7.48-7.43 (m, 1H), 6.67-6.48 (m, 2H), 5.53 (d, J = 7.1 Hz, 1H), 3.99 (d, J = 11.9 Hz, 2H), 3.74 (s, 3H), 3.59 (d, J = 12.5 Hz, 2H), 3.45 – 3.35 (m, 2H), 3.28 (d, J = 11.6 Hz, 2H), 2.41 (s, 3H), 1.70 (d, J = 6.4 Hz, 3H).
469	(ES+) 544.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.69 (s, 2H), 8.17 (d, J = 1.8 Hz, 1H), 7.52 (d, J = 1.9 Hz, 1H), 6.95 (d, J = 8.6 Hz, 2H), 6.65 – 6.58 (m, 2H), 4.93 – 4.86 (m, 1H), 3.78 (s, 3H), 3.35 (s, 3H), 2.87 (s, 3H), 2.73 – 2.63 (m, 6H), 2.40 (s, 3H), 2.44 (s, 3H), 1.68 (d, J = 6.7 Hz, 3H).

470	(ES+) 547.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.69 (s, 2H), 8.08 (s, 1H), 7.61 (d, J = 1.8 Hz, 1H), 7.52 – 7.48 (m, 1H), 7.17 – 7.09 (m, 1H), 6.80 (s, 1H), 6.55 – 6.52 (m, 1H), 5.25 – 5.20 (m, 1H), 3.82 (d, J = 1.4 Hz, 3H), 3.21 (s, 3H), 2.70 (d, J = 8.6 Hz, 9H), 2.44 (s, 3H), 1.69 (d, J = 6.6 Hz, 3H).
471	(ES+) 547.2 [M+H]	
472	(ES+) 554.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.93 (s, 1H), 7.52 (d, J = 2.0 Hz, 1H), 7.38 (s, 1H), 7.29 – 7.00 (m, 2H), 6.86 (d, J = 8.6 Hz, 1H), 6.52 – 6.37 (m, 1H), 5.96 (d, J = 6.8 Hz, 1H), 5.59 – 5.41 (m, 1H), 4.82 – 4.42 (m, 2H), 3.69 (s, 3H), 3.32 (s, 3H), 3.11 (s, 8H), 2.35 – 2.19 (m, 6H), 2.10 (s, 3H).
473	(ES+) 564.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.89 (s, 1H), 7.46 (d, J = 1.2 Hz, 1H), 7.40-7.19 (m, 3H), 6.94 (d, J = 8.8 Hz, 1H), 6.83 (d, J = 6.0 Hz, 1H), 6.38 (s, 1H), 5.23 - 5.16 (m, 1H), 3.76 (br s, 3H), 3.55 - 3.50 (m, 4H), 3.32 (s, 3H), 3.29 - 2.77 (m, 6H), 2.32 (d, J = 12.4 Hz, 6H), 1.53 (d, J = 6.4 Hz, 3H), 1.29 - 0.96 (m, 3H).
474	(ES+) 558.3 [M+H]	^{1}H NMR (400 MHz, CDCl3): δ 8.82 (s, 2H), 8.30 - 8.12 (m, 2H), 7.57 (s, 1H), 6.98 - 6.86 (m, 2H), 6.67 (s, 1H), 6.55 (d, J = 8.4 Hz, 1H), 4.97 - 4.80 (m, 1H), 3.90 (s, 3H), 3.54 (s, 3H), 3.33 (s, 3H), 2.78 (s, 3H), 2.45 (s, 3H), 2.38 (s, 3H), 1.63 (d, J = 6.8 Hz, 3H).
475	(ES+) 558.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.80 (s, 2H), 8.22 (s, 1H), 8.14 (s, 1H), 7.57 (d, J = 1.6 Hz, 1H), 6.98 - 6.88 (m, 2H), 6.67 (s, 1H), 6.55 (d, J = 8.8 Hz, 1H), 4.89 - 4.85 (m, 1H), 3.94 (s, 3H), 3.54 (s, 3H), 3.33 (s, 3H), 2.68 (s, 3H), 2.45 (s, 3H), 2.38 (s, 3H), 1.62 (d, J = 6.8 Hz, 3H).
476	(ES+) 585.3 [M+Na]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.14 (s, 1H), 7.79-7.77 (m, 1H), 7.46 (s, 1H), 7.40 (s, 1H), 7.24 - 7.22 (m, 1H), 6.77 - 6.73 (m, 2H), 6.35 - 6.34 (m, 1H), 6.27 (s, 1H), 4.97 - 4.90 (m, 1H), 3.90 - 3.85 (m, 5H), 3.70 - 3.69 (m, 5H), 3.39 - 3.38 (m, 2H), 3.14 (s, 3H), 2.40 (s, 3H), 2.22 (s, 3H), 1.65 (d, J = 6.4 Hz, 3H).
477	(ES+) 544.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.17 (s, 1H), 8.07 (s, 2H), 7.83 - 7.73 (m, 1H), 7.47 (s, 1H), 7.26 - 7.19 (m, 1H), 6.81 - 6.70 (m, 2H), 6.56 (s, 1H), 6.36 (d, J = 8.4 Hz, 1H), 5.07 - 4.91 (m, 1H), 3.84 (d, J = 9.2 Hz, 2H), 3.78 (s, 3H), 3.52 - 3.41 (m, 2H), 3.13 (s, 3H), 2.64 (s, 3H), 2.41 (s, 3H), 2.26 - 2.20 (m, 1H), 2.20 - 2.12 (m, 1H), 2.03 - 1.95 (m, 1H), 1.66 (d, J = 6.8 Hz, 3H).
478	(ES+) 568.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.88 (s, 1H), 7.72 (s, 2H), 7.55 (d, J = 1.9 Hz, 1H), 7.43 – 7.37 (m, 2H), 7.16 – 7.09 (m, 1H), 6.48 (d, J = 22.6 Hz, 1H), 6.39– 6.34 (m, 1H), 6.21 (d, J = 5.6 Hz, 1H), 5.22– 5.16 (m, 1H), 3.68 (s, 3H), 3.53 (s, 3H), 3.12 (s, 8H), 2.31 (s, 3H), 2.10 (s, 3H), 1.53 (d, J = 6.5 Hz, 3H).

479	(ES+) 583.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.47 (s, 2H), 7.51 (d, J = 6.7 Hz, 1H), 7.45-7.41 (m, 1H), 7.33-7.26 (m, 1H), 6.49-6.45 (m, 1H), 6.42 (d, J = 5.5 Hz, 1H), 6.33 (d, J = 1.9 Hz, 1H), 5.18-5.10 (m, 1H), 3.81-3.51 (m, 2H), 3.50 (s, 3H), 3.37-3.32 (m, 1H), 3.31 (s, 3H), 3.23-2.88 (m, 5H), 2.51 (s, 3H), 2.21 (d, J = 2.2 Hz, 3H), 1.53 (d, J = 6.5 Hz, 3H).
480	(ES+) 577.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.59 (s, 2H), 9.27 (s, 2H), 7.64 (d, J = 6.6 Hz, 1H), 7.44-7.41 (m, 1H), 7.29-7.24 (m, 1H), 7.10 (s, 1H), 6.47-6.44 (m, 2H), 5.24-5.21 (m, 1H), 3.41 (s, 3H), 3.32 (s, 3H), 2.75 (s, 3H), 2.28 (d, J = 2.2 Hz, 3H), 1.52 (d, J = 6.5 Hz, 3H).
481	(ES+) 573.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.58 (s, 2H), 9.01 (s, 1H), 8.06 (s, 1H), 7.60 (s, 1H), 7.43 (s, 1H), 7.26 (s, 1H), 7.09 (s, 1H), 6.48 (s, 2H), 5.21 (s, 1H), 3.31 (d, J = 5.9 Hz, 6H), 2.76 (s, 3H), 2.56 (d, J = 14.3 Hz, 3H), 2.42 (s, 3H), 1.53 (s, 3H).
482	(ES+) 588.4 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.47 (s, 2H), 8.02 (s, 1H), 7.75 – 7.72 (m, 1H), 7.60 (s, 1H), 7.24 – 7.18 (m, 1H), 6.74 – 6.65 (m, 1H), 6.57 (s, 1H), 6.44 (d, J = 8.4 Hz, 1H), 5.21 – 5.17 (m, 1H), 4.05 – 3.75 (m, 1H), 3.72 (s, 3H), 3.35 – 3.00 (m, 7H), 2.62 (s, 3H), 2.40 (s, 3H), 2.27 – 2.22 (m, 1H), 1.66 (d, J = 6.4 Hz, 3H), 0.59 – 0.43 (m, 4H).
483	(ES+) 584.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.47 (s, 2H), 8.00 (d, J = 2.2 Hz, 1H), 7.80 – 7.60 (m, 3H), 7.43 (m, 1H), 7.12 (m, 1H), 6.33 (m, 1H), 6.28 – 6.22 (m, 1H), 5.35 – 5.25 (m, 1H), 3.78 – 3.72 (m, 2H), 3.56 (s, 3H), 3.45 – 3.28 (m, 7H), 3.01 – 2.90 (m, 2H), 2.33 (s, 3H), 1.56 (d, J = 6.4 Hz, 3H).
484	(ES+) 575.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.96 (d, J = 2.1 Hz, 2H), 7.91 (s, 2H), 7.66 – 7.60 (m, 1H), 7.52 (d, J = 1.9 Hz, 1H), 7.29 (s, 1H), 6.93 (m, 1H), 6.52 (d, J = 8.8 Hz, 1H), 6.43 (s, 1H), 5.40 – 5.31 (m, 1H), 3.69 (s, 3H), 3.54 (s, 3H), 3.28 – 3.05 (m, 4H), 3.01 – 2.89 (m, 4H), 2.33 (s, 3H), 2.18 (s, 3H), 1.58 (d, J = 6.5 Hz, 3H).
485	(ES+) 568.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.88 (s, 1H), 7.72 (s, 2H), 7.55 (d, J = 1.9 Hz, 1H), 7.42 – 7.39 (m, 1H), 7.29 (s, 1H), 7.15 – 7.10 (m, 1H), 6.46 (s, 1H), 6.38 – 6.34 (m, 1H), 6.22 (d, J = 5.6 Hz, 1H), 5.20 – 5.17 (m, 1H), 3.68 (s, 3H), 3.54 (s, 3H), 3.32 – 2.80 (m, 8H), 2.31 (s, 3H), 2.18 (s, 3H), 1.53 (d, J = 6.4 Hz, 3H).
486	(ES+) 554.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.60 (s, 2H), 8.20 (s, 1H), 8.08 (d, J = 2.0 Hz, 1H), 7.44 – 7.40 (m, 1H), 7.38 (d, J = 1.9 Hz, 1H), 7.33 (d, J = 5.5 Hz, 1H), 6.50 (s, 1H), 6.39 (d, J = 8.8 Hz, 1H), 5.05 –5.02 (m, 1H), 3.80 (s, 3H), 3.17 (s, 3H), 2.77 (s, 3H), 2.65 – 2.60 (m, 6H), 2.43 (s, 3H), 1.72 (d, J = 6.6 Hz, 3H).
487	(ES-) 568.2 [M-H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.23 – 8.21 (m, 1H), 8.02 (s, 1H), 7.61 (d, J = 1.9 Hz, 1H), 7.37 – 7.34 (m, 1H), 7.15 – 7.08 (m, 1H), 6.90 – 6.83 (m, 2H), 6.61 (s, 1H), 6.41 – 6.38 (m, 1H), 5.11 – 5.10 (m, 1H), 3.71 (s, 3H), 3.33 – 3.32 (m, 8H), 2.54 (s, 3H), 2.41 (s, 3H), 1.65 – 1.63 (m, 3H).

488	(ES+) 581.5 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.87 (s, 2H), 8.35 (d, J = 10.5 Hz, 1H), 8.02 (s, 1H), 7.60 – 7.56 (m, 2H), 7.37 – 7.00 (m, 4H), 6.35 (s, 1H), 5.77 – 5.73 (m, 1H), 5.20 (d, J = 10.8 Hz, 1H), 3.32 (s, 3H), 2.29 (s, 6H), 1.52 (d, J = 6.5 Hz, 3H).
489	(ES+) 577.1 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 9.69 (s, 2H), 9.18 (s, 2H), 8.23 (s, 1H), 7.71 (d, J = 1.9 Hz, 1H), 7.60 – 7.42 (m, 1H), 7.18 (s, 1H), 7.20 – 7.08 (m, 1H), 6.96 (d, J = 6.2 Hz, 1H), 6.70 – 6.42 (m, 1H), 5.65 – 5.40 (m, 1H), 4.97 – 4.61 (m, 2H), 3.58 (s, 3H), 3.28 – 3.18 (m, 3H), 2.83 (s, 3H), 2.49 (s, 3H).
490	(ES+) 574.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.61 (s, 2H), 9.30 (s, 2H), 8.10 (s, 1H), 7.58 (s, 1H), 7.41 – 7.11 (m, 3H), 7.03 (d, J = 8.7 Hz, 1H), 5.87 – 5.48 (m, 1H), 5.01 – 4.48 (m, 2H), 3.48 (s, 3H), 3.37 (s, 3H), 2.76 (s, 3H), 2.42 (s, 3H), 2.33 (s, 3H).
491	(ES+) 549.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.81 (s, 2H), 9.01 (s, 2H), 8.32 (d, J = 1.8 Hz, 1H), 7.67 (d, J = 1.9 Hz, 1H), 7.12 – 7.05 (m, 1H), 6.85 (d, J = 8.3 Hz, 1H), 6.85 – 6.50 (m, 2H), 6.32 – 6.24 (m, 1H), 5.21 – 5.11 (m, 1H), 5.05-4.85 (m, br s), 4.80 – 4.45 (m, 2H), 3.56 (s, 3H), 3.02 (s, 3H), 2.50 (s, 3H).
492	(ES+) 556.4 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.03 (s, 1H), 7.56 (s, 1H), 7.51 – 7.45 (m, 1H), 7.15 – 7.05 (m, 1H), 6.57 – 6.46 (m, 2H), 5.19 – 5.13 (m, 1H), 4.20 – 4.05 (m, 4H), 4.04 - 3.80 (m, 2H), 3.68 (s, 3H), 3.25 - 3.15 (m, 6H), 3.07 – 2.60 (m, 3H), 2.41 (s, 3H), 2.49 – 2.20 (m, 2H), 1.66 (d, J = 6.4 Hz, 3H).
493	(ES+) 574.4 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.03 (s, 1H), 7.56 (d, J = 1.2 Hz, 1H), 7.52 – 7.45 (m, 1H), 7.15 – 6.95 (m, 1H), 6.57 – 6.47 (m, 1H), 6.50 (s, 1H), 5.50 – 5.20 (m, 1H), 5.18 – 5.14 (m, 1H), 4.44 – 4.30 (m, 2H), 4.21 – 4.13 (m, 1H), 4.13 – 4.06 (m, 1H), 4.05 - 3.90 (m, 2H), 3.69 (s, 3H), 3.30 (s, 6H), 3.29 - 2.80 (m, 3H), 2.41 (s, 3H), 1.66 (d, J = 6.4 Hz, 3H).
494	(ES+) 575.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.69 (s, 2H), 9.29 (s, 2H), 8.01 (s, 1H), 7.61 (d, J = 1.2 Hz, 1H), 7.50 - 7.21 (m, 1H), 7.19 (s, 1H), 7.15 - 7.13 (m, 1H), 6.99 - 3.97 (m, 1H), 6.34 - 6.32 (m, 1H), 5.78 (d, J = 6.4 Hz, 1H), 5.26 (s, 1H), 5.20 (br t, J = 6.4 Hz, 1H), 3.46 (s, 3H), 2.39 (s, 3H), 1.57 (s, 6H), 1.51 (d, J = 6.4 Hz, 3H).
495	(ES+) 567.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.16 (s, 1H), 8.07 - 7.95 (m, 1H), 7.50 (d, J = 1.6 Hz, 1H), 7.04 – 7.00 (m, 1H), 6.88 - 6.50 (m, 4H), 6.26 - 6.22 (m, 1H), 5.01 - 4.83 (m, 1H), 4.78 - 4.36 (m, 1H), 3.78 (s, 3H), 3.73 - 3.66 (m, 2H), 3.32 - 3.26 (m, 2H), 2.51 (s, 3H), 2.41 (s, 3H), 2.36 – 2.34 (m, 1H), 2.12 – 2.04 (m, 2H), 1.61 (d, J = 6.8 Hz, 3H).
496	(ES+) 523.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.12 (s, 1H), 7.49 (br s, 1H), 7.02 - 7.00 (m, 1H), 6.88 - 6.81 (m, 1H), 6.81 - 6.48 (m, 1H), 6.31 - 6.20 (m, 2H), 4.88 - 4.86 (m, 1H), 4.01 - 3.72 (m, 2H), 3.64 (s, 3H), 3.37 - 2.90 (m, 6H), 2.89 (s, 3H), 2.40 (s, 3H), 1.61 (d, J = 6.8 Hz, 3H).

497	(ES+) 549.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.13 (s, 1H), 7.50 (s, 1H), 7.03 - 7.02 (m, 1H), 6.89 - 6.83 (m, 1H), 6.83 - 6.49 (m, 1H), 6.32 - 6.22 (m, 2H), 4.94 - 4.84 (m, 1H), 4.70 - 4.50 (br s, 1H), 3.95 - 3.77 (m, 2H), 3.66 (s, 3H), 3.31 - 3.08 (m, 4H), 3.06 - 2.88 (m, 2H), 2.43 - 2.39 (m, 3H), 2.38 - 2.32 (m, 1H), 1.62 (d, J = 6.4 Hz, 3H), 1.28 - 1.23 (m, 2H), 1.12 - 1.06 (m, 2H).
498	(ES+) 552.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.86 (s, 2H), 7.86 (s, 1H), 7.47 - 7.16 (m, 2H), 7.15 - 7.13 (m, 1H), 7.01 - 7.00 (m, 1H), 6.41 (s, 1H), 6.31 - 6.29 (m, 1H), 5.72 (d, J = 6.0 Hz, 1H), 5.41 (s, 1H), 5.09 - 5.07 (m, 1H), 3.56 (s, 3H), 3.22 - 3.06 (m, 4H), 2.62 (s, 3H), 2.31 (s, 3H), 2.22 (br s, 2H), 1.81 (d, J = 12.8 Hz, 2H), 1.52 (d, J = 6.4 Hz, 3H).
499	(ES+) 601.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.52 (s, 2H), 9.24 (s, 2H), 8.04 (s, 1H), 7.58 (d, J = 1.2 Hz, 1H), 7.43 (m, 1H), 7.26 (m, 1H), 7.15 (s, 1H), 6.54 - 6.42 (m, 2H), 5.29 (m, 1H), 4.45 (m, 1H), 3.47 (s, 3H), 2.40 (s, 3H), 1.54 (d, J = 6.4 Hz, 3H), 0.87 - 0.77 (m, 4H).
500	(ES+) 547.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.12 (s, 2H), 8.22 (s, 2H), 7.95 (s, 1H), 7.55 - 7.51 (m, 1H), 7.47 (d, J = 1.2 Hz, 1H), 6.97 - 6.95 (m, 1H), 6.77 (s, 1H), 6.57 (d, J = 4.8 Hz, 1H), 6.32 - 6.30 (m, 1H), 4.96 - 4.87 (m, 1H), 3.64 (s, 3H), 3.16 (s, 3H), 2.84 (s, 3H), 2.45 (s, 3H), 1.67 (d, J = 6.8 Hz, 3H).
501	(ES+) 561.3 [M+H]	
502	(ES+) 550.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.44 (s, 1H), 8.20 (s, 1H), 8.07 - 8.05 (m, 1H), 7.80 - 7.79 (m, 1H), 7.77 - 7.71 (m, 2H), 7.47 - 7.46 (m, 1H), 7.26 - 7.21 (m, 1H), 6.78 (d, J = 8.4 Hz, 2H), 6.70 (s, 1H), 6.26 (d, J = 8.4 Hz, 1H), 5.04 - 4.90 (m, 1H), 3.53 (s, 3H), 3.16 (s, 3H), 2.22 (s, 3H), 1.66 (d, J = 6.8 Hz, 3H).
503	(ES+) 561.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.90 (s, 2H), 8.23 (s, 1H), 7.82 (s, 1H), 7.53 - 7.51 (m, 1H), 7.47 (s, 1H), 7.01 - 6.94 (m, 1H), 6.67 (s, 1H), 6.52 (d, J = 5.2 Hz, 1H), 6.28 - 6.25 (m, 1H), 4.93 - 4.90 (m, 1H), 3.55 (s, 3H), 3.16 (s, 3H), 2.87 (s, 3H), 2.43 (d, J = 13.6 Hz, 6H), 1.64 (d, J = 6.8 Hz, 3H).
504	(ES+) 533.2 [M+H]	
505	(ES+) 557.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.76 (s, 2H), 8.99 (s, 2H), 8.24 (s, 1H), 7.63 (d, J = 1.6 Hz, 1H), 7.21 (d, J = 7.6 Hz, 1H), 7.12 - 7.10 (m, 1H), 6.81 - 6.52 (m, 3H), 6.30 (d, J = 8.4 Hz, 1H), 4.99 - 4.96 (m, 1H), 3.55 (s, 3H), 2.47 (s, 3H), 1.69 (s, 6H), 1.63 (d, J = 6.8 Hz, 3H).
506	(ES+) 581.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.13 (s, 1H), 7.54 - 7.52 (m, 1H), 7.45 - 7.38 (m, 2H), 7.03 - 6.95 (m, 1H), 6.49 (d, J = 4.4 Hz, 1H), 6.30 - 6.28 (m, 1H), 6.21 (s, 1H), 4.97 - 4.86 (m, 1H), 3.79 (s, 3H), 3.69 (s, 3H), 3.20 - 3.09 (m, 7H), 3.05 - 2.91 (m, 2H), 2.66 - 2.49 (m, 1H), 2.39 (s, 3H), 2.21 (s, 3H), 1.66 (d, J = 6.4 Hz, 3H), 0.93 - 0.88 (m, 3H).

507	(ES+) 620.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.62 (s, 2H), 8.10 (s, 1H), 7.84 (d, J = 1.9 Hz, 1H), 7.53-7.50 (m, 1H), 6.98-6.95 (m, 1H), 6.67 (s, 1H), 6.38-6.35 (m, 1H), 5.40 (d, J = 6.8 Hz, 1H), 3.99 (d, J = 11.9 Hz, 2H), 3.73 (s, 3H), 3.63 – 3.55 (m, 2H), 3.44 – 3.34 (m, 2H), 3.26 (d, J = 11.8 Hz, 2H), 2.39 (s, 3H), 1.64 (d, J = 6.4 Hz, 3H).
508	(ES+) 564.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.31 (s, 2H), 8.83 – 8.79 (m, 1H), 8.02 (s, 1H), 7.79 – 7.75 (m, 1H), 7.61 (d, J = 1.9 Hz, 1H), 7.37 (s, 1H), 7.21 – 7.12 (m, 2H), 7.04 – 6.95 (m, 1H), 6.37 – 6.32 (m, 1H), 5.78 (d, J = 6.1 Hz, 1H), 5.24 – 5.16 (m, 1H), 3.47 (s, 3H), 2.61 (s, 3H), 2.40 (s, 3H), 1.52 (d, J = 6.6 Hz, 3H).
509	(ES+) 584.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.60 (s, 2H), 9.30 (s, 2H), 8.13 (s, 1H), 8.07 – 8.02 (m, 1H), 7.78 – 7.71 (m, 1H), 7.66 (d, J = 6.4 Hz, 1H), 7.59 (s, 1H), 7.24 (s, 1H), 6.67 (d, J = 8.9 Hz, 1H), 5.80 – 5.70 (m, 1H), 4.91 – 4.73 (m, 2H), 3.49 (s, 3H), 3.39 (s, 3H), 2.76 (s, 3H), 2.43 (s, 3H).
510	(ES+) 556.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 9.68 (s, 2H), 9.16 (s, 2H), 8.21 (s, 1H), 7.68 (d, J = 1.2 Hz, 2H), 7.45 – 7.43 (m, 1H), 7.17 – 6.90 (m, 2H), 6.54 (d, J = 8.8 Hz, 1H), 5.63 – 5.55 (m, 1H), 4.86 – 4.81 (m, 1H), 4.80 – 4.69 (m, 1H), 3.56 (s, 3H), 2.82 (s, 3H), 2.47 (s, 3H).
511	(ES+) 576.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6) δ 8.78 (s, 2H), 7.90 (s, 1H), 7.64 – 7.59 (m, 1H), 7.49 (d, J = 1.9 Hz, 1H), 7.40 – 7.31 (m, 1H), 6.75 – 6.70 (m, 1H), 6.59 (d, J = 5.7 Hz, 1H), 6.54 (d, J = 8.4 Hz, 1H), 6.38 (s, 1H), 5.27 – 5.20 (m, 1H), 3.54 (s, 3H), 3.23 (s, 3H), 3.07 (s, 4H), 2.99 (s, 3H), 2.65 (s, 3H), 2.34 (s, 3H), 2.18 – 2.05 (m, 4H), 1.57 (d, J = 6.5 Hz, 3H).
512	(ES+) 578.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.61 (s, 2H), 9.31 (s, 2H), 7.99 – 7.91 (m, 1H), 7.62 – 7.48 (m, 1H), 7.31 – 7.21 (m, 3H), 7.00 (d, J = 8.7 Hz, 1H), 5.79 – 5.58 (m, 1H), 4.90 – 4.78 (m, 2H), 3.50 (s, 3H), 3.38 (s, 3H), 2.77 (s, 3H), 2.34 (s, 3H).
513	(ES+) 553.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.91 (s, 1H), 7.64 – 7.62 (m, 1H), 7.48 (d, J = 1.9 Hz, 1H), 7.33 – 7.31 (m, 1H), 6.75 – 6.72 (m, 2H), 6.61 (d, J = 5.8 Hz, 1H), 6.48 – 6.46 (m, 1H), 5.27 (s, 1H), 4.05 – 3.95 (m, 3H), 3.53 (s, 3H), 3.35 (s, 1H), 3.32 – 3.24 (m, 4H), 3.07 (s, 1H), 2.70 – 3.67 (m, 2H), 2.34 (s, 3H), 1.51 (d, J = 6.5 Hz, 3H), 0.91 (s, 3H), 0.70 – 0.61 (m, 4H).
514	(ES+) 553.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.91 (s, 1H), 7.63 – 7.61 (m, 1H), 7.53 (d, 1H), 7.31 – 7.27 (m, 1H), 6.75 – 6.73 (m, 2H), 6.61 (d, J = 5.8 Hz, 1H), 6.54 – 6.52 (m, 1H), 5.24 (s, 1H), 4.03 – 3.87 (m, 3H), 3.53 (s, 3H), 3.35 (s, 1H), 3.32 – 3.04 (m, 5H), 2.68 – 3.65 (m, 2H), 2.35 (s, 3H), 1.52 (d, 3H), 0.91 (s, 3H), 0.67 – 0.64 (m, 4H).

515	(ES+) 585.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.02 (s, 1H), 7.64 (s, 1H), 7.45 (d, J = 8.4, 3.2 Hz, 1H), 7.37 (s, 1H), 7.27 (d, J = 11.2 Hz, 1H), 6.53 (s, 1H), 6.45 (s, 1H), 5.29 (s, 1H), 3.68 (s, 3H), 3.55 (s, 3H), 3.44 (s, 2H), 3.24-3.17 (m, 2H), 3.07 (d, J = 11.1 Hz, 2H), 2.76-2.70 (m, 2H), 2.35 (s, 3H), 2.09 (s, 3H), 1.58 (d, J = 6.4 Hz, 3H).
516	(ES+) 546.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.94 (d, J = 1.5 Hz, 1H), 7.52 (d, J = 2.1 Hz, 1H), 7.42 (s, 1H), 7.22 (d, J = 8.7 Hz, 1H), 6.96 (d, J = 8.8 Hz, 1H), 6.82 (d, J = 6.2 Hz, 1H), 6.60 (s, 1H), 5.25-5.15 (m, 1H), 3.69 (s, 3H), 3.64 (s, 3H), 3.32 (s, 3H), 2.44 (d, J = 1.6 Hz, 6H), 2.37 (s, 3H), 2.31 (s, 3H), 2.17 (s, 3H), 1.55 (d, J = 6.6 Hz, 3H).
517	(ES+) 574.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.29 (s, 2H), 8.05 (d, J = 1.6 Hz, 1H), 7.62 – 7.54 (m, 2H), 7.44-7.42 (m, 1H), 7.28-7.23 (m, 1H), 7.16 (s, 1H), 6.69-6.66 (m, 1H), 6.63-6.60 (m, 1H), 6.54 – 6.43 (m, 2H), 5.30-5.27 (m, 1H), 3.53 (s, 6H), 3.32 (s, 3H), 2.41 (s, 3H), 1.55 (d, J = 6.5 Hz, 3H).
518	(ES+) 617.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.68 (s, 2H), 8.02 (s, 1H), 7.66 (s, 1H), 7.58 (br s, 2H), 7.09 (d, J = 8.5 Hz, 1H), 6.86 – 6.67 (m, 3H), 5.27 (s, 1H), 4.01 (d, J = 11.9 Hz, 2H), 3.58 (s, 3H), 3.40 – 3.30 (m, 4H), 3.22 – 3.13 (m, 2H), 2.33 – 2.30 (m, 6H), 1.54 (d, J = 6.4 Hz, 3H).
519	(ES+) 595.1 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 9.71 (s, 2H), 9.19 (s, 2H), 8.32 (s, 1H), 7.83 (s, 1H), 7.61 – 7.58 (m, 1H), 7.22-7.11 (m, 1H), 7.00 (d, J = 6.6 Hz, 1H), 6.62 – 6.49 (m, 1H), 5.77 – 5.55 (m, 1H), 5.00 – 4.61 (m, 2H), 3.48 (s, 3H), 3.25 (s, 3H), 2.83 (s, 3H), 2.49 (s, 3H).
520	(ES+) 640.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.61 (s, 2H), 9.31 (s, 2H), 8.03 – 7.90 (m, 1H), 7.62 – 7.50 (m, 1H), 7.50 – 7.40 (m, 1H), 7.40 – 7.32 (m, 1H), 7.29 (s, 1H), 6.88 (d, J = 6.8 Hz, 1H), 6.68 – 6.52 (m, 1H), 5.82 – 5.62 (m, 1H), 5.49 – 5.12 (m, 1H), 5.01 – 4.66 (m, 2H), 4.38 – 4.08 (m, 2H), 4.06 – 3.78 (m, 2H), 3.51 (s, 3H), 2.76 (s, 3H).
521	(ES+) 553.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.61 (s, 2H), 9.30 (s, 2H), 8.10 – 7.91 (m, 1H), 7.78 – 7.67 (m, 1H), 7.34 – 7.17 (m, 3H), 7.11 – 7.01 (m, 1H), 6.53 – 6.43 (m, 1H), 6.04 (d, J = 6.8 Hz, 1H), 5.66 – 5.56 (m, 1H), 4.87 – 4.67 (m, 2H), 3.49 (s, 3H), 2.76 (s, 3H).
522	(ES+) 550.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 9.69 (s, 2H), 9.16 (s, 2H), 8.05 – 8.01 (m, 1H), 7.68 – 7.64 (m, 1H), 7.19 (s, 1H), 7.04 (d, J = 8.5 Hz, 1H), 6.87 – 6.81 (m, 2H), 5.59 – 5.49 (m, 2H), 5.02 – 4.71 (m, 1H), 3.57 (s, 3H), 2.83 (s, 3H), 2.37 (s, 3H).
523	(ES+) 587.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.90 (d, J = 1.9 Hz, 1H), 7.49 – 7.39 (m, 2H), 7.34 – 7.24 (m, 1H), 6.52-6.48 (m, 1H), 6.45 (d, J = 5.8 Hz, 1H), 6.34 (s, 1H), 5.19-5.16 (m, 1H), 4.73-4.69 (m, 1H), 4.26 (d, J = 12.5 Hz, 1H), 4.02 – 3.95 (m, 1H), 3.80-3.77 (m, 1H), 3.53 (s, 4H), 3.33-3.27 (m, 3H), 3.35 (s, 2H), 3.12-3.06 (m, 2H), 2.96-2.91 (m, 2H), 2.75 (s, 2H), 2.34 (s, 3H), 1.55 (d, J = 6.5 Hz, 3H), 1.19 (d, J = 5.0 Hz, 3H), 1.00 (s, 3H).

524	(ES+) 567.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.47 – 8.43 (m, 1H), 7.84 (d, J = 1.8 Hz, 1H), 7.51 – 7.35 (m, 2H), 7.24 – 7.13 (m, 2H), 7.04 – 6.97 (m, 1H), 6.50 (d, J = 13.9 Hz, 1H), 6.32 – 6.26 (m, 1H), 5.72 (d, J = 6.0 Hz, 1H), 5.13 – 5.04 (m, 1H), 3.64 – 3.57 (m, 2H), 3.48 (s, 3H), 3.34 (s, 1H), 3.28 (s, 1H), 2.47 (s, 3H), 2.38 – 2.35 (m, 1H), 2.31 (s, 3H), 2.14 (d, J = 3.3 Hz, 2H), 1.50 (d, J = 6.6 Hz, 3H).
525	(ES+) 555.1 [M+H]	
526	(ES+) 597.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.29 (s, 2H), 8.99 (d, J = 1.9 Hz, 1H), 8.84 – 8.77 (m, 1H), 8.20-8.13 (m, 1H), 7.95 – 7.82 (m, 2H), 7.65-7.58 (m, 1H), 7.53 – 7.22 (m, 2H), 7.21-7.13 (m, 1H), 7.06 – 6.97 (m, 1H), 6.37-6.29 (m, 1H), 5.84 (d, J = 6.2 Hz, 1H), 5.31-5.23 (m, 1H), 3.48 (s, 3H), 3.32 (s, 3H), 1.54 (d, J = 6.5 Hz, 3H).
527	(ES+) 552.1 [M+H]	
528	(ES+) 549.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.85 (s, 2H), 8.12 (s, 1H), 7.48 (s, 1H), 6.89 (d, J = 8.8 Hz, 1H), 6.79 - 6.68 (m, 1H), 6.65 - 6.64 (m, 1H), 6.34 (s, 1H), 5.05 - 4.95 (m, 1H), 4.93 - 4.84 (m, 1H), 3.67 (s, 3H), 3.25 - 3.10 (m, 3H), 2.78 (s, 3H), 2.39 (s, 5H), 2.32 - 2.22 (m, 2H), 2.10 - 1.95 (m, 2H), 1.65 (d, J = 6.4 Hz, 3H), 1.26 (s, 2H).
529	(ES+) 598.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.86 (s, 2H), 8.20 (s, 1H), 7.59 - 7.53 (m, 2H), 7.04 - 6.95 (m, 1H), 6.54 (d, J = 5.2 Hz, 1H), 6.37 - 6.35 (m, 1H), 5.35 (br s, 1H), 3.81 - 3.80 (m, 2H), 3.69 (s, 3H), 3.18 (s, 3H), 3.17 - 3.06 (m, 2H), 2.78 (s, 3H), 2.40 (s, 3H), 2.26 - 2.23 (m, 2H), 1.99 - 1.95 (m, 2H), 1.64 (s, 3H).
530	(ES+) 563.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.69 (s, 2H), 9.00 (s, 2H), 8.09 - 8.08 (m, 1H), 7.56 - 7.54 (m, 1H), 7.46 - 7.44 (m, 1H), 6.99 - 6.98 (m, 1H), 6.69 (s, 1H), 6.58 (d, J = 4.4 Hz, 1H), 6.20 - 6.19 (m, 1H), 5.00 - 4.86 (m, 1H), 3.56 (s, 3H), 3.18 (s, 3H), 2.89 (s, 3H), 1.66 (d, J = 6.8 Hz, 3H).
531	(ES+) 554.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 7.97 (m, 1H), 7.80 (m, 1H), 7.38 (m, 1H), 7.27 - 7.22 (m, 1H), 6.83 - 6.71 (m, 2H), 6.32 - 6.20 (m, 2H), 5.05 - 4.85 (m, 1H), 4.02 (s, 3H), 3.67 (s, 3H), 3.58 - 3.37 (m, 2H), 3.31 - 3.03 (m, 9H), 2.27 (s, 3H), 1.67 (d, J = 6.8 Hz, 3H).
532	(ES+) 554.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 7.96 (m, 1H), 7.79 (m, 1H), 7.37 (m, 1H), 7.26 - 7.19 (m, 1H), 6.82 - 6.67 (m, 2H), 6.27 (d, J = 8.4 Hz, 1H), 6.19 (s, 1H), 5.03 - 4.85 (m, 1H), 4.19 - 3.92 (m, 2H), 3.68 (d, J = 6.0 Hz, 6H), 3.28 - 2.90 (m, 9H), 2.38 (s, 3H), 1.66 (d, J = 6.8 Hz, 3H).
533	(ES+) 581.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.98 (s, 2H), 8.81 (s, 1H), 8.69 (d, J = 7.6 Hz, 1H), 8.07 (d, J = 8.0 Hz, 1H), 7.91 (d, J = 7.6 Hz, 1H), 7.75 (m, 1H), 7.53 (d, J = 8.0 Hz, 1H), 7.03 (d, J = 8.4 Hz, 1H), 6.89 - 6.80 (m, 1H), 6.77 - 6.49 (m, 2H), 6.16 (m, 1H), 4.94 (br s, 1H), 4.63 (br s, 1H), 3.55 (s, 3H), 2.83 (s, 3H), 1.63 (d, J = 6.4 Hz, 3H).

534	(ES+) 581.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.98 (s, 2H), 8.81 (s, 1H), 8.69 (d, J = 7.6 Hz, 1H), 8.07 (m, 1H), 7.91 (d, J = 7.6 Hz, 1H), 7.75 (m, 1H), 7.53 (m, 1H), 7.03 (m, 1H), 6.84 (m, 1H), 6.80 - 6.50 (m, 2H), 6.16 (m, 1H), 4.94 (br s, 1H), 4.63 (br s, 1H), 3.55 (s, 3H), 2.83 (s, 3H), 1.63 (d, J = 6.4 Hz, 3H).
535	(ES+) 581.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.61 (s, 2H), 9.31 (s, 2H), 8.05 – 8.00 (m, 1H), 7.69 – 7.57 (m, 1H), 7.55 – 7.43 (m, 1H), 7.36 – 7.26 (m, 2H), 6.92 (d, J = 6.2 Hz, 1H), 6.60 – 6.39 (m, 1H), 5.73 – 5.63 (m, 1H), 5.01 – 4.62 (m, 2H), 3.51 (s, 3H), 3.37 (s, 3H), 2.77 (s, 3H).
536	(ES+) 595.1 [M+H]	
537	(ES+) 592.1 [M+H]	
538	(ES+) 592.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.33 – 8.32 (m, 1H), 7.81 – 7.78 (m, 1H), 7.58 – 7.56 (m, 1H), 7.47 – 7.20 (m, 3H), 7.09 – 7.07 (m, 1H), 6.60 (s, 1H), 6.46 – 6.44 (m, 1H), 6.01 (d, J = 6.6 Hz, 1H), 5.61 – 5.51 (m, 1H), 4.83 – 4.70 (m, 2H), 3.57 (s, 3H), 3.32 – 2.92 (m, 8H), 2.37 (s, 3H).
539	(ES+) 589.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.87 (s, 2H), 9.37 (s, 2H), 7.98 – 7.90 (m, 1H), 7.75 – 7.70 (m, 1H), 7.50 – 7.00 (m, 5H), 6.49 – 6.45 (m, 1H), 6.05 (d, J = 6.8 Hz, 1H), 5.62 – 5.45 (m, 1H), 4.88 – 4.77 (m, 1H), 4.71 – 4.65 (m, 1H), 3.50 (s, 3H).
540	(ES+) 563.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.03-8.01 (m, 1H), 7.51-7.48 (m, 1H), 7.09-7.06 (m, 1H), 6.91 - 6.84 (m, 1H), 6.84 - 6.55 (m, 1H), 6.26 - 6.13 (m, 2H), 5.18 - 5.07 (m, 1H), 4.96 (s, 1H), 4.90 - 4.66 (m, 2H), 4.64 - 4.48 (m, 1H), 4.48 - 4.26 (m, 1H), 3.71 (s, 3H), 3.70 - 3.38 (m, 1H), 3.21 (d, J = 11.6 Hz, 1H), 3.11 (d, J = 11.6 Hz, 1H), 3.12-3.09 (d, J = 8.4 Hz, 1H), 2.79 - 2.60 (m, 1H), 1.57 (s, 3H), 1.36 (s, 3H), 1.05 - 0.92 (m, 2H), 0.64 (s, 2H).
541	(ES+) 563.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.03 - 8.01 (m, 1H), 7.50 - 7.48 (m, 1H), 7.08 - 7.07 (m, 1H), 6.91 - 6.84 (m, 1H), 6.84 - 6.54 (m, 1H), 6.29 - 6.12 (m, 2H), 5.17 - 5.06 (m, 1H), 4.96 (br s, 1H), 4.89 - 4.82 (m, 1H), 4.82 - 4.66 (m, 1H), 4.64 - 4.49 (m, 1H), 4.48 - 4.25 (m, 1H), 3.71 (s, 3H), 3.70 - 3.34 (m, 1H), 3.26 - 3.17 (m, 1H), 3.10 (d, J = 11.2 Hz, 1H), 2.90 (d, J = 9.6 Hz, 1H), 2.76 - 2.63 (m, 1H), 1.56 (s, 3H), 1.36 (s, 3H), 1.06 - 0.95 (m, 2H), 0.65 (d, J = 1.2 Hz, 2H).
542	(ES+) 591.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.05 - 8.03 (m, 1H), 7.59 - 7.57 (m, 1H), 7.42 - 7.40 (m, 1H), 7.01 - 7.00 (m, 1H), 6.86 (d, J = 4.4 Hz, 1H), 6.24 - 6.22 (m, 1H), 6.14 (s, 1H), 5.13 - 5.10 (mz, 1H), 4.98 - 4.82 (m, 1H), 4.73 - 4.58 (m, 1H), 4.48 - 4.48 (m, 1H), 4.47 - 4.24 (m, 1H), 3.72 (s, 3H), 3.69 - 3.33 (m, 1H), 3.22 - 3.20 (m, 1H), 3.19 (s, 3H), 3.12 - 3.10 (m, 1H), 2.92 - 2.90 (m, 1H), 2.81 - 2.64 (m, 1H), 1.56 (s, 3H), 1.36 (s, 3H), 1.04 - 0.95 (m, 2H), 0.65 (d, J = 1.2 Hz, 2H).

543	(ES+) 591.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.05 - 8.03 (m 1H), 7.59 - 7.58 (m, 1H), 7.42 - 7.41 (m, 1H), 7.01 - 7.00 (m, 1H), 6.86 (d, J = 4.4 Hz, 1H), 6.24 - 6.23 (m, 1H), 6.13 (s, 1H), 5.19 - 5.06 (m, 1H), 4.84 (d, J = 12.8 Hz, 1H), 4.72 - 4.59 (m, 1H), 4.53 - 4.48 (m, 1H), 4.48 - 4.24 (m, 1H), 3.72 (s, 3H), 3.71 - 3.41 (m, 1H), 3.23 (d, J = 11.2 Hz, 1H), 3.19 (s, 3H), 3.11 (d, J = 11.6 Hz, 1H), 2.93 (d, J = 10.0 Hz, 1H), 2.77 - 2.65 (m, 1H), 1.59 (br s, 3H), 1.36 (s, 3H), 1.06 - 0.92 (m, 2H), 0.65 (d, J = 0.8 Hz, 2H).
544	(ES+) 610.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.74 - 9.71 (m, 1H), 9.04 - 9.01 (m, 1H), 8.97 (s, 2H), 8.07 - 8.05 (m, 1H), 7.54 - 7.52 (m, 1H), 7.06 - 7.00 (m, 1H), 6.88 - 6.81 (m, 1H), 6.81 - 6.50 (m, 2H), 6.15 - 6.14 (m, 1H), 4.98 - 4.90 (m, 1H), 4.63 - 4.62 (m, 1H), 3.55 (s, 3H), 3.02 (s, 3H), 1.96 (s, 3H), 1.93 (s, 3H), 1.63 (d, J = 6.8 Hz, 3H).
545	(ES+) 608.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.03 - 8.02 (m, 1H), 7.67 - 7.56 (m, 2H), 7.50 (s, 1H), 7.40 - 7.39 (m, 1H), 7.26 - 6.97 (m, 2H), 6.85 (d, J = 4.0 Hz, 1H), 6.25 - 6.24 (m, 1H), 6.20 (s, 1H), 5.22 - 5.06 (m, 1H), 4.76 - 4.49 (m, 2H), 3.65 - 3.57 (m, 5H), 3.26 - 3.25 (m, 2H), 3.20 (s, 3H), 2.20 - 2.19 (m, 1H), 1.87 (br s, 2H).
546	(ES+) 569.3 [M+H]	
547	(ES+) 595.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.95 (d, J = 8.6 Hz, 1H), 7.70 – 7.60 (m, 1H), 7.52 – 7.46 (m, 1H), 7.33 – 7.25 (m, 1H), 6.91 (d, J = 6.0 Hz, 1H), 6.55 – 6.44 (m, 1H), 5.51 (d,J = 19.1 Hz, 1H), 5.02 – 4.60 (m, 3H), 4.35 – 4.14 (m, 1H), 3.64 (s, 3H), 3.37 (s, 3H), 3.29 – 3.19 (m, 4H), 2.01 (s, 1H), 1.46 (d, J = 6.7 Hz, 1H), 1.32 – 1.21 (m, 3H), 0.82 – 0.68 (m, 4H).
548	(ES+) 611.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.96-7.91 (m, 1H), 7.64 (d, 1H), 7.52-7.47 (m, 1H), 7.34-7.24 (m, 1H), 6.90 (d, 1H), 6.50 (d, 1H), 5.52 (d, 1H), 5.12-4.62 (m, 2H), 3.91 (s, 2H), 3.55 (s, 3H), 3.36 (s, 3H), 3.21 (s, 2H), 3.10 (s, 4H), 1.50 (s, 3H), 0.85-0.73 (m, 2H), 0.67-0.59 (m, 2H).
549	(ES+) 595.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.60 (s, 2H), 9.29 (s, 2H), 8.16 (s, 1H), 7.64 (d, J = 1.8 Hz, 1H), 7.52 – 7.46 (m, 1H), 7.41 – 7.30 (m, 2H), 6.97 (d, J = 7.8 Hz, 1H), 6.77 (s, 1H), 6.62 – 6.38 (m, 1H), 5.91 (d, J =10.8 Hz, 1H), 3.49 (s, 3H), 3.32 (s, 3H), 2.76 (s, 3H), 2.45 (s, 3H).
550	(ES+) 563.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.10 (s, 1H), 7.90 (d, J = 1.6 Hz, 1H), 7.70 (d, J = 0.8 Hz, 1H), 7.65-7.61 (m, 1H), 7.48 (d, J = 1.9 Hz, 1H), 7.35-7.29 (m, 1H), 6.77 – 6.70 (m, 1H), 6.61 (d, J = 5.8 Hz, 1H), 6.47 (d, J = 8.4 Hz, 1H), 6.42 (s, 1H), 5.25 – 5.15 (m, 1H), 4.65-4.05 (m, 2H), 3.87 (s, 3H), 3.56 (s, 3H), 3.54-3.34 (m, 2H), 3.24 (s, 3H), 3.17- 2.75 (m, 4H), 2.33 (s, 3H), 1.54 (d, J = 6.5 Hz, 3H).

551	(ES+) 610.3 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.22 – 8.01 (m, 1H), 8.01 – 7.98 (m, 1H), 7.76 – 7.73 (m, 1H), 7.37 – 7.35 (m, 1H), 7.18 – 6.87 (m, 3H), 6.43 – 6.40 (m, 1H), 5.67 – 5.61 (m, 1H), 4.96 – 4.94 (m, 1H), 4.76 – 4.65 (m, 2H), 3.73 (s, 3H), 3.72 – 3.62 (m, 2H), 3.39 – 3.37 (m, 1H), 3.26 (s, 3H), 3.18 – 3.16 (m, 2H), 2.55 (s, 3H).
552	(ES+) 595.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.26 (s, 2H), 8.89 (d, J = 12.0 Hz, 1H), 8.65 (d, J = 7.9 Hz, 1H), 8.03 – 7.94 (m, 1H), 7.89 – 7.82 (m, 1H), 7.80 – 7.70 (m, 1H), 7.65 – 7.57 (m, 1H), 7.45 – 7.25 (m, 2H), 7.22 – 7.13 (m, 1H), 7.06 – 6.98 (m, 1H), 6.37 – 6.30 (m, 1H), 5.86 (d, J = 6.1 Hz, 1H), 5.31 – 5.24 (m, 1H), 3.48 (s, 3H), 1.80 – 1.70 (m, 6H), 1.54 (d, J = 6.5 Hz, 3H).
553	(ES+) 623.4 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.05 – 8.00 (m, 1H), 7.89 (s, 1H), 7.57 – 7.18 (m, 3H), 7.12 (d, J = 9.2, 7.9, 3.1 Hz, 1H), 6.56 – 6.49 (m, 2H), 5.18 (d, J = 6.6 Hz, 1H), 3.69 (s, 3H), 3.42 (d, J = 31.3 Hz, 2H), 3.37 – 3.32 (S, 3H), 3.30 – 3.23 (m, 1H), 3.04 (s, 3H), 3.13 – 2.93 (s, 3H), 2.40 (s, 3H), 1.67 (d, J = 6.6 Hz, 3H).
554	(ES+) 623.4 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.05 – 8.00 (m, 1H), 7.89 (s, 1H), 7.57 – 7.18 (m, 3H), 7.12 (d, J = 9.2, 7.9, 3.1 Hz, 1H), 6.56 – 6.49 (m, 2H), 5.18 (s, J = 6.6 Hz, 1H), 3.69 (s, 3H), 3.42 (d, J = 31.3 Hz, 2H), 3.37 – 3.32 (m, 3H), 3.30 – 3.23 (m, 1H), 3.21 (s, 3H), 3.13 – 2.85 (m, 3H), 2.40 (s, 3H), 1.67 (d, J = 6.6 Hz, 3H).
555	(ES+) 585.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.03 (s, 1H), 7.77 – 7.70 (m, 2H), 7.58 (d, J = 1.8 Hz, 1H), 7.36 – 7.26 (m, 2H), 6.77 – 6.70 (m, 1H), 6.59 – 6.51 (m, 2H), 5.25 – 5.20 (m, 1H), 3.69 (s, 3H), 3.16 – 2.80 (m, 11H), 2.41 (s, 3H), 2.29 (s, 3H), 1.69 (d, J = 6.6 Hz, 3H).
556	(ES+) 568.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.33 (s, 2H), 8.82 – 8.81 (m, 1H), 7.87 – 7.86 (m, 1H), 7.78 – 7.76 (m, 1H), 7.62 – 7.52 (m, 1H), 7.51 – 7.27 (m, 2H), 7.18 – 7.04 (m, 1H), 7.02 (s, 1H), 6.33 – 6.31 (m, 1H), 5.86 (d, J = 6.2 Hz, 1H), 5.32 – 5.24 (m, 1H), 3.49 (s, 3H), 2.62 (s, 3H), 1.54 (d, J = 6.6 Hz, 3H).
557	(ES+) 623.0 [M+H]	
558	(ES+) 510.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.60 (s, 2H), 9.29 (s, 2H), 7.98 – 7.82 (m, 1H), 7.81 – 7.63 (m, 1H), 7.61 – 7.33 (m, 1H), 7.22 – 7.08 (m, 2H), 6.59 (d, J = 7.0 Hz, 1H), 6.45 – 6.21 (m, 1H), 5.40 – 5.15 (m, 1H), 3.48 (s, 3H), 2.76 (s, 3H), 1.56 (d, J = 6.5 Hz, 3H).
559	(ES+) 560.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.71 – 8.66 (m, 2H), 7.91 – 7.90 (m, 2H), 7.64 (d, J = 8.0, 1.6 Hz, 1H), 7.54 – 7.48 (m, 2H), 7.40 – 7.30 (m, 1H), 6.75 – 6.72 (m, 1H), 6.61 (d, J = 5.8 Hz, 1H), 6.49 – 6.41 (m, 2H), 5.25 – 5.16 (m, 1H), 4.81 – 4.01 (m, 1H), 3.68 – 3.38 (m, 6H), 3.24 (s, 3H), 3.17 – 2.72 (m, 4H), 2.34 (s, 3H), 1.55 (d, J = 6.5 Hz, 3H).

560	(ES+) 574.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.55 (d, J = 2.1 Hz, 1H), 7.90 (d, J = 1.9 Hz, 1H), 7.82 – 7.75 (m, 1H), 7.68 – 7.58 (m, 1H), 7.49 (d, J = 1.9 Hz, 1H), 7.39 – 7.30 (m, 2H), 6.78 – 6.66 (m, 1H), 6.61 (d, J = 5.8 Hz, 1H), 6.47 (d, J = 8.4 Hz, 1H), 6.42 (s, 1H), 5.25 – 5.16 (m, 1H), 4.50 (s, 1H), 3.54 (s, 6H), 3.24 (s, 3H), 3.07 (s, 4H), 2.53 (s, 3H), 2.34 (s, 3H), 1.55 (d, J = 6.5 Hz, 3H).
561	(ES+) 574.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.62 – 8.45 (m, 1H), 7.91 (d, J = 1.9 Hz, 1H), 7.80 – 7.58 (m, 2H), 7.49 (d, J = 1.9 Hz, 1H), 7.42 – 7.18 (m, 2H), 6.88 – 6.68 (m, 1H), 6.61 (d, J = 5.8 Hz, 1H), 6.50 (d, J = 8.5 Hz, 1H), 6.39 (s, 1H), 5.39 – 5.01 (m, 1H), 4.85 – 4.20 (m, 1H), 3.38 – 3.32 (m, 3H), 3.32 (s, 3H), 3.28 – 2.65 (m, 7H), 2.46 (s, 3H), 2.34 (s, 3H), 1.56 (d, J = 6.5 Hz, 3H).
562	(ES+) 560.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.04 – 8.03 (m, 1H), 7.53 – 7.51 (m, 1H), 6.92 (d, J = 8.4 Hz, 1H), 6.74 (t, J = 54.4 Hz, 1H), 6.53 (d, J = 8.4 Hz, 1H), 6.21 (s, 1H), 5.36 (br s, 1H), 5.18 – 5.06 (m, 1H), 4.84 – 4.80 (m, 2H), 4.76 – 4.63 (m, 1H), 4.50 – 4.25 (m, 1H), 3.72 (s, 3H), 3.27 – 3.16 (m, 1H), 3.14 – 3.05 (m, 1H), 2.96 – 2.85 (m, 1H), 2.80 – 2.60 (m, 1H), 2.41 (s, 3H), 1.58 (s, 3H), 1.38 (s, 3H), 1.06 – 0.96 (m, 2H), 0.66 (d, J = 1.2 Hz, 2H).
563	(ES+) 595.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.99 (s, 2H), 8.67 – 8.65 (m, 2H), 8.07 – 8.05 (m, 1H), 7.93 – 7.90 (m, 2H), 7.53 – 7.50 (m, 1H), 7.03 – 7.01 (m, 1H), 6.87 – 6.81 (m, 1H), 6.81 – 6.52 (m, 2H), 6.15 – 6.13 (m, 1H), 5.00 – 4.89 (m, 1H), 4.63 – 4.62 (m, 1H), 3.56 (s, 3H), 1.84 (s, 3H), 1.81 (s, 3H), 1.63 (d, J = 6.8 Hz, 3H).
564	(ES+) 577.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.06 – 8.03 (m, 1H), 7.60 – 7.57 (m, 1H), 7.44 – 7.41 (m, 1H), 7.04 – 6.99 (m, 1H), 6.86 (d, J = 4.4 Hz, 1H), 6.33 – 6.19 (m, 1H), 6.15 (s, 1H), 5.22 – 5.03 (m, 1H), 4.93 – 4.35 (m, 4H), 3.68 (s, 3H), 3.33 – 3.04 (m, 7H), 2.94 – 2.67 (m, 2H), 1.37 (s, 3H), 1.05 – 0.95 (m, 2H), 0.70 – 0.60 (m, 2H).
565	(ES+) 592.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.96 (s, 2H), 8.87 (d, J = 12.4 Hz, 1H), 8.72 – 8.70 (m, 1H), 8.14 – 7.94 (m, 2H), 7.71 – 7.70 (m, 1H), 7.54 – 7.52 (m, 1H), 6.88 (d, J = 8.6 Hz, 1H), 6.85 – 6.71 (m, 2H), 6.47 (d, J = 8.4 Hz, 1H), 5.02 – 4.88 (m, 2H), 3.55 (s, 3H), 2.38 (s, 3H), 1.85 (d, J = 13.2 Hz, 6H), 1.66 (d, J = 6.4 Hz, 3H).
566	(ES+) 583.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.80 (s, 2H), 8.19 – 8.12 (m, 2H), 7.59 – 7.58 (m, 1H), 7.51 – 7.50 (m, 1H), 7.07 – 6.96 (m, 1H), 6.90 (d, J = 4.8 Hz, 1H), 6.65 (s, 1H), 6.25 – 6.23 (m, 1H), 5.26 – 5.08 (m, 1H), 4.87 – 4.45 (m, 2H), 3.94 (s, 3H), 3.56 (s, 3H), 3.19 (s, 3H), 2.68 (s, 3H).
567	(ES+) 605.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.87 (s, 2H), 8.64 (s, 1H), 8.41 (s, 1H), 8.16 – 8.15 (m, 1H), 7.60 – 7.58 (m, 1H), 7.53 – 7.52 (m, 1H), 7.45 – 7.28 (m, 1H), 7.08 – 6.98 (m, 1H), 6.91 (d, J = 4.8 Hz, 1H), 6.67 (s, 1H), 6.25 – 6.23 (m, 1H), 5.22 – 5.12 (m, 1H), 4.83 – 4.52 (m, 2H), 3.55 (s, 3H), 3.19 (s, 3H).

568	(ES+) 527.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 7.95 – 7.93 (m, 1H), 7.44 – 7.42 (m, 1H), 7.03 – 7.01 (m, 1H), 6.88 – 6.81 (m, 1H), 6.66 (t, J = 55.2 Hz, 1H), 6.26 (s, 1H), 6.16 – 6.15 (m, 1H), 4.96 – 4.83 (m, 1H), 4.73 – 4.48 (m, 1H), 4.06 – 3.75 (m, 2H), 3.65 (s, 3H), 3.36 – 2.93 (m, 6H), 2.90 (s, 3H), 1.62 (d, J = 6.8 Hz, 3H).
569	(ES+) 532.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.68 (s, 2H), 8.98 (s, 2H), 8.07 – 8.05 (m, 1H), 7.54 – 7.53 (m, 1H), 6.87 (d, J = 8.6 Hz, 1H), 6.85 – 6.58 (m, 2H), 6.47 (d, J = 8.4 Hz, 1H), 5.11 – 4.83 (m, 2H), 3.55 (s, 3H), 2.88 (s, 3H), 2.38 (s, 3H), 1.65 (d, J = 6.4 Hz, 3H).
570	(ES+) 545.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 7.95 – 7.94 (m, 1H), 7.43 – 7.41 (m, 1H), 7.02 – 7.00 (m, 1H), 6.88 – 6.81 (m, 1H), 6.65 (t, J = 55.0 Hz, 1H), 6.25 – 6.10 (m, 2H), 4.96 – 4.75 (m, 2H), 4.58 (br s, 1H), 4.49 – 4.22 (m, 1H), 3.71 (s, 3H), 3.20 (d, J = 11.2 Hz, 1H), 3.10 (d, J = 11.2 Hz, 1H), 2.88 – 2.86 (m, 1H), 2.75 – 2.62 (m, 1H), 1.62 (d, J = 6.7 Hz, 3H), 1.56 – 1.40 (m, 3H), 1.36 (s, 3H), 1.05 – 0.91 (m, 2H), 0.64 (s, 2H).
571	(ES+) 542.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 7.96 – 7.94 (m, 1H), 7.44 – 7.42 (m, 1H), 6.87 (d, J = 8.4 Hz, 1H), 6.71 (t, J = 54.6 Hz, 1H), 6.47 (d, J = 8.4 Hz, 1H), 6.20 (s, 1H), 4.94 (br s, 1H), 4.91 – 4.76 (m, 2H), 4.59 – 4.20 (m, 1H), 3.71 (s, 3H), 3.26 – 3.16 (m, 1H), 3.15 – 3.05 (m, 1H), 2.89 – 2.86 (m, 1H), 2.76 – 2.62 (m, 1H), 2.38 (s, 3H), 1.64 (d, J = 6.6 Hz, 3H), 1.57 (s, 3H), 1.36 (s, 3H), 1.04 – 0.93 (m, 2H), 0.64 (d, J = 1.2 Hz, 2H).
572	(ES+) 593.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.12 – 8.05 (m, 1H), 7.71 (s, 1H), 7.65 – 7.57 (m, 2H), 7.50 – 7.42 (m, 1H), 7.27 (d, J = 64.0 Hz, 1H), 7.09 – 6.99 (m, 1H), 6.89 (d, J = 4.6 Hz, 1H), 6.51 (s, 1H), 6.27 – 6.24 (m, 1H), 5.22 – 5.18 (m, 1H), 4.89 – 4.49 (m, 2H), 3.80 (s, 3H), 3.21 (s, 3H), 2.58 (s, 6H).
573	(ES+) 580.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.61 (s, 2H), 9.31 (s, 2H), 7.97 – 7.93 (m, 1H), 7.89 (d, J = 5.9 Hz, 1H), 7.63 – 7.58 (m, 1H), 7.51 – 7.50 (m, 1H), 7.32 (s, 1H), 7.29 – 7.21 (m, 1H), 6.47 – 6.42 (m, 1H), 5.64 (d, J = 4.7 Hz, 1H), 5.05 – 4.70 (m, 3H), 3.50 (s, 3H), 3.21 (s, 3H), 2.76 (s, 3H).
574	(ES+) 580.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.61 (s, 2H), 9.31 (s, 2H), 7.97 – 7.93 (m, 1H), 7.89 (d, J = 5.9 Hz, 1H), 7.63 – 7.58 (m, 1H), 7.51 – 7.50 (m, 1H), 7.32 (s, 1H), 7.29 – 7.21 (m, 1H), 6.47 – 6.42 (m, 1H), 5.64 (d, J = 4.7 Hz, 1H), 5.00 – 4.70 (m, 3H), 3.50 (s, 3H), 3.21 (s, 3H), 2.76 (s, 3H).
575	(ES+) 605.1 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.93 (s, 2H), 8.00 – 7.95 (m, 1H), 7.62 – 7.57 (m, 2H), 7.23 – 7.14 (m, 1H), 6.98 – 6.63 (m, 3H), 5.54 – 5.50 (m, 1H), 5.50 – 4.79 (m, 2H), 3.84 (s, 3H), 3.25 (s, 3H), 2.77 (s, 6H).
576	(ES+) 599.1 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 9.71 (s, 2H), 9.19 (s, 2H), 8.29 – 8.02 (m, 1H), 7.82 – 7.70 (m, 1H), 7.22 – 7.11 (m, 1H), 7.06 (d, J = 6.4 Hz, 1H), 6.72 – 6.45 (m, 1H), 5.85 – 5.53 (m, 1H), 5.00 – 4.67 (m, 2H), 3.49 (s, 3H), 3.27 (s, 3H), 2.83 (s, 3H).

577	(ES+) 604.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.34 (s, 2H), 8.82 – 8.81 (m, 1H), 7.97 – 7.94 (m, 1H), 7.78 – 7.76 (m, 1H), 7.70 – 7.69 (m, 1H), 7.42 – 7.37 (m, 1H), 7.35– 7.33 (m, 1H), 7.25 – 7.21 (m, 1H), 6.60 – 6.57 (m, 1H), 5.81 – 5.80 (m, 1H), 5.69 – 5.67 (m, 1H), 4.98 – 4.73 (m, 2H), 3.50 (s, 3H), 2.62 (s, 3H).
578	(ES+) 545.3 [M+H]	
579	(ES-) 572.1 [M-H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.33 – 8.32 (m, 1H), 7.72 – 7.70 (m, 1H), 7.55 – 7.45 (m, 1H), 7.39 – 7.21 (m, 3H), 7.06 – 7.01 (m, 1H), 6.56 (s, 1H), 6.33 – 6.30 (m, 1H), 5.85 – 5.52 (m, 1H), 5.23 – 5.20 (m, 1H), 3.57 (s, 3H), 3.32 – 2.89 (m, 8H), 2.37 (s, 3H), 1.55 – 1.53 (m, 3H).
580	(ES-) 511.3 [M-H]	
581	(ES+) 513.3 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 7.79 (d, J = 9.1, 2.8 Hz, 1H), 7.49 (d, J = 9.8, 2.9 Hz, 1H), 7.13 – 6.85 (m, 3H), 6.52 (s, 1H), 6.30 (d, J = 9.2, 4.3 Hz, 1H), 5.09 (m, 1H), 3.70 (s, 3H), 3.26 – 3.18 (m, 2H), 3.13 – 3.04 (m, 2H), 3.01 (d, J = 5.7 Hz, 2H), 2.33 – 2.17 (m, 3H), 2.10 – 2.02 (m, 2H), 1.62 (d, J = 6.7 Hz, 3H), 1.41 (s, 3H).
582	(ES+) 607.1 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 7.84 – 7.80 (m, 1H), 7.75 (s, 1H), 7.55 – 7.46 (m, 2H), 7.28 – 7.14 (m, 2H), 6.55 (s, 1H), 6.48 – 6.40 (m, 1H), 5.22 – 5.15 (m, 1H), 3.70 (s, 3H), 3.24 – 2.80 (m, 11H), 2.29 (s, 3H), 1.69 (d, J = 6.6 Hz, 3H).
583	(ES+) 616.2 [M+H]	
584	(ES+) 616.2 [M+H]	
585	(ES+) 545.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.02 (d, J = 8.4 Hz, 1H), 7.63 – 7.61 (m, 1H), 7.03 – 7.01 (m, 1H), 6.89 – 6.46 (m, 2H), 6.20 – 6.19 (m, 1H), 5.27 (br s, 1H), 4.66 (br s, 1H), 3.85 (d, J = 11.6 Hz, 2H), 3.65 (s, 3H), 3.61 – 3.47 (m, 2H), 3.30 – 3.12 (m, 2H), 3.05 – 3.04 (m, 2H), 2.90 (s, 3H), 1.60 – 1.58 (m, 3H).
586	(ES+) 523.1 [M+H]	
587	(ES+) 565.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.90 (s, 2H), 8.07 – 8.05 (m, 1H), 7.82 (s, 1H), 7.56 – 7.53 (m, 1H), 7.43 – 7.40 (m, 1H), 7.00 – 6.95 (m, 1H), 6.65 (s, 1H), 6.55 – 6.54 (m, 1H), 6.23 – 6.20 (m, 1H), 4.95 – 4.91 (m, 1H), 3.55 (s, 3H), 3.17 (s, 3H), 2.87 (s, 3H), 2.42 (s, 3H), 1.66 (d, J = 6.8 Hz, 3H).

588	(ES+) 585.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.72 (s, 1H), 8.42 – 8.35 (m, 1H), 8.07 – 8.06 (m, 1H), 7.71 – 7.70 (m, 1H), 7.59 – 7.51 (m, 1H), 7.25 – 7.19 (m, 1H), 7.03 – 7.01 (m, 1H), 6.87 – 6.81 (m, 1H), 6.81 – 6.50 (m, 2H), 6.15 – 6.13 (m, 1H), 4.99 – 4.90 (m, 1H), 4.67 – 4.57 (m, 1H), 3.55 (s, 3H), 2.47 (s, 3H), 1.64 (d, J = 6.4 Hz, 3H).
589	(ES+) 542.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 7.96 – 7.94 (m, 1H), 7.44 – 7.42 (m, 1H), 6.88 (d, J = 8.4 Hz, 1H), 6.71 (t, J = 54.4 Hz, 1H), 6.47 – 6.46 (m, 1H), 6.20 (s, 1H), 4.94 (d, J = 2.8 Hz, 1H), 4.91 – 4.76 (m, 2H), 4.62 – 4.22 (m, 1H), 3.71 (s, 3H), 3.70 – 3.29 (m, 1H), 3.22 (d, J = 10.4 Hz, 1H), 3.09 (d, J = 10.8 Hz, 1H), 2.98 – 2.84 (m, 1H), 2.78 – 2.60 (m, 1H), 2.38 (s, 3H), 1.64 (d, J = 6.4 Hz, 3H), 1.57 (s, 3H), 1.36 (s, 3H), 1.06 – 0.93 (m, 2H), 0.64 (d, J = 1.2 Hz, 2H).
590	(ES+) 595.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.21 – 8.05 (m, 1H), 7.67 – 7.54 (m, 2H), 7.09 – 6.98 (m, 1H), 6.98 - 6.88 (m, 1H), 6.34 – 6.30 (m, 1H), 5.64 – 5.44 (m, 1H), 4.99 – 4.74 (m, 1H), 4.67 – 4.39 (m, 3H), 3.68 (s, 3H), 3.41 – 3.30 (m, 2H), 3.25 – 3.07 (m, 7H), 1.38 (s, 3H), 1.07 – 0.93 (m, 2H), 0.73 – 0.60 (m, 2H).
591	(ES-) 545.0 [M-H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.72 – 7.68 (m, 1H), 7.52 – 7.46 (m, 1H), 7.39 – 7.22 (m, 2H), 7.20– 7.15 (m, 1H), 7.06 – 6.99 (m, 1H), 6.49 (s, 1H), 6.31 – 6.26 (m, 1H), 5.81 (d, J = 6.1 Hz, 1H), 5.21 – 5.12 (m, 1H), 3.67 (d, J = 1.2 Hz, 3H), 3.54 (s, 3H), 3.11 (s, 8H), 1.53 (d, J = 6.5 Hz, 3H).
592	(ES+) 583.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.86 – 7.84 (m, 1H), 7.84 – 7.62 (m, 4H), 7.46 (d, 1H), 7.27 – 7.16 (m, 1H), 7.06 – 6.99 (m, 1H), 6.30 – 6.24 (m, 1H), 5.89 (d, 1H), 5.29 – 5.21 (m, 1H), 3.55 (s, 3H), 3.44 (d, 4H), 3.32 – 3.22 (m, 2H), 2.90 – 2.78 (m, 2H), 1.56 (d, 3H).
593	(ES+) 549.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.73 – 7.66 (m, 1H), 7.54 – 7.23 (m, 2H), 7.21 – 7.13 (m, 1H), 7.07 – 6.98 (m, 1H), 6.45 (s, 1H), 6.32 – 6.24 (m, 1H), 5.82 (d, J = 6.1 Hz, 1H), 5.21 – 5.12 (m, 1H), 4.78 – 4.69 (m, 1H), 4.18 (d, J = 12.2 Hz, 2H), 3.95 – 3.87 (m, 2H), 3.53 (s, 3H), 3.20 – 2.60 (m, 8H), 2.33 (s, 1H), 1.52 (d, J = 6.5 Hz, 3H), 1.18 (d, J = 5.0 Hz, 3H).
594	(ES+) 549.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.73 – 7.65 (m, 1H), 7.52 – 7.22 (m, 2H), 7.20 – 7.12 (m, 1H), 7.06 – 6.97 (m, 1H), 6.42 (s, 1H), 6.31 – 6.23 (m, 1H), 5.81 (d, J = 6.1 Hz, 1H), 5.19 – 5.11 (m, 1H), 4.58 (d, J = 5.0 Hz, 1H), 4.23 – 4.14 (m, 2H), 3.57 – 3.45 (m, 5H), 3.23 – 2.53 (m, 8H), 1.51 (d, J = 6.6 Hz, 3H), 1.19 (d, J = 5.0 Hz, 3H).
595	(ES+) 589.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.47 – 8.44 (m, 1H), 7.86 – 7.83 (m, 1H), 7.66 (d, J = 8.4 Hz, 1H), 7.52 – 7.25 (m, 1H), 7.22 – 7.17 (m, 2H), 7.03 (s, 1H), 6.27 (d, J = 8.5 Hz, 1H), 5.90 (d, J = 6.2 Hz, 1H), 5.27 – 5.24 (m, 1H), 3.60 (d, J = 10.3 Hz, 2H), 3.54 (d, J = 8.3 Hz, 2H), 3.49 (s, 3H), 2.48 (s, 3H), 2.29 – 2.26 (m, 1H), 2.18 – 2.15 (m, 2H), 1.56 (d, J = 6.5 Hz, 3H).

596	(ES+) 520.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.08 – 9.06 (m, 1H), 8.47 – 8.45 (m, 1H), 8.23 – 8.21 (m, 1H), 7.86 – 7.84 (m, 1H), 7.62 – 7.60 (m, 1H), 7.51 (s, 1H), 7.24 – 7.19 (m, 2H), 7.02 – 6.98 (m, 1H), 6.32 – 6.29 (m, 1H), 5.86 (d, J = 6.2 Hz, 1H), 5.27 – 5.24 (m, 1H), 3.38 – 3.33 (m, 6H), 1.51 (d, J = 6.6 Hz, 3H).
597	(ES+) 638.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.33 – 8.31 (m, 1H), 7.97 – 7.94 (m, 1H), 7.66 (d, J = 10.0 Hz, 1H), 7.52 – 7.49 (m, 1H), 7.36 – 7.30 (m, 1H), 7.24 – 7.21 (m, 1H), 6.93 – 6.92 (m, 1H), 6.54 (s, 1H), 5.60 – 5.55 (m, 1H), 5.02 – 4.91 (m, 2H), 4.03 – 4.01 (m, 1H), 3.60 (s, 3H), 3.48 – 3.43 (m, 2H), 3.34 (s, 3H), 3.38 – 3.32 (s, 1H), 3.18 – 3.16 (m, 2H), 3.05 – 3.04 (m, 2H), 2.36 (s, 3H).
598	(ES+) 592.1 [M+H]	
599	(ES+) 614.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.36 (s, 2H), 8.84 – 8.79 (m, 1H), 8.02 – 7.94 (m, 1H), 7.80 – 7.73 (m, 1H), 7.66 – 7.57 (m, 1H), 7.51 – 7.47 (m, 1H), 7.31 (d, J = 5.4 Hz, 2H), 6.92 (d, J = 6.0 Hz, 1H), 6.56 – 6.52 (m, 1H), 5.69 (d, J = 19.8 Hz, 1H), 4.99 – 4.70 (m, 2H), 3.51 (s, 3H), 3.37 (s, 3H), 2.62 (s, 3H).
600	(ES+) 550.0 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.07 – 8.03 (m, 1H), 7.55 – 7.48 (m, 1H), 7.20 – 7.01 (m, 1H), 6.93 – 6.87 (m, 1H), 6.85 – 6.58 (m, 1H), 6.47 (s, 1H), 6.28 – 6.20 (m, 1H), 5.50 – 5.26 (m, 1H), 5.25 – 5.10 (m, 1H) , 4.97 (s, 1H), 4.88 – 4.70 (m, 1H), 4.67 – 4.31 (m, 4H), 4.28 – 4.15 (m, 1H), 3.74 (s, 3H), 2.57 (s, 6H).
601	(ES+) 568.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.29 (s, 2H), 7.87 – 7.84 (m, 1H), 7.65 – 7.50 (m, 2H), 7.50 – 7.16 (m, 3H), 7.03 – 7.01 (m, 1H), 6.76 – 6.72 (m, 1H), 6.33 – 6.30 (m, 1H), 5.86 (d, J = 6.2 Hz, 1H), 5.28 – 5.25 (m, 1H), 3.65 (s, 3H), 3.32 (s, 3H), 1.53 (d, J = 6.6 Hz, 3H).
602	(ES+) 585.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.88 (d, J = 1.6 Hz, 1H), 8.42 – 8.32 (m, 1H), 7.90 – 7.80 (m, 1H), 7.64 – 7.50 (m, 2H), 7.49 – 6.90 (m, 4H), 6.50 – 6.42 (m, 1H), 6.35 – 6.27 (m, 1H), 5.85 (d, J = 6.1 Hz, 1H), 5.31 – 5.23 (m, 1H), 3.52 – 3.38 (m, 6H), 1.53 (d, J = 6.6 Hz, 3H).
603	(ES+) 586.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.33 (s, 2H), 8.82 (d, J = 4.3 Hz, 1H), 7.88 (d, J = 9.0 Hz, 1H), 7.77 (d, J = 8.4 Hz, 1H), 7.61 (d, J = 9.8 Hz, 1H), 7.35 (d, J = 8.9 Hz, 1H), 7.25 (s, 1H), 7.20 – 7.15 (m, 1H), 6.50 – 6.44 (m, 1H), 5.56 (d, J = 6.2 Hz, 1H), 5.38 – 5.31 (m, 1H), 3.49 (s, 3H), 2.62 (s, 3H), 1.58 (d, J = 6.5 Hz, 3H).
604	(ES+) 541.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.99 (s, 1H), 7.67 (d, J = 1.8 Hz, 1H), 7.38 (s, 1H), 7.18 – 7.03 (m, 1H), 7.02 – 6.99 (m, 1H), 6.28 (s, 1H), 5.80 (d, J = 6.1 Hz, 1H), 5.26 – 5.19 (m, 1H), 3.54 (s, 5H), 3.36 (s, 1H), 3.25 (s, 3H), 3.07 (d, J = 11.5 Hz, 2H), 2.98 (s, 3H), 2.34 (s, 3H), 1.53 (d, J = 6.5 Hz, 3H).

605	(ES+) 563.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.08 – 7.99 (m, 1H), 7.65 – 7.58 (m, 1H), 7.28 – 7.21 (m, 1H), 6.96 – 6.87 (m, 1H), 6.29 – 6.20 (m, 1H), 5.28 (d, J = 6.8 Hz, 1H), 4.68 – 4.50 (m, 1H), 3.93 – 3.82 (m, 2H), 3.66 (s, 3H), 3.61 – 3.51 (m, 2H), 3.27 – 3.15 (m, 2H), 3.11 – 3.01 (m, 2H), 2.91 (s, 3H), 1.61 (d, J = 6.6 Hz, 3H).
606	(ES+) 592.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.32 – 8.31 (m, 1H), 7.86 – 7.84 (m, 1H), 7.69 – 7.65 (m, 1H), 7.53 – 7.22 (m, 3H), 7.03 – 6.95 (m, 1H), 6.30 – 6.27 (m, 1H), 5.90 (d, J = 6.2 Hz, 1H), 5.29 – 5.26 (m, 1H), 3.59 (s, 3H), 3.47 – 3.45 (m, 2H), 3.42 – 3.36 (m, 1H), 3.35 – 3.32 (m, 1H), 3.18 – 3.16 (m, 2H), 3.06 – 3.04 (m, 2H), 2.36 (s, 3H), 1.76 – 1.57 (m, 3H).
607	(ES+) 512.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.01 (s, 1H), 7.93 – 7.69 (m, 1H), 7.58 – 7.49 (m, 2H), 7.21– 7.12 (m, 1H), 7.10 – 6.01 (m, 1H), 6.79 (s, 1H), 6.39 – 6.16 (m, 1H), 5.47 – 5.02 (m, 1H), 5.42 – 5.01 (m, 1H), 3.68 (s, 3H), 2.90 – 2.80 (m, 6H), 2.27 (s, 3H), 1.62 – 1.41 (m, 3H).
608	(ES+) 531.3 [M+H]	
609	(ES+) 531.3 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 7.91 (d, J = 8.8, 2.3 Hz, 1H), 7.69 (d, J = 10.1, 2.8 Hz, 1H), 7.17 – 6.84 (m, 3H), 6.29 (d, J = 9.1, 4.3 Hz, 1H), 5.35 (d, J = 6.6 Hz, 1H), 4.94 – 4.89 (m, 1H), 3.67 (s, 3H), 3.54 (d, J = 9.8, 5.3 Hz, 2H), 3.25 – 2.97 (m, 4H), 2.29 – 2.21 (m, 2H), 2.11 – 2.01 (m, 5H), 1.59 (s, 3H).
610	(ES+) 563.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.13 (s, 1H), 7.80 – 7.78 (m, 1H), 7.45 (s, 1H), 7.25 (s, 1H), 6.79 – 6.70 (m, 2H), 6.39 – 6.32 (m, 1H), 6.21 (d, J = 5.2 Hz, 1H), 4.95 – 4.88 (m, 1H), 4.52 – 4.48 (m, 1H), 3.75 (s, 3H), 3.40 – 3.36 (m, 1H), 3.35 – 3.26 (m, 1H), 3.14 (s, 3H), 3.10 – 3.03 (m, 2H), 2.87 – 2.72 (m, 1H), 2.40 (s, 3H), 2.17 – 1.99 (m, 3H), 1.98 – 1.88 (m, 1H), 1.87 – 1.74 (m, 3H), 1.66 (d, J = 6.6 Hz, 3H), 1.08 – 1.06 (m, 2H), 0.85 – 0.82 (m, 2H).
611	(ES+) 535.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.61 (s, 2H), 9.29 (s, 2H), 7.99 – 7.72 (m, 1H), 7.71 – 7.59 (m, 1H), 7.54 – 7.22 (m, 2H), 7.21 (s, 1H), 7.10 – 6.85 (m, 1H), 6.49 – 6.18 (m, 1H), 5.46 – 5.12 (m, 1H), 5.45 – 5.09 (m, 1H), 3.48 (s, 3H), 2.76 (s, 3H), 1.53 (d, J = 6.6 Hz, 3H).
612	(ES+) 523.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.80 (s, 2H), 8.25 (s, 1H), 8.17 (s, 1H), 8.06 – 8.04 (m, 1H), 7.52 – 7.50 (m, 1H), 7.03 – 7.01 (m, 1H), 6.87 – 6.52 (m, 3H), 6.14 – 6.13 (m, 1H), 5.01 – 4.87 (m, 1H), 4.62 (d, J = 1.6 Hz, 1H), 4.02 (s, 3H), 3.54 (s, 3H), 1.62 (d, J = 6.4 Hz, 3H).
613	(ES+) 545.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.02 – 8.01 (m, 1H), 7.64 – 7.62 (m, 1H), 7.26 – 6.99 (m, 2H), 6.37 – 6.34 (m, 1H), 6.02 (d, J = 8.8 Hz, 1H), 5.38 – 5.29 (m, 1H), 5.24 (br s, 1H), 3.85 (d, J = 11.6 Hz, 2H), 3.64 (s, 3H), 3.55 – 3.52 (m, 2H), 3.26 – 3.14 (m, 2H), 3.10 – 3.00 (m, 2H), 2.90 (s, 3H), 1.60 (d, J = 6.0 Hz, 3H).

614	(ES+) 563.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.03 – 8.02 (m, 1H), 7.62 – 7.60 (m, 1H), 7.09 (t, J = 53.6 Hz, 1H), 6.92 (d, J = 9.6 Hz, 1H), 5.91 (d, J = 8.8 Hz, 1H), 5.26 – 5.25 (m, 1H), 5.06 – 5.05 (m, 1H), 3.85 (d, J = 11.6 Hz, 2H), 3.64 (s, 3H), 3.58 – 3.50 (m, 2H), 3.27 – 3.14 (m, 2H), 3.10 – 3.00 (m, 2H), 2.90 (s, 3H), 1.60 (br s, 3H).
615	(ES+) 545.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 7.95 – 7.94 (m, 1H), 7.43 – 7.42 (m, 1H), 7.03 – 7.00 (m, 1H), 6.88 – 6.81 (m, 1H), 6.65 (t, J = 55.2 Hz, 1H), 6.21 – 6.13 (m, 2H), 4.93 – 4.76 (m, 2H), 4.58 (br s, 1H), 4.53 – 4.16 (m, 1H), 3.71 (s, 3H), 3.50 (s, 1H), 3.21 (d, J = 12.2 Hz, 1H), 3.13 – 3.04 (m, 1H), 2.88 – 2.86 (m, 1H), 2.74 – 2.61 (m, 1H), 1.61 (d, J = 6.8 Hz, 3H), 1.58 (s, 3H), 1.36 (s, 3H), 1.05 – 0.92 (m, 2H), 0.64 (d, J = 1.2 Hz, 2H).
616	(ES+) 555.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.80 (s, 1H), 8.89 (s, 2H), 8.27 (d, J = 1.2 Hz, 1H), 8.08 – 8.07 (m, 1H), 7.56 – 7.54 (m, 1H), 7.44 – 7.42 (m, 1H), 7.01 – 6.96 (m, 1H), 6.67 (s, 1H), 6.56 (d, J = 4.4 Hz, 1H), 6.20 – 6.18 (M, 1H), 4.96 – 4.89 (m, 1H), 3.55 (s, 3H), 3.18 (s, 3H), 1.65 (d, J = 6.8 Hz, 3H).
617	(ES+) 535.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.23 (s, 1H), 8.07 – 8.02 (m, 1H), 7.98 (s, 1H), 7.53 – 7.49 (m, 1H), 7.06 – 7.02 (m, 1H), 6.85 – 6.54 (m, 3H), 6.16 – 6.14 (m, 1H), 4.94 – 4.91 (m, 1H), 4.62 – 4.61 (m, 1H), 3.61 (s, 3H), 2.91 – 2.87 (m, 1H), 1.63 – 1.55 (m, 5H), 1.35 – 1.30 (m, 2H).
618	(ES+) 535.2 [M+H]	
619	(ES+) 524.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.73 (d, J = 7.2 Hz, 1H), 7.55 – 7.45 (m, 1H), 7.43 – 7.22 (m, 1H), 7.21 – 7.12 (m, 1H), 7.06 – 6.95 (m, 1H), 6.83 (s, 1H), 6.24 – 6.22 (m, 1H), 5.94 – 5.75 (m, 1H), 5.39 – 5.15 (m, 1H), 3.66 (s, 3H), 3.59 (d, J = 10.0 Hz, 2H), 3.49 – 3.45 (m, 2H), 3.00 (s, 3H), 2.40 – 2.25 (m, 3H), 2.09 (br s, 1H), 1.48 (d, J = 6.0 Hz, 3H).
620	(ES+) 563.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.03 – 8.01 (m, 1H), 7.62 – 7.60 (m, 1H), 7.02 – 7.01 (m, 1H), 6.87 – 6.81 (m, 1H), 6.81 – 6.53 (m, 1H), 6.18 – 6.16 (m, 1H), 5.33 – 5.17 (m, 1H), 4.91 – 4.73 (m, 1H), 4.71 – 4.58 (m, 1H), 4.56 – 4.16 (m, 1H), 3.73 (s, 3H), 3.62 – 3.53 (m, 1H), 3.36 – 3.21 (m, 1H), 3.14 – 3.00 (m, 2H), 1.59 (br s, 3H), 1.55 – 1.39 (m, 3H), 1.37 (s, 3H), 1.08 – 0.94 (m, 2H), 0.64 (d, J = 1.2 Hz, 2H).
621	(ES+) 583.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.91 (s, 2H), 8.15 – 8.13 (m, 1H), 7.83 (s, 1H), 7.59 – 7.58 (m, 1H), 7.50 – 7.48 (m, 1H), 7.04 – 6.97 (m, 1H), 6.89 (d, J = 4.4 Hz, 1H), 6.8 (s, 1H), 6.25 – 6.24 (m, 1H), 5.22 – 5.13 (m, 1H), 4.85 – 4.49 (m, 2H), 3.57 (s, 3H), 3.19 (s, 3H), 2.87 (s, 3H), 2.42 (s, 3H).
622	(ES+) 589.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.82 – 7.80 (m, 1H), 7.50 – 7.48 (m, 2H), 7.47 – 7.26 (m, 2H), 6.86 (d, J = 6.0 Hz, 1H), 6.55 – 6.52 (m, 2H), 5.63 (s, 1H), 4.95 – 4.70 (m, 2H), 3.68 (s, 3H), 3.56 (s, 3H), 3.35 (s, 3H), 3.31 – 2.83 (m, 8H), 2.09 (s, 3H).

623	(ES+) 560.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.85 (d, J = 8.3 Hz, 1H), 7.66 (d, J = 10.1 Hz, 1H), 7.16 (d, J = 8.6 Hz, 1H), 6.81 (d, J = 8.8 Hz, 1H), 5.74 (d, J = 6.4 Hz, 1H), 5.31 – 5.28 (m, 1H), 3.55 (s, 4H), 3.38 – 3.22 (m, 5H), 3.09 – 3.03 (m, 2H), 2.98 (s, 3H), 2.30 (s, 3H), 1.61 (d, J = 6.4 Hz, 3H).
624	(ES+) 549.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.86 (d, J = 8.5 Hz, 1H), 7.68 (d, J = 9.9 Hz, 1H), 7.54 – 7.37 (m, 1H), 7.23 – 7.16 (m, 1H), 7.05 – 6.97 (m, 1H), 6.26 (s, 1H), 5.90 (s, 1H), 5.27 – 5.18 (m, 1H), 4.69 (d, J = 25.5 Hz, 1H), 4.32 – 4.17 (m, 1H), 3.64 (s, 3H), 3.27 – 2.98 (m, 5H), 2.02 (s, 1H), 1.58 – 1.23 (m, 6H), 0.75 (s, 4H).
625	(ES+) 568.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.85 – 7.80 (m, 1H), 7.69 – 7.61 (m, 1H), 7.54 – 7.23 (m, 1H), 7.22 – 7.17 (m, 1H), 7.05 – 6.97 (m, 1H), 6.29 – 6.21 (m, 1H), 5.92 – 5.86 (m, 1H), 5.48 – 5.26 (m, 1H), 5.26 – 5.18 (m, 1H), 4.32 – 4.19 (m, 2H), 4.08 – 3.92 (m, 2H), 3.79 – 3.72 (m, 2H), 3.55 (s, 3H), 3.29 – 2.97 (m, 6H), 1.56 – 1.51 (m, 3H).
626	(ES+) 605.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.54 (s, 2H), 7.99 – 7.92 (m, 1H), 7.66 (d, J = 9.2 Hz, 1H), 7.54 – 7.47 (m, 1H), 7.35 – 7.25 (m, 1H), 6.91 (d, J = 5.9 Hz, 1H), 6.53 (s, 1H), 5.55 (d, J = 19.3 Hz, 1H), 5.10 – 4.73 (m, 2H), 3.82 (d, J = 11.7 Hz, 2H), 3.59 (s, 3H), 3.40 – 3.34 (m, 7H), 3.10 – 3.04 (m, 2H), 2.55 (s, 3H).
627	(ES+) 605.0 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.65 (s, 2H), 8.15 – 8.08 (m, 1H), 7.64 – 7.58 (m, 1H), 7.53 – 7.47 (m, 1H), 7.10 – 7.01 (m, 1H), 6.90 (d, J = 5.0 Hz, 1H), 6.70 (s, 1H), 6.34 – 6.26 (m, 1H), 5.26 – 5.16 (m, 1H), 4.90 – 4.53 (m, 2H), 3.79 (s, 3H), 3.19 (s, 3H), 2.95 (br s, 2H), 2.81 (s, 3H), 2.50 – 2.40 (m, 2H).
628	(ES+) 557.4 [M+H]	^{1}H NMR (400 MHz, CD_3CN): δ 7.95 (d, J = 6.4, 1H), 7.56 – 7.50 (m, 2H), 7.41 (s, 1H), 7.35 (s, 1H), 7.18 – 7.12 (m, 1H), 6.87 (d, J = 5.2 Hz, 1H), 6.60 (s, 1H), 6.57 – 6.41 (m, 1H), 5.60 – 5.30 (m, 1H), 5.05 – 4.62 (m, 2H), 3.83 (s, 3H), 3.73 (s, 3H), 3.20 (s, 3H), 2.20 – 2.15 (m, 6H).
629	(ES+) 532.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.75 – 7.65 (m, 1H), 7.61 – 7.48 (m, 2H), 7.25 – 7.15 (m, 1H), 7.04 – 7.01 (m, 1H), 6.64 (s, 1H), 6.31 – 6.27 (m, 1H), 5.80 (d, J = 6.0 Hz, 1H), 5.50 – 5.36 (m, 1H), 5.18 – 5.15 (m, 1H), 4.71 – 4.56 (m, 1H), 4.45 – 4.31 (m, 1H), 4.30 – 4.19 (m, 1H), 4.02 – 3.98 (m, 1H), 3.63 (s, 3H), 2.51 – 2.47 (m, 6H), 1.55 – 1.53 (m, 3H).
630	(ES+) 577.1 [M+H]	
631	(ES+) 577.1 [M+H]	
632	(ES+) 544.1 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.00 (s, 1H), 7.90 – 7.80 (m, 1H), 7.70 (s, 1H), 7.69 – 7.24 (m, 2H), 7.07 – 7.01 (m, 1H), 6.81 – 6.69 (m, 3H), 5.31 – 5.14 (m, 1H), 3.80 (s, 3H), 2.61 – 2.55 (m, 6H), 2.36 (s, 3H), 1.67 (d, J = 6.7 Hz, 3H).

633	(ES+) 546.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.12 – 9.06 (m, 1H), 8.51 – 8.39 (m, 1H), 8.19 (d, J = 8.1 Hz, 1H), 7.90 – 7.81 (m, 1H), 7.65 – 7.56 (m, 1H), 7.38 (s, 1H), 7.18 (d, J = 8.4 Hz, 2H), 7.05 – 6.96 (m, 1H), 6.38 – 6.28 (m, 1H), 5.84 (d, J = 6.2 Hz, 1H), 5.35 – 5.22 (m, 1H), 3.39 (s, 3H), 3.10 – 3.01 (m, 1H), 1.52 (d, J = 6.6 Hz, 3H), 1.26 – 1.12 (m, 4H).
634	(ES+) 569.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.50 (s, 2H), 8.04 – 8.00 (m, 1H), 7.52 – 7.46 (m, 1H), 7.04 – 6.99 (m, 1H), 6.85 – 6.80 (m, 1H), 6.67 – 6.52 (m, 3H), 6.15 – 6.10 (m, 1H), 4.92 – 4.90 (m, 1H), 4.05 – 3.97 (m, 4H), 3.96 – 3.73 (m, 2H), 3.71 – 3.61 (m, 2H), 3.52 (s, 3H), 2.18 (s, 3H), 1.59 (d, J = 7.5 Hz, 3H).
635	(ES+) 575.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.04 (m, 1H), 7.59 (m, 1H), 7.42 (m, 1H), 7.26 (s, 1H), 7.07 – 6.97 (m, 2H), 6.86 (d, J = 4.4 Hz, 1H), 6.26 (m, 1H), 6.19 (s, 1H), 5.23 – 5.07 (m, 1H), 4.87 – 4.67 (m, 1H), 4.66 – 4.45 (m, 1H), 3.87 (s, 3H), 3.67 (s, 3H), 3.36 – 2.93 (m, 11H).
636	(ES+) 611.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.05 – 8.03 (m, 1H), 7.59 – 7.58 (m, 1H), 7.47 (s, 1H), 7.43 – 7.41 (m, 1H), 7.35 (s, 1H), 7.27 – 6.95 (m, 2H), 6.87 (d, J = 4.4 Hz, 1H), 6.26 – 6.24 (m, 1H), 6.20 (s, 1H), 5.20 – 5.10 (m, 1H), 4.86 – 4.47 (m, 2H), 3.67 (s, 3H), 3.48 – 2.96 (m, 11H).
637	(ES+) 550.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 7.98 – 7.96 (m, 1H), 7.44 – 7.42 (m, 1H), 7.05 – 7.00 (m, 1H), 6.86 – 6.79 (m, 1H), 6.70 – 6.52 (m, 1H), 6.51 (s, 1H), 6.14 – 6.11 (m, 1H), 4.96 – 4.88 (m, 1H), 4.63 – 4.57 (m, 1H), 3.86 – 3.85 (m, 2H), 3.75 (s, 3H), 3.59 – 3.57 (m, 2H), 2.40 – 2.38 (m, 1H), 2.18 – 2.13 (m, 1H), 2.06 – 1.99 (m, 2H), 1.61 (d, J = 6.8 Hz, 3H), 1.26 – 1.21 (m, 2H), 1.07 – 1.02 (m, 2H).
638	(ES+) 547.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 7.96 – 7.94 (m, 1H), 7.43 – 7.41 (m, 1H), 7.02 – 7.00 (m, 1H), 6.86 – 6.79 (m, 1H), 6.79 – 6.51 (m, 1H), 6.50 (s, 1H), 6.12 – 6.10 (m, 1H), 5.43 – 5.20 (m, 1H), 4.92 – 4.88 (m, 1H), 4.62 – 4.58 (m, 1H), 4.35 – 4.21 (m, 2H), 4.17 – 4.13 (m, 1H), 4.11 – 4.07 (m, 1H), 3.91 (d, J = 11.2Hz, 2H), 3.72 (s, 1H), 3.56 – 3.52 (m, 2H), 2.03 – 1.93 (m, 2H), 1.70 – 1.68 (m, 1H), 1.59 (d, J = 6.8 Hz, 3H).
639	(ES+) 509.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.26 (s, 1H), 8.03 (m, 1H), 7.99 (s, 1H), 7.50 (m, 1H), 7.03 (m, 1H), 6.83 (br s, 1H), 6.80 – 6.51 (m, 2H), 6.14 (m, 1H), 4.99 – 4.87 (m, 1H), 4.61 – 4.60 (m, 1H), 3.59 (s, 3H), 3.50 (s, 3H), 1.62 (d, J = 6.8 Hz, 3H).
640	(ES+) 551.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.43 (d, J = 1.6 Hz, 1H), 9.20 (d, J = 1.6 Hz, 1H), 9.00 (s, 2H), 8.07 – 8.06 (m, 1H), 7.54 – 7.52 (m, 1H), 7.03 – 7.00 (m, 1H), 6.89 – 6.80 (m, 1H), 6.79 – 6.78 (m, 1H), 6.75 – 6.50 (m, 1H), 6.14 – 6.13 (m, 1H), 5.02 – 4.85 (m, 1H), 4.69 – 4.57 (m, 1H), 3.55 (s, 3H), 2.87 (s, 3H), 1.63 (d, J = 6.8 Hz, 3H).

641	(ES+) 571.1 [M+Na]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.06 – 7.99 (m, 1H), 7.66 – 7.59 (m, 1H), 7.05 – 7.01 (m, 1H), 6.86 – 6.80 (m, 1H), 6.70 – 6.50 (m, 1H), 6.23 – 6.16 (m, 1H), 5.32 – 5.21 (m, 1H), 4.65 (br s, 1H), 4.01 (br d, J = 12.6 Hz, 2H), 3.68 (s, 3H), 3.58 – 3.51 (m, 2H), 3.42 – 3.34 (m, 2H), 3.22 – 3.12 (m, 2H), 2.44 (s, 3H), 1.62 – 1.55 (m, 3H).
642	(ES+) 549.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.03 – 8.01 (m, 1H), 7.62 – 7.60 (m, 1H), 7.03 – 7.02 (m, 1H), 6.89 – 6.82 (m, 1H), 6.67 (t, J = 55.2 Hz, 1H), 6.21 (br d, J = 4.8 Hz, 1H), 5.34 – 5.21 (m, 1H), 4.82 – 4.41 (m, 2H), 4.29 (br s, 1H), 3.69 (s, 3H), 3.50 – 3.31 (m, 2H), 3.20 – 2.98 (m, 4H), 1.58 (br d, J = 6.4 Hz, 6H), 1.06 – 1.00 (m, 2H), 0.64 – 0.63 (m, 2H).
643	(ES+) 535.5 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.03 – 8.01 (m, 1H), 7.62 – 7.60 (m, 1H), 7.03 – 7.02 (m, 1H), 6.89 – 6.82 (m, 1H), 6.67 – 6.53 (m, 1H), 6.21 – 6.20 (m, 1H), 5.34 – 5.21 (m, 1H), 4.82 – 4.41 (m, 2H), 4.29 (br s, 1H), 3.69 (s, 3H), 3.50 – 3.31 (m, 3H), 3.20 – 2.98 (m, 3H), 1.83 – 1.77 (m, 1H), 1.62 – 1.56 (m, 3H), 1.06 – 1.05 (m, 2H), 0.86 – 0.82 (m, 2H).
644	(ES-) 511.2 [M-H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.77 – 7.74 (m, 1H), 7.55 – 7.52 (m, 1H), 7.51 – 7.24 (m, 1H), 7.20 – 7.17 (m, 1H), 7.10 – 6.96 (m, 1H), 6.72 (s, 1H), 6.31 – 6.28 (m, 1H), 5.82 (d, J = 6.1 Hz, 1H), 5.21 (t, J = 6.6 Hz, 1H), 3.66 (s, 3H), 2.76 – 2.66 (m, 6H), 2.49 (s, 3H), 1.54 (d, J = 6.6 Hz, 3H).
645	(ES+) 516.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.76 – 7.72 (m, 1H), 7.53 – 7.49 (m, 1H), 7.48 – 7.20 (m, 1H), 7.19 – 7.15 (m, 1H), 7.07 – 6.99 (m, 1H), 6.67 (s, 1H), 6.32 – 6.25 (m, 1H), 5.79 (d, J = 6.1 Hz, 1H), 5.20 – 5.10 (m, 1H), 3.61 (d, J = 3.7 Hz, 7H), 2.48 – 2.40 (m, 4H), 2.24 – 2.18 (m, 6H), 1.53 (d, J = 6.5 Hz, 3H).
646	(ES+) 571.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.75 – 7.68 (m, 1H), 7.54 – 7.44 (m, 1H), 7.38 (s, 1H), 7.22 – 7.14 (m, 1H), 7.05 (d, J = 13.2 Hz, 2H), 6.55 (s, 1H), 6.34 – 6.26 (m, 1H), 5.82 (d, J = 6.1 Hz, 1H), 5.24 – 5.17 (m, 1H), 3.57 (s, 3H), 3.47 (s, 3H), 3.24 – 3.12 (m, 8H), 2.26 (s, 3H), 1.54 (d, J = 6.6 Hz, 3H).
647	(ES+) 580.2 [M+H]	
648	(ES+) 578.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.83 – 7.77 (m, 1H), 7.60 – 7.54 (m, 1H), 7.39 (d, J = 1.9 Hz, 1H), 7.35 (d, J = 8.8 Hz, 1H), 7.28 – 7.11 (m, 1H), 7.03 – 6.97 (m, 1H), 6.59 – 6.51 (m, 2H), 5.63 (d, J = 11.0 Hz, 1H), 4.92 – 4.80 (m, 1H), 4.79 – 4.62 (m, 1H), 3.69 (d, J = 2.0 Hz, 3H), 3.55 (d, J = 1.9 Hz, 3H), 3.10 – 3.02 (m, 8H), 2.11 (d, J = 1.9 Hz, 3H).
649	(ES+) 531.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.71 (dd, J = 9.1, 2.8 Hz, 1H), 7.53 – 7.44 (m, 1H), 7.17 (dd, J = 9.1, 3.1 Hz, 1H), 7.04 – 6.99 (m, 1H), 6.49 (s, 1H), 6.28 (dd, J = 9.2, 4.4 Hz, 1H), 5.82 (d, J = 6.1 Hz, 1H), 5.20 – 5.13 (m, 1H), 3.6 – 3.52 (m, 5H), 3.35 – 3.25 (m, 6H), 1.52 (d, J = 6.6 Hz, 3H), 1.28 (s, 3H), 0.86 – 0.79 (m, 2H), 0.62 – 0.55 (m, 2H).

650	(ES+) 598.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.33 (s, 2H), 8.71 – 8.62 (m, 1H), 8.22 – 8.17 (m, 1H), 8.01 – 7.92 (m, 1H), 7.63 – 7.60 (m, 1H), 7.51 – 7.48 (m, 1H), 7.31 (d, J = 4.9 Hz, 2H), 6.92 (d, J = 6.1 Hz, 1H), 6.57 – 6.52 (m, 1H), 5.77 – 5.59 (m, 1H), 4.98 – 4.70 (m, 2H), 3.51 (s, 3H), 3.38 (s, 3H), 2.82 (s, 3H).
651	(ES+) 559.4 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 7.92 – 7.86 (m, 1H), 7.54 – 7.50 (m, 2H), 7.17 – 7.12 (m, 1H), 6.53 – 6.50 (m, 1H), 6.48 (s, 1H), 5.48 – 5.39 (m, 1H), 4.96 (m, 1H) 4.78 (m, 2H), 3.70 (s, 3H), 3.25 – 3.21 (m, 5H), 3.14 – 3.10 (m, 2H), 3.05 – 2.98 (m, 2H), 2.29 – 2.23 (m, 2H), 2.09 – 1.99 (m, 2H), 1.41 (s, 3H).
652	(ES+) 559.4 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 7.90 – 7.86 (m, 1H), 7.55 – 7.49 (m, 2H), 7.18 – 7.13 (m, 1H), 6.51 (d, J = 10.3 Hz, 2H), 5.49 – 5.42 (m, 1H), 4.95 (m, 1H), 4.83 – 4.74 (m, 2H), 3.67 (s, 3H), 3.26 – 3.22 (m, 5H), 2.96 – 3.19 (m, 4H), 2.53 – 2.47 (m, 2H), 1.66 – 1.59 (m, 2H), 1.53 (s, 3H).
653	(ES+) 631.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.92 (d, J = 1.6 Hz, 1H), 8.82 – 8.79 (m, 1H), 8.39 – 8.37 (m, 1H), 7.98 – 7.96 (m, 1H), 7.62 – 7.58 (m, 2H), 7.57 (d, J = 2.0, 1H), 7.31 – 7.28 (m, 1H), 7.26 (s, 1H), 6.92 (d, J = 6.4 Hz, 1H), 6.54 – 6.52 (m, 1H), 5.73 – 5.65 (m, 1H), 4.95 – 4.76 (m, 2H), 3.48 (s, 3H), 3.37 (s, 3H), 2.29 (s, 3H).
654	(ES+) 615.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.92 (d, J = 1.6 Hz, 1H), 8.80 – 8.79 (m, 1H), 8.39 – 8.37 (m, 1H), 7.98 – 7.96 (m, 1H), 7.88 – 7.85 (m, 1H), 7.58 – 7.55 (m, 1H), 7.49 – 7.47 (m, 1H), 7.31 – 7.28 (m, 1H), 7.26 (s, 1H), 6.91 (d, J = 6.0 Hz, 1H), 6.75 – 6.68 (m, 2H), 4.95 – 4.74 (m, 2H), 3.48 (s, 3H), 3.36 (m, 3H), 2.46 (s, 3H).
655	(ES+) 529.1 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 7.88 – 7.80 (m, 1H), 7.60 – 7.50 (m, 1H), 7.17 – 7.10 (m, 1H), 7.00 (s, 1H), 6.94 – 6.84 (m, 1H), 6.82 (s, 1H), 6.37 – 6.30 (m, 1H), 5.21 – 5.13 (m, 1H), 3.80 (s, 3H), 2.85 – 2.75 (m, 9H), 1.65 (d, J = 6.7 Hz, 3H).
656	(ES+) 529.1 [M+H]	
657	(ES+) 584.1 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.39 (s, 1H), 8.20 (s, 1H), 7.93 – 7.90 (m, 1H), 7.57 – 7.50 (m, 1H), 7.54 – 7.46 (m, 2H), 7.14 (s, 1H), 7.15 – 7.05 (m, 1H), 6.64 – 6.57 (m, 1H), 6.45 – 6.40 (m, 1H), 5.25 – 5.20 (m, 1H), 3.69 (s, 3H), 3.45 (s, 3H), 3.24 (s, 3H), 1.68 (d, J = 6.6 Hz, 3H).
658	(ES+) 568.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.30 (s, 2H), 8.16 (d, J = 6.7 Hz, 1H), 7.87 – 7.84 (m, 1H), 7.63 – 7.60 (m, 1H), 7.25 – 7.16 (m, 2H), 7.10 – 7.06 (m, 1H), 7.03 – 6.97 (m, 2H), 6.34 – 6.31 (m, 1H), 5.85 (d, J = 6.2 Hz, 1H), 5.31 – 5.25 (m, 1H), 3.49 (s, 3H), 3.46 (s, 3H), 1.53 (d, J = 6.6 Hz, 3H).
659	(ES+) 568.1 [M+H]	

660	(ES+) 558.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 7.92 – 7.87 (m, 1H), 7.54 – 7.51 (m, 1H), 7.38 (s, 1H), 7.08 (d, J = 8.5 Hz, 1H), 6.89 – 6.82 (m, 2H), 6.53 (s, 1H), 5.52 – 5.43 (m, 1H), 4.83 – 4.69 (m, 2H), 3.78 (s, 3H), 3.72 (s, 3H), 3.30 – 2.86 (m, 8H), 2.38 (s, 3H), 2.22 (s, 3H).
661	(ES+) 575.5 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.83 (s, 2H), 7.91 (s, 1H), 7.64 (d, J = 7.9 Hz, 1H), 7.49 (s, 1H), 7.35 – 7.30 (m, 1H), 6.79 – 6.69 (m, 1H), 6.63 (d, J = 5.7 Hz, 1H), 6.47 (d, J = 8.5 Hz, 1H), 6.42 (s, 1H), 5.19 (d, J = 8.0 Hz, 1H), 4.52 (s, 1H), 3.52 (s, 6H), 3.25 (s, 3H), 3.20 – 2.78 (m, 4H), 2.69 (s, 3H), 2.34 (s, 3H), 1.56 (d, J = 6.4 Hz, 3H).
662	(ES+) 575.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 7.99 – 7.97 (m, 1H), 7.54 – 7.52 (m, 1H), 7.36 – 7.34 (m, 1H), 7.05 – 6.92 (m, 1H), 6.53 (d, J = 4.4 Hz, 1H), 6.48 (s, 1H), 6.18 – 6.16 (m, 1H), 5.43 – 5.15 (m, 1H), 4.97 – 4.80 (m, 1H), 4.38 – 4.21 (m, 2H), 4.18 – 4.15 (m, 1H), 4.10 – 4.05 (m, 1H), 3.93 – 3.91 (m, 2H), 3.73 (s, 3H), 3.58 – 3.49 (m, 2H), 3.17 (s, 3H), 2.07 – 1.93 (m, 2H), 1.71 - 1.68 (m, 1H), 1.63 (d, J = 6.8 Hz, 3H).
663	(ES+) 523.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.04 - 8.03 (m, 1H), 7.81 (s, 1H), 7.51 – 7.50 (m, 1H), 7.03 – 7.01 (m, 1H), 6.79 – 6.78 (m, 1H), 6.66 – 6.52 (m, 2H), 6.19 – 6.10 (m, 1H), 4.98 – 4.83 (m, 1H), 4.61 (br s, 1H), 3.49 – 3.44 (m, 6H), 2.35 – 2.32 (m, 3H), 1.62 – 1.60 (m, 3H).
664	(ES+) 538.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.17 (s, 1H), 7.67 (d, J = 1.2 Hz, 1H), 6.88 (d, J = 8.8 Hz, 1H), 6.86 – 6.69 (m, 1H), 6.58 (d, J = 8.0 Hz, 1H), 5.32 – 5.26 (m, 1H), 5.03 – 4.96 (m, 1H), 3.86 – 3.80 (m, 2H), 3.64 (s, 3H), 3.54 – 3.41 (m, 2H), 3.27 – 3.11 (m, 2H), 3.04 – 3.02 (m, 2H), 2.89 (s, 3H), 2.40 – 2.36 (m, 6H), 1.61 (d, J = 5.4 Hz, 3H).
665	(ES+) 520.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.12 (s, 1H), 7.50 (s, 1H), 6.88 (d, J = 8.4 Hz, 1H), 6.84 – 6.58 (m, 1H), 6.55 (d, J = 8.6 Hz, 1H), 6.28 (s, 1H), 4.96 – 4.9 (m, 1H), 4.90 – 4.82 (m, 1H), 3.98 – 3.76 (m, 2H), 3.63 (s, 3H), 3.31 – 3.17 (m, 2H), 3.13 – 2.92 (m, 4H), 2.89 (s, 3H), 2.40 (s, 3H), 2.38 (s, 3H), 1.63 (d, J = 6.8 Hz, 3H).
666	(ES+) 596.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.81 (dd, J = 9.1, 2.8 Hz, 1H), 7.53 – 7.44 (m, 2H), 7.34 – 7.29 (m, 1H), 6.85 (d, J = 6.0 Hz, 1H), 6.57 – 6.45 (m, 2H), 5.60 (d, J = 19.6 Hz, 1H), 5.47 – 5.28 (m, 1H), 4.93 – 4.68 (m, 2H), 4.31 – 4.21 (m, 2H), 4.05 – 3.95 (m, 2H), 3.76 – 3.70 (m, 5H), 3.32 (s, 3H), 3.15 – 3.08 (m, 6H).
667	(ES+) 529.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.72 – 7.68 (m, 1H), 7.52 – 7.32 (m, 3H), 7.25 – 7.16 (m, 2H), 7.06 –6.99 (m, 1H), 6.48 (s, 1H), 6.32 –6.27 (m, 1H), 5.82 (d, J = 6.1 Hz, 1H), 5.22 –5.13 (m, 1H), 3.75 (s, 3H), 3.54 (br s, 5H), 3.16 – 3.10 (m, 6H), 1.53 (d, J = 6.6 Hz, 3H).
668	(ES+) 538.2 [M+H]	^{1}H NMR (400 MHz, CD_3CN): δ 7.85 – 7.80 (m, 1H), 7.49 – 7.44 (m, 1H), 7.16 – 7.05 (m, 1H), 6.93 – 6.77 (m, 2H), 6.61 (s, 1H), 6.32 – 6.27 (m, 1H), 5.16 – 5.09 (m, 1H), 4.82 (d, J = 5.1 Hz, 1H), 3.65 (s, 3H), 2.88 (d, J = 3.2 Hz, 6H), 2.57 – 2.52 (m, 6H), 1.58 (d, J = 6.7 Hz, 3H).

669	(ES+) 584.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.84 – 8.80 (m, 1H), 8.69 (d, 1H), 8.30 (d, 1H), 7.86 – 7.82 (m, 1H), 7.79 – 7.74 (m, 1H), 7.59 – 7.54 (m, 1H), 7.47 – 7.42 (m, 1H), 7.32 – 7.24 (m, 1H), 7.10 (s, 1H), 6.50 (d, 1H), 6.43 – 6.37 (m, 1H), 5.35 – 5.27 (m, 1H), 3.63 (s, 3H), 3.35 (s, 3H), 2.38 (s, 3H), 1.60 – 1.56 (m, 3H).
670	(ES+) 580.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.07 (s, 1H), 7.91 (d, J = 7.4 Hz, 1H), 7.89 – 7.82 (m, 1H), 7.62 – 7.54 (m, 1H), 7.49 – 7.41 (m, 1H), 7.31 – 7.22 (m, 1H), 6.98 (s, 1H), 6.68 – 6.58 (m, 2H), 6.48 (d, J = 5.3 Hz, 1H), 6.45 – 6.37 (m, 1H), 5.30 – 5.23 (m, 1H), 3.47 (d, J = 14.4 Hz, 6H), 3.35 (s, 3H), 2.51 (s, 3H), 1.55 (d, J = 6.5 Hz, 3H).
671	(ES+) 560.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.82 – 7.75 (m, 1H), 7.59 – 7.51 (m, 1H), 7.50 – 7.42 (m, 1H), 7.36 – 7.27 (m, 1H), 6.59 (s, 1H), 6.50 – 6.41 (m, 2H), 5.47 – 5.41 (m, 1H), 5.29 – 5.21 (m, 1H), 4.73 – 4.56 (m, 1H), 4.53 – 4.30 (m, 1H), 4.30 – 4.17 (m, 1H), 4.03 – 3.86 (m, 1H), 3.62 (s, 3H), 3.31 (s, 3H), 2.52 – 2.45 (m, 6H), 1.58 (d, J = 6.6 Hz, 3H).
672	(ES+) 509.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.92 (s, 1H), 7.54 (d, J = 1.9 Hz, 1H), 7.50 – 7.20 (m, 1H), 7.19 – 7.14 (m, 1H), 7.07 – 6.99 (m, 1H), 6.68 (s, 1H), 6.36 – 6.33 (m, 1H), 5.72 (d, J = 6.0 Hz, 1H), 5.18 – 5.05 (m, 1H), 3.64 (s, 3H), 2.69 (s, 6H), 2.50 (s, 3H), 2.35 (s, 3H), 1.53 (d, J = 6.6 Hz, 3H).
673	(ES+) 527.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.87 (d, J = 1.6 Hz, 1H), 7.50 – 7.20 (m, 2H), 7.17-7.12 (m, 1H), 7.05-6.96 (m, 1H), 6.44 (s, 1H), 6.35-6.26 (m, 1H), 5.72 (d, J = 6.0 Hz, 1H), 5.13-5.03 (m, 1H), 4.33-4.26 (m, 2H), 3.54 (s, 3H), 3.31-2.56 (m, 6H), 2.32 (s, 3H), 1.50 (d, J = 6.6 Hz, 3H), 1.27 (s, 3H), 0.86-0.81 (m, 2H), 0.60 – 0.53 (m, 2H).
674	(ES+) 574.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.46 – 8.40 (m, 1H), 7.90 (d, J = 1.8 Hz, 1H), 7.80 – 7.73 (m, 1H), 7.66 – 7.59 (m, 1H), 7.48 (d, J = 1.9 Hz, 1H), 7.42 – 7.36 (m, 1H), 7.36 – 7.28 (m, 1H), 6.77 – 6.68 (m, 1H), 6.59 (d, J = 5.8 Hz, 1H), 6.50 (d, J = 8.4 Hz, 1H), 6.40 (s, 1H), 5.28 – 5.15 (m, 1H), 3.53 (br s, 5H), 3.26-3.20 (m, 5H), 2.93-2.86 (m, 4H), 2.33 (s, 3H), 2.29 (s, 3H), 1.54 (d, J = 6.5 Hz, 3H).
675	(ES+) 574.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.56 (d, J = 5.0 Hz, 1H), 7.90 (s, 1H), 7.66 – 7.62 (m, 1H), 7.49 (d, J = 1.9 Hz, 1H), 7.31 (d, J = 9.7 Hz, 2H), 7.26 – 7.21 (m, 1H), 6.75 – 6.71 (m, 1H), 6.61 (d, J = 5.7 Hz, 1H), 6.47 (d, J = 8.4 Hz, 1H), 6.41 (s, 1H), 5.24 – 5.14 (m, 1H), 3.6-3.51 (m, 7H), 3.24 (s, 3H), 3.10-3.03 (m, 4H), 2.53 (s, 3H), 2.34 (s, 3H), 1.55 (d, J = 6.5 Hz, 3H).
676	(ES+) 577.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.90 (d, J = 1.8 Hz, 1H), 7.64-7.62 (m, 1H), 7.54 (s, 1H), 7.48 (d, J = 1.9 Hz, 1H), 7.34-7.30 (m, 1H), 6.75-6.71 (m, 1H), 6.61 (d, J = 5.8 Hz, 1H), 6.48 (d, J = 8.4 Hz, 1H), 6.42 (s, 1H), 5.24-5.18 (m, 1H), 4.08-4.04 (m, 2H), 3.75 (s, 3H), 3.60-3.51 (m, 4H), 3.3-3.2 (m, 8H), 2.33 (s, 6H), 1.55 (d, J = 6.5 Hz, 3H).

677	(ES+) 578.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.11 – 8.05 (m, 1H), 7.64 – 7.58 (m, 1H), 7.50 – 7.42 (m, 1H), 7.09 – 6.99 (m, 1H), 6.89 (s, 1H), 6.45 (s, 1H), 6.31 – 6.23 (m, 1H), 5.45 – 5.31 (m, 1H), 5.22 – 5.17 (m, 1H), 4.88 – 4.18 (m, 6H), 3.75 (s, 3H), 3.20 (s, 3H), 2.62-2.56 (br s, 6H).
678	(ES+) 542.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.05 – 7.92 (m, 1H), 7.71 – 7.58 (m, 1H), 6.97 – 6.60 (m, 2H), 6.55 (d, J = 8.4 Hz, 1H), 5.28 (d, J = 4.8 Hz, 1H), 5.02 (s, 1H), 3.84 (d, J = 11.6 Hz, 2H), 3.66 (s, 3H), 3.61 – 3.49 (m, 2H), 3.28 – 3.11 (m, 2H), 3.11 – 2.97 (m, 2H), 2.91 (s, 3H), 2.42 (s, 3H), 1.61 (d, J = 6.4 Hz, 3H).
679	(ES+) 524.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.05 – 7.92 (m, 1H), 7.49 – 7.35 (m, 1H), 7.21 – 6.79 (m, 2H), 6.58 (d, J = 8.4 Hz, 1H), 6.22 (s, 1H), 5.05 (s, 1H), 4.97 – 4.77 (m, 1H), 3.93 - 3.79 (m, 2H), 3.64 (s, 3H), 3.39 – 2.93 (m, 6H), 2.91 (s, 3H), 2.49 (s, 3H), 1.66 (d, J = 6.8 Hz, 3H).
680	(ES+) 617.4 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 7.92 (d, J = 9.0, 2.7 Hz, 1H), 7.58 – 7.52 (m, 2H), 7.22 – 7.13 (m, 2H), 6.95 (d, J = 5.9 Hz, 1H), 6.62 – 6.53 (m, 2H), 5.50 (d, J = 18.6 Hz, 1H), 5.02 – 4.91 (m, 1H), 4.82 – 4.65 (m, 1H), 4.63-4.58 (m, 1H), 3.72 (s, 3H), 3.62 (s, 3H), 3.37 (s, 3H), 3.31-3.21 (m, 8H), 2.37 (s, 3H).
681	(ES+) 565.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 9.26 (s, 2H), 8.82 (s, 1H), 8.18 (m, 1H), 8.15 (m, 1H), 7.67 (d, J = 1.8 Hz, 1H), 7.59 – 7.48 (m, 1H), 7.16 (s, 1H), 7.16 – 7.07 (m, 1H), 6.96 (d, J = 6.0 Hz, 1H), 6.56 – 6.49 (m, 1H), 5.50 (s, 1H), 4.91 – 4.95 (m, 1H), 4.69 – 4.58 (m, 1H), 3.71 (s, 3H), 3.24 (s, 3H), 2.78 (s, 3H), 2.46 (s, 3H).
682	(ES+) 576.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 7.92 – 7.85 (m, 1H), 7.57 – 7.49 (m, 1H), 7.08 (d, J = 8.5 Hz, 1H), 6.85 (d, J = 8.2 Hz, 2H), 6.53 (s, 1H), 5.53 – 5.41 (m, 1H), 4.99 – 4.62 (m, 2H), 3.69 (s, 3H), 3.64 (s, 3H), 3.28 – 2.86 (m, 8H), 2.38 (s, 3H), 2.18 (s, 3H).
683	(ES+) 551.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.67 (s, 2H), 7.81 – 7.79 (m, 1H), 7.57 – 7.54 (m, 1H), 7.47 – 7.45 (m, 1H), 7.32 – 7.29 (m, 1H), 6.68 (s, 1H), 6.47 – 6.46 (m, 2H), 5.29 – 5.26 (m, 1H), 3.69 (s, 3H), 3.33 (s, 3H), 2.67 – 2.62 (m, 9H), 1.60 – 1.59 (m, 3H).
684	(ES+) 535.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.07 – 7.97 (m, 1H), 7.58 – 7.42 (m, 1H), 7.13 – 7.03 (m, 1H), 6.95 – 6.56 (m, 2H), 6.25 – 6.11 (m, 2H), 5.21 – 4.98 (m, 1H), 4.87 – 4.40 (m, 4H), 3.68 (s, 3H), 3.59 – 2.49 (m, 6H), 1.89 – 1.69 (m, 2H), 1.13 – 0.98 (m, 2H), 0.93 – 0.73 (m, 2H).
685	(ES-) 542.2 [M-H]	^{1}H NMR (400 MHz, CD_3OD): δ 7.83 – 7.80 (m, 1H), 7.47 – 7.42 (m, 1H), 7.33 (d, J = 14.6 Hz, 2H), 7.11 (d, J = 8.6 Hz, 1H), 6.81 (d, J = 8.6 Hz, 1H), 6.53 (s, 1H), 5.23 – 5.02 (m, 1H), 3.85 (s, 3H), 3.69 (s, 3H), 3.60 – 2.80 (m, 8H), 2.38 (s, 3H), 1.68 (d, J = 6.6 Hz, 3H).

686	(ES+) 589.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.58 (s, 1H), 7.90 (s, 1H), 7.69 – 7.60 (m, 1H), 7.49 (d, J = 2.0 Hz, 1H), 7.39 – 7.27 (m, 1H), 6.8 (m, 1H), 6.61 (d, J = 5.8 Hz, 1H), 6.48 (d, J = 8.5 Hz, 1H), 6.40 (s, 1H), 5.22-5.18 (m, 1H), 3.54 (s, 3H), 3.24 (s, 3H), 3.18 – 2.70 (m, 4H), 2.62 (s, 3H), 2.7-2.55 (m, 4H), 2.43 (s, 3H), 2.34 (s, 3H), 1.56 (d, J = 6.5 Hz, 3H).
687	(ES+) 588.4 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.47 (s, 1H), 8.03 (s, 1H), 7.73 – 7.71 (m, 1H), 7.59 (d, J = 1.2 Hz, 1H), 7.51 (s, 1H), 7.32 - 7.28 (m, 1H), 6.78 – 6.73 (m, 1H), 6.55 (d, J = 8.0 Hz, 2H), 5.20 – 5.15 (m, 1H), 4.78 (s, 1H), 3.69 (s, 3H), 3.60 – 3.49 (m, 2H), 3.45 – 3.36 (m, 1H), 3.31 – 3.22 (m, 1H), 3.18-3.14 (m, 4H), 3.08 – 2.79 (m, 2H), 2.64 (s, 3H), 2.46 (s, 3H), 2.42 (s, 3H), 1.68 (d, J = 6.4 Hz, 3H).
688	(ES+) 588.4 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.46 (s, 1H), 8.03 (s, 1H), 7.86 (s, 1H), 7.74 - 7.71 (m, 1H), 7.59 (d, J = 1.6 Hz, 1H), 7.31 – 7.26 (m, 1H), 6.77 – 6.73 (m, 1H), 6.55 – 6.52 (m, 2H), 5.20 – 5.15 (m, 1H), 4.71 (s, 1H), 4.00 – 3.56 (m, 5H), 3.48 – 3.37 (m, 1H), 3.31 – 3.23 (m, 1H), 3.19-3.15 (m, 4H), 3.08 – 2.81 (m, 2H), 2.62 (s, 3H), 2.44 (s, 3H), 2.41 (s, 3H), 1.67 (d, J = 6.4 Hz, 3H).
689	(ES-) 572.1 [M-H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.48 – 8.43 (m, 1H), 7.90 (d, J = 1.8 Hz, 1H), 7.82 – 7.74 (m, 1H), 7.64 – 7.62 (m, 1H), 7.56 – 7.54 (m, 1H), 7.48 (d, J = 1.9 Hz, 1H), 7.35 – 7.30 (m, 1H), 6.75 – 6.71 (m, 1H), 6.61 – 6.59 (m, 1H), 6.49 (d, J = 8.5 Hz, 1H), 6.43 (s, 1H), 5.26 – 5.21 (m, 1H), 4.71 – 3.97 (m, 2H), 3.55 (s, 3H), 3.21 (s, 3H), 3.24 (s, 3H), 3.06 – 2.89 (m, 3H), 2.35 – 2.31 (m, 6H), 1.55 – 1.52 (m, 3H).
690	(ES+) 586.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.05 (s, 2H), 8.41 - 8.40 (m, 1H), 8.11 - 8.05 (m, 1H), 7.78 - 7.73 (m, 1H), 7.57 - 7.52 (m, 1H), 7.23 - 6.86 (m, 2H), 6.75 (s, 1H), 5.84 (br d, J = 8.4 Hz, 1H), 5.04 (br d, J = 3.2 Hz, 1H), 4.97 - 4.89 (m, 1H), 3.56 (s, 3H), 2.82 (s, 3H), 1.65 (br d, J = 6.8 Hz, 3H).
691	(ES+) 603.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.05 - 8.03 (m, 1H), 7.70 (d, J = 2.8 Hz, 1H), 7.58 - 7.57 (m, 1H), 7.43 - 7.42 (m, 1H), 7.04 - 6.96 (m, 1H), 6.87 (d, J = 4.4 Hz, 1H), 6.27 - 6.22 (m, 1H), 6.20 (s, 1H), 6.03 (d, J = 2.8 Hz, 1H), 5.13 - 5.12 (m, 1H), 4.80 - 4.51 (m, 2H), 3.90 - 3.70 (m, 5H), 3.68 (s, 3H), 3.43 - 3.21 (m, 4H), 3.19 (s, 3H), 3.11 - 2.83 (m, 2H).
692	(ES+) 575.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.03 - 8.02 (m, 1H), 7.69 (d, J = 2.8 Hz, 1H), 7.63 - 7.61 (m, 1H), 7.05 - 7.00 (m, 1H), 6.88 - 6.82 (m, 1H), 6.82 - 6.50 (m, 1H), 6.25 - 6.16 (m, 1H), 6.03 (d, J = 3.2 Hz, 1H), 5.23 - 5.20 (m, 1H), 4.69 - 4.60 (m, 1H), 3.81 - 3.75 (m, 2H), 3.73 (s, 3H), 3.68 (s, 3H), 3.60 - 3.51 (m, 2H), 3.27 - 3.17 (m, 4H), 1.59 (br s, 3H).
693	(ES+) 557.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 7.97- 7.94 (m, 1H), 7.70 (d, J = 2.8 Hz, 1H), 7.45 - 7.42 (m, 1H), 7.04 - 7.03 (m, 1H), 6.89 - 6.83 (m, 1H), 6.80 - 6.48 (m, 1H), 6.24 (s, 1H), 6.16 - 6.14 (m, 1H), 6.02 (d, J = 2.8 Hz, 1H), 4.95 - 4.83 (m, 1H), 4.60 (br d, J = 1.2 Hz, 1H), 3.89 - 3.70 (m, 5H), 3.69 (s, 3H), 3.40 - 2.82 (m, 6H), 1.63 (d, J = 6.4 Hz, 3H).

694	(ES+) 575.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.05 - 8.03 (m, 1H), 7.71 (d, J = 2.8 Hz, 1H), 7.52 - 7.50 (m, 1H), 7.10 - 7.08 (m, 1H), 6.91 - 6.49 (m, 2H), 6.26 (s, 1H), 6.22 - 6.20 (m, 1H), 6.05 (d, J = 2.8 Hz, 1H), 5.13 (br s, 1H), 4.98 (br s, 1H), 4.82 - 4.75 (m, 2H), 3.76-3.73 (m, 5H), 3.69 (s, 3H), 3.27 (br s, 4H), 3.00 (br s, 2H).
695	(ES+) 575.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.01 (s, 1H), 7.63 (s, 1H), 7.48-7.40 (m, 1H), 7.31 – 7.21 (m, 1H), 6.51 (s, 1H), 6.42 (s, 1H), 5.30-5.18 (m, 1H), 4.08 – 3.99 (m, 1H), 3.87 (s, 2H), 3.53 (s, 3H), 3.33 (s, 3H), 3.18-3.13 (m, 6H), 2.35 (s, 3H), 1.58-1.54 (m, 3H), 0.68-0.61 (m, 4H).
696	(ES+) 557.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.90 (d, 1H), 7.47 (d, 1H), 7.45-7.40 (m, 1H), 7.31-7.24 (m, 1H), 6.49-6.43 (m, 2H), 6.39 (s, 1H), 5.23-5.13 (m, 1H), 4.08 – 3.77 (m, 3H), 3.52 (s, 3H), 3.31 (s, 3H), 2.86-2.82 (m, 6H), 2.36 – 2.29 (m, 3H), 1.53 (d, 3H), 0.72 – 0.58 (m, 4H).
697	(ES+) 589.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.76-7.72 (m, 1H), 7.50-7.44 (m, 2H), 7.32-7.27 (m, 1H), 6.68 – 6.24 (m, 3H), 5.39 – 5.15 (m, 1H), 3.77 – 3.47 (m, 6H), 3.35 (s, 3H), 3.1-3.06 (m, 8H), 2.09 (s, 3H), 1.56 (d, J = 6.5 Hz, 3H).
698	(ES+) 553.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.63 (s, 1H), 8.36 (s, 1H), 7.83-7.77 (m, 1H), 7.59-7.53 (m, 1H), 7.53 – 7.15 (m, 3H), 7.13 (s, 1H), 7.05-6.97 (m, 1H), 6.31-6.25 (m, 1H), 5.87-5.83 (m, 1H), 5.29-5.21 (m, 1H), 3.61 (s, 3H), 3.28 (s, 3H), 2.41 (s, 3H), 1.53 (d, 3H).
699	(ES+) 540.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.70 (s, 1H), 8.65 (d, J = 2.7 Hz, 1H), 8.27 (s, 1H), 8.08-8.03 (m, 1H), 7.83-7.77 (m, 1H), 7.58 – 7.23 (m, 2H), 7.20-7.15 (m, 1H), 7.11 (s, 1H), 7.04 – 6.95 (m, 1H), 6.31-6.25 (m, 1H), 5.85 (d, J = 6.1 Hz, 1H), 5.29-5.21 (m, 1H), 3.63 (s, 3H), 2.56 (d, J = 1.3 Hz, 3H), 1.54 (d, J = 6.5 Hz, 3H).
700	(ES+) 568.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.70 (d, J = 0.7 Hz, 1H), 8.65 (d, J = 2.7 Hz, 1H), 8.28 (d, J = 0.7 Hz, 1H), 8.07-8.04 (m, 1H), 7.86-7.83 (m, 1H), 7.58-7.55 (m, 1H), 7.47-7.44 (m, 1H), 7.31-7.25 (m, 1H), 7.10 (s, 1H), 6.50 (d, J = 5.3 Hz, 1H), 6.43-6.40 (m, 1H), 5.34-5.30 (m, 1H), 3.64 (s, 3H), 3.36 (s, 3H), 2.55 (d, J = 1.2 Hz, 3H), 1.59 (d, J = 6.5 Hz, 3H).
701	(ES+) 551.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.85-7.82 (m, 1H), 7.67-7.64 (m, 1H), 7.52-7.24 (m, 1H), 7.21-7.18 (m, 1H), 7.04-6.99 (m, 1H), 6.27-6.24 (m, 1H), 5.91 – 5.85 (m, 1H), 5.24-5.21 (m, 1H), 4.06-3.94 (m, 1H), 3.96-3.92 (m, 2H), 3.55 (s, 3H), 3.25 – 3.02 (m, 6H), 1.54 (d, J = 6.5 Hz, 3H), 0.69 – 0.60 (m, 4H).
702	(ES+) 533.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.71-7.68 (m, 1H), 7.54 – 7.23 (m, 2H), 7.19-7.6 (m, 1H), 7.04-6.99 (m, 1H), 6.48 (s, 1H), 6.29-6.25 (m, 1H), 5.81 (d, J = 6.1 Hz, 1H), 5.20-5.13 (m, 1H), 4.06-3.90 (m, 3H), 3.53 (s, 3H), 3.13-3.09 (m, 6H), 1.51 (d, J = 6.5 Hz, 3H), 0.72 – 0.59 (m, 4H).

703	(ES+) 545.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.98 (s, 1H), 7.66 (d, J = 1.9 Hz, 1H), 7.53-7.21 (m, 1H), 7.20-7.13 (m, 1H), 7.04-6.95 (m, 1H), 6.30-6.20 (m, 1H), 5.79 (d, J = 6.2 Hz, 1H), 5.25-5.15 (m, 1H), 4.27 (d, J = 10.1 Hz, 2H), 3.56 (s, 3H), 3.30 – 3.06 (m, 6H), 2.33 (s, 3H), 1.51 (d, J = 6.4 Hz, 3H), 1.27 (s, 3H), 0.86-0.81 (m, 2H), 0.60-0.53 (m, 2H).
704	(ES+) 538.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.87 (s, 1H), 7.46 (s, 1H), 7.17 (s, 1H), 7.06 – 6.97 (m, 1H), 6.68 (d, J = 8.7 Hz, 1H), 6.42 (s, 1H), 5.73 (d, J = 6.2 Hz, 1H), 5.15 – 5.07 (m, 1H), 4.62 (s, 1H), 4.21 (s, 1H), 3.58 (s, 3H), 3.21 – 2.67 (m, 5H), 2.31 (s, 3H), 2.26 (s, 3H), 1.52 (d, J = 6.6 Hz, 3H), 1.34 (s, 3H), 1.27 (s, 3H), 0.84 (d, J = 11.8 Hz, 2H), 0.61-0.55 (m, 2H).
705	(ES+) 524.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.87 (s, 1H), 7.46 (d, J = 1.9 Hz, 1H), 7.33 – 7.02 (m, 1H), 7.00 (d, J = 8.5 Hz, 1H), 6.69 (d, J = 8.6 Hz, 1H), 6.43 (s, 1H), 5.73 (d, J = 6.3 Hz, 1H), 5.16 – 5.08 (m, 1H), 4.3-4.26 (m, 2H), 3.54 (s, 3H), 3.18-3.14 (m, 6H), 2.31 (s, 3H), 2.26 (s, 3H), 1.52 (d, J = 6.6 Hz, 3H), 1.28 (s, 3H), 0.84 (q, J = 4.1 Hz, 2H), 0.58 (q, J = 4.2 Hz, 2H).
706	(ES+) 620.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.09 – 8.04 (m, 1H), 7.62 – 7.58 (m, 1H), 7.47 – 7.43 (m, 1H), 7.15 – 7.10 (m, 1H), 7.05 – 7.00 (m, 1H), 6.90 (s, 1H), 6.30 - 6.25 (m, 1H), 5.80 – 5.75 (m, 1H), 5.15 (d, J = 8.8 Hz, 1H), 4.87 – 4.72 (m, 1H), 4.69 – 4.52 (m, 1H), 3.69 (s, 3H), 3.68 (s, 3H), 3.50 – 2.90 (m, 11H).
707	(ES+) 521.1 [M+H]	
708	(ES+) 589.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.17–7.85 (m, 2H), 7.44–7.34 (m, 1H), 7.19–7.05 (m, 1H), 6.99 - 6.90 (m, 1H), 6.22 (s, 1H), 5.68 (s, 1H), 5.81–5.65 (m, 1H), 5.22 (s, 1H), 4.92–4.80 (m, 1H), 4.74–4.50 (m, 1H), 3.70 (s, 6H) , 3.55 –2.89 (m, 8H), 2.76 (s, 3H).
709	(ES+) 562.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.08 – 8.00 (m, 1H), 7.55 – 7.48 (m, 1H), 7.01 – 6.91 (m, 3H), 6.56 (d, J = 8.0 Hz, 1H), 6.24 (s, 1H), 5.38 (s, 1H), 5.18 – 5.00 (s, 1H), 4.92 – 4.21 (m, 2H), 3.77 (s, 3H), 3.65 (s, 3H), 3.45 – 2.84 (m, 8H), 2.43 (s, 3H).
710	(ES+) 553.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.12 – 8.02 (m, 1H), 7.77 – 7.57 (m, 1H), 7.15 – 7.05 (m, 1H), 6.93 – 6.49 (m, 2H), 6.26 – 6.15 (m, 1H), 5.55 – 5.40 (m, 1H), 4.92 – 4.75 (m, 1H), 4.67 – 4.58 (m, 1H), 4.55 - 4.35 (m, 2H), 3.70 - 3.05 (m, 3H), 3.50 – 3.00 (m, 6H), 1.81 - 1.73 (m, 1H), 1.14 – 0.97 (m, 2H), 0.95 – 0.70 (m, 2H).
711	(ES+) 528.0 [M+H]	^{1}H NMR(400 MHz, DMSO-d_6): δ 9.60 (s, 2H), 9.28 (s, 2H), 8.02 (s, 1H), 7.60 (s, 1H), 7.32 - 7.05 (m, 2H), 7.07 – 6.97 (m, 2H), 5.80 (d, J = 6.4 Hz, 1H), 5.25 – 5.21 (m, 1H), 3.46 (s, 3H), 2.76 (s, 3H), 2.39 (s, 3H), 2.27 (s, 3H), 1.53 (d, J = 6.4 Hz, 3H).

712	(ES+) 586.0 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6) δ 9.30 (s, 2H), 7.88 (d, J = 8.9 Hz, 1H), 7.59 – 7.50 (m, 2H), 7.35 (d, J = 9.1 Hz, 1H), 7.27 – 7.13 (m, 2H), 6.75 – 6.70 (m, 1H), 6.46 – 6.41 (m, 1H), 5.57 (d, J = 6.3 Hz, 1H), 5.38 – 5.30 (m, 1H), 3.65 (s, 3H), 3.49 (s, 3H), 1.58 (d, J = 6.5 Hz, 3H).
713	(ES+) 579.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.29 (s, 2H), 8.03 (s, 1H), 7.63 – 7.53 (m, 2H), 7.19 – 7.10 (m, 2H), 6.86 – 6.84 (m, 1H), 6.76 – 6.72 (m, 1H), 5.60 (d, J = 6.4 Hz, 1H), 5.30 – 5.29 (m, 1H), 3.65 (s, 3H), 3.32 (s, 3H), 2.39 (s, 3H), 2.29 (s, 3H), 1.57 – 1.55 (m, 3H).
714	(ES+) 546.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.60 (s, 2H), 9.28 (s, 2H), 8.02 (d, J = 1.7 Hz, 1H), 7.60 (d, J = 1.9 Hz, 1H), 7.19 – 7.10 (m, 2H), 6.87 (d, J = 8.7 Hz, 1H), 5.60 – 5.58 (m, 1H), 5.30 – 5.27 (m, 1H), 3.47 (s, 3H), 2.76 (s, 3H), 2.39 (s, 3H), 2.29 (s, 3H), 1.56 – 1.55 (m, 3H).
715	(ES+) 551.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.91 (d, J = 1.7 Hz, 1H), 7.48 (d, J = 1.9 Hz, 1H), 7.44 – 7.31 (m, 1H), 7.29 – 7.26 (m, 1H), 6.53 – 6.43 (m, 2H), 6.42 (s, 1H), 5.20 – 5.18 (m, 1H), 3.53 (s, 3H), 3.40 – 3.38 (m, 11H), 2.98 (s, 3H), 2.34 (s, 3H), 1.55 (d, J = 6.6 Hz, 3H).
716	(ES+) 555.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.78 – 7.72 (m, 1H), 7.53 – 7.41 (m, 2H), 7.30 – 7.26 (m, 1H), 6.50 – 6.47 (m, 2H), 6.44 – 6.41 (m, 1H), 5.30 – 5.22 (m, 1H), 3.55 (s, 3H), 3.45 (s, 3H), 3.37-3.32 (m, 4H), 3.07-3.03 (m, 4H), 2.98 (s, 3H), 1.57 (d, J = 6.5 Hz, 3H).
717	(ES-) 496.1 [M-H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.88 (s, 1H), 7.56 (d, J = 1.9 Hz, 1H), 7.47 – 7.45 (m, 1H), 7.20 – 7.18 (m, 1H), 6.47 (s, 1H), 6.38 – 6.36 (m, 2H), 5.15 – 5.11 (m, 1H), 3.61 (s, 3H), 3.45-3.40 (m, 4H), 2.98 (s, 3H), 2.6-2.4 (m, 4H), 2.35 (s, 3H), 1.55 (d, J = 6.6 Hz, 3H).
718	(ES+) 627.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.07 - 8.06 (m, 1H), 7.57 - 7.44 (m, 2H), 7.33 (s, 1H), 7.27 - 6.85 (m, 1H), 7.19 (s, 1H), 6.96 - 6.95 (m, 1H), 6.54 (s, 1H), 6.00 - 5.90 (m, 1H), 5.44 (br d, J = 1.2 Hz, 2H), 5.19 - 5.06 (m, 1H), 4.86 - 4.49 (m, 2H), 3.79 (s, 3H), 3.68 - 3.66 (m, 2H), 3.26 - 3.24 (m, 2H), 2.20 (d, J = 3.6 Hz, 1H), 2.18 - 2.05 (m, 2H).
719	(ES+) 551.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.03 (s, 2H), 8.81 (d, J = 2.0 Hz, 1H), 8.08 - 8.07 (m, 1H), 8.03 (d, J = 2.0 Hz, 1H), 7.56 - 7.54 (m, 1H), 7.04 - 7.02 (m, 1H), 6.88 - 6.82 (m, 1H), 6.82 - 6.52 (m, 2H), 6.15 - 6.13 (m, 1H), 5.01 - 4.87 (m, 1H), 4.65 (br s, 1H), 3.92 (s, 3H), 3.56 (s, 3H), 1.64 (d, J = 6.8 Hz, 3H).
720	(ES+) 616.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.37 (br s, 1H), 7.96 - 7.94 (m, 1H), 7.87 - 7.85 (m, 1H), 7.44 - 7.42 (m, 1H), 7.03 - 7.01 (m, 1H), 6.85 - 6.83 (m, 1H), 6.66 - 6.50 (m, 1H), 6.26 (s, 1H), 6.18 - 6.17 (m, 1H), 4.99 - 4.85 (m, 1H), 4.69 - 4.49 (m, 1H), 3.88 - 3.61 (m, 5H), 3.39 - 2.98 (m, 6H), 2.68 (s, 3H), 1.86 (d, J = 13.2 Hz, 6H), 1.63 (d, J = 6.4 Hz, 3H).

721	(ES+) 546.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.11 (s, 1H), 7.47 (s, 1H), 7.02 - 7.00 (m, 1H), 6.89 - 6.80 (m, 1H), 6.65 (t, J = 55.2 Hz, 1H), 6.24 - 6.22 (m, 1H), 6.21 (s, 1H), 5.31 - 5.20 (m, 1H), 4.91 - 4.81 (m, 1H), 4.55 (br s, 1H), 4.29 - 4.26 (m, 2H), 4.18 - 4.15 (m, 1H), 4.12 - 4.10 (m, 1H), 4.05 - 3.75 (m, 2H), 3.64 (s, 3H), 3.30 - 2.97 (m, 4H), 2.90 - 2.60 (m, 2H), 2.39 (s, 3H), 1.60 (d, J = 6.8 Hz, 3H).
722	(ES+) 543.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.11 (s, 1H), 7.48 (s, 1H), 6.92 - 6.48 (m, 3H), 6.23 (s, 1H), 5.44 - 5.17 (m, 1H), 5.00 - 4.79 (m, 2H), 4.34 – 4.24 (m, 2H), 4.21 - 4.08 (m, 2H), 4.02 - 3.78 (m, 2H), 3.64 (d, J = 0.8 Hz, 3H), 3.29 - 2.98 (m, 4H), 2.93 - 2.62 (m, 2H), 2.38 (d, J = 6.4 Hz, 6H), 1.61 (br s, 3H).
723	(ES+) 544.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 7.98 -7.96 (m, 1H), 7.41 - 7.39 (m, 1H), 7.04 (d, J = 8.8 Hz, 1H), 6.69 (t, J = 54.2 Hz, 1H), 6.52 (d, J = 8.8 Hz, 1H), 6.21 (s, 1H), 5.11 (br d, J = 2.8 Hz, 1H), 4.87 -4.85 (m, 1H), 4.01 - 3.77 (m, 2H), 3.65 (s, 3H), 3.37 - 3.18 (m, 2H), 3.15 - 2.93 (m, 4H), 2.90 (s, 3H), 1.67 (d, J = 6.4 Hz, 3H).
724	(ES+) 582.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.12 (s, 1H), 7.48 (s, 1H), 7.02 - 7.00 (m, 1H), 6.89 - 6.80 (m, 1H), 6.65 (t, J = 55.2 Hz, 1H), 6.27 - 6.21 (m, 2H), 5.44 - 5.15 (m, 1H), 4.91 - 4.80 (m, 1H), 4.79 - 4.50 (m, 1H), 4.24 - 4.06 (m, 4H), 3.90 - 3.68 (m, 2H), 3.63 (s, 3H), 3.29 - 2.99 (m, 4H), 2.97 - 2.75 (m, 2H), 2.40 (s, 3H), 1.61 (d, J = 6.8 Hz, 3H).
725	(ES+) 557.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.13 (s, 1H), 7.45 (d, J = 1.2 Hz, 1H), 7.14 - 7.12 (m, 1H), 7.05 - 6.91 (m, 1H), 6.24 - 6.14 (m, 2H), 5.40 - 5.14 (m, 1H), 4.95 - 4.84 (m, 1H), 4.81 (d, J = 4.8 Hz, 1H), 4.25 - 4.05 (m, 4H), 3.90 - 3.69 (m, 2H), 3.63 (s, 3H), 3.31 - 3.03 (m, 4H), 3.01 - 2.78 (m, 2H), 2.41 (s, 3H), 1.65 (d, J = 6.8 Hz, 3H).
726	(ES+) 607.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.11 (s, 1H), 7.80 (d, J = 9.6 Hz, 2H), 7.47 (s, 1H), 7.20 - 7.19 (m, 1H), 6.95 - 6.83 (m, 1H), 6.28 - 6.20 (m, 2H), 4.92 - 4.80 (m, 1H), 4.58 (br s, 1H), 4.02 (s, 3H), 3.89 - 3.72 (m, 2H), 3.55 (s, 3H), 3.30 - 3.12 (m, 2H), 3.09 - 2.95 (m, 2H), 2.76 - 2.50 (m, 2H), 2.39 (s, 3H), 1.61 (d, J = 6.8 Hz, 3H).
727	(ES+) 545.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.13 (s, 1H), 7.47 (d, J = 1.6 Hz, 1H), 7.23 - 7.16 (m, 1H), 6.93 - 6.86 (m, 1H), 6.29 - 6.21 (m, 2H), 4.92 - 4.83 (m, 1H), 4.58 (br d, J = 2.8 Hz, 1H), 4.16 - 3.85 (m, 2H), 3.67 (s, 3H), 3.51 - 3.14 (m, 4H), 3.06 - 2.83 (m, 2H), 2.44 (s, 3H), 2.40 (s, 3H), 1.61 (d, J = 6.8 Hz, 3H).
728	(ES+) 501.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.11 (s, 1H), 7.46 (d, J = 1.2 Hz, 1H), 7.02 - 7.00 (m, 1H), 6.88 - 6.81 (m, 1H), 6.79 - 6.51 (m, 1H), 6.26 (s, 1H), 6.26 - 6.21 (m, 1H), 4.91 - 4.85 (m, 1H), 4.74 - 4.71 (m, 2H), 4.68 - 4.64 (m, 2H), 4.56 (br s, 1H), 3.65 - 3.61 (m, 4H), 3.17 - 2.80 (m, 6H), 2.39 (s, 3H), 2.38 - 2.17 (m, 2H), 1.61 (d, J = 6.8 Hz, 3H).

729	(ES+) 553.1 [M+Na]	^{1}H NMR (400 MHz, $CDCl_3$): δ 7.98 - 7.93 (m, 1H), 7.46 - 7.41 (m, 1H), 7.05 - 7.00 (m, 1H), 6.86 - 6.52 (m, 2H), 6.24 (s, 1H), 6.17 - 6.13 (m, 1H), 4.94 - 4.55 (m, 2H), 4.14 - 3.91 (m, 2H), 3.67 (s, 3H), 3.51 - 3.15 (m, 4H), 2.97 -2.95 (m, 2H), 2.44 (s, 3H), 1.62 (d, J = 6.8 Hz, 3H).
730	(ES+) 513.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.87 (d, J = 1.6 Hz, 1H), 7.52 – 7.45 (m, 1H), 7.36 (s, 1H), 7.19 – 7.11 (m, 1H), 7.05 – 6.95 (m, 1H), 6.45 (s, 1H), 6.34 – 6.27 (m, 1H), 5.72 (d, J = 6.0 Hz, 1H), 5.13 – 5.05 (m, 1H), 4.38 (s, 2H), 3.55 (s, 3H), 3.25 – 2.67 (m, 6H), 2.32 (s, 3H), 2.10 – 1.99 (m, 1H), 1.50 (d, J = 6.6 Hz, 3H), 0.82 – 0.69 (m, 4H).
731	(ES+) 556.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.99 (s, 1H), 7.65 (s, 1H), 7.25 (d, J = 53.9 Hz, 1H), 7.07 – 6.96 (m, 1H), 6.64 (d, J = 8.4 Hz, 1H), 5.80 (s, 1H), 5.21 (s, 1H), 4.61 (s, 1H), 4.16 (s, 1H), 3.61 (d, J = 2.1 Hz, 3H), 3.33 – 2.93 (m, 5H), 2.33 (s, 3H), 2.31 – 2.24 (m, 3H), 1.54 (d, J = 6.5 Hz, 3H), 1.35 (s, 3H), 1.26 (s, 3H), 0.88 – 0.76 (m, 2H), 0.57 (s, 2H).
732	(ES+) 542.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.98 (s, 1H), 7.64 (s, 1H), 7.19 (s, 1H), 7.07 – 6.97 (m, 1H), 6.65 (d, J = 8.4 Hz, 1H), 5.80 (d, J = 6.2 Hz, 1H), 5.27 – 5.19 (m, 1H), 4.27 (d, J = 10.2 Hz, 2H), 3.56 (s, 3H), 3.14 (s, 6H), 2.33 (s, 3H), 2.27 (s, 3H), 1.54 (d, J = 6.5 Hz, 3H), 1.27 (s, 3H), 0.83 (q, J = 4.0 Hz, 2H), 0.58 (t, J = 3.2 Hz, 2H).
733	(ES+) 556.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.99 (d, J = 2.6 Hz, 1H), 7.66 (s, 1H), 7.15 (d, J = 8.6 Hz, 1H), 6.80 (d, J = 8.5 Hz, 1H), 5.59 (d, J = 6.4 Hz, 1H), 5.31 – 5.23 (m, 1H), 3.57-3.53 (m, 1H), 3.34-3.25 (m, 6H), 3.08-3.02 (m, 2H), 2.97 (s, 3H), 2.31 (d, J = 16.3 Hz, 6H), 1.58 (d, J = 6.4 Hz, 3H).
734	(ES+) 538.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.88 (s, 1H), 7.48 (d, J = 1.9 Hz, 1H), 7.15 (d, J = 8.6 Hz, 1H), 6.84 (d, J = 8.7 Hz, 1H), 6.46 (s, 1H), 5.51 (d, J = 6.3 Hz, 1H), 5.22-5.16 (m, 1H), 3.55-3.5 (m, 5H), 3.17-3.12 (m, 6H), 2.98 (s, 3H), 2.33-2.28 (m, 6H), 1.55 (d, J = 6.6 Hz, 3H).
735	(ES+) 521.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.88 (s, 1H), 7.59 – 7.44 (m, 2H), 7.26 – 7.16 (m, 1H), 6.47 – 6.32 (m, 3H), 5.48 – 5.09 (m, 2H), 4.34 – 4.20 (m, 2H), 4.07 – 3.93 (m, 2H), 3.86 – 3.47 (m, 5H), 3.25 – 2.65 (m, 6H) 2.34 (s, 3H), 1.54 (d, J = 6.5 Hz, 3H).
736	(ES+) 539.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.99 (s, 1H), 7.73 (d, J = 1.9 Hz, 1H), 7.51 – 7.43 (m, 1H), 7.24 – 7.16 (m, 1H), 6.55 – 6.31 (m, 2H), 5.48 – 5.19 (m, 2H), 4.35 – 4.19 (m, 2H), 4.09 – 3.94 (m, 2H), 3.74 (d, J = 11.5 Hz, 2H), 3.53 (s, 3H), 3.24 – 3.03 (m, 6H), 2.35 (s, 3H), 1.55 (d, J = 6.5 Hz, 3H).
737	(ES+) 583.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.10 – 7.98 (m, 1H), 7.58 – 7.48 (m, 3H), 7.19 – 6.98 (m, 2H), 6.93 – 6.58 (m, 2H), 6.30 – 6.20 (m, 2H), 5.25 – 5.10 (m, 1H), 5.10 – 4.48 (m, 3H), 3.68 (s, 3H), 3.61 - 2.90 (m, 8H).

738	(ES+) 548.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.60 (s, 2H), 9.28 (s, 2H), 8.03 (d, J = 1.9 Hz, 1H), 7.60 (d, J = 1.9 Hz, 1H), 7.32 – 7.14 (m, 3H), 6.85 (d, J = 8.9 Hz, 1H), 6.34 (d, J = 6.4 Hz, 1H), 5.29 – 5.23 (m, 1H), 3.47 (s, 3H), 2.76 (s, 3H), 2.41 (s, 3H), 1.55 (d, J = 6.6 Hz, 3H).
739	(ES+) 569.1 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.12 (s, 1H), 7.72 (s, 1H), 7.50 – 7.19 (m, 1H), 7.10 – 7.08 (m, 1H), 6.61 (d, J = 5.9 Hz, 1H), 6.51 – 6.44 (m, 1H), 5.42 (s, 1H), 3.75 (d, J = 11.5 Hz, 2H), 3.73-3.66 (m, 4H), 3.5-3.44 (m, 2H), 3.25 (s, 3H), 3.15 – 3.11 (m, 2H), 2.95 (s, 3H), 2.41 (s, 3H), 1.65 (d, J = 6.5 Hz, 3H).
740	(ES+) 573.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.88 (d, J = 8.6 Hz, 1H), 7.65 (d, J = 9.5 Hz, 1H), 7.52 – 7.44 (m, 1H), 7.32 – 7.22 (m, 1H), 6.53 (s, 1H), 6.43 (s, 1H), 5.32 – 5.24 (m, 1H), 3.6-3.54 (m, 5H), 3.4-3.35 (m, 4H), 3.27 (s, 3H), 3.08 (d, J = 11.4 Hz, 2H), 2.98 (s, 3H), 1.61 (d, J = 6.4 Hz, 3H).
741	(ES+) 569.1 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.09 (s, 1H), 7.59 (s, 1H), 7.52 – 7.51 (m, 1H), 7.14 – 7.11 (m, 1H), 6.90 (d, J = 6.0 Hz, 1H), 6.55 - 6.52 (m, 2H), 5.50 – 5.40 (m, 1H), 4.76 – 4.73 (m, 1H), 4.64 – 4.61 (m, 2H), 3.89-3.82 (m, 5H), 3.73 - 3.70 (m, 4H), 3.35 - 3.20 (m, 2H), 3.15 – 2.95 (m, 5H), 2.41 (s, 3H).
742	(ES+) 524.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.60 (s, 2H), 9.29 (s, 2H), 8.09 (s, 1H), 7.77 (d, J = 1.9 Hz, 1H), 7.58 – 7.47 (m, 1H), 7.29 – 7.18 (m, 2H), 6.72 (d, J = 7.2 Hz, 1H), 6.55 – 6.46 (m, 1H), 5.57 (d, J = 14.0 Hz, 1H), 4.93 – 4.60 (m, 2H), 3.47 (s, 3H), 2.76 (s, 3H), 2.43 (s, 3H).
743	(ES+) 500.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.88 (d, J = 1.9 Hz, 1H), 7.56 (d, J = 1.9 Hz, 1H), 7.56 – 7.39 (m, 1H), 7.33 (d, J = 1.0 Hz, 1H), 7.26 – 7.16 (m, 2H), 6.44 – 6.34 (m, 3H), 5.45 – 5.00 (m, 1H), 3.75 (s, 3H), 3.52 (s, 3H), 3.34 – 2.72 (m, 8H), 2.35 (s, 3H), 1.56 (d, J = 6.5 Hz, 3H).
744	(ES+)518.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.95 (d, J = 1.7 Hz, 1H), 7.62 (d, J = 1.9 Hz, 1H), 7.54 – 7.47 (m, 1H), 7.33 (d, J = 0.9 Hz, 1H), 7.30 – 7.22 (m, 1H), 7.22 (d, J = 0.9 Hz, 1H), 6.65 (d, J = 7.2 Hz, 1H), 6.56 – 6.48 (m, 2H), 5.65 – 5.55 (m, 1H), 4.82 – 4.62 (m, 2H), 3.75 (s, 3H), 3.53 (s, 3H), 3.34 – 2.80 (m, 8H), 2.36 (s, 3H).
745	(ES+) 516.2[M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.19 (s, 1H), 7.51 (d, J = 3.6 Hz, 1H), 7.20 – 7.15 (m, 1H), 7.10 – 6.90 (m, 1H), 6.30 – 6.23 (m, 1H), 6.20 (s, 1H), 5.15 – 5.10 (m, 2H), 4.85 – 4.45 (m, 2H), 4.05 – 3.75 (m, 2H), 3.63 (s, 3H), 3.35 - 2.99 (m, 6H), 2.89 (s, 3H), 2.42 (s, 3H).
746	(ES+) 562.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.92 (d, J = 0.8 Hz, 1H), 8.33 (d, J = 7.7 Hz, 1H), 8.03 (s, 1H), 7.56 (d, J = 1.8 Hz, 1H), 7.09 – 7.05 (m, 2H), 6.86 – 6.79 (m, 2H), 6.56 (s, 1H), 5.19 – 5.05 (m, 1H), 4.20 – 3.50 (m, 5H), 3.50 – 3.00 (m, 6H), 2.39 (s, 3H), 2.36 (s, 3H), 1.66 (d, J = 6.6 Hz, 3H).

747	(ES+) 589.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.69 (s, 2H), 9.05 (s, 2H), 8.09 - 8.03 (m, 1H), 7.59 - 7.54 (m, 1H), 7.46 - 7.41 (m, 1H), 7.02 - 6.96 (m, 1H), 6.68 (s, 1H), 6.58 (d, J = 4.4 Hz, 1H), 6.23 - 6.18 (m, 1H), 4.97 - 4.90 (m, 1H), 3.21 - 3.16 (m, 4H), 2.88 (s, 3H), 1.67 (d, J = 6.8 Hz, 3H), 1.14 - 1.03 (m, 2H), 0.67 - 0.55 (m, 2H).
748	(ES+) 634.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.37 - 8.36 (m, 1H), 8.04 - 8.02 (m, 1H), 7.87 - 7.85 (m, 1H), 7.62 - 7.61 (m, 1H), 7.03 - 7.01 (m, 1H), 6.86 - 6.85 (m, 1H), 6.68 (t, J = 55.2 Hz, 1H), 6.23 - 6.22 (m, 1H), 5.40 - 5.16 (m, 1H), 4.65 (br d, J = 2.0 Hz, 1H), 3.81 - 3.56 (m, 7H), 3.33 - 3.05 (m, 4H), 2.69 (s, 3H), 1.9-1.83 (m, 6H), 1.59 (br s, 3H).
749	(ES+) 571.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.14 (s, 1H), 7.55 - 7.53 (m, 1H), 7.41 (d, J = 1.6 Hz, 1H), 6.98 - 6.96 (m, 1H), 6.51 (d, J = 5.2 Hz, 1H), 6.27 - 6.24 (m, 1H), 6.18 (s, 1H), 4.89 - 4.86 (m, 1H), 4.45 - 3.75 (m, 2H), 3.66 (s, 3H), 3.23 - 3.18 (m, 1H), 3.18 (s, 3H), 3.15 (br d, J = 5.6 Hz, 3H), 2.88 - 2.61 (m, 2H), 2.40 (s, 3H), 1.64 (d, J = 6.8 Hz, 3H), 1.60 (s, 3H), 0.94 - 0.90 (m, 2H), 0.71 - 0.66 (m, 2H).
750	(ES+) 578.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 7.97 - 7.95 (m, 1H), 7.57 - 7.53 (m, 1H), 7.35 - 7.33 (m, 1H), 6.98 - 6.97 (m, 1H), 6.53 (d, J = 4.4 Hz, 1H), 6.21 - 6.15 (m, 2H), 4.90 - 4.83 (m, 1H), 4.35 - 4.25 (m, 2H), 4.21 - 4.10 (m, 2H), 3.97 - 3.89 (m, 2H), 3.66 (s, 3H), 3.21 (br s, 1H), 3.30 - 3.04 (m, 7H), 2.93 - 2.69 (m, 2H), 1.64 (d, J = 6.8 Hz, 3H).
751	(ES+) 592.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.19 (s, 1H), 7.57 - 7.55 (m, 1H), 7.45 (d, J = 1.6 Hz, 1H), 7.00 - 6.98 (m, 1H), 6.78 (d, J = 5.6 Hz, 1H), 6.29 - 6.27 (m, 1H), 6.16 (s, 1H), 5.45 - 5.19 (m, 1H), 5.16 - 5.05 (m, 1H), 4.84 - 4.43 (m, 2H), 4.38 - 4.23 (m, 2H), 4.21 - 4.09 (m, 2H), 4.05 - 3.80 (m, 2H), 3.65 (s, 3H), 3.32 - 3.02 (m, 7H), 2.95 - 2.71 (m, 2H), 2.40 (s, 3H).
752	(ES+) 541.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.09 (s, 2H), 8.14 (s, 1H), 8.05 (m, 1H), 7.96 (s, 1H), 7.48 (m, 1H), 7.22 (m, 1H), 6.95 - 6.81 (m, 1H), 6.76 (s, 1H), 6.18 (m, 1H), 5.07 - 4.85 (m, 1H), 4.63-4.59 (m, 1H), 3.64 (s, 3H), 2.84 (s, 3H), 1.64 (d, J = 6.8 Hz, 3H).
753	(ES+) 559.3 [M+H]	
754	(ES+) 527.2 [M+H]	
755	(ES+) 547.3 [M+H]	
756	(ES+) 561.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.01 (s, 2H), 8.25 (s, 1H), 7.56 (d, J = 1.2 Hz, 1H), 7.46 - 7.45 (m, 1H), 6.94 (d, J = 8.8 Hz, 1H), 6.81 - 6.73 (m, 3H), 6.57 (d, J = 8.8 Hz, 1H), 5.03 - 4.88 (m, 1H), 4.73 (br s, 1H), 3.72 (s, 3H), 3.55 (s, 3H), 2.47 (s, 3H), 2.42 (s, 3H), 1.66 (d, J = 6.4 Hz, 3H).

757	(ES+) 582.5 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 7.9- 7.98 (m, 1H), 7.56 - 7.54 (m, 1H), 7.36 - 7.34 (m, 1H), 7.04 (s, 1H), 7.03 - 6.97 (m, 1H), 6.54 (d, J = 4.4 Hz, 1H), 6.24 - 6.20 (m, 2H), 4.96 - 4.85 (m, 1H), 3.93 (s, 3H), 3.67 (s, 3H), 3.64 - 3.21 (m, 4H), 3.19 (s, 3H), 3.15 - 2.98 (m, 4H), 1.67 (d, J = 6.4 Hz, 3H).
758	(ES+) 561.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.19 (s, 1H), 7.52 (s, 1H), 7.26 - 7.21 (m, 2H), 7.01 (s, 1H), 6.96 - 6.85 (m, 1H), 6.30 - 6.27 (m, 1H), 6.25 (s, 1H), 5.20 - 5.06 (m, 1H), 5.01 (br s, 1H), 4.85 - 4.65 (m, 1H), 4.65 - 4.45 (m, 1H), 3.87 (s, 3H), 3.66 (s, 3H), 3.46 - 2.79 (m, 8H), 2.41 (s, 3H).
759	(ES+) 519.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.06 (s, 1H), 7.41 (s, 1H), 7.19 - 7.17 (m, 1H), 6.90 - 6.87 (m, 1H), 6.26 - 6.24 (m, 1H), 5.77 (s, 1H), 4.90 - 4.81 (m, 1H), 4.60 (d, J = 2.4 Hz, 1H), 4.05 - 3.98 (m, 2H), 3.76 - 3.73 (m, 4H), 3.72 - 3.70 (m, 2H), 3.55 (s, 3H), 2.44 (d, J = 4.0 Hz, 4H), 2.36 (s, 3H), 1.61 (d, J = 6.8 Hz, 3H).
760	(ES+) 537.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.03 (s, 2H), 8.10 (s, 1H), 7.84 – 7.81 (m, 1H), 7.61 – 7.49 (m, 1H), 7.38 (s, 1H), 7.24 – 7.16 (m, 1H), 7.09 – 7.00 (m, 1H), 6.98 (s, 1H), 6.31 – 6.25 (m, 1H), 5.85 (d, J = 6.0 Hz, 1H), 5.21 – 5.17 (m, 1H), 3.48 (s, 3H), 2.75 (s, 3H), 2.45 (s, 3H), 1.53 (d, J = 6.4 Hz, 3H).
761	(ES+) 587.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.76 (s, 2H), 8.08 – 8.01 (m, 1H), 7.61 – 7.54 (m, 1H), 7.47 – 7.40 (m, 1H), 7.08 – 6.98 (m, 1H), 6.72 (s, 1H), 6.58 (s, 1H), 6.30 – 6.22 (m, 1H), 4.99 – 6.95 (m, 1H), 3.78 (s, 3H), 3.19 (s, 3H), 2.97 – 2.90 (m, 2H), 2.91 (s, 3H), 2.50 – 2.45 (m, 2H), 1.70 (d, J = 6.3 Hz, 3H).
762	(ES+) 616.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.13 – 7.90 (m, 1H), 7.62 – 7.30 (m, 4H), 7.12 – 6.92 (m, 1H), 6.45 (d, J = 4.8 Hz, 1H), 6.32 – 6.17 (m, 2H), 5.43 – 5.14 (m, 1H), 5.02 – 4.75 (m, 1H), 4.33 – 3.99 (m, 4H), 3.90 (s, 3H), 3.68 (s, 3H), 3.55 – 2.82 (m, 8H), 1.65 (d, J = 6.8 Hz, 3H).
763	(ES+) 630.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.96 (s, 1H), 7.47 – 7.40 (m, 2H), 7.40 – 7.31 (m, 2H), 7.22 (d, J = 1.0 Hz, 1H), 6.83 (d, J = 6.4 Hz, 1H), 6.57 – 6.62 (m , 1H), 6.45 (s, 1H), 5.65 – 5.55 (m, 1H), 5.48 – 5.28 (m, 1H), 4.90 – 4.60 (m, 2H), 4.27 – 4.14 (m, 2H), 4.00 – 3.83 (m, 2H), 3.75 (s, 3H), 3.53 (s, 3H), 3.32 – 3.00 (m, 8H), 2.33 (s, 3H).
764	(ES+) 618.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.76 (s, 2H), 9.00 (s, 2H), 8.24 (s, 1H), 7.52 (d, J = 4.8 Hz, 1H), 7.46 – 7.40 (m, 1H), 7.04 – 6.95 (m, 1H), 6.70 (s, 1H), 6.47 (d, J = 4.8 Hz, 1H), 6.35 – 6.15 (m, 1H), 5.32 – 5.13 (m, 1H), 5.00 – 4.90 (m, 1H), 4.29 – 4.15 (m, 2H), 4.15 – 3.85 (m, 2H), 3.54 (s, 3H), 2.94 (s, 3H), 2.46 (s, 3H), 1.62 (d, J = 6.4 Hz, 3H).

765	(ES+) 651.3 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.58 (d, J = 2.2 Hz, 1H), 8.03 (s, 1H), 7.90 – 7.86 (m, 1H), 7.57 (d, J = 1.8 Hz, 1H), 7.48 – 7.39 (m, 2H), 7.19 – 7.07 (m, 1H), 6.58 – 6.49 (m, 3H), 5.33 – 5.11 (m, 2H), 4.73 (s, 1H), 4.27 – 4.14 (m, 2H), 4.01 – 3.90 (m, 2H), 3.78 (s, 1H), 3.70 (s, 3H), 3.63 (s, 1H), 3.41 (s, 1H), 3.22 (s, 2H), 2.94 (s, 2H), 2.62 (s, 3H), 2.41 (s, 3H), 1.65 (d, J = 6.6 Hz, 3H).
766	(ES+) 539.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.23 (s, 1H), 7.49 (d, J = 1.6 Hz, 1H), 7.20 – 7.15 (m, 1H), 7.05 – 6.90 (m, 1H), 6.30 – 6.20 (m, 1H), 6.16 (s, 1H), 5.39 – 5.20 (m, 1H) , 5.17 – 5.07 (m, 2H), 4.80 – 4.41 (m, 2H), 4.38 – 4.22 (m, 2H), 4.20 – 4.05 (m, 2H), 4.04 - 3.80 (m, 2H), 3.66 (s, 3H), 3.47 – 2.50 (m, 6H), 2.41 (s, 3H).
767	(ES+) 516.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.00 (s, 1H), 7.74 (d, J = 1.9 Hz, 1H), 7.48 – 7.45 (m, 1H), 7.20 – 7.17 (m, 1H), 6.46 (s, 1H), 6.38 (s, 1H), 5.28 – 5.25 (m, 1H), 3.62 – 3.49 (m, 5H), 3.34 (s, 1H), 3.31 (s, 3H), 3.05 – 3.02 (m, 2H), 2.98 (s, 3H), 2.36 (s, 3H), 1.57 (d, J = 6.5 Hz, 3H).
768	(ES+) 534.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.22 (s, 1H), 7.66 (s, 1H), 7.25 – 7.15 (m, 1H), 7.10 – 6.90 (m, 1H), 6.35 – 6.23 (m, 1H), 5.55 – 5.50 (m, 1H), 5.49 – 5.25 (m, 1H), 4.91 – 4.76 (m, 2H), 4.64 – 4.46 (m, 1H), 3.87 – 3.80 (m, 2H), 3.63 (s, 3H), 3.60 – 3.40 (m, 1H), 3.25 – 3.16 (m, 2H), 3.15 – 3.00 (m, 2H), 2.89 (s, 3H), 2.45 (s, 3H).
769	(ES+) 571.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.89 (s, 1H), 7.75 (s, 1H), 7.49 (d, J = 1.9 Hz, 1H), 7.36 – 7.30 (m, 1H), 7.23 – 7.16 (m, 2H), 6.52 – 6.42 (m, 2H), 5.34 – 5.17 (m, 2H), 3.56 (s, 3H), 3.47 (s, 3H), 3.30 – 3.00 (m, 8H), 2.33 (s, 3H), 1.56 (d, J = 6.5 Hz, 3H).
770	(ES+) 527.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.92 (s, 1H), 7.51 (d, J = 1.9 Hz, 1H), 7.17 (d, J = 8.6 Hz, 1H), 6.86 (d, J = 8.7 Hz, 1H), 6.61 (s, 1H), 5.47 (d, J = 6.3 Hz, 1H), 5.18 – 5.15 (m, 1H), 3.61 – 3.58 (m, 7H), 2.51 – 2.43 (m, 4H), 2.35 (s, 3H), 2.30 (s, 3H), 2.18 – 2.16 (m, 6H), 1.57 – 1.55 (m, 3H).
771	(ES-) 569.3 [M-H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.16 (s, 1H), 7.98 (s, 1H), 7.59 – 7.49 (m, 1H), 7.28 – 7.15 (m, 1H), 7.12 – 6.88 (m, 2H), 6.34 (s, 1H), 5.97 (d, J = 8.8 Hz, 1H), 4.97 – 4.83 (m, 1H), 3.68 (s, 3H), 3.60 (s, 3H), 3.46 – 2.93 (m, 8H), 2.44 (s, 3H), 1.65 (d, J = 6.4, 3H).
772	(ES+) 589.3 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.09 (s, 1H), 7.82 (s, 1H), 7.62 (d, J = 1.9 Hz, 1H), 7.31 - 7.26 (m, 2H), 7.06 – 7.00 (m, 1H), 6.61 (s, 1H), 6.55 – 6.45 (m, 1H), 5.43 – 5.40 (m, 1H), 4.79 – 4.50 (m, 1H), 3.71 (s, 3H), 3.63 (s, 3H), 2.42 (s, 3H).
773	(ES+) 607.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.19 (d, J = 2.5 Hz, 1H), 7.82 (s, 1H), 7.79 (d, J = 1.9 Hz, 1H), 7.30 (d, J = 5.4 Hz, 2H), 7.05 – 7.00 (m, 1H), 6.50 – 6.40 (m, 1H), 5.69 - 5.61 (m, 1H), 5.02 – 4.57 (m, 2H), 3.73 (s, 3H), 3.64 – 3.60 (m, 5H), 3.42 – 3.34 (m, 4H), 3.28 – 3.17 (m, 2H), 2.42 (s, 3H).

774	(ES+) 550.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.71 (s, 2H), 9.00 (s, 2H), 8.13 – 8.06 (m, 1H), 7.55 – 7.48 (m, 1H), 6.97 (d, J = 8.2 Hz, 1H), 6.72 (s, 1H), 6.53 (d, J = 8.3 Hz, 1H), 5.00 – 4.99 (m, 1H), 4.79 – 4.74 (m, 1H), 3.57 (s, 3H), 2.96 (s, 3H), 2.44 (s, 3H), 1.68 (d, J = 6.0 Hz, 3H).
775	(ES+) 550.2 [M+H]	
776	(ES+) 598.2 [M+H]	^{1}H NMR (400 MHz, CD_3CN): δ 8.38 (s, 1H), 7.94-7.91 (m, 1H), 7.82 (s, 1H), 7.52 – 7.38 (m, 3H), 7.11 – 7.02 (m, 1H), 6.78 (s, 1H), 6.49 (d, J = 5.0 Hz, 1H), 6.39-6.39 (m, 1H), 5.10-5.07 (m, 1H), 3.46 (s, 3H), 3.17 (s, 3H), 2.41 (d, J = 2.5 Hz, 6H), 1.61 (d, J = 6.6 Hz, 3H).
777	(ES+) 531.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.99 (s, 1H), 7.69 – 7.64 (m, 1H), 7.44 (m, 1H), 7.21 – 7.14 (m, 1H), 7.05 – 6.96 (m, 1H), 6.27 (s, 1H), 5.80 (d, J = 6.3 Hz, 1H), 5.25 – 5.17 (m, 1H), 4.35 (s, 2H), 3.57 (s, 3H), 3.42 (s, 1H), 3.06 - 2.96 (m, 5H), 2.33 (s, 3H), 2.10 – 1.99 (m, 1H), 1.52 (d, J = 6.5 Hz, 3H), 0.79 – 0.70 (m, 4H).
778	(ES+) 593.3 [M+H]	^{1}H NMR (400 MHz, CD_3CN): δ 7.95 – 7.90 (m, 1H), 7.61 – 7.55 (m, 1H), 7.50 – 7.46 (m, 1H), 7.12 – 7.03 (m, 2H), 6.54 – 6.39 (m, 2H), 5.40 – 5.29 (m, 1H), 3.65 (d, J = 1.1 Hz, 3H), 3.59 (s, 3H), 3.52 – 3.42 (m, 2H), 3.27 – 3.12 (m, 7H), 2.91 – 2.81 (m, 2H), 1.64 – 1.59 (m, 3H).
779	(ES+) 589.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.02 (s, 1H), 7.75 (s, 1H), 7.68 (s, 1H), 7.30 - 7.32 (m, 1H), 7.21 - 7.12 (m, 2H), 6.44 (s, 1H), 5.47 – 5.35 (m, 1H), 5.32 – 5.24 (m, 1H), 3.58 (s, 3H), 3.49 - 3.40 (mz, 5H), 3.37 - 3.35 (m, 2H), 3.29 – 3.24 (m, 2H), 3.12 - 3.06 (m, 2H), 2.35 (s, 3H), 1.58 (d, J = 6.4 Hz, 3H).
780	(ES+) 530.0 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.07 – 8.02 (m, 1H), 7.60 (d, J = 1.9 Hz, 1H), 7.26 – 7.23 (m, 1H), 7.05 – 7.02 (m, 1H), 6.78 (s, 1H), 6.47 – 6.44 (m, 1H), 5.17 – 5.12 (m, 1H), 3.75 – 3.65 (m, J = 7.8 Hz, 7H), 2.62 – 2.56 (m, 4H), 2.42 (s, 3H), 2.31 (s, 6H), 1.64 (d, J = 6.7 Hz, 3H).
781	(ES+) 530.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.94 – 7.89 (m, 1H), 7.52 – 7.45 (m, 2H), 7.36 – 7.20 (m, 1H), 6.61 (s, 1H), 6.15 – 6.08 (m, 1H), 6.05 (d, J = 6.0 Hz, 1H), 5.08 – 5.04 (m, 1H), 3.65 – 3.57 (m, 7H), 2.51 – 2.42 (m, 4H), 2.36 (s, 3H), 2.18 – 2.17 (m, 6H), 1.52 (d, J = 6.6 Hz, 3H).
782	(ES+) 530.2 [M+H]	
783	(ES+) 560.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.29 (s, 2H), 9.21 (s, 1H), 8.03 (s, 1H), 7.60 (d, J = 1.9 Hz, 1H), 7.19 – 7.10 (m, 2H), 6.87 (d, J = 8.7 Hz, 1H), 5.60 (d, J = 6.5 Hz, 1H), 5.34 – 5.26 (m, 1H), 3.47 (s, 3H), 2.83 (s, 3H), 2.69 (s, 3H), 2.39 (s, 3H), 2.29 (s, 3H), 1.57 – 1.55 (m, 3H).

784	(ES+) 579.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.03 (s, 2H), 8.43 - 8.38 (m, 1H), 8.25 (s, 1H), 7.77 - 7.73 (m, 1H), 7.56 (d, J = 1.2 Hz, 1H), 6.94 (d, J = 8.4 Hz, 1H), 6.74 (s, 1H), 6.57 (d, J = 8.4 Hz, 1H), 4.99 - 4.90 (m, 1H), 4.73 (br s, 1H), 3.56 (s, 3H), 2.82 (s, 3H), 2.47 (s, 3H), 2.42 (s, 3H), 1.65 (d, J = 6.8 Hz, 3H).
785	(ES+) 565.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.02 (s, 2H), 8.09 - 8.07 (m, 1H), 7.54 - 7.44 (m, 2H), 6.95 (d, J = 8.4 Hz, 1H), 6.83 - 6.76 (m, 2H), 6.73 (s, 1H), 6.51 (d, J = 8.8 Hz, 1H), 5.02 - 4.90 (m, 1H), 4.73 (br s, 1H), 3.72 (s, 3H), 3.56 (s, 3H), 2.43 (s, 3H), 1.67 (d, J = 6.4 Hz, 3H).
786	(ES+) 568.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.01 (s, 2H), 8.09 - 8.08 (m, 1H), 7.49 - 7.48 (m, 1H), 7.47 - 7.44 (m, 1H), 7.08 (t, J = 53.6 Hz, 1H), 6.94 - 6.84 (m, 1H), 6.82 - 6.73 (m, 3H), 5.91 - 5.81 (m, 1H), 5.04 (d, J = 3.4 Hz, 1H), 4.93 (br s, 1H), 3.73 (s, 3H), 3.56 (s, 3H), 1.65 (d, J = 6.8 Hz, 3H).
787	(ES+) 540.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.12 (s, 1H), 7.44 (d, J = 1.6 Hz, 1H), 7.25 (s, 1H), 7.01 (s, 1H), 6.95 (d, J = 8.4 Hz, 1H), 6.60 (d, J = 8.4 Hz, 1H), 6.23 (s, 1H), 4.94 - 4.85 (m, 1H), 4.73 (br s, 1H), 3.87 (s, 3H), 3.65 (s, 3H), 3.40 - 2.87 (m, 8H), 2.42 (s, 3H), 2.39 (s, 3H), 1.64 (d, J = 6.4 Hz, 3H).
788	(ES+) 558.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.19 (s, 1H), 7.50 (s, 1H), 7.26 (s, 1H), 7.01 (s, 1H), 6.97 (d, J = 8.8 Hz, 1H), 6.62 (d, J = 8.8 Hz, 1H), 6.22 (s, 1H), 5.23 - 5.02 (m, 2H), 4.89 - 4.67 (m, 1H), 4.67 - 4.41 (m, 1H), 3.87 (s, 3H), 3.66 (s, 3H), 3.42 - 2.87 (m, 8H), 2.42 (d, J = 13.2 Hz, 6H).
789	(ES+) 608.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.08 - 8.07 (m, 1H), 7.60 - 7.58 (m, 1H), 7.44 - 7.43 (m, 1H), 7.32 (s, 1H), 7.25 - 6.95 (m, 3H), 6.52 (s, 1H), 6.25 - 6.24 (m, 1H), 5.19 - 5.17 (m, 1H), 4.84 - 4.47 (m, 2H), 3.79 (s, 3H), 3.67 - 3.65 (m, 2H), 3.27 - 3.22 (m, 2H), 3.20 (s, 3H), 2.23 - 2.19 (m, 1H), 2.15 - 2.07 (m, 2H).
790	(ES+) 589.5 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.19 (s, 1H), 7.57 - 7.55 (m, 1H), 7.45 (d, J = 1.6 Hz, 1H), 7.05 - 6.95 (m, 1H), 6.78 (d, J = 5.2 Hz, 1H), 6.28 - 6.26 (m, 1H), 6.16 (s, 1H), 5.22 - 5.06 (m, 1H), 4.80 - 4.43 (m, 2H), 4.41 - 3.75 (m, 2H), 3.65 (s, 3H), 3.31 - 2.96 (m, 7H), 2.94 - 2.67 (m, 2H), 2.40 (s, 3H), 1.59 (s, 3H), 0.95 - 0.87 (m, 2H), 0.71 - 0.64 (m, 2H).
791	(ES+) 523.0 [M+H]	
792	(ES+) 568.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.01 (s, 2H), 8.09 - 8.07 (m, 1H), 7.53 - 7.52 (m, 1H), 7.47 - 7.46 (m, 1H), 7.23 - 7.22 (m, 1H), 6.94 - 6.86 (m, 1H), 6.81 - 6.75 (m, 2H), 6.74 (s, 1H), 6.17 -6.16 (m, 1H), 5.00 - 4.91 (m, 1H), 4.61 (br s, 1H), 3.72 (s, 3H), 3.56 (s, 3H), 1.65 (d, J = 6.8 Hz, 3H).
793	(ES+) 541.3 [M+H]	^{1}H NMR (400 MHz, CDCl3): δ 8.12 (s, 1H), 7.44 (d, J = 1.6 Hz, 1H), 6.99 - 6.89 (m, 2H), 6.59 (d, J = 8.8 Hz, 1H), 6.23 (s, 1H), 4.95 - 4.85 (m, 1H), 4.72 (s, 1H), 4.05 (s, 3H), 3.87 - 3.57 (m, 5H), 3.35 - 2.93 (m, 6H), 2.41 (s, 3H), 2.39 (s, 3H), 1.64 (d, J = 6.8 Hz, 3H).

794	(ES+) 526.3 [M+H]	
795	(ES+) 514.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.15 (s, 1H), 7.49 (d, J = 1.6 Hz, 1H), 7.17 - 7.15 (m, 1H), 7.10 (s, 1H), 6.93 - 6.82 (m, 2H), 6.55 (s, 1H), 6.27 - 6.25 (m, 1H), 5.00 - 4.86 (m, 1H), 4.57 (br s, 1H), 4.30 - 4.08 (m, 3H), 3.84 (s, 3H), 3.74 - 3.72 (m, 2H), 3.54 (s, 3H), 2.42 (s, 3H), 1.62 (d, J = 6.8 Hz, 3H).
796	(ES+) 541.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.17 (s, 1H), 7.51 (d, J = 1.6 Hz, 1H), 7.18 - 7.16 (m, 1H), 6.99 - 6.97 (m, 1H), 6.94 - 6.87 (m, 1H), 6.63 (d, J = 9.6 Hz, 1H), 6.58 (s, 1H), 6.45 (d, J = 2.8 Hz, 1H), 6.31 - 6.30 (m, 1H), 5.00 - 4.83 (m, 1H), 4.56 (br s, 1H), 4.28 - 4.09 (m, 3H), 3.74 - 3.72 (m, 2H), 3.59 - 3.50 (m, 6H), 2.43 (s, 3H), 1.65 - 1.63 (m, 3H).
797	(ES+) 573.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.33 (s, 2H), 9.05 (d, J = 2.0 Hz, 1H), 8.26 - 8.22 (m, 2H), 7.58 (d, J = 1.6 Hz, 1H), 7.21 - 7.19 (m, 1H), 6.89 - 6.87 (m, 1H), 6.74 (s, 1H), 6.23 - 6.20 (m, 1H), 4.95 - 4.89 (m, 1H), 4.60 (br s, 1H), 3.53 (s, 3H), 2.90 (s, 3H), 2.47 (s, 3H), 1.63 (d, J = 6.8 Hz, 3H).
798	(ES+) 570.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.33 (s, 2H), 9.05 (d, J = 2.4 Hz, 1H), 8.26 - 8.22 (m, 2H), 7.56 (d, J = 1.6 Hz, 1H), 6.94 (d, J = 8.4 Hz, 1H), 6.71 (s, 1H), 6.55 (d, J = 8.8 Hz, 1H), 4.97 - 4.88 (m, 1H), 4.73 (br s, 1H), 3.53 (s, 3H), 2.90 (s, 3H), 2.46 (s, 3H), 2.42 (s, 3H), 1.64 (d, J = 6.8 Hz, 3H).
799	(ES+) 583.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.33 (s, 2H), 9.06 (d, J = 2.4 Hz, 1H), 8.27 - 8.24 (m, 2H), 7.56 - 7.51 (m, 2H), 7.01 - 6.95 (m, 1H), 6.69 (s, 1H), 6.56 (d, J = 5.4 Hz, 1H), 6.25 - 6.23 (m, 1H), 4.93 - 4.89 (m, 1H), 3.53 (s, 3H), 3.17 (s, 3H), 2.90 (s, 3H), 2.47 (s, 3H), 1.65 (d, J = 6.8 Hz, 3H).
800	(ES+) 589.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.91 – 7.84 (m, 1H), 7.64 (d, J = 9.9 Hz, 1H), 7.49 – 7.45 (m, 1H), 7.37 (s, 1H), 7.31 –7.23 (m, 1H), 6.53 (s, 1H), 6.43 (s, 1H), 5.35 – 5.23 (m, 1H), 3.68 (s, 3H), 3.56 (s, 3H), 3.47 – 3.37 (m, 5H), 3.27 – 3.18 (m, 2H), 3.11 - 3.07 (m, 2H), 2.79 – 2.69 (m, 2H), 2.09 (s, 3H), 1.61 (d, J = 6.4 Hz, 3H).
801	(ES+) 565.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.31 (s, 2H), 7.89-7.80 (m, 1H), 7.68 (s, 1H), 7.64-7.45 (m, 2H), 7.24 (s, 1H), 7.21-7.14 (m, 1H), 7.00 (d, J = 8.8 Hz, 1H), 6.34 – 6.28 (m, 1H), 5.87 (d, J = 6.2 Hz, 1H), 5.27 (s, 1H), 3.64 (s, 3H), 3.48 (s, 3H), 2.42 (s, 3H), 1.53 (d, J = 6.7 Hz, 3H).
802	(ES+) 587.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.09 (s, 1H), 7.72 (s, 1H), 7.55 – 7.51 (m, 1H), 7.17 - 7.11 (m, 1H), 6.56 - 6.52 (m, 1H), 5.68 – 5.60 (m, 1H), 4.76 – 4.73 (m, 1H), 4.64 – 4.61 (m, 2H), 3.80 - 3.73 (m, 2H), 3.69 (s, 3H), 3.52 - 3.45 (m, 2H), 3.42 - 3.33 (m, 2H), 3.26 (s, 3H), 3.18 – 3.12 (m, 2H), 2.95 (s, 3H), 2.42 (s, 3H).

803	(ES+) 552.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.88 (s, 1H), 7.47 (d, J = 1.9 Hz, 1H), 7.14 (d, J = 8.6 Hz, 1H), 6.81 (d, J = 8.7 Hz, 1H), 6.43 (s, 1H), 5.52 (d, J = 6.4 Hz, 1H), 5.18 – 5.16 (m, 1H), 4.09 (s, 1H), 3.56 (s, 4H), 3.47 (d, J = 29.5 Hz, 1H), 3.19 (d, J = 12.0 Hz, 1H), 3.12 (d, J = 12.0 Hz, 1H), 3.03 (s, 3H), 3.01 – 2.93 (m, 1H), 2.81 (s, 1H), 2.31 (s, 3H), 2.28 (s, 3H), 1.55 (d, J = 6.6 Hz, 3H), 1.43 (d, J = 6.7 Hz, 3H).
804	(ES+) 559.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.06 (s, 2H), 8.75 (s, 1H), 8.26 (s, 1H), 7.80 (s, 1H), 7.52 (d, J = 1.2 Hz, 1H), 6.94 (s, 1H), 6.89 - 6.50 (m, 2H), 4.93 - 4.85 (m, 1H), 4.73 (s, 1H), 3.56 (s, 3H), 2.96 (s, 3H), 2.62 (s, 3H), 2.45 (s, 6H), 1.65 (s, 3H).
805	(ES+) 554.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.87 (s, 1H), 7.47 (s, 1H), 7.16 - 7.14 (m, 3H), 6.85 (d, J = 8.4 Hz, 1H), 6.40 (s, 1H), 5.50 (d, J = 5.6 Hz, 1H), 5.21-5.14 (m, 1H), 3.75 (s, 3H), 3.55 (s, 3H), 3.19 - 2.60 (m, 7H), 2.32 (s, 3H), 2.28 (s, 3H), 1.56 (d, J = 6.4 Hz, 3H), 1.19 - 0.96 (m, 3H).
806	(ES+) 588.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.50 (s, 2H), 8.14 (s, 1H), 7.46 (d, J = 1.6 Hz, 1H), 6.95 (d, J = 8.4 Hz, 1H), 6.79 - 6.49 (m, 2H), 6.27 (s, 1H), 4.95 - 4.83 (m, 1H), 4.72 (br s, 1H), 4.00 - 3.73 (m, 2H), 3.68 (s, 3H), 3.47 - 3.17 (m, 4H), 3.14 - 2.94 (m, 2H), 2.41 (d, J = 5.2 Hz, 6H), 1.65 (d, J = 6.8 Hz, 3H).
807	(ES+) 497.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.14 (s, 1H), 7.42 (s, 1H), 7.25 (s, 1H), 7.01 (s, 1H), 6.97 (d, J = 8.8 Hz, 1H), 6.54 (d, J = 8.8 Hz, 1H), 6.19 (s, 1H), 4.97 - 4.83 (m, 2H), 3.87 (s, 3H), 3.65 (s, 3H), 3.38 - 2.90 (m, 8H), 2.40 (d, J = 3.5 Hz, 6H), 1.68 (d, J = 6.4 Hz, 3H).
808	(ES+) 476.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.13 (s, 1H), 7.44 (d, J = 1.6 Hz, 1H), 7.14 - 7.12 (m, 1H), 6.95 - 6.94 (m, 1H), 6.23 - 6.17 (m, 2H), 4.93 - 4.86 (m, 1H), 4.82 (d, J = 4.8 Hz, 1H), 4.75 - 4.70 (m, 2H), 4.69 - 4.64 (m, 2H), 3.65 - 3.59 (m, 4H), 3.23 - 2.72 (m, 6H), 2.40 (s, 3H), 2.40 - 2.15 (m, 2H), 1.64 (d, J = 6.4 Hz, 3H).
809	(ES+) 516.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.12 (s, 1H), 7.43 (s, 1H), 6.94 (d, J = 8.0 Hz, 1H), 6.58 (d, J = 8.4 Hz, 1H), 6.23 (s, 1H), 4.91 - 4.84 (m, 1H), 4.76 - 4.66 (m, 5H), 3.67 - 3.59 (m, 4H), 3.20 - 2.80 (m, 6H), 2.42 (s, 3H), 2.38 (s, 3H), 2.36 - 2.12 (m, 2H), 1.63 (d, J = 6.0 Hz, 3H).
810	(ES+) 571.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.13 (s, 1H), 7.69 (d, J = 2.8 Hz, 1H), 7.47 (d, J = 1.2 Hz, 1H), 7.20 - 7.18 (m, 1H), 6.93 - 6.85 (m, 1H), 6.29 - 6.22 (m, 2H), 6.02 (d, J = 2.8 Hz, 1H), 4.93 - 4.83 (m, 1H), 4.58 (d, J = 2.0 Hz, 1H), 3.79 - 3.62 (m, 8H), 3.36 - 2.87 (m, 6H), 2.40 (s, 3H), 1.62 (d, J = 6.8 Hz, 3H).
811	(ES+) 589.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.19 (s, 1H), 7.69 (d, J = 2.8 Hz, 1H), 7.64 (s, 1H), 7.20 - 7.18 (m, 1H), 6.93 - 6.85 (m, 1H), 6.32 - 6.23 (m, 1H), 6.02 (d, J = 2.8 Hz, 1H), 5.27 (d, J = 2.4 Hz, 1H), 4.64 (s, 1H), 3.83 - 3.75 (m, 2H), 3.73 (s, 3H), 3.67 (s, 3H), 3.59 - 3.50 (m, 2H), 3.27 - 3.16 (m, 4H), 2.40 (s, 3H), 1.58 (d, J = 6.4 Hz, 3H).

812	(ES+) 562.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.00 (s, 2H), 8.79 (d, J = 2.0 Hz, 1H), 8.23 (s, 1H), 8.00 (d, J = 2.0 Hz, 1H), 7.54 (s, 1H), 6.92 (d, J = 8.4 Hz, 1H), 6.70 (s, 1H), 6.55 (d, J = 8.4 Hz, 1H), 4.94-4.71 (m, 1H), 4.71 (br s, 1H), 3.89 (s, 3H), 3.53 (s, 3H), 2.45 (s, 3H), 2.41 (s, 3H), 1.63 (d, J = 6.8 Hz, 3H).
813	(ES+) 565.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.01 (s, 2H), 8.80 (d, J = 2.0 Hz, 1H), 8.24 (s, 1H), 8.01 (d, J = 2.0 Hz, 1H), 7.57 (d, J = 1.6 Hz, 1H), 7.22 - 7.19 (m, 1H), 6.92 - 6.85 (m, 1H), 6.74 (s, 1H), 6.26 - 6.19 (m, 1H), 4.95 - 4.89 (m, 1H), 4.59 (d, J = 1.2 Hz, 1H), 3.90 (s, 3H), 3.54 (s, 3H), 2.47 (s, 3H), 1.62 (d, J = 6.8 Hz, 3H).
814	(ES+) 565.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.01 (s, 2H), 8.80 (d, J = 2.0 Hz, 1H), 8.24 (s, 1H), 8.01 (d, J = 2.0 Hz, 1H), 7.59 (d, J = 1.6 Hz, 1H), 7.21 - 6.87 (m, 2H), 6.75 (s, 1H), 5.90 (br d, J = 9.2 Hz, 1H), 5.05 - 5.01 (m, 1H), 4.94 - 4.87 (m, 1H), 3.90 (s, 3H), 3.53 (s, 3H), 2.48 (s, 3H), 1.62 (d, J = 6.6 Hz, 3H).
815	(ES+) 561.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.83 (s, 2H), 8.22 (s, 1H), 7.53 (s, 1H), 7.43 (d, J = 7.2 Hz, 1H), 6.93 (d, J = 8.4 Hz, 1H), 6.85 (d, J = 1.2 Hz, 1H), 6.76 (s, 1H), 6.55 (d, J = 8.4 Hz, 1H), 6.41 - 6.40 (m, 1H), 5.01 - 4.87 (m, 1H), 4.74 (br s, 1H), 3.60 (s, 3H), 2.86 (s, 3H), 2.43 (d, J = 10.4 Hz, 6H), 1.64 (d, J = 6.4 Hz, 3H).
816	(ES+) 574.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.83 (s, 2H), 8.22 (s, 1H), 7.54 - 7.52 (m, 1H), 7.49 (s, 1H), 7.43 (d, J = 7.2 Hz, 1H), 7.04 - 6.92 (m, 1H), 6.86 (d, J = 1.2 Hz, 1H), 6.75 (s, 1H), 6.55 (d, J = 5.4 Hz, 1H), 6.42 - 6.41 (m, 1H), 6.25 - 6.23 (m, 1H), 5.02 - 4.85 (m, 1H), 3.60 (s, 3H), 3.18 (s, 3H), 2.86 (s, 3H), 2.45 (s, 3H), 1.64 (d, J = 6.8 Hz, 3H).
817	(ES+) 542.2 [M+H]	
818	(ES+) 565.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.32 (s, 2H), 8.21 (s, 1H), 8.03 (d, J = 1.6 Hz, 1H), 7.78 (s, 1H), 7.60 (d, J = 1.8 Hz, 1H), 7.36 – 7.29 (m, 1H), 7.19 (s, 1H), 7.16 (s, 1H), 6.51 – 6.43 (m, 1H), 5.39 (d, J = 6.2 Hz, 1H), 5.31 – 5.23 (m, 1H), 3.62 (s, 3H), 3.47 (s, 3H), 2.39 (s, 3H), 1.55 (d, J = 6.6 Hz, 3H).
819	(ES+) 565.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.32 (s, 2H), 8.21 (s, 1H), 8.03 (s, 1H), 7.78 (s, 1H), 7.66 – 7.36 (m, 2H), 7.28 – 7.14 (m, 2H), 6.17 – 6.08 (m, 2H), 5.26 – 5.15 (m, 1H), 3.62 (s, 3H), 3.47 (s, 3H), 2.41 (s, 3H), 1.52 (d, J = 6.6 Hz, 3H).
820	(ES+) 561.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.98 (s, 1H), 7.64 (s, 1H), 7.30 – 7.00 (m, 2H), 6.65 (d, J = 8.6 Hz, 1H), 5.80 (d, J = 6.5 Hz, 1H), 5.48 – 5.39 (m, 1H), 5.33 – 5.19 (m, 1H), 4.34 – 4.19 (m, 2H), 4.07 – 4.01 (m, 1H), 4.01 – 3.93 (m, 1H), 3.78 – 3.65 (m, 2H), 3.54 (s, 3H), 3.21 – 3.02 (m, 6H), 2.32 (s, 3H), 2.27 (s, 3H), 1.54 (d, J = 6.5 Hz, 3H).

821	(ES+) 572.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.02 (s, 1H), 7.56 (d, J = 1.6 Hz, 1H), 7.08 (d, J = 8.8 Hz, 1H), 6.81 (d, J = 8.4 Hz, 1H), 6.54 (s, 1H), 5.20 - 5.12 (m, 1H), 4.25 - 4.20 (m, 1H), 3.76 - 3.73 (m, 5H), 3.36 - 3.33 (m, 1H), 3.26 - 3.12 (m, 2H), 3.02 - 2.94 (m, 1H), 2.60 (s, 3H), 2.39 (s, 3H), 2.35 (s, 3H), 1.66 (s, 3H), 1.64 (s, 3H).
822	(ES+) 558.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.14 (s, 1H), 7.44 (d, J = 1.2 Hz, 1H), 6.94 (d, J = 8.8 Hz, 1H), 6.60 (d, J = 8.4 Hz, 1H), 6.22 (s, 1H), 4.89 - 4.85 (m, 1H), 4.78 - 4.70 (m, 1H), 4.15 - 3.89 (m, 2H), 3.66 (s, 3H), 3.64 - 3.48 (m, 2H), 3.45 - 3.20 (m, 2H), 3.15 - 2.90 (m, 2H), 2.63 (s, 3H), 2.40 (s, 3H), 2.39 (s, 3H) 1.62 (d, J = 6.4 Hz, 3H).
823	(ES+) 548.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 7.97 - 7.96 (m, 1H), 7.60 - 7.58 (m, 1H), 7.44 - 7.43 (m, 1H), 7.07 (d, J = 7.2 Hz, 1H), 6.89 - 6.88 (m, 2H), 6.71 (t, J = 54.8 Hz, 1H), 6.47 (d, J = 8.4 Hz, 1H), 6.24 (s, 1H), 4.95 (d, J = 1.2 Hz, 1H), 4.92 - 4.82 (m, 1H), 4.59 - 4.11 (m, 2H), 3.70 (s, 3H), 3.38 - 2.83 (m, 6H), 2.38 (s, 3H), 1.64 (d, J = 6.8 Hz, 3H).
824	(ES+) 580.2 [M+H]	
825	(ES+) 518.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 7.98 - 7.96 (m, 1H), 7.39 - 7.38 (m, 1H), 7.16 - 7.15 (m, 1H), 7.07 (s, 1H), 7.06 - 7.04 (m, 1H), 6.21 (s, 1H), 6.14 - 6.12 (m, 1H), 4.97 - 4.87 (m, 1H), 4.83 (d, J = 4.4 Hz, 1H), 3.81 (s, 3H), 3.67 (s, 3H), 3.30 - 2.80 (m, 8H), 2.25 (s, 3H), 1.68 (d, J = 6.8 Hz, 3H).
826	(ES+) 597.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.12 (s, 1H), 7.45 (d, J = 1.6 Hz, 1H), 6.95 (d, J = 8.8 Hz, 1H), 6.59 (d, J = 8.4 Hz, 1H), 6.21 (s, 1H), 5.40 - 5.17 (m, 1H), 4.93 - 4.81 (m, 1H), 4.70 (d, J = 1.6 Hz, 1H), 4.23 - 4.07 (m, 4H), 3.91 - 3.64 (m, 2H), 3.63 (s, 3H), 3.30 - 3.01 (m, 4H), 3.00 - 2.76 (m, 2H), 2.42 (s, 3H), 2.39 (s, 3H), 1.63 (d, J = 6.8 Hz, 3H).
827	(ES+) 583.3 [M+Na]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.12 (s, 1H), 7.44 (s, 1H), 6.94 (d, J = 8.8 Hz, 1H), 6.57 (d, J = 8.4 Hz, 1H), 6.18 (s, 1H), 5.45 - 5.16 (m, 1H), 4.94 - 4.81 (m, 1H), 4.71 (br s, 1H), 4.36 - 4.23 (m, 2H), 4.22 - 4.08 (m, 2H), 4.01 - 3.81 (m, 2H), 3.65 (s, 3H), 3.31 - 2.98 (m, 4H), 2.91 - 2.61 (m, 2H), 2.40 (d, J = 12.0 Hz, 6H), 1.62 (d, J = 6.8 Hz, 3H).
828	(ES+) 579.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.18 (s, 1H), 7.60 (s, 1H), 6.94 (d, J = 8.8 Hz, 1H), 6.62 (d, J = 8.8 Hz, 1H), 5.47 - 5.17 (m, 2H), 4.84 - 4.66 (m, 1H), 4.39 - 4.23 (m, 2H), 4.22 - 4.05 (m, 2H), 3.97 - 3.81 (m, 2H), 3.65 (s, 3H), 3.42 - 3.31 (m, 2H), 3.23 - 2.99 (m, 4H), 2.40 (d, J = 12.0 Hz, 6H), 1.61 - 1.60 (m, 3H).
829	(ES+) 631.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.36 (s, 1H), 7.98 - 7.97 (m, 1H), 7.87 - 7.85 (m, 1H), 7.40 - 7.39 (m, 1H), 6.96 (d, J = 8.8 Hz, 1H), 6.53 (d, J = 8.4 Hz, 1H), 6.23 (s, 1H), 4.97 - 4.83 (m, 1H), 4.73 (br s, 1H), 3.91 - 3.59 (m, 5H), 3.44 - 2.89 (m, 6H), 2.68 (s, 3H), 2.42 (s, 3H), 1.86 (d, J = 13.2 Hz, 6H), 1.66 (d, J = 6.8 Hz, 3H).

830	(ES+) 575.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 7.98 - 7.95 (m, 1H), 7.69 (d, J = 2.8 Hz, 1H), 7.43 - 7.41 (m, 1H), 7.22 - 4.20 (m, 1H), 6.90 - 6.89 (m, 1H), 6.23 (s, 1H), 6.17 - 6.16 (m, 1H), 6.03 (d, J = 2.8 Hz, 1H), 4.92 - 4.84 (m, 1H), 4.59 (s, 1H), 3.87 - 3.69 (m, 5H), 3.68 (s, 3H), 3.39 - 2.88 (m, 6H), 1.63 (d, J = 6.4 Hz, 3H).
831	(ES+) 593.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.05 - 8.03 (m, 1H), 7.69 (d, J = 2.8 Hz, 1H), 7.61 - 7.59 (m, 1H), 7.22 - 7.21 (m, 1H), 6.93 - 6.87 (m, 1H), 6.23 - 6.21 (m, 1H), 6.03 (d, J = 2.8 Hz, 1H), 5.36 - 5.14 (m, 1H), 4.63 (s, 1H), 3.78 - 3.75 (m, 2H), 3.73 (s, 3H), 3.68 (s, 3H), 3.60 - 3.51 (m, 2H), 3.27 - 3.17 (m, 4H), 1.59 (d, J = 6.4 Hz, 3H).
832	(ES+) 575.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.27 (s, 2H), 8.02 (s, 1H), 7.72 (d, J = 8.0 Hz, 1H), 7.62 - 7.52 (m, 2H), 7.20 - 7.09 (m, 2H), 6.86 (d, J = 8.8 Hz, 1H), 5.60 (d, J = 6.0 Hz, 1H), 5.37 - 5.24 (m, 1H), 3.47 (s, 3H), 2.68 (s, 3H), 2.48 (s, 3H), 2.38 (s, 3H), 2.28 (s, 3H), 1.56 (d, J = 6.4 Hz, 3H).
833	(ES+) 542.3 [M+H]	
834	(ES+) 562.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.33 (s, 2H), 8.21 (s, 1H), 8.02 (s, 1H), 7.78 (s, 1H), 7.60 (d, J = 1.8 Hz, 1H), 7.18 (s, 1H), 7.13 (d, J = 8.6 Hz, 1H), 6.85 (d, J = 8.7 Hz, 1H), 5.61 (d, J = 6.4 Hz, 1H), 5.31-5.28 (m, 1H), 3.62 (s, 3H), 3.47 (s, 3H), 2.39 (s, 3H), 2.28 (s, 3H), 1.56 (d, J = 6.6 Hz, 3H).
835	(ES+) 576.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.30 (s, 2H), 8.02 (s, 1H), 7.68 (s, 1H), 7.60 (d, J = 1.8 Hz, 1H), 7.19 – 7.09 (m, 2H), 6.85 (d, J = 8.7 Hz, 1H), 5.59 (d, J = 6.5 Hz, 1H), 5.33-5.24 (m, 1H), 3.64 (s, 3H), 3.47 (s, 3H), 2.42 (s, 3H), 2.39 (s, 3H), 2.28 (s, 3H), 1.56 (d, J = 6.6 Hz, 3H).
836	(ES+) 570.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.00 (s, 1H), 7.67 (s, 1H), 7.14 (d, J = 8.6 Hz, 1H), 6.79 (s, 1H), 5.60 (s, 1H), 5.29 – 5.22 (m, 1H), 4.11 (s, 1H), 3.59 (s, 3H), 3.44 – 3.40 (m, 3H), 3.25 – 3.08 (m, 3H), 3.04 (s, 3H), 2.32 (d, J = 17.5 Hz, 6H), 1.59 (d, J = 6.5 Hz, 3H), 1.43 (d, J = 6.7 Hz, 3H).
837	(ES+) 528.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.14 (s, 1H), 7.43 (s, 1H), 6.96 (d, J = 8.4 Hz, 1H), 6.57 (d, J = 8.8 Hz, 1H), 6.19 (s, 1H), 4.88 - 4.80 (m, 1H), 4.73 - 4.63 (m, 2H), 4.70 - 4.20 (m, 1H), 3.67 (s, 3H), 3.65 - 2.60 (m, 6H), 2.41 (s, 3H), 2.38 (s, 3H), 1.85 – 1.74 (m, 1H), 1.62 (d, J = 6.8 Hz, 3H), 1.12 – 0.95 (m, 2H), 0.90 – 0.80 (m, 2H).
838	(ES+) 577.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 9.23 (s, 1H), 8.03 (d, J = 1.6 Hz, 1H), 7.60 – 7.47 (m, 3H), 7.09 (d, J = 8.6 Hz, 1H), 6.83 (d, J = 8.7 Hz, 1H), 6.72 – 6.63 (m, 2H), 5.25 – 5.20 (m, 1H), 3.73 (s, 3H), 3.60 – 3.30 (m, 8H), 2.40 (s, 3H), 2.36 (s, 3H), 1.69 (d, J = 6.7 Hz, 3H).
839	(ES+) 566.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 7.98 - 7.97 (m, 1H), 7.60 - 7.58 (m, 1H), 7.40 - 7.38 (m, 1H), 7.07 (d, J = 7.2 Hz, 1H), 6.93 - 6.91 (m, 2H), 6.52 (d, J = 8.8 Hz, 1H), 6.20 (s, 1H), 4.95 - 4.82 (m, 1H), 4.71 (br s, 1H), 4.63 - 3.86 (m, 2H), 3.70 (s, 3H), 3.49 - 2.80 (m, 6H), 2.42 (s, 3H), 1.65 (d, J = 6.8 Hz, 3H).

840	(ES+) 560.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.11 (s, 2H), 8.84 (d, J = 8.0 Hz, 1H), 8.14 - 8.06 (m, 2H), 7.91 (d, J = 7.6 Hz, 1H), 7.50 - 7.49 (m, 1H), 6.95 (d, J = 8.4 Hz, 1H), 6.72 (s, 1H), 6.52 (d, J = 8.4 Hz, 1H), 4.99 - 4.89 (m, 1H), 4.72 (br s, 1H), 3.55 (s, 3H), 2.43 (s, 3H), 1.66 (d, J = 6.8 Hz, 3H).
841	(ES+) 627.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.36 (s, 1H), 8.13 (s, 1H), 7.86 - 7.84 (m, 1H), 7.45 (d, J = 1.6 Hz, 1H), 6.95 (d, J = 8.4 Hz, 1H), 6.60 (d, J = 8.8 Hz, 1H), 6.25 (s, 1H), 4.96 - 4.85 (m, 1H), 4.73 (br s, 1H), 3.67 - 3.65 (m, 5H), 3.39 - 2.95 (m, 6H), 2.68 (s, 3H), 2.42 (s, 3H), 2.39 (s, 3H), 1.87 (s, 3H), 1.84 (s, 3H), 1.68 - 1.66 (m, 3H).
842	(ES+) 576.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.04 (s, 2H), 8.38 (s, 1H), 8.25 (s, 1H), 7.56 (s, 1H), 6.93 (d, J = 8.8 Hz, 1H), 6.73 (s, 1H), 6.56 (d, J = 8.8 Hz, 1H), 4.95 - 4.92 (m, 1H), 4.73 (br s, 1H), 3.89 (s, 3H), 3.56 (s, 3H), 2.62 (s, 3H), 2.46 (s, 3H), 2.42 (s, 3H), 1.65 (d, J = 6.4 Hz, 3H).
843	(ES+) 585.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.46 (s, 2H), 8.20 (s, 1H), 7.50 (d, J = 1.6 Hz, 1H), 6.92 (d, J = 8.4 Hz, 1H), 6.60 (s, 1H), 6.55 (d, J = 8.4Hz, 1H), 4.93-4.90 (m, 1H), 4.73 (br d, J = 2.1 Hz, 1H), 4.49 - 4.34 (m, 2H), 4.18 - 4.03 (m, 2H), 3.53 (s, 3H), 2.43 (s, 3H), 2.41 (s, 3H), 2.18 - 2.05 (m, 2H), 1.94 - 1.92 (m, 2H), 1.64 (d, J = 9.4 Hz, 3H), 1.62 (d, J = 3.3 Hz, 3H).
844	(ES+) 561.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.09 - 8.91 (s, 2H), 8.24 (s, 1H), 7.89 - 7.42 (m, 3H), 7.25 - 7.00 (m, 1H), 6.94 (d, J = 8.4 Hz, 1H), 6.76 - 6.66 (m, 1H), 6.56 (d, J = 8.8 Hz, 1H), 5.07 - 4.85 (m, 1H), 4.72 (s, 1H), 3.94 - 3.40 (m, 6H), 2.46 (s, 3H), 2.42 (s, 3H), 1.63 (d, J = 6.4 Hz, 3H).
845	(ES+) 575.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.25 (s, 2H), 8.01 (s, 1H), 7.70 - 7.68 (m, 1H), 7.59 (s, 1H), 7.16 (s, 1H), 7.13 - 7.11 (m, 1H), 6.86 - 6.84 (m, 1H), 6.61 - 6.59 (m, 1H), 5.60 - 5.68 (m, 1H), 5.30 - 5.27 (m, 1H), 3.51 (s, 3H), 3.45 (s, 3H), 2.38 (s, 3H), 2.27 (d, J = 3.6 Hz, 6H), 1.55 (d, J = 6.8 Hz, 3H).
846	(ES+) 565.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.13 (s, 1H), 7.45 (d, J = 1.6 Hz, 1H), 7.03 (s, 1H), 6.96 (d, J = 8.8 Hz, 1H), 6.60 (d, J = 8.8 Hz, 1H), 6.24 (s, 1H), 4.93 - 4.90 (m, 1H), 4.72 (br s, 1H), 3.92 (s, 3H), 3.65 (s, 3H), 3.63 - 3.36 (m, 2H), 3.27 - 2.96 (m, 6H), 2.41 (d, J = 10.4 Hz, 6H), 1.65 (d, J = 6.8 Hz, 3H).
847	(ES+) 576.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.52 (s, 2H), 8.21 (s, 2H), 7.50 (s, 1H), 6.92 (d, J = 8.4 Hz, 1H), 6.60 (s, 1H), 6.55 (d, J = 8.4 Hz, 1H), 5.32 (s, 2H), 4.91 - 4.87 (m, 1H), 4.72 (s, 1H), 4.45 - 4.39 (m, 2H), 4.27- 4.19 (m, 2H), 3.51 (s, 3H), 2.42 (d, J = 9.6 Hz, 6H), 1.62 (d, J = 6.4 Hz, 3H).
848	(ES+) 566.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.47 (s, 2H), 8.20 (s, 1H), 7.50 (d, J = 1.2 Hz, 1H), 6.92 (d, J = 8.8 Hz, 1H), 6.63 - 6.50 (m, 2H), 4.97 - 4.84 (m, 1H), 4.73 (br s, 1H), 4.51 (s, 2H), 4.18 (m, 2H), 3.58 - 3.44 (m, 5H), 3.07 (s, 3H), 2.50 - 2.35 (m, 6H), 1.60 (s, 3H).
849	(ES+) 526.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.47 (s, 2H), 8.22 (s, 1H), 7.51 (s, 1H), 7.14 (m, 1H), 6.94 (m, 1H), 6.56 (s, 1H), 6.16 (m, 1H), 4.98 - 4.87 (m, 1H), 4.82 (d, J = 4.8 Hz, 1H), 4.51 (s, 2H), 4.18 (m, 2H), 3.54 - 3.47 (m, 5H), 3.07 (s, 3H), 2.45 (s, 3H), 1.63 (d, J = 6.8 Hz, 3H).

850	(ES+) 580.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.65 (s, 2H), 7.97 (s, 1H), 7.54 (d, J = 1.2 Hz, 1H), 7.12 (d, J = 8.8 Hz, 1H), 6.94 (s, 1H), 6.83 (d, J = 8.8 Hz, 1H), 5.55 (d, J = 6.2 Hz, 1H), 5.24 - 5.22 (m, 1H), 3.91 - 3.85 (m, 2H), 3.84 - 3.78 (m, 2H), 3.59 - 3.54 (m, 4H), 3.42 (s, 3H), 2.36 (s, 3H), 2.28 (s, 3H), 2.07 (s, 3H), 1.53 (d, J = 6.6 Hz, 3H).
851	(ES+) 546.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.99 (s, 1H), 7.64 (s, 1H), 7.25 (t, J = 53.8 Hz, 1H), 7.07 – 6.97 (m, 1H), 6.65 (d, J = 8.3 Hz, 1H), 5.80 (d, J = 6.5 Hz, 1H), 5.27 – 5.19 (m, 1H), 4.26 (d, J = 12.2 Hz, 2H), 3.57 (s, 3H), 3.30 – 3.06 (m, 6H), 2.33 (s, 3H), 2.27 (s, 3H), 1.54 (d, J = 6.5 Hz, 3H), 1.38 – 1.16 (m, 4H).
852	(ES+) 546.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.21 (s, 1H), 7.59 (s, 1H), 7.00 – 6.94 (m, 1H), 6.66 (d, J = 8.8 Hz, 1H), 5.30 – 5.26 (m, 1H), 4.90 – 4.68 (m, 1H), 4.65 – 3.90 (m, 2H), 3.67 (s, 3H), 3.50 – 3.31 (m, 3H), 3.29 – 3.00 (m, 2H), 2.43 (s, 3H), 2.39 (s, 3H), 1.85 – 1.75 (m, 2H), 1.63 (d, J = 6.4 Hz, 3H), 1.12 – 1.01 (m, 2H), 0.91 – 0.80 (m, 2H).
853	(ES+) 577.3 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.92 (s, 1H), 8.32 (d, J = 7.6 Hz, 1H), 8.03 (s, 1H), 7.56 (s, 1H), 7.09 - 7.04 (m, 2H), 6.86 - 6.79 (m, 2H), 6.56 (s, 1H), 5.22 - 5.13 (m, 1H), 4.00 - 3.90 (m, 2H), 3.73 (s, 3H), 3.50 - 3.00 (m, 5H), 2.43 (s, 3H), 2.39 (s, 3H), 1.66 (d, J = 6.4 Hz, 3H).
854	(ES+) 494.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.19 (s, 1H), 7.59 (s, 1H), 7.14 - 7.12 (m, 1H), 6.96 - 6.93 (m, 1H), 6.25 - 6.23 (m, 1H), 5.36 - 5.25 (m, 1H), 4.90-4.80 (m, 1H), 4.74 - 4.66 (m, 4H), 3.65 - 3.60 (m, 4H), 3.57 - 3.49 (m, 2H), 3.14 - 3.04 (m, 2H), 2.79 (d, J = 10.4 Hz, 2H), 2.41 (s, 3H), 2.28 - 2.20 (m, 2H), 1.62 (d, J = 6.4 Hz, 3H).
855	(ES+) 615.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.18 (s, 1H), 7.61 (s, 1H), 6.95 (d, J = 8.8 Hz, 1H), 6.63 (d, J = 8.8 Hz, 1H), 5.42 - 5.17 (m, 2H), 4.82 - 4.68 (m, 1H), 4.26 - 4.06 (m, 4H), 3.79 - 3.64 (m, 2H), 3.63 (s, 3H), 3.52 - 3.42 (m, 2H), 3.22 - 3.04 (m, 4H), 2.42 (s, 3H), 2.39 (s, 3H), 1.60 (br d, J = 6.4 Hz, 3H).
856	(ES+) 589.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.53 (s, 2H), 8.21 (s, 2H), 7.53 - 7.52 (m, 1H), 7.47 (d, J = 1.6 Hz, 1H), 7.01 - 6.93 (m, 1H), 6.60 (s, 1H), 6.52 (d, J = 5.2 Hz, 1H), 6.26 - 6.24 (m, 1H), 5.32 (s, 2H), 4.92 - 4.89 (m, 1H), 4.42 - 4.41 (m, 2H), 4.27 - 4.20 (m, 2H), 3.52 (s, 3H), 3.16 (s, 3H), 2.44 (s, 3H), 1.62 (d, J = 6.8 Hz, 3H).
857	(ES+) 536.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.53 (s, 2H), 8.22 (s, 2H), 7.51 (s, 1H), 7.14 - 7.12 (m, 1H), 6.94 - 6.92 (m, 1H), 6.58 (s, 1H), 6.17 - 6.14 (m, 1H), 5.32 (s, 2H), 4.95 - 4.88 (m, 1H), 4.82 (d, J = 4.4 Hz, 1H), 4.45 - 4.39 (m, 2H), 4.23 (t, J = 5.2 Hz, 2H), 3.52 (s, 3H), 2.46 (s, 3H), 1.63 (d, J = 6.8 Hz, 3H).
858	(ES+) 599.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.04 (m, 1H), 7.54 (m, 2H), 7.08 - 6.94 (m, 1H), 6.57 (m, 1H), 6.29 (m, 1H), 5.36 - 5.21 (m, 1H), 3.85 (m, 2H), 3.66 (s, 3H), 3.53 (m, 2H), 3.24 - 3.13 (m, 7H), 2.42 - 2.27 (m, 1H), 1.71 - 1.52 (br d, J = 6.4 Hz, 3H), 1.28 - 1.23 (m, 2H), 1.11 - 1.04 (m, 2H).

859	(ES+) 589.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.06 (s, 2H), 8.38 (s, 1H), 8.25 (s, 1H), 7.58 - 7.48 (m, 2H), 6.97 - 6.95 (m, 1H), 6.71 (s, 1H), 6.56 (d, J = 5.2 Hz, 1H), 6.26 - 6.24 (m, 1H), 4.97 - 4.91 (m, 1H), 3.89 (s, 3H), 3.56 (s, 3H), 3.16 (s, 3H), 2.62 (s, 3H), 2.47 (s, 3H), 1.65 (d, J = 6.7 Hz, 3H).
860	(ES+) 536.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.05 (s, 2H), 8.38 (s, 1H), 8.26 (s, 1H), 7.56 (s, 1H), 7.20 - 7.10 (m, 1H), 7.00 - 6.89 (m, 1H), 6.70 (s, 1H), 6.18 - 6.16 (m, 1H), 5.01 - 4.90 (m, 1H), 4.86 - 4.80 (m, 1H), 3.89 (s, 3H), 3.56 (s, 3H), 2.62 (s, 3H), 2.48 (s, 3H), 1.75 - 1.55 (m, 3H).
861	(ES+) 543.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.05 (s, 2H), 8.41 - 8.40 (m, 1H), 8.11 - 8.09 (m, 1H), 7.75 - 7.53 (m, 1H), 7.52 - 7.51 (m, 1H), 7.18 - 7.16 (m, 1H), 7.05 - 6.91 (m, 1H), 6.70 (s, 1H), 6.13 - 6.11 (m, 1H), 5.07 - 4.90 (m, 1H), 4.84 (d, J = 4.4 Hz, 1H), 3.57 (s, 3H), 2.83 (s, 3H), 1.69 (d, J = 6.8 Hz, 3H).
862	(ES+) 546.2 [M+H]	^{1}H NMR (400 MHz, CDCl3): δ 8.09 - 8.02 (m, 1H), 7.58 - 7.56 (m, 1H), 7.17 - 7.15 (m, 1H), 7.02 - 6.93 (m, 1H), 6.20 - 6.18 (m, 1H), 5.35 - 5.23 (m, 1H), 4.91 - 4.79 (m, 1H), 3.88 - 3.81 (m, 2H), 3.66 (s, 3H), 3.57 - 3.48 (m, 2H), 3.23 - 3.13 (m, 4H), 2.41 - 2.30 (m, 1H), 1.64 (d, J = 6.4 Hz, 3H), 1.28 - 1.23 (m, 2H), 1.11 - 1.04 (m, 2H).
863	(ES+) 546.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.21 (s, 1H), 7.69 (d, J = 2.8 Hz, 1H), 7.61 (s, 1H), 7.14 - 7.13 (m, 1H), 7.00 - 6.92 (m, 1H), 6.24 - 6.21 (m, 1H), 6.03 (d, J = 2.8 Hz, 1H), 5.35 - 5.19 (m, 1H), 4.87 (br s, 1H), 3.79 - 3.74 (m, 2H), 3.73 (s, 3H), 3.67 (s, 3H), 3.54 - 3.51 (m, 2H), 3.26 - 3.17 (m, 4H), 2.42 (s, 3H), 1.62 (br s, 3H).
864	(ES+) 589.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.12 - 7.98 (m, 1H), 7.79 (d, J = 2.4 Hz, 1H), 7.50 - 7.48 (m, 1H), 7.19 - 7.18 (m, 1H), 6.75 (br d, J = 4.4 Hz, 1H), 6.28 (d, J = 8.8 Hz, 1H), 5.38 - 5.24 (m, 1H), 3.91-3.79 (m, 2H), 3.65 (s, 3H), 3.55 - 3.51 (m, 2H), 3.26 - 3.18 (m, 2H), 3.17 (s, 3H), 3.09 - 3.02 (m, 2H), 2.90 (s, 3H), 1.63 (d, J = 6.4 Hz, 3H).
865	(ES+) 547.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 7.96 - 7.94 (m, 1H), 7.41 - 7.40 (m, 1H), 7.35 (s, 1H), 7.22 - 7.20 (m, 1H), 6.95 - 6.86 (m, 1H), 6.26 (s, 1H), 6.19 - 6.18 (m, 1H), 5.00 - 4.83 (m, 1H), 4.61 (br s, 1H), 3.68 (s, 3H), 3.23 - 2.97 (m, 8H), 2.30 (s, 3H), 1.64 (d, J = 6.8 Hz, 3H).
866	(ES+) 579.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.03 (s, 2H), 8.80 (d, J = 2.0 Hz, 1H), 8.09 - 8.10 (m, 1H), 8.02 (d, J = 2.0 Hz, 1H), 7.54-7.57 (m, 1H), 7.44-7.47 (m, 1H), 6.95-7.00 (m, 1H), 6.69 (s, 1H), 6.58 (d, J = 4.4 Hz, 1H), 6.17-6.21 (m, 1H), 4.99 - 4.85 (m, 1H), 3.90 (s, 3H), 3.55 (s, 3H), 3.18 (s, 3H), 1.66 (d, J = 6.4 Hz, 3H).
867	(ES+) 560.4 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.11 (s, 1H), 7.73 (d, J = 1.9 Hz, 1H), 7.08 (d, J = 8.6 Hz, 1H), 6.82 (d, J = 8.7 Hz, 1H), 5.42 – 5.30 (m, 1H), 4.48 (d, J = 10.3 Hz, 2H), 3.72 (d, J = 1.3 Hz, 3H), 3.35 (s, 1H), 3.36 – 3.22 (m, 3H), 2.42 – 2.34 (m, 6H), 1.64 (d, J = 6.5 Hz, 3H), 1.38 (d, J = 1.3 Hz, 3H), 1.01 – 0.94 (m, 2H), 0.73 – 0.66 (m, 2H).

868	(ES+) 564.3 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.12 (s, 1H), 7.73 (s, 1H), 7.08 (d, J = 8.6 Hz, 1H), 6.82 (d, J = 8.7 Hz, 1H), 5.44 – 5.37 (m, 1H), 4.46 (d, J = 11.9 Hz, 2H), 3.73 (d, J = 1.2 Hz, 3H), 3.38 (s, 3H), 3.34 – 3.24 (m, 2H), 2.42 – 2.34 (m, 6H), 1.64 (d, J = 6.5 Hz, 3H), 1.41 – 1.27 (m, 4H).
869	(ES+) 559.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.11 (d, J = 2.4 Hz, 1H), 7.73 (d, J = 1.8 Hz, 1H), 7.42 (s, 1H), 7.09 (d, J = 8.6 Hz, 1H), 6.83 (d, J = 8.6 Hz, 1H), 5.20 – 5.10 (m, 1H), 4.02 (s, 3H), 3.81 – 3.45 (m, 5H), 3.31 – 3.00 (m, 6H), 2.39 (s, 3H), 2.38 (s, 3H), 1.65 (d, J = 6.0 Hz, 3H).
870	(ES+) 576.2[M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.19 (s, 1H), 7.60 (s, 1H), 6.97 (d, J = 8.4 Hz, 1H), 6.65 (d, J = 8.4 Hz, 1H), 5.30 – 5.20 (m, 1H), 4.80 – 4.70 (m, 1H), 4.10 – 4.00 (m, 2H), 3.66 (s, 3H), 3.64 – 3.40 (m, 4H), 3.27 – 3.10 (m, 2H), 2.64 (s, 3H), 2.41 (s, 3H), 2.39 (s, 3H), 1.62 (d, J = 6.4 Hz, 3H).
871	(ES+) 579.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.04 (s, 2H), 8.24 (s, 1H), 7.55 (d, J = 1.6 Hz, 1H), 7.24 - 7.23 (m, 1H), 6.96 - 6.88 (m, 2H), 6.71 (s, 1H), 6.56 (d, J = 8.8 Hz, 1H), 5.06 - 4.84 (m, 1H), 4.73 (br s, 1H), 3.69 (s, 3H), 3.55 (s, 3H), 2.46 (s, 3H), 2.41 (s, 3H), 1.64 (d, J = 6.8 Hz, 3H).
872	(ES+) 583.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.19 (s, 1H), 7.61 (d, J = 1.6 Hz, 1H), 7.03 (s, 1H), 6.96 (d, J = 8.4 Hz, 1H), 6.65 (d, J = 8.8 Hz, 1H), 5.40 - 5.23 (m, 1H), 4.85 - 4.69 (m, 1H), 3.92 (s, 3H), 3.68 - 3.61 (m, 5H), 3.53 - 3.50 (m, 2H), 3.21 - 3.10 (m, 2H), 3.05 - 2.95 (m, 2H), 2.42 (s, 3H), 2.39 (s, 3H), 1.61 (d, J = 6.4 Hz, 3H).
873	(ES+) 593.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.06 (s, 2H), 8.38 (s, 1H), 8.08 - 8.06 (m, 1H), 7.54 - 7.52 (m, 1H), 7.46 - 7.45 (m, 1H), 7.02 - 6.93 (m, 1H), 6.71 (s, 1H), 6.57 (d, J = 4.4 Hz, 1H), 6.19 - 6.18 (m, 1H), 5.00 - 4.88 (m, 1H), 3.88 (s, 3H), 3.56 (s, 3H), 3.18 (s, 3H), 2.61 (s, 3H), 1.66 (d, J = 6.8 Hz, 3H).
874	(ES+) 580.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.05 (s, 2H), 8.38 (s, 1H), 8.09 - 8.07 (m, 1H), 7.51 - 7.49 (m, 1H), 6.95 (d, J = 8.8 Hz, 1H), 6.71 (s, 1H), 6.51 (d, J = 8.4 Hz, 1H), 5.02 - 4.88 (m, 1H), 4.73 (br s, 1H), 3.89 (s, 3H), 3.56 (s, 3H), 2.62 (s, 3H), 2.43 (s, 3H), 1.67 (d, J = 6.8 Hz, 3H).
875	(ES+) 540.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.05 (s, 2H), 8.38 (s, 1H), 8.10 - 8.08 (m, 1H), 7.51 - 7.50 (m, 1H), 7.18 - 7.16 (m, 1H), 7.00 - 6.93 (m, 1H), 6.69 (s, 1H), 6.13 - 6.11 (m, 1H), 5.02 - 4.92 (m, 1H), 4.83 (d, J = 4.0 Hz, 1H), 3.89 (s, 3H), 3.56 (s, 3H), 2.62 (s, 3H), 1.68 (d, J = 6.8 Hz, 3H).
876	(ES+) 596.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.06 (s, 2H), 8.41 - 8.40 (m, 1H), 8.11 - 8.10 (m, 1H), 7.76 - 7.75 (m, 1H), 7.56 - 7.55 (m, 1H), 7.47 - 7.46 (m, 1H), 7.09 - 6.93 (m, 1H), 6.71 (s, 1H), 6.60 (d, J = 4.8 Hz, 1H), 6.21 - 6.20 (m, 1H), 5.04 - 4.84 (m, 1H), 3.57 (s, 3H), 3.18 (s, 3H), 2.83 (s, 3H), 1.68 (d, J = 6.8 Hz, 3H).

877	(ES+) 526.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.02 (s, 2H), 8.79 (d, J = 2.0 Hz, 1H), 8.10 - 8.08 (m, 1H), 8.01 (d, J = 2.0 Hz, 1H), 7.51 - 7.50 (m, 1H), 7.18 - 7.16 (m, 1H), 7.01 - 6.90 (m, 1H), 6.68 (s, 1H), 6.12 - 6.10 (m, 1H), 5.01 - 4.90 (m, 1H), 4.84 (d, J = 4.4 Hz, 1H), 3.90 (s, 3H), 3.55 (s, 3H), 1.67 (d, J = 6.6 Hz, 3H).
878	(ES+) 542.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.20 (s, 1H), 7.61 (s, 1H), 6.97 - 6.94 (m, 1H), 7.00 - 6.91 (m, 1H), 6.24 - 6.22 (m, 1H), 5.34 - 5.22 (m, 1H), 4.92 - 4.79 (m, 1H), 3.88 - 3.82 (m, 2H), 3.65 (s, 3H), 3.56 - 3.47 (m, 2H), 3.21 - 3.12 (m, 4H), 2.42 (s, 3H), 2.38 - 2.31 (m, 1H), 1.62 (d, J = 6.4 Hz, 3H), 1.26 - 1.22 (m, 2H), 1.11 - 1.04 (m, 2H).
879	(ES+) 585.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.19 (s, 1H), 7.77 (d, J = 2.8 Hz, 1H), 7.53 (d, J = 1.2 Hz, 1H), 7.17 - 7.16 (m, 1H), 6.75 - 6.69 (m, 1H), 6.32 (d, J = 8.8 Hz, 1H), 5.42 - 5.17 (m, 1H), 3.87 - 3.81 (m, 2H), 3.64 (s, 3H), 3.54 - 3.51 (m, 2H), 3.26 - 3.13 (m, 5H), 3.09 - 3.00 (m, 2H), 2.89 (s, 3H), 2.40 (s, 3H), 1.61 (d, J = 6.4 Hz, 3H).
880	(ES+) 569.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.11 (s, 1H), 7.55 - 7.41 (m, 2H), 7.05- 6.97 (m, 1H), 6.44 - 6.28 (m, 1H), 6.29 (s, 1H), 5.58 - 5.39 (m, 1H), 3.99 - 3.75 (m, 2H), 3.61 (s, 3H), 3.33 - 3.17 (m, 5H), 3.11 - 2.93 (m, 4H), 2.89 (s, 3H), 2.44 (s, 3H), 1.60 (d, J = 6.4 Hz, 3H).
881	(ES+) 586.4 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.19 (s, 1H), 7.69 (d, J = 2.8 Hz, 1H), 7.61 (s, 1H), 6.95 (d, J = 8.8 Hz, 1H), 6.63 (d, J = 8.4 Hz, 1H), 6.02 (d, J = 2.8 Hz, 1H), 5.29 - 5.25 (m, 1H), 4.76 (br s, 1H), 3.80 - 3.74 (m, 2H), 3.73 (s, 3H), 3.67 (s, 3H), 3.54 - 3.50 (m, 2H), 3.25 - 3.16 (m, 4H), 2.42 (s, 3H), 2.39 (s, 3H), 1.60 (br d, J = 6.4 Hz, 3H).
882	(ES+) 532.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.20 (s, 1H), 7.58 (s, 1H), 7.39 (d, J = 2.4 Hz, 1H), 7.15 - 7.13 (m, 1H), 6.24 (d, J = 9.2 Hz, 1H), 5.46 - 5.18 (m, 1H), 5.04 - 4.95 (m, 1H), 3.90 - 3.81 (m, 2H), 3.64 (s, 3H), 3.54 - 3.50 (m, 2H), 3.24 - 3.15 (m, 2H), 3.08 - 3.01 (m, 2H), 2.89 (s, 3H), 2.42 (s, 3H), 1.62 (d, J = 6.4 Hz, 3H).
883	(ES+) 611.3 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.50 – 8.44 (m, 1H), 8.04 – 7.99 (m, 1H), 7.95 – 7.89 (m, 1H), 7.58 (d, J = 1.8 Hz, 1H), 7.04 – 6.95 (m, 1H), 6.83 – 6.76 (m, 2H), 6.57 (s, 1H), 5.19 – 5.09 (m, 1H), 4.05 – 3.65 (m, 5H), 3.44 – 3.35 (m, 1H), 3.30 – 3.17 (m, 5H), 3.21 – 2.96 (m, 3H), 2.81 (s, 3H), 2.39 (s, 3H), 2.37 – 2.32 (m, 3H), 1.68 – 1.62 (m, 3H).
884	(ES+) 589.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.28 (s, 2H), 8.07 – 8.02 (m, 1H), 7.92 (d, J = 2.0 Hz, 1H), 7.69 – 7.62 (m, 1H), 7.62 – 7.53 (m, 2H), 7.16 (s, 1H), 6.78 – 6.70 (m, 1H), 6.58 (d, J = 9.0 Hz, 1H), 6.43 (d, J = 6.6 Hz, 1H), 5.46 – 5.37 (m, 1H), 3.65 (s, 3H), 3.47 (s, 3H), 2.40 (s, 3H), 1.60 (d, J = 6.6 Hz, 3H).

885	(ES+) 586.4 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.33 (s, 2H), 8.33 (s, 1H), 8.15 – 7.95 (m, 1H), 7.94 – 7.90 (m, 1H), 7.71 – 7.62 (m, 1H), 7.60 (d, J = 1.8 Hz, 1H), 7.18 (s, 1H), 6.59 (d, J = 9.0 Hz, 1H), 6.43 (d, J = 6.6 Hz, 1H), 5.47 – 5.40 (m, 1H), 3.76 (s, 3H), 3.47 (s, 3H), 2.45 (s, 3H), 2.41 (s, 3H), 1.60 (d, J = 6.6 Hz, 3H).
886	(ES+) 595.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 9.26 (s, 1H), 8.13 (s, 1H), 7.75 (d, J = 1.9 Hz, 1H), 7.57 – 7.49 (m, 2H), 7.10 (d, J = 8.6 Hz, 1H), 6.84 (d, J = 8.8 Hz, 1H), 6.71 – 6.64 (m, 1H), 5.45 – 5.35 (m, 1H), 3.84 – 3.73 (m, 5H), 3.63 - 3.55 (d, J m, 2H), 2.42 – 2.33 (m, 6H), 1.68 (d, J = 6.5 Hz, 3H).
887	(ES+) 572.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 9.23 (s, 1H), 8.05 (s, 1H), 7.74 (m, 1H), 7.61 (d, J = 1.8 Hz, 1H), 7.55 – 7.45 (m, 2H), 7.32 (m, 1H), 6.80 – 6.76 (m, 1H), 6.71 – 6.63 (m, 2H), 6.57 (d, J = 8.3 Hz, 1H), 5.25 – 5.22 (m, 1H), 3.73 (s, 3H), 3.69 – 3.33 (m, 8H), 3.18 (s, 3H), 2.43 (s, 3H), 1.71 (d, J = 6.7 Hz, 3H).
888	(ES+) 577.4 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.44 (s, 1H), 8.04 (s, 1H), 7.76 – 7.67 (m, 1H), 7.57 (d, J = 1.9 Hz, 1H), 7.52 – 7.42 (m, 1H), 7.10 (d, J = 8.7 Hz, 1H), 6.86 (d, J = 8.7 Hz, 1H), 6.73 (d, J = 7.6 Hz, 1H), 6.61 (s, 1H), 5.25 – 5.16 (m, 1H), 4.30 – 4.01 (m, 2H), 3.74 (s, 3H), 3.38 – 3.29 (m, 6H), 2.40 (s, 3H), 2.33 (s, 3H), 1.68 (d, J = 6.6 Hz, 3H).
889	(ES+) 577.3 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.82 (d, J = 0.7 Hz, 1H), 8.09 – 8.01 (m, 2H), 7.90 (d, J = 1.3 Hz, 1H), 7.70 (s, 1H), 7.58 (d, J = 1.9 Hz, 1H), 7.09 (d, J = 8.7 Hz, 1H), 6.84 (d, J = 8.7 Hz, 1H), 6.65 (s, 1H), 5.25 – 5.16 (m, 1H), 3.75 – 3.52 (m, 6H), 3.50 – 3.31 (m, 5H), 2.43 – 2.25 (m, 6H), 1.68 (d, J = 6.7 Hz, 3H).
890	(ES+) 548.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.05 – 8.00 (m, 1H), 7.55 (d, J = 1.9 Hz, 1H), 7.41 – 7.21 (m, 1H), 7.09 (d, J = 7.5 Hz, 1H), 6.76 (d, J = 8.7 Hz, 1H), 6.54 (s, 1H), 5.32 – 5.09 (m, 1H), 3.89 – 3.75 (m, 2H), 3.68 (s, 3H), 3.47 – 3.33 (m, 2H), 3.24 – 3.12 (m, 2H), 3.00 –2.80 (m, 5H), 2.39 (s, 3H), 1.67 (d, J = 6.7 Hz, 3H).
891	(ES+) 560.1 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 9.69 (d, J = 1.1 Hz, 2H), 9.18 (s, 2H), 8.01 – 7.94 (m, 1H), 7.61 – 7.53 (m, 1H), 7.38 – 7.29 (m, 1H), 7.19 – 7.10 (m, 2H), 6.74 (d, J = 8.7 Hz, 1H), 5.39 – 5.29 (m, 1H), 3.58 (s, 3H), 2.83 (s, 3H), 1.69 (d, J = 6.6 Hz, 3H).
892	(ES+) 583.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.05 (s, 2H), 8.38 (s, 1H), 8.08 - 8.07 (m, 1H), 7.53 - 7.52 (m, 1H), 7.23 - 7.21 (m, 1H), 6.95 - 6.84 (m, 1H), 6.73 (s, 1H), 6.17 - 6.15 (m, 1H), 5.00 - 4.89 (m, 1H), 4.60 (br s, 1H), 3.89 (s, 3H), 3.56 (s, 3H), 2.62 (s, 3H), 1.64 (d, J = 6.8 Hz, 3H).
893	(ES+) 583.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.05 (s, 2H), 8.38 (s, 1H), 8.08 - 8.06 (m, 1H), 7.54 - 7.52 (m, 1H), 7.23 - 6.87 (m, 2H), 6.74 (s, 1H), 5.90 - 5.79 (m, 1H), 5.04 (d, J = 3.2 Hz, 1H), 4.97 - 4.87 (m, 1H), 3.89 (s, 3H), 3.56 (s, 3H), 2.62 (s, 3H), 1.64 (d, J = 6.8 Hz, 3H).

894	(ES+) 558.1 [M+Na]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.06 - 8.04 (m, 1H), 7.54 - 7.52 (m, 1H), 7.42 - 7.41 (m, 1H), 7.16 - 7.14 (m, 1H), 6.19 (d, J = 9.2 Hz, 1H), 5.38 - 5.19 (m, 1H), 4.97 (br s, 1H), 3.89 - 3.80 (m, 2H), 3.65 (s, 3H), 3.60 - 3.49 (m, 2H), 3.19 - 3.16 (m, 2H), 3.05 - 3.01 (m, 2H), 2.90 (s, 3H), 1.64 (d, J = 6.4 Hz, 3H).
895	(ES+) 612.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.56 (d, J = 2.8 Hz, 1H), 8.06 - 8.05 (m, 1H), 7.92 (d, J = 2.8 Hz, 1H), 7.77 (d, J = 0.8 Hz, 1H), 7.55 - 7.52 (m, 2H), 7.49 (d, J = 1.2 Hz, 1H), 7.05 - 6.97 (m, 1H), 6.60 - 6.56 (m, 1H), 6.31 - 6.30 (m, 1H), 5.36 - 5.26 (m, 1H), 3.78 - 3.69 (m, 2H), 3.69 (s, 3H), 3.60 -3.51 (m, 2H), 3.27 - 3.26 (m, 2H), 3.19 (s, 3H), 3.17 - 2.99 (m, 2H), 1.65 (d, J = 6.4 Hz, 3H).
896	(ES+) 522.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.19 (s, 1H), 7.59 (d, J = 0.8 Hz, 1H), 7.14 (m, 1H), 6.96 (m, 1H), 6.25 (m, 1H), 5.36 - 5.22 (m, 1H), 4.86 (br d, J = 2.4 Hz, 1H), 4.46 - 4.31 (m, 2H), 3.95 (m, 1H), 3.70 - 3.51 (m, 5H), 3.41 (m, 2H), 3.30 - 3.11 (m, 2H), 2.41 (s, 3H), 1.99 - 1.83 (m, 4H).
897	(ES+) 520.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.18 (s, 1H), 7.59 (d, J = 1.6 Hz, 1H), 7.13 (m, 1H), 7.02 - 6.92 (m, 1H), 6.28 -6.22 (m, 1H), 5.37 - 5.22 (m, 1H), 4.86 (br d, J = 3.2 Hz, 1H), 4.30 - 4.12 (m, 1H), 3.64 (s, 3H), 3.50 - 3.37 (m, 4H), 3.28 - 3.13 (m, 2H), 2.47 - 2.42 (m, 2H), 2.41 (s, 3H), 2.14 - 2.02 (m, 2H), 1.94 - 1.80 (m, 4H).
898	(ES+) 565.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.13 (s, 2H), 8.23 (s, 1H), 8.06 (d, J = 2.4 Hz, 1H), 7.58 (d, J = 1.2 Hz, 1H), 7.24 - 7.17 (m, 2H), 6.92 - 6.85 (m, 1H), 6.83 (s, 1H), 6.21 - 6.19 (m, 1H), 5.02 - 4.87 (m, 1H), 4.63 - 4.57 (m, 1H), 3.61 (s, 3H), 2.85 (s, 3H), 2.47 (s, 3H), 1.63 (d, J = 6.4 Hz, 3H).
899	(ES+) 522.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.13 (s, 2H), 8.25 (s, 1H), 8.06 (d, J = 2.4 Hz, 1H), 7.57 (s, 1H), 7.19 (d, J = 2.4 Hz, 1H), 7.16 - 7.14 (m, 1H), 6.95 - 6.90 (m, 1H), 6.77 (s, 1H), 6.16 - 6.14 (m, 1H), 5.03 - 4.90 (m, 1H), 4.83 (d, J = 4.4 Hz, 1H), 3.62 (s, 3H), 2.85 (s, 3H), 2.48 (s, 3H), 1.66 (d, J = 6.4 Hz, 3H).
900	(ES+) 468.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.21 (s, 1H), 7.81 (d, J = 2.0 Hz, 1H), 7.55 - 7.52 (m, 1H), 7.23 (s, 1H), 7.15 - 7.14 (m, 1H), 7.09 (d, J = 2.0 Hz, 1H), 7.01 - 6.91 (m, 1H), 6.16 - 6.13 (m, 1H), 5.04 - 4.94 (m, 1H), 4.85 (d, J = 4.4 Hz, 1H), 3.81 (d, J = 7.6 Hz, 6H), 2.46 (s, 3H), 1.68 (d, J = 6.8 Hz, 3H).
901	(ES+) 511.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.20 (s, 1H), 7.80 (d, J = 2.0 Hz, 1H), 7.55 (s, 1H), 7.29 (s, 1H), 7.21 - 7.19 (m, 1H), 7.09 (d, J = 2.0 Hz, 1H), 6.91 - 6.84 (m, 1H), 6.21 - 6.19 (m, 1H), 5.03 - 4.93 (m, 1H), 4.62 (d, J = 2.4 Hz, 1H), 3.81 (d, J = 9.2 Hz, 6H), 2.44 (s, 3H), 1.64 (d, J = 6.4 Hz, 3H).
902	(ES+) 629.3 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.50 – 8.44 (m, 1H), 8.14 – 8.08 (m, 1H), 7.95 – 7.89 (m, 1H), 7.58 (d, J = 1.8 Hz, 1H), 7.04 – 6.95 (m, 1H), 6.87 – 6.76 (m, 2H), 5.42 – 5.35 (m, 1H), 3.90 – 3.81 (m, 2H), 3.72 (s, 3H), 3.65 – 3.55 (m, 2H), 3.30 – 3.17 (m, 5H), 2.81 (s, 3H), 2.39 (s, 3H), 2.37 – 2.32 (m, 3H), 1.68 – 1.62 (m, 3H).

903	(ES+) 595.2 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 8.92 (s, 1H), 8.32 (d, J = 7.7 Hz, 1H), 8.12 (s, 1H), 7.74 (s, 1H), 7.19 – 6.93 (m, 2H), 6.87 – 6.79 (m, 2H), 5.51 – 5.32 (m, 1H), 4.05 – 3.80 (m, 2H), 3.74 (s, 3H), 3.63 – 3.48 (m, 2H), 3.41 – 3.33 (m, 2H), 3.30 –3.26 (m, 2H), 2.39 (s, 3H), 2.32 (s, 3H), 1.65 (d, J = 6.5 Hz, 3H).
904	(ES+) 539.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.02 (s, 2H), 8.10 - 8.08 (m, 1H), 7.52 - 7.50 (m, 1H), 7.32 (d, J = 7.2 Hz, 1H), 7.18 - 7.16 (m, 1H), 6.99 - 6.92 (m, 1H), 6.72 - 6.66 (m, 2H), 6.13 - 6.11 (m, 1H), 5.03 - 4.92 (m, 1H), 4.84 (d, J = 4.4 Hz, 1H), 3.65 (s, 3H), 3.56 (s, 3H), 2.45 (s, 3H), 1.68 (d, J = 6.8 Hz, 3H).
905	(ES+) 526.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.12 (s, 2H), 8.18 - 7.94 (m, 2H), 7.52 - 7.50 (m, 1H), 7.22 - 7.14 (m, 2H), 7.00 - 6.92 (m, 1H), 6.76 (s, 1H), 6.11 - 6.09 (m, 1H), 5.05 - 4.89 (m, 1H), 4.84 (d, J = 4.4 Hz, 1H), 3.62 (s, 3H), 2.85 (s, 3H), 1.68 (d, J = 6.8 Hz, 3H).
906	(ES+) 569.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.13 (s, 2H), 8.12 - 7.99 (m, 2H), 7.55 - 7.53 (m, 1H), 7.20 (d, J = 2.4 Hz, 1H), 7.09 (t, J = 52 Hz, 1H), 6.90 - 6.85 (m, 1H), 6.81 (s, 1H), 5.88 - 5.75 (m, 1H), 5.04 - 5.03 (m, 1H), 4.97 - 4.86 (m, 1H), 3.62 (s, 3H), 2.85 (s, 3H), 1.64 (d, J = 6.8 Hz, 3H).
907	(ES+) 569.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.13 (s, 2H), 8.13 - 8.00 (m, 2H), 7.54 - 7.52 (m, 1H), 7.23 - 7.20 (m, 1H), 7.20 (d, J = 2.4 Hz, 1H), 6.70 - 6.88 (m, 1H), 6.81 (s, 1H), 6.14 - 6.12 (m, 1H), 5.02 - 4.79 (m, 1H), 4.61 - 4.60 (m, 1H), 3.62 (s, 3H), 2.85 (s, 3H), 1.64 (d, J = 6.8 Hz, 3H).
908	(ES+) 570.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.40 (s, 1H), 9.06 (s, 2H), 8.94 (s, 1H), 8.27 (s, 1H), 7.58 (d, J = 1.6 Hz, 1H), 6.95 (d, J = 8.8 Hz, 1H), 6.76 (s, 1H), 6.59 (d, J = 8.4 Hz, 1H), 5.06 - 4.90 (m, 1H), 4.75 - 4.74 (m, 1H), 3.58 (s, 3H), 2.96 (s, 3H), 2.48 (s, 3H), 2.43 (s, 3H), 1.67 (d, J = 6.8 Hz, 3H).
909	(ES+) 599.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.19 (s, 1H), 7.77 (d, J = 2.4 Hz, 1H), 7.53 (d, J = 1.6 Hz, 1H), 7.18 - 7.16 (m, 1H), 6.71 (d, J = 5.6 Hz, 1H), 6.33 (d, J = 9.2 Hz, 1H), 5.37 - 5.25 (m, 1H), 4.37 - 4.21 (m, 1H), 3.79 - 3.66 (m, 5H), 3.53 - 3.37 (m, 2H), 3.16 (s, 4H), 3.00 - 2.94 (m, 4H), 2.40 (s, 3H), 1.53 (d, J = 6.8 Hz, 3H), 1.26 (s, 3H).
910	(ES+) 575.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.98 (s, 2H), 8.24 (s, 1H), 7.56 (d, J = 1.6 Hz, 1H), 7.36 - 7.34 (m, 1H), 6.93 (d, J = 8.8 Hz, 1H), 6.79 - 6.70 (m, 2H), 6.56 (d, J = 8.8 Hz, 1H), 5.01 - 4.88 (m, 1H), 4.73 - 4.72 (m, 1H), 3.76 (s, 3H), 3.55 (s, 3H), 2.46 (s, 3H), 2.41 (s, 3H), 2.27 (s, 3H), 1.65 (d, J = 6.8 Hz, 3H).
911	(ES+) 553.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.10 (s, 1H), 7.43 (s, 1H), 6.96 (d, J = 8.4 Hz, 1H), 6.63 (d, J = 8.4 Hz, 1H), 5.90 (s, 1H), 4.85 - 4.72 (m, 1H), 4.71 - 4.59 (m, 2H), 3.58 (s, 3H), 3.47 - 3.31 (m, 4H), 2.85 (s, 3H), 2.42 (s, 3H), 2.38 (s, 3H), 2.16 - 2.00 (m, 4H), 1.63 (d, J = 6.8 Hz, 3H).

912	(ES+) 513.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.11 (s, 1H), 7.43 (d, J = 1.6 Hz, 1H), 7.14 - 7.12 (m, 1H), 7.03 - 6.88 (m, 1H), 6.27 - 6.25 (m, 1H), 5.91 (s, 1H), 4.92 - 4.72 (m, 2H), 4.67-4.63 (m, 1H), 3.57 (s, 3H), 3.48 - 3.30 (m, 4H), 2.85 (s, 3H), 2.40 (s, 3H), 2.21 - 2.06 (m, 4H), 1.66 (s, 3H).
913	(ES+) 522.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.04 (s, 2H), 8.32 (s, 1H), 8.26 (s, 1H), 7.93 (s, 1H), 7.57 (d, J = 1.6 Hz, 1H), 7.16 - 7.14 (m, 1H), 6.95 - 6.92 (m, 1H), 6.72 (s, 1H), 6.18 - 6.16 (m, 1H), 5.00 - 4.90 (m, 1H), 4.83 - 4.82 (m, 1H), 3.78 (s, 3H), 3.56 (s, 3H), 2.49 (s, 3H), 1.67 (d, J = 6.8 Hz, 3H).
914	(ES+) 589.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.02 (s, 2H), 8.25 (s, 1H), 7.85 (s, 1H), 7.59 - 7.48 (m, 2H), 7.06 - 6.89 (m, 1H), 6.72 (s, 1H), 6.56 (d, J = 4.8 Hz, 1H), 6.30 -6.23 (m, 1H), 4.95 - 4.93 (m, 1H), 3.80 (s, 3H), 3.56 (s, 3H), 3.16 (s, 3H), 2.59 (s, 3H), 2.47 (s, 3H), 1.66 (d, J = 6.8 Hz, 3H).
915	(ES+) 536.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.01 (s, 2H), 8.26 (s, 1H), 7.84 (s, 1H), 7.57 (d, J = 1.2 Hz, 1H), 7.15 - 7.13 (m, 1H), 7.00 - 6.90 (m, 1H), 6.71 (s, 1H), 6.22 - 6.10 (m, 1H), 5.03 - 4.90 (m, 1H), 4.84 - 4.83 (m, 1H), 3.79 (s, 3H), 3.56 (s, 3H), 2.59 (s, 3H), 2.48 (s, 3H), 1.67 - 1.66 (m, 3H).
916	ES+ 595.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.28 (s, 2H), 8.15 (s, 1H), 7.78 (s, 1H), 7.71 (d, J = 7.1 Hz, 1H), 7.23 (s, 1H), 7.16 (d, J = 8.7 Hz, 1H), 6.86 (d, J = 8.7 Hz, 1H), 6.62 (d, J = 7.1 Hz, 1H), 5.79 – 5.78 (m, 1H), 5.39 – 5.29 (m, 1H), 3.53 (s, 3H), 3.48 (s, 3H), 2.29 (s, 3H), 2.27 (s, 3H) 1.58 (d, J = 6.6 Hz, 3H).
917	ES+ 567.1 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 9.29 (s, 1H), 9.20 (s, 2H), 7.97 – 7.95 (m, 1H), 7.61 – 7.58 (m, 1H), 7.40 – 7.10 (m, 2H), 7.10 – 7.00 (m, 1H), 6.14 – 6.08 (m, 1H), 5.25 – 5.20 (m, 1H), 3.58 (s, 3H), 2.92 (s, 3H), 2.77 (s, 3H), 1.64 (d, J = 6.8 Hz, 3H).
918	ES+ 548.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.94 – 7.88 (m, 2H), 7.61 – 7.58 (m, 2H), 7.18 (d, J = 6.6 Hz, 1H), 6.55 (d, J = 9.1 Hz, 1H), 6.45 (s, 1H), 5.29 – 5.26 (m, 1H), 3.53 (s, 3H), 3.32 – 2.89 (m, 11H), 2.36 (s, 3H), 1.60 (d, J = 6.7 Hz, 3H).
919	ES+ 530.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.89 (s, 1H), 7.71 (s, 1H), 7.59 (s, 1H), 7.47 – 7.45 (m, 1H), 6.97 – 6.91 (m, 1H), 6.90 – 6.66 (m, 1H), 6.52 (d, J = 9.0 Hz, 1H), 6.46 (s, 1H), 5.26 – 5.23 (m, 1H), 3.53 (s, 3H), 3.32 – 2.89 (m, 11H), 2.35 (s, 3H), 1.59 (d, J = 6.7 Hz, 3H).
920	ES+ 534.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.01 (s, 1H), 7.73 (s, 1H), 7.45 – 7.40 (m, 1H), 6.99 – 6.92 (m, 1H), 6.17 – 6.15 (m, 1H), 5.30 – 5.28 (m, 1H), 3.65 – 3.57 (m, 2H), 3.54 (s, 3H), 3.30 – 3.18 (m, 4H), 3.15 – 3.00 (m, 2H), 2.97 (s, 3H), 2.37 (s, 3H), 1.57 (d, J = 6.4 Hz, 3H).
921	(ES+) 596.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.17 (s, 1H), 7.59 (s, 1H), 6.95 (d, J = 8.4 Hz, 1H), 6.64 (d, J = 8.4 Hz, 1H), 5.29 - 5.28 (m, 1H), 4.79 - 4.69 (m, 1H), 3.69 - 3.61 (m, 4H), 3.43 - 3.35 (m, 4H), 3.26 - 3.17 (m, 4H), 2.43 - 2.37 (m, 8H), 2.08 - 2.06 (m, 2H), 1.99 - 1.89 (m, 2H), 1.60 (d, J = 6.8 Hz, 3H).

922	(ES+) 599.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.98 (s, 1H), 7.64 (s, 1H), 7.34 (m, 1H), 7.17 (m, 1H), 6.42 - 6.41 (m, 1H), 5.39 (d, J = 6.4 Hz, 1H), 5.32 - 5.13 (m, 1H), 3.51 (s, 3H), 3.43 - 3.40 (m, 2H), 3.30 - 3.12 (m, 7H), 2.32 (s, 3H), 2.28 - 2.18 (m, 2H), 2.01 - 1.80 (m, 4H), 1.56 (d, J = 6.8 Hz, 3H).
923	(ES+) 572.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.19 (s, 1H), 7.55 (s, 1H), 7.38 (s, 1H), 7.17 - 7.12 (m, 1H), 6.24 (d, J = 9.2 Hz, 1H), 5.37 - 5.24 (m, 1H), 5.03 - 4.92 (m, 1H), 3.69 - 3.58 (m, 4H), 3.43 - 3.32 (m, 4H), 3.27 - 3.16 (m, 4H), 2.44 - 2.37 (m, 5H), 2.08 - 2.06 (m, 2H), 1.93 - 1.92 (m, 2H), 1.62 (d, J = 6.8 Hz, 3H).
924	(ES+) 562.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.13 (s, 2H), 8.23 (s, 1H), 8.06 (d, J = 2.0 Hz, 1H), 7.56 (d, J = 1.6 Hz, 1H), 7.19 (d, J = 2.4 Hz, 1H), 6.94 (d, J = 8.4 Hz, 1H), 6.80 (s, 1H), 6.54 (d, J = 8.4 Hz, 1H), 5.03 - 4.88 (m, 1H), 4.73 (br s, 1H), 3.61 (s, 3H), 2.85 (s, 3H), 2.46 (s, 3H), 2.42 (s, 3H), 1.65 (d, J = 6.8 Hz, 3H).
925	(ES+) 560.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.98 (s, 1H), 7.64 (s, 1H), 7.14 (d, J = 8.4 Hz, 1H), 6.89 - 6.66 (m, 1H), 5.59 (d, J = 5.6 Hz, 1H), 5.27 - 5.25 (m, 1H), 3.51 (s, 3H), 3.30 - 3.22 (m, 4H), 3.18 - 3.08 (m, 2H), 2.92 - 2.90 (m, 2H), 2.71 - 2.65 (m, 2H), 2.32 (s, 3H), 2.29 (s, 3H), 1.57 (d, J = 6.8 Hz, 3H).
926	(ES+) 555.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.04 (s, 2H), 8.42 - 8.38 (m, 1H), 8.27 (s, 1H), 7.75 - 7.73 (m, 1H), 7.54 (d, J = 1.2 Hz, 1H), 7.40 (d, J = 2.4 Hz, 1H), 7.14 - 7.12 (m, 1H), 6.69 (s, 1H), 6.18 (d, J = 9.2 Hz, 1H), 5.02 - 4.93 (m, 2H), 3.56 (s, 3H), 2.82 (s, 3H), 2.49 (s, 3H), 1.67 (d, J = 6.8 Hz, 3H).
927	(ES+) 559.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.90 (s, 2H), 8.64 (s, 1H), 8.24 (s, 1H), 7.56 (s, 1H), 6.93 (d, J = 8.4 Hz, 1H), 6.72 (s, 1H), 6.57 (d, J = 8.4 Hz, 1H), 4.96 - 4.86 (m, 1H), 4.72 -4.71 (m, 1H), 3.53 (s, 3H), 2.87 (s, 3H), 2.47 (s, 3H), 2.42 (s, 3H), 1.64 (d, J = 6.8 Hz, 3H).
928	(ES+) 599.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.19 (s, 1H), 7.76 (d, J = 2.4 Hz, 1H), 7.54 (d, J = 1.6 Hz, 1H), 7.16 - 7.14 (m, 1H), 6.72 (d, J = 5.6 Hz, 1H), 6.29 (d, J = 8.8 Hz, 1H), 5.39 - 5.15 (m, 1H), 4.30 - 4.28 (m, 1H), 3.79 - 3.70 (m, 2H), 3.70 (s, 3H), 3.52 - 3.37 (m, 2H), 3.16 (s, 3H), 3.06 - 3.05 (m, 2H), 2.96 (s, 3H), 2.40 (s, 3H), 1.61 (d, J = 6.8 Hz, 3H), 1.55 (d, J = 6.8 Hz, 3H).
929	(ES+) 556.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.98 (s, 1H), 7.72 (s, 1H), 7.47 (m, 1H), 7.19 (m, 1H), 6.56 - 6.26 (m, 2H), 5.26 (m 1H), 3.51 (s, 3H), 3.42 - 3.40 (m, 2H), 3.28 - 3.13 (m, 7H), 2.34 (s, 3H), 2.27 - 2.19 (m, 2H), 1.88 - 1.87 (m, 4H), 1.55 (d, J = 6.8 Hz, 3H).
930	ES+ 516.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.90 (s, 1H), 7.80 – 7.78 (m, 1H), 7.60 (s, 1H), 6.78 (d, J = 6.5 Hz, 1H), 6.50 (s, 1H), 6.49 – 6.40 (m, 1H), 5.22 – 5.10 (m, 1H), 3.70 (s, 3H), 3.30 – 3.00 (m, 8H), 2.98 (s, 3H), 2.44 (s, 3H), 1.55 (d, J = 6.4 Hz, 3H).

931	ES+ 516.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.89 (s, 1H), 7.57 (s, 1H), 7.46 – 7.41 (m, 1H), 6.87 (d, J = 6.5 Hz, 1H), 6.46 (s, 1H), 6.16 – 6.14 (m, 1H), 5.17 – 5.13 (m, 1H), 3.53 (s, 3H), 3.44 – 3.33 (m, 8H), 2.98 (s, 3H), 2.35 (s, 3H), 1.55 (d, J = 6.5 Hz, 3H).
932	(ES+) 551.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.02 (s, 2H), 8.26 (s, 1H), 7.81 (d, J = 8.0 Hz, 1H), 7.54 (d, J = 1.6 Hz, 1H), 7.40 (d, J = 2.4 Hz, 1H), 7.33 (d, J = 8.4 Hz, 1H), 7.14 - 7.12 (m, 1H), 6.68 (s, 1H), 6.18 (d, J = 9.2 Hz, 1H), 5.01 - 4.94 (m, 2H), 3.56 (s, 3H), 2.90 (s, 3H), 2.65 (s, 3H), 2.48 (s, 3H), 1.67 (d, J = 6.4 Hz, 3H).
933	(ES+) 553.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.02 (s, 2H), 8.27 (s, 1H), 7.80 (d, J = 8.0 Hz, 1H), 7.53 (d, J = 1.6 Hz, 1H), 7.33 (d, J = 8.0 Hz, 1H), 7.09 - 6.98 (m, 1H), 6.67 (s, 1H), 5.94 - 5.87 (m, 1H), 5.02 - 4.93 (m, 1H), 4.88 - 4.87 (m, 1H), 3.56 (s, 3H), 2.90 (s, 3H), 2.65 (s, 3H), 2.49 (s, 3H), 1.67 (d, J = 6.4 Hz, 3H).
934	(ES+) 557.2[M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.04 (s, 2H), 8.40 (br s, 1H), 8.27 (s, 1H), 7.75 (d, J = 8.4 Hz, 1H), 7.54 (d, J = 1.2 Hz, 1H), 7.03 - 7.01 (m, 1H), 6.68 (s, 1H), 5.92 - 5.88 (m, 1H), 5.00 - 4.93 (m, 1H), 4.88 (d, J = 4.8 Hz, 1H), 3.56 (s, 3H), 2.83 (s, 3H), 2.49 (s, 3H), 1.67 (d, J = 6.8 Hz, 3H).
935	(ES+) 535.3[M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.02 (s, 2H), 8.26 (s, 1H), 7.81 (d, J = 8.4 Hz, 1H), 7.56 (d, J = 1.2 Hz, 1H), 7.34 (d, J = 8.4 Hz, 1H), 7.20 - 7.13 (m, 1H), 7.00 - 6.91 (m, 1H), 6.70 (s, 1H), 6.22 - 6.13 (m, 1H), 5.02 - 4.92 (m, 1H), 4.84 (d, J = 4.4 Hz, 1H), 3.57 (s, 3H), 2.90 (s, 3H), 2.66 (s, 3H), 2.48 (s, 3H), 1.66 (d, J = 6.8 Hz, 3H).
936	(ES+) 539.2[M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.31 (s, 2H), 8.80 - 8.79 (m, 1H), 8.02 (s, 1H), 7.76 - 7.74 (m, 1H), 7.69 (s, 1H), 7.47 - 7.45 (m, 1H), 7.23 - 7.14 (m, 2H), 6.45 (d, J = 6.4 Hz, 1H), 6.39 - 6.38 (m, 1H), 5.24 - 5.20 (m, 1H), 3.47 (s, 3H), 2.60 (s, 3H), 2.41 (s, 3H), 1.54 (d, J = 6.4 Hz, 3H).
937	(ES+) 520.2[M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.97 (s, 1H), 7.72 (s, 1H), 7.47 - 7.45 (m, 1H), 7.19 - 7.17 (m, 1H), 6.50 - 6.33 (m, 2H), 5.27 - 5.27 (m, 1H), 3.51 (s, 3H), 3.37 - 3.36 (m, 2H), 3.30 - 3.27 (m, 4H), 3.16 - 3.09 (m, 2H), 2.95 - 2.90 (m, 2H), 2.35 (s, 3H), 1.55 (d, J = 6.4 Hz, 3H).
938	(ES+) 521.2[M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.01 (s, 2H), 8.26 (s, 1H), 7.57 (d, J = 1.6 Hz, 1H), 7.46 - 7.44 (m, 1H), 7.15 - 7.13 (m, 1H), 6.99 - 6.90 (m, 1H), 6.84 - 6.74 (m, 2H), 6.71 (s, 1H), 6.18 - 6.17 (m, 1H), 4.97 - 4.96 (m, 1H), 4.83 (d, J = 4.4 Hz, 1H), 3.72 (s, 3H), 3.55 (s, 3H), 2.49 (s, 3H), 1.67 (d, J = 6.8 Hz, 3H).
939	(ES+) 583.1[M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.19 (s, 1H), 7.58 - 7.51 (m, 2H), 6.99 - 6.97 (m, 1H), 6.58 - 6.49 (m, 1H), 6.35 - 6.32 (m, 1H), 5.30 - 5.29 (m, 1H), 4.30 - 4.29 (m, 1H), 3.81 - 3.62 (m, 5H), 3.45 - 3.42 (m, 2H), 3.20 - 3.11 (m, 4H), 3.01 - 2.93 (m, 4H), 2.40 (s, 3H), 1.60 (s, 3H), 1.53 (d, J = 6.8 Hz, 3H).

940	(ES+) 583.1[M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.19 (s, 1H), 7.58 - 7.51 (m, 2H), 7.03 - 6.94 (m, 1H), 6.54 (d, J = 5.6 Hz, 1H), 6.30 - 6.28 (m, 1H), 5.31 - 5.25 (m, 1H), 4.30 (d, J = 4.4 Hz, 1H), 3.79 - 3.70 (m, 2H), 3.70 (s, 3H), 3.55 - 3.38 (m, 2H), 3.17 (s, 3H), 3.13 - 3.01 (m, 2H), 2.96 (s, 3H), 2.39 (s, 3H), 1.61 (d, J = 6.4 Hz, 3H), 1.55 (d, J = 6.8 Hz, 3H).
941	(ES+) 586.2[M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.05 (s, 2H), 8.38 (s, 1H), 8.28 (s, 1H), 7.70 (d, J = 1.6 Hz, 1H), 7.53 (d, J = 1.2 Hz, 1H), 7.41 - 7.40 (m, 1H), 6.67 (s, 1H), 6.31 (d, J = 8.8 Hz, 1H), 5.28 (d, J = 5.2 Hz, 1H), 5.10 - 4.99 (m, 1H), 3.89 (s, 3H), 3.56 (s, 3H), 2.62 (s, 3H), 2.49 (s, 3H), 1.70 (d, J = 6.8 Hz, 3H).
942	(ES+) 552.2[M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.05 (s, 2H), 8.38 (s, 1H), 8.26 (s, 1H), 7.54 (s, 1H), 7.40 (d, J = 2.4 Hz, 1H), 7.14 - 7.12 (m, 1H), 6.68 (s, 1H), 6.17 (d, J = 9.2 Hz, 1H), 5.01 - 4.91 (m, 2H), 3.89 (s, 3H), 3.56 (s, 3H), 2.62 (s, 3H), 2.48 (s, 3H), 1.67 (d, J = 6.0 Hz, 3H).
943	(ES+) 600.4[M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.20 (s, 1H), 7.62 (s, 1H), 7.03 (s, 1H), 6.95 (d, J = 8.4 Hz, 1H), 6.64 (d, J = 8.4 Hz, 1H), 5.41 - 5.17 (m, 1H), 4.78 (br s, 1H), 3.70 - 3.57 (m, 8H), 3.27 - 3.15 (m, 4H), 3.14 - 3.05 (m, 2H), 2.44 (s, 3H), 2.43 - 2.38 (m, 6H), 1.62 (d, J = 6.8 Hz, 3H).
944	(ES+) 586.3[M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.23 (s, 1H), 7.99 (s, 1H), 7.65 (s, 1H), 7.17 (s, 1H), 6.98 (d, J = 8.4 Hz, 1H), 6.67 (d, J = 8.4 Hz, 1H), 5.33 (d, J = 5.2 Hz, 1H), 4.93 - 4.66 (m, 1H), 3.71 (s, 3H), 3.67 - 3.65 (m, 2H), 3.63 (s, 3H), 3.32 - 3.12 (m, 6H), 2.45 (s, 3H), 2.44 (s, 3H), 1.65 (d, J = 6.4 Hz, 3H).
945	(ES+) 560.2[M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.68 (s, 2H), 8.99 (s, 2H), 8.25 (s, 1H), 7.57 - 7.56 (m, 1H), 7.52 (s, 1H), 6.99 - 6.89 (m, 1H), 6.71 (s, 1H), 6.28 - 6.26 (m, 1H), 6.21 - 6.08 (m, 1H), 5.00 - 4.88 (m, 3H), 3.55 (s, 3H), 2.88 (s, 3H), 2.46 (s, 3H), 1.65 (d, J = 6.8 Hz, 3H).
946	ES+ 520.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.19 (s, 1H), 7.49 (s, 1H), 7.10 (s, 1H), 6.94 (d, J = 8.5 Hz, 1H), 6.56 (d, J = 8.5 Hz, 1H), 4.99 – 4.92 (m, 1H), 4.75 – 4.70 (m, 1H), 3.76 (s, 3H), 3.11 (s, 3H), 2.44 (s, 3H), 2.43 (s, 3H), 1.84 (s, 6H), 1.66 (d, J = 6.6 Hz, 3H).
947	(ES+) 624.2[M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.32 (s, 1H), 9.02 (s, 2H), 8.28 (s, 1H), 7.56 (s, 1H), 7.43 (d, J = 8.8 Hz, 1H), 7.26 - 7.24 (m, 1H), 6.74 - 6.70 (m, 2H), 5.00 - 4.89 (m, 1H), 3.56 (s, 3H), 3.43 (s, 3H), 2.93 (s, 3H), 2.82 (s, 3H), 2.49 (s, 3H), 1.71 (d, J = 6.8 Hz, 3H).
948	(ES+) 535.3[M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.26 (s, 2H), 8.03 (s, 1H), 7.72 - 7.67 (m, 2H), 7.48 - 7.46 (m, 1H), 7.22 - 7.15 (m, 2H), 6.61 (d, J = 7.2 Hz, 1H), 6.48 - 6.37 (m, 2H), 5.25 - 5.22 (m, 1H), 3.53 (s, 3H), 3.46 (s, 3H), 2.41 (s, 3H), 2.27 (s, 3H), 1.55 (d, J = 6.8 Hz, 3H).

949	(ES+) 506.3[M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 7.99 (s, 1H), 7.76 - 7.67 (m, 1H), 7.47 - 7.45 (m, 1H), 7.19 - 7.16 (m, 1H), 6.53 - 6.41 (m, 1H), 6.37 - 6.34 (m, 1H), 5.27 - 5.25 (m, 1H), 4.43 - 4.23 (m, 2H), 3.56 (s, 3H), 3.46 - 3.33 (m, 2H), 3.28 - 3.14 (m, 2H), 3.12 - 2.84 (m, 2H), 2.35 (s, 3H), 2.10 - 2.00 (m, 1H), 1.55 (d, J = 6.4 Hz, 3H), 0.79 - 0.70 (m, 4H).
950	(ES+) 520.3[M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.28 (s, 2H), 9.19 (s, 1H), 8.02 (s, 1H), 7.68 (d, J = 1.6 Hz, 1H), 7.47 - 7.45 (m, 1H), 7.16 - 7.15 (m, 2H), 6.51 - 6.32 (m, 2H), 5.24 - 5.22 (m, 1H), 3.47 (s, 3H), 2.82 (s, 3H), 2.68 (s, 3H), 2.41 (s, 3H), 1.54 (d, J = 6.4 Hz, 3H).
951	(ES+) 558.2[M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.68 (s, 2H), 8.99 (s, 2H), 8.25 (s, 1H), 7.62 - 7.60 (m, 1H), 7.53 (s, 1H), 7.38 - 7.27 (m, 1H), 6.98 - 6.90 (m, 1H), 6.72 (s, 1H), 6.23 - 6.21 (m, 1H), 4.94 - 4.88 (m, 1H), 3.55 (s, 3H), 3.23 (s, 3H), 2.88 (s, 3H), 2.46 (s, 3H), 1.63 (d, J = 6.4 Hz, 3H).
952	(ES+) 558.2[M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.68 (s, 2H), 8.99 (s, 2H), 8.24 (s, 1H), 7.61 - 7.59 (m, 1H), 7.52 - 7.46 (m, 1H), 7.42 - 7.28 (m, 1H), 6.99 - 6.88 (m, 1H), 6.71 (s, 1H), 6.23 - 6.21 (m, 1H), 4.99 - 4.89 (m, 1H), 3.55 (s, 3H), 3.21 (s, 3H), 2.88 (s, 3H), 2.46 (s, 3H), 1.64 (d, J = 6.4 Hz, 3H).
953	(ES+) 615.3[M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.46 (s, 2H), 8.20 (s, 1H), 7.50 (d, J = 1.6 Hz, 1H), 6.93 (d, J = 8.4 Hz, 1H), 6.61 (s, 1H), 6.55 (d, J = 8.4 Hz, 1H), 4.98 - 4.87 (m, 1H), 4.82 - 4.68 (m, 3H), 4.26 - 4.13 (m, 2H), 3.76 - 3.63 (m, 2H), 3.53 (s, 3H), 2.42 (d, J = 8.0 Hz, 6H), 2.07 - 1.97 (m, 4H), 1.63 (d, J = 6.4 Hz, 3H), 1.42 (t, J = 7.2 Hz, 3H).
954	(ES+) 615.3[M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.46 (s, 2H), 8.20 (s, 1H), 7.50 (d, J = 1.6 Hz, 1H), 6.92 (d, J = 8.4 Hz, 1H), 6.61 (s, 1H), 6.55 (d, J = 8.4 Hz, 1H), 4.99 - 4.88 (m, 1H), 4.85 - 4.67 (m, 3H), 4.22 - 4.15 (m, 2H), 3.76 - 3.62 (m, 2H), 3.53 (s, 3H), 2.42 (d, J = 8.0 Hz, 6H), 2.08 - 1.96 (m, 4H), 1.63 - 1.61 (m, 3H), 1.42 (t, J = 7.2 Hz, 3H).
955	(ES+) 536.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.05 (d, J = 8.4 Hz, 1H), 7.56 - 7.54 (m, 1H), 7.17 - 7.15 (m, 1H), 7.06 (s, 1H), 6.98 - 6.96 (m, 1H), 6.22 - 6.20 (m, 1H), 5.39 - 5.26 (m, 1H), 4.87 (d, J = 3.2 Hz, 1H), 3.81 (s, 3H), 3.67 (s, 3H), 3.66 - 3.57 (m, 2H), 3.21 - 3.07 (m, 4H), 2.84 - 2.83 (m, 2H), 2.26 (s, 3H), 1.65 (d, J = 6.4 Hz, 3H).
964	(ES+) 536.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.99 (s, 2H), 8.26 (s, 1H), 7.56 (d, J = 1.6 Hz, 1H), 7.35 - 7.33 (m, 1H), 7.15 - 7.13 (m, 1H), 6.95 - 6.90 (m, 1H), 6.76 (d, J = 7.2 Hz, 1H), 6.70 (s, 1H), 6.18 - 6.17 (m, 1H), 4.96 - 4.95 (m, 1H), 4.83 - 4.82 (m, 1H), 3.76 (s, 3H), 3.55 (s, 3H), 2.48 (s, 3H), 2.27 (s, 3H), 1.67 (d, J = 6.8 Hz, 3H).
967	ES+ 551.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.99 (s, 2H), 8.25 (s, 1H), 7.58 - 7.50 (m, 1H), 7.40 (s, 1H), 7.35 (d, J = 7.6 Hz, 1H), 7.13 (d, J = 8.8 Hz, 1H), 6.76 (d, J = 7.2 Hz, 1H), 6.68 (s, 1H), 6.17 (d, J = 8.8 Hz, 1H), 5.04 - 4.89 (m, 2H), 3.76 (s, 3H), 3.55 (s, 3H), 2.48 (s, 3H), 2.27 (s, 3H), 1.67 (d, J = 6.0 Hz, 3H).

986	ES+ 534.3 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 9.25 (s, 1H), 8.93 (d, J = 9.7 Hz, 1H), 8.16 (s, 1H), 7.70 (s, 1H), 7.28 – 7.20 (m, 1H), 7.12 (s, 1H), 7.10 – 7.00 (m, 1H), 6.47 – 6.38 (m, 1H), 5.23 – 5.14 (m, 1H), 3.44 (s, 3H), 2.91 (s, 3H), 2.76 (s, 3H), 2.60 (d, J = 13.2 Hz, 3H), 2.49 (s, 3H), 1.69 – 1.61 (m, 3H).
989	ES+ 550.3 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 9.25 (s, 1H), 8.93 (d, J = 9.1 Hz, 1H), 8.17 (s, 1H), 7.70 (s, 1H), 7.49 – 7.43 (m, 1H), 7.25 – 7.20 (m, 1H), 7.10 (s, 1H), 6.47 – 6.39 (m, 1H), 5.27 – 5.17 (m, 1H), 3.44 (s, 3H), 2.91 (s, 3H), 2.77 (s, 3H), 2.60 (d, J = 11.7 Hz, 3H), 2.50 (s, 3H), 1.70 – 1.62 (m, 3H).
1022	ES+ 539.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.05 (s, 2H), 8.25 (s, 1H), 7.56 (d, J = 1.6 Hz, 1H), 7.24 - 7.23 (m, 1H), 7.15 - 7.13 (m, 1H), 6.99 - 6.92 (m, 1H), 6.91 - 6.90 (m, 1H), 6.69 (s, 1H), 6.17 - 6.16 (m, 1H), 4.98 - 4.91 (m, 1H), 4.84 (d, J = 4.4 Hz, 1H), 3.69 (s, 3H), 3.55 (s, 3H), 2.48 (s, 3H), 1.64 (br s, 3H).
1025	ES+ 555.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.05 (s, 2H), 8.26 (s, 1H), 7.53 (s, 1H), 7.40 (d, J = 2.4 Hz, 1H), 7.24 (d, J = 7.2 Hz, 1H), 7.13 - 7.11 (m, 1H), 6.93 - 6.89 (m, 1H), 6.67 (s, 1H), 6.17 (d, J = 9.2 Hz, 1H), 5.02 - 4.91 (m, 2H), 3.69 (s, 3H), 3.55 (s, 3H), 2.48 (s, 3H), 1.66 (d, J = 6.0 Hz, 3H).
1043	ES+ 611.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.28 (s, 2H), 8.07 (d, J = 7.0 Hz, 1H), 8.03 (s, 1H), 7.60 (s, 1H), 7.32 – 6.95 (m, 3H), 6.86 (d, J = 8.7 Hz, 1H), 6.58 (d, J = 6.9 Hz, 1H), 5.60 (d, J = 6.4 Hz, 1H), 5.35 – 5.24 (m, 1H), 3.56 (s, 3H), 3.46 (s, 3H), 2.39 (s, 3H), 2.28 (s, 3H), 1.56 (d, J = 6.6 Hz, 3H).
1044	ES+ 534.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.01 (s, 1H), 7.81 – 7.76 (m, 1H), 7.73 (s, 1H), 6.90 – 6.70 (m, 1H), 6.37 – 6.32 (m, 1H), 5.30 – 5.24 (m, 1H), 3.56 – 3.54 (m, 2H), 3.53 (s, 3H), 3.32 – 3.19 (m, 4H), 3.07 – 3.05 (m, 2H), 2.97 (s, 3H), 2.38 (s, 3H), 1.57 (d, J = 8.0 Hz, 3H).
1045	ES+ 548.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.01 (s, 1H), 7.77 – 7.70 (m, 2H), 7.51 – 7.43 (m, 1H), 7.05 – 6.95 (m, 1H), 6.95 – 6.67 (m, 1H), 6.51 (d, J = 8.8 Hz, 1H), 5.40 – 5.36 (m, 1H), 3.57 – 3.55 (m, 2H), 3.54 (s, 3H), 3.40 – 3.25 (m, 4H), 3.11 – 3.00 (m, 2H), 2.98 (s, 3H), 2.37 (s, 3H), 1.60 (d, J = 6.6 Hz, 3H).
1046	ES+ 566.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.01 (s, 1H), 7.92 (s, 1H), 7.74 (s, 1H), 7.60 – 7.58 (m, 1H), 7.30 – 7.15 (m, 1H), 6.54 (d, J = 9.0 Hz, 1H), 5.41 – 5.38 (m, 1H), 3.57 – 3.55 (m, 2H), 3.54 (s, 3H), 3.40 – 3.19 (m, 4H), 3.08 – 3.05 (m, 2H), 2.98 (s, 3H), 2.37 (s, 3H), 1.62 (d, J = 6.5 Hz, 3H).
1047	ES+ 579.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.27 (s, 2H), 7.90 – 7.84 (m, 1H), 7.70 (d, J = 7.1 Hz, 1H), 7.64 – 7.59 (m, 1H), 7.23 (s, 1H), 7.15 (d, J = 8.6 Hz, 1H), 6.85 (d, J = 8.7 Hz, 1H), 6.61 (d, J = 7.0 Hz, 1H), 5.76 – 5.75 (m, 1H), 5.40 – 5.34 (m, 1H), 3.52 (s, 3H), 3.47 (s, 3H), 3.33 (s, 3H), 3.27 (s, 3H), 1.58 (d, J = 6.5 Hz, 3H).

1048	ES+ 560.2 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.59 (s, 2H), 9.00 (d, J = 15.0 Hz, 1H), 8.03 (s, 1H), 7.73 – 7.49 (m, 1H), 7.18 – 7.07 (m, 2H), 6.96 – 6.72 (m, 1H), 5.73 – 5.36 (m, 1H), 5.25 – 5.17 (m, 1H), 3.30 (s, 3H), 2.76 (s, 3H), 2.58 – 2.53 (m, 3H), 2.40 (s, 3H), 2.28 (d, J = 5.3 Hz, 3H), 1.66 – 1.31 (m, 3H).
1049	ES+ 520.1 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.58 (s, 2H), 9.00 (d, J = 7.1 Hz, 1H), 8.04 (s, 1H), 7.78 – 7.63 (m, 1H), 7.51 – 7.35 (m, 1H), 7.31 – 7.12 (m, 1H), 7.10 (s, 1H), 6.47 – 6.34 (m, 2H), 5.28 – 5.13 (m, 1H), 3.30 (s, 3H), 2.76 (s, 3H), 2.63 – 2.51 (m, 3H), 2.42 (s, 3H), 1.62 – 1.47 (m, 3H).
1050	ES+ 536.1 [M+H]	^{1}H NMR (400 MHz, CD_3OD): δ 9.75 (s, 2H), 8.90 (d, J = 7.9 Hz, 1H), 8.17 (s, 1H), 7.70 (s, 1H), 7.49 – 7.43 (m, 1H), 7.25 – 7.17 (m, 1H), 7.08 (s, 1H), 6.46 – 6.38 (m, 1H), 5.26 – 5.18 (m, 1H), 3.43 (s, 3H), 2.83 (s, 3H), 2.64 – 2.57 (m, 3H), 2.49 (s, 3H), 1.70 – 1.62 (m, 3H).
1051	ES+ 534.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.18 (s, 1H), 7.59 (s, 1H), 6.95 (d, J = 8.6 Hz, 1H), 6.64 (d, J = 8.6 Hz, 1H), 5.38 - 5.21 (m, 1H), 4.87 - 4.58 (m, 5H), 3.63 (s, 4H), 3.58 - 3.45 (m, 2H), 3.18 - 3.00 (m, 2H), 2.88 - 2.74 (m, 2H), 2.42 (s, 3H), 2.38 (s, 3H), 2.32 - 2.16 (m, 2H), 1.61 - 1.60 (m, 3H).
1052	ES+ 522.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.17 (s, 1H), 7.58 (d, J = 0.8 Hz, 1H), 6.94 (d, J = 8.4 Hz, 1H), 6.63 (d, J = 8.4 Hz, 1H), 5.42 - 5.17 (m, 1H), 4.76 - 7.75 (m, 1H), 3.83 - 3.80 (m, 2H), 3.63 (s, 3H), 3.61 - 3.44 (m, 2H), 3.34 - 3.32 (m, 2H), 3.18 - 3.01 (m, 2H), 2.91 - 2.64 (m, 2H), 2.41 (s, 3H), 2.38 (s, 3H), 1.59 - 1.57 (m, 3H), 1.23 (t, J = 6.8 Hz, 3H).
1053	ES+ 551.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 9.02 (s, 2H), 8.26 (s, 1H), 7.53 (d, J = 1.6 Hz, 1H), 7.40 (d, J = 2.4 Hz, 1H), 7.32 (d, J = 7.2 Hz, 1H), 7.13 - 7.12 (m, 1H), 6.75 - 6.62 (m, 2H), 6.17 (d, J = 8.8 Hz, 1H), 5.06 - 4.90 (m, 2H), 3.65 (s, 3H), 3.56 (s, 3H), 2.48 (s, 3H), 2.45 (s, 3H), 1.67 (d, J = 6.4 Hz, 3H).
1054	ES+ 553.3 [M+H]	^{1}H NMR (400 MHz, DMSO-d_6): δ 9.25 (s, 2H), 8.02 (s, 1H), 7.72 - 7.66 (m, 2H), 7.40 - 7.36 (m, 1H), 7.15 (s, 1H), 6.91 (d, J = 6.8 Hz, 1H), 6.60 (d, J = 7.2 Hz, 1H), 6.21 - 6.12 (m, 1H), 5.30 - 5.23 (m, 1H), 3.52 (s, 3H), 3.45 (s, 3H), 2.41 (s, 3H), 2.26 (s, 3H), 1.54 (d, J = 6.4 Hz, 3H).
1055	ES+ 570.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.18 (s, 1H), 7.60 (s, 1H), 6.95 (d, J = 8.4 Hz, 1H), 6.64 (d, J = 8.4 Hz, 1H), 5.28 (br s, 1H), 4.75 (br s, 1H), 4.31 - 4.26 (m, 1H), 3.75 (d, J = 12.4 Hz, 1H), 3.72 - 3.65 (m, 4H), 3.56 - 3.45 (m, 1H), 3.44 - 3.35 (m, 1H), 3.14 - 3.13 (m, 1H), 2.99 - 2.98 (m, 1H), 2.96 (s, 3H), 2.42 (s, 3H), 2.39 (s, 3H), 1.58 (d, J = 6.8 Hz, 3H), 1.53 (d, J = 6.8 Hz, 3H).
1056	ES+ 559.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.18 (s, 1H), 7.64 (s, 1H), 7.20 (m, 1H), 6.95 - 6.81 (m, 1H), 6.27 (m, 1H), 5.27 (br s, 1H), 4.64 (br s, 1H), 3.83 (d, J = 11.2 Hz, 2H), 3.64 (s, 3H), 3.59 - 3.49 (m, 2H), 3.25 - 3.12 (m, 2H), 3.04 (m, 2H), 2.89 (s, 3H), 2.40 (s, 3H), 1.58 (d, J = 6.4 Hz, 3H).

1057	ES+ 559.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.18 (s, 1H), 7.66 (s, 1H), 7.23 - 6.95 (m, 1H), 6.90 (m, 1H), 5.95 (d, J = 9.2 Hz, 1H), 5.27 (br s, 1H), 5.07 (br s, 1H), 3.83 (d, J = 11.6 Hz, 2H), 3.64 (s, 3H), 3.59 - 3.50 (m, 2H), 3.19 (m, 2H), 3.04 (m, 2H), 2.89 (s, 3H), 2.40 (s, 3H), 1.58 (d, J = 6.4 Hz, 3H).
1058	ES+ 573.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.18 (s, 1H), 7.66 (s, 1H), 7.21 - 6.95 (m, 1H), 6.89 - 6.85 (m, 1H), 5.92 (d, J = 8.8 Hz, 1H), 5.24 - 5.23 (m, 1H), 5.07 (br s, 1H), 4.34 - 4.23 (m, 1H), 3.78 - 3.69 (m, 2H), 3.69 (s, 3H), 3.51 - 3.38 (m, 2H), 3.11 - 3.00 (m, 2H), 2.96 (s, 3H), 2.40 (s, 3H), 1.60 - 1.51 (m, 6H).
1059	ES+ 573.3 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.18 (s, 1H), 7.65 (s, 1H), 7.23 - 6.95 (m, 1H), 6.90 - 6.86 (m, 1H), 5.96 (d, J = 8.8 Hz, 1H), 5.26 (br s, 1H), 5.06 (br s, 1H), 4.31 - 4.25 (m, 1H), 3.85 - 3.70 (m, 2H), 3.69 (s, 3H), 3.55 - 3.37 (m, 2H), 3.17 - 2.97 (m, 2H), 2.96 (s, 3H), 2.40 (s, 3H), 1.56 (s, 3H), 1.55 - 1.50 (m, 3H).
1060	ES+ 482.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.19 (s, 1H), 7.58 (s, 1H), 7.15 - 7.12 (m, 1H), 6.95 - 6.93 (m, 1H), 6.25 - 6.22 (m, 1H), 5.41 - 5.20 (m, 1H), 4.86 (br s, 1H), 3.86 - 3.75 (m, 2H), 3.63 (s, 3H), 3.56 - 3.55 (m, 2H), 3.41 - 3.26 (m, 2H), 3.18 - 3.00 (m, 2H), 2.77 - 2.76 (m, 2H), 2.41 (s, 3H), 1.61 (d, J = 6.4 Hz, 3H), 1.23 (t, J = 6.8 Hz, 3H).
1062	ES+ 611.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.97 (s, 2H), 8.24 (s, 1H), 7.65 (t, J = 60 Hz, 1H), 7.56 (s, 1H), 7.37 (d, J = 6.8 Hz, 1H), 6.94 (d, J = 8.4 Hz, 1H), 6.73 (s, 1H), 6.69 (d, J = 7.2 Hz, 1H), 6.57 (d, J = 8.4 Hz, 1H), 5.02 - 4.89 (m, 1H), 4.73 (br s, 1H), 3.53 (s, 3H), 2.46 (s, 3H), 2.41 (s, 3H), 2.25 (s, 3H), 1.65 (d, J = 6.8 Hz, 3H).
1068	ES+ 546.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.20 (s, 1H), 7.58 (d, J = 1.6 Hz, 1H), 7.39 (d, J = 2.4 Hz, 1H), 7.14 - 7.12 (m, 1H), 6.21 (d, J = 9.2 Hz, 1H), 5.41 - 5.20 (m, 1H), 4.98 (br s, 1H), 4.40 - 4.17 (m, 1H), 3.82 - 3.55 (m, 5H), 3.53 - 3.37 (m, 2H), 3.12 - 3.00 (m, 2H), 2.96 (s, 3H), 2.42 (s, 3H), 1.63 (br s, 3H), 1.54 (d, J = 6.8 Hz, 3H).
1071	ES+ 546.1 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.20 (br s, 1H), 7.57 (s, 1H), 7.39 (s, 1H), 7.15 - 7.13 (m, 1H), 6.24 (d, J = 9.2 Hz, 1H), 5.30 (br s, 1H), 4.98 (br s, 1H), 4.33 - 4.24 (m, 1H), 3.75 - 3.73 (m, 2H), 3.69 (s, 3H), 3.55 - 3.36 (m, 2H), 3.16 - 2.96 (m, 2H), 2.96 (s, 3H), 2.42 (s, 3H), 1.60 (br s, 3H), 1.53 (d, J = 6.4 Hz, 3H).
1072	ES+ 510.2 [M+H]	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.19 (s, 1H), 7.56 (d, J = 1.2 Hz, 1H), 7.38 (d, J = 2.4 Hz, 1H), 7.14 - 7.12 (m, 1H), 6.25 (d, J = 9.2 Hz, 1H), 5.32 (br s, 1H), 4.99 (br s, 1H), 4.74 - 4.65 (m, 4H), 3.62 (s, 3H), 3.62 - 3.57 (m, 1H), 3.52 - 3.49 (m, 2H), 3.14 - 3.03 (m, 2H), 2.79 - 2.77 (m, 2H), 2.41 (s, 3H), 2.26 - 2.24 (m, 2H), 1.62 (d, J = 6.4 Hz, 3H).

Assays and Compound Testing

[0396] In vitro cell proliferation: determination of EC50 values for inhibition of proliferation in T47D cells expressing mutant PI3Ka (H1047R) mutation and SKBR3 cells express WT PI3Ka.

[0397] T47D or SKBR3 cells were trypsinized, resuspended in culture media and seeded onto assay ready plates. T47D culture media consisted of RPMI, 10% FBS and Insulin (0.2 units/mL). SKBR3 culture media consisted of McCoys 5a and 10% FBS. Cells were seeded at a density of 1,500 cells/well and dispensed in 50 µL onto 384 well assay ready plates (Corning, 89089-790). Assay ready plates had previously been stamped with 10-point dilutions of compounds of interest, as well as controls. The Echo655 is used to stamp plates at 40 nL of compound or DMSO. Cells were grown for 72 hours at 37 ° Celsius and 5% CO_2. After 72 hours, cells were equilibrated at room temperature for 15 minutes. 30 uL of CellTiter-Glo reagent is added to the plate, which is then shaken for 30 minutes at temperature at 300-500 rpm. Cells are then read on an Envision plate reader. The percentage of inhibition of proliferation was calculated using the following formula: %Inhibition = 100 x (Lum_D – Lum_{Sample}) / (Lum_D –Lum_{Inh}), where D is obtained from cells treated with 0.1% DMSO only; Inh is obtained from cells treated with 10uM Alpelisib. The effective concentration achieving 50% inhibition of proliferation (EC50) is calculated by fitting the Curve using Xlfit (v5.3.1.3), equation 201: Y = Bottom + (Top - Bottom)/(1 + 10^((LogEC50 - X)*HillSlope)).

Reagent table

Reagent	**Vendor**	**Cat No.**
Cell Titer Glo 2.0 Assay 500 mL	Promega	G9243
Corning 384-well Low Flange Black Flat Bottom Polystyrene TC-treated Microplates, 10 per Bag, with Lid, Sterile SKU: 3571	Corning	89089-790
PBS	Solarbio	P1020
Trypan blue solution 0.4%	Fisher	T10282
Fetal Bovine Serum Australia origin	Sigma	82051-458
Gibco RPMI 1640 Medium	Fisher	11875093

Gibco McCoy's 5A (modified) Medium, HEPES	Fisher	12330031
DMEM, high glucose, HEPES, no phenol red	Fisher	21063045
Insulin, human recombinant, zinc solution	Fisher	12585-014

[0398] For EC50 values shown in Table 2, "A" refers to 1 nM < EC50 < 500 nM; "B" refers to 500 nM < EC50 < 2 μM; "C" refers to 2 μM < EC50 < 15 μM; and "D" refers to an EC50 > 15 μM.

Table 3. Cellular proliferation data

Example #	**Avg T-47D EC50**	**Avg SKBR3 EC50**
1	B	C
2	B	D
3	B	D
4	D	D
5	A	C
6	B	C
7	A	C
8	A	C
9	B	D
10	-	-
11	B	C
12	A	A

13	A	B
14	A	C
15	A	B
16	A	B
17	A	C
18	B	C
19	C	C
20	C	D
21	D	D
22	A	C
23	B	C
24	B	C
25	B	C
26	B	C
27	A	C
28	C	C
29	B	C
30	A	B
31	A	B
32	A	B
33	A	D

34	A	C
35	A	C
36	A	C
37	B	C
38	C	C
39	B	C
40	B	C
41	B	C
42	B	D
43	B	C
44	B	C
45	A	C
46	B	C
47	A	C
48	A	B
49	A	B
50	A	C
51	A	C
52	A	C
53	A	C
54	A	C

55	A	C
56	C	C
57	C	C
58	A	C
59	B	C
60	B	C
61	B	C
62	A	C
63	D	C
64	C	C
65	A	B
66	A	B
67	A	C
68	A	B
69	-	-
70	A	C
71	A	B
72	A	C
73	C	D
74	C	C
75	B	C

76	B	C
77	B	D
78	C	C
79	A	C
80	B	C
81	A	C
82	A	B
83	B	C
84	B	C
85	A	C
86	A	B
87	A	B
88	A	B
89	A	B
90	A	B
91	A	B
92	A	C
93	A	B
94	A	B
95	A	C
96	A	C

97	C	D
98	A	D
99	C	D
100	C	D
101	C	C
102	C	D
103	D	D
104	D	D
105	C	D
106	D	D
107	B	D
108	D	D
109	B	C
110	B	C
111	A	C
112	A	B
113	A	B
114	B	C
115	B	D
116	A	C
117	C	D

118	B	D
119	A	C
120	B	D
121	A	C
122	C	C
123	B	D
124	B	D
125	B	D
126	A	C
127	A	C
128	A	C
129	A	C
130	C	D
131	C	D
132	B	C
133	B	D
134	D	D
135	D	D
136	A	B
137	A	B
138	A	B

139	A	A
140	A	B
141	A	B
142	A	B
143	A	B
144	A	C
145	A	C
146	B	D
147	A	C
148	A	C
149	C	C
150	A	B
151	A	B
152	C	C
153	B	C
154	A	B
155	A	C
156	A	C
157	A	C
158	B	C
159	A	B

160	A	C
161	A	C
162	A	C
163	A	C
164	A	A
165	A	B
166	A	C
167	A	B
168	A	C
169	C	C
170	A	A
171	B	C
172	B	C
173	B	C
174	A	C
175	B	C
176	A	C
177	A	C
178	A	B
179	A	B
180	A	B

181	A	C
182	B	D
183	A	C
184	A	B
185	A	B
186	A	B
187	A	B
188	A	B
189	A	A
190	A	A
191	A	C
192	C	C
193	A	B
194	A	B
195	B	D
196	A	C
197	A	B
198	A	B
199	A	A
200	A	B
201	A	B

202	B	C
203	A	C
204	B	B
205	B	B
206	B	B
207	B	B
208	B	B
209	A	C
210	A	B
211	A	B
212	A	B
213	A	B
214	A	B
215	A	A
216	A	B
217	A	C
218	A	B
219	A	B
220	A	C
221	B	C
222	A	B

223	A	B
224	A	B
225	A	B
226	A	B
227	A	B
228	A	B
229	B	B
230	A	B
231	A	B
232	A	B
233	A	B
234	A	B
235	A	B
236	A	B
237	A	B
238	A	B
239	A	B
240	A	B
241	A	C
242	B	C
243	A	C

244	A	B
245	A	C
246	A	C
247	C	D
248	A	B
249	A	B
250	A	B
251	A	B
252	A	C
253	A	A
254	A	B
255	A	B
256	A	B
257	C	D
258	A	B
259	A	B
260	A	B
261	A	B
262	B	C
263	A	B
264	A	A

265	A	B
266	D	D
267	A	A
268	A	B
269	A	B
270	A	C
271	A	C
272	A	A
273	B	C
274	B	C
275	A	C
276	A	C
277	B	D
278	A	B
279	A	C
280	A	C
281	B	C
282	C	C
283	A	B
284	A	B
285	A	B

286	A	C
287	C	D
288	A	C
289	D	D
290	A	B
291	A	C
292	A	B
293	A	B
294	A	B
295	A	A
296	D	D
297	A	B
298	A	C
299	A	A
300	A	B
301	A	C
302	A	B
303	A	C
304	A	C
305	A	C
306	A	B

307	A	A
308	A	C
309	A	C
310	A	C
311	A	B
312	A	C
313	A	C
314	A	C
315	A	C
316	A	B
317	A	C
318	A	B
319	A	C
320	A	C
321	A	C
322	A	B
323	A	C
324	A	C
325	A	C
326	A	B
327	A	B

328	A	B
329	A	B
330	A	B
331	A	B
332	A	B
333	A	B
334	A	C
335	A	C
336	A	C
337	A	C
338	A	C
339	B	D
340	A	B
341	A	B
342	A	B
343	A	C
344	A	B
345	B	C
346	A	C
347	B	C
348	A	C

349	B	D
350	A	B
351	B	D
352	A	C
353	A	B
354	A	B
355	A	C
356	A	A
357	A	A
358	A	A
359	A	C
360	A	C
361	A	C
362	A	C
363	C	C
364	A	C
365	A	B
366	A	B
367	A	C
368	A	C
369	A	C

370	A	C
371	A	C
372	A	D
373	A	D
374	B	C
375	A	C
376	D	D
377	B	C
378	A	C
379	A	C
380	A	C
381	A	B
382	A	B
383	A	B
384	A	B
385	A	A
386	A	B
387	A	B
388	A	A
389	A	B
390	A	C

391	A	C
392	A	C
393	A	A
394	A	A
395	A	A
396	A	A
397	A	C
398	A	C
399	A	C
400	A	C
401	A	B
402	A	B
403	A	B
404	A	C
405	A	C
406	A	C
407	A	B
408	B	C
409	A	C
410	B	C
411	A	C

412	A	C
413	A	A
414	A	A
415	A	B
416	A	C
417	A	C
418	A	A
419	A	A
420	A	A
421	A	B
422	A	A
423	A	A
424	A	B
425	A	B
426	A	C
427	A	B
428	A	B
429	A	B
430	A	B
431	A	C
432	A	B

433	A	B
434	A	A
435	A	B
436	A	B
437	A	A
438	A	B
439	A	C
440	A	B
441	A	B
442	A	C
443	A	C
444	A	C
445	B	C
446	B	D
447	A	C
448	A	C
449	A	B
450	A	B
451	A	A
452	A	B
453	A	B

454	A	A
455	A	B
456	A	A
457	A	B
458	A	B
459	A	B
460	A	B
461	A	A
462	A	C
463	A	B
464	A	C
465	A	C
466	A	C
467	A	A
468	A	B
469	A	B
470	A	B
471	C	D
472	A	C
473	A	C
474	A	C

475	B	C
476	B	C
477	A	B
478	A	A
479	A	A
480	A	C
481	A	B
482	A	B
483	A	B
484	A	C
485	A	A
486	A	B
487	A	A
488	A	B
489	A	C
490	A	D
491	A	C
492	A	B
493	A	B
494	A	C
495	A	B

496	A	B
497	A	C
498	A	B
499	A	B
500	A	C
501	C	C
502	C	D
503	A	B
504	C	D
505	A	C
506	A	B
507	A	A
508	A	B
509	B	D
510	B	D
511	A	B
512	C	D
513	A	B
514	B	C
515	A	B
516	A	B

517	A	B
518	A	A
519	A	B
520	B	D
521	A	D
522	B	C
523	A	C
524	A	C
525	C	D
526	B	D
527	C	C
528	A	C
529	A	B
530	A	C
531	A	C
532	B	D
533	B	C
534	C	D
535	A	C
536	D	D
537	C	C

538	A	B
539	A	D
540	B	C
541	A	C
542	A	C
543	A	C
544	A	C
545	B	D
546	C	D
547	C	C
548	A	C
549	A	B
550	A	C
551	A	B
552	B	C
553	A	B
554	A	B
555	A	B
556	A	C
557	D	D
558	A	C

559	A	C
560	A	C
561	A	B
562	B	C
563	A	C
564	B	C
565	C	C
566	B	D
567	B	D
568	A	C
569	A	C
570	A	C
571	A	C
572	A	B
573	B	D
574	B	D
575	B	C
576	A	C
577	A	C
578	C	D
579	A	A

580	C	D
581	A	C
582	A	B
583	C	D
584	C	D
585	A	C
586	C	C
587	A	C
588	A	C
589	A	C
590	B	C
591	A	C
592	B	C
593	B	C
594	A	B
595	B	C
596	B	C
597	A	B
598	C	C
599	B	C
600	C	C

601	A	C
602	A	C
603	A	B
604	A	C
605	A	C
606	A	B
607	A	C
608	C	D
609	B	D
610	A	B
611	A	C
612	B	C
613	B	C
614	A	C
615	A	C
616	B	C
617	B	D
618	C	C
619	B	C
620	B	C
621	C	C

622	A	C
623	A	D
624	B	C
625	B	C
626	A	C
627	C	C
628	A	C
629	A	C
630	D	D
631	C	C
632	A	C
633	B	C
634	A	C
635	A	C
636	A	B
637	B	C
638	A	C
639	B	C
640	A	C
641	B	C
642	A	C

643	A	C
644	A	C
645	A	B
646	A	A
647	C	C
648	A	C
649	A	C
650	A	C
651	A	B
652	B	D
653	B	C
654	A	B
655	A	B
656	C	C
657	A	B
658	B	C
659	C	C
660	A	C
661	B	C
662	A	C
663	A	C

664	A	C
665	A	C
666	B	C
667	A	C
668	A	C
669	A	C
670	A	C
671	A	C
672	A	C
673	A	B
674	A	B
675	A	B
676	A	B
677	B	C
678	A	C
679	A	C
680	A	B
681	B	C
682	B	C
683	A	B
684	B	C

685	A	C
686	A	C
687	A	B
688	A	B
689	A	B
690	A	C
691	A	B
692	A	B
693	A	B
694	A	B
695	A	B
696	A	A
697	A	B
698	A	C
699	A	C
700	A	B
701	A	C
702	A	C
703	A	C
704	A	C
705	A	C

706	A	B
707	A	B
708	A	B
709	B	C
710	B	C
711	A	C
712	A	C
713	A	C
714	A	C
715	A	B
716	A	C
717	A	C
718	A	C
719	A	B
720	A	C
721	A	B
722	A	C
723	A	B
724	A	B
725	A	B
726	B	C

727	A	B
728	A	C
729	A	C
730	A	B
731	A	C
732	A	C
733	A	C
734	A	C
735	A	B
736	A	B
737	B	C
738	A	B
739	A	B
740	A	C
741	A	C
742	A	C
743	A	C
744	B	C
745	B	C
746	A	C
747	A	B

748	A	C
749	A	B
750	A	B
751	A	C
752	B	C
753	C	C
754	C	D
755	C	C
756	A	C
757	A	B
758	A	C
759	B	C
760	A	C
761	A	B
762	B	C
763	B	C
764	A	B
765	A	B
766	B	B
767	A	B
768	A	C

769	A	A
770	A	B
771	A	A
772	A	B
773	A	B
774	A	C
775	B	B
776	A	C
777	A	C
778	A	C
779	A	B
780	A	C
781	A	B
782	C	C
783	A	C
784	A	C
785	A	C
786	A	C
787	A	C
788	B	C
789	A	C

790	A	B
791	C	D
792	A	C
793	A	C
794	C	C
795	B	C
796	B	C
797	A	C
798	A	C
799	A	B
800	A	B
801	A	C
802	A	B
803	A	C
804	A	C
805	A	C
806	A	B
807	A	D
808	A	C
809	A	C
810	A	A

811	A	B
812	A	B
813	A	B
814	A	B
815	A	C
816	A	B
817	C	C
818	A	B
819	A	B
820	A	C
821	A	C
822	A	B
823	B	C
824	C	C
825	A	C
826	A	B
827	A	C
828	A	C
829	A	B
830	A	A
831	A	C

832	A	C
833	B	C
834	A	C
835	A	C
836	A	C
837	A	B
838	A	A
839	B	D
840	B	C
841	A	C
842	A	B
843	A	C
844	A	C
845	A	B
846	A	C
847	A	C
848	A	C
849	A	C
850	A	C
851	A	C
852	A	C

853	A	B
854	A	C
855	A	B
856	A	C
857	A	C
858	A	B
859	A	A
860	A	A
861	A	C
862	A	C
863	A	B
864	A	B
865	A	C
866	A	B
867	A	B
868	A	C
869	A	C
870	A	A
871	A	C
872	A	C
873	A	B

874	A	B
875	A	C
876	A	C
877	B	B
878	A	C
879	A	B
880	C	D
881	A	B
882	A	C
883	A	C
884	A	C
885	A	B
886	A	B
887	A	A
888	A	A
889	A	B
890	B	C
891	C	D
892	A	B
893	A	B
894	A	D

895	A	B
896	A	B
897	A	B
898	A	B
899	A	C
900	D	C
901	D	D
902	A	B
903	A	B
904	A	C
905	A	C
906	A	C
907	A	C
908	A	B
909	A	B
910	A	B
911	B	D
912	B	C
913	A	C
914	A	B
915	A	B

916	A	B
917	A	C
918	B	C
919	C	D
920	A	B
921	A	C
922	A	C
923	A	C
924	A	B
925	A	C
926	A	B
927	A	C
928	A	B
929	A	C
930	B	C
931	A	C
932	A	C
933	A	C
934	A	C
935	A	C
936	A	C

937	A	C
938	A	C
939	A	A
940	A	C
941	A	D
942	A	B
943	A	A
944	A	A
945	A	B
946	B	D
947	A	C
948	A	C
949	A	C
950	A	C
951	A	C
952	A	B
953	A	A
954	B	C
955	A	C
1044	A	C
1045	B	D

1046	A	C
1047	A	C
1048	A	C
1049	A	C
1050	A	C

[0399] In vitro cell pAKT: determination of IC50 values for inhibition of phosphorylation of AKT (pAKT) in T47D cells expressing mutant PI3Ka (H1047R) mutation and SKBR3 cells express WT PI3Ka.

[0400] T47D or SKBR3 cells were trypsinized, resuspended in culture media and seeded onto assay ready plates. T47D culture media consisted of RPMI, 10% FBS and Insulin (0.2 units/mL). SKBR3 culture media consisted of McCoy's 5a and 10% FBS. Cells were seeded at a density of 5000 cells/well and dispensed in 12.5 µL onto 384 well assay ready plates (Perkin Elmer, 6008238)). Assay ready plates had previously been stamped with 10-point dilutions of compounds of interest, as well as controls. The Echo655 is used to stamp plates at 12.5 nL of compound or DMSO. Cells were grown for 6 hours at 37 ° Celsius and 5% CO_2. After 6 hours, 4 µL of Lysis buffer reagent was added to the plate, which was then centrifuged for 1 minute at 1000 rpm. Then the plate was incubated at room temperature for 30 minutes. After 30 minutes, 4 µL of antibody mix containing Eu Cryptate, d2 Cryptate, and detection buffer, was added to the plate. The plate was centrifuged for 1 minute at 1000 rpm and then incubated overnight at room temperature. The plate was read on an Envision plate reader using the HTRF protocol. The percentage of inhibition of AKT phosphorylation was calculated using the following formula: %Inhibition = 100 x (pAKTHC – pAKTSample) / (pAKTHC –pAKTLC)), where pAKTHC is obtained from cells treated with 0.1% DMSO only; pAKTLC is obtained from cells treated with 10uM Alpelisib. The IC50 (concentration achieving 50% inhibition of pAKT) is calculated by fitting the Curve using Xlfit (v5.3.1.3), equation 201: Y = Bottom + (Top - Bottom)/(1 + 10^((LogIC50 - X)*HillSlope)).

Reagent table

Reagent	**Vendor**	**Cat No.**

Gibco RPMI 1640 Medium, no phenol red	Fisher	11835030
Gibco RPMI 1640 Medium	Fisher	11875093
McCoy's 5A (Modified) Medium, HEPES	Fisher	12330031
DMEM, high glucose, HEPES, no phenol red	Fisher	21063045
Gibco Trypsin-EDTA (0.5%), no phenol red	Fisher	15400054
PBS	Solarbio	P1020
Trypan blue solution 0.4%	Fisher	T10282
Fetal Bovine Serum Australia origin	Sigma	82051-458
ProxiPlate-384 Plus, White, TC treated, Case of 160	Perkin Elmer	6008238
pAKT (Ser473) HTRF	Cisbio	64AKSPEH

[0401] For IC50 values shown in Table 3, “A” refers to 1 nM < IC50 < 500 nM; “B” refers to 500 nM < IC50 < 2 μM; “C” refers to 2 μM < IC50 < 15 μM; and “D” refers to an IC50 > 15 μM.

Table 4. Cellular pAKT data

Example #	**Avg T-47D IC50**	**Avg SKBR3 IC50**
1	A	C
2	C	D
3	C	D
4	D	D
5	A	C

6	A	C
7	A	C
8	A	B
9	A	D
10	-	-
11	A	C
12	A	A
13	A	B
14	A	C
15	A	B
16	A	A
17	A	B
18	A	C
19	C	D
20	-	-
21	-	-
22	A	C
23	A	C
24	A	C
25	A	C
26	A	C

27	A	B
28	D	D
29	A	C
30	A	A
31	A	C
32	A	B
33	A	D
34	A	C
35	A	B
36	A	C
37	C	C
38	C	D
39	B	C
40	A	C
41	A	C
42	B	D
43	A	C
44	A	C
45	A	C
46	A	C
47	A	C

48	A	A
49	A	A
50	A	C
51	A	C
52	A	B
53	A	C
54	A	C
55	A	B
56	D	D
57	D	D
58	A	B
59	B	C
60	B	C
61	B	C
62	A	B
63	D	D
64	D	D
65	A	B
66	A	B
67	A	C
68	A	C

69	-	-
70	A	C
71	A	A
72	A	B
73	B	D
74	C	D
75	A	C
76	A	C
77	A	C
78	B	D
79	A	C
80	A	C
81	A	C
82	A	C
83	B	C
84	B	D
85	A	B
86	A	A
87	A	A
88	A	B
89	A	B

90	A	A
91	A	A
92	A	B
93	A	A
94	A	A
95	A	B
96	A	B
97	C	D
98	A	C
99	C	D
100	C	D
101	C	D
102	C	D
103	C	D
104	C	D
105	C	D
106	C	D
107	B	D
108	C	D
109	B	C
110	B	C

111	A	C
112	A	B
113	A	B
114	A	C
115	B	C
116	A	B
117	C	D
118	B	C
119	A	C
120	B	D
121	A	C
122	B	D
123	B	D
124	B	D
125	B	D
126	A	C
127	A	C
128	A	C
129	A	C
130	C	D
131	C	D

132	B	C
133	B	C
134	C	D
135	D	D
136	A	A
137	A	A
138	A	A
139	A	A
140	A	A
141	A	A
142	A	A
143	A	A
144	A	A
145	A	B
146	A	C
147	A	A
148	A	B
149	C	D
150	A	A
151	A	B
152	B	C

153	B	C
154	A	A
155	A	B
156	A	B
157	A	B
158	A	C
159	A	A
160	A	B
161	A	B
162	A	B
163	A	B
164	A	A
165	A	C
166	A	C
167	A	A
168	A	C
169	C	D
170	A	A
171	B	C
172	B	C
173	B	C

174	A	B
175	A	C
176	A	B
177	A	A
178	A	B
179	A	B
180	A	B
181	A	C
182	B	D
183	B	C
184	A	A
185	A	A
186	A	A
187	A	A
188	A	A
189	A	A
190	A	A
191	A	C
192	C	D
193	A	A
194	A	B

195	B	C
196	A	B
197	A	B
198	A	A
199	A	A
200	A	B
201	A	B
202	A	C
203	A	B
204	B	B
205	B	B
206	B	B
207	A	B
208	A	B
209	A	C
210	A	B
211	A	B
212	A	B
213	A	A
214	A	A
215	A	A

216	A	A
217	A	B
218	B	B
219	A	A
220	A	B
221	B	D
222	A	B
223	A	A
224	A	A
225	A	B
226	A	B
227	A	B
228	A	B
229	A	B
230	A	B
231	A	A
232	A	B
233	A	B
234	A	B
235	A	B
236	A	A

237	A	A
238	A	B
239	A	A
240	A	A
241	A	C
242	A	C
243	A	B
244	A	A
245	A	B
246	A	B
247	B	C
248	A	C
249	A	A
250	A	A
251	A	A
252	A	C
253	A	A
254	A	B
255	A	A
256	A	A
257	B	D

258	A	A
259	A	A
260	A	A
261	A	A
262	A	C
263	A	B
264	A	A
265	A	A
266	D	D
267	A	A
268	A	B
269	A	A
270	A	C
271	A	C
272	A	A
273	A	C
274	A	C
275	A	C
276	A	C
277	A	C
278	A	A

279	A	A
280	A	C
281	A	C
282	B	C
283	A	B
284	A	B
285	A	A
286	A	C
287	D	D
288	A	B
289	D	D
290	A	A
291	A	A
292	A	A
293	A	A
294	A	A
295	A	A
296	D	D
297	A	B
298	A	C
299	A	A

300	A	A
301	A	B
302	A	B
303	A	B
304	A	C
305	C	D
306	A	A
307	A	A
308	A	C
309	A	B
310	A	B
311	A	B
312	A	B
313	A	B
314	A	B
315	A	B
316	A	A
317	A	A
318	A	A
319	A	A
320	A	A

321	A	A
322	A	A
323	A	B
324	A	B
325	A	C
326	A	A
327	A	A
328	A	A
329	A	A
330	A	A
331	A	A
332	A	A
333	A	A
334	A	B
335	A	C
336	A	B
337	A	C
338	A	B
339	A	D
340	A	A
341	A	B

342	A	B
343	A	B
344	A	B
345	A	D
346	B	C
347	A	D
348	A	C
349	B	D
350	A	A
351	B	D
352	A	B
353	A	A
354	A	A
355	A	B
356	A	A
357	A	A
358	A	A
359	A	B
360	A	C
361	A	A
362	A	C

363	B	D
364	A	C
365	A	A
366	A	A
367	A	B
368	A	C
369	A	B
370	A	B
371	A	B
372	A	B
373	A	B
374	A	C
375	A	C
376	D	D
377	A	C
378	A	C
379	A	C
380	A	B
381	A	A
382	A	A
383	A	A

384	A	A
385	A	A
386	A	A
387	A	A
388	A	A
389	A	B
390	A	B
391	A	A
392	A	B
393	A	A
394	A	A
395	A	A
396	A	A
397	A	B
398	A	B
399	A	B
400	A	B
401	A	A
402	A	A
403	A	A
404	A	C

405	A	A
406	A	B
407	A	A
408	A	C
409	A	C
410	A	C
411	A	C
412	A	B
413	A	A
414	A	A
415	A	A
416	A	B
417	A	C
418	A	A
419	A	A
420	A	A
421	A	A
422	A	A
423	A	A
424	A	A
425	A	A

426	A	A
427	A	A
428	A	A
429	A	A
430	A	B
431	A	B
432	A	A
433	A	B
434	A	A
435	A	A
436	A	B
437	A	A
438	A	A
439	A	B
440	A	A
441	A	A
442	A	C
443	A	B
444	A	B
445	A	D
446	A	C

447	A	C
448	A	B
449	A	A
450	A	A
451	A	A
452	A	A
453	A	A
454	A	A
455	A	A
456	A	B
457	A	B
458	A	A
459	A	A
460	A	A
461	A	A
462	A	B
463	A	A
464	A	B
465	A	C
466	A	C
467	A	A

468	A	B
469	A	A
470	A	A
471	C	D
472	A	B
473	A	B
474	A	C
475	A	C
476	A	C
477	A	A
478	A	A
479	A	A
480	A	B
481	A	A
482	A	B
483	A	A
484	A	B
485	A	A
486	A	B
487	A	A
488	A	B

489	A	B
490	A	C
491	A	C
492	A	A
493	A	A
494	A	C
495	A	A
496	A	B
497	A	B
498	A	A
499	A	B
500	A	B
501	C	D
502	B	D
503	A	A
504	C	D
505	A	C
506	A	B
507	A	A
508	A	A
509	A	D

510	A	D
511	A	A
512	B	D
513	A	C
514	A	C
515	A	A
516	A	A
517	A	A
518	A	A
519	A	A
520	B	D
521	A	C
522	B	C
523	A	C
524	A	B
525	B	D
526	A	D
527	B	D
528	A	A
529	A	A
530	A	A

531	A	C
532	A	D
533	A	C
534	B	D
535	A	C
536	D	D
537	D	D
538	A	B
539	A	D
540	A	C
541	A	C
542	A	C
543	A	C
544	A	C
545	B	D
546	B	D
547	A	C
548	A	B
549	A	A
550	A	B
551	A	C

552	A	C
553	A	A
554	A	A
555	A	A
556	A	B
557	D	D
558	A	B
559	A	C
560	A	B
561	A	A
562	A	D
563	A	C
564	A	C
565	B	D
566	B	D
567	B	D
568	A	C
569	A	C
570	A	B
571	A	B
572	A	B

573	A	C
574	A	C
575	A	B
576	A	B
577	A	C
578	B	D
579	A	A
580	D	D
581	A	B
582	A	A
583	C	D
584	B	D
585	A	C
586	B	C
587	A	B
588	A	C
589	A	B
590	A	C
591	A	B
592	A	D
593	A	C

594	A	A
595	A	C
596	A	C
597	A	B
598	D	C
599	A	C
600	B	D
601	A	B
602	A	C
603	A	B
604	A	A
605	A	C
606	A	A
607	A	B
608	B	D
609	B	D
610	A	B
611	A	B
612	A	C
613	A	D
614	A	C

615	A	B
616	A	C
617	A	D
618	D	D
619	A	C
620	A	C
621	B	C
622	A	B
623	A	B
624	A	C
625	A	C
626	A	B
627	B	C
628	A	B
629	A	C
630	B	D
631	C	C
632	A	C
633	A	C
634	A	C
635	A	C

636	A	C
637	A	C
638	A	C
639	A	C
640	A	B
641	A	C
642	A	C
643	A	C
644	A	C
645	A	A
646	A	A
647	D	D
648	A	B
649	A	C
650	A	B
651	A	B
652	B	C
653	A	C
654	A	B
655	A	B
656	D	D

657	A	B
658	A	C
659	D	D
660	A	C
661	A	C
662	A	C
663	A	C
664	A	B
665	A	B
666	A	C
667	A	B
668	A	B
669	A	C
670	A	C
671	A	C
672	A	B
673	A	B
674	A	A
675	A	B
676	A	A
677	B	D

678	A	C
679	A	C
680	A	B
681	A	C
682	A	D
683	A	B
684	A	C
685	A	B
686	A	C
687	A	B
688	A	B
689	A	B
690	A	B
691	A	B
692	A	A
693	A	A
694	A	C
695	A	A
696	A	A
697	A	B
698	A	C

699	A	C
700	A	C
701	A	C
702	A	C
703	A	B
704	A	B
705	A	B
706	A	B
707	C	C
708	A	B
709	A	D
710	A	D
711	A	B
712	A	B
713	A	B
714	A	A
715	A	A
716	A	B
717	A	B
718	A	B
719	A	B

720	A	B
721	A	C
722	A	C
723	A	B
724	A	B
725	A	B
726	A	D
727	A	C
728	A	C
729	A	C
730	A	B
731	A	C
732	A	B
733	A	A
734	A	B
735	A	C
736	A	C
737	A	D
738	A	A
739	A	A
740	A	B

741	A	B
742	A	C
743	A	B
744	A	C
745	A	C
746	A	B
747	A	B
748	A	B
749	A	A
750	A	B
751	A	B
752	B	D
753	C	D
754	C	D
755	C	D
756	A	B
757	A	A
758	A	C
759	A	D
760	A	C
761	A	B

762	A	C
763	A	C
764	A	B
765	A	B
766	A	C
767	A	B
768	A	C
769	A	A
770	A	A
771	A	A
772	A	B
773	A	B
774	A	C
775	D	D
776	A	C
777	A	B
778	A	B
779	A	A
780	A	B
781	A	A
782	C	D

783	A	A
784	A	B
785	A	C
786	A	B
787	A	B
788	A	C
789	A	C
790	A	B
791	B	D
792	A	B
793	A	B
794	C	D
795	A	C
796	A	C
797	A	B
798	A	B
799	A	A
800	A	B
801	A	B
802	A	A
803	A	B

804	A	C
805	A	C
806	A	A
807	A	C
808	A	C
809	A	C
810	A	A
811	A	B
812	A	A
813	A	B
814	A	A
815	A	A
816	A	A
817	C	D
818	A	B
819	A	A
820	A	C
821	A	B
822	A	A
823	B	D
824	B	D

825	A	A
826	A	B
827	A	B
828	A	B
829	A	B
830	A	A
831	A	B
832	A	A
833	B	C
834	A	B
835	A	B
836	A	B
837	A	A
838	A	A
839	B	D
840	B	D
841	A	A
842	A	A
843	A	C
844	A	C
845	A	A

846	A	B
847	A	C
848	A	B
849	A	B
850	A	C
851	A	B
852	A	B
853	A	B
854	A	B
855	A	B
856	A	B
857	A	C
858	A	B
859	A	A
860	A	A
861	A	B
862	A	C
863	A	A
864	A	A
865	A	B
866	A	A

867	A	A
868	A	B
869	A	A
870	A	A
871	A	B
872	A	C
873	A	A
874	A	B
875	A	B
876	A	B
877	A	B
878	A	B
879	A	A
880	B	D
881	A	A
882	A	A
883	A	A
884	A	B
885	A	A
886	A	A
887	A	A

888	A	A
889	A	A
890	A	C
891	B	D
892	A	A
893	A	A
894	A	B
895	A	B
896	A	B
897	A	B
898	A	A
899	A	B
900	D	D
901	D	D
902	A	A
903	A	A
904	A	B
905	A	C
906	A	B
907	A	B
908	A	B

909	A	A
910	A	A
911	A	A
912	A	B
913	A	B
914	A	A
915	A	A
916	A	A
917	A	B
918	A	C
919	B	D
920	A	B
921	A	B
922	A	B
923	A	B
924	A	A
925	A	C
926	A	A
927	A	B
928	A	A
929	A	B

930	A	C
931	A	C
932	A	A
933	A	B
934	A	B
935	A	A
936	A	B
937	A	C
938	A	B
939	A	A
940	A	B
941	A	B
942	A	A
943	A	A
944	A	A
945	A	A
946	A	C
947	A	B
948	A	A
949	A	C
950	A	B

951	A	A
952	A	A
953	D	D
954	A	C
955	A	C
967	A	A
986	A	C
989	A	B
1044	A	B
1045	A	D
1046	A	D
1047	A	C
1048	A	B
1049	A	C
1050	A	B
1051	A	A
1052	A	C
1053	A	A
1054	A	B
1055	A	A
1056	A	B

1057	A	A
1058	A	B
1059	A	A

References

[0402] Ali, K., Bilancio, A., Thomas, M., Pearce, W., Gilfillan, A. M., Tkaczyk, C., Kuehn, N., Gray, A., Giddings, J., Peskett, E., Fox, R., Bruce, I., Walker, C., Sawyer, C., Okkenhaug, K., Finan, P., and Vanhaesebroeck, B. 2004. Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature 431(7011): 1007-1011.

[0403] Backer, J. M. 2016. The intricate regulation and complex functions of the Class III phosphoinositide 3-kinase Vps34. Biochem J. 473(15): 2251–2271.

[0404] Castel, P., Toska, E., Engelman, J. A., and Scaltriti, M. 2021. The present and future of PI3K inhibitors for cancer therapy. Nat Cancer 2(6): 587-597.

[0405] Fruman, D. A., Chiu H., Hopkins B. D., Bagrodia, S., Cantley, L. C., and Abraham R. T. 2017. The PI3K pathway in human disease. Cell 170(4): 605-635.

[0406] Gadkar, K., Friedrich, C., Hurez, V., Ruiz, M. L., Dickmann, L., Jolly, M. K., Schutt, L., Jin, J., Ware, J. A., and Ramanujan, S. 2021. Quantitative systems pharmacology model-based investigation of adverse gastrointestinal events associated with prolonged treatment with PI3-kinase inhibitors. CPT Pharmacometrics Syst Pharmacol. 11(5): 616-627.

[0407] Goncalves, M. D., Hopkins, B. D., and Cantley, L. C. 2018. Phosphatidylinositol 3-Kinase, growth disorders, and cancer. N Engl J Med. 379(21): 2052-2062.

[0408] Hang, H.C. and Bertozzi, C. R. 2001. Chemoselective approaches to glycoproteon assembly. Accounts of Chemical Research 34(9): 727-736.

[0409] Hawkins, P. T. and Stephens, L. R. 2015. PI3K signalling in inflammation. 2015. Biochimica et Biophysica Acta 1851(6): 882-897.

[0410] Hopkins, B. D., Pauli, C., Du, X., Wang, D. G., Li, X., Wu, D., Amadiume, S. C., Goncalves, M. D., Hodakoski, C., Lundquist, M. R., Bareja, R., Ma, Y., Harris, E. M., Sboner, A., Beltran, H., Rubin, M. A., Mukherjee, S., and Cantley, L. C. 2018. Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature 560(7719): 499-503.

[0411] Jackson, S. P., Schoenwaelder, S. M., Goncalves, I., Nesbitt, W. S., Yap, C. L., Wright, C. E., Kenche, V., Anderson, K. E., Dopheide, S. M., Yuan, Y., Sturgeon, S. A., Prabaharan, H., Thompson, P. E., Smith, G. D., Shepherd, P. R., Daniele, N., Kulkarni, S., Abbott, B., Saylik, D., Jones, C., Lu, L., Giuliano, S., Hughan, S. C., Angus, J. A., Robertson, A. D., and Salem, H. H. 2005. PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med. 11(5): 507-514.

[0412] Jiang, N., Dai, Q., Su, X., Fu, J., and Feng, X. 2020. Role of PI3K/AKT pathway in cancer: the framework of malignant behavior. Mol Biol Rep. 47(6): 4587–4629.

[0413] Keppler-Noreuil, K. M., Rios, J. J., Parker, V. E., Semple, R. K., Lindhurst, M. J.; Sapp, J. C., Alomari, A., Ezaki, M., Dobyns, W., and Biesecker, L. G. 2015. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation. Am J Med Genet A. 167A(2): 287–295.

[0414] Kiick, K. L., Saxon, E., Tirrell, D. A., and Bertozzi, C. R. 2002. Incorporation of azides into recombinant proteins for chemoselective modification by the Staudinger ligation. Proc Natl Acad Sci USA. 99(1): 19-24.

[0415] Klaus, S., Neumann, H., Zapf, A., Strübing, D., Hübner, S., Almena, J., Riermeier, T., Groß, P., Sarich, M., Krahnert, W., Rossen, K., and Beller, M. 2006. A general and efficient method for the formylation of aryl and heteroaryl bromides. Ang Chem Int Ed. 45(1): 154–158.

[0416] Kurek, K. C., Luks, V. L., Ayturk, U. M., Alomari, A. I., Fishman, S. J., Spencer S. A., Mulliken, J. B., Bowen, M. E., Yamamoto, G. L., Kozakewich, H. P., and Warman, M. L. 2012. Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. Am J Hum Genet. 90(6): 1108–1115.

[0417] Lemieux, G. A. and Bertozzi, C. R. 1998. Chemoselective ligation reactions with proteins, oligosaccharides and cells. Trends in Biotechnology 16(12): 506-513.

[0418] Liu, P., Cheng, H., Roberts, T. M., and Zhao, J. J. 2009. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 8(8): 627-644.

[0419] Okkenhaug, K., Bilancio, A., Farjot, G., Priddle, H., Sancho, S., Peskett, E., Pearce, W., Meek, S. E., Salpekar, A., Waterfield, M. D., Smith, A. J., and Vanhaesebroeck, B. 2002. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 297(5583): 1031-1034.

[0420] Porta, C., Paglino, C., and Mosca, A. 2014. Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol. 4(64): 1-11.

[0421] Posor, Y., Eichhorn-Grünig, M., and Haucke, V. 2015. Phosphoinositides in endocytosis. Biochim Biophys Acta 1851(6): 794-804.

[0422] Prakash, G., Krishnamurti, R., and Olah, G. 1989. Synthetic methods and reactions. 141. Fluoride-induced trifluoromethylation of carbonyl compounds with trifluormethyltrimethylsilane (TMS-CF_3). A trifluoromethide equivalent. J Am Chem Soc. 111(1): 393–395.

[0423] Reichel, M. and Karaghiosoff, K. 2020. Reagents for selective fluoromethylation: A challenge in organofluorine chemistry. Ang Chem Int Ed. 59(30): 12268-12281.

[0424] Rugo, H. S., Lacouture, M. E., Goncalves, M. D., Masharani, U., Aapro, M. S., and O'Shaughnessy, J. A. 2022. A multidisciplinary approach to optimizing care of patients treated with alpelisib. The Breast 61: 156-167.

[0425] Soler, A., Serra, H., Pearce, W., Angulo, A., Guillermet-Guibert, J., Friedman, L. S., Viñals, F., Gerhardt, H., Casanovas, O., Graupera, M., and Vanhaesebroeck, B. 2004. Inhibition of the p110α isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis. J Exp Med. 210(10): 1937–1945.

[0426] Thorpe, L. M., Yuzugullu, H., and Zhao, J. J. 2015. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer 15(1): 7-24.


[0427] Vanhaesebroeck, B., Whitehead M. A., and Piñeiro, R. 2016. Molecules in medicine mini-review: isoforms of PI3K in biology and disease. J Mol Med (Berl). 94(1): 5-11.

[0428] Yang, J., Nie, J., Ma, X., Wei, Y., Peng, Y., and Wei, X. 2019. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer 18(26): 1-28.

[0429] Zhao, Y., Huang, W., Zheng, J., and Hu, J. 2011. Efficient and direct nucleophilic difluoromethylation of carbonyl compounds and imines with Me_3SiCF_2H at ambient or low temperature. Org. Lett. 13(19): 5342-5345.

IN THE CLAIMS

1. A compound of Formula (1)




(1)

or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound thereof, or a pharmaceutically acceptable salt thereof,

wherein:

R_1 is selected from



each A is independently C_1-C_4 alkyl, fluoroalkyl, C_3-C_7 cycloalkyl, $N(R_a)_2$, $(CH_2)_{0-5}$-NR_a-C(O)-C_3-C_7 cycloalkyl, $(CH_2)_{1-5}$-O-$(CH_2)_{0-5}$-C_1-C_4 alkyl, $(CH_2)_{1-5}$-O-C_1-C_3 cycloalkyl, $(CH_2)_{1-5}$-O-$(CH_2)_{0-5}$-CF_3, $(CH_2)_{1-5}$-O-$(CH_2)_{1-5}$-C_1-C_3 fluoroalkyl, $(CH_2)_{0-5}$-aryl, $(CH_2)_{0-5}$-heteroaryl, $(CH_2)_{0-5}$-heterocyclyl, $(CH_2)_{0-5}$-NR_a-$(CH_2)_{0-5}$-heteroaryl or $(CH_2)_{0-5}$-NR_a-$(CH_2)_{1-5}$-N-heterocyclyl, where the alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl are substituted or unsubstituted, or alternatively, A and A together with the attached -P(=O)- moiety may form a substituted or unsubstituted heterocyclyl ring;

each B is independently H, C_1-C_4 alkyl, C_3-C_7 cycloalkyl, $(CH_2)_{1-5}$-OH, $(CH_2)_{0-5}$-$N(R_a)_2$, $(CH_2)_{1-5}$-NR_a-C(O)-C_3-C_7 cycloalkyl, $(CH_2)_{0-5}$-aryl, $(CH_2)_{0-5}$-heteroaryl, $(CH_2)_{0-5}$-heterocyclyl, $(CH_2)_{0-5}$-C(O)-$(CH_2)_{1-5}$-O-C_1-C_4 alkyl, $(CH_2)_{1-5}$-NR_a-$(CH_2)_{0-5}$-heteroaryl or $(CH_2)_{1-5}$-NR_a-$(CH_2)_{2-5}$-N-heterocyclyl, O-C_{1-5}-alkyl, O-C_{0-5}-cycloalkyl, O-C_{0-5}-heterocyclyl, where the alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl are substituted or unsubstituted, or alternatively, B and B together with the attached -[O or NH]-P(=O)-O- moiety may form a substituted or unsubstituted heterocyclyl ring, or alternatively, A and B together with the attached -P(=O)-O- moiety may form a substituted or unsubstituted heterocyclyl ring;

each R_a is independently H, C_1-C_4 alkyl, C_3-C_7 cycloalkyl, C(O)C_1-C_3 alkyl, $(CH_2)_{1-5}$-fluoroalkyl, $(CH_2)_{1-5}$-OH, $(CH_2)_{1-5}$-NH_2, $(CH_2)_{1-5}$-NH(C_1-C_4 alkyl), $(CH_2)_{1-5}$-N(C_1-C_4 alkyl)$_2$ or C(O)-$(CH_2)_{1-5}$-O-C_1-C_3 alkyl, where the alkyl and cycloalkyl are substituted or unsubstituted, or alternatively, for -S(=O)(A)(=NR_a) or for -S(=O)(A)(NR_a), R_a and A together with the attached atoms, may form a substituted or unsubstituted heterocyclyl ring;

R_2 is H, C_1-C_4 alkyl, C_3-C_7 cycloalkyl, CF_3, CFH_2 or CF_2H, and where R_2 is not H, the carbon atom attached to R_2 is a chiral center and exists as a (R)- and (S)-racemic mixture or as either the (R)- or (S)- enantiomer;

R_3 is H or C_1-C_4 alkyl;

R_4 is H, C_1-C_4 alkyl, C_3-C_7 cycloalkyl, halogen, CN, CF_3, OCF_3, CFH_2 or CF_2H;

R_6 is H, C_1-C_4 alkyl, C_3-C_7 cycloalkyl, heteroaromatic, CF_3, CFH_2 or CF_2H;

R_7 is H, C_1-C_4 alkyl, C_3-C_7 cycloalkyl, halogen, CN, CF_3, OCF_3, CFH_2 or CF_2H;

each R_8 is independently H, C_1-C_4 alkyl, C_3-C_7 cycloalkyl, halogen, CN, CF_3, OCF_3, CFH_2 or CF_2H;

each of X_1, X_2 and X_3 is independently N, CH or substituted C;

X_4 is CH or substituted C;

R_5 is

halogen;

-O-L_1-L_2-L_3-L_4-L_5-L_6-L_7-R_9;

-S-L_1-L_2-L_3-L_4-L_5-L_6-L_7-R_9;

-S(O)-L_1-L_2-L_3-L_5-L_6-L_7-R_9;

-$S(O)_2$-L_1-L_2-L_3-L_5-L_6-L_7-R_9;

-(NR_{10})-L_1-L_2-L_3-L_4-L_5-L_6-L_7-R_9; or

-L_8-L_9-L_{10}-L_{11}-L_{12}-R_{14},

wherein:

each of L_1, L_2, L_3, L_6 and L_7 is independently (CHR_{11}), (CHR_{11}-O), (CHR_{11}-S), (C_3-C_7 cycloalkyl), $(CH_2)_{1-4}$ or a bond;

L_4 is C=O, C=S or a bond;

L_5 is NR_{10}, S, O or a bond;

R_9 is H, C(=O)R_{12}, C(=O)N$R_{12}R_{13}$, N$R_{12}R_{13}$, C(=O)OR_{12}, C_1-C_6 alkyl, C_1-C_6 fluoroalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, where each of the C_1-C_6 alkyl, C_1-C_6 fluoroalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is unsubstituted or substituted; or alternatively when NR_{10} is present, R_9 and R_{10} together with the attached nitrogen atom may form a substituted or unsubstituted ring;

each of R_{10} and R_{11} is independently H or C_1-C_4 alkyl (such as CH_3, CH_2CH_3 or $CH(CH_3)_2$), where the C_1-C_4 alkyl is unsubstituted or substituted;

each of R_{12} and R_{13} is independently H, C_1-C_6 alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, where each of the C_1-C_6 alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is unsubstituted or substituted; or alternatively, R_{12} and R_{13} together with the attached nitrogen atom may form a substituted or unsubstituted ring;

L_8 is (CHR_{15}), (CHR_{15}-O), (CHR_{15}-S), (CHR_{15}-NR_{16}), C=O, C=S or a bond;

L_9 is C_3-C_7 cycloalkyl that is optionally part of a bridged, fused or spiro ring system, C(R_{15})=C(R_{15}), C≡C or a bond;

L_{10} is independently (CHR_{15}), O, S, (NCR_{15}), N(C=O) or a bond;

L_{11} is (CHR_{15}), C=O, C=S or a bond;

L_{12} is H, (C_3-C_7 cycloalkyl), heterocyclyl, aryl, heteroaryl or a bond, where each of the C_3-C_7 cycloalkyl, heterocyclyl, aryl or heteroaryl is unsubstituted or substituted, and the C_3-C_7 cycloalkyl and/or heterocyclyl is optionally part of a bridged, fused or spiro ring system;

R_{14} is H, $CR_{15}R_{16}R_{17}$, OR_{17}, SR_{17}, $NR_{16}R_{17}$, C_1-C_6 alkyl, C_1-C_6 fluoroalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, where each of the C_1-C_6 alkyl, C_1-C_6 fluoroalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is unsubstituted or substituted,

each of R_{15} and R_{16} is independently H or C_1-C_3 alkyl; and

each R_{17} is independently H, C_1-C_6 alkyl, C_1-C_6 fluoroalkyl, C_1-C_6 aminoalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, where each of the C_1-C_6 alkyl, C_1-C_6 fluoroalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is unsubstituted or substituted; or alternatively, R_{16} and R_{17} together with the attached nitrogen atom may form a substituted or unsubstituted ring,

with the proviso that when R_5 is -L_8-L_9-L_{10}-L_{11}-L_{12}-R_{14}, at least one of L_8, L_9, L_{10}, L_{11}, L_{12} and R_{14} is a carbon-containing moiety and R_5 is directly attached to the (isoquinolone) core structure by a carbon atom;

or R_5 is

a non-aromatic N-linked heterocyclic ring  , where the heterocyclic ring is substituted or unsubstituted, optionally contains one or more additional ring atoms selected from N, O, Si and S, and is optionally part of a bridged, fused or spiro ring system.

2. The compound according to claim 1 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein R_5 is $-(NR_{10})-L_1-L_2-L_3-L_4-L_5-L_6-L_7-R_9$, where L_1 to L_7, R_9 and R_{10} are as defined.


3. The compound according to claim 1 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein R_5 is $-O-L_1-L_2-L_3-L_4-L_5-L_6-L_7-R_9$, where L_1 to L_7 and R_9 are as defined.

4. The compound according to claim 1 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein R_5 is $-S-L_1-L_2-L_3-L_4-L_5-L_6-L_7-R_9$; $-S(O)-L_1-L_2-L_3-L_5-L_6-L_7-R_9$; or $-S(O)_2-L_1-L_2-L_3-L_5-L_6-L_7-R_9$, where L_1 to L_7 and R_9 are as defined.

5. The compound according to claim 1 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein R_5 is $-L_8-L_9-L_{10}-L_{11}-L_{12}-R_{14}$, where L_8 to L_{12} and R_{14} are as defined.


6. The compound according to claim 1 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein R_5 is a non-aromatic N-linked heterocyclyl ring  , where the heterocyclyl ring is substituted or unsubstituted, optionally contains one or more additional ring atoms selected from N, O, Si and S, and is optionally part of a bridged, fused or spiro ring system.

7. The compound according to claim 1 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein R_1 is selected from




wherein A and B are as defined in claim 1.

8. The compound according to claim 1 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein R_1 is selected from



wherein A, B and R_a are as defined in claim 1.

9. The compound according to claim 1 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein R_1 is selected from



wherein B is as defined in claim 1.

10. The compound according to claim 1 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein X_4 is CH or CF.

11. The compound according to claim 1 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein R_2 is CH_3 or CH_2F.

12. The compound according to claim 1 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein R_3 is H.

13. The compound according to claim 1 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein X_1 is N, and X_2 and X_3 are independently CH or substituted C.

14. The compound according to claim 1 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein X_2 is N, and X_1 and X_3 are independently CH or substituted C.

15. The compound according to claim 1 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein X_3 is N, and X_1 and X_3 are independently CH or substituted C.

16. The compound according to claim 1 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein X_1 and X_3 are N, and X_2 is CH or substituted C.

17. The compound according to claim 1 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein X_1 and X_2 are N, and X_3 is CH or substituted C.

18. The compound according to claim 1 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein X_2 and X_3 are N, and X_1 is CH or substituted C.

19. The compound according to claim 1 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein X_1, X_2 and X_3 are N.

20. The compound according to claim 1 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein X_1, X_2 and X_3 are independently CH or substituted C.

21. The compound according to claim 1 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein R_2 is CH_3 or CH_2F, R_3 is H and X_4 is N.

22. The compound according to claim 1 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein R_2 is CH_3 or CH_2F, R_3 is H and X_4 is CH or CF.

23. The compound according to claim 1 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein R_2 is CH_3 or CH_2F, R_3 is H and R_5 is $-L_8-L_9-L_{10}-L_{11}-L_{12}-R_{14}$.


24. The compound according to claim 1 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein R_2 is CH_3 or CH_2F, R_3 is H and R_5 is $-O-L_1-L_2-L_3-L_4-L_5-L_6-L_7-R_9$.

25. The compound according to claim 1 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein R_2 is CH_3 or CH_2F, R_3 is H and R_5 is $-S-L_1-L_2-L_3-L_4-L_5-L_6-L_7-R_9$.

26. The compound according to claim 1 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein R_2 is CH_3 or CH_2F, R_3 is H and R_5 is $-(NR_{10})-L_1-L_2-L_3-L_4-L_5-L_6-L_7-R_9$.

27. The compound according to claim 1 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein X_4 is CH, R_2 is CH_3 or CH_2F, R_3 is H and R_5 is $-L_8-L_9-L_{10}-L_{11}-L_{12}-R_{14}$.

28. The compound according to claim 1 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula (1) is a compound of Formula (2)



(2)

or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof,

wherein:

X_1, X_2, X_3, R_1 and R_5 are defined as in the compound of Formula (1), and

the carbon marked with * is a chiral center and exists as a (R)- and (S)-racemic mixture or as either the (R)- or (S)- enantiomer.

29. The compound according to claim 28 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein each of X_1, X_2 and X_3 is independently CH or CF.

30. A pharmaceutical composition comprising the compound of any one of claims 1 to 29 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

31. The pharmaceutical composition according to claim 30, further comprising one or more anti-cancer agents.

32. The pharmaceutical composition according to claim 31, wherein the one or more anti-cancer agents are selected from the group consisting of cyclophosphamide, dacarbazine, cisplatin, methotrexate, mercaptopurine, thioguanine, fluorouracil, cytarabine, vinblastine, paclitaxel, doxorubicin, bleomycin, mitomycin, prednisone, tamoxifen, flutamide, asparaginase, rituximab,

trastuzumab, imatinib, retinoic acid, amifostine, camptothecin, topotecan, thalidomide, lenalidomide, a CDK inhibitor and a proteasome inhibitor.

33. A method of treating a disease in which PI3K activity is implicated in a subject in need of such treatment, the method comprising administering to the subject a therapeutically effective amount of the compound of any one of claims 1 to 29 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof.

34. The method of claim 33, wherein the disease is cancer.

35. The method of claim 33, wherein the disease is congenital lipomatous overgrowth, vascular malformations, epidermal naevi, scoliosis/skeletal and spinal syndrome (CLOVES), mosaic tissue overgrowth syndromes, venous malformations and brain malformations associated with severe epilepsy or PIK3CA-related overgrowth syndrome (PROS).

36. The method of claim 33, wherein the disease is a cancer bearing a PI3Kα H1047R mutation.